>>NCT01778946	O
Inclusion	O
Criteria:	O
.	O

-	O
Cognitive	B-Observation
complaints	I-Observation
and	O
/	O
or	O
memory	B-Observation
difficulties	I-Observation
which	O
are	O
verified	O
as	O
new	O
onset	O
by	O
an	O
informant	O
.	O

-	O
Cognitive	B-Observation
Global	I-Observation
Rating	I-Observation
consistent	O
with	O
mild	O
impairment	B-Condition
or	O
deterioration	B-Condition
from	O
premorbid	O
baseline	O
.	O

-	O
General	B-Observation
cognition	I-Observation
and	O
functional	O
performance	O
sufficiently	O
preserved	O
such	O
that	O
a	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
/	I-Condition
dementia	I-Condition
cannot	B-Negation_cue
be	O
made	O
by	O
the	O
physician	O
at	O
the	O
time	O
of	O
the	O
screening	O
visit	O
.	O

-	O
No	B-Negation_cue
significant	O
cerebrovascular	B-Condition
disease	I-Condition
Modified	B-Observation
Hachinski	I-Observation
score	I-Observation
of	O
less	O
than	O
or	O
equal	O
to	O
4	O
.	O

-	O
Age	B-Observation
25+	O
.	O

-	O
Stable	O
medications	B-Drug
for	O
at	O
least	O
1	O
month	O
prior	O
to	O
screening	O
.	O

Central	B-Drug
nervous	I-Drug
system	I-Drug
(	I-Drug
CNS	I-Drug
)	I-Drug
medications	I-Drug
should	O
be	O
stable	O
for	O
3	O
months	O
.	O

-	O
No	B-Negation_cue
evidence	O
of	O
major	B-Condition
depression	I-Condition
.	O

-	O
Informant	O
is	O
available	O
who	O
has	O
frequent	O
contact	O
with	O
the	O
subject	O
(	O
eg	O
an	O
average	O
of	O
10	O
hours	O
per	O
week	O
or	O
more	O
)	O
.	O

-	O
Adequate	O
visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
to	O
allow	O
neuropsychological	B-Procedure_Device
testing	I-Procedure_Device
.	O

-	O
Good	O
general	B-Observation
health	I-Observation
with	O
no	B-Negation_cue
additional	B-Condition
diseases	I-Condition
expected	O
to	O
interfere	O
with	O
the	O
study	O
.	O

-	O
Normal	O
B12	B-Observation
,	O
rapid	B-Observation
plasma	I-Observation
reagin	I-Observation
(	I-Observation
RPR	I-Observation
)	I-Observation
and	O
Thyroid	B-Observation
Function	I-Observation
Tests	I-Observation
or	O
without	B-Negation_cue
any	O
clinically	O
significant	O
abnormalities	B-Condition
that	O
would	O
be	O
expected	O
to	O
interfere	O
with	O
the	O
study	O
.	O

-	O
ECG	B-Procedure_Device
without	B-Negation_cue
clinically	O
significant	O
abnormalities	B-Observation
that	O
would	O
be	O
expected	O
to	O
interfere	O
with	O
the	O
study	O
.	O

-	O
Subject	O
is	O
not	B-Negation_cue
pregnant	B-Condition
,	O
lactating	B-Condition
.	O

-	O
Subjects	O
will	O
be	O
taking	O
no	B-Negation_cue
drugs	B-Drug
with	I-Drug
cholinergic	I-Drug
properties	I-Drug
(	O
e.g	O
donepezil	B-Drug
)	O
.	O

-	O
Agreement	O
not	B-Negation_cue
to	O
take	O
other	O
vitamin	B-Drug
or	O
supplements	B-Drug
other	B-Negation_cue
than	I-Negation_cue
multivitamins	B-Drug
.	O

-	O
Negative	O
urine	B-Observation
pregnancy	I-Observation
test	I-Observation
in	O
females	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Any	O
significant	O
neurologic	B-Condition
disease	I-Condition
such	O
as	O
Alzheimer's	B-Condition
disease	I-Condition
Parkinson's	B-Condition
disease	I-Condition
multi-infarct	B-Condition
dementia	I-Condition
Huntington's	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
brain	B-Condition
tumor	I-Condition
progressive	B-Condition
supranuclear	I-Condition
palsy	I-Condition
seizure	B-Condition
disorder	I-Condition
subdural	B-Condition
hematoma	I-Condition
multiple	B-Condition
sclerosis	I-Condition
or	O
history	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
followed	O
by	O
persistent	O
neurologic	B-Condition
deficits	I-Condition
or	O
known	O
structural	B-Condition
brain	I-Condition
abnormalities	I-Condition
.	O

-	O
Active	O
Major	B-Condition
depression	I-Condition
or	O
another	O
major	O
psychiatric	B-Condition
disorder	I-Condition
as	O
described	O
in	O
DSM-IV	B-Observation
.	O

-	O
History	O
of	O
alcohol	B-Drug
or	I-Drug
substance	I-Drug
abuse	I-Drug
or	I-Drug
dependence	I-Drug
within	O
the	O
past	O
2	O
years	O
(	O
DSM	B-Observation
IV	I-Observation
criteria	I-Observation
)	O
.	O

-	O
Any	O
significant	O
systemic	B-Condition
illness	I-Condition
or	O
unstable	O
medical	B-Condition
condition	I-Condition
which	O
could	O
lead	O
to	O
difficulty	O
complying	O
with	O
the	O
protocol	O
including:	O
.	O

-	O
History	O
of	O
myocardial	B-Condition
infarction	I-Condition
in	O
the	O
past	O
year	O
or	O
unstable	O
or	O
severe	O
cardiovascular	B-Condition
disease	I-Condition
including	O
angina	B-Condition
or	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
(	I-Condition
CHF	I-Condition
)	I-Condition
with	O
symptoms	O
at	O
rest	O
.	O

-	O
Clinically	O
significant	O
obstructive	B-Condition
pulmonary	I-Condition
disease	I-Condition
or	O
asthma	B-Condition
.	O

-	O
Clinically	O
significant	O
and	O
unstable	O
gastrointestinal	B-Condition
disorder	I-Condition
such	O
as	O
ulcer	B-Condition
disease	I-Condition
or	O
a	O
history	O
of	O
active	O
or	O
occult	O
gastrointestinal	B-Condition
bleeding	I-Condition
within	O
two	O
years	O
.	O

-	O
Clinically	O
significant	O
laboratory	B-Observation
test	I-Observation
abnormalities	I-Observation
on	O
the	O
battery	O
of	O
screening	O
tests	O
(	O
hematology	B-Observation
,	O
chemistry	B-Observation
,	O
urinalysis	B-Observation
,	O
ECG	B-Procedure_Device
)	O
.	O

-	O
Insulin-requiring	O
diabetes	B-Condition
or	O
uncontrolled	O
diabetes	B-Condition
mellitus	I-Condition
.	O

-	O
Uncontrolled	O
hypertension	B-Condition
(	O
systolic	B-Observation
BP	I-Observation
>	O
170	O
or	O
diastolic	B-Observation
BP	I-Observation
>	O
100	O
)	O
.	O

-	O
Use	O
of	O
any	O
investigational	B-Drug
drugs	I-Drug
within	O
30	O
days	O
or	O
5	O
half-lives,	O
whichever	O
is	O
longer,	O
prior	O
to	O
screening	O
.	O

>>NCT01659398	O
Inclusion	O
Criteria:	O
.	O

-	O
An	O
adult	O
between	O
18	O
and	O
85	O
years	O
of	O
age	B-Observation
.	O

-	O
Has	O
been	O
evaluated	O
to	O
have	O
a	O
CDR	B-Observation
(	I-Observation
Clinical	I-Observation
Dementia	I-Observation
Rating	I-Observation
)	I-Observation
Score	I-Observation
of	O
0.5	O
.	O

-	O
Male	O
or	O
female	O
(	O
if	O
female	O
must	O
be	O
postmenopausal	B-Condition
for	O
at	O
least	O
1	O
year,	O
surgically	B-Condition
sterile	I-Condition
or	O
using	O
an	O
effective	O
form	O
of	O
contraception	O
)	O
.	O

-	O
Able	O
to	O
speak	O
and	O
read	O
English	O
.	O

-	O
Willing	O
to	O
comply	O
with	O
study	O
specific	O
instructions	O
and	O
complete	O
all	O
study	O
procedures	O
according	O
to	O
protocol	O
.	O

-	O
Able	O
to	O
understand	O
study	O
rationale	O
and	O
sign	O
informed	O
consent	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Diagnosed	O
with	O
glaucoma	B-Condition
.	O

-	O
History	O
of	O
developing	O
adverse	B-Condition
effects	I-Condition
to	O
ophthalmic	B-Drug
dilating	I-Drug
agents	I-Drug
(	O
phenylephrine	B-Drug
or	O
tropicamide	B-Drug
)	O
.	O

-	O
Currently	O
taking	O
warfarin	B-Drug
and	O
dabigatran	B-Drug
(	O
Pradaxa	B-Drug
)	O
.	O

-	O
History	O
of	O
having	O
arrhythmias	B-Condition
-	O
can	O
interfere	O
with	O
EECP	O
triggering	O
.	O

-	O
Subject	O
has	O
bleeding	B-Condition
diathesis	I-Condition
.	O

-	O
Subject	O
has	O
active	O
thrombophlebitis	B-Condition
.	O

-	O
Subject	O
has	O
severe	O
lower	B-Condition
extremity	I-Condition
vaso-occlusive	I-Condition
disease	I-Condition
.	O

-	O
Subject	O
has	O
a	O
documented	O
aortic	B-Condition
aneurysm	I-Condition
requiring	O
surgical	B-Procedure_Device
repair	I-Procedure_Device
.	O

-	O
Subject	O
is	O
pregnant	B-Condition
.	O

-	O
Subject	O
with	O
blood	B-Observation
pressure	I-Observation
higher	O
than	O
180	O
-	O
110	O
mmHg	O
.	O

-	O
Subject	O
with	O
a	O
heart	B-Observation
rate	I-Observation
more	O
than	O
120	O
bpm	O
.	O

-	O
Subject	O
with	O
high	O
risk	O
of	O
complications	O
from	O
increased	O
venous	O
return	O
.	O

-	O
Subject	O
with	O
clinically	O
significant	O
valvular	B-Condition
disease	I-Condition
.	O

-	O
Subjects	O
with	O
severe	O
vascular	B-Condition
disease	I-Condition
as	O
established	O
by	O
the	O
Hachinski	B-Observation
Ischemic	I-Observation
Index	I-Observation
.	O

-	O
Subjects	O
with	O
pacemakers	B-Procedure_Device
and	O
other	O
metallic	B-Procedure_Device
implantable	I-Procedure_Device
devices	I-Procedure_Device
.	O

>>NCT01522404	O
Inclusion	O
.	O

-	O
Subjective	O
memory	B-Condition
concern	I-Condition
per	O
subject,	O
study	O
partner	O
or	O
clinician	O
.	O

-	O
Clinician	O
diagnosis	O
of	O
amnestic	B-Condition
MCI	I-Condition
single	O
or	O
multi-domain	O
.	O

-	O
Abnormal	O
memory	B-Condition
per	O
Logical	O
Memory	O
subscale	O
from	O
Wechsler	B-Observation
Memory	I-Observation
Scale-Revised	I-Observation
.	O

-	O
MMSE	B-Observation
score	I-Observation
24	O
-	O
30	O
inclusive	O
.	O

Exceptions	O
considered	O
for	O
<	O
8	O
yrs.education	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
0.5	O
.	O

Memory	B-Observation
Box	I-Observation
score	I-Observation
must	O
be	O
>=	O
0.5	O
.	O

-	O
General	O
cognition	O
&	O
functional	O
performance	O
preserved	O
.	O

-	O
Cholinesterase	B-Drug
inhibitors	I-Drug
&	O
memantine	B-Drug
,	O
if	O
stable	O
x12	O
wks	O
.	O

-	O
Stability	O
of	O
medications	B-Drug
x4	O
wks	O
.	O

May	O
washout	O
from	O
psychoactive	B-Drug
medication	I-Drug
x4	O
wks	O
.	O

-	O
Geriatric	B-Observation
Depression	I-Observation
Scale	I-Observation
<=	O
6	O
.	O

-	O
Male	O
/	O
female	O
outpatients	O
aged	B-Observation
50	O
-	O
90	O
(	O
inclusive	O
)	O
.	O

-	O
Study	O
partner	O
has	O
regular	O
contact	O
w/	O
subject,	O
can	O
provide	O
reliable	O
assessment	O
of	O
subject's	O
level	O
of	O
function,	O
&	O
can	O
be	O
available	O
for	O
all	O
visits,	O
either	O
in	O
person	O
or	O
by	O
telephone,	O
throughout	O
trial	O
.	O

-	O
Visual	B-Observation
&	I-Observation
auditory	I-Observation
acuity	I-Observation
adequate	O
for	O
testing	O
.	O

-	O
Good	O
general	B-Observation
health	I-Observation
.	O

-	O
Women	O
of	O
child-bearing	O
potential	O
willing	O
to	O
use	O
medically	O
acceptable	O
birth	O
control	O
or	O
practice	O
abstinence	O
throughout	O
trial	O
.	O

-	O
Modified	B-Observation
Rosen	I-Observation
Hachinski	I-Observation
<=	O
4	O
.	O

-	O
Completed	O
6th	O
grade	O
or	O
has	O
good	O
work	O
history	O
.	O

-	O
Fluent	O
in	O
English	O
.	O

-	O
Able	O
to	O
understand	O
nature	O
of	O
study	O
.	O

Must	O
provide	O
written	O
informed	O
consent	O
prior	O
to	O
conduct	O
of	O
any	O
study	O
procedures	O
.	O

-	O
Willing	O
to	O
undergo	O
repeated	O
MRIs	O
&	O
PET	O
scans	O
.	O

-	O
Agrees	O
to	O
APOE,	O
CYP2D6	O
&	O
biomarker	O
testing	O
.	O

-	O
Agrees	O
to	O
3	O
lumbar	O
punctures	O
over	O
course	O
of	O
study	O
.	O

Exclusion	O
.	O

-	O
Significant	O
neurologic	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
MCI	B-Condition
.	O

-	O
Screening	O
/	O
baseline	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
w/	O
evidence	O
of	O
infection	B-Condition
,	O
large	B-Condition
vessel	I-Condition
infarction	I-Condition
or	O
other	O
focal	B-Condition
structural	I-Condition
lesion	I-Condition
that	O
could	O
account	O
for	O
memory	B-Condition
deficits	I-Condition
.	O

Subjects	O
w/	O
multiple	O
lacunes	B-Observation
or	O
lacunes	B-Observation
in	O
a	O
critical	O
memory	O
structure	O
.	O

-	O
Contraindication	B-Condition
to	O
MRI	B-Procedure_Device
(	O
pacemakers	B-Procedure_Device
,	O
aneurysm	B-Procedure_Device
clips	I-Procedure_Device
artificial	B-Procedure_Device
heart	I-Procedure_Device
valves	I-Procedure_Device
ear	B-Procedure_Device
implants	I-Procedure_Device
metal	B-Procedure_Device
fragments	I-Procedure_Device
or	O
foreign	B-Procedure_Device
objects	I-Procedure_Device
in	O
the	O
eyes,	O
skin	O
or	O
body	O
or	O
excessive	O
weight	B-Observation
)	O
.	O

-	O
Clinically	O
significant	O
suicide	B-Condition
risk	I-Condition
based	O
on	O
MD's	O
judgment	O
per	O
structured	O
clinician	O
interview	O
.	O

Suicide	B-Condition
attempt	I-Condition
within	O
past	O
yr	O
.	O
-	O
Major	B-Condition
depression	I-Condition
bipolar	B-Condition
disorder	I-Condition
within	O
past	O
yr	O
.	O
or	O
history	O
of	O
schizophrenia	B-Condition
.	O

Psychotic	B-Condition
features	I-Condition
agitation	B-Condition
or	O
behavioral	B-Condition
problems	I-Condition
within	O
last	O
3	O
mos	O
.	O

-	O
History	O
of	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
/	I-Condition
dependence	I-Condition
within	O
past	O
2	O
yrs	O
.	O

-	O
Allergic	B-Condition
to	O
atomoxetine	B-Drug
.	O

-	O
Uncontrolled	O
medical	B-Condition
condition	I-Condition
that	O
may	O
preclude	O
completion	O
of	O
study	O
or	O
medical	B-Condition
condition	I-Condition
which	O
would	O
represent	O
contraindication	B-Condition
to	O
atomoxetine	B-Drug
(	O
eg	O
hepatic	B-Condition
insufficiency	I-Condition
untreated	O
hypertension	B-Condition
,	O
untreated	O
cardiovascular	B-Condition
or	I-Condition
cerebrovascular	I-Condition
disease	I-Condition
)	O
.	O

-	O
Known	O
serious	O
cardiac	B-Condition
problems	I-Condition
.	O

History	O
of	O
narrow	B-Condition
angle	I-Condition
glaucoma	I-Condition
.	O

History	O
of	O
pheochromocytoma	B-Condition
.	O

-	O
Clinically	O
significant	O
abnormal	B-Observation
findings	I-Observation
on	O
screening	O
lab	O
tests	O
or	O
exam	O
.	O

Abnormalities	O
in	O
Vitamin	B-Observation
B12	I-Observation
level	I-Observation
TFTs	B-Observation
or	O
LFTs	B-Observation
that	O
may	O
interfere	O
w/	O
study	O
.	O

Low	O
Vitamin	B-Observation
B12	I-Observation
level	I-Observation
(	O
unless	O
homocysteine	B-Observation
&	O
methylmalonic	B-Observation
acid	I-Observation
indicate	O
no	B-Negation_cue
clinical	O
significance	O
)	O
.	O

-	O
Slow	O
metabolizer	O
of	O
atomoxetine	O
.	O

-	O
Women	O
who	O
are	O
pregnant	B-Condition
or	O
lactating	B-Condition
or	O
plan	O
to	O
become	O
pregnant	O
during	O
study	O
.	O

-	O
Behavioral	O
symptoms	O
requiring	O
current	O
use	O
of	O
neuroleptics	B-Drug
,	O
chronic	B-Drug
anxiolytics	I-Drug
sedative	B-Drug
hypnotics	I-Drug
.	O

-	O
Current	O
use	O
of	O
warfarin	B-Drug
.	O

-	O
Inability	O
to	O
obtain	O
initial	O
Cerebrospinal	O
fluid	O
sample	O
.	O

-	O
Use	O
within	O
60	O
days	O
of	O
a	O
monoamine	B-Drug
oxidase	I-Drug
inhibitor	I-Drug
or	O
potent	B-Drug
CYP2D6	I-Drug
inhibitor	I-Drug
.	O

-	O
Current	O
use	O
of	O
anti-psychotics	B-Drug
or	O
the	O
following	O
anti-depressant	B-Drug
medications	I-Drug
duloxetine	B-Drug
,	O
venlafaxine	B-Drug
,	O
desvenlafaxine	B-Drug
,	O
imipramine	B-Drug
,	O
amitryptiline	B-Drug
.	O

-	O
Current	O
participation	O
in	O
another	O
clinical	O
trial	O
.	O

-	O
Current	O
/	O
recent	O
participation	O
in	O
procedures	O
involving	O
radioactive	B-Drug
agents	I-Drug
such	O
that	O
total	B-Drug
radiation	I-Drug
dose	I-Drug
exposure	I-Drug
to	O
subject	O
in	O
any	O
given	O
year	O
>	O
limits	O
of	O
annual	O
&	O
total	O
dose	O
commitment	O
set	O
forth	O
in	O
US	O
CFR	O
Title	O
21	O
Section	O
361.1	O
.	O

-	O
Cerebrospinal	B-Observation
fluid	I-Observation
profile	I-Observation
inconsistent	O
with	O
underlying	O
AD	B-Condition
pathology	O
.	O

-	O
Reasonable	O
likelihood	O
for	O
non-compliance	O
w/	O
protocol	O
or	O
any	O
other	O
reason,	O
in	O
opinion	O
of	O
investigator	O
.	O

-	O
Exceptions	O
may	O
be	O
considered	O
on	O
individual	O
basis	O
at	O
discretion	O
of	O
protocol	O
director	O
.	O

>>NCT01330160	O
Inclusion	O
Criteria:	O
.	O

-	O
patients	O
>	O
40	O
years	O
olds	O
.	O

-	O
hemispheric	B-Condition
stroke	I-Condition
.	O

-	O
stroke	B-Condition
dating	O
from	O
less	O
72h	O
.	O

-	O
IQ-code	B-Observation
<	O
64	O
.	O

-	O
patient	O
(	O
or	O
his	O
family	O
)	O
given	O
an	O
informed	O
consent	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
non	B-Condition
hemispheric	I-Condition
stroke	I-Condition
.	O

-	O
malformative	B-Condition
intracranial	I-Condition
hemorrhage	I-Condition
.	O

-	O
traumatic	B-Condition
intracranial	I-Condition
hemorrhage	I-Condition
.	O

-	O
subarachnoidal	B-Condition
hemorrhage	I-Condition
.	O

-	O
contra-indication	B-Condition
to	O
MRI	B-Procedure_Device
.	O

-	O
patients	O
unable	O
to	O
answer	O
to	O
cognitive	O
battery	O
.	O

>>NCT00937846	O
Inclusion	O
Criteria:	O
.	O

-	O
Generally	O
healthy	B-Condition
.	O

-	O
Male	O
between	O
35	O
and	O
55	O
years	O
of	O
age	B-Observation
.	O

-	O
Willing	O
to	O
use	O
appropriate	O
contraception	O
method	O
.	O

-	O
Weight	B-Observation
more	O
than	O
50	O
kg	O
.	O

-	O
BMI	B-Observation
within	O
the	O
range	O
19	O
-	O
29	O
kg	O
/	O
m2	O
.	O

-	O
Adequate	O
blood	B-Observation
supply	I-Observation
to	O
the	O
hand	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Abuse	B-Condition
of	I-Condition
drugs	I-Condition
or	I-Condition
alcohol	I-Condition
.	O

-	O
Smoker	B-Observation
or	O
history	O
of	O
regular	O
use	O
of	O
tobacco-	B-Drug
or	I-Drug
nicotine-containing	I-Drug
products	I-Drug
in	O
the	O
past	O
6	O
months	O
.	O

-	O
ECG	B-Observation
abnormality	I-Observation
(	O
personal	O
or	O
family	O
history	O
)	O
.	O

-	O
Psychiatric	B-Condition
disorder	I-Condition
.	O

-	O
Asthma	B-Condition
or	O
a	O
history	O
of	O
asthma	B-Condition
.	O

-	O
Medical	B-Condition
illness	I-Condition
.	O

-	O
Worked	O
as	O
a	O
welder,	O
metal	O
worker	O
or	O
machinist	O
.	O

-	O
Suffers	O
from	O
claustrophobia	B-Condition
or	O
would	O
be	O
unable	O
to	O
lie	O
still	O
in	O
a	O
PET	B-Procedure_Device
or	O
MRI	B-Procedure_Device
scanner	O
for	O
1	O
-	O
2	O
hours	O
.	O

-	O
Has	O
a	O
cardiac	B-Procedure_Device
pacemaker	I-Procedure_Device
or	O
other	O
electrical	B-Procedure_Device
device	I-Procedure_Device
or	O
ferromagnetic	B-Procedure_Device
metal	I-Procedure_Device
foreign	I-Procedure_Device
bodies	I-Procedure_Device
.	O

-	O
Neurological	B-Condition
disorder	I-Condition
.	O

>>NCT00596284	O
Inclusion	O
Criteria:	O
.	O

-	O
Alzheimer's	B-Condition
disease	I-Condition
that	O
is	O
in	O
the	O
mild	O
or	O
moderate	O
range	O
according	O
to	O
a	O
score	O
of	O
0.5	O
to	O
2.0	O
on	O
the	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
Scale	I-Observation
.	O

-	O
Significant	O
anxiety	B-Condition
as	O
defined	O
by	O
a	O
score	O
of	O
4	O
on	O
the	O
Neuropsychiatric	B-Observation
Inventory	I-Observation
(	I-Observation
NPI	I-Observation
)	I-Observation
.	O

-	O
Agrees	O
to	O
permit	O
participation	O
of	O
a	O
collateral	O
.	O

-	O
English-speaking	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Suicidal	B-Condition
intent	I-Condition
.	O

-	O
Current	O
psychosis	B-Condition
or	O
bipolar	B-Condition
disorder	I-Condition
.	O

-	O
History	O
of	O
substance	B-Condition
abuse	I-Condition
within	O
1	O
month	O
prior	O
to	O
study	O
entry.	O

>>NCT01227252	O
Inclusion	O
Criteria:	O
.	O

-	O
Healthy	B-Condition
men	O
and	O
non-childbearing	B-Condition
potential	I-Condition
women	O
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
between	O
18.0	O
-	O
32.0	O
kg	O
/	O
m2	O
.	O

-	O
Are	O
reliable	O
and	O
willing	O
to	O
make	O
yourself	O
available	O
for	O
the	O
duration	O
of	O
the	O
study	O
and	O
are	O
willing	O
to	O
follow	O
study	O
procedures	O
and	O
research	O
unit	O
policies	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Taking	O
over-the-counter	B-Drug
or	O
prescription	B-Drug
medication	I-Drug
with	O
the	O
exception	B-Negation_cue
of	O
vitamins	B-Drug
or	O
minerals	B-Drug
.	O

-	O
Smoke	B-Observation
more	O
than	O
10	O
cigarettes	O
per	O
day	O
.	O

-	O
Drink	O
more	O
than	O
5	O
cups	O
of	O
caffeine	B-Drug
containing	I-Drug
beverages	I-Drug
(	O
eg	O
,	O
coffee	B-Drug
,	O
tea	B-Drug
)	O
per	O
day	O
.	O

>>NCT01203384	O
Inclusion	O
Criteria:	O
.	O

-	O
Subject	O
is	O
judged	O
to	O
be	O
in	O
good	O
health	B-Observation
on	O
the	O
basis	O
of	O
medical	B-Observation
history	I-Observation
complete	B-Observation
physical	I-Observation
examination	I-Observation
including	O
vital	B-Observation
signs	I-Observation
12	B-Procedure_Device
-lead	I-Procedure_Device
electrocardiogram	I-Procedure_Device
(	I-Procedure_Device
ECG	I-Procedure_Device
)	I-Procedure_Device
and	O
standard	B-Observation
laboratory	I-Observation
tests	I-Observation
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Medical	O
history	O
(	O
within	O
the	O
last	O
10	O
years	O
)	O
of	O
major	O
cardiovascular,	B-Condition
hepatic	I-Condition
or	I-Condition
renal	I-Condition
disease	I-Condition
.	O

-	O
Abnormal	O
results	O
of	O
liver	B-Observation
function	I-Observation
tests	I-Observation
renal	B-Observation
function	I-Observation
tests	I-Observation
or	O
thyroid	B-Observation
tests	I-Observation
performed	O
at	O
screening	O
.	O

-	O
Significant	O
allergic	B-Condition
conditions	I-Condition
that	O
require	O
medical	O
treatment	O
.	O

-	O
Use	O
of	O
any	O
psychoactive,	B-Drug
recreational	I-Drug
or	I-Drug
prescription	I-Drug
drug	I-Drug
within	O
the	O
4	O
weeks	O
prior	O
to	O
study	O
drug	O
administration	O
.	O

-	O
Use	O
of	O
ibuprofen	B-Drug
,	O
sulindac	B-Drug
sulfide	I-Drug
indomethacin	B-Drug
,	O
flurbiprofen	B-Drug
within	O
2	O
weeks	O
prior	O
to	O
study	O
drug	O
administration	O
.	O

>>NCT01079819	O
Inclusion	O
Criteria:	O
.	O

-	O
Healthy	B-Condition
male	O
subjects	O
18	O
-	O
45	O
yrs	O
old	O
and	O
65	O
yrs	O
or	O
older	O
inclusive	O
and	O
postmenopausal	B-Condition
female	O
65	O
yrs	O
or	O
older	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Women	O
of	O
childbearing	B-Condition
potential	I-Condition
.	O

-	O
Gastrointestinal	B-Condition
disorders	I-Condition
.	O

-	O
Bleeding	B-Condition
disorders	I-Condition
.	O

-	O
Peptic	B-Condition
ulcer	I-Condition
disease	I-Condition
.	O

-	O
Abnormal	O
ECG	B-Procedure_Device
.	O

-	O
Abnormal	O
Clinical	B-Observation
laboratory	I-Observation
tests	I-Observation
.	O

-	O
Abnormal	O
Thyroid	B-Observation
.	O

-	O
Congestive	B-Condition
heart	I-Condition
failure	I-Condition
.	O

-	O
Cholecystectomy	B-Procedure_Device
.	O

-	O
Asthma	B-Condition
.	O

-	O
Hypertension	B-Condition
.	O

-	O
Inability	B-Negation_cue
to	O
tolerate	O
oral	B-Drug
medication	I-Drug
.	O

-	O
Inability	B-Negation_cue
to	O
be	B-Condition
venipunctured	I-Condition
and	O
/	O
or	O
tolerate	O
venous	B-Condition
access	I-Condition
.	O

>>NCT01023425	O
Inclusion	O
Criteria:	O
.	O

1	O
.	O

A	O
diagnosis	O
of	O
probable	O
AD	B-Condition
according	O
to	O
the	O
criteria	O
of	O
the	O
NINCDS-ADRDA	B-Observation
.	O

2	O
.	O

Korean	B-Observation
version	I-Observation
Mini-Mental	I-Observation
State	I-Observation
Examination	I-Observation
scores	I-Observation
between	O
10	O
and	O
26	O
.	O

3	O
.	O

History	O
of	O
cognitive	B-Condition
decline	I-Condition
that	O
had	O
been	O
gradual	O
in	O
onset	O
and	O
progressive	O
over	O
at	O
least	O
6	O
months	O
.	O

4	O
.	O

A	O
caregiver	O
who	O
could	O
assist	O
the	O
patient	O
with	O
medication,	O
attend	O
the	O
assessment	O
and	O
provide	O
information	O
about	O
the	O
patient	O
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O
they	O
had	O
evidence	O
of	O
any	O
neurodegenerative	B-Condition
diseases	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
(	O
i.e	O
.	O

Parkinson's	B-Condition
disease	I-Condition
Huntington's	B-Condition
disease	I-Condition
)	O
.	O

2	O
.	O

Psychiatric	B-Condition
disorder	I-Condition
or	O
severe	O
behavioral	B-Condition
disturbances	I-Condition
that	O
required	O
psychotropic	B-Drug
medications	I-Drug
.	O

3	O
.	O

Cerebral	B-Condition
injuries	I-Condition
induced	O
by	O
trauma	B-Condition
,	O
hypoxia	B-Condition
,	O
and	O
/	O
or	O
ischemia	B-Condition
.	O

4	O
.	O

Clinically	O
active	O
cerebrovascular	B-Condition
disease	I-Condition
History	O
of	O
seizure	B-Condition
disorder	I-Condition
.	O

5	O
.	O

Other	O
physical	B-Condition
conditions	I-Condition
that	O
required	O
acute	O
treatment	B-Procedure_Device
.	O

>>NCT00987220	O
Inclusion	O
Criteria:	O
.	O

-	O
Healthy	B-Condition
male	O
and	O
/	O
or	O
female	O
subjects	O
between	O
the	O
ages	B-Observation
of	O
18	O
and	O
55	O
years,	O
inclusive	O
(	O
Healthy	B-Condition
is	O
defined	O
as	O
no	O
clinically	O
relevant	O
abnormalities	B-Condition
identified	O
by	O
a	O
detailed	O
medical	B-Observation
history	I-Observation
full	B-Observation
physical	I-Observation
examination	I-Observation
including	O
blood	B-Observation
pressure	I-Observation
and	O
pulse	B-Observation
rate	I-Observation
measurement	I-Observation
12	B-Procedure_Device
-lead	I-Procedure_Device
ECG	I-Procedure_Device
and	O
clinical	B-Observation
laboratory	I-Observation
tests	I-Observation
)	O
.	O

-	O
Body	B-Observation
Mass	I-Observation
Index	I-Observation
(	I-Observation
BMI	I-Observation
)	I-Observation
of	O
approximately	O
18	O
to	O
33	O
kg	O
/	O
m2;	O
and	O
a	O
total	B-Observation
body	I-Observation
weight	I-Observation
>	O
50	O
kg	O
(	O
110	O
lbs	O
)	O
.	O

-	O
Subject	O
has	O
the	O
ability	O
to	O
understand	O
the	O
requirements	O
of	O
the	O
study,	O
provide	O
written	O
informed	O
consent	O
and	O
abide	O
by	O
the	O
requirements	O
of	O
the	O
study	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Evidence	O
or	O
history	O
of	O
clinically	O
significant	O
hematological,	B-Condition
renal,	I-Condition
endocrine,	I-Condition
pulmonary,	I-Condition
gastrointestinal,	I-Condition
cardiovascular,	I-Condition
hepatic,	I-Condition
psychiatric,	I-Condition
neurological	I-Condition
or	I-Condition
allergic	I-Condition
disease	I-Condition
(	O
including	O
drug	B-Condition
allergies	I-Condition
but	O
excluding	B-Negation_cue
untreated,	O
asymptomatic,	O
seasonal	B-Condition
allergies	I-Condition
at	O
time	O
of	O
dosing	O
)	O
.	O

-	O
History	O
of	O
febrile	B-Condition
illness	I-Condition
within	O
5	O
days	O
prior	O
to	O
the	O
first	O
study	O
period	O
.	O

-	O
History	O
of	O
regular	O
alcohol	B-Drug
consumption	O
exceeding	O
14	O
drinks	O
/	O
week	O
(	O
1	O
drink	O
=	O
5	O
ounces	O
(	O
150	O
mL	O
)	O
of	O
wine	O
or	O
12	O
ounces	O
(	O
360	O
mL	O
)	O
of	O
beer	O
or	O
1.5	O
ounces	O
(	O
45	O
mL	O
)	O
of	O
hard	O
liquor	O
)	O
within	O
6	O
months	O
of	O
screening	O
.	O

-	O
A	O
positive	O
urine	B-Observation
drug	I-Observation
screen	I-Observation
at	O
screening	O
.	O

-	O
Use	O
of	O
tobacco-	B-Drug
or	I-Drug
nicotine-containing	I-Drug
products	I-Drug
in	O
excess	O
of	O
the	O
equivalent	O
of	O
5	O
cigarettes	O
per	O
day	O
.	O

-	O
Use	O
of	O
prescription	B-Drug
or	I-Drug
nonprescription	I-Drug
drugs	I-Drug
vitamins	B-Drug
and	O
dietary	B-Drug
supplements	I-Drug
within	O
7	O
days	O
or	O
5	O
half-lives	O
(	O
whichever	O
is	O
longer	O
)	O
prior	O
to	O
the	O
first	O
study	O
period	O
.	O

As	O
an	O
exception	B-Negation_cue
,	O
analgesics	B-Drug
,	O
caffeine	B-Drug
and	O
non-pharmacological	B-Procedure_Device
methods	I-Procedure_Device
may	O
be	O
used	O
on	O
the	O
discretion	O
of	O
the	O
investigator	O
to	O
manage	O
symptoms	O
related	O
to	O
the	O
lumbar	O
catheterization	O
.	O

Aspirin	B-Drug
,	O
aspirin	B-Drug
containing	I-Drug
products	I-Drug
and	O
non-steroidal	B-Drug
anti-inflammatory	I-Drug
agents	I-Drug
that	O
affect	O
platelet	O
function	O
should	O
not	O
be	O
used	O
.	O

Other	O
exceptions	O
may	O
be	O
granted	O
by	O
a	O
qualified	O
member	O
of	O
Pfizer	O
study	O
management	O
.	O

-	O
Treatment	O
with	O
an	O
investigational	B-Drug
drug	I-Drug
within	O
30	O
days	O
preceding	O
the	O
first	O
study	O
period	O
.	O

-	O
Pregnant	B-Condition
or	O
nursing	B-Condition
females;	O
females	O
of	O
childbearing	B-Condition
potential	I-Condition
who	O
are	O
unwilling	O
or	O
unable	O
to	O
use	O
an	O
acceptable	O
method	O
of	O
non-hormonal	O
contraception	O
(	O
as	O
will	O
be	O
outlined	O
in	O
the	O
protocol	O
)	O
from	O
at	O
least	O
14	O
days	O
prior	O
to	O
enrollment	O
in	O
the	O
study	O
until	O
completion	O
of	O
the	O
study	O
.	O

-	O
Blood	B-Procedure_Device
donation	I-Procedure_Device
of	O
approximately	O
1	O
pint	O
(	O
500	O
mL	O
)	O
within	O
56	O
days	O
prior	O
to	O
dosing	O
.	O

-	O
Subjects	O
with	O
papilledema	B-Condition
on	O
exam	O
at	O
screening	O
or	O
on	O
Day	O
0	O
.	O

-	O
Subject	O
has	O
any	O
laboratory	B-Observation
values	I-Observation
outside	O
the	O
normal	O
ranges	O
on	O
screening	O
or	O
on	O
Day	O
0	O
which	O
are	O
deemed	O
clinically	O
significant	O
by	O
the	O
investigator	O
.	O

Coagulation	B-Observation
indices	I-Observation
including	O
PT	B-Observation
/	I-Observation
aPTT	I-Observation
and	O
platelet	B-Observation
count	I-Observation
must	O
be	O
normal	O
.	O

-	O
Subjects	O
with	O
lower	B-Condition
spinal	I-Condition
malformations	I-Condition
local	B-Condition
infection	I-Condition
or	O
other	O
abnormalities	B-Condition
that	O
would	O
exclude	B-Negation_cue
lumbar	B-Procedure_Device
puncture	I-Procedure_Device
(	I-Procedure_Device
LP	I-Procedure_Device
)	I-Procedure_Device
.	O

-	O
Subjects	O
who	O
are	O
unwilling	O
or	O
unable	O
to	O
comply	O
with	O
the	O
Lifestyle	O
guidelines	O
presented	O
in	O
the	O
protocol	O
.	O

-	O
Other	O
severe	O
acute	O
or	O
chronic	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
condition	I-Condition
/	I-Condition
status	I-Condition
or	O
laboratory	B-Observation
abnormality	I-Observation
that	O
may	O
increase	O
the	O
risk	O
associated	O
with	O
trial	O
participation	O
or	O
investigational	O
product	O
administration	O
or	O
may	O
interfere	O
with	O
the	O
interpretation	O
of	O
trial	O
results	O
and	O
in	O
the	O
judgment	O
of	O
the	O
investigator,	O
would	O
make	O
the	O
subject	O
inappropriate	O
for	O
entry	O
into	O
this	O
trial	O
.	O

>>NCT00966017	O
Inclusion	O
Criteria:	O
.	O

-	O
Age	B-Observation
45	O
years	O
or	O
older	O
.	O

-	O
No	B-Negation_cue
significant	O
cerebrovascular	B-Condition
disease	I-Condition
-	O
modified	B-Observation
Ischemic	I-Observation
Score	I-Observation
of	O
<	O
4	O
.	O

-	O
Adequate	O
visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
to	O
allow	O
neuropsychological	O
testing	O
.	O

-	O
Screening	B-Observation
laboratory	I-Observation
tests	I-Observation
and	O
ECG	B-Procedure_Device
without	B-Negation_cue
significant	O
abnormalities	B-Observation
that	O
might	O
interfere	O
with	O
the	O
study	O
.	O

Additional	O
Inclusion	O
Criteria	O
for	O
Controls	O
.	O

-	O
MMSE	B-Observation
score	I-Observation
between	O
24	O
and	O
30	O
(	O
unless	O
<	O
8	O
years	O
of	O
educational	O
achievement	O
)	O
.	O

-	O
The	O
following	O
medications	O
are	O
allowed	O
if	O
stable	O
for	O
>	O
1	O
month:	O
antidepressants	B-Drug
(	O
without	B-Negation_cue
anticholinergic	B-Observation
effects	I-Observation
)	O
if	O
not	B-Negation_cue
currently	O
depressed	B-Condition
and	O
no	B-Negation_cue
history	O
of	O
major	B-Condition
depression	I-Condition
for	O
2	O
years;	O
estrogen	B-Drug
replacement	I-Drug
therapy	I-Drug
thyroid	B-Drug
replacement	I-Drug
therapy	I-Drug
as	O
long	O
as	O
individual	O
is	O
euthyroid	B-Condition
;	O
antihypertensives	B-Drug
that	O
do	O
not	O
influence	O
cognitive	O
function	O
.	O

Additional	O
Inclusion	O
Criteria	O
for	O
Individuals	O
with	O
Down	B-Condition
syndrome	I-Condition
.	O

-	O
Family	O
member	O
or	O
caregiver	O
available;	O
caregiver	O
relationship	O
2	O
years	O
or	O
longer	O
.	O

-	O
Karyotype	B-Observation
DX	I-Observation
of	I-Observation
trisomy	I-Observation
or	O
translocation	B-Observation
DS	I-Observation
Mosaic	I-Observation
form	I-Observation
of	O
Down	B-Condition
syndrome	I-Condition
.	O

-	O
English-speaking	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Evidence	O
of	O
neurological	B-Condition
or	I-Condition
other	I-Condition
physical	I-Condition
illness	I-Condition
that	O
could	O
produce	O
cognitive	B-Condition
deterioration	I-Condition
volunteers	O
with	O
a	O
history	O
of	O
TIAs	B-Condition
,	O
carotid	B-Condition
bruits	I-Condition
or	O
lacunes	B-Condition
on	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
will	O
be	O
excluded	O
.	O

-	O
Parkinson's	B-Condition
Disease	I-Condition
.	O

-	O
History	O
of	O
myocardial	B-Condition
infarction	I-Condition
within	O
the	O
previous	O
year	O
or	O
unstable	O
cardiac	B-Condition
disease	I-Condition
.	O

-	O
Uncontrolled	O
hypertension	B-Condition
(	O
systolic	B-Observation
BP	I-Observation
>	O
170	O
or	O
diastolic	B-Observation
BP	I-Observation
>	O
100	O
),	O
history	O
of	O
significant	O
liver	B-Condition
disease	I-Condition
clinically	O
significant	O
pulmonary	B-Condition
disease	I-Condition
diabetes	B-Condition
or	O
cancer	B-Condition
.	O

-	O
Major	O
psychiatric	B-Condition
disorders	I-Condition
such	O
as	O
bipolar	B-Condition
disorder	I-Condition
or	O
schizophrenia	B-Condition
.	O

-	O
Medicines	B-Drug
that	O
could	O
influence	O
psychometric	B-Observation
test	I-Observation
results	I-Observation
.	O

-	O
Use	O
of	O
any	O
of	O
the	O
following	O
drugs:	O
centrally	B-Drug
active	I-Drug
beta-blockers	I-Drug
narcotics	B-Drug
,	O
clonidine	B-Drug
,	O
anti-Parkinsonian	B-Drug
medications	I-Drug
benzodiazepines	B-Drug
,	O
systemic	B-Drug
corticosteroids	I-Drug
medications	B-Drug
with	I-Drug
significant	I-Drug
cholinergic	I-Drug
or	I-Drug
anticholinergic	I-Drug
effects	I-Drug
anti-convulsants	B-Drug
or	O
warfarin	B-Drug
.	O

-	O
Current	O
diagnosis	O
or	O
history	O
of	O
alcoholism	B-Condition
or	O
drug	B-Condition
dependence	I-Condition
.	O

-	O
Evidence	O
of	O
untreated	O
depression	B-Condition
or	O
untreated	O
anxiety	B-Condition
.	O

-	O
Use	O
of	O
any	O
investigational	B-Drug
drugs	I-Drug
within	O
the	O
previous	O
month	O
or	O
longer,	O
depending	O
on	O
drug	O
half-life	O
.	O

-	O
Contraindication	B-Condition
for	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
(	O
eg	O
,	O
metal	B-Procedure_Device
in	O
body,	O
claustrophobia	B-Condition
)	O
.	O

-	O
Diagnosis	O
of	O
possible	O
or	O
probable	O
AD	B-Condition
or	O
any	O
other	O
dementia	B-Condition
(	O
eg	O
,	O
vascular	B-Condition
,	O
Lewy	B-Condition
body	I-Condition
frontotemporal	B-Condition
)	O
or	O
MCI	B-Condition
.	O

Additional	O
Exclusion	O
Criteria	O
for	O
Individuals	O
with	O
Down	B-Condition
syndrome	I-Condition
.	O

-	O
Mosaic	B-Condition
form	I-Condition
of	I-Condition
Down	I-Condition
syndrome	I-Condition
.	O

-	O
History	O
of	O
clinically	O
significant	O
neurological	B-Condition
disorder	I-Condition
or	I-Condition
disease	I-Condition
and	O
Psychiatric	B-Condition
diagnosis	I-Condition
or	O
treatment	B-Procedure_Device
within	O
3	O
months	O
prior	O
to	O
screening.	O

>>NCT00931073	O
Inclusion	O
Criteria:	O
.	O

-	O
Subjects	O
who	O
are	O
willing	O
and	O
able	O
to	O
comply	O
with	O
scheduled	O
visits,	O
treatment	O
plan,	O
laboratory	O
tests	O
and	O
other	O
study	O
procedures	O
.	O

-	O
Subjects	O
must	O
have	O
either	O
a	O
CYP2D6	O
EM	O
(	O
n	O
=	O
12	O
)	O
or	O
PM	O
(	O
n	O
=	O
12	O
)	O
status	O
based	O
on	O
genotyping	O
at	O
screening	O
.	O

-	O
Subjects	O
must	O
have	O
a	O
CYP2C19	O
EM	O
status	O
based	O
on	O
status	O
at	O
screening	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Evidence	O
or	O
history	O
of	O
clinically	O
significant	O
hematological,	B-Condition
renal,	I-Condition
endocrine,	I-Condition
pulmonary,	I-Condition
gastrointestinal,	I-Condition
cardiovascular,	I-Condition
hepatic,	I-Condition
psychiatric,	I-Condition
neurologic	I-Condition
or	I-Condition
allergic	I-Condition
disease	I-Condition
.	O

-	O
Subjects	O
with	O
any	O
history	O
of	O
a	O
previous	O
seizure	B-Condition
or	O
convulsion	B-Condition
or	O
significant	O
head	B-Condition
trauma	I-Condition
.	O

-	O
Subjects	O
specifically	O
allergic	B-Condition
to	O
imidazole	B-Drug
antifungal	I-Drug
agents	I-Drug
.	O

-	O
Subjects	O
specifically	O
allergic	B-Condition
to	O
omeprazole	B-Drug
or	O
other	O
proton	B-Drug
pump	I-Drug
inhibitors	I-Drug
.	O

-	O
Any	O
condition	B-Condition
possibly	O
affecting	O
drug	O
absorption	O
(	O
eg,	O
gastrectomy	B-Procedure_Device
)	O
.	O

-	O
Subjects	O
with	O
hypersensitivity	B-Condition
reactions	O
to	O
Dimebon	B-Drug
or	O
other	O
antihistamines	B-Drug
.	O

-	O
Consumption	O
of	O
grapefruit	B-Drug
or	O
grapefruit	B-Drug
containing	I-Drug
products	I-Drug
within	O
7	O
days	O
prior	O
to	O
the	O
first	O
dose	O
of	O
study	O
medication	O
.	O

-	O
Subjects	O
currently	O
taking	O
omeprazole	B-Drug
,	O
other	O
proton	B-Drug
pump	I-Drug
inhibitors	I-Drug
antacids	B-Drug
,	O
H2	B-Drug
-blockers	I-Drug
or	O
CYP2C19	B-Drug
inhibitors	I-Drug
.	O

-	O
Pregnant	B-Condition
or	O
nursing	B-Condition
females;	O
females	O
of	O
childbearing	B-Condition
potential	I-Condition
who	O
are	O
unwilling	O
or	O
unable	O
to	O
use	O
an	O
acceptable	O
method	O
of	O
nonhormonal	B-Procedure_Device
contraception	I-Procedure_Device
as	O
outlined	O
in	O
this	O
protocol	O
from	O
at	O
least	O
14	O
days	O
prior	O
to	O
the	O
first	O
dose	O
of	O
study	O
medication	O
.	O

>>NCT00884533	O
Inclusion	O
Criteria:	O
.	O

-	O
Healthy	B-Condition
male	O
and	O
female	O
volunteers	O
aged	B-Observation
between	O
18	O
and	O
45	O
.	O

-	O
Female	O
of	O
non	B-Condition
child	I-Condition
bearing	I-Condition
potential	I-Condition
or	O
if	O
of	O
child	B-Condition
bearing	I-Condition
potential	I-Condition
they	O
must	O
use	O
adequate	O
contraception	O
for	O
the	O
duration	O
of	O
the	O
study	O
up	O
until	O
14	O
days	O
after	O
the	O
last	O
dose	O
.	O

-	O
Body	B-Observation
weight	I-Observation
greater	O
than	O
or	O
equal	O
to	O
45	O
kg	O
and	O
BMI	B-Observation
within	O
the	O
range	O
19	O
-	O
32	O
inclusive	O
.	O

-	O
Subjects	O
must	O
provide	O
full	O
written	O
informed	O
consent	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Cardiac	B-Condition
conduction	I-Condition
abnormalities	I-Condition
.	O

-	O
Any	O
history	O
of	O
myocardial	B-Condition
infarction	I-Condition
syncope	B-Condition
or	O
cardiac	B-Condition
arrhythmias	I-Condition
or	O
a	O
history	O
of	O
uncontrolled	O
hypertension	B-Condition
or	O
unstable	O
heart	B-Condition
disease	I-Condition
.	O

-	O
Subjects	O
with	O
a	O
systolic	B-Observation
blood	I-Observation
pressure	I-Observation
outside	O
the	O
range	O
of	O
90	O
to	O
150	O
mmHg	O
or	O
diastolic	B-Observation
blood	I-Observation
pressure	I-Observation
outside	O
the	O
range	O
of	O
50	O
to	O
100	O
mmHg	O
.	O

-	O
Subjects	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
QTc	B-Condition
prolongation	I-Condition
or	O
unexplained	O
cardiac	B-Condition
arrest	I-Condition
.	O

-	O
Has	O
a	O
history	O
of	O
illicit	B-Drug
drug	I-Drug
use	O
or	O
alcohol	B-Condition
abuse	I-Condition
within	O
the	O
past	O
year	O
or	O
a	O
positive	O
pre-study	B-Observation
test	I-Observation
for	O
alcohol,	B-Condition
cotinine	I-Condition
or	I-Condition
drugs	I-Condition
of	I-Condition
abuse	I-Condition
at	O
Screening	O
or	O
prior	O
to	O
the	O
start	O
of	O
dosing	O
.	O

-	O
Alanine	B-Observation
aminotransferase	I-Observation
(	I-Observation
ALT	I-Observation
)	I-Observation
aspartate	B-Observation
aminotransferase	I-Observation
(	I-Observation
AST	I-Observation
)	I-Observation
or	O
alkaline	B-Observation
phosphatase	I-Observation
values	I-Observation
greater	O
than	O
2.5	O
times	O
the	O
ULN,	O
total	B-Observation
bilirubin	I-Observation
values	I-Observation
>	O
1.5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
or	O
history	O
of	O
severe	O
hepatobiliary	B-Condition
disease	I-Condition
(	O
eg	O
hepatitis	B-Condition
B	I-Condition
or	I-Condition
C	I-Condition
or	I-Condition
cirrhosis	I-Condition
Child-Pugh	B-Condition
Class	I-Condition
B	I-Condition
/	I-Condition
C	I-Condition
)	O
.	O

-	O
A	O
positive	O
test	O
at	O
Screening	O
for	O
Hepatitis	B-Observation
B	I-Observation
Hepatitis	B-Observation
C	I-Observation
or	O
Human	B-Observation
Immunodeficiency	I-Observation
Virus	I-Observation
(	I-Observation
HIV	I-Observation
)	I-Observation
.	O

-	O
Use	O
of	O
any	O
agents	B-Drug
that	O
are	O
known	O
to	O
inhibit	O
or	O
induce	O
cytochrome	B-Drug
CYP3A4	I-Drug
enzymes	I-Drug
within	O
7	O
days	O
prior	O
to	O
the	O
first	O
dose	O
of	O
study	O
drug	O
(	O
including	O
foods	O
or	O
supplements	O
such	O
as	O
grapefruit-containing	B-Drug
products	I-Drug
mustard	B-Drug
greens	I-Drug
kale	B-Drug
,	O
kohlrabi	B-Drug
,	O
broccoli	B-Drug
,	O
collard	B-Drug
greens	I-Drug
brussel	B-Drug
sprouts	I-Drug
watercress	B-Drug
,	O
charbroiled	B-Drug
meats	I-Drug
or	O
St.	B-Drug
John's	I-Drug
Wort	I-Drug
.	O

-	O
Use	O
of	O
any	O
prescription	B-Drug
or	I-Drug
non-prescription	I-Drug
drugs	I-Drug
in	O
particular	O
drugs	O
known	O
to	O
inhibit	O
or	O
induce	O
CYP2C8	B-Drug
,	O
vitamins	B-Drug
(	O
exceptions	O
may	O
be	O
considered	O
on	O
a	O
case-by-case	O
basis	O
with	O
the	O
GSK	O
medical	O
monitor	O
),	O
herbal	B-Drug
and	O
dietary	B-Drug
supplements	I-Drug
within	O
fourteen	O
days	O
prior	O
to	O
the	O
first	O
dose	O
of	O
study	O
drug	O
.	O

-	O
Lactating	B-Condition
or	O
pregnant	B-Condition
females	O
.	O

>>NCT00857415	O
Inclusion	O
Criteria	O
(	O
autopsy	O
cohort	O
):	O
.	O

-	O
Have	O
a	O
projected	O
life	B-Observation
expectancy	I-Observation
of	O
<=	O
6	O
months	O
as	O
determined	O
by	O
the	O
principal	O
investigator	O
(	O
eg	O
terminal	O
medical	B-Condition
condition	I-Condition
)	O
or	O
are	O
already	O
enrolled	O
in	O
a	O
longitudinal	O
study	O
of	O
aging	O
with	O
an	O
autopsy	O
component;	O
.	O

-	O
Can	O
tolerate	O
a	O
10	O
minute	O
PET	B-Procedure_Device
scan	I-Procedure_Device
and	O
.	O

-	O
Give	O
informed	O
consent	O
for	O
study	O
procedures	O
and	O
brain	O
donation	O
consistent	O
with	O
the	O
legal	O
requirements	O
of	O
the	O
State	O
in	O
which	O
they	O
are	O
enrolled	O
and	O
the	O
State	O
in	O
which	O
they	O
die	O
.	O

Inclusion	O
Criteria	O
(	O
specificity	O
cohort	O
):	O
.	O

-	O
Cognitively	B-Condition
and	I-Condition
neurologically	I-Condition
health	I-Condition
males	O
and	O
females	O
18	O
to	O
40	O
years	O
of	O
age	B-Observation
;	O
.	O

-	O
Who	O
had	O
no	B-Negation_cue
known	O
risk	B-Condition
factors	I-Condition
for	O
AD	B-Condition
,	O
including:	O
.	O

-	O
Known	O
genetic	O
risk	B-Condition
factors	I-Condition
for	O
AD	B-Condition
,	O
including	O
an	O
ApoE	B-Condition
4	I-Condition
allele	I-Condition
(	O
note:	O
ApoE	O
genotype	O
was	O
determined	O
after	O
enrollment	O
and	O
was	O
not	O
disclosed	O
to	O
healthy	O
control	O
subjects	O
)	O
.	O

Scans	O
from	O
subjects	O
carrying	B-Condition
an	I-Condition
ApoE	I-Condition
4	I-Condition
allele	I-Condition
were	O
not	B-Negation_cue
included	O
in	O
the	O
primary	O
specificity	O
analysis	O
but	O
were	O
included	O
in	O
an	O
exploratory	O
analysis;	O
.	O

-	O
First	O
degree	O
relative	O
with	O
a	O
known	O
progressive	B-Condition
dementing	I-Condition
disorder	I-Condition
.	O

-	O
History	O
of	O
cognitive	B-Condition
decline	I-Condition
.	O

-	O
History	O
of	O
neurologic,	B-Condition
neurodegenerative	I-Condition
or	I-Condition
psychiatric	I-Condition
disease	I-Condition
.	O

-	O
History	O
of	O
head	B-Condition
trauma	I-Condition
or	O
.	O

-	O
Evidence	O
of	O
brain	B-Condition
abnormality	I-Condition
on	O
a	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
.	O

-	O
Who	O
performed	O
in	O
an	O
age-appropriate	O
normal	O
range	O
on	O
the	O
Wechsler	B-Observation
Logical	I-Observation
Memory	I-Observation
I	I-Observation
&	I-Observation
II	I-Observation
story	O
A;	O
.	O

-	O
Who	O
could	O
tolerate	O
a	O
10	O
-minute	O
PET	B-Procedure_Device
scan	I-Procedure_Device
and	O
.	O

-	O
Who	O
provided	O
informed	O
consent	O
before	O
any	O
study	O
procedures	O
were	O
performed	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Have	O
primary	O
brain	B-Condition
tumor	I-Condition
known	O
metastases	B-Condition
to	O
the	O
brain,	O
central	B-Condition
nervous	I-Condition
system	I-Condition
(	I-Condition
CNS	I-Condition
)	I-Condition
lymphoma	I-Condition
.	O

-	O
Have	O
any	O
major,	O
focal	B-Condition
structural	I-Condition
loss	I-Condition
of	I-Condition
brain	I-Condition
matter	I-Condition
.	O

-	O
Are	O
aggressively	O
being	O
treated	O
with	O
life	B-Procedure_Device
sustaining	I-Procedure_Device
measures	I-Procedure_Device
(	O
eg	O
currently	O
on	O
respirator	B-Procedure_Device
;	O
receiving	O
high	O
dose	O
chemotherapy	B-Drug
);	O
.	O

-	O
Have	O
a	O
clinically	O
significant	O
infectious	B-Condition
disease	I-Condition
including	O
Acquired	B-Condition
Immune	I-Condition
Deficiency	I-Condition
Syndrome	I-Condition
(	I-Condition
AIDS	I-Condition
)	I-Condition
Human	B-Condition
Immunodeficiency	I-Condition
Virus	I-Condition
(	I-Condition
HIV	I-Condition
)	I-Condition
infection	I-Condition
previous	O
positive	O
test	O
for	O
hepatitis	B-Observation
or	O
HIV	B-Observation
or	O
Creutzfeldt-Jakob	B-Observation
disease	I-Observation
(	I-Observation
CJD	I-Observation
)	I-Observation
.	O

-	O
Are	O
receiving	O
any	O
investigational	B-Drug
medications	I-Drug
or	O
have	O
participated	O
in	O
a	O
trial	O
with	O
investigational	B-Drug
medications	I-Drug
within	O
the	O
last	O
30	O
days;	O
.	O

-	O
Have	O
ever	O
participated	O
in	O
an	O
experimental	O
study	O
with	O
an	O
amyloid	B-Drug
targeting	I-Drug
agent	I-Drug
(	O
eg	O
anti-amyloid	B-Drug
immunotherapy	I-Drug
secretase	B-Drug
inhibitor	I-Drug
);	O
.	O

-	O
Have	O
had	O
a	O
radiopharmaceutical	B-Procedure_Device
imaging	I-Procedure_Device
or	O
treatment	B-Procedure_Device
procedure	I-Procedure_Device
within	O
7	O
days	O
prior	O
to	O
the	O
study	O
imaging	O
session;	O
or	O
.	O

-	O
Are	O
females	O
of	O
childbearing	B-Condition
potential	I-Condition
who	O
are	O
pregnant	B-Condition
or	O
not	O
using	O
adequate	O
contraception	O
.	O

>>NCT00825084	O
Inclusion	O
Criteria:	O
.	O

-	O
Healthy	B-Condition
male	O
and	O
/	O
or	O
female	O
subjects	O
between	O
the	O
ages	B-Observation
of	O
18	O
and	O
55	O
years,	O
inclusive	O
(	O
Healthy	B-Condition
is	O
defined	O
as	O
no	B-Negation_cue
clinically	O
relevant	O
abnormalities	B-Condition
identified	O
by	O
a	O
detailed	O
medical	B-Observation
history	I-Observation
full	B-Observation
physical	I-Observation
examination	I-Observation
including	O
blood	B-Observation
pressure	I-Observation
and	O
pulse	B-Observation
rate	I-Observation
measurement	I-Observation
12	B-Procedure_Device
-lead	I-Procedure_Device
ECG	I-Procedure_Device
and	O
clinical	B-Observation
laboratory	I-Observation
tests	I-Observation
)	O
.	O

-	O
Body	B-Observation
Mass	I-Observation
Index	I-Observation
(	I-Observation
BMI	I-Observation
)	I-Observation
of	O
17.5	O
to	O
30.5	O
kg	O
/	O
m2;	O
and	O
a	O
total	B-Observation
body	I-Observation
weight	I-Observation
within	O
the	O
range	O
of	O
50	O
to	O
100	O
kg	O
.	O

-	O
An	O
informed	O
consent	O
document	O
signed	O
and	O
dated	O
by	O
the	O
subject	O
or	O
a	O
legally-acceptable	O
representative	O
.	O

-	O
Subjects	O
who	O
are	O
willing	O
and	O
able	O
to	O
comply	O
with	O
scheduled	O
visits,	O
treatment	O
plan,	O
laboratory	O
tests	O
and	O
other	O
study	O
procedures	O
.	O

-	O
Japanese	O
subjects	O
must	O
have	O
four	O
Japanese	O
grandparents	O
who	O
were	O
born	O
in	O
Japan	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Asian	O
or	O
Polynesian	O
subjects	O
in	O
Western	O
subject	O
groups	O
.	O

-	O
Any	O
condition	B-Condition
possibly	O
affecting	O
drug	B-Observation
absorption	I-Observation
(	O
eg	O
,	O
gastrectomy	B-Procedure_Device
,	O
active	B-Procedure_Device
peptic	I-Procedure_Device
ulcer	I-Procedure_Device
within	O
last	O
3	O
months	O
)	O
.	O

-	O
History	O
of	O
regular	O
alcohol	B-Drug
consumption	O
exceeding	O
an	O
average	O
of	O
7	O
drinks	O
/	O
week	O
for	O
females	O
and	O
14	O
drinks	O
/	O
week	O
for	O
men	O
(	O
1	O
drink	O
=	O
5	O
ounces	O
(	O
150	O
mL	O
)	O
of	O
wine	O
or	O
12	O
ounces	O
(	O
360	O
mL	O
)	O
of	O
beer	O
or	O
1.5	O
ounces	O
(	O
45	O
mL	O
)	O
of	O
hard	O
liquor	O
)	O
within	O
6	O
months	O
of	O
screening	O
.	O

-	O
Subjects	O
who,	O
by	O
history,	O
smoke	B-Observation
more	O
than	O
5	O
cigarettes	O
per	O
day	O
.	O

-	O
Treatment	O
with	O
an	O
investigational	B-Drug
drug	I-Drug
within	O
30	O
days	O
or	O
5	O
half-lives	O
(	O
whichever	O
is	O
longer	O
)	O
preceding	O
the	O
first	O
dose	O
of	O
study	O
medication	O
.	O

-	O
12	B-Procedure_Device
-lead	I-Procedure_Device
ECG	I-Procedure_Device
demonstrating	O
QTc	B-Observation
>	O
450	O
msec	O
at	O
screening	O
.	O

If	O
QTc	B-Observation
exceeds	O
450	O
msec,	O
the	O
ECG	O
may	O
be	O
repeated	O
two	O
more	O
times	O
and	O
the	O
average	O
of	O
the	O
three	O
QTc	O
values	O
should	O
be	O
used	O
to	O
determine	O
the	O
subject's	O
eligibility	O
.	O

-	O
Pregnant	B-Condition
or	O
nursing	B-Condition
females;	O
females	O
of	O
childbearing	B-Condition
potential	I-Condition
who	O
are	O
unwilling	O
or	O
unable	O
to	O
use	O
an	O
acceptable	O
method	O
of	O
nonhormonal	B-Drug
contraception	I-Drug
as	O
outlined	O
in	O
this	O
protocol	O
from	O
at	O
least	O
14	O
days	O
prior	O
to	O
the	O
first	O
dose	O
of	O
study	O
medication	O
.	O

-	O
Use	O
of	O
prescription	B-Drug
or	I-Drug
nonprescription	I-Drug
drugs	I-Drug
vitamins	B-Drug
and	O
dietary	B-Drug
supplements	I-Drug
within	O
7	O
days	O
or	O
5	O
half-lives	O
(	O
whichever	O
is	O
longer	O
)	O
of	O
the	O
first	O
dose	O
of	O
study	O
medication	O
.	O

>>NCT00751907	O
Inclusion	O
Criteria:	O
.	O

-	O
Adult	O
(	O
ages	B-Observation
40	O
-	O
65	O
)	O
children	O
of	O
parent	O
with	O
documented	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Current	O
use	O
of	O
cholesterol	B-Drug
lowering	I-Drug
medication	I-Drug
.	O

-	O
History	O
of	O
liver	B-Condition
disease	I-Condition
.	O

-	O
History	O
of	O
adverse	B-Condition
reaction	I-Condition
to	O
statin	B-Drug
medications	I-Drug
.	O

-	O
Elevated	O
lab	B-Observation
values	I-Observation
(	O
CK	B-Observation
and	O
creatinine	B-Observation
)	O
.	O

-	O
Use	O
of	O
medications	B-Drug
that	O
counteract	O
with	O
atorvastatin	B-Drug
.	O

-	O
History	O
of	O
dementia	B-Condition
.	O

-	O
Currently	O
pregnant	B-Condition
.	O

-	O
Use	O
of	O
large	O
quantities	O
of	O
grapefruit	B-Drug
juice	I-Drug
(	O
more	O
than	O
1	O
quart	O
/	O
day	O
)	O
.	O

-	O
Current	O
involvement	O
in	O
another	O
investigational	B-Drug
drug	I-Drug
study	O
.	O

-	O
Contraindications	B-Condition
to	O
MRI	B-Procedure_Device
.	O

>>NCT01421056	O
Inclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
amnestic	O
or	O
non-amnestic	O
Mild	O
Cognitive	B-Condition
Impairment	I-Condition
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
score	I-Observation
higher	O
than	O
24	O
at	O
screening	O
.	O

-	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
of	O
the	O
brain	O
at	O
screening	O
with	O
fluid-attenuation	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
and	O
T2*-weighted	O
gradient-recalled-echo	O
(	O
GRE	O
)	O
sequences	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
the	O
(	O
DSM-IV-TR	B-Observation
)	O
or	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
.	O

-	O
Any	O
medical	B-Condition
condition	I-Condition
that	O
could	O
explain	O
the	O
patients	O
cognitive	B-Condition
deficits	I-Condition
.	O

-	O
CT	B-Procedure_Device
or	O
MRI	B-Procedure_Device
brain	I-Procedure_Device
imaging	I-Procedure_Device
results	O
obtained	O
within	O
12	O
months	O
prior	O
to	O
baseline	O
showing	O
evidence	O
of	O
infection	B-Condition
,	O
infarction	B-Condition
or	O
focal	B-Condition
lesions	I-Condition
of	O
clinical	O
significance	O
.	O

-	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
at	O
screening	O
showing	O
more	O
than	O
4	O
cerebral	B-Condition
microhemorrhages	I-Condition
(	O
lesions	B-Condition
with	O
diameter	B-Observation
<=	O
10	O
mm	O
)	O
.	O

-	O
Geriatric	B-Observation
Depression	I-Observation
Scale	I-Observation
(	I-Observation
30	I-Observation
-point	I-Observation
scale	I-Observation
)	I-Observation
score	I-Observation
>	O
9	O
at	O
screening	O
.	O

-	O
History	O
of	O
stroke	B-Condition
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
ischemic	I-Observation
scale	I-Observation
score	I-Observation
>	O
4	O
at	O
screening	O
.	O

-	O
Women	O
of	O
childbearing	B-Condition
potential	I-Condition
.	O

-	O
Vitamin	B-Condition
B12	I-Condition
or	I-Condition
folate	I-Condition
deficiency	I-Condition
.	O

-	O
Diagnosis	O
of	O
schizophrenia	B-Condition
or	O
recurrent	O
mood	B-Condition
disorder	I-Condition
(	O
including	O
unipolar	B-Condition
and	I-Condition
bipolar	I-Condition
disorders	I-Condition
)	O
within	O
3	O
years	O
of	O
screening	O
.	O

-	O
Current	O
diagnosis	O
of	O
peptic	B-Condition
ulcer	I-Condition
or	O
gastrointestinal	B-Condition
bleeding	I-Condition
within	O
the	O
last	O
year	O
and	O
/	O
or	O
chronic	O
inflammatory	B-Condition
bowel	I-Condition
disease	I-Condition
.	O

-	O
Concomitant	O
use	O
of	O
donepezil	B-Drug
at	O
doses	O
>	O
5	O
mg	O
/	O
day	O
or	O
other	O
cholinesterase	B-Drug
inhibitors	I-Drug
(	O
rivastigmine	B-Drug
or	O
galantamine	B-Drug
)	O
at	O
any	O
dose	O
.	O

-	O
Concomitant	O
use	O
of	O
memantine	B-Drug
at	O
dose	O
>	O
20	O
mg	O
/	O
day	O
.	O

-	O
Concomitant	O
use	O
of	O
psychoactive	B-Drug
drugs	I-Drug
(	O
sedatives	B-Drug
,	O
hypnotics	B-Drug
,	O
etc	O
)	O
.	O

>>NCT02353845	O
Inclusion	O
Criteria:	O
.	O

-	O
Memory	B-Condition
loss	I-Condition
complaint	I-Condition
and	O
confirmed	O
by	O
an	O
informant	O
.	O

-	O
Cognitive	B-Condition
impairment	I-Condition
in	O
single	O
or	O
multiple	O
domains,	O
adjusted	O
for	O
age	O
and	O
education	O
.	O

-	O
Normal	O
or	O
near-normal	O
performance	O
on	O
general	B-Observation
cognitive	I-Observation
function	I-Observation
and	O
no	O
or	O
minimum	O
impairment	B-Condition
of	I-Condition
daily	I-Condition
life	I-Condition
activities	I-Condition
.	O

-	O
A	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
score	I-Observation
is	O
0.5	O
and	O
consistent	O
with	O
the	O
boundary	O
of	O
neuropsychological	O
scale	O
.	O

-	O
Failure	B-Negation_cue
to	O
meet	O
the	O
criteria	O
for	O
dementia	B-Condition
.	O

-	O
Must	O
be	O
able	O
to	O
accept	O
examination	O
of	O
MRI,	O
sight	O
and	O
hearing	O
allow	O
to	O
complete	O
test	O
.	O

-	O
Right	O
handedness	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Other	O
diseases	B-Condition
that	O
cause	O
cognitive	B-Condition
impairment	I-Condition
such	O
as	O
thyroid	B-Condition
disease	I-Condition
stroke	B-Condition
and	O
so	O
on	O
.	O

-	O
People	O
who	O
have	O
severe	O
visual	B-Condition
and	I-Condition
hearing	I-Condition
impairment	I-Condition
.	O

>>NCT02363504	O
Inclusion	O
Criteria:	O
.	O

For	O
the	O
patients:	O
.	O

-	O
diagnosis	O
of	O
prodromal	O
Alzheimer's	B-Condition
disease	I-Condition
based	O
on	O
the	O
latest	O
research	O
criteria	O
(	O
clinical	O
assessment	O
at	O
the	O
memory	O
clinic	O
:	O
presence	O
of	O
at	O
least	O
a	O
memory	B-Condition
impairment	I-Condition
memory	B-Condition
complaints	I-Condition
expressed	O
by	O
the	O
patient	O
or	O
informant,	O
no	B-Negation_cue
problems	B-Condition
in	I-Condition
daily	I-Condition
life	I-Condition
functioning	I-Condition
no	B-Negation_cue
dementia	B-Condition
and	O
presence	O
of	O
biomarkers	B-Observation
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
score	I-Observation
of	O
0.5	O
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
>=	O
23	O
and	O
being	O
mentally	B-Condition
competent	I-Condition
(	O
in	O
general,	O
individuals	O
with	O
a	O
MMSE	B-Observation
>=	O
18	O
are	O
considered	O
mentally	O
competent	O
)	O
.	O

-	O
Age	B-Observation
:	O
between	O
60	O
and	O
85	O
years	O
old	O
.	O

-	O
50%	O
female	O
.	O

-	O
Right-handedness	O
.	O

-	O
Average	O
level	O
of	O
education	O
.	O

-	O
Informed	O
consent	O
before	O
participation	O
in	O
the	O
study	O
.	O

For	O
the	O
healthy	O
older	O
individuals:	O
.	O

-	O
Average	O
neuropsychological	B-Observation
test	I-Observation
results	I-Observation
in	O
accordance	O
with	O
normative	O
data,	O
corrected	O
for	O
age,	O
education	O
and	O
gender	O
.	O

-	O
No	B-Negation_cue
substantial	B-Condition
memory	I-Condition
complaints	I-Condition
(	O
according	O
to	O
the	O
participant	O
)	O
.	O

-	O
Age	B-Observation
:	O
between	O
60	O
and	O
85	O
years	O
old	O
.	O

-	O
50%	O
female	O
.	O

-	O
Right-handedness	O
.	O

-	O
Average	O
level	O
of	O
education	O
.	O

-	O
Informed	O
consent	O
before	O
participation	O
in	O
the	O
study	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Reduced	B-Condition
vision	I-Condition
.	O

-	O
Psychoactive	B-Drug
medication	I-Drug
use	O
.	O

-	O
Abuse	B-Condition
of	I-Condition
alcohol	I-Condition
and	I-Condition
drugs	I-Condition
.	O

-	O
Cognitive	B-Condition
impairment	I-Condition
due	O
to	O
alcohol	B-Condition
/	I-Condition
drug	I-Condition
abuse	I-Condition
or	O
abuse	B-Condition
of	I-Condition
other	I-Condition
substances	I-Condition
.	O

-	O
Past	O
or	O
present	O
psychiatric	B-Condition
or	I-Condition
neurological	I-Condition
disorders	I-Condition
(	O
major	B-Condition
depression	I-Condition
schizophrenia	B-Condition
,	O
bipolar	B-Condition
disorder	I-Condition
psychotic	B-Condition
disorder	I-Condition
(	O
or	O
treatment	O
for	O
it	O
),	O
epilepsy	B-Condition
,	O
stroke	B-Condition
,	O
Parkinson's	B-Condition
disease	I-Condition
multiple	B-Condition
sclerosis	I-Condition
brain	B-Procedure_Device
surgery	I-Procedure_Device
brain	B-Condition
trauma	I-Condition
electroshock	B-Procedure_Device
therapy	I-Procedure_Device
kidney	B-Procedure_Device
dialysis	I-Procedure_Device
Menire's	B-Condition
disease	I-Condition
brain	B-Condition
infections	I-Condition
)	O
.	O

-	O
Major	O
vascular	B-Condition
disorders	I-Condition
(	O
eg	O
stroke	B-Condition
)	O
.	O

-	O
Heart	B-Condition
diseases	I-Condition
or	O
pacemakers	B-Procedure_Device
.	O

-	O
Contraindications	B-Condition
for	O
scanning	B-Procedure_Device
(	O
eg	O
brain	B-Procedure_Device
surgery	I-Procedure_Device
cardiac	B-Procedure_Device
pacemaker	I-Procedure_Device
metal	B-Procedure_Device
implants	I-Procedure_Device
claustrophobia	B-Condition
,	O
body	B-Procedure_Device
tattoos	I-Procedure_Device
)	O
.	O

>>NCT02420756	O
Inclusion	O
Criteria:	O
.	O

-	O
65	O
and	O
older;	O
.	O

-	O
Medicare	O
beneficiary;	O
.	O

-	O
Diagnosis	O
of	O
MCI	B-Condition
or	O
dementia	B-Condition
,	O
according	O
to	O
DSM-IV	B-Observation
and	O
/	O
or	O
National	B-Observation
Institutes	I-Observation
of	I-Observation
Aging-Alzheimer's	I-Observation
Association	I-Observation
criteria	I-Observation
verified	O
by	O
a	O
dementia	O
specialist	O
within	O
24	O
months	O
(	O
American	O
Psychiatric	O
Association	O
.	O

2000;	O
McKhann	O
et	O
al	O
.	O

2011;	O
Albert	O
et	O
al	O
.	O

2011	O
);	O
.	O

-	O
Meets	O
AUC:	O
.	O

-	O
Cognitive	B-Condition
complaint	I-Condition
verified	O
by	O
objectively	O
confirmed	O
cognitive	B-Condition
impairment	I-Condition
.	O

-	O
The	O
etiologic	B-Condition
cause	I-Condition
of	O
cognitive	B-Condition
impairment	I-Condition
is	O
uncertain	O
after	O
a	O
comprehensive	O
evaluation	O
by	O
a	O
dementia	O
specialist,	O
including	O
general	B-Procedure_Device
medical	I-Procedure_Device
and	I-Procedure_Device
neurological	I-Procedure_Device
examination	I-Procedure_Device
mental	B-Procedure_Device
status	I-Procedure_Device
testing	I-Procedure_Device
including	O
standard	O
measures	O
of	O
cognitive	B-Condition
impairment	I-Condition
laboratory	B-Observation
testing	I-Observation
and	O
structural	B-Procedure_Device
neuroimaging	I-Procedure_Device
as	O
below;	O
.	O

-	O
Alzheimer's	B-Condition
disease	I-Condition
is	O
a	O
diagnostic	O
consideration;	O
.	O

-	O
Knowledge	O
of	O
amyloid	B-Observation
PET	I-Observation
status	I-Observation
is	O
expected	O
to	O
alter	O
diagnosis	O
and	O
management	O
.	O

-	O
Head	B-Procedure_Device
MRI	I-Procedure_Device
and	O
/	O
or	O
CT	B-Procedure_Device
within	O
24	O
months	O
prior	O
to	O
enrollment;	O
.	O

-	O
Clinical	B-Observation
laboratory	I-Observation
assessment	I-Observation
(	O
complete	B-Observation
blood	I-Observation
count	I-Observation
[CBC]	I-Observation
standard	B-Observation
blood	I-Observation
chemistry	I-Observation
profile	I-Observation
thyroid	B-Observation
stimulating	I-Observation
hormone	I-Observation
[TSH]	I-Observation
vitamin	B-Observation
B12	I-Observation
)	O
within	O
the	O
12	O
months	O
prior	O
to	O
enrollment;	O
.	O

-	O
Able	O
to	O
tolerate	O
amyloid	B-Procedure_Device
PET	I-Procedure_Device
required	O
by	O
protocol,	O
to	O
be	O
performed	O
at	O
a	O
participating	O
PET	O
facility;	O
.	O

-	O
English	O
or	O
Spanish	O
speaking	O
(	O
for	O
the	O
purposes	O
of	O
informed	O
consent	O
);	O
.	O

-	O
Willing	O
and	O
able	O
to	O
provide	O
consent	O
.	O

Consent	O
may	O
be	O
by	O
proxy	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Normal	O
cognition	B-Condition
or	O
subjective	B-Condition
complaints	I-Condition
that	O
are	O
not	B-Negation_cue
verified	O
by	O
cognitive	B-Procedure_Device
testing	I-Procedure_Device
.	O

-	O
Knowledge	O
of	O
amyloid	O
status,	O
in	O
the	O
opinion	O
of	O
the	O
referring	O
dementia	O
expert,	O
may	O
cause	O
significant	O
psychological	B-Condition
harm	I-Condition
or	O
otherwise	O
negatively	O
impact	O
the	O
patient	O
or	O
family	O
.	O

-	O
Scan	O
is	O
being	O
ordered	O
solely	O
based	O
on	O
a	O
family	O
history	O
of	O
dementia	B-Condition
,	O
presence	O
of	O
apolipoprotein	B-Drug
E	I-Drug
or	O
in	O
lieu	O
of	O
genotyping	O
for	O
suspected	O
autosomal	O
mutation	O
carriers	O
.	O

-	O
Scan	O
being	O
ordered	O
for	O
nonmedical	O
purposes	O
(	O
eg	O
,	O
legal,	O
insurance	O
coverage	O
or	O
employment	O
screening	O
)	O
.	O

-	O
Cancer	B-Condition
requiring	O
active	O
therapy	B-Procedure_Device
(	O
excluding	B-Negation_cue
non-melanoma	B-Condition
skin	I-Condition
cancer	I-Condition
);	O
.	O

-	O
Hip	B-Condition
/	I-Condition
pelvic	I-Condition
fracture	I-Condition
within	O
the	O
12	O
months	O
prior	O
to	O
enrollment;	O
.	O

-	O
Body	B-Observation
weight	I-Observation
exceeds	O
PET	O
scanner	O
weight	O
limit;	O
.	O

-	O
Life	B-Observation
expectancy	I-Observation
less	O
than	O
24	O
months	O
based	O
on	O
medical	B-Condition
co-morbidities	I-Condition
.	O

-	O
Residence	O
in	O
a	O
skilled	O
nursing	O
facility	O
.	O

>>NCT02120664	O
Inclusion	O
Criteria:	O
.	O

-	O
Cognitively	B-Condition
Normal	I-Condition
Subjects	O
.	O

-	O
Males	O
or	O
females	O
>=	O
21	O
and	O
<=	O
45	O
years	O
of	O
age	B-Observation
.	O

-	O
Mini-mental	B-Observation
state	I-Observation
examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
>=	O
29	O
.	O

-	O
Clinically	O
Diagnosed	O
AD	B-Condition
Subject	O
.	O

-	O
Males	O
or	O
females	O
>=	O
50	O
years	O
of	O
age	B-Observation
.	O

-	O
Meet	O
clinical	O
criteria	O
for	O
dementia	B-Condition
due	O
to	O
probable	O
AD	B-Condition
.	O

-	O
MMSE	B-Observation
>=	O
16	O
and	O
<=	O
26	O
.	O

-	O
Possible	O
AD	B-Condition
Subject	O
.	O

-	O
Males	O
or	O
females	O
>=	O
50	O
years	O
of	O
age	B-Observation
.	O

-	O
Meet	O
clinical	O
criteria	O
for	O
dementia	B-Condition
due	O
to	O
possible	O
AD	B-Condition
.	O

-	O
MMSE	B-Observation
>=	O
16	O
and	O
<=	O
26	O
.	O

-	O
MCI	B-Condition
Subject	O
.	O

-	O
Males	O
or	O
females	O
>=	O
60	O
years	O
of	O
age	B-Observation
with	O
cognitive	B-Condition
impairment	I-Condition
(	O
not	B-Negation_cue
dementia	B-Condition
)	O
.	O

-	O
MMSE	B-Observation
>	O
24	O
and	O
<	O
29	O
.	O

-	O
At	O
Risk	O
Elderly	O
Subject	O
.	O

-	O
Cognitively	B-Condition
normal	I-Condition
males	O
or	O
females	O
that	O
are	O
known	O
ApoE4	O
carriers	O
and	O
>=	O
75	O
years	O
of	O
age	B-Observation
.	O

-	O
MMSE	B-Observation
>=	O
27	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Have	O
had	O
or	O
currently	O
have	O
a	O
diagnosis	O
of	O
neurodegenerative	B-Condition
disorders	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
.	O

-	O
Have	O
a	O
current	O
serious	O
or	O
unstable	O
illness	B-Condition
that	O
could	O
interfere	O
with	O
completion	O
of	O
the	O
study	O
.	O

-	O
Subject	O
has	O
a	O
known	O
brain	B-Condition
lesion	I-Condition
pathology	B-Condition
or	O
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
.	O

-	O
Have	O
received	O
or	O
participated	O
in	O
a	O
trial	O
with	O
investigational	B-Drug
medications	I-Drug
in	O
the	O
past	O
30	O
days	O
.	O

-	O
Have	O
had	O
a	O
radiopharmaceutical	B-Procedure_Device
imaging	I-Procedure_Device
or	I-Procedure_Device
treatment	I-Procedure_Device
procedure	O
within	O
7	O
days	O
of	O
study	O
imaging	O
session	O
.	O

-	O
Females	O
of	O
childbearing	B-Condition
potential	I-Condition
who	O
are	O
not	B-Negation_cue
surgically	B-Condition
sterile	I-Condition
not	O
refraining	O
from	O
sexual	O
activity	O
or	O
not	O
using	O
reliable	O
methods	O
of	O
contraception.	O

>>NCT02061878	O
Inclusion	O
Criteria:	O
.	O

-	O
Young	O
healthy	B-Condition
adults	O
(	O
age	B-Observation
21	O
-	O
50	O
)	O
.	O

-	O
APOE3	O
-	O
3	O
genotype	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Contraindications	B-Condition
for	O
blood	B-Procedure_Device
or	I-Procedure_Device
CSF	I-Procedure_Device
sampling	I-Procedure_Device
.	O

-	O
Bleeding	B-Condition
disorder	I-Condition
or	O
taking	O
anticoagulants	B-Drug
antiplatelets	B-Drug
.	O

-	O
Chronic	O
active	O
infection	B-Condition
.	O

-	O
Blood	B-Procedure_Device
donation	I-Procedure_Device
within	O
the	O
past	O
month	O
.	O

-	O
Active	O
drug	B-Condition
/	I-Condition
alcohol	I-Condition
dependence	I-Condition
or	I-Condition
abuse	I-Condition
history	O
with	O
in	O
the	O
last	O
12	O
months	O
.	O

-	O
Thyroid	B-Condition
dysfunction	I-Condition
.	O

-	O
High	O
triglycerides	B-Observation
(	O
>	O
3.5	O
mmol	O
/	O
L	O
)	O
.	O

-	O
High	O
cholesterol	B-Observation
(	O
>	O
4.0	O
mmoL	O
/	O
L	O
)	O
.	O

-	O
Leukopenia	B-Condition
,	O
including	O
low	O
neutrophil	B-Observation
count	I-Observation
(	O
<	O
3	O
x	O
10^9	O
/	O
L	O
)	O
.	O

-	O
Neurological	B-Condition
or	I-Condition
psychiatric	I-Condition
disorders	I-Condition
.	O

-	O
Homeless	O
or	O
prisoner	O
.	O

-	O
Pregnancy	B-Condition
.	O

-	O
Incapable	O
of	O
self-informed	O
consent	O
.	O

-	O
Blood	B-Condition
borne	I-Condition
disease	I-Condition
(	O
HIV	B-Condition
,	O
Hepatitis	B-Condition
)	O
.	O

-	O
Actively	O
smoking	B-Observation
and	O
incapable	B-Negation_cue
of	O
using	O
nicotine	B-Drug
patches	I-Drug
.	O

-	O
Known	O
drug	B-Condition
allergy	I-Condition
to	O
pain	B-Drug
medication	I-Drug
or	O
local	B-Drug
anesthetic	I-Drug
.	O

-	O
Subjects	O
that	O
have	O
participated	O
in	O
another	O
study	O
in	O
the	O
last	O
30	O
days	O
.	O

-	O
Abnormalities	B-Condition
in	O
lumbar	O
spine	O
previously	O
known	O
within	O
12	O
months	O
.	O

-	O
APOE2	O
or	O
APOE4	O
allele	O
.	O

-	O
Abnormal	O
EKG	B-Procedure_Device
.	O

>>NCT02453763	O
Inclusion	O
Criteria:	O
.	O

-	O
right	O
handed	O
(	O
as	O
determined	O
by	O
the	O
Edinburgh	O
battery	O
),	O
.	O

-	O
English	O
as	O
native	O
language	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
appreciable	O
deficits	B-Condition
in	I-Condition
hearing	I-Condition
.	O

-	O
appreciable	O
problems	B-Condition
with	O
articulation,	O
.	O

-	O
appreciable	O
accent	O
schizophrenia	B-Condition
,	O
bipolar	B-Condition
disorder	I-Condition
or	O
major	B-Condition
depression	I-Condition
.	O

-	O
any	O
neurological	B-Condition
disorder	I-Condition
associated	O
with	O
cognitive	B-Condition
impairment	I-Condition
or	O
neuroanatomic	B-Condition
abnormality	I-Condition
.	O

-	O
language-based	O
learning	B-Condition
disorder	I-Condition
.	O

-	O
any	O
implanted	B-Procedure_Device
metal	I-Procedure_Device
device	I-Procedure_Device
(	O
precludes	O
use	O
of	O
tDCS	O
),	O
any	O
implanted	B-Procedure_Device
cardiac	I-Procedure_Device
pacemaker	I-Procedure_Device
.	O

-	O
dementia	B-Condition
or	O
mini-mental	B-Observation
state	I-Observation
exam	I-Observation
<	O
24	O
.	O

-	O
estimated	B-Observation
verbal	I-Observation
intelligence	I-Observation
<	O
70	O
.	O

-	O
active	O
or	O
prior	O
history	O
of	O
seizure	B-Condition
disorder	I-Condition
family	O
history	O
of	O
seizure	B-Condition
disorder	I-Condition
prescribed	O
seizure	B-Drug
inducing	I-Drug
medication	I-Drug
.	O

>>NCT02524405	O
Inclusion	O
Criteria:	O
.	O

General	O
Inclusion	O
Criteria	O
(	O
All	O
Subgroups	O
)	O
.	O

Subjects	O
must	O
meet	O
each	O
of	O
the	O
following	O
criteria	O
for	O
enrolment	O
into	O
the	O
study:	O
.	O

1	O
.	O

Written	O
informed	O
consent	O
obtained	O
and	O
documented	O
.	O

2	O
.	O

Male	O
or	O
post-menopausal	B-Condition
female	O
(	O
minimum	O
of	O
one	O
year	O
since	O
the	O
last	O
menstrual	O
period	O
)	O
.	O

3	O
.	O

50	O
-	O
90	O
years	O
of	O
age	B-Observation
.	O

4	O
.	O

Self-reported	O
proficiency	O
in	O
speaking	O
and	O
understanding	O
spoken	O
English	O
(	O
score	O
7	O
out	O
of	O
10	O
or	O
higher	O
on	O
the	O
two	O
LEAP-Q103	O
questions	O
)	O
.	O

5	O
.	O

>=	O
8	O
years	O
education	O
.	O

6	O
.	O

Capable	O
of	O
cooperating	O
for	O
the	O
duration	O
of	O
the	O
study	O
procedures	O
and	O
assessments	O
.	O

7	O
.	O

Willing	O
to	O
undergo	O
study	O
procedures	O
and	O
remain	O
unaware	O
of	O
the	O
results	O
.	O

8	O
.	O

Sufficient	O
vision	B-Observation
(	O
corrected	B-Observation
near	I-Observation
visual	I-Observation
acuity	I-Observation
of	I-Observation
Snellen	I-Observation
20	O
-	O
70	O
in	O
at	O
least	O
one	O
eye	O
)	O
and	O
hearing	B-Observation
to	O
participate	O
in	O
cognitive	O
testing	O
.	O

9	O
.	O

Able	O
to	O
complete	O
at	O
least	O
75%	O
of	O
the	O
neuropsychological	O
battery	O
and	O
questionnaires	O
.	O

(	O
An	O
individual	O
test	O
will	O
be	O
considered	O
"complete"	O
when	O
the	O
participant	O
has	O
been	O
administered	O
the	O
task	O
instructions	O
and	O
has	O
adequately	O
attempted	O
the	O
measure	O
.	O

With	O
this	O
criterion,	O
if	O
a	O
subject	O
fails	O
the	O
practice	O
item(	O
s	O
)	O
and	O
/	O
or	O
the	O
task	O
is	O
discontinued	O
for	O
cognitive	O
reasons,	O
the	O
test	O
will	O
still	O
be	O
considered	O
"complete.")	O
.	O

10	O
.	O

Sufficient	O
vision	B-Observation
at	O
least	O
one	O
eye	O
to	O
identify	O
symbols	O
and	O
stimuli	O
presented	O
on	O
a	O
computer	O
screen	O
in	O
front	O
of	O
them	O
.	O

11	O
.	O

Good	O
venous	O
access	O
for	O
phlebotomy	B-Procedure_Device
to	O
be	O
performed	O
.	O

12	O
.	O

Able	O
to	O
walk,	O
with	O
or	O
without	O
an	O
assistive	O
aid	O
(	O
eg	O
,	O
cane,	O
walker	O
)	O
.	O

Subgroup-Specific	O
Inclusion	O
Criteria	O
.	O

Normal	O
Controls	O
.	O

(	O
1	O
)	O
Within	O
normal	O
limits	O
on	O
the	O
study	O
neuropsychological	B-Observation
battery	I-Observation
.	O

Subcortical	B-Condition
VCI	I-Condition
.	O

1	O
.	O

Meets	O
the	O
American	B-Observation
Heart	I-Observation
Association-American	I-Observation
Stroke	I-Observation
Association	I-Observation
(	I-Observation
AHA-ASA	I-Observation
)	I-Observation
criteria	I-Observation
for	O
probable	O
vascular	B-Condition
dementia	I-Condition
(	I-Condition
VaD	I-Condition
)	I-Condition
or	O
probable	O
vascular	B-Condition
mild	I-Condition
cognitive	I-Condition
impairment	I-Condition
(	I-Condition
VaMCI	I-Condition
)	I-Condition
due	O
to	O
subcortical	O
ischemic	B-Condition
vascular	I-Condition
disease	I-Condition
.	O

2	O
.	O

Presence	O
of	O
subcortical	B-Condition
disease	I-Condition
as	O
indicated	O
by	O
Fazekas	B-Observation
score	I-Observation
=	O
3	O
for	O
periventricular	B-Condition
hyperintensities	I-Condition
on	O
MRI	B-Procedure_Device
or	O
hypodensity	B-Condition
on	O
CT	B-Procedure_Device
and	O
/	O
or	O
more	O
than	O
2	O
subcortical	O
lacunar	B-Condition
infarcts	I-Condition
(	O
>	O
1.5	O
cm	O
diameter	B-Observation
)	O
in	O
the	O
white	O
matter	O
.	O

3	O
.	O

Montreal	B-Observation
Cognitive	I-Observation
Assessment	I-Observation
(	I-Observation
MoCA	I-Observation
)	I-Observation
score	I-Observation
>=	O
18	O
for	O
VaMCI	B-Condition
;	O
Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
(	I-Observation
MMSE	I-Observation
)106	I-Observation
score	I-Observation
>=	O
20	O
for	O
VaD	B-Condition
.	O

4	O
.	O

Must	O
have	O
a	O
reliable	O
and	O
capable	O
caregiver	O
who	O
has	O
regular	O
interaction	O
with	O
them,	O
will	O
be	O
present	O
for	O
all	O
visits,	O
can	O
provide	O
a	O
collateral	O
history,	O
can	O
assist	O
in	O
compliance	O
with	O
study	O
procedures	O
and	O
who	O
is	O
willing	O
to	O
act	O
as	O
the	O
Study	O
Partner	O
(	O
provide	O
written	O
informed	O
consent	O
)	O
and	O
remain	O
unaware	O
of	O
the	O
results	O
.	O

MCI	B-Condition
.	O

1	O
.	O

Meets	O
the	O
National	B-Observation
Institute	I-Observation
on	I-Observation
Aging-Alzheimer's	I-Observation
Association	I-Observation
criteria	I-Observation
for	O
amnestic	B-Condition
or	I-Condition
multi-domain	I-Condition
MCI	I-Condition
.	O

2	O
.	O

MoCA	B-Observation
score	I-Observation
>=	O
18	O
.	O

3	O
.	O

Must	O
have	O
a	O
reliable	O
and	O
capable	O
caregiver	O
who	O
has	O
regular	O
interaction	O
with	O
them,	O
will	O
be	O
present	O
for	O
all	O
visits,	O
can	O
provide	O
a	O
collateral	O
history,	O
can	O
assist	O
in	O
compliance	O
with	O
study	O
procedures	O
and	O
who	O
is	O
willing	O
to	O
act	O
as	O
the	O
Study	O
Partner	O
(	O
provide	O
written	O
informed	O
consent	O
)	O
and	O
remain	O
unaware	O
of	O
the	O
results	O
.	O

AD	B-Condition
.	O

1	O
.	O

Meets	O
the	O
National	B-Observation
Institute	I-Observation
on	I-Observation
Aging-Alzheimer's	I-Observation
Association	I-Observation
(	I-Observation
NIA-AA	I-Observation
)	I-Observation
core	I-Observation
clinical	I-Observation
criteria	I-Observation
for	O
probable	O
AD	B-Condition
dementia	I-Condition
.	O

2	O
.	O

Mild	O
early	O
AD	B-Condition
stage	O
(	O
MMSE	B-Observation
score	I-Observation
>=	O
20	O
)	O
.	O

3	O
.	O

Non-AD	B-Condition
causes	O
of	O
dementia	B-Condition
ruled	B-Negation_cue
out	I-Negation_cue
by	O
standardized	O
work	O
up	O
for	O
dementia	B-Condition
including	O
brain	B-Procedure_Device
imaging	I-Procedure_Device
and	O
blood	B-Procedure_Device
work	I-Procedure_Device
screen	I-Procedure_Device
.	O

4	O
.	O

Reliable	O
and	O
capable	O
caregiver	O
who	O
has	O
regular	O
interaction	O
with	O
them,	O
will	O
be	O
present	O
for	O
all	O
visits,	O
can	O
provide	O
a	O
collateral	O
history,	O
can	O
assist	O
in	O
compliance	O
with	O
study	O
procedures	O
and	O
who	O
is	O
willing	O
to	O
act	O
as	O
the	O
Study	O
Partner	O
(	O
provide	O
written	O
informed	O
consent	O
)	O
and	O
remain	O
unaware	O
of	O
the	O
results	O
.	O

LBD	B-Condition
Spectrum	I-Condition
DLB	I-Condition
.	O

1	O
.	O

Subject	O
meets	O
the	O
criteria	O
for	O
probable	O
Dementia	B-Condition
with	I-Condition
Lewy	I-Condition
Bodies	I-Condition
.	O

2	O
.	O

MMSE	B-Observation
score	I-Observation
>=	O
20	O
.	O

3	O
.	O

Reliable	O
and	O
capable	O
caregiver	O
who	O
has	O
regular	O
interaction	O
with	O
them,	O
will	O
be	O
present	O
for	O
all	O
visits,	O
can	O
provide	O
a	O
collateral	O
history,	O
can	O
assist	O
in	O
compliance	O
with	O
study	O
procedures	O
and	O
who	O
is	O
willing	O
to	O
act	O
as	O
the	O
Study	O
Partner	O
(	O
provide	O
written	O
informed	O
consent	O
)	O
and	O
remain	O
unaware	O
of	O
the	O
results	O
.	O

PD-MCI	B-Condition
.	O

1	O
.	O

Meets	O
the	O
proposed	B-Observation
Level	I-Observation
I	I-Observation
criteria	I-Observation
for	O
Mild	B-Condition
Cognitive	I-Condition
Impairment	I-Condition
in	O
Parkinson's	O
Disease110	O
.	O

2	O
.	O

MoCA	B-Observation
score	I-Observation
18	O
-	O
24	O
.	O

3	O
.	O

Hoehn	B-Observation
&	I-Observation
Yahr	I-Observation
stage	I-Observation
2	O
or	O
3	O
.	O

4	O
.	O

Reliable	O
and	O
capable	O
caregiver	O
who	O
has	O
regular	O
interaction	O
with	O
them,	O
will	O
be	O
present	O
for	O
all	O
visits,	O
can	O
provide	O
a	O
collateral	O
history,	O
can	O
assist	O
in	O
compliance	O
with	O
study	O
procedures	O
and	O
who	O
is	O
willing	O
to	O
act	O
as	O
the	O
Study	O
Partner	O
(	O
provide	O
written	O
informed	O
consent	O
)	O
and	O
remain	O
unaware	O
of	O
the	O
results	O
.	O

PDD	B-Condition
.	O

1	O
.	O

Meets	O
the	O
criteria	O
for	O
probable	O
Parkinson's	B-Condition
Disease	I-Condition
-	I-Condition
Dementia	I-Condition
.	O

2	O
.	O

MMSE	B-Observation
score	I-Observation
>=	O
20	O
.	O

3	O
.	O

Hoehn	B-Observation
&	I-Observation
Yahr	I-Observation
stage	I-Observation
2	O
or	O
3	O
.	O

4	O
.	O

Reliable	O
and	O
capable	O
caregiver	O
who	O
has	O
regular	O
interaction	O
with	O
them,	O
will	O
be	O
present	O
for	O
all	O
visits,	O
can	O
provide	O
a	O
collateral	O
history,	O
can	O
assist	O
in	O
compliance	O
with	O
study	O
procedures	O
and	O
who	O
is	O
willing	O
to	O
act	O
as	O
the	O
Study	O
Partner	O
(	O
provide	O
written	O
informed	O
consent	O
)	O
and	O
remain	O
unaware	O
of	O
the	O
results	O
.	O

Exclusion	O
Criteria:	O
.	O

General	O
Exclusion	O
Criteria	O
(	O
All	O
Subgroups	O
)	O
.	O

Subjects	O
who	O
exhibit	O
any	O
of	O
the	O
following	O
conditions	O
will	O
be	O
excluded	O
from	O
the	O
study:	O
.	O

1	O
.	O

Serious	O
underlying	B-Condition
disease	I-Condition
(	O
other	O
than	O
the	O
disease	O
being	O
studied	O
)	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
may	O
interfere	O
with	O
the	O
participant's	O
ability	O
to	O
participate	O
in	O
the	O
study	O
.	O

2	O
.	O

Any	O
disease	B-Condition
that	O
would	O
/	O
could	O
lead	O
to	O
death	B-Condition
over	O
the	O
next	O
2	O
years	O
.	O

3	O
.	O

Unstable	O
cardiac,	B-Condition
pulmonary,	I-Condition
renal,	I-Condition
hepatic,	I-Condition
endocrine,	I-Condition
hematologic	I-Condition
or	I-Condition
active	I-Condition
malignancy	I-Condition
or	O
infectious	B-Condition
disease	I-Condition
.	O

4	O
.	O

Significant	O
psychiatric	B-Condition
illness	I-Condition
.	O

5	O
.	O

Significant	O
neurologic	B-Condition
disease	I-Condition
(	O
eg	O
,	O
Huntington's	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
brain	B-Condition
tumor	I-Condition
progressive	B-Condition
supranuclear	I-Condition
palsy	I-Condition
seizure	B-Condition
disorder	I-Condition
subdural	B-Condition
hematoma	I-Condition
multiple	B-Condition
sclerosis	I-Condition
)	O
.	O

6	O
.	O

History	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
followed	O
by	O
persistent	O
neurologic	B-Condition
defaults	I-Condition
or	O
known	O
structural	B-Condition
brain	I-Condition
abnormalities	I-Condition
.	O

7	O
.	O

Brain	B-Procedure_Device
MRI	I-Procedure_Device
scan	I-Procedure_Device
abnormalities	B-Condition
detected	O
on	O
clinical	B-Procedure_Device
MRI	I-Procedure_Device
prior	O
to	O
enrollment	O
or	O
on	O
study	O
MRI:	O
Evidence	O
of	O
infection	B-Condition
,	O
cortical	B-Condition
stroke	I-Condition
or	O
other	O
focal	B-Condition
lesions	I-Condition
(	O
tumours	B-Condition
,	O
subdural	B-Condition
hematomas	I-Condition
malformations	B-Condition
,	O
etc.)	O
.	O

8	O
.	O

AIDS	B-Condition
or	O
AIDS	B-Condition
related	I-Condition
complications	I-Condition
.	O

9	O
.	O

Substance	B-Condition
abuse	I-Condition
within	O
the	O
past	O
year	O
.	O

10	O
.	O

History	O
of	O
alcohol	B-Condition
or	I-Condition
drug	I-Condition
abuse	I-Condition
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
may	O
interfere	O
with	O
the	O
participant's	O
ability	O
to	O
comply	O
with	O
the	O
study	O
procedures	O
.	O

11	O
.	O

Participant	O
is	O
currently	O
enrolled	O
in	O
a	O
disease	O
modifying	O
therapeutic	O
trial	O
that	O
the	O
Steering	O
Committee	O
feels	O
would	O
compromise	O
study	O
results	O
.	O

12	O
.	O

Moderate	O
-	O
severe	O
cognitive	B-Condition
impairment	I-Condition
(	O
MMSE	B-Observation
score	I-Observation
<	O
20	O
),	O
aphasia	B-Condition
,	O
inability	O
to	O
write	O
and	O
/	O
or	O
severe	O
functional	B-Condition
disability	I-Condition
limiting	O
ability	O
to	O
perform	O
assessments	O
Pain	O
or	O
sleep	B-Condition
disorder	I-Condition
that	O
could	O
interfere	O
with	O
cognitive	O
testing	O
.	O

13	O
.	O

Clinical	O
diagnosis	O
of	O
glaucoma	B-Condition
,	O
taking	O
eyedrops	B-Drug
for	O
glaucoma	B-Condition
or	O
previous	O
surgery	B-Procedure_Device
(	O
including	O
laser	B-Procedure_Device
)	O
for	O
glaucoma	B-Condition
.	O

14	O
.	O

Any	O
other	O
serious	O
eye	B-Procedure_Device
disease	I-Procedure_Device
or	O
treatment	B-Procedure_Device
or	O
eye	B-Procedure_Device
surgery	I-Procedure_Device
including	O
any	O
history	O
of	O
intra-vitreal	B-Procedure_Device
injections	I-Procedure_Device
.	O

15	O
.	O

Diagnosis	O
of	O
multiple	B-Condition
sclerosis	I-Condition
.	O

16	O
.	O

History	O
of	O
optic	B-Condition
neuritis	I-Condition
.	O

17	O
.	O

Poorly	O
controlled	O
diabetes	B-Condition
,	O
defined	O
as	O
HbA1c	B-Observation
>=	O
7.5	O
.	O

18	O
.	O

Previous	O
retinal	B-Procedure_Device
laser	I-Procedure_Device
therapy	I-Procedure_Device
(	O
either	O
pan-retinal	O
or	O
grid	O
/	O
focal	O
)	O
for	O
diabetic	B-Condition
retinopathy	I-Condition
.	O

19	O
.	O

Contra-indication	B-Condition
to	O
an	O
MRI	B-Procedure_Device
procedure	O
as	O
listed	O
in	O
the	O
site-specific	O
Magnetic	O
Resonance	O
Environment	O
Screening	O
Questionnaire	O
(	O
eg	O
metal	B-Procedure_Device
implant	I-Procedure_Device
)	O
.	O

20	O
.	O

Unable	B-Negation_cue
to	O
tolerate	O
the	O
MRI	B-Procedure_Device
environment	O
eg	O
,	O
due	O
to	O
physical	O
size	O
and	O
/	O
or	O
claustrophobia	B-Condition
.	O

21	O
.	O

Known	O
hypersensitivity	B-Condition
to	O
[18F]flutemetamol	B-Drug
or	O
any	O
components	O
of	O
the	O
Flutemetamol	B-Drug
(	I-Drug
18F	I-Drug
)	I-Drug
Injection	I-Drug
formulation	I-Drug
.	O

22	O
.	O

Subject	O
participated	O
in	O
any	O
studies	O
involving	O
radiopharmaceuticals	B-Drug
within	O
the	O
past	O
12	O
months	O
.	O

23	O
.	O

Intra-ocular	B-Observation
pressure	I-Observation
greater	O
than	O
22mmHg	O
or	O
a	O
difference	O
in	O
intra-ocular	B-Observation
pressure	I-Observation
(	O
Goldmann	B-Observation
tonometry	I-Observation
)	O
greater	O
than	O
5mmHg	O
between	O
the	O
two	O
eyes	O
(	O
assessed	O
as	O
part	O
of	O
SD-OCT	O
visit	O
at	O
Kensington	O
Eye	O
Institute	O
)	O
.	O

24	O
.	O

Cupping	B-Observation
of	O
the	O
optic	O
nerve	O
head	O
(	O
ONH	O
)	O
consistent	O
with	O
a	O
diagnosis	O
of	O
glaucoma	B-Condition
,	O
as	O
clinically	O
determined	O
by	O
expert	O
ophthalmological	O
assessment	O
of	O
digital	O
colour	O
fundus	O
images	O
centered	O
on	O
the	O
ONH	O
.	O

Specifically,	O
one	O
or	O
more	O
of	O
the	O
following	O
(	O
assessed	O
as	O
part	O
of	O
SD-OCT	O
visit	O
at	O
Kensington	O
Eye	O
Institute	O
):	O
.	O

i	O
.	O
a	O
cup	B-Observation
/	I-Observation
disc	I-Observation
ratio	I-Observation
of	O
0.7	O
or	O
greater	O
in	O
either	O
eye	O
ii	O
.	O

a	O
cup	B-Observation
/	I-Observation
disc	I-Observation
asymmetry	I-Observation
of	O
more	O
than	O
0.2	O
iii	O
.	O

disc	B-Condition
hemorrhage	I-Condition
iv	O
.	O

notch	B-Condition
.	O

25	O
.	O

Wet	O
/	O
exudative	O
age-related	B-Condition
macular	I-Condition
degeneration	I-Condition
(	O
ARMD	O
)	O
in	O
one	O
or	O
both	O
eyes,	O
as	O
clinically	O
determined	O
by	O
expert	O
ophthalmological	O
assessment	O
of	O
digital	O
colour	O
fundus	O
images	O
centered	O
on	O
the	O
fovea	O
(	O
assessed	O
as	O
part	O
of	O
SD-OCT	O
visit	O
at	O
Kensington	O
Eye	O
Institute	O
)	O
.	O

Subgroup-Specific	O
Exclusion	O
Criteria	O
Normal	O
Controls	O
.	O

1	O
.	O

History	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
or	O
learning	B-Condition
disability	I-Condition
.	O

2	O
.	O

Subjective	B-Condition
memory	I-Condition
complaints	I-Condition
.	O

3	O
.	O

Presence	O
of	O
subcortical	B-Condition
disease	I-Condition
as	O
indicated	O
by	O
Fazekas	B-Observation
score	I-Observation
=	O
3	O
for	O
periventricular	B-Condition
hyperintensities	I-Condition
on	O
MRI	B-Procedure_Device
or	O
hypodensity	B-Condition
on	O
CT	B-Procedure_Device
and	O
/	O
or	O
more	O
than	O
2	O
subcortical	B-Condition
lacunar	I-Condition
infarcts	I-Condition
(	O
>	O
1.5	O
cm	O
diameter	B-Observation
)	O
in	O
the	O
white	O
matter	O
.	O

MCI	B-Condition
,	O
AD	B-Condition
,	O
PDD	B-Condition
,	O
LBD	B-Condition
.	O

(	O
1	O
)	O
Presence	O
of	O
subcortical	B-Condition
ischemic	I-Condition
disease	I-Condition
as	O
indicated	O
by	O
Fazekas	B-Observation
score	I-Observation
=	O
3	O
for	O
periventricular	B-Condition
hyperintensities	I-Condition
on	O
MRI	B-Procedure_Device
or	O
hypodensity	B-Condition
on	O
CT	B-Procedure_Device
and	O
/	O
or	O
more	O
than	O
2	O
subcortical	B-Condition
lacunar	I-Condition
infarcts	I-Condition
(	O
>	O
1.5	O
cm	O
diameter	B-Observation
)	O
in	O
the	O
white	O
matter	O
.	O

>>NCT01953705	O
Inclusion	O
Criteria:	O
.	O

1	O
.	O

Non-demented	O
or	O
mild	O
cognitive	B-Condition
impairment	I-Condition
defined	O
as	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
=	O
0	O
or	O
0.5	O
.	O

2	O
.	O

Age	B-Observation
80	O
and	O
older,	O
male	O
and	O
female	O
.	O

3	O
.	O

Total	B-Observation
WMH	I-Observation
volume	I-Observation
>=	O
6	O
cc	O
(	O
>	O
80%	O
of	O
our	O
Oregon	O
Brain	O
Aging	O
Study	O
population	O
meets	O
this	O
criterion	O
)	O
.	O

4	O
.	O

Plasma	B-Observation
PUFA	I-Observation
(	O
EPA	B-Observation
+	I-Observation
DHA	I-Observation
)	O
<	O
110	O
ug	O
/	O
ml	O
or	O
<	O
5	O
weight	O
percent	O
(	O
>	O
85%	O
of	O
our	O
OBAS	O
population	O
meets	O
this	O
)	O
.	O

5	O
.	O

Sufficient	O
English	O
language	O
skills	O
to	O
complete	O
all	O
tests	O
.	O

6	O
.	O

Geriatric	B-Observation
Depression	I-Observation
Scale	I-Observation
-	I-Observation
15	I-Observation
<	O
6	O
documenting	O
absence	B-Negation_cue
of	O
a	O
significant	O
depressive	B-Condition
syndrome	I-Condition
.	O

7	O
.	O

Sufficient	O
vision	B-Observation
and	I-Observation
hearing	I-Observation
to	O
complete	O
all	O
tests	O
.	O

8	O
.	O

Informant	O
available	O
with	O
frequent	O
(	O
at	O
least	O
1	O
hour	O
/	O
day	O
or	O
1	O
day	O
/	O
week	O
)	O
contact	O
with	O
subject	O
to	O
verify	O
functional	O
status	O
and	O
CDR	O
rating	O
.	O

9	O
.	O

General	O
health	O
status	O
that	O
will	O
not	O
interfere	O
with	O
the	O
ability	O
to	O
complete	O
the	O
prospective	O
study	O
(	O
these	O
conditions	O
are	O
listed	O
below	O
in	O
the	O
study	O
exclusion	O
list	O
)	O
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

Any	O
dementing	B-Condition
illness	I-Condition
(	O
AD	B-Condition
,	O
vascular	B-Condition
dementia	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
or	O
Parkinson's	B-Condition
disease	I-Condition
);	O
dementia	B-Condition
defined	O
by	O
CDR	B-Observation
>=	O
1	O
.	O

2	O
.	O

Significant	O
disease	B-Condition
of	O
the	O
CNS	O
such	O
as	O
brain	B-Condition
tumor	I-Condition
seizure	B-Condition
disorder	I-Condition
subdural	B-Condition
hematoma	I-Condition
cranial	B-Condition
arteritis	I-Condition
.	O

3	O
.	O

Alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
according	O
to	O
DSM-IV	B-Observation
criteria	I-Observation
within	O
the	O
last	O
2	O
years	O
.	O

4	O
.	O

Major	B-Condition
depression	I-Condition
schizophrenia	B-Condition
or	O
other	O
major	O
psychiatric	B-Condition
disorder	I-Condition
defined	O
by	O
DSM-IV	B-Observation
criteria	I-Observation
.	O

5	O
.	O

Abnormal	O
labs	B-Observation
indicating	O
vitamin	B-Condition
B12	I-Condition
deficiency	I-Condition
thyroid	B-Condition
disease	I-Condition
or	O
UTI	B-Condition
(	O
documented	O
bacterial	O
colonization	O
is	O
acceptable	O
)	O
.	O

6	O
.	O

Unstable	O
or	O
significantly	O
symptomatic	B-Condition
CVD	I-Condition
(	O
eg	O
CAD	B-Condition
with	O
frequent	O
angina	B-Condition
,	O
CHF	B-Condition
with	O
dyspnea	B-Condition
at	O
rest	O
)	O
.	O

7	O
.	O

Hypertension	B-Condition
:	O
either	O
1	O
)	O
blood	B-Observation
pressure	I-Observation
>	O
150	O
-	O
90	O
or	O
2	O
)	O
>	O
2	O
medications	B-Drug
to	O
control	O
.	O

8	O
.	O

Clinical	B-Condition
symptomatic	I-Condition
orthostatic	I-Condition
hypotension	I-Condition
.	O

9	O
.	O

Diabetes	B-Condition
mellitus	I-Condition
that	O
requires	O
insulin	B-Drug
injections	O
.	O

10	O
.	O

History	O
of	O
cortical	B-Condition
stroke	I-Condition
.	O

11	O
.	O

Cancer	B-Condition
within	O
the	O
last	O
5	O
years,	O
with	O
the	O
exception	O
of	O
localized	B-Condition
prostate	I-Condition
cancer	I-Condition
(	O
Gleason	B-Observation
Grade	I-Observation
<	O
3	O
)	O
and	O
non-metastatic	B-Condition
skin	I-Condition
cancers	I-Condition
(	O
melanoma	B-Condition
)	O
.	O

12	O
.	O

Illness	O
that	O
requires	O
>	O
1	O
visit	O
/month	O
to	O
a	O
clinician	O
.	O

13	O
.	O

Progressive	O
vision	B-Condition
loss	I-Condition
(	O
age-related	B-Condition
macular	I-Condition
degeneration	I-Condition
already	O
beginning	O
to	O
degrade	O
vision	O
)	O
.	O

14	O
.	O

Contraindications	B-Condition
to	O
MRI	B-Procedure_Device
(	O
i.e.,	O
heart	B-Procedure_Device
pacemaker	I-Procedure_Device
metal	B-Procedure_Device
plates	I-Procedure_Device
or	O
objects	B-Procedure_Device
in	O
head,	O
metal	O
worker	O
)	O
.	O

15	O
.	O

Medications:	O
.	O

1	O
.	O

Analgesics	B-Drug
:	O
frequent	O
use	O
of	O
high	O
doses	O
.	O

2	O
.	O

Sedatives	B-Drug
:	O
except	O
for	O
those	O
used	O
occasionally	O
for	O
sleep	O
(	O
use	O
limited	O
to	O
<=	O
twice	O
per	O
week	O
)	O
.	O

3	O
.	O

CNS	B-Drug
active	I-Drug
meds	I-Drug
that	O
have	O
not	B-Negation_cue
been	O
on	O
stable	O
doses	O
for	O
at	O
least	O
2	O
months	O
(	O
cimetidine	B-Drug
,	O
beta-blockers	B-Drug
and	O
SSRIs	B-Drug
)	O
.	O

4	O
.	O

Active	O
hypertension	B-Condition
on	O
>	O
2	O
meds	B-Drug
or	O
using	O
CNS	B-Drug
active	I-Drug
agents	I-Drug
(	O
propranolol	B-Drug
or	O
clonidine	B-Drug
)	O
.	O

5	O
.	O

Neuroleptics,	B-Drug
antiparkinsonian	I-Drug
agents	I-Drug
systemic	B-Drug
corticosteroids	I-Drug
and	O
narcotic	B-Drug
analgesics	I-Drug
in	O
the	O
case	O
where	O
these	O
were	O
used	O
for	O
a	O
self-limited	O
time	O
they	O
must	O
have	O
been	O
discounted	O
for	O
a	O
period	O
of	O
five	O
half-lives	O
prior	O
to	O
baseline	O
visit	O
.	O

6	O
.	O

Over	O
the	O
counter	O
supplements	O
are	O
not	O
by	O
themselves	O
exclusionary,	O
however,	O
subjects	O
are	O
asked	O
not	O
to	O
change	O
the	O
dosing	O
regimen	O
over	O
the	O
course	O
of	O
the	O
trial	O
unless	O
medically	O
indicated;	O
the	O
presence	O
and	O
dose	O
of	O
these	O
agents	O
are	O
recorded	O
.	O

7	O
.	O

Taking	O
omega	B-Drug
3	I-Drug
PUFA	I-Drug
supplements	I-Drug
and	O
a	O
screen	B-Drug
plasma	I-Drug
PUFA	I-Drug
>	O
5	O
weight	O
percent	O
of	O
total	O
fatty	O
acids	O
for	O
EPA+DHA	O
will	O
confirm	O
supplementation	O
of	O
O3PUFA	O
history	O
.	O

8	O
.	O

Cholinesterase	B-Drug
inhibitors	I-Drug
(	O
i.e.,	O
Aricept	B-Drug
)	O
.	O

9	O
.	O

Investigational	B-Drug
drugs	I-Drug
within	O
five	O
half-lives	O
prior	O
to	O
baseline	O
.	O

10	O
.	O

Anticoagulation	B-Drug
therapy	I-Drug
vitamin	B-Drug
K	I-Drug
agonist	I-Drug
warfarin	B-Drug
,	O
Factor	B-Drug
Xa	I-Drug
inhibitors	I-Drug
Low	B-Drug
molecular	I-Drug
weight	I-Drug
heparins	I-Drug
.	O

>>NCT01747213	O
-	O
INCLUSION	O
CRITERIA:	O
.	O

-	O
Age	B-Observation
greater	O
than	O
or	O
equal	O
to	O
55	O
years	O
.	O

-	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
>	O
27	O
at	O
screening	O
and	O
at	O
Visit	O
2	O
-Day	O
1	O
.	O

-	O
Women	O
who	O
are	O
able	O
to	O
become	O
pregnant	O
must	O
have	O
a	O
negative	O
urine	B-Observation
pregnancy	I-Observation
test	I-Observation
(	O
minimum	O
sensitivity	O
25	O
IU	O
/	O
L	O
or	O
equivalent	O
units	O
of	O
HCG	O
)	O
at	O
screening	O
and	O
prior	O
to	O
study	O
drug	O
administration	O
.	O

-	O
Both	O
men	O
who	O
are	O
able	O
to	O
father	B-Condition
children	I-Condition
and	O
women	O
of	O
childbearing	B-Condition
potential	I-Condition
must	O
be	O
willing	O
to	O
use	O
an	O
adequate	O
method	O
of	O
contraception	O
(	O
see	O
section	O
7	O
)	O
to	O
avoid	O
conception	O
throughout	O
the	O
study	O
and	O
for	O
up	O
to	O
30	O
days	O
of	O
study	O
drug	O
administration	O
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
(	I-Observation
BMI	I-Observation
)	I-Observation
of	O
18.5	O
to	O
34.0,	O
inclusive	O
and	O
a	O
total	B-Observation
body	I-Observation
weight	I-Observation
of	O
>	O
50	O
kg	O
(	O
110	O
pounds	O
)	O
.	O

-	O
Participants	O
should	O
be	O
in	O
good	O
general	B-Observation
physical	I-Observation
and	I-Observation
mental	I-Observation
health	I-Observation
as	O
determined	O
by	O
medical	O
history	B-Observation
,	O
a	O
baseline	B-Observation
physical	I-Observation
examination	I-Observation
vital	B-Observation
signs	I-Observation
clinical	B-Observation
laboratory	I-Observation
tests	I-Observation
and	O
electrocardiogram	B-Procedure_Device
(	I-Procedure_Device
EKG	I-Procedure_Device
)	I-Procedure_Device
.	O

Participants	O
may	O
have	O
common	O
age-related	B-Condition
disorders	I-Condition
(	O
such	O
as	O
hypertension	B-Condition
,	O
type	B-Condition
II	I-Condition
diabetes	I-Condition
dyslipidemia	B-Condition
,	O
hypothyroidism	B-Condition
)	O
as	O
long	O
as	O
these	O
disorders	O
are	O
under	O
good	O
control	O
by	O
diet	O
or	O
medications	O
.	O

-	O
Able	O
to	O
sign	O
own	O
consent	O
.	O

EXCLUSION	O
CRITERIA:	O
.	O

-	O
Any	O
clinically	O
significant	O
medical	B-Condition
and	I-Condition
psychiatric	I-Condition
condition	I-Condition
(	O
including	O
asthma	B-Condition
active	O
within	O
the	O
last	O
10	O
years	O
or	O
COPD	B-Condition
and	O
drug	B-Condition
abuse	I-Condition
and	I-Condition
dependency	I-Condition
)	O
.	O

-	O
Subject	O
has	O
used	O
any	O
tobacco	B-Drug
products	I-Drug
in	O
the	O
past	O
3	O
months	O
.	O

-	O
A	O
history	O
of	O
significant	O
allergy	B-Condition
to	O
any	O
drug	B-Drug
or	O
systemic	B-Condition
allergic	I-Condition
disease	I-Condition
(	O
eg	O
,	O
urticaria	B-Condition
,	O
atopic	B-Condition
dermatitis	I-Condition
)	O
.	O

-	O
Pregnant	B-Condition
or	O
lactating	B-Condition
females	O
.	O

-	O
Subject	O
with	O
a	O
positive	O
urine	B-Observation
test	I-Observation
for	O
drugs	B-Condition
of	I-Condition
abuse	I-Condition
at	O
screening	O
or	O
at	O
admission	O
to	O
the	O
clinic	O
on	O
study	O
Day	O
1	O
.	O

-	O
Subject	O
has	O
consumed	O
any	O
alcohol	B-Drug
within	O
48	O
hours	O
prior	O
to	O
Visit	O
2;	O
and	O
cannot	O
or	O
is	O
unwilling,	O
thereafter	O
to	O
abstain	O
from	O
drinking	O
alcohol	O
for	O
the	O
remainder	O
of	O
the	O
subject	O
s	O
study	O
participation	O
.	O

-	O
Subject	O
is	O
positive	O
for	O
HIV	B-Observation
,	O
hepatitis	B-Observation
B	I-Observation
surface	I-Observation
antigen	I-Observation
or	O
hepatitis	B-Observation
C	I-Observation
antibody	I-Observation
tests	I-Observation
at	O
screening	O
.	O

-	O
Any	O
clinically	O
significant	O
laboratory	B-Observation
abnormality	I-Observation
.	O

These	O
include:	O
.	O

-	O
CBC	B-Observation
:	O
WBC	B-Observation
<	O
3000	O
/mm^3;	O
Hb	B-Observation
<	O
12	O
g	O
/	O
dL;	O
Liver	B-Observation
function	I-Observation
tests	I-Observation
ALT	B-Observation
,	O
AST	B-Observation
,	O
Bilirubin	B-Observation
(	O
total,	O
direct,	O
indirect	O
),	O
Alkaline	B-Observation
Phosphatase	I-Observation
>	O
1.5	O
x	O
the	O
upper	O
normal	O
limit	O
of	O
the	O
laboratory	O
.	O

-	O
Serum	B-Observation
Creatinine	I-Observation
>	O
1.5	O
mg	O
/	O
dL;	O
Serum	B-Observation
Glucose	I-Observation
>	O
150mg	O
/	O
dL	O
.	O

-	O
Resting	B-Observation
supine	I-Observation
blood	I-Observation
pressure	I-Observation
outside	O
of	O
a	O
systolic	B-Observation
blood	I-Observation
pressure	I-Observation
range	O
of	O
90	O
-	O
140	O
mmHg	O
or	O
a	O
diastolic	B-Observation
blood	I-Observation
pressure	I-Observation
outside	O
a	O
range	O
of	O
50	O
-	O
90	O
mmHg	O
on	O
two	O
consecutive	O
measurements	O
taken	O
up	O
to	O
10	O
minutes	O
apart.Resting	O
supine	B-Observation
heart	I-Observation
rate	I-Observation
greater	O
than	O
100	O
bpm	O
or	O
less	O
than	O
or	O
equal	O
to	O
55	O
55	O
bpm	O
on	O
two	O
consecutive	O
measurements	O
taken	O
up	O
to	O
10	O
minutes	O
apart	O
.	O

-	O
Any	O
clinically	O
significant	O
abnormality	B-Condition
on	O
screening	O
12	B-Procedure_Device
-lead	I-Procedure_Device
EKG	I-Procedure_Device
(	O
eg	O
,	O
heart	B-Condition
block	I-Condition
conduction	B-Condition
disorders	I-Condition
ventricular	B-Condition
and	I-Condition
/	I-Condition
or	I-Condition
atrial	I-Condition
arrhythmias	I-Condition
)	O
.	O

-	O
Routine	O
or	O
PRN	O
consumption	O
of	O
the	O
following	O
herbal	B-Drug
/	I-Drug
dietary	I-Drug
supplements	I-Drug
are	O
not	B-Negation_cue
permitted,	O
if	O
used	O
within	O
2	O
weeks	O
before	O
the	O
screening	O
visit	O
at	O
doses	O
higher	O
than	O
the	O
recommended	O
daily	O
intake:	O
Omega-	B-Drug
3	I-Drug
fatty	I-Drug
acids	I-Drug
(>	O
1000	O
mg	O
/	O
day	O
),	O
Vitamin	B-Drug
E	I-Drug
(>	O
400IU	O
/	O
day	O
)	O
.	O

Ginkgo	B-Drug
biloba	I-Drug
St.	B-Drug
John's	I-Drug
wort	I-Drug
and	O
ginseng	B-Drug
are	O
not	O
permitted,	O
if	O
used	O
at	O
any	O
dose	O
within	O
2	O
weeks	O
before	O
the	O
screening	O
visit	O
.	O

-	O
Medications	O
that	O
are	O
excluded	O
are:	O
.	O

-	O
Insulin	B-Drug
.	O

-	O
Anti-parkinsonian	B-Drug
medications	I-Drug
(	O
such	O
as	O
levodopa	B-Drug
carbidopa	B-Drug
,	O
amantadine	B-Drug
,	O
bromocriptine	B-Drug
,	O
pergolide	B-Drug
,	O
selegiline	B-Drug
)	O
.	O

-	O
Typical	O
or	O
atypical	O
neuroleptics	B-Drug
.	O

-	O
Narcotic	B-Drug
analgesics	I-Drug
at	O
any	O
dose	O
within	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Long-acting	O
benzodiazepines	B-Drug
or	O
barbiturates	B-Drug
(	O
such	O
as	O
clonazepam	B-Drug
,	O
diazepam	B-Drug
,	O
phenobarbital	B-Drug
)	O
within	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Short-acting	O
anxiolytics	B-Drug
or	O
sedative	B-Drug
hypnotics	I-Drug
more	O
frequently	O
than	O
2	O
times	O
per	O
week	O
within	O
4	O
weeks	O
prior	O
to	O
screening	O
(	O
sedative	B-Drug
hypnotics	I-Drug
should	O
not	B-Negation_cue
be	O
used	O
within	O
102	O
hours	O
of	O
study	O
drug	O
administration	O
)	O
.	O

-	O
Medications	B-Drug
with	O
known	O
significant	O
cholinergic	B-Condition
or	I-Condition
anticholinergic	I-Condition
side	I-Condition
effects	I-Condition
(	O
such	O
as	O
pyridostigmine	B-Drug
,	O
tricyclic	B-Drug
antidepressants	I-Drug
meclizine	B-Drug
,	O
oxybutynin	B-Drug
)	O
within	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Anti-convulsants	B-Drug
(	O
such	O
as	O
phenytoin	B-Drug
,	O
Phenobarbital	B-Drug
,	O
carbamazepine	B-Drug
)	O
within	O
2	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Medications	B-Drug
for	O
Alzheimer	B-Condition
s	I-Condition
disease	I-Condition
(	O
such	O
as	O
donepezil	B-Drug
or	O
memantine	B-Drug
)	O
.	O

-	O
Beta-Blockers	B-Drug
.	O

-	O
Corticosteroids	B-Drug
(	O
Systemic	O
)	O
.	O

-	O
Neuromuscular-Blocking	B-Drug
Agents	I-Drug
(	O
non-depolarizing	O
)	O
.	O

-	O
Succinylcholine	B-Drug
.	O

-	O
Any	O
other	O
drug	B-Drug
(	O
including	O
prescription,	O
over	O
the	O
counter	O
medications	O
and	O
supplements	O
)	O
that	O
may	O
pose	O
a	O
risk	O
to	O
the	O
subject	O
or	O
produce	O
overlapping	B-Condition
side	I-Condition
effects	I-Condition
with	O
the	O
study	O
medication	O
.	O

Participants	O
will	O
not	O
be	O
taken	O
off	O
of	O
medications	O
for	O
the	O
purpose	O
of	O
this	O
study	O
.	O

-	O
Donation	B-Procedure_Device
or	I-Procedure_Device
loss	I-Procedure_Device
of	O
400	O
mL	O
or	O
more	O
of	O
blood	O
within	O
56	O
days	O
prior	O
to	O
and	O
subsequent	O
to	O
screening	O
.	O

-	O
Participation	O
in	O
another	O
research	O
study	O
involving	O
an	O
investigational	B-Drug
drug	I-Drug
within	O
30	O
days	O
or	O
5	O
half-lives,	O
whichever	O
is	O
longer	O
.	O

-	O
Known	O
allergy	B-Condition
or	O
hypersensitivity	B-Condition
to	O
the	O
investigational	B-Drug
study	I-Drug
drug	I-Drug
and	O
to	O
the	O
microcrystalline	B-Drug
cellulose	I-Drug
used	O
as	O
placebo	O
.	O

>>NCT01723670	O
Inclusion	O
Criteria:	O
.	O

-	O
One	O
or	O
two	O
4	O
alleles	O
of	O
the	O
apolipoprotein	O
E	O
(	O
APOE	O
)	O
gene	O
.	O

-	O
Diagnosis	O
of	O
amnestic	B-Condition
Mild	I-Condition
Cognitive	I-Condition
Impairment	I-Condition
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
score	I-Observation
higher	O
than	O
24	O
at	O
screening	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Any	O
medical	B-Condition
condition	I-Condition
that	O
could	O
explain	O
the	O
subject's	O
cognitive	B-Condition
deficits	I-Condition
.	O

-	O
MRI	B-Procedure_Device
scans	I-Procedure_Device
having	O
evidence	O
of	O
pre-specified	O
brain	B-Condition
abnormalities	I-Condition
.	O

-	O
History	O
of	O
stroke	B-Condition
.	O

-	O
Vitamin	B-Condition
B12	I-Condition
or	I-Condition
folate	I-Condition
deficiency	I-Condition
.	O

-	O
Skin	B-Condition
cancers	I-Condition
and	O
any	O
cancer	B-Condition
that	O
is	O
being	O
actively	O
treated	O
.	O

-	O
Diagnosis	O
of	O
schizophrenia	B-Condition
or	O
recurrent	O
mood	B-Condition
disorder	I-Condition
.	O

-	O
Abnormal	O
kidney	B-Observation
function	I-Observation
.	O

-	O
Concomitant	O
use	O
of	O
any	O
study	B-Drug
prohibitive	I-Drug
medication	I-Drug
.	O

>>NCT01703702	O
Inclusion	O
Criteria:	O
.	O

Patients	O
may	O
be	O
enrolled	O
in	O
the	O
mild	B-Condition
impairment	I-Condition
(	O
not	B-Negation_cue
demented	B-Condition
)	O
group	O
if	O
the	O
following	O
criteria	O
are	O
met:	O
.	O

1	O
.	O

Males	O
or	O
females	O
>=	O
50	O
to	O
<=	O
90	O
years	O
of	O
age	B-Observation
.	O

2	O
.	O

Have	O
cognitive	B-Condition
decline	I-Condition
verified	O
by	O
a	O
study	O
partner	O
or	O
cognitive	B-Condition
impairment	I-Condition
verified	O
by	O
the	O
study	O
physician	O
.	O

3	O
.	O

Have	O
a	O
study	O
partner	O
who	O
provides	O
separate	O
consent	O
and	O
is	O
willing	O
to	O
accompany	O
the	O
patient	O
on	O
all	O
of	O
the	O
study	O
visits	O
.	O

4	O
.	O

Have	O
an	O
MMSE	B-Observation
score	I-Observation
of	O
24	O
to	O
30	O
inclusive	O
.	O

5	O
.	O

Can	O
tolerate	O
a	O
10	O
-minute	O
PET	B-Procedure_Device
scan	I-Procedure_Device
.	O

6	O
.	O

Have	O
the	O
ability	O
to	O
cooperate	O
and	O
comply	O
with	O
all	O
study	O
procedures	O
.	O

7	O
.	O

Have	O
an	O
enrolling	O
physician	O
who	O
has	O
less	O
than	O
high	O
confidence	O
in	O
their	O
diagnosis	O
for	O
the	O
patient	O
related	O
to	O
the	O
cognitive	O
decline	O
at	O
the	O
time	O
of	O
enrollment	O
.	O

8	O
.	O

Ability	O
to	O
provide	O
informed	O
consent	O
for	O
study	O
procedures	O
.	O

Patients	O
may	O
be	O
enrolled	O
in	O
the	O
dementia	B-Condition
group	O
if	O
the	O
following	O
criteria	O
are	O
met:	O
.	O

1	O
.	O

Are	O
males	O
or	O
females	O
>=	O
50	O
to	O
<=	O
90	O
years	O
of	O
age	B-Observation
.	O

2	O
.	O

Meet	O
clinical	O
criteria	O
for	O
dementia	B-Condition
.	O

3	O
.	O

Have	O
a	O
caregiver	O
who	O
provides	O
separate	O
consent	O
and	O
is	O
willing	O
to	O
accompany	O
the	O
patient	O
on	O
all	O
of	O
the	O
study	O
visits	O
.	O

4	O
.	O

Have	O
an	O
MMSE	B-Observation
score	I-Observation
of	O
16	O
to	O
24	O
inclusive	O
.	O

5	O
.	O

Have	O
not	O
received	O
a	O
clinical	B-Observation
examination	I-Observation
and	O
/	O
or	O
laboratory	B-Observation
test	I-Observation
results	I-Observation
that	O
strongly	O
indicates	O
a	O
non-neurodegenerative	B-Condition
cause	I-Condition
for	O
the	O
patients	O
cognitive	B-Condition
impairment	I-Condition
.	O

6	O
.	O

Can	O
tolerate	O
a	O
10	O
-minute	O
PET	B-Procedure_Device
scan	I-Procedure_Device
.	O

7	O
.	O

Have	O
the	O
ability	O
to	O
cooperate	O
and	O
comply	O
with	O
all	O
study	O
procedures	O
.	O

8	O
.	O

Have	O
an	O
enrolling	O
physician	O
who	O
has	O
less	O
than	O
high	O
confidence	O
in	O
their	O
diagnosis	O
for	O
the	O
patient	O
related	O
to	O
the	O
cognitive	O
decline	O
at	O
the	O
time	O
of	O
enrollment	O
.	O

9	O
.	O

Ability	O
to	O
provide	O
informed	O
consent	O
for	O
study	O
procedures	O
.	O

(	O
If	O
the	O
patient	O
is	O
incapable	O
of	O
giving	O
informed	O
consent,	O
the	O
patient's	O
legal	O
representative	O
may	O
consent	O
on	O
behalf	O
of	O
the	O
patient	O
but	O
the	O
patient	O
must	O
still	O
confirm	O
assent	O
.	O

This	O
person	O
may	O
serve	O
as	O
the	O
study	O
partner	O
as	O
well	O
)	O
.	O

Exclusion	O
Criteria:	O
.	O

Patients	O
will	O
be	O
excluded	O
from	O
enrollment	O
if	O
they:	O
.	O

1	O
.	O

Have	O
a	O
current	O
serious	O
or	O
unstable	O
illness	B-Condition
;	O
.	O

2	O
.	O

The	O
patient	O
or	O
enrolling	O
physician	O
knows	O
the	O
result	O
of	O
a	O
previous	O
amyloid	B-Procedure_Device
imaging	I-Procedure_Device
scan	I-Procedure_Device
.	O

3	O
.	O

The	O
patient	O
has	O
a	O
known	O
brain	B-Condition
lesion	I-Condition
pathology	B-Condition
or	O
alternative	O
diagnosis	B-Condition
that	O
strongly	O
explains	O
the	O
patient's	O
clinical	O
presentation;	O
.	O

4	O
.	O

Are	O
receiving	O
any	O
investigational	B-Drug
medications	I-Drug
or	O
have	O
participated	O
in	O
a	O
trial	O
with	O
investigational	B-Drug
medications	I-Drug
within	O
the	O
last	O
30	O
days;	O
.	O

5	O
.	O

Have	O
ever	O
participated	O
in	O
an	O
experimental	O
study	O
with	O
an	O
amyloid	B-Drug
targeting	I-Drug
agent	I-Drug
(	O
eg	O
anti-amyloid	B-Drug
immunotherapy	I-Drug
-secretase	B-Drug
or	I-Drug
-secretase	I-Drug
inhibitor	I-Drug
)	O
unless	O
it	O
can	O
be	O
documented	O
that	O
the	O
patient	O
received	O
only	O
placebo	O
during	O
the	O
course	O
of	O
the	O
trial;	O
.	O

6	O
.	O

Have	O
had	O
a	O
radiopharmaceutical	B-Procedure_Device
imaging	I-Procedure_Device
or	O
treatment	B-Procedure_Device
procedure	I-Procedure_Device
within	O
7	O
days	O
prior	O
to	O
the	O
study	O
imaging	O
session;	O
or	O
.	O

7	O
.	O

Are	O
females	O
of	O
childbearing	B-Condition
potential	I-Condition
who	O
are	O
not	B-Negation_cue
surgically	B-Condition
sterile	I-Condition
not	O
refraining	O
from	O
sexual	O
activity	O
or	O
not	O
using	O
reliable	O
methods	O
of	O
contraception	O
.	O

Patients	O
will	O
also	O
be	O
excluded	O
from	O
enrollment	O
if	O
their	O
enrolling	O
physician:	O
.	O

1	O
.	O

Does	O
not	B-Negation_cue
consider	O
Alzheimer's	B-Condition
disease	I-Condition
as	O
a	O
potential	O
cause	O
of	O
the	O
patient's	O
cognitive	B-Condition
decline	I-Condition
.	O

2	O
.	O

Is	O
not	O
the	O
primary	O
physician	O
taking	O
care	O
of	O
the	O
patient	O
with	O
respect	O
to	O
the	O
management	O
of	O
their	O
cognitive	B-Condition
impairment	I-Condition
.	O

3	O
.	O

Cannot	B-Negation_cue
categorize	O
the	O
patient	O
as	O
either:	O
a	O
)	O
having	O
a	O
documented	O
and	O
completed	O
evaluation	O
for	O
cognitive	B-Condition
decline	I-Condition
within	O
the	O
past	O
18	O
months	O
old;	O
or	O
b	O
)	O
currently	O
undergoing	O
evaluation	B-Procedure_Device
for	O
cognitive	B-Condition
decline	I-Condition
.	O

4	O
.	O

Is	O
unwilling	O
to	O
suspend	O
all	O
testing	O
and	O
other	O
evaluation	O
procedures	O
between	O
the	O
time	O
of	O
the	O
baseline	O
evaluation	O
of	O
the	O
enrolling	O
physician's	O
diagnosis	O
and	O
management	O
plan	O
and	O
the	O
time	O
the	O
completion	O
of	O
the	O
PET	O
scan.	O

>>NCT02546310	O
Inclusion	O
Criteria:	O
.	O

-	O
Healthy	B-Condition
on	O
the	O
basis	O
of	O
medical	O
history,	O
physical	B-Observation
examination	I-Observation
vital	B-Observation
signs	I-Observation
12	B-Procedure_Device
-lead	I-Procedure_Device
ECG	I-Procedure_Device
haematology	B-Observation
,	O
blood	B-Observation
chemistry	I-Observation
urinalysis	B-Observation
and	O
a	O
pre-study	B-Observation
psychological	I-Observation
assessment	I-Observation
.	O

-	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
Score	I-Observation
of	O
>=	O
24	O
.	O

-	O
Intermediate	O
or	O
extensive	O
metaboliser	O
as	O
determined	O
by	O
CYP2D6	O
genotype	O
.	O

-	O
Fluent	O
English	O
speaker	O
.	O

-	O
Right-handed	O
.	O

-	O
Not	B-Negation_cue
a	O
regular	O
smoker	B-Observation
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Recreational	B-Drug
drug	I-Drug
use	O
within	O
3	O
months	O
prior	O
to	O
Screening	O
Visit	O
.	O

-	O
Positive	O
alcohol	B-Observation
breath	I-Observation
test	I-Observation
.	O

-	O
Positive	O
urine	B-Observation
drug	I-Observation
screen	I-Observation
.	O

-	O
Consumption	O
of	O
large	O
amounts	O
of	O
caffeinated	B-Drug
drinks	I-Drug
.	O

-	O
Consumption	O
of	O
any	O
food	O
or	O
any	O
drinks	O
containing	O
cranberry	B-Drug
,	O
pomegranate	B-Drug
,	O
star	B-Drug
fruit	I-Drug
grapefruit	B-Drug
,	O
pomelos	B-Drug
,	O
exotic	B-Drug
citrus	I-Drug
fruits	I-Drug
or	O
Seville	B-Drug
oranges	I-Drug
.	O

-	O
Ultra-rapid	O
or	O
poor	O
metabolizer	O
as	O
determined	O
by	O
CYP2D6	O
genotype	O
.	O

-	O
By	O
self-report,	O
taking	O
two	O
or	O
more	O
daytime	O
naps	O
per	O
week	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
is	O
likely	O
to	O
interfere	O
with	O
the	O
ability	O
of	O
the	O
subject	O
to	O
complete	O
the	O
study	O
procedures	O
.	O

-	O
History	O
of	O
or	O
presents	O
(	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
)	O
with,	O
significant	O
neurological	B-Condition
or	I-Condition
psychiatric	I-Condition
conditions	I-Condition
.	O

-	O
Personal	O
or	O
family	O
history	O
of	O
congenital	B-Condition
long	I-Condition
QT	I-Condition
syndrome	I-Condition
or	O
sudden	B-Condition
death	I-Condition
.	O

-	O
Concomitant	O
use	O
of	O
drugs	O
that	O
are	O
metabolised	O
by	O
and	O
/	O
or	O
are	O
inhibitors	O
of	O
CYP2D6	O
.	O

-	O
Concomitant	O
use	O
of	O
drugs	O
that	O
are	O
substrates	O
for	O
the	O
organic	O
cation	O
transporter	O
2	O
.	O

-	O
History	O
of	O
significant	O
claustrophobia	B-Condition
.	O

-	O
Fulfils	O
any	O
of	O
the	O
MRI	B-Procedure_Device
contraindications	B-Condition
on	O
the	O
standard	O
site	O
radiography	O
screening	O
questionnaire	O
(	O
eg	O
history	O
of	O
surgery	B-Procedure_Device
involving	I-Procedure_Device
metal	I-Procedure_Device
implants	I-Procedure_Device
)	O
.	O

>>NCT01594346	O
Inclusion	O
Criteria:	O
.	O

-	O
presence	O
of	O
clinically	O
determined	O
Down	B-Condition
syndrome	I-Condition
(	O
karyotypes	O
optional	O
)	O
.	O

-	O
appropriately	O
signed	O
and	O
witnessed	O
consent	O
form	O
.	O

-	O
age	B-Observation
of	O
50	O
years	O
or	O
older	O
at	O
the	O
start	O
of	O
the	O
protocol	O
.	O

-	O
medically	O
stable	O
.	O

-	O
medications	B-Drug
stable	O
more	O
than	O
1	O
month	O
.	O

-	O
involvement	O
/	O
cooperation	O
of	O
informant	O
/	O
caregiver	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
medical	B-Condition
/	I-Condition
neurological	I-Condition
condition	I-Condition
(	O
other	B-Negation_cue
than	I-Negation_cue
Alzheimer	B-Condition
disease	I-Condition
)	O
associated	O
with	O
dementia	B-Condition
.	O

-	O
inability	B-Observation
to	O
adequately	O
perform	O
the	O
Brief	B-Observation
Praxis	I-Observation
Test	I-Observation
as	O
demonstrated	O
by	O
a	O
score	O
<	O
20	O
.	O

-	O
in	O
the	O
presence	O
of	O
dementia	B-Condition
,	O
modified	B-Observation
Hachinski	I-Observation
score	I-Observation
>	O
4	O
at	O
Screening	O
Visit	O
.	O

-	O
major	B-Condition
depression	I-Condition
within	O
3	O
months	O
.	O

-	O
history	O
of	O
coagulopathy	B-Condition
(	O
inherited	O
or	O
acquired	O
)	O
.	O

-	O
current	O
use	O
of	O
anticoagulants	B-Drug
.	O

-	O
use	O
of	O
experimental	B-Drug
medications	I-Drug
within	O
2	O
months	O
.	O

-	O
regular	O
use	O
of	O
vitamin	B-Drug
E	I-Drug
greater	O
than	O
50	O
units	O
per	O
day	O
during	O
the	O
previous	O
6	O
months	O
.	O

-	O
allergy	B-Condition
to	O
vitamin	B-Drug
E	I-Drug
.	O

>>NCT01642420	O
Inclusion	O
Criteria:	O
.	O

For	O
patients:	O
.	O

-	O
age	B-Observation
50	O
to	O
90	O
.	O

-	O
diagnosed	O
with	O
MCI	B-Condition
or	O
AD	B-Condition
.	O

-	O
cerebrospinal	B-Procedure_Device
fluid	I-Procedure_Device
examination	I-Procedure_Device
and	O
EEG	B-Procedure_Device
performed	O
at	O
baseline	O
.	O

For	O
control	O
persons:	O
.	O

-	O
age	B-Observation
50	O
to	O
90	O
.	O

-	O
MMSE	B-Observation
score	I-Observation
equal	O
or	O
above	O
26	O
.	O

-	O
ACE	B-Observation
score	I-Observation
equal	O
or	O
above	O
85	O
.	O

-	O
Normal	O
physical	B-Procedure_Device
examination	I-Procedure_Device
including	O
normal	O
blood	B-Procedure_Device
samples	I-Procedure_Device
CT	B-Procedure_Device
of	O
cerebrum	O
and	O
EEG	B-Procedure_Device
examination	I-Procedure_Device
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Pregnant	B-Condition
or	O
breastfeeding	B-Condition
.	O

-	O
psychiatric	B-Condition
disease	I-Condition
former	O
depression	B-Condition
is	O
allowed	O
if	O
antidepressive	B-Drug
treatment	I-Drug
has	O
been	O
initiated	O
of	O
a	O
leat	O
3	O
months	O
duration	O
.	O

-	O
Neurologic	B-Condition
or	I-Condition
somatic	I-Condition
disease	I-Condition
including	O
former	O
severe	O
head	B-Condition
trauma	I-Condition
or	O
neuroinfection	B-Condition
.	O

-	O
Antipsychotic	B-Drug
treatment	I-Drug
.	O

-	O
Former	O
severe	O
abuse	B-Condition
of	I-Condition
alcohol,	I-Condition
medication	I-Condition
or	I-Condition
drugs	I-Condition
.	O

-	O
ECT	B-Procedure_Device
treatment	I-Procedure_Device
or	O
anaesthesia	B-Procedure_Device
within	O
the	O
last	O
3	O
months	O
.	O

-	O
no	O
closely	O
related	O
person	O
to	O
assist	O
the	O
patient	O
.	O

Additionally	O
exclusion	O
criteria	O
for	O
healthy	O
control	O
persons:	O
.	O

-	O
meet	O
the	O
diagnostic	O
criteria	O
for	O
MCI	B-Condition
or	O
AD	B-Condition
.	O

>>NCT01454453	O
Inclusion	O
Criteria	O
.	O

Treatment	O
and	O
Control	O
(	O
antipsychotic	O
free	O
)	O
Group	O
.	O

Schizophrenia	B-Condition
.	O

-	O
meet	O
diagnostic	O
criteria	O
for	O
schizophrenia-like	B-Condition
illness	I-Condition
.	O

-	O
aged	O
between	O
60	O
and	O
95	O
years	O
of	O
age	B-Observation
.	O

-	O
score	O
<	O
6	O
on	O
the	O
Geriatric	B-Observation
depression	I-Observation
scale	I-Observation
.	O

Alzheimer's	B-Condition
.	O

-	O
meet	O
diagnostic	O
criteria	O
for	O
AD	B-Condition
.	O

-	O
score	O
<=	O
4	O
on	O
the	O
Modified	B-Observation
Hachinski	I-Observation
Ischaemia	I-Observation
Scale	I-Observation
.	O

-	O
score	O
<	O
8	O
on	O
a	O
modified	B-Observation
version	I-Observation
of	I-Observation
the	I-Observation
UPDRS	I-Observation
.	O

-	O
aged	O
between	O
60	O
and	O
95	O
years	O
of	O
age	B-Observation
.	O

-	O
score	O
<	O
6	O
on	O
the	O
Geriatric	B-Observation
depression	I-Observation
scale	I-Observation
.	O

Exclusion	O
Criteria	O
.	O

Treatment	O
Group	O
.	O

Schizophrenia	B-Condition
.	O

-	O
current	O
or	O
past	O
history	O
of	O
addiction	B-Condition
,	O
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
or	O
epilepsy	B-Condition
.	O

-	O
prescribed	O
any	O
drug	B-Drug
that	O
interferes	O
with	O
brain	B-Drug
dopamine	I-Drug
in	O
past	O
2	O
weeks	O
(	O
6	O
weeks	O
if	O
depot	O
antipsychotic	B-Drug
medication	I-Drug
)	O
.	O

-	O
medical	B-Condition
conditions	I-Condition
that	O
might	O
affect	O
Ability	O
to	O
tolerate	O
a	O
brain	B-Procedure_Device
scan	I-Procedure_Device
.	O

-	O
unable	O
to	O
give	O
informed	O
consent	O
.	O

Alzheimer's	B-Condition
.	O

-	O
current	O
or	O
past	O
history	O
of	O
psychiatric	B-Condition
illness	I-Condition
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
or	O
epilepsy	B-Condition
.	O

-	O
prescribed	O
an	O
antipsychotic	B-Drug
or	O
other	O
oral	B-Drug
drug	I-Drug
that	O
interferes	O
with	O
brain	O
dopamine	O
function	O
within	O
the	O
past	O
2	O
weeks	O
(	O
6	O
weeks	O
if	O
depot	O
antipsychotic	B-Drug
medication	I-Drug
)	O
.	O

-	O
medical	B-Condition
conditions	I-Condition
that	O
might	O
affect	O
a	O
person's	O
ability	O
to	O
tolerate	O
a	O
brain	B-Procedure_Device
scan	I-Procedure_Device
.	O

Control	O
(	O
antipsychotic	O
free	O
)	O
Group	O
.	O

Schizophrenia	B-Condition
.	O

-	O
Prescribed	O
psychotropic	B-Drug
medication	I-Drug
.	O

-	O
unable	O
to	O
give	O
informed	O
consent	O
.	O

Alzheimer's	B-Condition
.	O

Prescribed	O
psychotropic	B-Drug
medication	I-Drug
.	O

>>NCT01013610	O
Inclusion	O
Criteria:	O
.	O

Part	O
A	O
and	O
Part	O
B:	O
.	O

1	O
.	O

Males	O
or	O
females	O
aged	B-Observation
60	O
years	O
or	O
older	O
.	O

Females	O
must	O
be	O
surgically	B-Condition
sterilized	I-Condition
or	O
postmenopausal	B-Condition
for	O
at	O
least	O
two	O
years	O
.	O

Males	O
must	O
be	O
actively	O
practicing	O
double-barrier	O
contraception	O
(	O
condom	O
plus	O
spermicide	O
),	O
unless	O
they	O
have	O
had	O
a	O
vasectomy	O
or	O
their	O
partner(	O
s	O
)	O
meet	O
the	O
above	O
criteria	O
for	O
females	O
.	O

2	O
.	O

Voluntarily	O
consent	O
to	O
participate	O
in	O
this	O
study	O
and	O
provide	O
written	O
informed	O
consent	O
prior	O
to	O
start	O
of	O
any	O
study-specific	O
procedures	O
.	O

3	O
.	O

Be	O
prepared	O
to	O
adhere	O
to	O
the	O
protocol	O
requirements	O
and	O
be	O
willing	O
and	O
able	O
to	O
remain	O
in	O
the	O
study	O
unit	O
for	O
the	O
entire	O
duration	O
of	O
the	O
confinement	O
period	O
.	O

They	O
must	O
also	O
be	O
willing	O
to	O
return	O
for	O
the	O
End-of-Study	O
Visit	O
one	O
week	O
after	O
the	O
last	O
dosing	O
.	O

Part	O
A	O
only:	O
.	O

4	O
.	O

Subjects	O
must	O
be	O
generally	O
healthy	B-Condition
but	O
may	O
be	O
enrolled	O
with	O
a	O
stable,	O
chronic	O
illness	B-Condition
,	O
if	O
it	O
is	O
well	O
controlled	O
and	O
does	O
not	O
interfere	O
with	O
the	O
primary	O
objective	O
of	O
the	O
study	O
.	O

Subjects	O
may	O
be	O
included	O
with	O
clinical	O
deviations	O
from	O
normal	O
limits	O
in	O
medical	O
history,	O
physical	B-Observation
examination	I-Observation
vital	B-Observation
sign	I-Observation
measurements	I-Observation
ECG	B-Procedure_Device
or	O
laboratory	B-Observation
test	I-Observation
results	I-Observation
that	O
are	O
associated	O
with	O
stable,	O
well	O
controlled	O
chronic	O
illness	B-Condition
.	O

Subjects	O
with	O
concomitant	O
diseases	B-Condition
or	O
using	O
concomitant	O
medication	B-Drug
will	O
be	O
allowed	O
to	O
participate	O
provided	O
a	O
stable	O
condition	B-Condition
and	O
stable	O
treatment	B-Drug
for	O
1	O
month	O
(	O
30	O
days	O
)	O
prior	O
to	O
administration	O
of	O
the	O
first	O
dose	O
of	O
study	O
medication	O
.	O

Inclusion	O
of	O
each	O
subject	O
will	O
be	O
reviewed	O
with	O
the	O
Link	O
Medical	O
Monitor	O
prior	O
to	O
enrollment	O
in	O
the	O
trial	O
.	O

Part	O
B	O
only:	O
.	O

5	O
.	O

Subjects	O
with	O
Mild	O
Alzheimer's	B-Condition
Disease	I-Condition
as	O
defined	O
by	O
DSM-IV	B-Observation
.	O

6	O
.	O

Subjects	O
with	O
a	O
score	O
of	O
>=	O
18	O
-	O
26	O
on	O
the	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
.	O

7	O
.	O

Subjects	O
with	O
a	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
total	I-Observation
score	I-Observation
of	O
0.5	O
or	O
1.0	O
(	O
possible	O
or	O
mild	O
dementia	B-Condition
)	O
.	O

8	O
.	O

Subjects	O
with	O
a	O
Rosen-Modified	B-Observation
Hachinski	I-Observation
Ischemic	I-Observation
score	I-Observation
of	O
<=	O
4	O
.	O

Exclusion	O
Criteria:	O
.	O

Part	O
A	O
and	O
Part	O
B:	O
.	O

1	O
.	O

Any	O
significant	O
unstable	O
or	O
uncontrolled	O
cardiovascular,	B-Condition
hepatic,	I-Condition
renal,	I-Condition
respiratory,	I-Condition
gastrointestinal,	I-Condition
endocrine,	I-Condition
immunologic,	I-Condition
dermatologic,	I-Condition
hematologic,	I-Condition
neurologic	I-Condition
or	I-Condition
psychiatric	I-Condition
disease	I-Condition
as	O
determined	O
by	O
medical	B-Observation
history	I-Observation
physical	B-Observation
examination	I-Observation
or	O
laboratory	B-Observation
tests	I-Observation
.	O

2	O
.	O

Subjects	O
who	O
have	O
positive	O
serologic	B-Observation
findings	I-Observation
for	O
human	B-Observation
immunodeficiency	I-Observation
virus	I-Observation
(	I-Observation
HIV	I-Observation
)	I-Observation
antibodies	I-Observation
hepatitis	B-Observation
B	I-Observation
surface	I-Observation
antigen	I-Observation
(	I-Observation
HBsAg	I-Observation
)	I-Observation
and	O
/	O
or	O
hepatitis	B-Observation
C	I-Observation
virus	I-Observation
(	I-Observation
HCV	I-Observation
)	I-Observation
antibodies	I-Observation
.	O

3	O
.	O

Subjects	O
who	O
have	O
received	O
any	O
experimental	B-Drug
drugs	I-Drug
or	O
devices	B-Procedure_Device
within	O
30	O
days	O
prior	O
to	O
dosing	O
or	O
who	O
wish	O
to	O
receive	O
any	O
experimental	B-Drug
drug	I-Drug
within	O
30	O
days	O
after	O
completing	O
the	O
study	O
.	O

4	O
.	O

Subjects	O
unable	O
to	O
understand	O
the	O
protocol	O
requirements,	O
instructions	O
and	O
study	O
related	O
restrictions,	O
the	O
nature,	O
scope	O
and	O
possible	O
consequences	O
of	O
the	O
clinical	O
study	O
.	O

>>NCT01760005	O
Inclusion	O
Criteria:	O
.	O

-	O
Between	O
18	O
-	O
80	O
years	O
of	O
age	B-Observation
.	O

-	O
Individuals	O
who	O
know	O
they	O
have	O
an	O
Alzheimer's	O
disease-causing	O
mutation	O
or	O
are	O
unaware	O
of	O
their	O
genetic	O
status	O
and	O
have	O
a	O
50%	O
chance	O
of	O
having	O
an	O
autosomal	O
dominant	O
Alzheimer's	O
disease	O
(	O
ADAD	O
)	O
mutation	O
(	O
eg	O
parent	O
or	O
sibling	O
with	O
a	O
known	O
AD-causing	O
mutation	O
)	O
.	O

-	O
Are	O
within	O
-	O
15	O
to	O
+	O
10	O
years	O
of	O
the	O
predicted	O
or	O
actual	O
age	B-Observation
of	I-Observation
cognitive	I-Observation
symptom	I-Observation
onset	I-Observation
.	O

-	O
Cognitively	B-Condition
normal	I-Condition
or	O
with	O
mild	B-Condition
cognitive	I-Condition
impairment	I-Condition
or	O
mild	B-Condition
dementia	I-Condition
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
of	O
0	O
-	O
1	O
(	O
inclusive	O
)	O
.	O

-	O
Able	O
to	O
undergo	O
Magnetic	B-Procedure_Device
Resonance	I-Procedure_Device
Imaging	I-Procedure_Device
(	I-Procedure_Device
MRI	I-Procedure_Device
)	I-Procedure_Device
Lumbar	B-Procedure_Device
Puncture	I-Procedure_Device
(	I-Procedure_Device
LP	I-Procedure_Device
)	I-Procedure_Device
Positron	B-Procedure_Device
Emission	I-Procedure_Device
Tomography	I-Procedure_Device
(	I-Procedure_Device
PET	I-Procedure_Device
)	I-Procedure_Device
and	O
complete	O
all	O
study	O
related	O
testing	O
and	O
evaluations	O
.	O

-	O
For	O
women	O
of	O
childbearing	O
potential,	O
if	O
partner	O
is	O
not	O
sterilized,	O
subject	O
must	O
agree	O
to	O
use	O
effective	O
contraceptive	O
measures	O
(	O
hormonal	O
contraception,	O
intra-uterine	O
device,	O
sexual	O
abstinence,	O
barrier	O
method	O
with	O
spermicide	O
)	O
.	O

-	O
Adequate	O
visual	B-Observation
and	I-Observation
auditory	I-Observation
abilities	I-Observation
to	O
perform	O
all	O
aspects	O
of	O
the	O
cognitive	O
and	O
functional	O
assessments	O
.	O

-	O
Has	O
a	O
Study	O
Partner	O
who	O
in	O
the	O
investigator's	O
judgment	O
is	O
able	O
to	O
provide	O
accurate	O
information	O
as	O
to	O
the	O
subject's	O
cognitive	O
and	O
functional	O
abilities,	O
who	O
agrees	O
to	O
provide	O
information	O
at	O
the	O
study	O
visits	O
which	O
require	O
informant	O
input	O
for	O
scale	O
completion	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
History	O
or	O
presence	O
of	O
brain	B-Procedure_Device
MRI	I-Procedure_Device
scans	I-Procedure_Device
indicative	O
of	O
any	O
other	O
significant	B-Condition
abnormality	I-Condition
.	O

-	O
Presence	O
of	O
pacemakers	B-Procedure_Device
,	O
aneurysm	B-Procedure_Device
clips	I-Procedure_Device
artificial	B-Procedure_Device
heart	I-Procedure_Device
valves	I-Procedure_Device
ear	B-Procedure_Device
implants	I-Procedure_Device
or	O
oreign	B-Procedure_Device
metal	I-Procedure_Device
objects	I-Procedure_Device
in	O
the	O
eyes,	O
skin	O
or	O
body	O
which	O
would	O
preclude	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
.	O

-	O
History	O
or	O
presence	O
of	O
clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
hepatic	B-Condition
/	I-Condition
renal	I-Condition
disorders	I-Condition
infectious	B-Condition
disease	I-Condition
or	O
immune	B-Condition
disorder	I-Condition
or	O
metabolic	B-Condition
/	I-Condition
endocrine	I-Condition
disorders	I-Condition
.	O

-	O
Anticoagulants	B-Drug
except	B-Negation_cue
low	O
dose	O
(<=	O
325	O
mg	O
)	O
aspirin	B-Drug
.	O

-	O
Have	O
been	O
exposed	O
to	O
a	O
monoclonal	B-Drug
antibody	I-Drug
targeting	I-Drug
beta	I-Drug
amyloid	I-Drug
peptide	I-Drug
within	O
the	O
past	O
six	O
months	O
.	O

-	O
History	O
of	O
cancer	B-Condition
within	O
the	O
last	O
5	O
years,	O
except	B-Negation_cue
basal	B-Condition
cell	I-Condition
carcinoma	I-Condition
non-squamous	B-Condition
skin	I-Condition
carcinoma	I-Condition
prostate	B-Condition
cancer	I-Condition
or	O
carcinoma	B-Condition
in	I-Condition
situ	I-Condition
with	O
no	B-Negation_cue
significant	O
progression	B-Condition
over	O
the	O
past	O
2	O
years	O
.	O

-	O
Positive	O
urine	B-Observation
or	I-Observation
serum	I-Observation
pregnancy	I-Observation
test	I-Observation
or	O
plans	O
or	O
desires	O
to	O
become	O
pregnant	B-Condition
during	O
the	O
course	O
of	O
the	O
trial	O
.	O

-	O
Subjects	O
unable	O
to	O
complete	O
all	O
study	O
related	O
testing,	O
including	O
implanted	B-Procedure_Device
metal	I-Procedure_Device
that	O
cannot	O
be	O
removed	O
for	O
MRI	B-Procedure_Device
scanning	I-Procedure_Device
required	O
anticoagulation	B-Drug
and	O
pregnancy	B-Condition
.	O

>>NCT00955422	O
-	O
Patients	O
with	O
signs	O
and	O
symptoms	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
will	O
be	O
recruited	O
from	O
neurological	O
and	O
psychiatric	O
clinics,	O
from	O
self	O
or	O
family	O
referral	O
in	O
response	O
to	O
advertisements	O
or	O
from	O
private	O
physicians	O
.	O

Healthy	B-Condition
volunteers	O
will	O
be	O
recruited	O
by	O
the	O
MIB	O
.	O

INCLUSION	O
CRITERIA:	O
.	O

1	O
.	O

Patients	O
and	O
healthy	O
volunteers	O
must	O
be	O
age	B-Observation
45	O
or	O
older	O
.	O

2	O
.	O

Patients	O
must	O
have	O
a	O
history	O
of	O
progressive	B-Condition
memory	I-Condition
impairment	I-Condition
.	O

3	O
.	O

Patients	O
must	O
have	O
a	O
caregiver	O
who	O
is	O
willing	O
to	O
accompany	O
the	O
subject	O
to	O
the	O
NIH	O
.	O

EXCLUSION	O
CRITERIA	O
FOR	O
PATIENTS:	O
.	O

1	O
.	O

The	O
diagnosis	O
of	O
a	O
different	O
type	O
of	O
dementia	B-Condition
,	O
including	O
frontotemporal	B-Condition
dementia	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
Lewy	B-Condition
body	I-Condition
dementia	I-Condition
Parkinson's	B-Condition
disease	I-Condition
dementia	I-Condition
Huntington's	B-Condition
disease	I-Condition
vascular	B-Condition
dementia	I-Condition
.	O

Pregnant	B-Condition
nant	O
women	O
.	O

Wome	O
childbearing	B-Condition
potential	I-Condition
will	O
be	O
screened	O
by	O
history	O
for	O
the	O
possibility	O
of	O
pregnancy	O
and	O
under	O
urine	B-Observation
pregnancy	I-Observation
test	I-Observation
.	O

3	O
.	O

Any	O
med	O
contraindication	B-Condition
tion	O
to	O
the	O
procedures	O
performed	O
in	O
the	O
study	O
or	O
any	O
current	O
se	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer	B-Condition
s	I-Condition
disease	I-Condition
.	O

4	O
.	O

Behavioral	O
symptoms	O
that	O
would	O
preclude	O
the	O
gathering	O
of	O
data	O
for	O
the	O
study	O
or	O
advanced	O
disease	O
such	O
that	O
subjects	O
cannot	O
provide	O
assent	O
.	O

EXCLUSION	O
CRITERIA	O
FOR	O
CONTROLS:	O
.	O

1	O
.	O

The	O
diagnosis	O
brain	B-Condition
disorder	I-Condition
.	O

Pregnant	B-Condition
nant	O
women	O
.	O

3	O
.	O

Any	O
med	O
contraindication	B-Condition
tion	O
to	O
the	O
procedures	O
performed	O
in	O
the	O
study	O
or	O
any	O
current	O
se	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
.	O

>>NCT01609348	O
Inclusion	O
Criteria:	O
Dementia	B-Condition
ntia	O
du	O
Alzheimer's	B-Condition
disease	I-Condition
by	O
DSM-IV	O
(	O
TR	O
)	O
criteria	O
(	O
90	O
),	O
wi	O
Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
(	I-Observation
82	I-Observation
)	I-Observation
score	I-Observation
of	O
10	O
-	O
26	O
inclusive;	O
dAD	B-Condition
dAD	O
as	O
defined	O
by	O
NIMH(	B-Observation
National	I-Observation
Institute	I-Observation
of	I-Observation
Mental	I-Observation
Health	I-Observation
)	I-Observation
Consensus	I-Observation
Criteria	I-Observation
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
Scale	I-Observation
of	O
1	O
"mild"	O
or	O
2	O
"moderate"	O
.	O

Ratings	O
of	O
3	O
"severe"	O
wil	O
excluded	B-Negation_cue
uded	O
because	O
many	O
of	O
the	O
instruments	O
lack	O
validity	O
in	O
the	O
presence	O
of	O
se	O
cognitive	B-Condition
impairment	I-Condition
particularly	O
language	O
deficits	O
.	O

-	O
Sufficie	O
good	B-Condition
health	I-Condition
to	O
be	O
treated	O
using	O
the	O
study	O
protocol	O
in	O
usual	O
care	O
circumstances;	O
.	O

-	O
Patient	O
or	O
surrogate	O
and	O
caregiver	O
provides	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
study;	O
.	O

-	O
A	O
caregiver	O
is	O
available	O
who	O
spends	O
at	O
least	O
10	O
hours	O
per	O
week	O
with	O
the	O
patient,	O
supervises	O
her	O
care	O
and	O
is	O
willing	O
to	O
accompany	O
the	O
patient	O
to	O
study	O
visits	O
and	O
to	O
provide	O
information	O
about	O
the	O
patient	O
.	O

-	O
Female	O
participants	O
must	O
be	O
at	O
least	O
2	O
y	O
post	B-Condition
menopause	I-Condition
surgically	B-Condition
sterilized	I-Condition
.	O

Exclusion	O
Criteria	O
.	O

-	O
Presence	O
brain	B-Condition
disease	I-Condition
that	O
might	O
otherwise	O
fully	O
explain	O
the	O
presenc	O
dementia	B-Condition
ntia,	O
suc	O
stroke	B-Condition
r	O
Parkinson's	B-Condition
disease	I-Condition
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
multiple	B-Condition
sclerosis	I-Condition
and	O
sim	O
neurologic	B-Condition
diseases	I-Condition
.	O

-	O
Clinically	O
signifi	O
psychosis	B-Condition
osis	O
that	O
requ	O
antipsychotic	B-Drug
treatment	I-Drug
-Treatment	O
venlafaxine	B-Drug
xin	O
contraindicated	B-Condition
ated	O
in	O
the	O
opinion	O
of	O
the	O
attending	O
psychiatrist,	O
for	O
example	O
if	O
there	O
is	O
a	O
p	O
history	B-Observation
tory	O
of	O
dangerous	O
or	O
-unaccept	O
side	B-Condition
effects	I-Condition
when	O
treated	O
venlafaxine	B-Drug
xine;	O
.	O

-	O
Failure	O
of	O
treatment	O
venlafaxine	B-Drug
xine	O
in	O
the	O
past	O
depression	B-Condition
sion	O
after	O
convincing	O
evidence	O
of	O
a	O
"good	O
trial,"	O
for	O
example	O
8	O
weeks	O
at	O
the	O
highest	O
tolerated	O
dose;	O
.	O

-	O
Treatment	O
for	O
a	O
condition	O
or	O
wi	O
medication	B-Drug
tion	O
that	O
would	O
prohibit	O
the	O
safe	O
concurrent	O
us	O
venlafaxine	B-Drug
xine	O
(	O
specifically	O
inclu	O
systolic	B-Observation
blood	I-Observation
pressure	I-Observation
>	O
180	O
mm	O
H	O
diastolic	B-Observation
blood	I-Observation
pressure	I-Observation
>	O
100	O
mm	O
Hg	O
);	O
.	O

-	O
Diagnosi	O
congenital	B-Condition
long	I-Condition
Q-T	I-Condition
syndrome	I-Condition
.	O

-	O
The	O
patient	O
requires	O
psychiatric	O
hospitalization	O
for	O
depression	O
or	O
is	O
suicidal;	O
.	O

-	O
Initiation,	O
discontinuation	O
or	O
dose	O
change	O
cholinesterase	B-Drug
inhibitor	I-Drug
memantine	B-Drug
tine	O
use	O
within	O
the	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

>>NCT02494531	O
Inclusion	O
Criteria:	O
.	O

1	O
.	O

For	O
all	O
patients	O
enrolled	O
in	O
the	O
study:	O
Aged	B-Observation
Aged	O
18	O
years	O
and	O
above	O
Visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
adequate	O
for	O
neuropsychological	O
testing	O
.	O

-	O
Having	O
signed	O
an	O
informed	O
consent	O
.	O

-	O
Being	O
affiliated	O
to	O
health	O
insurance	O
.	O

2	O
.	O

MCI	B-Condition
MCI	O
patients:	O
.	O

For	O
this	O
group,	O
the	O
criteria	O
are	O
the	O
same	O
as	O
those	O
of	O
Memento	O
but	O
with	O
specially	O
designed	O
neuropsychological	O
tests	O
for	O
illiterate	O
/	O
low	O
educated	O
patients	O
.	O

-	O
Performing	O
worse	O
than	O
one	O
standard	O
deviation	O
to	O
the	O
mean	O
(	O
compared	O
to	O
age	O
and	O
educational	O
norms	O
)	O
in	O
one	O
or	O
more	O
cognitive	O
domains	O
(	O
neuropsychological	O
tests	O
battery	O
exploring	O
memory,	O
language,	O
praxis,	O
vision,	O
executive	O
functions	O
);	O
this	O
deviation	O
is	O
required	O
to	O
be	O
documented	O
by	O
tests	O
performed	O
less	O
than	O
6	O
months	O
age	O
Clinical	B-Observation
dementia	I-Observation
Rating	I-Observation
scale	I-Observation
<	O
or	O
=	O
0.5	O
.	O

3	O
.	O

AD	B-Condition
r	O
AD	O
patients	O
.	O

-	O
Fulfil	O
DSM	B-Observation
IV	I-Observation
criteria	I-Observation
AD	B-Condition
f	O
AD	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
scale	I-Observation
>	O
0.5	O
Patients	O
are	O
defined	O
as	O
"illiterate"	O
having	O
5	O
or	O
less	O
years	O
of	O
schooling	O
and	O
"literate"	O
when	O
having	O
more	O
than	O
5	O
years	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Being	O
under	O
guardianship	O
.	O

-	O
Residence	O
in	O
skilling	O
nursing	O
facility	O
Pregnant	B-Condition
nan	O
breast	B-Condition
feeding	I-Condition
women	O
.	O

-	O
Alzheimer's	O
disease	O
caused	O
by	O
gene	O
mutations	O
Brain	B-Procedure_Device
MRI	I-Procedure_Device
MRI	O
exclusion	O
criter	O
pacemakers	B-Procedure_Device
k	O
aneurysm	B-Procedure_Device
clips	I-Procedure_Device
artificial	B-Procedure_Device
heart	I-Procedure_Device
valves	I-Procedure_Device
ear	B-Procedure_Device
implants	I-Procedure_Device
metal	B-Procedure_Device
fragments	I-Procedure_Device
foreign	B-Procedure_Device
objects	I-Procedure_Device
in	O
the	O
eyes,	O
skin	O
or	O
body	O
)	O
or	O
refu	O
MRI	B-Procedure_Device
MRI	O
Neurological	B-Condition
disease	I-Condition
such	O
as:	O
tre	O
epilepsy	B-Condition
epsy,	O
tre	O
Parkinson's	B-Condition
disease	I-Condition
Huntington	B-Condition
disease	I-Condition
brain	B-Condition
tumour	I-Condition
subdural	B-Condition
haematoma	I-Condition
progressive	B-Condition
supranuclear	I-Condition
palsy	I-Condition
histor	O
head	B-Condition
trauma	I-Condition
followe	O
persistent	B-Condition
neurological	I-Condition
deficits	I-Condition
histor	O
stroke	B-Condition
roke	O
Schizophrenia	B-Condition
enia	O
or	O
o	O
psychiatric	B-Observation
history	I-Observation
DSM-IV	B-Observation
criteria	I-Observation
).	O

>>NCT01847586	O
Inclusion	O
Criteria	O
for	O
patients:	O
.	O

-	O
Age	B-Observation
65	O
or	O
above	O
.	O

-	O
Meet	O
NINCDS-ADRDA	B-Observation
and	O
DSM-IV	B-Observation
TR	I-Observation
criteria	I-Observation
for	O
a	O
current	O
diagnosis	O
of	O
Alzheimer's	B-Condition
Disease	I-Condition
.	O

-	O
Stable	O
does	O
of	O
acetylcholinesterase	B-Drug
inhibitors	I-Drug
for	O
at	O
least	O
3	O
months	O
.	O

-	O
Willingness	O
and	O
ability	O
to	O
speak	O
English	O
.	O

-	O
Willingness	O
and	O
ability	O
to	O
provide	O
informed	O
consent	O
.	O

-	O
Corrected	O
visual	O
ability	O
that	O
enables	O
reading	O
of	O
newspaper	O
headlines	O
and	O
corrected	O
hearing	O
capacity	O
that	O
is	O
adequate	O
to	O
respond	O
to	O
a	O
raised	O
conversational	O
voice	O
.	O

Exclusion	O
Criteria	O
for	O
patients:	O
.	O

-	O
Meets	O
criteria	O
for	O
an	O
Axis	B-Observation
I	I-Observation
diagnosis	I-Observation
within	O
the	O
past	O
12	O
months	O
other	B-Negation_cue
than	I-Negation_cue
Dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer	I-Condition
type	I-Condition
.	O

-	O
Mini	B-Observation
Mental	I-Observation
Status	I-Observation
Examination	I-Observation
score	I-Observation
of	O
16	O
or	O
less	O
as	O
described	O
above	O
.	O

-	O
Meets	O
diagnostic	O
criteria	O
for	O
current	O
alcohol	B-Condition
or	I-Condition
other	I-Condition
drug	I-Condition
dependence	I-Condition
within	O
6	O
months	O
of	O
testing	O
.	O

-	O
Electroconvulsive	B-Procedure_Device
Therapy	I-Procedure_Device
(	I-Procedure_Device
ECT	I-Procedure_Device
)	I-Procedure_Device
within	O
6	O
months	O
of	O
testing	O
.	O

-	O
Left	O
handedness	O
.	O

-	O
Incompetency	O
to	O
consent	O
.	O

-	O
Any	O
contraindication	B-Condition
for	O
TMS	B-Procedure_Device
.	O

Inclusion	O
Criteria	O
for	O
healthy	O
controls:	O
.	O

-	O
Age	B-Observation
65	O
or	O
above	O
.	O

-	O
Willingness	O
and	O
ability	O
to	O
speak	O
English	O
.	O

-	O
Willingness	O
and	O
ability	O
to	O
provide	O
informed	O
consent	O
.	O

-	O
Corrected	O
visual	B-Observation
ability	I-Observation
that	O
enables	O
reading	O
of	O
newspaper	O
headlines	O
and	O
corrected	O
hearing	O
capacity	O
that	O
is	O
adequate	O
to	O
respond	O
to	O
a	O
raised	O
conversational	O
voice	O
.	O

Exclusion	O
Criteria	O
for	O
healthy	O
controls:	O
.	O

-	O
Meets	O
criteria	O
for	O
an	O
Axis	B-Observation
I	I-Observation
diagnosis	I-Observation
other	B-Negation_cue
than	I-Negation_cue
simple	B-Condition
phobias	I-Condition
or	O
adjustment	B-Condition
disorder	I-Condition
.	O

-	O
Other	O
neurological	B-Condition
disorder	I-Condition
affecting	O
central	O
nervous	O
system	O
.	O

-	O
Psychotropic	B-Drug
medication	I-Drug
except	B-Negation_cue
for	I-Negation_cue
sedative	B-Drug
/hypnotics	I-Drug
at	O
a	O
stable	O
dose	O
for	O
at	O
least	O
4	O
weeks	O
.	O

-	O
Left	O
handedness	O
.	O

-	O
Any	O
contraindication	B-Condition
for	O
TMS	B-Procedure_Device
.	O

>>NCT02119546	O
Inclusion	O
Criteria:	O
.	O

-	O
45	O
-	O
85	O
years	O
old	O
and	O
had	O
independent	O
walking	O
ability	O
.	O

-	O
The	O
MCI	B-Condition
is	O
diagnosed	O
basically	O
on	O
Petersen's	B-Observation
criteria	I-Observation
(	O
Petersen,	O
2001	O
),	O
CDR	B-Observation
score	I-Observation
of	O
0.5	O
but	O
normal	O
activity	O
of	O
daily	O
living	O
/instrumental	O
activities	O
of	O
daily	O
living	O
and	O
not	O
demented	O
.	O

-	O
Diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
based	O
on	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
for	O
probable	O
Alzheimer	B-Condition
disease	I-Condition
(	O
McKhann,	O
et	O
al.,	O
1984	O
)	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
The	O
subjects	O
who	O
had	O
any	O
neurological,	B-Condition
musculoskeletal,	I-Condition
cardio-pulmonary	I-Condition
disorder	I-Condition
which	O
would	O
cause	O
gait	B-Condition
disorder	I-Condition
or	O
cognitive	B-Condition
dysfunction	I-Condition
such	O
as	O
stroke	B-Condition
,	O
Parkinson	B-Condition
disease	I-Condition
or	O
arthritis	B-Condition
were	O
excluded	B-Negation_cue
.	O

>>NCT01066481	O
Inclusion	O
Criteria:	O
.	O

-	O
Mild-to-Moderate	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
MMSE	B-Observation
score	I-Observation
10	O
-	O
24	O
inclusive	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Administration	O
of	O
anti-dementia	B-Drug
drugs	I-Drug
including	O
cholinesterase-inhibitors	B-Drug
or	O
NMDA	B-Drug
receptor	I-Drug
antagonists	I-Drug
within	O
90	O
days	O
.	O

-	O
Complication	O
of	O
other	O
causes	B-Condition
of	I-Condition
dementia	I-Condition
.	O

>>NCT01841125	O
Inclusion	O
Criteria:	O
.	O

1	O
)	O
over	O
the	O
age	B-Observation
of	O
50	O
.	O

2	O
)	O
Medical	O
diagnostic	O
criteria	O
must	O
meet	O
the	O
standard	O
.	O

1	O
.	O

Subject	O
diagnosed	O
with	O
Alzheimer's	B-Condition
disease	I-Condition
in	O
accordance	O
with	O
NINCDS-ADRDA	B-Observation
Criteria	I-Observation
.	O

2	O
.	O

Subject	O
with	O
three	O
or	O
more	O
symptoms	O
of	O
the	O
Olin	B-Condition
depression	I-Condition
(	O
major	B-Condition
depressive	I-Condition
episode	I-Condition
)	O
diagnostic	O
criteria	O
.	O

3	O
.	O
clinical	B-Observation
dementia	I-Observation
rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
of	O
0.5	O
to	O
2	O
.	O

4	O
.	O

MMSE	B-Observation
10	O
-	O
26	O
(	O
K-MMSE	B-Observation
)	O
.	O

5	O
.	O

GDS-	B-Observation
15	I-Observation
>=	O
5	O
points	O
.	O

3	O
)	O
When	O
screening,	O
Cholinesterase	B-Drug
inhibitors	I-Drug
taking	O
a	O
minimum	O
of	O
four	O
weeks	O
or	O
more	O
stable	O
subject	O
.	O

4	O
)	O
During	O
the	O
clinical	O
trials,	O
Subject	O
does	O
not	O
change	O
the	O
capacity	O
of	O
Cholinesterase	B-Drug
Inhibitors	I-Drug
.	O

5	O
)	O
MRI	B-Procedure_Device
or	O
CT	B-Procedure_Device
results	O
within	O
24	O
months	O
of	O
subject	O
with	O
Alzheimer's	B-Condition
disease	I-Condition
(	I-Condition
AD	I-Condition
)	I-Condition
.	O

6	O
)	O
Participation	O
in	O
clinical	O
trials	O
to	O
determine	O
their	O
own	O
and	O
written	O
informed	O
consent	O
form	O
and	O
subject	O
who	O
actively	O
perform	O
clinical	O
procedure	O
including	O
the	O
questionnaire	O
.	O

But	O
the	O
subjects	O
with	O
cognitive	O
dysfunction	O
that	O
cannot	O
voluntarily	O
make	O
the	O
decision,	O
can	O
be	O
determined	O
by	O
an	O
authorized	O
representative	O
to	O
participate	O
in	O
.	O

7	O
)	O
Subjects	O
must	O
be	O
accompanied	O
their	O
guardian	O
to	O
every	O
visit	O
.	O

More	O
than	O
three	O
days	O
a	O
week,	O
more	O
than	O
4	O
hours	O
per	O
day,	O
spend	O
the	O
day	O
with	O
the	O
guardian	O
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

If	O
you	O
are	O
taking	O
other	O
depression	B-Drug
drugs	I-Drug
within	O
4	O
weeks	O
before	O
the	O
start	O
of	O
the	O
clinical	O
trials(	O
eg	O
SSRI	B-Drug
,	O
Stablon	B-Drug
,	O
TCA	B-Drug
,	O
wellbutrin	B-Drug
,	O
ixel	B-Drug
)	O
.	O

2	O
.	O

If	O
you	O
have	O
any	O
other	O
mental	B-Condition
illness	I-Condition
(	O
bipolar	B-Condition
disorder	I-Condition
schizophrenia	B-Condition
,	O
etc.)	O
.	O

3	O
.	O

If	O
you	O
have	O
a	O
serious	O
medical	B-Condition
illness	I-Condition
(	O
heart	B-Condition
failure	I-Condition
angina	B-Condition
pectoris	I-Condition
myocardial	B-Condition
infarction	I-Condition
arteriosclerosis	B-Condition
,	O
etc.)	O

or	O
psychiatric	B-Condition
illness	I-Condition
.	O

4	O
.	O

Seizures	B-Condition
,	O
brain	B-Procedure_Device
surgery	I-Procedure_Device
organic	B-Condition
brain	I-Condition
disease	I-Condition
and	O
history	O
of	O
organic	B-Condition
affective	I-Condition
disorder	I-Condition
and	O
at	O
the	O
brain	B-Procedure_Device
MRI	I-Procedure_Device
abnormalities	B-Condition
other	B-Negation_cue
than	I-Negation_cue
brain	B-Condition
atrophy	I-Condition
.	O

5	O
.	O

If	O
you	O
have	O
a	O
history	O
of	O
the	O
test	B-Condition
drug	I-Condition
hypersensitivity	I-Condition
.	O

6	O
.	O

If	O
you	O
are	O
taking	O
memantin	B-Drug
(	O
dementia	B-Condition
)	O
.	O

7	O
.	O

If	O
you	O
participated	O
in	O
another	O
clinical	O
trial	O
within	O
3	O
months	O
.	O

8	O
.	O

If	O
pregnant	B-Condition
or	O
fertile	B-Condition
women,	O
who	O
have	O
not	O
received	O
sterilization	O
or	O
if	O
you	O
do	O
not	O
want	O
to	O
use	O
an	O
effective	O
method	O
of	O
contraception	O
.	O

9	O
.	O

In	O
laboratory	B-Observation
tests	I-Observation
if	O
you	O
have	O
kidney	B-Condition
failure	I-Condition
or	O
liver	B-Condition
failure	I-Condition
.	O

10	O
.	O

If	O
you	O
have	O
history	O
or	O
habitual	O
drinking	B-Condition
or	O
a	O
history	O
of	O
drug	B-Condition
abuse	I-Condition
.	O

11	O
.	O

Uncontrolled	O
diabetes	B-Condition
or	O
hypertension	B-Condition
.	O

12	O
.	O

If	O
determined	O
to	O
be	O
inappropriate	O
for	O
clinical	O
trials	O
.	O

>>NCT01948791	O
Inclusion	O
Criteria:	O
.	O

1	O
.	O

Have	O
a	O
diagnosis	O
of	O
dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
type	I-Condition
according	O
to	O
the	O
DSM-IV	B-Observation
criteria	I-Observation
and	O
have	O
a	O
clinical	O
diagnosis	O
of	O
probable	O
AD	B-Condition
according	O
to	O
NINCDS	B-Observation
/	I-Observation
ADRDA	I-Observation
criteria	I-Observation
.	O

2	O
.	O

MMSE	B-Observation
score	I-Observation
of	O
>=	O
10	O
and	O
<=	O
26	O
.	O

3	O
.	O

The	O
treatment	O
nave	O
patient	O
and	O
the	O
one	O
who	O
have	O
stopped	O
the	O
donepezil	B-Drug
,	O
galantamine	B-Drug
,	O
huperzine	B-Drug
A	I-Drug
or	O
memantine	B-Drug
at	O
least	O
2	O
weeks	O
.	O

4	O
.	O

Be	O
in	O
stable	O
medical	B-Condition
condition	I-Condition
.	O

5	O
.	O

Have	O
signed	O
off	O
informed	O
consent	O
form	O
by	O
patients	O
or	O
his	O
/	O
her	O
legal	O
guardian	O
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

Severe	O
AD	B-Condition
.	O

2	O
.	O

Patients	O
with	O
a	O
history	O
of	O
cerebrovascular	B-Condition
disease	I-Condition
Active	O
or	O
uncontrolled	O
epilepsy	B-Condition
,	O
Active	O
hypothyroidism	B-Condition
,	O
asthma	B-Condition
,	O
CNS	B-Condition
infection	I-Condition
other	O
Neurodegenerative	B-Condition
disorders	I-Condition
an	O
advanced,	O
severe,	O
progressive	O
or	O
unstable	O
medical	B-Condition
condition	I-Condition
.	O

3	O
.	O

Attending	O
other	O
clinical	O
trials	O
or	O
taking	O
other	O
clinical	B-Drug
trial	I-Drug
drugs	I-Drug
.	O

4	O
.	O

A	O
score	O
of	O
>	O
4	O
on	O
the	O
Modified	B-Observation
Hachinski	I-Observation
Ischemic	I-Observation
Scale	I-Observation
(	I-Observation
MHIS	I-Observation
)	I-Observation
.	O

5	O
.	O

Patients	O
who	O
is	O
using	O
any	O
AChEI	B-Drug
or	O
memantine	B-Drug
.	O

>>NCT02079909	O
Inclusion	O
Criteria:	O
.	O

-	O
Male	O
or	O
female	O
(	O
post-menopausal	B-Condition
or	O
surgically	B-Condition
sterile	I-Condition
)	O
.	O

-	O
Patients	O
with	O
Mild	O
to	O
moderate	O
Alzheimer's	B-Condition
disease	I-Condition
who	O
are	O
receiving	O
donepezil	B-Drug
(	O
Aricept	B-Drug
)	O
or	O
rivastigmine	B-Drug
transdermal	I-Drug
system	I-Drug
(	O
Exelon	B-Drug
Patch	I-Drug
),	O
.	O

Memantine	B-Drug
(	O
Namenda	B-Drug
)	O
is	O
allowed	O
only	O
when	O
prescribed	O
in	O
combination	O
with	O
donepezil	B-Drug
or	O
rivastigmine	B-Drug
transdermal	I-Drug
system	I-Drug
.	O

-	O
Age	B-Observation
55	O
to	O
85	O
inclusive	O
.	O

-	O
Patients	O
must	O
be	O
living	O
in	O
the	O
community	O
.	O

-	O
Patients	O
must	O
have	O
an	O
eligible	O
informant	O
or	O
study	O
partner	O
(	O
caregiver	O
)	O
.	O

-	O
Patients	O
and	O
eligible	O
informant	O
or	O
study	O
partner	O
(	O
caregiver	O
)	O
must	O
be	O
able	O
to	O
read	O
and	O
understand	O
English	O
.	O

-	O
Informed	O
consent	O
obtained	O
from	O
both	O
the	O
patient	O
and	O
the	O
caregiver	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Patients	O
with	O
clinically	O
significant	O
cardiac,	B-Condition
hepatic	I-Condition
or	I-Condition
renal	I-Condition
impairment	I-Condition
.	O

-	O
Patient	O
have	O
a	O
dementia	B-Condition
not	I-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
type	I-Condition
etc	O
(	O
According	O
to	O
the	O
protocol	O
)	O
.	O

-	O
Patients	O
who	O
are	O
taking	O
any	O
drug	B-Drug
other	B-Negation_cue
than	I-Negation_cue
donepezil	B-Drug
or	O
rivastigmine	B-Drug
transdermal	I-Drug
system	I-Drug
for	O
Alzheimer's	B-Condition
disease	I-Condition
including	O
olal	B-Drug
rivastigmine	I-Drug
(	O
Exelon	B-Drug
),	O
galantamine	B-Drug
(	O
Razadyne	B-Drug
)	O
.	O

>>NCT00414622	O
Inclusion	O
Criteria:	O
.	O

-	O
probable	O
Alzheimer	B-Condition
.	O

Exclusion	O
Criteria:	O
.	O

-	O
others	O
.	O

>>NCT00096473	O
Inclusion	O
Criteria:	O
.	O

-	O
Clinically	O
diagnosed	O
Alzheimer's	B-Condition
Disease	I-Condition
with	O
MMSE	B-Observation
score	I-Observation
1	O
-	O
12	O
.	O

-	O
Have	O
not	B-Negation_cue
been	O
treated	O
by	O
any	O
medication	B-Drug
for	O
Alzheimer's	B-Condition
Disease	I-Condition
in	O
past	O
3	O
months	O
.	O

-	O
Live	O
in	O
community	O
or	O
Assisted	O
Living	O
Facility	O
.	O

-	O
Healthy	B-Condition
or	O
with	O
chronic	B-Condition
diseases	I-Condition
that	O
are	O
medically	O
controlled	O
or	O
stabilized	O
.	O

-	O
Able	O
to	O
swallow	O
tablets	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Any	O
primary	O
neurological	B-Condition
or	I-Condition
psychiatric	I-Condition
diagnosis	I-Condition
(	O
including	O
depressive	B-Condition
disorder	I-Condition
)	O
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
Disease	I-Condition
.	O

-	O
Dementia	B-Condition
caused	O
by	O
organic	B-Condition
diseases	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
Disease	I-Condition
.	O

>>NCT00040378	O
Inclusion	O
Criteria:	O
.	O

-	O
Participating	O
in	O
SELECT	O
Prevention	O
study;	O
.	O

-	O
62	O
years	O
or	O
older	O
if	O
other	O
ethnic	O
origin	O
or	O
60	O
years	O
or	O
older	O
if	O
African-American	O
or	O
Hispanic;	O
.	O

-	O
General	O
good	B-Condition
health	I-Condition
with	O
no	B-Negation_cue
neurological	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
.	O

Exclusion	O
Criteria:	O
.	O

The	O
SELECT	O
doctors	O
or	O
staff	O
will	O
review	O
the	O
PREADVISE	O
applicants'	O
medical	O
history	O
and	O
drugs	O
to	O
verify	O
that	O
they	O
have	O
no	O
condition(	O
s	O
)	O
that	O
would	O
exclude	O
them	O
from	O
this	O
study	O
.	O

The	O
participant	O
must	O
not	O
have	O
any	O
of	O
the	O
following	O
neurological	B-Condition
conditions	I-Condition
based	O
on	O
self	O
report	O
(	O
were	O
told	O
by	O
a	O
physician	O
):	O
.	O

-	O
Alzheimer's	B-Condition
disease	I-Condition
or	O
any	O
other	O
form	O
of	O
dementia	B-Condition
such	O
as	O
Pick's	B-Condition
disease	I-Condition
dementia	B-Condition
with	I-Condition
Lewy	I-Condition
bodies	I-Condition
frontotemporal	B-Condition
dementia	I-Condition
vascular	B-Condition
dementia	I-Condition
significant	O
cognitive	B-Condition
and	I-Condition
motor	I-Condition
impairment	I-Condition
from	O
a	O
stroke	B-Condition
or	O
corticobasal	B-Condition
degeneration	I-Condition
.	O

-	O
Huntington's	B-Condition
disease	I-Condition
epilepsy	B-Condition
,	O
Parkinson's	B-Condition
disease	I-Condition
brain	B-Condition
tumor	I-Condition
multiple	B-Condition
sclerosis	I-Condition
manic-depressive	B-Condition
disorder	I-Condition
or	O
schizophrenia	B-Condition
;	O
.	O

-	O
The	O
participant	O
must	O
not	B-Negation_cue
have	O
had	O
a	O
head	B-Condition
injury	I-Condition
with	O
prolonged	O
loss	B-Condition
of	I-Condition
consciousness	I-Condition
(	O
over	O
30	O
minutes	O
)	O
within	O
the	O
past	O
five	O
years;	O
.	O

-	O
The	O
participant	O
must	O
not	B-Negation_cue
have	O
a	O
current	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
diagnosis	O
or	O
must	O
have	O
been	O
treatment	O
free	O
for	O
the	O
past	O
24	O
months;	O
.	O

-	O
The	O
participant	O
must	O
not	B-Negation_cue
have	O
had	O
a	O
diagnosis	O
of	O
depression	B-Condition
or	O
anxiety	B-Condition
disorder	I-Condition
in	O
the	O
past	O
4	O
months	O
and	O
must	O
not	B-Negation_cue
currently	O
be	O
under	O
treatment	B-Drug
for	O
depression	B-Condition
or	O
anxiety	B-Condition
disorder	I-Condition
.	O

[A	O
participant	O
who	O
was	O
previously	O
diagnosed	O
with	O
depression	B-Condition
or	O
anxiety	B-Condition
disorder	I-Condition
but	O
completed	O
treatment	B-Procedure_Device
more	O
than	O
four	O
months	O
ago	O
is	O
eligible.];	O
.	O

-	O
The	O
participant	O
must	O
not	B-Negation_cue
currently	O
use	O
of	O
any	O
of	O
the	O
following	O
medications:	O
Aricept	B-Drug
,	O
Cognex	B-Drug
,	O
Exelon	B-Drug
,	O
Reminyl	B-Drug
or	O
Hydergine	B-Drug
;	O
.	O

-	O
The	O
participant	O
must	O
not	B-Negation_cue
have	O
blindness	B-Condition
,	O
deafness	B-Condition
,	O
language	B-Condition
difficulties	I-Condition
or	O
any	O
other	O
disability	B-Condition
that	O
may	O
prevent	O
completion	O
of	O
the	O
memory	O
screen	O
.	O

>>NCT02051244	O
Inclusion	O
Criteria:	O
.	O

-	O
age	B-Observation
60	O
and	O
above	O
.	O

-	O
able	O
to	O
read,	O
understand	O
and	O
sign	O
independently	O
a	O
consent	O
form	O
.	O

-	O
able	O
to	O
undergo	O
a	O
cognitive	B-Procedure_Device
test	I-Procedure_Device
.	O

-	O
results	O
of	O
their	O
cognitive	O
test	O
fall	O
into	O
one	O
of	O
the	O
three	O
cohort	O
groups	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
other	O
diseases	B-Condition
affecting	O
the	O
optic	O
nerve	O
such	O
as	O
glaucoma	B-Condition
.	O

-	O
unclear	B-Condition
media	I-Condition
such	O
as	O
dense	B-Condition
cataracts	I-Condition
that	O
will	O
not	O
allow	O
assessment	O
by	O
OCT	O
.	O
-	O
Cognitive	B-Observation
test	I-Observation
scores	I-Observation
that	O
are	O
less	O
than	O
mild	O
cognitive	B-Condition
impairment	I-Condition
.	O

>>NCT01993836	O
Inclusion	O
Criteria:	O
.	O

-	O
Surgical	O
patients	O
60	O
years	O
of	O
age	B-Observation
or	O
older	O
.	O

-	O
Surgery	O
scheduled	O
to	O
last	O
at	O
least	O
2	O
hours	O
(	O
including	O
time	O
for	O
anesthesia	O
induction,	O
etc	O
)	O
.	O

-	O
English	O
speaking	O
ability	O
.	O

-	O
Ability	O
to	O
give	O
informed	O
consent	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Inmate	O
of	O
a	O
correctional	O
facility	O
(	O
i.e	O
.	O

prisoners	O
)	O
.	O

-	O
Pregnancy	B-Condition
.	O

-	O
Documented	O
or	O
suspected	O
family	O
or	O
personal	O
history	O
of	O
malignant	B-Condition
hyperthermia	I-Condition
.	O

-	O
Patient	O
unable	O
to	O
receive	O
either	O
propofol	B-Drug
or	O
isoflurane	B-Drug
due	O
to	O
allergy	B-Condition
or	O
other	O
specific	O
contraindication	B-Condition
.	O

>>NCT01078168	O
Inclusion	O
Criteria:	O
.	O

-	O
mild	O
to	O
moderate	O
AD	B-Condition
(	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
)	O
.	O

-	O
MMSE	B-Observation
:	O
27	O
-	O
14	O
points	O
.	O

-	O
Geriatric	B-Observation
Depression	I-Observation
Scale	I-Observation
<=	O
14	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
hereditary	O
cognitive	B-Condition
impairment	I-Condition
.	O

-	O
known	O
history	O
of	O
brain	B-Condition
injuries	I-Condition
.	O

-	O
Insufficient	O
German	O
language	O
skills	O
.	O

-	O
actual	O
treatment	O
with	O
other	O
potential	O
disease	O
modifying	O
drugs	O
of	O
AD	O
.	O

-	O
multimorbidity	B-Condition
or	O
significant	O
organ	B-Condition
(	I-Condition
esp.	I-Condition
liver	I-Condition
or	I-Condition
renal	I-Condition
)	I-Condition
dysfunction	I-Condition
.	O

-	O
evidence	O
of	O
Non-AD	B-Condition
neurodegenerative	I-Condition
disorder	I-Condition
(	O
eg	O
Parkinson	B-Condition
)	O
.	O

-	O
contraindication	B-Condition
to	O
acitretin	B-Drug
such	O
as	O
osteoporosis	B-Drug
,	O
hypoalbuminaemia	B-Drug
.	O

>>NCT00001662	O
INCLUSION	O
CRITERIA	O
-	O
ALZHEIMER'S	B-Condition
DISEASE	I-Condition
.	O

Study	O
subjects	O
will	O
satisfy	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
for	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

Dementia	B-Condition
severity	O
will	O
be	O
mild	O
to	O
moderate	O
range	O
with	O
Mini-Mental	B-Observation
Status	I-Observation
Examination	I-Observation
total	I-Observation
score	I-Observation
between	O
12	O
and	O
26,	O
inclusive	O
.	O

The	O
modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
Score	I-Observation
must	O
be	O
less	O
than	O
4	O
and	O
brain	B-Procedure_Device
MRI	I-Procedure_Device
performed	O
within	O
15	O
months	O
of	O
enrollment	O
must	O
be	O
compatible	O
with	O
the	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

Dementia	B-Condition
must	O
be	O
present	O
historically	O
for	O
at	O
least	O
one	O
year	O
.	O

Baseline	O
electroencephalogram	B-Procedure_Device
must	O
not	B-Negation_cue
show	O
significant	O
epileptiform	B-Condition
features	I-Condition
.	O

INCLUSION	O
CRITERIA	O
-	O
RELATED	O
DEMENTING	O
DISORDERS:	O
.	O

Study	O
subjects	O
will	O
show	O
deficits	B-Condition
in	O
at	O
least	O
two	O
cognitive	O
spheres,	O
including	O
memory	O
.	O

Modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
Score	I-Observation
must	O
be	O
less	O
than	O
4	O
and	O
Folstein	B-Observation
mini-mental	I-Observation
status	I-Observation
examination	I-Observation
total	I-Observation
score	I-Observation
must	O
be	O
between	O
12	O
and	O
26	O
.	O

Cognitive	B-Condition
difficulties	I-Condition
must	O
e	O
present	O
historically	O
for	O
at	O
least	O
one	O
year	O
.	O

Brain	B-Procedure_Device
MRI	I-Procedure_Device
performed	O
with	O
15	O
months	O
of	O
enrollment	O
must	O
be	O
normal	O
or	O
show	O
atrophy	B-Condition
.	O

Baseline	B-Procedure_Device
electroencephalogram	I-Procedure_Device
must	O
not	B-Negation_cue
show	O
epileptiform	B-Condition
features	I-Condition
.	O

In	O
addition,	O
all	O
patients	O
must	O
have	O
acceptable	O
nutritional	O
status	O
.	O

Patients	O
must	O
be	O
between	O
ages	B-Observation
40	O
and	O
85	O
.	O

Patients	O
must	O
be	O
sterile	B-Condition
,	O
post-menopausal	B-Condition
or	O
using	O
an	O
acceptable	O
forms	O
of	O
birth	O
control	O
.	O

Chest	B-Procedure_Device
x-ray	I-Procedure_Device
within	O
15	O
months	O
before	O
enrollment	O
must	O
be	O
acceptable	O
for	O
the	O
trial	O
.	O

Participants	O
in	O
this	O
study	O
will	O
reflect	O
the	O
diversity	O
of	O
those	O
suffering	O
from	O
dementia	B-Condition
.	O

No	O
one	O
will	O
be	O
excluded	O
or	O
discriminated	O
against	O
based	O
on	O
the	O
grounds	O
of	O
race,	O
creed	O
or	O
gender	O
.	O

Every	O
attempt	O
will	O
be	O
made	O
to	O
include	O
women	O
and	O
minorities	O
in	O
the	O
study	O
population	O
.	O

EXCLUSION	O
CRITERIA	O
-	O
NEUROLOGIC:	O
.	O

Hemispheric	B-Condition
stroke	I-Condition
hydrocephalus	B-Condition
,	O
subdural	B-Condition
hematoma	I-Condition
or	O
mass	B-Condition
lesion	I-Condition
on	O
neuroimaging	B-Procedure_Device
study	I-Procedure_Device
"epileptiform"	B-Procedure_Device
baseline	I-Procedure_Device
EEG	I-Procedure_Device
or	O
known	O
seizure	B-Condition
disorder	I-Condition
head	B-Condition
trauma	I-Condition
with	O
loss	B-Condition
of	I-Condition
consciousness	I-Condition
concurrent	O
with	O
onset	O
of	O
dementia	B-Condition
;	O
chronic	O
CNS	B-Condition
infection	I-Condition
(	O
positive	O
MHA-TP	B-Observation
or	O
FTA-ABS	B-Observation
acceptable	O
if	O
luetic	B-Condition
brain	I-Condition
disease	I-Condition
excluded	B-Negation_cue
by	O
documented	O
studies	O
or	O
treatment	O
)	O
.	O

EXCLUSION	O
CRITERIA	O
-	O
GENERAL	O
MEDICAL:	O
.	O

Acute	O
serious	B-Condition
infection	I-Condition
including	O
hepatitis	B-Condition
;	O
hypothyroidism	B-Condition
(	O
TSH	B-Observation
greater	O
than	O
6.0	O
microunits	O
/	O
mL	O
);	O
folic	B-Condition
acid	I-Condition
deficiency	I-Condition
(	O
less	O
than	O
0.9	O
ng	O
/	O
mL	O
);	O
vitamin	B-Condition
B12	I-Condition
deficiency	I-Condition
(	O
less	O
than	O
160	O
pg	O
/	O
mL	O
)	O
within	O
one	O
year	O
prior	O
to	O
enrollment;	O
severe	O
renal	B-Condition
insufficiency	I-Condition
(	O
creatinine	B-Observation
clearance	I-Observation
less	O
than	O
25	O
mL	O
/	O
min,	O
BUN	B-Observation
greater	O
than	O
40	O
mg	O
/	O
dL	O
or	O
serum	B-Observation
creatinine	I-Observation
greater	O
than	O
2.0	O
mg	O
/	O
dL	O
);	O
hepatic	B-Condition
insufficiency	I-Condition
(	O
SGPT	B-Observation
or	I-Observation
SGOT	I-Observation
greater	O
than	O
3	O
x	O
upper	O
limit	O
of	O
normal	O
or	O
total	B-Observation
bilirubin	I-Observation
greater	O
than	O
2.0	O
mg	O
/	O
dL	O
)	O
.	O

Due	O
to	O
the	O
serious	O
adverse	O
event	O
transient	O
agranulocytosis	O
report	O
in	O
another	O
study	O
of	O
CX516,	O
patients	O
will	O
neutropenia	B-Condition
or	O
low	O
normal	O
white	B-Observation
blood	I-Observation
cell	I-Observation
counts	I-Observation
(	O
greater	O
than	O
or	O
equal	O
to	O
3.5	O
K	O
/	O
microliter	O
)	O
will	O
be	O
excluded	O
from	O
this	O
study	O
.	O

PSYCHIATRIC:	O
.	O

Depression	B-Condition
if	O
present	O
during	O
screening	O
.	O

Depression	B-Condition
will	O
be	O
diagnosed	O
clinically	O
and	O
with	O
depression	B-Observation
rating	I-Observation
scale(	I-Observation
s	I-Observation
)	I-Observation
such	O
as	O
Hamilton	B-Observation
Depression	I-Observation
Rating	I-Observation
Scale	I-Observation
if	O
needed	O
.	O

PREVIOUS	O
AND	O
CONCOMITANT	O
MEDICATIONS:	O
.	O

Administration	O
of	O
tacrine	B-Drug
,	O
donepezil	B-Drug
,	O
rivastigmine	B-Drug
,	O
galantamine	B-Drug
,	O
anti-depressants	B-Drug
are	O
prohibited	O
within	O
thirty	O
days	O
prior	O
to	O
enrollment	O
.	O

OTHER	O
CONDITIONS:	O
.	O

Any	O
hepatic,	B-Condition
cardiovascular,	I-Condition
gastrointestinal	I-Condition
or	I-Condition
hematological	I-Condition
illness	I-Condition
which	O
could	O
interfere	O
with	O
drug	O
absorption,	O
distribution,	O
metabolism	O
or	O
excretion;	O
known	O
hypersensitivity	B-Condition
to	O
CX516	B-Drug
or	O
its	O
vehicle	B-Drug
;	O
inability	O
to	O
swallow	O
tablets	O
or	O
to	O
comply	O
with	O
medication	O
schedule;	O
no	O
significant	O
care	O
giver;	O
uncorrectable	O
loss	B-Condition
of	I-Condition
hearing	I-Condition
or	I-Condition
eyesight	I-Condition
that	O
precludes	O
psychometric	O
testing;	O
inability	O
to	O
comprehend	O
instructions	O
or	O
to	O
respond	O
to	O
test	O
items	O
.	O

>>NCT00736775	O
Inclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
probable	O
AD	B-Condition
according	O
to	O
the	O
NINCDS-ADRDA	B-Observation
Criteria	I-Observation
.	O

-	O
Approved	O
AD	B-Drug
treatments	I-Drug
(	O
AchE	B-Drug
inhibitors+/-memantine	I-Drug
)	O
must	O
be	O
stable	O
for	O
>=	O
3	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Other	O
prescription	B-Drug
medications	I-Drug
must	O
be	O
stable	O
for	O
>=	O
1	O
month	O
prior	O
to	O
screening	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Female	O
patients	O
with	O
reproductive	B-Condition
potential	I-Condition
.	O

-	O
History	O
or	O
presence	O
of	O
any	O
clinically	O
significant	O
CNS	B-Condition
disease	I-Condition
.	O

-	O
History	O
of	O
treatment	O
with	O
any	O
protein	B-Drug
therapeutic	I-Drug
targeting	I-Drug
Abeta	I-Drug
.	O

>>NCT00094913	O
Inclusion	O
Criteria:	O
.	O

-	O
Males	O
and	O
females	O
with	O
a	O
minimum	O
high	O
school	O
education	O
and	O
between	O
the	O
ages	B-Observation
of	O
50	O
and	O
90	O
will	O
be	O
selected	O
for	O
Groups	O
1	O
and	O
2	O
.	O

For	O
Group	O
3,	O
normal	O
subjects	O
between	O
the	O
ages	B-Observation
of	O
20	O
and	O
49	O
years	O
of	O
age	B-Observation
will	O
be	O
selected	O
.	O

The	O
Groups	O
1	O
and	O
2	O
will	O
be	O
balanced	O
for	O
age	O
and	O
all	O
three	O
groups	O
balanced	O
for	O
gender	O
and	O
ApoE	O
genotype	O
.	O

-	O
Discontinuance	O
of	O
all	O
psychotropic	B-Drug
and	I-Drug
/	I-Drug
or	I-Drug
cognitively	I-Drug
active	I-Drug
medication	I-Drug
at	O
least	O
four	O
weeks	O
prior	O
to	O
evaluation	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Past	O
history	O
or	O
MRI	B-Procedure_Device
evidence	O
of	O
brain	B-Condition
damage	I-Condition
including	O
significant	O
trauma	B-Condition
,	O
stroke	B-Condition
,	O
hydrocephalus	B-Condition
,	O
lacunar	B-Condition
infarcts	I-Condition
seizures	B-Condition
,	O
mental	B-Condition
retardation	I-Condition
or	O
serious	O
neurological	B-Condition
disorder	I-Condition
.	O

-	O
Significant	O
history	O
of	O
alcoholism	B-Condition
or	O
drug	B-Condition
abuse	I-Condition
.	O

-	O
Any	O
history	O
of	O
psychiatric	B-Condition
illness	I-Condition
(	O
eg	O
,	O
schizophrenia	B-Condition
,	O
mania	B-Condition
or	O
depression	B-Condition
)	O
.	O

-	O
Any	O
focal	B-Condition
signs	I-Condition
or	O
significant	O
neuropathology	B-Condition
.	O

-	O
A	O
score	O
of	O
4	O
or	O
greater	O
on	O
the	O
Modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
Scale	I-Observation
indicative	O
of	O
cerebrovascular	B-Condition
disease	I-Condition
.	O

-	O
A	O
total	O
score	O
of	O
16	O
or	O
more	O
on	O
the	O
Hamilton	B-Observation
Depression	I-Observation
Scale	I-Observation
to	O
exclude	B-Negation_cue
possible	O
cases	O
of	O
primary	B-Condition
depression	I-Condition
.	O

-	O
Evidence	O
of	O
clinically	O
relevant	O
hypertensive,	B-Condition
cardiac,	I-Condition
pulmonary,	I-Condition
vascular,	I-Condition
metabolic	I-Condition
or	I-Condition
hematologic	I-Condition
conditions	I-Condition
.	O

Specific	O
exclusion	O
will	O
be	O
made	O
for	O
individuals	O
with	O
fasting	B-Observation
glucose	I-Observation
levels	I-Observation
>	O
110	O
mg	O
/	O
dl	O
.	O

-	O
Physical	B-Condition
impairment	I-Condition
of	O
such	O
severity	O
as	O
to	O
adversely	O
affect	O
the	O
validity	O
of	O
psychological	O
testing	O
.	O

-	O
Hostility	O
or	O
refusal	O
to	O
cooperate	O
.	O

-	O
Any	O
prosthetic	B-Procedure_Device
devices	I-Procedure_Device
(	O
eg	O
,	O
pacemaker	B-Procedure_Device
or	O
surgical	B-Procedure_Device
clips	I-Procedure_Device
)	O
that	O
could	O
be	O
affected	O
by	O
the	O
magnetic	O
field	O
employed	O
during	O
MRI	B-Procedure_Device
imaging	O
.	O

-	O
Evidence	O
of	O
cognitive	B-Condition
or	I-Condition
memory	I-Condition
impairment	I-Condition
reaching	O
early	O
AD	O
levels	O
at	O
the	O
initial	O
evaluation	O
.	O

At	O
baseline,	O
delayed	B-Observation
paragraph	I-Observation
recall	I-Observation
z-scores	I-Observation
>	O
2	O
below	O
the	O
reference	O
group.	O

>>NCT01703117	O
Inclusion	O
Criteria:	O
.	O

-	O
Male	O
or	O
female;	O
60	O
-	O
85	O
years	O
old	O
with	O
mild	O
Alzheimer's	B-Condition
disease	I-Condition
determined	O
after	O
neurological	O
and	O
neuropsychological	O
evaluation	O
following	O
the	O
National	O
Institute	O
on	O
Aging	O
-	O
Alzheimer's	O
disease	O
Association	O
criteria	O
that	O
recently	O
revisited	O
the	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
.	O

For	O
mild	O
Alzheimer's	B-Condition
disease	I-Condition
Clinical	B-Observation
Dementia	I-Observation
Ratings	I-Observation
Scale	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
should	O
be	O
0.5	O
or	O
1	O
and	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSS	I-Observation
)	I-Observation
between	O
19	O
and	O
27	O
.	O

-	O
Must	O
be	O
on	O
donepezil	B-Drug
(	O
Aricept	B-Drug
)	O
or	O
rivastigmine	B-Drug
(	O
Exelon	B-Drug
)	O
or	O
galantamine	B-Drug
(	O
Razadyne	B-Drug
)	O
at	O
a	O
consistent	O
dose	O
for	O
at	O
least	O
2	O
months	O
.	O

-	O
Must	O
be	O
fluent	O
in	O
English	O
.	O

-	O
The	O
subject	O
will	O
appoint	O
or	O
have	O
previously	O
appointed	O
a	O
health	O
care	O
proxy	O
specifically	O
designated	O
for	O
research	O
consent	O
and	O
that	O
this	O
be	O
documented	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Moderate-Severe	O
Alzheimer's	B-Condition
disease	I-Condition
and	O
other	O
dementias	B-Condition
as	O
determined	O
by	O
neuropsychological	O
testing	O
and	O
neurological	O
evaluation	O
.	O

-	O
Previous	O
riluzole	B-Drug
treatment	I-Drug
.	O

-	O
MRI	B-Procedure_Device
contra-indication	B-Condition
(	O
severe	O
claustrophobia	B-Condition
,	O
metal	B-Procedure_Device
implants	I-Procedure_Device
shunts	B-Procedure_Device
,	O
pacemaker	B-Procedure_Device
,	O
joint	B-Procedure_Device
implants	I-Procedure_Device
metal	B-Procedure_Device
valves	I-Procedure_Device
)	O
.	O

-	O
Currently	O
taking	O
medications	B-Drug
that	O
either	O
have	O
evidence	O
of	O
glutamatergic	O
activity	O
or	O
has	O
previous	O
MRS	O
evidence	O
of	O
effects	O
on	O
brain	O
glutamate	O
levels	O
at	O
the	O
discretion	O
of	O
the	O
PI	O
such	O
as	O
memantine	B-Drug
,	O
lamotrigine	B-Drug
,	O
lithium	B-Drug
,	O
opiates	B-Drug
,	O
bupropion	B-Drug
,	O
psychostimulants	B-Drug
such	O
as	O
amphetamines	B-Drug
and	O
methylphenidates	B-Drug
,	O
tricyclic	B-Drug
antidepressants	I-Drug
benzodiazepines	B-Drug
and	O
any	O
other	O
drug	B-Drug
that	O
the	O
investigators	O
judge	O
might	O
interfere	O
with	O
the	O
study	O
.	O

(	O
subjects	O
on	O
those	O
medications	O
may	O
still	O
be	O
included	O
in	O
the	O
study	O
however	O
only	O
the	O
values	O
of	O
NAA	O
from	O
MRS	O
will	O
be	O
utilized	O
and	O
not	O
the	O
glutamate	O
measurements	O
)	O
.	O

-	O
Currently	O
a	O
user	O
of	O
the	O
following	O
illicit	B-Drug
drugs	I-Drug
cocaine	B-Drug
,	O
MDMA	B-Drug
(	O
ecstasy	B-Drug
"),	O
heroin	B-Drug
and	O
other	O
opioids	B-Drug
(	O
as	O
verified	O
by	O
urine	B-Observation
drug	I-Observation
test	I-Observation
)	O
or	O
has	O
a	O
history	O
of	O
drug	B-Condition
or	I-Condition
alcohol	I-Condition
abuse	I-Condition
within	O
the	O
past	O
5	O
years	O
.	O

-	O
Serum	B-Observation
creatinine	I-Observation
>	O
1.5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O

-	O
Abnormal	O
liver	B-Observation
function	I-Observation
test	I-Observation
(	O
greater	O
than	O
2	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
for	O
alanine	B-Observation
aminotranferase	I-Observation
(	I-Observation
ALT	I-Observation
)	I-Observation
or	O
aspartate	B-Observation
aminotransferase	I-Observation
(	I-Observation
AST	I-Observation
)	I-Observation
or	O
bilirubin	B-Observation
>	O
1.5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O

-	O
History	O
of	O
brain	B-Condition
disease	I-Condition
including	O
Parkinson's	B-Condition
Disease	I-Condition
severe	O
brain	B-Condition
trauma	I-Condition
seizures	B-Condition
,	O
history	O
of	O
stroke	B-Condition
,clinically	O
significant	O
lacunar	B-Condition
infarct	I-Condition
in	O
a	O
region	O
important	O
for	O
cognition	O
or	O
multiple	B-Condition
lacunes	I-Condition
or	O
a	O
cortical	B-Condition
infarct	I-Condition
or	O
focal	B-Condition
lesions	I-Condition
of	O
clinical	O
significance,	O
multiple	B-Condition
sclerosis	I-Condition
mental	B-Condition
retardation	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
CNS	B-Condition
tumor	I-Condition
Huntington's	B-Condition
disease	I-Condition
subdural	B-Condition
hematoma	I-Condition
or	O
other	O
serious	O
neurological	B-Condition
disorder	I-Condition
.	O

-	O
Uncontrolled	O
diabetes	B-Condition
mellitus	I-Condition
(	O
Hba1c	B-Observation
higher	O
than	O
7	O
)	O
or	O
chronically	O
uncontrolled	O
hypertension	B-Condition
.	O

-	O
Subject	O
must	O
not	B-Negation_cue
be	O
taking	O
Namenda	B-Drug
(	O
memantine	B-Drug
)	O
for	O
at	O
least	O
2	O
months	O
.	O

-	O
Currently	O
taking	O
any	O
concomitant	O
hepatotoxic	B-Drug
drugs	I-Drug
such	O
as	O
allopurinol	B-Drug
,	O
methyldopa	B-Drug
and	O
sulfasalazine	B-Drug
.	O

-	O
Any	O
unstable	O
serious	O
co-existing	O
medical	B-Condition
condition(	I-Condition
s	I-Condition
)	I-Condition
including	O
but	O
not	O
limited	O
to	O
myocardial	B-Condition
infarction	I-Condition
coronary	B-Condition
artery	I-Condition
disease	I-Condition
requiring	O
coronary	B-Procedure_Device
bypass	I-Procedure_Device
surgery	I-Procedure_Device
unstable	O
angina	B-Condition
,	O
clinically	O
evident	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
within	O
6	O
months	O
prior	O
to	O
the	O
screening	O
visit	O
.	O

-	O
Current	O
smoker	B-Observation
or	O
user	O
of	O
nicotine-containing	B-Drug
products	I-Drug
such	O
as	O
chewing	B-Drug
tobacco	I-Drug
nicotine	B-Drug
patch	I-Drug
or	O
gum	B-Drug
for	O
the	O
past	O
2	O
months	O
.	O

-	O
Current	O
major	B-Condition
depression	I-Condition
defined	O
by	O
Hamilton	B-Observation
Psychiatric	I-Observation
Rating	I-Observation
Scale	I-Observation
>	O
18	O
.	O

-	O
Participation	O
in	O
any	O
investigational	B-Drug
or	I-Drug
marketed	I-Drug
drug	I-Drug
or	O
device	O
trial	O
within	O
30	O
days	O
prior	O
to	O
the	O
screening	O
visit	O
.	O

-	O
Significant	O
neuropsychiatric	B-Condition
illnesses	I-Condition
such	O
as	O
bipolar	B-Condition
disorder	I-Condition
schizophrenia	B-Condition
,	O
moderate-severe	B-Condition
anxiety	I-Condition
vascular	B-Condition
dementia	I-Condition
Creutzfeldt-Jakob	B-Condition
dementia	I-Condition
HIV	B-Condition
dementia	I-Condition
and	O
dementia	B-Condition
in	I-Condition
other	I-Condition
specified	I-Condition
diseases	I-Condition
.	O

-	O
Subjects	O
who	O
have	O
been	O
on	O
donepezil	B-Drug
for	O
longer	O
than	O
5	O
years	O
.	O

-	O
Weight	B-Observation
>	O
300	O
pounds	O
.	O

-	O
Lactose	B-Condition
intolerance	I-Condition
.	O

-	O
Any	O
medical	O
or	O
social	O
condition	O
that,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator,	O
might	O
pose	O
additional	O
risk	O
to	O
the	O
participant	O
or	O
confound	O
the	O
results	O
of	O
the	O
study	O
.	O

>>NCT00039702	O
INCLUSION	O
CRITERIA	O
-	O
ALZHEIMER'S	B-Condition
DISEASE	I-Condition
PATIENTS:	O
.	O

All	O
AD	B-Condition
patients	O
will	O
meet	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
for	O
probable	O
AD	B-Condition
with	O
age	B-Observation
of	I-Observation
onset	I-Observation
between	O
50	O
and	O
65	O
years	O
of	O
age	B-Observation
.	O

The	O
AD	B-Condition
patients	O
will	O
be	O
mild	O
to	O
moderately	O
demented	B-Condition
as	O
assessed	O
by	O
the	O
Mattis	B-Observation
Dementia	I-Observation
Rating	I-Observation
Scale	I-Observation
and	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
.	O

In	O
particular,	O
the	O
AD	B-Condition
patients	O
will	O
be	O
nonsmokers	B-Observation
because	O
of	O
known	O
effects	O
of	O
smoking	O
on	O
nAChRs	O
.	O

Patients	O
will	O
be	O
characterized	O
by	O
their	O
APOE	O
genotype	O
as	O
nAChR	O
changes	O
might	O
be	O
different	O
with	O
differing	O
doses	O
of	O
this	O
allele	O
.	O

We	O
will	O
not	O
exclude	O
AD	O
patients	O
from	O
participating	O
while	O
they	O
are	O
on	O
AChe	B-Drug
inhibitors	I-Drug
.	O

EXCLUSION	O
CRITERIA	O
-	O
ALZHEIMER'S	B-Condition
DISEASE	I-Condition
PATIENTS:	O
.	O

We	O
will	O
exclude	O
patients	O
who	O
are	O
on	O
galanthamine	B-Drug
(	O
Reminyl	B-Drug
)	O
.	O

We	O
will	O
exclude	O
patients	O
on	O
antidepressants	B-Drug
and	O
/	O
or	O
psychotropic	B-Drug
drugs	I-Drug
.	O

INCLUSION	O
CRITERIA	O
-	O
CONTROLS:	O
.	O

Nonsmoking	B-Observation
healthy	B-Condition
individuals	O
who	O
satisfy	O
the	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O

>>NCT01555827	O
Inclusion	O
Criteria:	O
.	O

-	O
Inclusion	O
criteria	O
for	O
AD	B-Condition
cases:	O
.	O

-	O
Diagnosis	O
of	O
probable	O
AD	B-Condition
,	O
defined	O
according	O
to	O
the	O
NINCDS-ARDRA	B-Observation
criteria51	I-Observation
.	O

-	O
Light	O
to	O
moderate	O
severity	O
of	O
the	O
disease	B-Condition
,	O
defined	O
by	O
a	O
MMSE	B-Observation
score	I-Observation
>	O
10	O
(	O
global	O
evaluation	O
of	O
cognition	O
)	O
.	O

-	O
Patient	O
aged	B-Observation
50	O
years	O
or	O
more	O
.	O

-	O
Patient	O
benefiting	O
from	O
social	O
insurance	O
.	O

Inclusion	O
criteria	O
for	O
controls:	O
.	O

-	O
Absence	O
of	O
suspicion	O
of	O
dementia	B-Condition
,	O
based	O
on	O
normal	O
performance	O
according	O
to	O
age	O
and	O
educational	O
level	O
at	O
neuropsychological	O
testing	O
defined	O
as:	O
.	O

-	O
Free	B-Observation
recall	I-Observation
>=	O
17	O
and	O
total	B-Observation
recall	I-Observation
>=	O
40	O
for	O
the	O
Free	B-Observation
and	I-Observation
Cued	I-Observation
Selective	I-Observation
Reminding	I-Observation
Test	I-Observation
(	O
Grober	O
and	O
Buschke	O
test	O
52	O
)	O
MMSE	B-Observation
>=	O
norm	O
for	O
age	O
and	O
educational	O
level	O
(	O
defined	O
by	O
mean	O
-	O
1	O
SD	O
)	O
.	O

-	O
Isaac's	B-Observation
set	I-Observation
test	I-Observation
>=	O
norm	O
for	O
age	O
and	O
educational	O
level	O
(	O
defined	O
by	O
mean	O
-	O
1	O
SD	O
)	O
.	O

-	O
Matched	O
to	O
age	O
and	O
gender	O
of	O
the	O
cases	O
.	O

-	O
Patient	O
benefiting	O
from	O
social	O
insurance	O
.	O

Exclusion	O
Criteria:	O
.	O

Exclusion	O
criteria	O
for	O
all	O
patients	O
:	O
.	O

-	O
History	O
of	O
Parkinson's	B-Condition
disease	I-Condition
or	O
other	O
neurodegenerative	B-Condition
disorder	I-Condition
.	O

-	O
History	O
of	O
Horton's	B-Condition
disease	I-Condition
.	O

-	O
History	O
of	O
inflammatory	B-Condition
neuropathies	I-Condition
(	O
in	O
particular	O
Devic's	B-Condition
disease	I-Condition
multiple	B-Condition
sclerosis	I-Condition
)	O
.	O

-	O
History	O
of	O
vascular	B-Condition
ischemic	I-Condition
neuropathies	I-Condition
and	O
chronic	B-Condition
intracranial	I-Condition
hypertension	I-Condition
.	O

-	O
History	O
of	O
pituitary	B-Condition
tumors	I-Condition
.	O

-	O
Presence	O
of	O
diseases	B-Condition
(	O
systemic	B-Condition
and	I-Condition
/	I-Condition
or	I-Condition
ocular	I-Condition
diseases	I-Condition
)	O
or	O
behavioural	B-Condition
or	I-Condition
cognitive	I-Condition
symptoms	I-Condition
incompatible	O
with	O
eye	O
examination	O
.	O

-	O
Known	O
diabetes	B-Condition
.	O

-	O
Person	O
under	O
tutorship	O
or	O
curatorship,	O
person	O
unable	O
to	O
express	O
consent	O
.	O

Additional	O
exclusion	O
criteria	O
for	O
AD	B-Condition
cases:	O
.	O

-	O
Dementia	B-Condition
of	I-Condition
other	I-Condition
cause	I-Condition
than	O
AD	B-Condition
.	O

-	O
Severe	O
AD	B-Condition
,	O
defined	O
by	O
MMSE	B-Observation
score	I-Observation
<=	O
10	O
.	O

Additional	O
exclusion	O
criteria	O
for	O
controls:	O
.	O

-	O
Presence	O
of	O
dementia	B-Condition
,	O
of	O
whatever	O
cause	O
.	O

>>NCT01504854	O
Inclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
probable	O
AD	B-Condition
(	O
NINDS-ADRDA	O
criteria	O
)	O
.	O

-	O
Age	B-Observation
must	O
be	O
50	O
years	O
or	O
older	O
.	O

-	O
Able	O
to	O
ingest	O
oral	O
medications	O
.	O

-	O
Caregiver	O
/	O
Study	O
Partner	O
who	O
has	O
direct	O
contact	O
with	O
the	O
participant	O
more	O
than	O
2	O
days	O
per	O
week	O
to	O
accompany	O
participant	O
to	O
all	O
visits	O
.	O

-	O
MMSE	B-Observation
score	I-Observation
between	O
14	O
and	O
26	O
(	O
inclusive	O
)	O
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
score	I-Observation
of	O
less	O
than	O
or	O
equal	O
to	O
4	O
.	O

-	O
Able	O
to	O
abstain	O
from	O
ingesting	O
large	O
quantities	O
of	O
resveratrol-containing	O
foods	O
(	O
including	O
red	O
wine	O
)	O
.	O

1	O
-	O
2	O
glasses	O
of	O
red	O
wine	O
or	O
red	O
grape	O
juice	O
daily	O
acceptable;	O
1	O
serving	O
of	O
red	O
grapes	O
daily	O
acceptable	O
.	O

-	O
Able	O
to	O
abstain	O
from	O
ingesting	O
herbal	O
/	O
natural	O
preparations	O
or	O
dietary	O
supplements	O
containing	O
resveratrol	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Non-AD	B-Condition
dementia	I-Condition
.	O

-	O
Probable	O
AD	B-Condition
with	O
Down	B-Condition
syndrome	I-Condition
.	O

-	O
History	O
of	O
clinically	O
significant	O
stroke	B-Condition
.	O

-	O
Current	O
evidence	O
or	O
history	O
in	O
past	O
two	O
years	O
of	O
epilepsy	B-Condition
,	O
focal	B-Condition
brain	I-Condition
lesion	I-Condition
head	B-Condition
injury	I-Condition
with	I-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition
or	O
DSM-IV	B-Observation
criteria	I-Observation
for	O
any	O
major	O
psychiatric	B-Condition
disorder	I-Condition
including	O
psychosis	B-Condition
,	O
major	B-Condition
depression	I-Condition
bipolar	B-Condition
disorder	I-Condition
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
.	O

-	O
Sensory	B-Condition
impairment	I-Condition
that	O
would	O
preclude	O
the	O
participant	O
from	O
participating	O
in	O
or	O
cooperating	O
with	O
the	O
protocol	O
.	O

-	O
Use	O
of	O
investigational	B-Drug
agent	I-Drug
within	O
two	O
months	O
of	O
Screening	O
.	O

-	O
Evidence	O
of	O
any	O
significant	O
clinical	O
disorder	B-Condition
or	O
aboratory	B-Observation
finding	I-Observation
that	O
renders	O
the	O
participant	O
unsuitable	O
for	O
receiving	O
an	O
investigational	B-Drug
drug	I-Drug
including	O
clinically	O
significant	O
or	O
unstable	O
hematologic,	B-Condition
hepatic,	I-Condition
cardiovascular,	I-Condition
pulmonary,	I-Condition
gastrointestinal,	I-Condition
endocrine,	I-Condition
metabolic,	I-Condition
renal	I-Condition
or	I-Condition
other	I-Condition
systemic	I-Condition
disease	I-Condition
or	O
laboratory	B-Condition
abnormality	I-Condition
.	O

-	O
Active	O
neoplastic	B-Condition
disease	I-Condition
history	O
of	O
cancer	B-Condition
five	O
years	O
prior	O
to	O
screening,	O
including	O
breast	B-Condition
cancer	I-Condition
(	O
history	O
or	O
skin	B-Condition
melanoma	I-Condition
or	O
stable	O
prostate	B-Condition
cancer	I-Condition
are	O
not	B-Negation_cue
excluded	O
)	O
.	O

-	O
History	O
of	O
seizure	B-Condition
within	O
past	O
five	O
years	O
.	O

-	O
Pregnancy	B-Condition
or	O
possible	O
pregnancy	B-Condition
.	O

-	O
Use	O
of	O
resveratrol	B-Drug
containing	O
supplements	O
.	O

>>NCT01172145	O
Inclusion	O
Criteria:	O
.	O

-	O
diagnosis	O
of	O
mild	O
to	O
moderate	O
stage	O
Probable	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
on	O
a	O
stable	O
dose	O
of	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
medication	O
for	O
at	O
least	O
30	O
days	O
.	O

-	O
clinically	O
elevated	O
levels	O
of	O
apathy	B-Condition
as	O
measured	O
by	O
the	O
Frontal	B-Observation
Systems	I-Observation
Behavior	I-Observation
Scale	I-Observation
.	O

Exclusion	O
Criteria:	O
.	O

-	O
diagnosis	O
of	O
Major	B-Condition
Depression	I-Condition
.	O

-	O
focal	B-Condition
brain	I-Condition
lesion	I-Condition
on	O
neuroimaging	B-Procedure_Device
.	O

-	O
history	O
of	O
significant	O
substance	B-Condition
abuse	I-Condition
.	O

-	O
history	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
with	O
loss	B-Observation
of	I-Observation
consciousness	I-Observation
>	O
10	O
minutes	O
.	O

>>NCT02360657	O
Inclusion	O
Criteria:	O
.	O

-	O
Participant	O
must	O
have	O
had	O
sufficient	O
education	O
or	O
work	O
experience	O
to	O
exclude	O
mental	O
retardation	O
based	O
on	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
4th	O
edition,	O
Text	O
Revision	O
(	O
DSM-IV-TR	O
)	O
and	O
must	O
be	O
able	O
to	O
read	O
and	O
write	O
and	O
must	O
have	O
adequate	O
hearing	O
and	O
visual	O
acuity	O
to	O
complete	O
the	O
required	O
psychometric	O
tests	O
.	O

-	O
Participant	O
must	O
have	O
a	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
Scale-	I-Observation
Japanese	I-Observation
version	I-Observation
(	I-Observation
CDR-J	I-Observation
)	I-Observation
score	I-Observation
of	O
'0'	O
and	O
as	O
such	O
rated	O
as	O
normal	O
.	O

-	O
Participant	O
must	O
have	O
evidence	O
of	O
amyloid	B-Observation
deposition	I-Observation
as	O
demonstrated	O
by	O
low	O
Cerebrospinal	B-Observation
Fluid	I-Observation
(	I-Observation
CSF	I-Observation
)	I-Observation
Amyloid	I-Observation
(	I-Observation
A	I-Observation
)-beta	I-Observation
1	I-Observation
-	I-Observation
42	I-Observation
levels	I-Observation
at	O
Screening	O
.	O

-	O
Participant	O
must	O
have	O
a	O
body	B-Observation
mass	I-Observation
index	I-Observation
between	O
18	O
and	O
35	O
kilogram	O
per	O
square	O
meter,	O
inclusive,	O
at	O
Screening	O
.	O

-	O
Participant	O
must	O
be	O
otherwise	O
healthy	B-Condition
for	O
their	O
age	O
group	O
or	O
medically	O
stable	O
with	O
or	O
without	O
medication	B-Drug
on	O
the	O
basis	O
of	O
physical	B-Observation
examination	I-Observation
medical	B-Observation
history	I-Observation
vital	B-Observation
signs	I-Observation
and	O
12	B-Procedure_Device
-lead	I-Procedure_Device
electrocardiogram	I-Procedure_Device
(	I-Procedure_Device
ECG	I-Procedure_Device
)	I-Procedure_Device
performed	O
at	O
Screening	O
or	O
at	O
Baseline	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Participant	O
has	O
evidence	O
of	O
any	O
brain	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
potential	O
very	O
early	O
signs	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
(	I-Condition
AD	I-Condition
)	I-Condition
or	O
typical	O
age	O
related	O
changes	O
or	O
any	O
other	O
abnormality	B-Condition
that	O
could	O
explain	O
a	O
possible	O
cognitive	B-Condition
deficit	I-Condition
.	O

-	O
Participant	O
has	O
been	O
diagnosed	O
with	O
dementia	B-Condition
due	O
to	O
AD	B-Condition
,	O
due	O
to	O
other	O
diseases	B-Condition
or	O
with	O
AD	B-Condition
and	O
contribution	O
of	O
other	O
disorders	B-Condition
(	O
mixed	B-Condition
dementia	I-Condition
)	O
.	O

-	O
Participant	O
has	O
evidence	O
of	O
familial	B-Condition
autosomal	I-Condition
dominant	I-Condition
AD	I-Condition
.	O

-	O
Participant	O
has	O
any	O
contra-indications	B-Condition
for	O
Magnetic	B-Procedure_Device
Resonance	I-Procedure_Device
Imaging	I-Procedure_Device
(	I-Procedure_Device
MRI	I-Procedure_Device
)	I-Procedure_Device
(	O
for	O
example,	O
prostheses	B-Procedure_Device
,	O
implants	B-Procedure_Device
,	O
claustrophobia	B-Procedure_Device
,	O
pacemakers	B-Procedure_Device
and	O
others	O
)	O
.	O

-	O
Participant	O
has	O
a	O
clinically	O
significant	O
abnormal	O
physical-	B-Observation
or	I-Observation
neurological	I-Observation
examination	I-Observation
vital	B-Observation
signs	I-Observation
or	O
12	B-Procedure_Device
-lead	I-Procedure_Device
ECG	I-Procedure_Device
(	O
including	O
QTc	B-Observation
greater	O
than	O
450	O
millisecond	O
for	O
males	O
and	O
females,	O
left	B-Condition
bundle	I-Condition
branch	I-Condition
block	I-Condition
atrio-ventricular	B-Condition
[AV]	I-Condition
block	I-Condition
second	O
degree	O
or	O
higher,	O
permanent	O
pacemaker	B-Procedure_Device
or	O
implantable	B-Procedure_Device
cardioverter	I-Procedure_Device
defibrillator	I-Procedure_Device
[ICD])	O
at	O
Screening	O
or	O
Baseline,	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
is	O
not	O
appropriate	O
and	O
reasonable	O
for	O
the	O
population	O
under	O
study.	O

>>NCT00009217	O
Inclusion	O
Criteria:	O
.	O

-	O
Meets	O
DSM-IV	O
criteria	O
for	O
dementia	B-Condition
either	O
sex,	O
age	B-Observation
50	O
-	O
95	O
years	O
.	O

-	O
Meets	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
for	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Meets	O
Folstein	B-Observation
Mini-Mental	I-Observation
State	I-Observation
Exam	I-Observation
score	I-Observation
of	O
5	O
-	O
26,	O
inclusive	O
.	O

-	O
Intellectual	B-Condition
impairment	I-Condition
reported	O
for	O
at	O
least	O
six	O
months	O
.	O

-	O
Availability	O
of	O
family	O
member	O
who	O
has	O
had	O
direct	O
contact	O
with	O
the	O
patient	O
for	O
an	O
average	O
of	O
at	O
least	O
once	O
every	O
week	O
during	O
the	O
three	O
months	O
prior	O
to	O
study	O
entry	O
.	O

-	O
Has	O
current	O
symptoms	O
of	O
psychosis	B-Condition
or	O
agitation	B-Condition
.	O

Criteria	O
for	O
psychosis	B-Condition
"	O
requires	O
the	O
presence	O
of	O
delusions	B-Condition
and	O
/	O
or	O
hallucinations	B-Condition
identified	O
by	O
the	O
Columbia	B-Observation
University	I-Observation
Scale	I-Observation
for	I-Observation
Psychopathology	I-Observation
in	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
(	I-Observation
CUSPAD	I-Observation
)	I-Observation
and	O
a	O
minimum	B-Observation
Brief	I-Observation
Psychiatric	I-Observation
Rating	I-Observation
Scale	I-Observation
(	I-Observation
BPRS	I-Observation
)	I-Observation
psychosis	I-Observation
factor	I-Observation
score	I-Observation
of	O
at	O
least	O
4	O
(	O
moderate	O
severity	O
)	O
on	O
one	O
of	O
the	O
following	O
two	O
items:	O
These	O
two	O
items	O
comprise	O
the	O
psychosis	B-Condition
factor	I-Condition
excluding	B-Negation_cue
the	O
item	O
for	O
conceptual	B-Condition
disorganization	I-Condition
.	O

Agitation	B-Condition
is	O
defined	O
as	O
a	O
score	O
of	O
greater	O
than	O
3	O
(	O
present	O
at	O
least	O
10	O
days	O
per	O
month	O
)	O
on	O
one	O
or	O
more	O
of	O
the	O
CERAD	B-Observation
Behavioral	I-Observation
Rating	I-Observation
Scale	I-Observation
for	O
Dementia	B-Condition
items	O
for	O
agitation	B-Condition
,	O
purposeless	B-Condition
wandering	I-Condition
verbal	B-Condition
aggression	I-Condition
or	O
physical	B-Condition
aggression	I-Condition
.	O

-	O
Free	B-Negation_cue
of	O
psychotropic	B-Drug
medication	I-Drug
for	O
at	O
least	O
two	O
weeks	O
prior	O
to	O
study	O
entry	O
or	O
able	O
to	O
tolerate	O
medication	O
washout	O
for	O
this	O
period	O
.	O

-	O
Informed	O
consent	O
by	O
patient	O
and	O
family	O
member,	O
as	O
per	O
IRB	O
procedures	O
at	O
New	O
York	O
State	O
Psychiatric	O
Institute	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Acute	O
unstable	O
medical	B-Condition
condition	I-Condition
delirium	B-Condition
,	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
within	O
the	O
past	O
1	O
year	O
.	O

-	O
Clinical	O
evidence	O
of	O
stroke	B-Condition
,	O
other	O
dementias	B-Condition
including	O
vascular	B-Condition
or	I-Condition
Lewy	I-Condition
body	I-Condition
or	I-Condition
frontotemporal	I-Condition
dementia	I-Condition
multiple	B-Condition
sclerosis	I-Condition
Parkinson's	B-Condition
disease	I-Condition
Huntington's	B-Condition
disease	I-Condition
tardive	B-Condition
dyskinesia	I-Condition
.	O

-	O
Diagnosis	O
of	O
a	O
psychotic	B-Condition
disorder	I-Condition
antedating	O
the	O
onset	O
of	O
dementia	B-Condition
.	O

-	O
Antipsychotic	B-Drug
medication	I-Drug
usage	O
during	O
4	O
weeks	O
prior	O
to	O
study	O
entry	O
.	O

-	O
Contraindication	B-Condition
to	O
the	O
use	O
of	O
haloperidol	B-Drug
.	O

>>NCT00089882	O
Inclusion	O
Criteria:	O
.	O

-	O
Adult	O
children	O
or	O
siblings	O
of	O
people	O
with	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Adult	O
children	O
or	O
siblings	O
of	O
people	O
with	O
Alzheimer's	B-Condition
disease	I-Condition
who	O
are	O
unable	O
to	O
visit	O
a	O
study	O
site	O
.	O

-	O
Persons	O
with	O
currently	O
untreated	O
depression	B-Condition
,	O
anxiety	B-Condition
or	O
severe	O
mood	B-Condition
disturbances	I-Condition
.	O

-	O
Persons	O
with	O
cognitive	B-Condition
deficits	I-Condition
.	O

>>NCT00076440	O
Inclusion	O
Criteria:	O
.	O

Patients	O
who	O
satisfy	O
all	O
of	O
the	O
inclusion	O
criteria	O
listed	O
below	O
will	O
be	O
eligible	O
for	O
entry	O
into	O
the	O
trial	O
.	O

-	O
Patient	O
and	O
responsible	O
caregiver	O
can	O
give	O
their	O
consent	O
by	O
signing	O
the	O
IRB-approved	O
Informed	O
Consent	O
Form;	O
or,	O
when	O
the	O
patient	O
is	O
judged	O
by	O
the	O
Investigator	O
to	O
be	O
unable	O
to	O
give	O
consent,	O
the	O
legally	O
authorized	O
representative	O
gives	O
consent	O
by	O
signing	O
the	O
consent	O
form	O
and	O
the	O
patient	O
gives	O
assent,	O
in	O
accord	O
with	O
local	O
regulations;	O
.	O

-	O
Male	B-Observation
;	O
.	O

-	O
65	O
years	O
of	O
age	B-Observation
or	O
older;	O
.	O

-	O
Diagnosis	O
of	O
probable	O
AD	B-Condition
according	O
to	O
the	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
Disorders-Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINDS-ADRDA	I-Observation
)	I-Observation
criteria	I-Observation
and	O
the	O
Investigator	O
ascertains	O
that	O
the	O
condition	B-Condition
was	O
present	O
at	O
least	O
6	O
months	O
prior	O
to	O
screening;	O
.	O

-	O
Taking	O
a	O
drug	B-Drug
for	O
the	O
treatment	O
of	O
AD	B-Condition
,	O
such	O
as	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
and	O
/	O
or	O
Memantine	B-Drug
,	O
which	O
they	O
began	O
taking	O
at	O
least	O
90	O
days	O
prior	O
to	O
baseline	O
and,	O
in	O
the	O
Investigator's	O
opinion,	O
the	O
dosage	B-Procedure_Device
will	O
likely	O
remain	O
stable	O
throughout	O
the	O
trial;	O
or,	O
they	O
have	O
never	B-Negation_cue
taken	O
such	O
a	O
drug	B-Drug
or	O
stopped	O
taking	O
it	O
at	O
least	O
90	O
days	O
prior	O
to	O
baseline	O
and	O
will	O
likely	O
refrain	O
from	O
taking	O
such	O
treatment	O
throughout	O
the	O
trial;	O
.	O

-	O
Taking	O
other	O
drugs	B-Drug
or	O
substances	B-Drug
that	O
have	O
purported	O
cognition-enhancing	O
properties	O
such	O
as	O
ginkgo	B-Drug
biloba	I-Drug
or	O
Vitamin	B-Drug
E	I-Drug
which	O
they	O
began	O
taking	O
at	O
least	O
60	O
days	O
prior	O
to	O
baseline	O
and,	O
in	O
the	O
Investigator's	O
opinion,	O
the	O
dosage	O
will	O
likely	O
remain	O
stable	O
throughout	O
the	O
trial;	O
or,	O
they	O
have	O
never	B-Negation_cue
taken	O
such	O
a	O
drug	B-Drug
or	O
stopped	O
taking	O
it	O
at	O
least	O
90	O
days	O
prior	O
to	O
baseline	O
and	O
will	O
likely	O
refrain	O
from	O
taking	O
such	O
treatment	O
throughout	O
the	O
trial;	O
.	O

-	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
of	O
12	O
to	O
24	O
(	O
inclusive	O
)	O
at	O
the	O
screening	O
visit;	O
.	O

-	O
Brain	B-Procedure_Device
imaging	I-Procedure_Device
study	I-Procedure_Device
(	O
CT	B-Procedure_Device
scan	I-Procedure_Device
MRI	B-Procedure_Device
or	O
PET	B-Procedure_Device
)	O
performed	O
at	O
the	O
time	O
of	O
their	O
initial	O
diagnosis	O
of	O
AD	B-Condition
or	O
after	O
that	O
time	O
and	O
the	O
findings	O
were	O
consistent	O
with	O
a	O
diagnosis	O
of	O
probable	O
AD	B-Condition
,	O
or,	O
if	O
a	O
brain	O
imaging	O
study	O
has	O
not	O
been	O
performed,	O
one	O
will	O
be	O
performed	O
during	O
the	O
screening	O
process;	O
.	O

-	O
Rosen	B-Observation
Modified	I-Observation
Hachinski	I-Observation
score	I-Observation
of	O
4	O
or	O
lower	O
at	O
the	O
screening	O
visit,	O
supporting	O
the	O
Investigator's	O
clinical	O
judgment	O
that	O
the	O
patient's	O
dementia	B-Condition
is	O
probable	O
AD	B-Condition
and	O
not	B-Negation_cue
of	B-Observation
vascular	I-Observation
origin	I-Observation
.	O

-	O
Fluent	O
in	O
English	O
or	O
Spanish	O
and	O
completed	O
at	O
least	O
6	O
years	O
of	O
education;	O
.	O

-	O
Live	O
at	O
home	O
or	O
in	O
a	O
congregate	O
living	O
facility	O
for	O
requirements	O
other	O
than	O
skilled	O
nursing	O
care	O
and	O
have	O
a	O
caregiver	O
who	O
sees	O
the	O
patient	O
at	O
least	O
three	O
times	O
a	O
week	O
for	O
a	O
total	O
of	O
at	O
least	O
10	O
hours	O
and	O
can	O
sign	O
the	O
consent	O
form,	O
provide	O
information	O
pertinent	O
to	O
the	O
patient's	O
cognitive	O
status,	O
accompany	O
the	O
patient	O
on	O
clinic	O
visits	O
and	O
participate	O
in	O
the	O
evaluations	O
.	O

-	O
Hamilton	B-Observation
Depression	I-Observation
Scale	I-Observation
(	I-Observation
17	I-Observation
-item	I-Observation
version	I-Observation
)	I-Observation
(	I-Observation
HamD	I-Observation
)	I-Observation
score	I-Observation
of	O
14	O
or	O
less	O
at	O
the	O
screening	O
visit;	O
.	O

-	O
DEXA	B-Procedure_Device
scan	I-Procedure_Device
performed	O
at	O
screening,	O
within	O
normal	O
limits	O
(	O
i.e.,	O
a	O
T-score	B-Observation
of	O
greater	O
than	O
-	O
2.0	O
);	O
or,	O
if	O
their	O
DEXA	B-Observation
measure	I-Observation
was	O
abnormally	O
low	O
(	O
i.e.,	O
a	O
T-score	B-Observation
of	O
-	O
2.0	O
or	O
lower	O
),	O
in	O
either	O
a	O
lumbar	O
vertebra	O
or	O
hip,	O
to	O
specifically	O
include	O
a	O
T-score	O
for	O
the	O
femoral	O
neck	O
),	O
they	O
were	O
receiving	O
treatment	B-Procedure_Device
for	O
osteoporosis	B-Condition
/	I-Condition
osteopenia	I-Condition
for	O
at	O
least	O
3	O
weeks	O
prior	O
to	O
baseline	O
and	O
that	O
treatment	O
is	O
not	O
expected	O
to	O
change	O
during	O
the	O
course	O
of	O
the	O
trial;	O
or,	O
if	O
their	O
DEXA	B-Observation
measure	I-Observation
was	O
abnormally	O
low	O
and	O
they	O
are	O
not	B-Negation_cue
receiving	O
treatment	B-Procedure_Device
for	O
osteoporosis	B-Condition
/	I-Condition
osteopenia	I-Condition
they	O
may	O
proceed	O
to	O
baseline	O
after	O
3	O
weeks	O
of	O
treatment	B-Procedure_Device
for	O
osteoporosis	B-Condition
/	I-Condition
osteopenia	I-Condition
provided	O
that	O
all	O
inclusion	O
/	O
exclusion	O
criteria	O
are	O
met,	O
including	O
assessment	O
of	O
the	O
HamD	B-Observation
,	O
concomitant	O
medications	B-Drug
,	O
ECG	B-Procedure_Device
and	O
laboratory	B-Observation
tests	I-Observation
performed	O
within	O
45	O
days	O
of	O
baseline	O
show	O
that	O
they	O
are	O
eligible;	O
.	O

-	O
Screening	O
laboratory	B-Observation
test	I-Observation
values	O
do	O
not	B-Negation_cue
indicate	O
significant	O
medical	B-Condition
conditions	I-Condition
that	O
would	O
interfere	O
with	O
their	O
participation	O
in	O
and	O
completion	O
of	O
the	O
study	O
.	O

Exclusion	O
criteria:	O
.	O

Patients	O
with	O
any	O
of	O
the	O
exclusion	O
criteria	O
listed	O
below	O
will	O
be	O
ineligible	O
for	O
entry	O
into	O
the	O
study	O
.	O

-	O
Female	B-Observation
;	O
.	O

-	O
Younger	O
than	O
65	O
years	O
of	O
age	B-Observation
;	O
.	O

-	O
Significant	O
neurological	B-Condition
disease	I-Condition
affecting	O
the	O
brain	O
or	O
psychiatric	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
,	O
such	O
as	O
major	B-Condition
depression	I-Condition
schizophrenia	B-Condition
,	O
epilepsy	B-Condition
,	O
Parkinson's	B-Condition
disease	I-Condition
or	O
stroke	B-Condition
;	O
.	O

-	O
Current	O
significant	O
systemic	B-Condition
illness	I-Condition
or	O
symptoms	O
of	O
organ	B-Condition
failure	I-Condition
.	O

-	O
Screening	O
ECG	B-Procedure_Device
shows	O
evidence	O
of	O
a	O
serious	O
and	O
/	O
or	O
unstable	O
condition	B-Condition
or	O
a	O
recent	O
(	O
within	O
6	O
months	O
)	O
myocardial	B-Condition
infarction	I-Condition
as	O
determined	O
by	O
the	O
Investigator;	O
.	O

-	O
PSA	B-Observation
test	I-Observation
result	I-Observation
exceeds	O
4.0	O
ng	O
/	O
mL;	O
.	O

-	O
Receiving	O
testosterone	B-Drug
;	O
.	O

-	O
Taking	O
a	O
drug	B-Drug
for	O
the	O
treatment	O
of	O
AD	B-Condition
for	O
less	O
than	O
90	O
days	O
prior	O
to	O
baseline;	O
or,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator,	O
they	O
are	O
likely	O
to	O
either	O
require	O
a	O
change	O
in	O
dose	O
or	O
discontinuation	O
of	O
the	O
drug;	O
.	O

-	O
Never	B-Negation_cue
received	O
cholinesterase	B-Drug
inhibitor	I-Drug
treatment	O
and	O
the	O
likelihood	O
of	O
their	O
starting	O
such	O
treatment	O
during	O
the	O
study	O
is	O
other	O
than	O
low	O
or	O
they	O
have	O
taken	O
and	O
discontinued	O
cholinesterase	B-Drug
inhibitor	I-Drug
treatment	O
in	O
the	O
past	O
and	O
the	O
likelihood	O
of	O
their	O
resuming	O
cholinesterase	B-Drug
inhibitor	I-Drug
treatment	O
during	O
the	O
study	O
is	O
other	O
than	O
low;	O
.	O

-	O
Started	O
or	O
changed	O
within	O
60	O
days	O
prior	O
to	O
the	O
screening	O
visit	O
the	O
dosage	B-Procedure_Device
of	O
any	O
drug	B-Drug
(	O
including	O
OTC	B-Drug
)	O
that	O
affects	O
cognitive	B-Observation
function	I-Observation
such	O
as	O
neuroleptics	B-Drug
,	O
antidepressants	B-Drug
,	O
anxiolytics	B-Drug
,	O
sedatives	B-Drug
,	O
hypnotics	B-Drug
,	O
anti-convulsants	B-Drug
,	O
centrally	B-Drug
acting	I-Drug
antihypertensive	I-Drug
agents	I-Drug
such	O
as	O
clonidine	B-Drug
and	O
Aldomet	B-Drug
;	O
or	O
other	O
medications	B-Drug
that	O
have	O
been	O
shown	O
to	O
have	O
possible	O
effects	O
on	O
cognition	O
such	O
as	O
Vitamin	B-Drug
E	I-Drug
nonsteroidal	B-Drug
anti-inflammatory	I-Drug
drugs	I-Drug
and	O
statins	B-Drug
or	O
if,	O
in	O
the	O
Investigator's	O
opinion,	O
the	O
dosage	O
of	O
such	O
medication	O
is	O
likely	O
to	O
be	O
changed	O
during	O
the	O
course	O
of	O
this	O
trial	O
.	O

Any	O
changes	O
in	O
the	O
dosage	O
of	O
any	O
of	O
these	O
drugs	O
during	O
the	O
course	O
of	O
the	O
trial	O
and	O
the	O
reason	O
for	O
the	O
change	O
must	O
be	O
fully	O
recorded	O
in	O
the	O
concomitant	O
medication	O
page	O
of	O
the	O
patient's	O
case	O
report	O
form	O
(	O
CRF	O
)	O
.	O

If	O
a	O
drug	B-Drug
that	O
affects	O
cognition	B-Observation
(	O
eg	O
,	O
a	O
hypnotic	B-Drug
or	I-Drug
anxiolytic	I-Drug
drug	I-Drug
)	O
is	O
given	O
on	O
a	O
PRN	O
basis,	O
such	O
treatment	O
should	O
be	O
interrupted	O
for	O
12	O
hours	O
before	O
a	O
visit,	O
if	O
possible;	O
.	O

-	O
Taking	O
coumadin	B-Drug
or	O
anti-Parkinsonian	B-Drug
medications	I-Drug
.	O

-	O
Have	O
taken	O
other	O
investigational	B-Drug
drugs	I-Drug
within	O
30	O
days	O
or	O
5	O
half-lives	O
prior	O
to	O
randomization,	O
whichever	O
is	O
longer;	O
.	O

-	O
Taking	O
other	O
medications	B-Drug
known	O
to	O
affect	O
serum	B-Observation
gonadotropin	I-Observation
(	I-Observation
Gn	I-Observation
)	I-Observation
concentrations	I-Observation
such	O
as	O
goserelin	B-Drug
or	O
danazol	B-Drug
;	O
.	O

-	O
A	O
screening	O
HamD	B-Observation
score	I-Observation
of	O
15	O
or	O
higher;	O
.	O

-	O
Abuse	B-Condition
or	I-Condition
dependence	I-Condition
on	I-Condition
alcohol	I-Condition
or	I-Condition
other	I-Condition
substances	I-Condition
satisfies	O
criteria	O
for	O
DSM-IV	B-Observation
categories	I-Observation
303.9	O
or	O
305;	O
.	O

-	O
Donated	B-Procedure_Device
blood	I-Procedure_Device
within	O
30	O
days	O
of	O
baseline	O
or	O
are	O
likely	O
to	O
do	O
so	O
during	O
the	O
course	O
of	O
the	O
trial;	O
.	O

-	O
History	O
of	O
cancer	B-Condition
,	O
particularly	O
breast	B-Condition
cancer	I-Condition
or	O
known	O
or	O
suspected	O
prostate	B-Condition
cancer	I-Condition
within	O
the	O
last	O
5	O
years,	O
except	B-Negation_cue
for	O
basal	B-Condition
cell	I-Condition
or	I-Condition
squamous	I-Condition
cell	I-Condition
cancer	I-Condition
of	I-Condition
the	I-Condition
skin	I-Condition
.	O

-	O
Clinically	O
significant	O
bladder	B-Condition
outlet	I-Condition
obstruction	I-Condition
in	O
the	O
judgment	O
of	O
the	O
Investigator	O
or	O
designated	O
examining	O
physician;	O
.	O

-	O
Abnormalities	B-Condition
of	O
the	O
esophagus	O
which	O
delay	O
esophageal	O
emptying	O
such	O
as	O
stricture	B-Condition
or	O
achalasia	B-Condition
or	O
are	O
unable	O
to	O
stand	O
or	O
sit	O
upright	O
for	O
at	O
least	O
30	O
minutes;	O
.	O

-	O
Sleep	B-Condition
apnea	I-Condition
.	O

>>NCT00495820	O
Inclusion	O
Criteria:	O
.	O

1	O
.	O

Diagnosis	O
of	O
dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer	I-Condition
type	I-Condition
(	O
DSM-IV	B-Observation
Text	I-Observation
Revision	I-Observation
(	I-Observation
TR	I-Observation
)	I-Observation
criteria	I-Observation
)	O
.	O

2	O
.	O

Mini-mental	B-Observation
state	I-Observation
examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
>	O
18	O
but	O
<	O
29	O
.	O

3	O
.	O

Apathy	B-Observation
Evaluation	I-Observation
Scale	I-Observation
(	I-Observation
AES	I-Observation
)	I-Observation
score	I-Observation
of	O
more	O
than	O
40	O
.	O

4	O
.	O

Ability	O
to	O
provide	O
informed	O
consent	O
by	O
either	O
the	O
patient	O
or	O
caregiver	O
.	O

5	O
.	O

If	O
subjects	O
are	O
being	O
treated	O
with	O
antidepressants	B-Drug
,	O
they	O
should	O
be	O
on	O
a	O
stable	O
dose	O
of	O
antidepressants	B-Drug
for	O
at	O
least	O
two	O
months	O
prior	O
to	O
the	O
enrollment	O
into	O
the	O
study	O
.	O

6	O
.	O

If	O
subjects	O
are	O
being	O
treated	O
with	O
cholinesterase	B-Drug
inhibitors	I-Drug
and	O
memantine	B-Drug
,	O
they	O
should	O
be	O
on	O
stable	O
dose	O
of	O
those	O
medications	B-Drug
at	O
least	O
four	O
months	O
prior	O
to	O
the	O
enrollment	O
into	O
the	O
study	O
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

Patient	O
currently	O
taking	O
methylphenidate	B-Drug
or	O
hypersensitivity	B-Condition
or	O
prior	O
significant	O
adverse	B-Condition
events	I-Condition
with	O
methylphenidate	B-Drug
.	O

2	O
.	O

Patients	O
currently	O
taking	O
Adderall	B-Drug
(	O
amphetamine	B-Drug
mixed	I-Drug
salts	I-Drug
)	O
or	O
Dexedrine	B-Drug
(	O
dextroamphetamine	B-Drug
sulphate	I-Drug
)	O
or	O
any	O
other	O
amphetamine	B-Drug
product	I-Drug
.	O

3	O
.	O

Uncontrolled	O
hypertension	B-Condition
(	O
BP	B-Observation
>	O
140	O
-	O
90	O
)	O
or	O
tachycardia	B-Condition
(	O
100	O
)	O
at	O
screening	O
visit	O
.	O

4	O
.	O

Patients	O
with	O
frontotemporal	B-Condition
dementia	I-Condition
.	O

5	O
.	O

Patients	O
meeting	O
criteria	O
for	O
Major	B-Condition
Depressive	I-Condition
Disorder	I-Condition
on	O
the	O
Mini	B-Observation
International	I-Observation
Neuropsychiatric	I-Observation
Inventory	I-Observation
(	I-Observation
MINI	I-Observation
)	I-Observation
.	O

6	O
.	O

Patients	O
with	O
active	O
psychosis	B-Condition
as	O
determined	O
by	O
MINI	B-Observation
.	O

7	O
.	O

Patients	O
currently	O
being	O
treated	O
with	O
antipsychotics	B-Drug
.	O

8	O
.	O

History	O
of	O
uncontrolled	O
seizure	B-Condition
disorder	I-Condition
.	O

9	O
.	O

History	O
of	O
malignant	B-Condition
hypertension	I-Condition
symptomatic	B-Condition
cardiovascular	I-Condition
disease	I-Condition
cardiomyopathy	B-Condition
,	O
known	O
structural	B-Condition
cardiac	I-Condition
defect	I-Condition
or	O
medically	O
unstable	O
arrhythmias	B-Condition
.	O

10	O
.	O

History	O
of	O
Tourette's	B-Condition
syndrome	I-Condition
or	O
presence	O
of	O
motor	B-Condition
tics	I-Condition
.	O

11	O
.	O

Patients	O
with	O
glaucoma	B-Condition
.	O

12	O
.	O

Patients	O
taking	O
monoamine	B-Drug
oxidase	I-Drug
inhibitors	I-Drug
(	I-Drug
MAOIs	I-Drug
)	I-Drug
.	O

13	O
.	O

Patient	O
taking	O
clonidine	B-Drug
.	O

>>NCT01615666	O
Inclusion	O
Criteria:	O
.	O

-	O
60	O
years	O
of	O
age	B-Observation
or	O
older	O
(	O
50	O
years	O
of	O
age	B-Observation
or	O
older	O
for	O
rontotemporal	B-Condition
dementia	I-Condition
patients	O
)	O
.	O

-	O
Normal	O
memory	B-Condition
,	O
mild	B-Condition
cognitive	I-Condition
impairment	I-Condition
(	O
memory	B-Condition
loss	I-Condition
that	O
does	O
not	O
significantly	O
affect	O
normal	O
daily	O
activities	O
)	O
or	O
clinical	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
or	O
frontotemporal	B-Condition
dementia	I-Condition
(	O
includes	O
primary	B-Condition
progressive	I-Condition
aphasia	I-Condition
)	O
.	O

-	O
Right-handed	O
.	O

-	O
General	O
good	O
physical	B-Condition
health	I-Condition
.	O

Exclusion	O
Criteria:	O
.	O

-	O
History	O
of	O
stroke	B-Condition
or	O
neurological	B-Condition
disease	I-Condition
(	O
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
or	O
frontotemporal	B-Condition
dementia	I-Condition
)	O
.	O

-	O
Seizures	B-Condition
or	O
head	B-Condition
injury	I-Condition
with	I-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition
within	O
the	O
last	O
five	O
years	O
.	O

-	O
Ferrous	B-Procedure_Device
(	I-Procedure_Device
magnetic	I-Procedure_Device
)	I-Procedure_Device
or	I-Procedure_Device
electronic	I-Procedure_Device
implants	I-Procedure_Device
(	O
due	O
to	O
the	O
magnet	O
in	O
the	O
MRI	B-Procedure_Device
scanner	O
)	O
.	O

-	O
Claustrophobia	B-Condition
.	O

>>NCT02129348	O
Inclusion	O
Criteria:	O
.	O

1	O
.	O

Age	B-Observation
55	O
-	O
95	O
years	O
.	O

2	O
.	O

Diagnosis	O
of	O
possible	O
or	O
probable	O
AD	B-Condition
by	O
standard	B-Observation
NIA	I-Observation
criteria	I-Observation
(	O
McKahnn	O
et	O
al,	O
1984;	O
McKhann	O
et	O
all,	O
2011	O
)	O
.	O

3	O
.	O

Folstein	B-Observation
MMSE	I-Observation
5	O
-	O
26	O
out	O
of	O
30	O
.	O

4	O
.	O

Neuropsychiatric	B-Observation
Inventory	I-Observation
(	I-Observation
NPI	I-Observation
)	I-Observation
agitation	I-Observation
/	I-Observation
aggression	I-Observation
subscale	I-Observation
score	I-Observation
>	O
4	O
.	O

On	O
each	O
subscale	O
(	O
frequency	O
X	O
severity	O
),	O
a	O
score	O
higher	O
than	O
4	O
represents	O
moderate	O
to	O
severe	O
symptoms	O
.	O

5	O
.	O

Female	O
patients	O
need	O
to	O
be	O
post-menopausal	B-Condition
.	O

6	O
.	O

Availability	O
of	O
informant;	O
patients	O
without	O
an	O
informant	O
will	O
not	O
be	O
recruited	O
.	O

Patients	O
who	O
lack	O
capacity	O
must	O
have	O
a	O
surrogate	O
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

Medical	O
contraindication	B-Condition
to	O
lithium	B-Drug
treatment	I-Drug
or	O
prior	O
history	O
of	O
intolerability	B-Condition
to	O
lithium	B-Observation
treatment	I-Observation
.	O

Contraindications	B-Condition
to	O
lithium	B-Drug
in	O
this	O
study	O
include:	O
resting	B-Condition
tremor	I-Condition
causing	O
functional	B-Condition
impairment	I-Condition
history	O
of	O
falls	B-Condition
in	O
the	O
last	O
month,	O
untreated	O
thyroid	B-Condition
disease	I-Condition
or	O
any	O
abnormal	O
thyroid	B-Observation
function	I-Observation
test	I-Observation
(	O
T3	B-Observation
,	O
T4	B-Observation
or	O
TSH	B-Observation
),	O
creatinine	B-Observation
level	I-Observation
greater	O
than	O
1.5	O
mg	O
/	O
100ml	O
or	O
a	O
glomerular	B-Observation
filtration	I-Observation
rate	I-Observation
less	O
than	O
44ml	O
/	O
min/	O
1.73m2;	O
blood	B-Observation
pressure	I-Observation
>	O
150	O
-	O
90	O
mm	O
Hg;	O
heart	B-Observation
rate	I-Observation
<	O
50	O
bpm;	O
unstable	O
cardiac	B-Condition
disease	I-Condition
based	O
on	O
history	B-Observation
,	O
physical	B-Observation
examination	I-Observation
and	O
ECG	B-Procedure_Device
.	O

2	O
.	O

Medications	B-Drug
,	O
in	O
combination	O
with	O
lithium	B-Drug
,	O
known	O
to	O
have	O
adverse	B-Condition
renal	I-Condition
effects	I-Condition
including	O
therapeutic	O
or	O
higher	O
doses	O
of	O
diuretics	B-Drug
,	O
i.e	O
.	O

hydrochlorothiazide	B-Drug
greater	O
than	O
25mg	O
daily	O
or	O
furosemide	B-Drug
greater	O
than	O
10mg	O
daily	O
.	O

Whenever	O
feasible,	O
patients	O
receiving	O
concomitant	O
antidepressants	B-Drug
or	O
antipsychotics	B-Drug
will	O
be	O
washed	B-Negation_cue
off	I-Negation_cue
these	O
medications	B-Drug
for	O
at	O
least	O
24	O
hours	O
before	O
starting	O
lithium	O
.	O

Patients	O
who	O
do	O
not	O
wish	O
to	O
discontinue	O
antipsychotics	B-Drug
or	O
antidepressants	B-Drug
,	O
typically	O
because	O
of	O
family	O
member	O
/	O
caregiver	O
objection,	O
will	O
be	O
allowed	O
to	O
enter	O
the	O
trial	O
provided	O
there	O
is	O
no	B-Negation_cue
contraindication	B-Condition
to	O
concomitant	O
lithium	B-Drug
use	O
with	O
that	O
specific	O
psychotropic	B-Drug
medication	I-Drug
.	O

During	O
the	O
trial,	O
patients	O
will	O
be	O
permitted	O
to	O
receive	O
lorazepam	B-Drug
as	O
needed	O
up	O
to	O
2	O
mg	O
/	O
day	O
for	O
anxiety	B-Condition
/	I-Condition
insomnia	I-Condition
and	O
non-benzodiazepine	B-Drug
hypnotics	I-Drug
eg	O
,	O
zolpidem	B-Drug
.	O

3	O
.	O

Current	O
clinical	O
diagnosis	O
of	O
schizophrenia	B-Condition
,	O
schizoaffective	B-Condition
disorder	I-Condition
other	O
psychosis	B-Condition
or	O
bipolar	B-Condition
1	I-Condition
disorder	I-Condition
(	O
DSM-IV	B-Observation
TR	I-Observation
criteria	I-Observation
)	O
.	O

4	O
.	O

Current	O
or	O
recent	O
(	O
past	O
6	O
months	O
)	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
dependence	I-Condition
(	O
DSM-IV	B-Observation
TR	I-Observation
criteria	I-Observation
)	O
.	O

5	O
.	O

Current	O
major	B-Condition
depression	I-Condition
or	O
suicidality	B-Condition
as	O
assessed	O
by	O
the	O
study	O
psychiatrist	O
.	O

6	O
.	O

Suicidal	O
behavior	O
or	O
dangerous	O
behavior	O
with	O
serious	O
safety	O
risk	O
or	O
risk	O
of	O
physical	O
harm	O
to	O
self	O
or	O
others	O
.	O

7	O
.	O

Parkinson's	B-Condition
disease	I-Condition
Lewy	B-Condition
body	I-Condition
disease	I-Condition
multiple	B-Condition
sclerosis	I-Condition
CNS	B-Condition
infection	I-Condition
Huntington's	B-Condition
disease	I-Condition
amyotrophic	B-Condition
lateral	I-Condition
sclerosis	I-Condition
other	O
major	O
neurological	B-Condition
disorder	I-Condition
.	O

8	O
.	O

Clinical	B-Condition
stroke	I-Condition
with	O
residual	B-Condition
neurological	I-Condition
deficits	I-Condition
.	O

MRI	B-Procedure_Device
findings	O
of	O
cerebrovascular	B-Condition
disease	I-Condition
(	O
smallinfarcts	B-Condition
,	O
lacunes	B-Condition
,	O
periventricular	B-Condition
disease	I-Condition
)	O
in	O
the	O
absence	O
of	O
clinical	B-Condition
stroke	I-Condition
with	O
residual	B-Condition
neurological	I-Condition
deficits	I-Condition
will	O
not	O
lead	O
to	O
exclusion	O
.	O

9	O
.	O

Acute,	O
severe,	O
unstable	O
medical	B-Condition
illness	I-Condition
.	O

For	O
cancer	B-Condition
,	O
patients	O
with	O
active	O
illness	B-Condition
or	O
metastases	B-Condition
will	O
be	O
excluded	O
but	O
past	O
history	O
of	O
successfully	O
treated	O
cancer	B-Condition
will	O
not	O
lead	O
to	O
exclusion	O
.	O

10	O
.	O

QTc	B-Observation
interval	I-Observation
>	O
460	O
ms	O
at	O
the	O
time	O
of	O
baseline	B-Procedure_Device
EKG	I-Procedure_Device
is	O
an	O
exclusion	O
criterion	O
for	O
treatment.	O

>>NCT00063310	O
Inclusion	O
Criteria:	O
.	O

Patients	O
who	O
satisfy	O
all	O
of	O
the	O
inclusion	O
criteria	O
listed	O
below	O
will	O
be	O
eligible	O
for	O
entry	O
into	O
the	O
trial	O
.	O

Patients	O
will	O
be	O
considered	O
eligible	O
if:	O
.	O

-	O
They	O
give	O
their	O
consent	O
by	O
signing	O
the	O
IRB-approved	O
Informed	O
Consent	O
Form	O
and	O
the	O
responsible	O
caregiver	O
also	O
signs	O
the	O
consent	O
form;	O
or,	O
if	O
the	O
patient	O
is	O
judged	O
by	O
the	O
Investigator	O
to	O
be	O
unable	O
to	O
give	O
consent,	O
if	O
the	O
legally	O
authorized	O
representative	O
gives	O
consent	O
by	O
signing	O
the	O
consent	O
form	O
and	O
the	O
patient	O
gives	O
assent,	O
in	O
accord	O
with	O
local	O
regulations;	O
.	O

-	O
They	O
are	O
female;	O
.	O

-	O
They	O
are	O
65	O
years	O
of	O
age	B-Observation
or	O
older;	O
.	O

-	O
They	O
have	O
a	O
diagnosis	O
of	O
probable	O
AD	B-Condition
according	O
to	O
the	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
Disorders-Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINDS-ADRDA	I-Observation
)	I-Observation
criteria	I-Observation
and	O
the	O
Investigator	O
ascertains	O
that	O
the	O
condition	B-Condition
was	O
present	O
at	O
least	O
6	O
months	O
prior	O
to	O
screening;	O
.	O

-	O
They	O
are	O
taking	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
they	O
began	O
taking	O
it	O
at	O
least	O
90	O
days	O
prior	O
to	O
baseline	O
and,	O
in	O
the	O
Investigator's	O
opinion,	O
the	O
dosage	O
will	O
likely	O
remain	O
stable	O
throughout	O
the	O
trial;	O
.	O

-	O
They	O
are	O
taking	O
other	O
drugs	B-Drug
or	O
substances	B-Drug
that	O
have	O
purported	O
cognition	O
enhancing	O
properties	O
such	O
as	O
ginkgo	B-Drug
biloba	I-Drug
and	O
Vitamin	B-Drug
E	I-Drug
they	O
began	O
taking	O
it	O
at	O
least	O
60	O
days	O
prior	O
to	O
baseline	O
and,	O
in	O
the	O
Investigator's	O
opinion,	O
the	O
dosage	O
will	O
likely	O
remain	O
stable	O
throughout	O
the	O
trial;	O
.	O

-	O
They	O
score	O
no	B-Negation_cue
lower	O
than	O
12	O
or	O
higher	O
than	O
24	O
on	O
the	O
(	O
MMSE	B-Observation
)	O
administered	O
at	O
the	O
screening	O
visit;	O
.	O

-	O
They	O
have	O
had	O
a	O
brain	B-Procedure_Device
imaging	I-Procedure_Device
study	I-Procedure_Device
(	O
CT	B-Procedure_Device
scan	I-Procedure_Device
MRI	B-Procedure_Device
or	O
PET	B-Procedure_Device
)	O
performed	O
at	O
the	O
time	O
of	O
their	O
initial	O
diagnosis	O
of	O
AD	B-Condition
or	O
after	O
that	O
time	O
and	O
the	O
findings	O
were	O
consistent	O
with	O
a	O
diagnosis	O
of	O
probable	O
AD	B-Condition
,	O
or,	O
if	O
a	O
brain	O
imaging	O
study	O
has	O
not	O
been	O
performed,	O
one	O
will	O
be	O
performed	O
during	O
the	O
screening	O
process;	O
.	O

-	O
Their	O
Rosen	B-Observation
Modified	I-Observation
Hachinski	I-Observation
score	I-Observation
was	O
4	O
or	O
lower	O
at	O
the	O
screening	O
visit,	O
supporting	O
the	O
Investigator's	O
clinical	O
judgment	O
that	O
the	O
patient's	O
dementia	B-Condition
is	O
probable	O
AD	B-Condition
and	O
not	B-Negation_cue
of	B-Observation
vascular	I-Observation
origin	I-Observation
.	O

-	O
They	O
are	O
fluent	O
in	O
English	O
or	O
Spanish	O
and	O
completed	O
at	O
least	O
6	O
years	O
of	O
education;	O
.	O

-	O
They	O
live	O
at	O
home	O
or	O
in	O
a	O
congregate	O
living	O
facility	O
for	O
requirements	O
other	O
than	O
skilled	O
nursing	O
care	O
and	O
have	O
a	O
caregiver	O
who	O
sees	O
the	O
patient	O
at	O
least	O
three	O
time	O
a	O
week	O
for	O
a	O
total	O
of	O
at	O
least	O
10	O
hours	O
and	O
can	O
sign	O
the	O
consent	O
form,	O
provide	O
information	O
pertinent	O
to	O
the	O
patient's	O
cognitive	O
status,	O
accompany	O
the	O
patient	O
on	O
clinic	O
visits	O
and	O
participate	O
in	O
the	O
evaluations;	O
.	O

-	O
Their	O
hormone	B-Drug
replacement	I-Drug
therapy	I-Drug
(	I-Drug
HRT	I-Drug
)	I-Drug
if	O
any,	O
has	O
been	O
stable	O
for	O
at	O
least	O
60	O
days	O
prior	O
to	O
baseline	O
and	O
is	O
not	O
expected	O
to	O
change	O
during	O
the	O
course	O
of	O
the	O
trial;	O
.	O

-	O
They	O
score	O
less	O
than	O
15	O
on	O
the	O
Hamilton	B-Observation
Depression	I-Observation
Scale	I-Observation
(	I-Observation
17	I-Observation
-item	I-Observation
version	I-Observation
)	I-Observation
(	I-Observation
HamD	I-Observation
)	I-Observation
administered	O
as	O
part	O
of	O
the	O
screening	O
evaluation;	O
.	O

-	O
Absorptiometry	B-Procedure_Device
(	O
dual-energy	B-Procedure_Device
x-ray	I-Procedure_Device
absorpometry	I-Procedure_Device
(	I-Procedure_Device
DEXA	I-Procedure_Device
)	I-Procedure_Device
scan	I-Procedure_Device
),	O
performed	O
at	O
screening,	O
was	O
within	O
normal	O
limits	O
(	O
i.e.,	O
a	O
T-	B-Observation
score	I-Observation
of	O
no	O
less	O
than	O
-	O
2.0	O
);	O
or,	O
if	O
their	O
DEXA	B-Observation
measure	I-Observation
was	O
abnormally	O
low,	O
they	O
were	O
receiving	O
treatment	B-Drug
for	O
osteoporosis	B-Condition
for	O
at	O
least	O
3	O
weeks	O
and	O
that	O
treatment	O
is	O
not	B-Negation_cue
expected	O
to	O
change	O
during	O
the	O
course	O
of	O
the	O
trial;	O
or,	O
if	O
their	O
DEXA	B-Observation
measure	I-Observation
was	O
abnormally	O
low	O
and	O
they	O
are	O
not	B-Negation_cue
receiving	O
treatment	B-Drug
for	O
osteoporosis	B-Condition
,	O
they	O
may	O
enter	O
the	O
trial	O
after	O
3	O
weeks	O
of	O
treatment	O
provided	O
that	O
assessments	O
of	O
the	O
HamD	B-Observation
,	O
concomitant	O
medications	B-Drug
,	O
ECG	B-Procedure_Device
tracing	O
and	O
laboratory	B-Observation
tests	I-Observation
performed	O
within	O
45	O
days	O
of	O
baseline	O
show	O
that	O
they	O
are	O
eligible	O
.	O

-	O
values	O
on	O
their	O
screening	O
laboratory	O
tests	O
do	O
not	O
indicate	O
significant	O
medical	B-Condition
conditions	I-Condition
that	O
would	O
interfere	O
with	O
their	O
participation	O
in	O
and	O
completion	O
of	O
the	O
study	O
.	O

Exclusion	O
Criteria:	O
.	O

Patients	O
with	O
any	O
of	O
the	O
exclusion	O
criteria	O
listed	O
below	O
will	O
be	O
ineligible	O
for	O
entry	O
into	O
the	O
study	O
.	O

Patients	O
will	O
be	O
declared	O
ineligible	O
if:	O
.	O

-	O
They	O
are	O
male;	O
.	O

-	O
They	O
are	O
younger	O
than	O
65	O
years	O
of	O
age	B-Observation
;	O
.	O

-	O
They	O
have	O
significant	O
neurological	B-Condition
disease	I-Condition
affecting	O
the	O
brain	O
or	O
psychiatric	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
,	O
such	O
as	O
major	B-Condition
depression	I-Condition
schizophrenia	B-Condition
,	O
epilepsy	B-Condition
,	O
Parkinson's	B-Condition
disease	I-Condition
or	O
stroke	B-Condition
;	O
.	O

-	O
They	O
have	O
current	O
significant	O
systemic	B-Condition
illness	I-Condition
or	O
symptoms	O
of	O
organ	B-Condition
failure	I-Condition
.	O

-	O
The	O
screening	O
ECG	B-Procedure_Device
shows	O
evidence	O
of	O
a	O
serious	O
and	O
/	O
or	O
unstable	O
condition	B-Condition
or	O
a	O
recent	O
(	O
within	O
6	O
months	O
)	O
myocardial	B-Condition
infarction	I-Condition
.	O

-	O
They	O
have	O
a	O
history	O
of	O
cancer	B-Condition
within	O
the	O
last	O
5	O
years,	O
except	B-Negation_cue
for	O
basal	B-Condition
cell	I-Condition
or	I-Condition
squamous	I-Condition
cell	I-Condition
cancer	I-Condition
or	O
cervical	B-Condition
carcinoma	I-Condition
in	I-Condition
situ	I-Condition
.	O

-	O
They	O
are	O
taking	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
(	O
tacrine	B-Drug
,	O
donepezil	B-Drug
,	O
rivastigmine	B-Drug
or	O
galantamine	B-Drug
)	O
for	O
less	O
than	O
90	O
days	O
prior	O
to	O
baseline;	O
or,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator,	O
they	O
are	O
likely	O
to	O
either	O
require	O
a	O
change	O
in	O
dose	O
or	O
discontinuation	O
of	O
the	O
drug	O
.	O

-	O
They	O
have	O
never	B-Negation_cue
received	O
cholinesterase	B-Drug
inhibitor	I-Drug
treatment	O
and	O
are	O
likely	O
to	O
initiate	O
it;	O
.	O

-	O
They	O
started	O
or	O
changed	O
within	O
60	O
days	O
prior	O
to	O
the	O
screening	O
visit	O
the	O
dosage	O
of	O
any	O
drug	B-Drug
(	O
including	O
an	O
over	B-Drug
the	I-Drug
counter	I-Drug
drug	I-Drug
)	O
that	O
affects	O
cognitive	B-Observation
function	I-Observation
such	O
as	O
neuroleptics	B-Drug
,	O
antidepressants	B-Drug
,	O
anxiolytics	B-Drug
,	O
sedatives	B-Drug
,	O
hypnotics	B-Drug
,	O
anti-convulsants	B-Drug
,	O
centrally	B-Drug
acting	I-Drug
antihypertensive	I-Drug
agents	I-Drug
such	O
as	O
clonidine	B-Drug
and	O
Aldomet	B-Drug
;	O
or	O
other	O
medications	B-Drug
that	O
have	O
been	O
shown	O
to	O
have	O
possible	O
effects	O
on	O
cognition	B-Observation
such	O
as	O
Vitamin	B-Drug
E	I-Drug
non	B-Drug
steroidal	I-Drug
anti-inflammatory	I-Drug
drugs	I-Drug
statins	B-Drug
and	O
hormone	B-Drug
replacement	I-Drug
therapy	I-Drug
or	O
if,	O
in	O
the	O
Investigator's	O
opinion,	O
the	O
dosage	O
of	O
such	O
medication	O
is	O
likely	O
to	O
be	O
changed	O
during	O
the	O
course	O
of	O
this	O
trial	O
.	O

Any	O
changes	O
in	O
the	O
dosage	O
of	O
any	O
of	O
these	O
drugs	O
during	O
the	O
course	O
of	O
the	O
trial	O
and	O
the	O
reason	O
for	O
the	O
change	O
must	O
be	O
fully	O
recorded	O
in	O
the	O
concomitant	O
medication	O
page	O
of	O
the	O
patient's	O
case	O
report	O
form	O
(	O
CRF	O
)	O
.	O

If	O
a	O
drug	O
that	O
affects	O
cognition	O
is	O
given	O
on	O
a	O
PRN	O
basis,	O
such	O
treatment	O
should	O
be	O
interrupted	O
for	O
12	O
hours	O
before	O
a	O
visit,	O
it	O
at	O
all	O
possible;	O
.	O

-	O
They	O
are	O
receiving	O
coumadin	B-Drug
or	O
anti-Parkinsonian	B-Drug
medications	I-Drug
.	O

-	O
They	O
have	O
received	O
other	O
investigational	B-Drug
drugs	I-Drug
within	O
30	O
days	O
or	O
5	O
half-lives	O
prior	O
to	O
randomization,	O
whichever	O
is	O
longer;	O
.	O

-	O
They	O
are	O
taking	O
other	O
medications	B-Drug
known	O
to	O
affect	O
serum	B-Observation
gonadotropin	I-Observation
(	I-Observation
Gn	I-Observation
)	I-Observation
concentrations	I-Observation
such	O
as	O
goserelin	B-Drug
or	O
danazol	B-Drug
,	O
except	B-Negation_cue
for	O
estrogen	B-Drug
and	O
/	O
or	O
progesterone	B-Drug
;	O
.	O

-	O
They	O
have	O
a	O
history	O
of	O
bone	B-Condition
fracture	I-Condition
possibly	O
secondary	O
to	O
low	B-Condition
bone	I-Condition
mass	I-Condition
density	I-Condition
.	O

-	O
They	O
have	O
a	O
history	O
of	O
osteoporosis	B-Condition
not	B-Negation_cue
associated	O
with	O
bone	B-Condition
fracture	I-Condition
unless	O
they	O
are	O
receiving	O
therapy	B-Drug
for	O
osteoporosis	B-Condition
for	O
at	O
least	O
3	O
weeks	O
and	O
the	O
treatment	B-Drug
regimen	O
is	O
expected	O
to	O
stay	O
stable	O
their	O
DEXA	B-Observation
measures	I-Observation
were	O
abnormally	O
low	O
(	O
i.e.,	O
T-score	B-Observation
<-	O
2.0	O
)	O
and	O
they	O
were	O
not	B-Negation_cue
receiving	O
treatment	B-Drug
for	O
osteoporosis	B-Condition
for	O
at	O
least	O
3	O
weeks;	O
.	O

-	O
They	O
have	O
a	O
screening	O
HamD	B-Observation
score	I-Observation
of	O
15	O
or	O
higher;	O
.	O

-	O
Their	O
abuse	B-Condition
or	I-Condition
dependence	I-Condition
on	I-Condition
alcohol	I-Condition
or	I-Condition
other	I-Condition
substances	I-Condition
satisfy	O
criteria	O
for	O
DSM-IV	B-Observation
categories	I-Observation
303.9	O
or	O
305;	O
or	O
.	O

-	O
They	O
have	O
donated	B-Procedure_Device
blood	I-Procedure_Device
within	O
30	O
days	O
of	O
baseline	O
or	O
are	O
likely	O
to	O
do	O
so	O
during	O
the	O
course	O
of	O
the	O
trial	O
.	O

>>NCT00480870	O
Inclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
based	O
on	O
the	O
probability	B-Observation
criteria	I-Observation
of	I-Observation
the	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
.	O

-	O
Rated	O
1	O
and	O
2	O
(	O
mild	O
to	O
moderate	O
level	O
)	O
on	O
the	O
Brazilian	B-Observation
version	I-Observation
of	I-Observation
the	I-Observation
Clinical	I-Observation
Dementia	I-Observation
Rating	I-Observation
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Other	O
causes	B-Condition
of	I-Condition
dementia	I-Condition
.	O

-	O
Other	O
severe	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
disease	I-Condition
.	O

-	O
Clinical	O
indication	O
of	O
psychoactive	B-Drug
drugs	I-Drug
other	B-Negation_cue
than	I-Negation_cue
experimental	B-Drug
drug	I-Drug
.	O

>>NCT01028053	O
Inclusion	O
Criteria:	O
.	O

-	O
The	O
subject	O
is	O
60	O
years	O
old	O
or	O
older	O
.	O

-	O
The	O
subject	O
meets	O
the	O
Petersen	O
criteria	O
for	O
amnestic	B-Condition
MCI	I-Condition
.	O

-	O
The	O
subject	O
has	O
a	O
score	O
of	O
less	O
than	O
or	O
equal	O
to	O
4	O
on	O
the	O
Modified	B-Observation
Hachinski	I-Observation
Ischemic	I-Observation
Scale	I-Observation
.	O

-	O
The	O
subject	O
has	O
a	O
MMSE	B-Observation
score	I-Observation
of	O
24	O
-	O
30	O
.	O

-	O
The	O
subject	O
has	O
a	O
non-contrast	B-Procedure_Device
MRI	I-Procedure_Device
examination	O
as	O
part	O
of	O
the	O
screening	O
visit	O
that	O
excludes	B-Negation_cue
aMCI	B-Condition
arising	O
from	O
structural	O
causes	O
.	O

-	O
The	O
subject	O
and	O
/	O
or	O
the	O
subject's	O
legally	O
acceptable	O
representative,	O
if	O
applicable,	O
in	O
accordance	O
with	O
local	O
regulations,	O
has	O
signed	O
and	O
dated	O
an	O
informed	O
consent	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
The	O
subject	O
has	O
any	O
significant	O
neurologic	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
suspected	O
aMCI	B-Condition
;	O
such	O
as	O
Parkinson's	B-Condition
disease	I-Condition
Huntington's	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
brain	B-Condition
tumor	I-Condition
supranuclear	B-Condition
palsy	I-Condition
seizure	B-Condition
disorder	I-Condition
subdural	B-Condition
hematoma	I-Condition
multiple	B-Condition
sclerosis	I-Condition
or	O
history	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
followed	O
by	O
persistent	O
neurologic	B-Condition
deficits	I-Condition
or	O
known	O
structural	B-Condition
brain	I-Condition
abnormalities	I-Condition
.	O

-	O
The	O
subject	O
has	O
one	O
or	O
more	O
aneurysm	B-Procedure_Device
clips	I-Procedure_Device
artificial	B-Procedure_Device
heart	I-Procedure_Device
valves	I-Procedure_Device
metal	B-Procedure_Device
implants	I-Procedure_Device
embedded	B-Procedure_Device
metal	I-Procedure_Device
fragments	I-Procedure_Device
or	O
pacemakers	B-Procedure_Device
that	O
would	O
pose	O
a	O
risk	O
during	O
an	O
MRI	B-Procedure_Device
.	O

-	O
The	O
subject	O
has	O
major	B-Condition
depression	I-Condition
bipolar	B-Condition
disorder	I-Condition
as	O
described	O
in	O
the	O
DSM-IV	B-Observation
within	O
the	O
past	O
year	O
.	O

-	O
The	O
subject	O
has	O
history	O
of	O
schizophrenia	B-Condition
(	O
DSM-IV	B-Observation
criteria	I-Observation
)	O
.	O

-	O
The	O
subject	O
has	O
had,	O
within	O
the	O
prior	O
3	O
months,	O
psychotic	B-Condition
features	I-Condition
agitation	B-Condition
or	O
behavioral	B-Condition
problems	I-Condition
that	O
could	O
lead	O
to	O
protocol	O
compliance	O
issues	O
.	O

>>NCT02290912	O
Inclusion	O
Criteria:	O
.	O

-	O
Age	B-Observation
.	O

-	O
Residing	O
or	O
working	O
in	O
Cache	O
County	O
Utah	O
.	O

-	O
Possessing	O
smart	O
phone	O
or	O
tablet	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Dementia	B-Condition
.	O

-	O
Pregnancy	B-Condition
.	O

-	O
Untreated	O
chronic	O
major	B-Condition
depression	I-Condition
or	O
other	O
psychiatric	B-Condition
condition	I-Condition
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
>	O
41	O
.	O

-	O
Heart	B-Condition
or	O
stroke	B-Condition
in	O
prior	O
6	O
weeks	O
.	O

-	O
Active	O
cancer	B-Drug
treatment	I-Drug
.	O

-	O
Unwillingness	O
to	O
seek	O
medical	O
help	O
when	O
serious	O
condition	O
identified	O
at	O
intake	O
.	O

>>NCT01479855	O
Inclusion	O
Criteria:	O
.	O

-	O
Cognitive	B-Condition
impairment	I-Condition
with	O
a	O
MMSE	B-Observation
score	I-Observation
of	O
24	O
or	O
better	O
.	O

-	O
Depression	B-Observation
score	I-Observation
below	O
9	O
both	O
on	O
MADRS	B-Observation
and	O
Cornell	B-Observation
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Acute	O
or	O
chronic	O
disease	B-Condition
with	O
CRP	B-Observation
above	O
10	O
.	O

-	O
Lewy	B-Condition
Body	I-Condition
Dementia	I-Condition
or	O
Frontal	B-Condition
Lobe	I-Condition
Dementia	I-Condition
.	O

-	O
Dementia	B-Condition
due	O
to	O
a	O
known	O
brain	B-Condition
vascular	I-Condition
disturbance	I-Condition
hemorrhage	B-Condition
or	O
thrombosis	B-Condition
.	O

-	O
Patients	O
who	O
had	O
not	B-Negation_cue
stopped	O
their	O
intake	O
of	O
vitamins	B-Drug
and	O
food	B-Drug
additives	I-Drug
the	O
last	O
four	O
weeks	O
.	O

>>NCT00013650	O
-	O
INCLUSION	O
CRITERIA:	O
.	O

Subjects	O
must	O
have	O
a	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
DSM-IV	B-Observation
and	I-Observation
NINDS	I-Observation
criteria	I-Observation
.	O

Subjects	O
must	O
have	O
mild-moderate	O
severity	O
of	O
dementia	B-Condition
according	O
to	O
the	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
Scale	I-Observation
at	O
the	O
time	O
of	O
study	O
.	O

They	O
must	O
also	O
have	O
the	O
ability	O
to	O
assign	O
a	O
DPA	O
or	O
have	O
already	O
assigned	O
a	O
DPA	O
and	O
give	O
informed	O
consent	O
for	O
this	O
medication	O
trial	O
and	O
be	O
willing	O
to	O
undergo	O
repeat	O
lumbar	O
punctures	O
for	O
the	O
assessment	O
of	O
cerebrospinal	O
fluid	O
.	O

EXCLUSION	O
CRITERIA:	O
.	O

Severe	O
dementia	B-Condition
(	O
CDR	B-Observation
score	I-Observation
greater	O
than	O
2	O
)	O
.	O

Diagnosis	O
of	O
probable	O
vascular	B-Condition
dementia	I-Condition
.	O

Inability	O
to	O
give	O
assent	O
for	O
participation	O
or	O
designate	O
a	O
durable	O
power	O
of	O
attorney	O
.	O

Medication	O
history	O
of	O
cytotoxic	B-Drug
drug	I-Drug
therapy	I-Drug
for	O
more	O
than	O
2	O
weeks	O
during	O
the	O
10	O
weeks	O
prior	O
to	O
study	O
entry,	O
for	O
more	O
than	O
10	O
weeks	O
at	O
any	O
time	O
or	O
for	O
anytime	O
during	O
the	O
30	O
day	O
period	O
prior	O
to	O
study	O
entry	O
.	O

Recent	O
use	O
of	O
continuous	O
(	O
more	O
than	O
3	O
doses	O
per	O
week	O
)	O
nonsteroidal	B-Drug
medication	I-Drug
(	O
at	O
least	O
one	O
month	O
before	O
entry	O
)	O
.	O

Low	O
dose	O
aspirin	B-Drug
will	O
not	B-Negation_cue
be	O
considered	O
as	O
continuous	O
nonsteroidal	B-Drug
anti-inflammatory	I-Drug
medication	I-Drug
.	O

Known	O
hypersensitivity	B-Condition
to	O
CY	B-Drug
,	O
aspirin	B-Drug
or	O
any	O
nonsteroidal	B-Drug
medication	I-Drug
.	O

Current	O
use	O
of	O
allopurinol	B-Drug
,	O
rifampin	B-Drug
,	O
methotrexate	B-Drug
or	O
warfarin	B-Drug
.	O

Inflammatory	B-Condition
conditions	I-Condition
(	O
such	O
as	O
SLE	B-Condition
,	O
autoimmune	B-Condition
disease	I-Condition
etc.)	O

which	O
could	O
respond	O
to	O
medications	O
given	O
in	O
the	O
medication	O
protocol	O
.	O

Medical	B-Condition
conditions	I-Condition
including:	O
active	O
or	O
chronic	O
infection	B-Condition
requiring	O
antimicrobial	B-Drug
therapy	I-Drug
serious	O
viral	B-Condition
infection	I-Condition
(	O
hepatitis	B-Condition
,	O
herpes	B-Condition
zoster	I-Condition
),	O
a	O
single	B-Condition
functioning	I-Condition
kidney	I-Condition
renal	B-Condition
insufficiency	I-Condition
(	O
less	O
than	O
one	O
third	O
of	O
normal	O
GFR	B-Observation
),	O
significant	O
hepatic	B-Condition
dysfunction	I-Condition
pre-existent	O
malignancy	B-Condition
,	O
insulin-treated	B-Condition
diabetes	I-Condition
mellitus	I-Condition
severe	O
benign	B-Condition
prostatic	I-Condition
hypertrophy	I-Condition
immunosuppression	B-Condition
,	O
myelosuppression	B-Condition
,	O
lymphopenia	B-Condition
,	O
severe	O
pulmonary	B-Condition
dysfunction	I-Condition
history	O
of	O
gastrointestinal	B-Condition
ulceration	I-Condition
active	O
within	O
the	O
last	O
5	O
years,	O
history	O
of	O
gastrointestinal	B-Condition
bleeding	I-Condition
or	I-Condition
perforation	I-Condition
or	O
severe	O
cardiac	B-Condition
dysfunction	I-Condition
.	O

>>NCT01560585	O
Inclusion	O
Criteria:	O
.	O

-	O
Probable	O
AD	B-Condition
by	O
DSM	B-Observation
IV	I-Observation
and	I-Observation
NINCDS-ADRDA	I-Observation
criteria	I-Observation
.	O

-	O
Females	O
must	O
be	O
surgically	B-Condition
sterile	I-Condition
(	O
bilateral	O
tubal	O
ligation,	O
both	O
ovaries	O
removed	O
or	O
hysterectomy	O
)	O
or	O
post-menopausal	B-Condition
for	O
at	O
least	O
2	O
years	O
.	O

-	O
>	O
50	O
years	O
of	O
age	B-Observation
.	O

-	O
Residing	O
in	O
the	O
community	O
at	O
baseline	O
(	O
includes	O
assisted	O
living	O
facilities,	O
long-term	O
care	O
nursing	O
facilities	O
)	O
.	O

-	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
at	O
screen	O
of	O
12	O
-	O
26	O
(	O
inclusive	O
)	O
.	O

-	O
No	B-Negation_cue
medical	B-Condition
contraindications	I-Condition
to	O
study	O
participation	O
.	O

-	O
Fluent	O
in	O
English	O
at	O
least	O
8	O
years	O
of	O
education	O
.	O

-	O
Supervision	O
available	O
for	O
study	O
medication	O
.	O

Caregiver	O
/	O
study	O
partner	O
to	O
accompany	O
participant	O
to	O
all	O
visits	O
.	O

Study	O
partner	O
must	O
have	O
direct	O
contact	O
with	O
the	O
participant	O
>	O
2	O
days	O
/	O
week	O
.	O

-	O
Able	O
to	O
ingest	O
oral	O
medication	O
.	O

-	O
Neuroimaging	B-Procedure_Device
(	O
CT	B-Procedure_Device
or	O
MRI	B-Procedure_Device
or	O
PET	B-Procedure_Device
)	O
consistent	O
with	O
the	O
diagnosis	O
of	O
AD	B-Condition
at	O
some	O
time	O
after	O
the	O
onset	O
of	O
the	O
memory	O
decline	O
.	O

-	O
Clinical	B-Observation
laboratory	I-Observation
values	I-Observation
must	O
be	O
within	O
normal	O
limits	O
or,	O
if	O
abnormal,	O
must	O
be	O
judged	O
to	O
be	O
clinically	O
insignificant	O
by	O
the	O
investigator	O
.	O

-	O
Stable	O
use	O
of	O
cholinesterase	B-Drug
inhibitors	I-Drug
and	O
memantine	B-Drug
is	O
permitted	O
if	O
doses	O
are	O
stable	O
for	O
3	O
months	O
prior	O
to	O
enrollment	O
.	O

Dose	O
should	O
be	O
stable	O
throughout	O
the	O
study	O
unless	O
it	O
is	O
clinically	O
necessary	O
to	O
adjust	O
the	O
medication	O
.	O

-	O
Stable	O
use	O
of	O
anti-depressants	B-Drug
is	O
permitted	O
if	O
doses	O
are	O
stable	O
for	O
3	O
months	O
prior	O
to	O
enrollment	O
.	O

Dose	O
should	O
be	O
stable	O
throughout	O
the	O
study	O
unless	O
it	O
is	O
clinically	O
necessary	O
to	O
adjust	O
the	O
medication	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Dementia	B-Condition
not	B-Negation_cue
due	O
to	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Pregnancy	B-Condition
,	O
breastfeeding	B-Condition
.	O

The	O
rationale	O
is	O
that	O
retinoids	O
are	O
teratogenic	O
and	O
are	O
excreted	O
in	O
breast	O
milk	O
.	O

-	O
History	O
of	O
clinically	O
significant	O
stroke	B-Condition
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
score	I-Observation
>=	O
4	O
.	O

-	O
Current	O
evidence	O
or	O
history	O
in	O
past	O
two	O
years	O
of	O
epilepsy	B-Condition
,	O
seizure	B-Condition
,	O
focal	B-Condition
brain	I-Condition
lesion	I-Condition
head	B-Condition
injury	I-Condition
with	I-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition
or	O
DSM	B-Observation
IV	I-Observation
criteria	I-Observation
for	O
any	O
major	O
psychiatric	B-Condition
disorder	I-Condition
including	O
psychosis	B-Condition
,	O
major	B-Condition
depression	I-Condition
bipolar	B-Condition
disorder	I-Condition
severe	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
.	O

-	O
Sensory	B-Condition
impairment	I-Condition
which	O
would	O
prevent	O
subject	O
from	O
participating	O
in	O
or	O
cooperating	O
with	O
the	O
protocol	O
.	O

-	O
Use	O
of	O
another	O
investigational	B-Drug
agent	I-Drug
within	O
two	O
months	O
.	O

-	O
Evidence	O
of	O
any	O
significant	O
clinical	O
disorder	B-Condition
or	O
laboratory	B-Observation
finding	I-Observation
that	O
renders	O
the	O
participant	O
unsuitable	O
for	O
receiving	O
an	O
investigational	B-Drug
new	I-Drug
drug	I-Drug
including	O
clinically	O
significant	O
or	O
unstable	O
hematologic,	B-Condition
hepatic,	I-Condition
cardiovascular	I-Condition
(	O
including	O
history	O
of	O
ventricular	B-Condition
fibrillation	I-Condition
or	O
ventricular	B-Condition
tachycardia	I-Condition
),	O
pulmonary,	B-Condition
gastrointestinal,	I-Condition
endocrine,	I-Condition
metabolic,	I-Condition
renal	I-Condition
or	I-Condition
other	I-Condition
systemic	I-Condition
disease	I-Condition
or	O
laboratory	B-Observation
abnormality	I-Observation
.	O

Abnormal	O
liver	B-Observation
function	I-Observation
test	I-Observation
including	O
AST	B-Observation
,	O
ALT	B-Observation
,	O
total	B-Observation
bilirubin	I-Observation
or	O
prothrombin	B-Observation
time	O
.	O

The	O
rationale	O
is	O
that	O
retinoids	O
can	O
be	O
hepatotoxic	O
.	O

-	O
Participants	O
receiving	O
behavioral	B-Drug
medications	I-Drug
(	O
including	O
antidepressants	B-Drug
,	O
antipsychotics	B-Drug
and	O
anxiolytics	B-Drug
)	O
must	O
be	O
on	O
stable	O
doses	O
for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
randomization	O
.	O

-	O
Active	O
neoplastic	B-Condition
disease	I-Condition
and	O
any	O
medical	B-Condition
conditions	I-Condition
requiring	O
concurrent	O
immunosuppression	B-Condition
.	O

-	O
Hypertriglyceridemia	B-Condition
greater	O
than	O
500	O
mg	O
/	O
dL	O
despite	O
statin	B-Drug
/	I-Drug
fibrate	I-Drug
therapy	I-Drug
.	O

The	O
rationale	O
is	O
that	O
retinoids	O
can	O
increase	O
lipids,	O
particularly	O
triglyceride	O
and	O
this	O
can	O
lead	O
to	O
pancreatitis	O
.	O

-	O
Any	O
medical	B-Condition
conditions	I-Condition
requiring	O
concurrent	O
use	O
of	O
tetracycline	B-Drug
,	O
minocycline	B-Drug
or	O
doxycycline	B-Drug
.	O

The	O
rationale	O
is	O
due	O
to	O
enhanced	O
risk	O
of	O
increased	O
intracranial	O
pressure	O
.	O

-	O
Hypersensitivity	B-Condition
to	O
retinoids	B-Drug
.	O

-	O
Presence	O
of	O
psychosis	B-Condition
or	O
hallucinations	B-Condition
at	O
baseline	O
as	O
determined	O
by	O
Neuropsychiatric	O
inventory	O
or	O
Geriatric	B-Observation
Depression	I-Observation
Scale-short	I-Observation
form	I-Observation
greater	O
than	O
or	O
equal	O
to	O
five	O
.	O

-	O
Presence	O
of	O
any	O
unstable	O
cardiovascular	B-Condition
disease	I-Condition
uncontrolled	O
diabetes	B-Condition
,	O
chronic	O
inflammatory	B-Condition
or	I-Condition
infectious	I-Condition
conditions	I-Condition
.	O

Retinoids	B-Drug
have	O
been	O
associated	O
with	O
chest	B-Condition
pain	I-Condition
of	I-Condition
unclear	I-Condition
etiology	I-Condition
increased	O
serum	B-Observation
glucose	I-Observation
myelosuppression	B-Condition
and	O
increased	O
risk	O
of	O
infection	B-Condition
.	O

-	O
Use	O
of	O
Drugs	B-Drug
and	O
supplements	B-Drug
such	O
as:	O
Vitamin	B-Drug
A	I-Drug
supplements	I-Drug
beyond	O
100%	O
RDA,	O
other	O
immunosuppressants	B-Drug
(	O
corticosteroids	B-Drug
,	O
chemotherapeutic	B-Drug
agents	I-Drug
etc	O
.	O

),	O
Warfarin	B-Drug
,	O
Fish	B-Drug
Oil	I-Drug
(	O
DHA	B-Drug
)	O
.	O

-	O
Any	O
other	O
disease	B-Condition
or	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
condition	I-Condition
or	O
laboratory	B-Observation
abnormality	I-Observation
that	O
may	O
increase	O
the	O
risk	O
associated	O
with	O
study	O
participation	O
or	O
investigational	O
product	O
administration	O
or	O
may	O
interfere	O
with	O
the	O
interpretation	O
of	O
study	O
results	O
and,	O
in	O
the	O
judgment	O
of	O
the	O
investigator,	O
would	O
make	O
the	O
participant	O
inappropriate	O
for	O
entry	O
into	O
this	O
clinical	O
trial.	O

>>NCT01142258	O
Inclusion	O
Criteria:	O
.	O

-	O
Fifty-five	O
years	O
of	O
age	B-Observation
or	O
older;	O
.	O

-	O
Diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
by	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke	I-Observation
/	I-Observation
the	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
criteria	I-Observation
.	O

-	O
Hachinski	B-Observation
Ischemia	I-Observation
Scale	I-Observation
score	I-Observation
less	O
than	O
5	O
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
score	I-Observation
of	O
O	O
to	O
26	O
.	O

-	O
Actigraph	O
evidence	O
of	O
a	O
mean	B-Observation
time	I-Observation
immobile	I-Observation
of	O
less	O
than	O
7	O
hours	O
per	O
night	O
based	O
on	O
at	O
least	O
7	O
nights	O
of	O
complete	O
actigraph	O
data	O
collected	O
over	O
a	O
single	O
week;	O
.	O

-	O
For-week	O
history	O
of	O
sleep	B-Condition
disorder	I-Condition
behaviors,	O
occurring	O
at	O
least	O
once	O
weekly,	O
as	O
reported	O
by	O
the	O
caregiver	O
using	O
the	O
Neuropsychiatric	O
Inventory	O
(	O
NPI	O
)	O
Nighttime	O
Behavior	O
scale;	O
.	O

-	O
Sleep	B-Condition
disturbance	I-Condition
observed	O
was	O
not	O
present	O
before	O
the	O
diagnosis	O
of	O
AD	B-Condition
;	O
.	O

-	O
Other	O
co-morbidities	B-Condition
,	O
especially	O
delirium	B-Condition
,	O
depression	B-Condition
,	O
chronic	B-Condition
pain	I-Condition
and	O
medication	B-Drug
use	O
may	O
be	O
present	O
but	O
do	O
not	O
cooperate	O
in	O
the	O
primary	O
symptoms;	O
.	O

-	O
Computed	B-Procedure_Device
tomography	I-Procedure_Device
or	O
magnetic	B-Procedure_Device
resonance	I-Procedure_Device
imaging	I-Procedure_Device
since	O
the	O
onset	O
of	O
memory	B-Condition
problems	I-Condition
showing	O
no	B-Negation_cue
more	O
than	O
1	O
lacunar	B-Condition
infarct	I-Condition
in	O
a	O
nonstrategic	O
area	O
and	O
no	B-Negation_cue
clinical	O
events	O
suggestive	O
of	O
stroke	B-Condition
or	O
other	O
intracranial	B-Condition
disease	I-Condition
or	O
normal;	O
.	O

-	O
Stable	O
medications	B-Drug
for	O
4	O
weeks	O
prior	O
to	O
the	O
screening	O
visit;	O
.	O

-	O
Having	O
a	O
mobile	O
upper	O
extremity	O
to	O
which	O
to	O
attach	O
an	O
actigraph;	O
.	O

-	O
Residing	O
with	O
a	O
responsible	O
spouse,	O
family	O
member	O
or	O
professional	O
caregiver	O
who	O
is	O
present	O
during	O
the	O
night	O
and	O
would	O
agree	O
to	O
assume	O
the	O
role	O
of	O
the	O
principal	O
caregiver	O
for	O
the	O
3	O
-week	O
protocol;	O
.	O

-	O
Ability	O
to	O
ingest	O
oral	O
medication	O
and	O
participate	O
in	O
all	O
scheduled	O
evaluations	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Sleep	B-Condition
disturbance	I-Condition
associated	O
with	O
an	O
acute	O
illness	B-Condition
,	O
delirium	B-Condition
or	O
psychiatric	B-Condition
disease	I-Condition
.	O

-	O
Clinically	O
significant	O
movement	B-Condition
disorder	I-Condition
such	O
as	O
akinesia	B-Condition
,	O
that	O
would	O
affect	O
actigraphic	O
differentiation	O
of	O
sleep	O
and	O
wakefulness	O
.	O

-	O
Severe	O
agitation	B-Condition
;	O
.	O

-	O
Unstable	O
medical	B-Condition
condition	I-Condition
.	O

-	O
Discontinuation	O
of	O
psychotropic	B-Drug
or	I-Drug
sleep	I-Drug
medications	I-Drug
within	O
2	O
weeks	O
of	O
the	O
screening	O
visit;	O
.	O

-	O
Patient	O
unwilling	O
to	O
maintain	O
caffeine	O
abstinence	O
after	O
2:00	O
PM	O
for	O
the	O
duration	O
of	O
the	O
protocol;	O
.	O

-	O
Patient	O
unwilling	O
to	O
comply	O
with	O
the	O
maximum	O
limit	O
of	O
2	O
alcoholic	O
drinks	O
per	O
day	O
and	O
only	O
1	O
alcoholic	O
drink	O
after	O
6:00	O
PM	O
for	O
the	O
duration	O
of	O
the	O
protocol;	O
.	O

-	O
Prior	O
use	O
of	O
trazodone	B-Drug
for	O
the	O
treatment	O
of	O
sleep	B-Condition
disturbances	I-Condition
.	O

-	O
Caregiver	O
deemed	O
too	O
unreliable	O
to	O
supervise	O
the	O
wearing	O
of	O
the	O
actigraph,	O
to	O
administer	O
trazodone	O
the	O
proper	O
time,	O
to	O
maintain	O
tbe	O
sleep	O
diary	O
or	O
to	O
bring	O
the	O
patient	O
to	O
the	O
scheduled	O
visits;	O
.	O

>>NCT01841905	O
Inclusion	O
Criteria:	O
.	O

-	O
Individuals	O
between	O
the	O
ages	B-Observation
of	O
55	O
and	O
80	O
years	O
old	O
(	O
inclusive	O
)	O
.	O

-	O
MMSE	B-Observation
total	I-Observation
score	I-Observation
>	O
27	O
.	O

-	O
Two	O
risk	B-Condition
factors	I-Condition
for	O
AD	B-Condition
:	O
.	O

-	O
Subjective	B-Observation
memory	I-Observation
complaints	I-Observation
.	O

-	O
A	O
positive	O
(	O
suspected	O
)	O
first-degree	O
family	O
history	O
for	O
the	O
disease	B-Condition
.	O

-	O
Permitted	B-Drug
medications	I-Drug
stable	O
for	O
at	O
least	O
1	O
month	O
prior	O
to	O
screening	O
.	O

-	O
Subjects	O
may	O
take	O
stable	O
doses	O
of	O
antidepressants	B-Drug
lacking	B-Negation_cue
significant	O
anticholinergic	B-Condition
side	I-Condition
effects	I-Condition
(	O
do	O
not	B-Negation_cue
have	O
a	O
history	O
of	O
major	B-Condition
depression	I-Condition
within	O
the	O
past	O
year	O
)	O
.	O

-	O
Estrogen	B-Drug
replacement	I-Drug
therapy	I-Drug
.	O

-	O
Adequate	O
visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
to	O
allow	O
neuropsychological	O
testing	O
.	O

-	O
Good	O
general	B-Condition
health	I-Condition
or	O
without	B-Negation_cue
any	O
clinically	O
significant	O
abnormalities	B-Condition
.	O

-	O
Vitamin	B-Drug
supplements	I-Drug
(	O
including	O
Vitamin	B-Drug
E	I-Drug
)	O
will	O
be	O
acceptable	O
.	O

-	O
Subjects	O
must	O
be	O
willing	O
and	O
able	O
to	O
provide	O
written	O
informed	O
consent	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
History	O
of	O
major	O
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
other	O
known	O
neurologic	B-Condition
disease	I-Condition
or	O
insult	B-Condition
.	O

-	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)total	I-Observation
score	I-Observation
<	O
27	O
.	O

-	O
Regular	O
(	O
daily	O
)	O
use	O
of	O
narcotics	B-Drug
or	O
antipsychotic	B-Drug
medications	I-Drug
.	O

-	O
Poorly-controlled	O
major	B-Condition
depression	I-Condition
or	O
another	O
Axis	B-Condition
I	I-Condition
psychiatric	I-Condition
disorder	I-Condition
as	O
described	O
in	O
DSM-IV	B-Observation
within	O
the	O
past	O
year	O
.	O

-	O
Psychotic	B-Condition
features	I-Condition
agitation	B-Condition
or	O
behavioral	B-Condition
problems	I-Condition
within	O
the	O
last	O
3	O
months	O
.	O

-	O
History	O
of	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
within	O
the	O
past	O
2	O
years	O
(	O
DSM	B-Observation
IV	I-Observation
criteria	I-Observation
)	O
.	O

-	O
History	O
of	O
schizophrenia	B-Condition
(	O
DSM	B-Observation
IV	I-Observation
criteria	I-Observation
)	O
.	O

-	O
Any	O
significant	O
systemic	B-Condition
illness	I-Condition
or	O
unstable	O
medical	B-Condition
condition	I-Condition
which	O
could	O
lead	O
to	O
difficulty	O
complying	O
with	O
the	O
protocol	O
including:	O
.	O

-	O
History	O
of	O
systemic	B-Condition
cancer	I-Condition
within	O
the	O
past	O
5	O
years	O
(	O
non-metastatic	B-Condition
skin	I-Condition
cancers	I-Condition
are	O
acceptable	O
)	O
.	O

-	O
History	O
of	O
myocardial	B-Condition
infarction	I-Condition
in	O
the	O
past	O
year	O
or	O
unstable	O
or	O
severe	O
cardiovascular	B-Condition
disease	I-Condition
including	O
angina	B-Condition
or	O
Congestive	B-Condition
Heart	I-Condition
Failure	I-Condition
(	I-Condition
CHF	I-Condition
)	I-Condition
with	O
symptoms	O
at	O
rest	O
.	O

-	O
Clinically	O
significant	O
obstructive	B-Condition
pulmonary	I-Condition
disease	I-Condition
or	O
asthma	B-Condition
.	O

-	O
Clinically	O
significant	O
and	O
unstable	O
gastrointestinal	B-Condition
disorder	I-Condition
within	O
two	O
years	O
.	O

-	O
Insulin-requiring	B-Condition
diabetes	I-Condition
or	O
uncontrolled	O
diabetes	B-Condition
mellitus	I-Condition
.	O

-	O
Uncontrolled	O
hypertension	B-Condition
(	O
systolic	B-Observation
BP	I-Observation
>	O
170	O
or	O
diastolic	B-Observation
BP	I-Observation
>	O
100	O
)	O
.	O

-	O
History	O
of	O
clinically	O
significant	O
liver	B-Condition
disease	I-Condition
coagulopathy	B-Condition
or	O
vitamin	B-Condition
K	I-Condition
deficiency	I-Condition
within	O
the	O
past	O
2	O
years	O
.	O

-	O
History	O
of	O
symptoms	O
of	O
narrow-angle	B-Condition
glaucoma	I-Condition
.	O

-	O
Clinically	O
significant	O
obstructive	B-Condition
uropathy	I-Condition
.	O

-	O
Use	O
of	O
centrally	O
active	O
beta-blockers	B-Drug
,	O
narcotics	B-Drug
,	O
methyldopa	B-Drug
and	O
clonidine	B-Drug
within	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Use	O
of	O
anti-Parkinsonian	B-Drug
medications	I-Drug
(	O
eg	O
,	O
Sinemet	B-Drug
,	O
amantadine	B-Drug
,	O
bromocriptine	B-Drug
,	O
pergolide	B-Drug
and	O
selegiline	B-Drug
)	O
within	O
2	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Use	O
of	O
neuroleptics	B-Drug
or	O
narcotic	B-Drug
analgesics	I-Drug
within	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Use	O
of	O
long-acting	O
benzodiazepines	B-Drug
or	O
barbiturates	B-Drug
within	O
4	O
weeks	O
prior	O
to	O
screen	O
.	O

-	O
Use	O
of	O
short-acting	O
anxiolytics	B-Drug
or	O
sedative-hypnotics	B-Drug
more	O
frequently	O
than	O
2	O
times	O
per	O
week	O
within	O
4	O
weeks	O
prior	O
to	O
screening	O
(	O
note:	O
sedative	B-Drug
agents	I-Drug
should	O
not	B-Negation_cue
be	O
used	O
within	O
72	O
hours	O
of	O
the	O
baseline	O
and	O
follow-up	O
visits	O
.	O

-	O
Initiation	O
or	O
change	O
in	O
dose	O
of	O
an	O
antidepressant	B-Drug
lacking	O
significant	O
cholinergic	B-Condition
side	I-Condition
effects	I-Condition
within	O
the	O
4	O
weeks	O
prior	O
to	O
screening	O
(	O
use	O
of	O
stable	O
doses	O
of	O
antidepressants	B-Drug
for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
screening	O
is	O
acceptable	O
)	O
.	O

-	O
Use	O
of	O
systemic	B-Drug
corticosteroids	I-Drug
within	O
3	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Medications	B-Drug
with	O
significant	O
cholinergic	B-Condition
or	I-Condition
anticholinergic	I-Condition
side	I-Condition
effects	I-Condition
within	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Use	O
of	O
anti-convulsants	B-Drug
within	O
2	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Use	O
of	O
warfarin	B-Drug
(	O
Coumadin	B-Drug
)	O
within	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Any	O
prior	O
use	O
of	O
any	O
FDA	B-Drug
approved	I-Drug
medications	I-Drug
for	O
the	O
treatment	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
(	O
eg	O
,	O
tacrine	B-Drug
,	O
donepezil	B-Drug
or	O
other	O
newly	B-Drug
approved	I-Drug
medications	I-Drug
)	O
.	O

-	O
Use	O
of	O
any	O
investigational	B-Drug
drugs	I-Drug
within	O
30	O
days	O
or	O
5	O
half-lives,	O
whichever	O
is	O
longer,	O
prior	O
to	O
screening	O
.	O

-	O
Subjects	O
who,	O
in	O
the	O
investigator's	O
opinion,	O
will	O
not	O
comply	O
with	O
study	O
procedures	O
.	O

-	O
Known	O
hypersensitivity	B-Condition
to	O
F-	B-Drug
18	I-Drug
tropicamide	B-Drug
,	O
and	O
/	O
or	O
scopolamine	B-Drug
or	O
agents	B-Drug
of	O
this	O
class	O
of	O
drugs	O
.	O

>>NCT00688207	O
Inclusion	O
Criteria:	O
.	O

-	O
Male	O
or	O
female	O
subjects	O
with	O
a	O
clinical	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
in	O
.	O

-	O
accordance	O
with	O
NINCDS-ADRDA3	B-Observation
criteria	I-Observation
for	O
at	O
least	O
3	O
months	O
.	O

-	O
Subject	O
has	O
mild	O
Alzheimer's	B-Condition
disease	I-Condition
as	O
defined	O
by	O
a	O
MMSE	B-Observation
score	I-Observation
18	O
to	O
26	O
inclusive	O
.	O

-	O
at	O
Screening	O
.	O

-	O
Hachinski	B-Observation
Ischemia	I-Observation
Score	I-Observation
<=	O
4	O
at	O
Screening	O
.	O

-	O
Subjects	O
aged	B-Observation
>=	O
50	O
and	O
<=	O
90	O
years	O
.	O

-	O
Subject	O
has	O
not	B-Negation_cue
taken	O
an	O
approved	O
Alzheimer's	B-Drug
therapy	I-Drug
in	O
the	O
last	O
30	O
days	O
.	O

-	O
Current	O
use	O
of	O
medication	O
is	O
in	O
accordance	O
with	O
the	O
criteria	O
listed	O
in	O
Section	O
9.1	O
)	O
.	O

-	O
Female	O
subjects	O
must	O
be	O
post-menopausal	B-Condition
(	O
i.e	O
.	O

>	O
1	O
year	O
without	B-Negation_cue
menstrual	B-Observation
period	I-Observation
),	O
.	O

-	O
surgically	B-Condition
sterile	I-Condition
or	O
agree	O
to	O
use	O
adequate	O
method	O
of	O
contraception	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

-	O
Female	O
subjects	O
who	O
are	O
pre-menopausal	B-Condition
or	O
who	O
have	O
been	O
postmenopausal	B-Condition
for	O
<	O
1	O
year	O
must	O
undertake	O
pregnancy	B-Observation
testing	I-Observation
at	O
screening,	O
which	O
must	O
.	O

-	O
be	O
negative	O
.	O

More	O
than	O
one	O
pregnancy	B-Observation
test	I-Observation
may	O
be	O
required	O
(	O
i.e.,	O
when	O
the	O
time	O
period	O
between	O
enrolment	O
and	O
study	O
treatment	O
is	O
>	O
7	O
days	O
)	O
.	O

-	O
Pregnancy	B-Observation
testing	I-Observation
will	O
be	O
performed	O
at	O
screening,	O
pre-dose	O
(	O
Day	O
1	O
)	O
and	O
follow-up	O
visit	O
for	O
all	O
women	O
of	O
child-bearing	B-Condition
potential	I-Condition
and	O
those	O
who	O
have	O
been	O
postmenopausal	B-Condition
for	O
less	O
than	O
1	O
year	O
.	O

If	O
clinically	O
indicated,	O
a	O
urine	B-Observation
or	I-Observation
serum	I-Observation
pregnancy	I-Observation
test	I-Observation
may	O
be	O
performed	O
at	O
anytime	O
during	O
the	O
study	O
.	O

-	O
Brain	B-Procedure_Device
CT	I-Procedure_Device
or	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
performed	O
within	O
the	O
past	O
12	O
months	O
or	O
at	O
Screening,	O
showing	O
no	B-Negation_cue
evidence	O
of	O
any	O
other	O
potential	O
cause	B-Condition
of	I-Condition
dementia	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Neurological	B-Procedure_Device
exam	I-Procedure_Device
without	B-Negation_cue
focal	B-Condition
changes	I-Condition
(	O
excluding	B-Negation_cue
changes	O
attributable	O
to	O
AD	B-Condition
or	O
peripheral	B-Condition
trauma	I-Condition
)	O
.	O

-	O
Subjects	O
who	O
live	O
with	O
or	O
who	O
have	O
a	O
regular	O
caregiver	O
who	O
is	O
willing	O
to	O
attend	O
all	O
visits,	O
oversee	O
the	O
subject's	O
compliance	O
with	O
the	O
protocol	O
specified	O
procedures	O
and	O
study	O
medication	O
and	O
who	O
is	O
willing	O
to	O
report	O
on	O
subject's	O
status	O
.	O

-	O
Subject	O
has	O
provided	O
full	O
written	O
informed	O
consent	O
prior	O
to	O
the	O
performance	O
of	O
any	O
protocol-specified	O
procedure	O
.	O

-	O
Subjects	O
considered	O
for	O
enrolment	O
must	O
have	O
a	O
QTc	B-Observation
(	O
either	O
QTc	O
B	O
(	O
Bazett's	O
.	O

-	O
correction	O
)	O
or	O
QTc	B-Observation
F	I-Observation
(	O
Fridericia's	O
correction	O
)	O
<	O
450msec	O
at	O
the	O
Screening	O
Visit,	O
with	O
the	O
exception	O
of	O
subjects	O
with	O
bundle	B-Condition
branch	I-Condition
block	I-Condition
(	O
for	O
whom	O
either	O
QTc	B-Observation
B	I-Observation
or	I-Observation
QTc	I-Observation
F	I-Observation
must	O
be	O
<	O
480msec	O
)	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
possible,	O
probable	O
or	O
definite	O
vascular	B-Condition
dementia	I-Condition
in	O
accordance	O
with	O
NINDS-AIREN6	B-Observation
criteria	I-Observation
.	O

-	O
History	O
or	O
evidence	O
of	O
any	O
other	O
CNS	B-Condition
disorder	I-Condition
that	O
could	O
be	O
interpreted	O
as	O
a	O
cause	O
of	O
dementia	B-Condition
:	O
eg	O
cerebrovascular	B-Condition
disease	I-Condition
(	O
stroke	B-Condition
,	O
hemorrhage	B-Condition
),	O
structural	B-Condition
abnormality	I-Condition
epilepsy	B-Condition
,	O
infectious	B-Condition
or	I-Condition
inflammatory	I-Condition
/	I-Condition
demyelinating	I-Condition
CNS	I-Condition
conditions	I-Condition
Parkinson's	B-Condition
disease	I-Condition
.	O

-	O
Evidence	O
of	O
the	O
following	O
disorders:	O
current	O
vitamin	B-Condition
B12	I-Condition
deficiency	I-Condition
positive	O
syphilis	B-Observation
serology	I-Observation
or	O
active	O
thyroid	B-Condition
dysfunction	I-Condition
(	O
particularly	O
that	O
suggestive	O
of	O
hypothyroidism	B-Condition
),	O
including	O
abnormally	O
high	O
or	O
low	O
serum	B-Observation
levels	I-Observation
of	I-Observation
thyroid	I-Observation
stimulating	I-Observation
hormone	I-Observation
(	I-Observation
TSH	I-Observation
)	I-Observation
that	O
is	O
clinically	O
significant	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
.	O

-	O
History	O
of	O
Type	B-Condition
1	I-Condition
diabetes	I-Condition
mellitus	I-Condition
or	O
secondary	B-Condition
diabetes	I-Condition
mellitus	I-Condition
.	O

-	O
Type	B-Condition
2	I-Condition
diabetes	I-Condition
mellitus	I-Condition
where	O
the	O
subject	O
is	O
being	O
treated	O
with	O
insulin	B-Drug
,	O
a	O
PPAR	B-Drug
agonist	I-Drug
or	O
an	O
insulin	B-Drug
secretagogue	I-Drug
(	O
eg	O
a	O
sulfonylurea	B-Drug
or	O
glitinide	B-Drug
)	O
.	O

-	O
Any	O
patient	O
with	O
an	O
HbA1c	B-Observation
>=	O
8.5%	O
.	O

-	O
History	O
or	O
clinical	O
/	O
laboratory	O
evidence	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
defined	O
by	O
the	O
New	B-Observation
York	I-Observation
Heart	I-Observation
Association	I-Observation
criteria	I-Observation
(	O
Class	O
I	O
to	O
IV	O
cardiac	B-Observation
status	I-Observation
)	O
(	O
Appendix	O
4	O
)	O
.	O

-	O
History	O
of	O
cardiovascular	B-Condition
event	I-Condition
within	O
the	O
last	O
6	O
months	O
(	O
i.e	O
.	O

intervention	B-Procedure_Device
,	O
percutaneous	B-Procedure_Device
coronary	I-Procedure_Device
intervention	I-Procedure_Device
vascular	B-Procedure_Device
surgery	I-Procedure_Device
acute	B-Condition
coronary	I-Condition
syndrome	I-Condition
non	B-Condition
Q-wave	I-Condition
myocardial	I-Condition
infarction	I-Condition
Q-wave	B-Condition
myocardial	I-Condition
infarction	I-Condition
unstable	O
angina	B-Condition
]	O
or	O
significant	O
arrhythmia	B-Condition
;	O
or	O
major	O
intervention	B-Procedure_Device
(	O
eg	O
cardiac	B-Procedure_Device
surgery	I-Procedure_Device
or	O
angiography	B-Procedure_Device
plus	I-Procedure_Device
stenting	I-Procedure_Device
)	O
scheduled	O
)	O
.	O

-	O
History	O
of	O
significant	O
psychiatric	B-Condition
illness	I-Condition
such	O
as	O
schizophrenia	B-Condition
or	O
bipolar	B-Condition
affective	I-Condition
disorder	I-Condition
that	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
would	O
interfere	O
with	O
participation	O
in	O
the	O
study,	O
major	B-Condition
depressive	I-Condition
disorder	I-Condition
(	O
according	O
to	O
DSM-IV	B-Observation
)	O
in	O
the	O
past	O
year	O
or	O
current	O
active	O
depression	B-Condition
requiring	O
initiation	O
of	O
treatment	O
.	O

-	O
History	O
or	O
presence	O
of	O
gastro-intestinal,	B-Condition
hepatic	I-Condition
or	I-Condition
renal	I-Condition
disease	I-Condition
or	O
other	O
condition	B-Condition
known	O
to	O
interfere	O
with	O
the	O
absorption	B-Observation
,	O
distribution	B-Observation
,	O
metabolism	B-Observation
or	O
excretion	B-Observation
of	O
drugs	B-Drug
or	O
any	O
other	O
clinically	O
relevant	O
abnormality	B-Condition
,	O
which,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator,	O
makes	O
the	O
subject	O
unsuitable	O
for	O
inclusion	O
in	O
the	O
study	O
.	O

-	O
Clinically	O
significant	O
peripheral	B-Condition
oedema	I-Condition
at	O
the	O
time	O
of	O
screening	O
.	O

-	O
Current	O
or	O
recent	O
drug	B-Condition
or	I-Condition
alcohol	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
(	O
defined	O
by	O
DSM-IV	B-Observation
criteria	I-Observation
for	O
substance-related	O
disorders	O
)	O
or	O
recent	O
or	O
remote	O
history	B-Observation
of	O
the	O
same	O
if	O
that	O
could	O
be	O
a	O
contributing	O
factor	O
to	O
the	O
dementia	B-Condition
.	O

-	O
Systolic	B-Observation
blood	I-Observation
pressure	I-Observation
>	O
165	O
or	O
<	O
90	O
mmHg	O
or	O
diastolic	B-Observation
blood	I-Observation
pressure	I-Observation
>	O
95	O
or	O
<	O
60	O
mmHg	O
at	O
the	O
time	O
of	O
screening	O
.	O

-	O
Clinically	O
significant	O
anaemia	B-Condition
(	O
i.e	O
.	O

haemoglobin	B-Observation
<	O
11	O
g	O
/	O
dL	O
for	O
males	B-Observation
or	O
<	O
10	O
g	O
/	O
dL	O
for	O
females	B-Observation
)	O
.	O

-	O
Patients	O
with	O
GFR	B-Observation
<=	O
50ml	O
/	O
min	O
(	O
assessed	O
by	O
Cockcroft-Gault	O
method	O
)	O
.	O

-	O
ALT	B-Observation
,	O
AST	B-Observation
or	O
alkaline	B-Observation
phosphatase	I-Observation
values	I-Observation
>	O
2.5	O
times	O
the	O
upper	O
limit	O
of	O
normal,	O
total	B-Observation
bilirubin	I-Observation
values	I-Observation
>	O
1.5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
history	O
of	O
severe	O
hepatobiliary	B-Condition
disease	I-Condition
(	O
eg	O
hepatitis	B-Condition
B	I-Condition
or	I-Condition
C	I-Condition
or	O
cirrhosis	B-Condition
,	O
Child-Pugh	B-Condition
Class	I-Condition
B	I-Condition
/	I-Condition
C	I-Condition
)	O
.	O

-	O
History	O
of	O
a	O
bone	B-Procedure_Device
marrow	I-Procedure_Device
transplant	I-Procedure_Device
.	O

-	O
Positive	O
hepatitis	B-Observation
B	I-Observation
virus	I-Observation
hepatitis	B-Observation
C	I-Observation
virus	I-Observation
or	O
HIV	B-Observation
test	I-Observation
at	O
screening	O
.	O

-	O
Subject	O
is	O
unable	O
(	O
with	O
assistance,	O
if	O
appropriate	O
)	O
to	O
take	O
study	O
medication	O
or	O
is	O
at	O
risk	O
of	O
non-compliance	O
with	O
study	O
procedures	O
.	O

>>NCT00088673	O
Inclusion	O
Criteria:	O
.	O

Patients	O
may	O
be	O
included	O
in	O
this	O
study	O
if	O
they	O
meet	O
all	O
of	O
the	O
following	O
criteria:	O
.	O

-	O
Male	O
or	O
Female	O
(	O
age	B-Observation
50	O
years	O
and	O
older	O
):	O
Female	O
must	O
be	O
of	O
non-childbearing	B-Condition
potential	I-Condition
(	O
i.e	O
.	O

surgically	B-Condition
sterilized	I-Condition
or	O
at	O
least	O
2	O
years	O
post-menopausal	B-Condition
)	O
.	O

-	O
Diagnosis	O
of	O
probable	O
Alzheimers	B-Condition
disease	I-Condition
based	O
on	O
the	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke	I-Observation
/	I-Observation
Alzheimers	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINCDS-ADRDA	I-Observation
criteria	I-Observation
)	I-Observation
.	O

-	O
Severity	O
of	O
dementia	B-Condition
of	O
mild	O
to	O
moderate	O
degree	O
as	O
assessed	O
by	O
the	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
performed	O
at	O
the	O
screening	O
visit	O
.	O

-	O
Patient	O
must	O
be	O
living	O
in	O
the	O
community	O
with	O
a	O
reliable	O
caregiver	O
.	O

Participant	O
living	O
in	O
an	O
assisted	O
living	O
facility	O
may	O
be	O
included	O
if	O
study	O
medication	O
intake	O
is	O
supervised	O
and	O
participant	O
has	O
a	O
reliable	O
caregiver	O
.	O

-	O
Potential	O
participant	O
must	O
be	O
treated	O
with	O
conventional	O
Alzheimers	B-Drug
disease	I-Drug
therapies	I-Drug
and	O
must	O
be	O
on	O
stable	O
dose	B-Observation
for	O
at	O
least	O
4	O
months	O
prior	O
to	O
the	O
screening	O
visit	O
and	O
during	O
the	O
entire	O
study	O
period	O
.	O

-	O
Fluency	O
in	O
English,	O
French	O
or	O
Spanish	O
(	O
oral	O
and	O
written	O
)	O
.	O

-	O
Signed	O
informed	O
consent	O
from	O
potential	O
participant	O
or	O
legal	O
representative	O
and	O
caregiver	O
.	O

Exclusion	O
Criteria:	O
.	O

Patients	O
will	O
not	O
be	O
eligible	O
to	O
participate	O
in	O
the	O
study	O
if	O
they	O
meet	O
any	O
of	O
the	O
following	O
criteria:	O
.	O

-	O
Potential	O
participant	O
with	O
any	O
other	B-Negation_cue
cause	O
of	O
dementia	B-Condition
.	O

-	O
Life	B-Observation
expectancy	I-Observation
less	O
than	O
2	O
years	O
.	O

-	O
Potential	O
participant	O
with	O
a	O
clinically	O
significant	O
and	O
/	O
or	O
uncontrolled	O
condition	B-Condition
or	O
other	O
significant	O
medical	B-Condition
disease	I-Condition
.	O

-	O
Use	O
of	O
an	O
investigational	B-Drug
drug	I-Drug
within	O
30	O
days	O
prior	O
to	O
the	O
screening	O
visit	O
or	O
during	O
the	O
entire	O
study	O
.	O

-	O
Previous	O
use	O
of	O
3APS	B-Drug
.	O

Patient	O
recruitment	O
is	O
done	O
by	O
participating	O
centers	O
.	O

>>NCT01638949	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Education	O
level	O
>	O
7	O
years	O
.	O

-	O
Native	O
language:	O
French	O
.	O

-	O
Medical,	O
neurological,	O
neuropsychological	O
and	O
neuroradiological	O
depth	O
in	O
accordance	O
with	O
the	O
criteria	O
for	O
inclusion	O
and	O
exclusion-specific	O
population,	O
that	O
is	O
to	O
say:	O
.	O

-	O
Healthy	B-Condition
young	O
volunteers:	O
between	O
18	O
and	O
40	O
years	O
old;	O
normal	O
performances	O
compared	O
to	O
the	O
age	O
and	O
the	O
educational	O
level	O
for	O
all	O
tests	O
of	O
the	O
diagnostic	O
battery	O
(	O
1.65	O
SD	O
)	O
.	O

-	O
Healthy	B-Condition
Middle-aged	O
volunteers:	O
between	O
40	O
and	O
60	O
years	O
old;	O
without	B-Negation_cue
memory	B-Observation
complaints	I-Observation
normal	O
performances	O
compared	O
to	O
the	O
age	O
and	O
the	O
educational	O
level	O
for	O
all	O
tests	O
of	O
the	O
diagnostic	O
battery	O
(	O
1.65	O
SD	O
)	O
.	O

-	O
Healthy	B-Condition
Elderly	O
volunteers:	O
over	O
60	O
years	O
old,	O
living	O
at	O
home,	O
without	B-Negation_cue
memory	B-Observation
complaints	I-Observation
normal	O
performances	O
compared	O
to	O
the	O
age	O
and	O
the	O
educational	O
level	O
for	O
all	O
tests	O
of	O
the	O
diagnostic	O
battery	O
(	O
1.65	O
SD	O
)	O
.	O

-	O
SCI	B-Condition
patients:	O
over	O
60	O
years	O
old	O
;	O
memory	B-Observation
complaints	I-Observation
memory	B-Observation
complaint	I-Observation
;	O
normal	O
performances	O
compared	O
to	O
the	O
age	O
and	O
the	O
educational	O
level	O
for	O
all	O
tests	O
of	O
the	O
diagnostic	O
battery	O
(	O
1.65	O
SD	O
)	O
.	O

-	O
MCI	B-Condition
patients:	O
presenting	O
the	O
current	O
criteria	O
for	O
amnestic	B-Condition
MCI	I-Condition
including:	O
i	O
)	O
memory	B-Observation
complaint	I-Observation
ii	O
)	O
deficits	B-Condition
of	I-Condition
the	I-Condition
episodic	I-Condition
memory	I-Condition
(	O
lower	O
performance	O
of	O
at	O
least	O
1.65	O
SD	O
from	O
the	O
norm	O
for	O
age	O
and	O
cultural	O
level	O
for	O
one	O
or	O
more	O
scores	O
of	O
episodic	O
memory	O
and	O
iii	O
)	O
normal	O
performances	O
compared	O
to	O
the	O
age	O
and	O
the	O
educational	O
level	O
of	O
all	O
other	O
cognitive	O
functions	O
as	O
memory,	O
including	O
tests	O
to	O
assess	O
cognitive	O
abilities	O
.	O

-	O
Alzheimer's	B-Condition
patients:	O
presenting	O
the	O
standard	O
criteria	O
of	O
NINCDS-ADRDA	B-Observation
probable	O
Alzheimer's	B-Condition
disease	I-Condition
including	O
abnormal	O
global	B-Observation
cognitive	I-Observation
function	I-Observation
and	O
deficits	B-Condition
in	O
at	O
least	O
two	O
cognitive	O
domains	O
identified	O
by	O
the	O
diagnostic	O
battery	O
and	O
a	O
mild	O
to	O
moderate	O
Alzheimer's	B-Condition
disease	I-Condition
(	O
MMSE	B-Observation
>=	O
15	O
)	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
The	O
sudden	O
onset	O
of	O
cognitive	B-Condition
impairments	I-Condition
(	O
as	O
opposed	B-Negation_cue
to	O
their	O
slow	O
and	O
gradual	O
installation	O
in	O
Alzheimer's	B-Condition
disease	I-Condition
)	O
.	O

-	O
A	O
chronic	O
neurological,	B-Observation
psychiatric,	I-Observation
endocrine,	I-Observation
hepatic	I-Observation
or	I-Observation
infectious	I-Observation
complaint	I-Observation
.	O

-	O
A	O
history	O
of	O
major	O
disease	B-Condition
(	O
an	O
uncontrolled	O
diabetes	B-Condition
,	O
a	O
lung,	B-Condition
heart,	I-Condition
metabolic,	I-Condition
hematologic,	I-Condition
endocrine	I-Condition
disease	I-Condition
or	O
a	O
severe	O
cancer	B-Condition
)	O
.	O

-	O
A	O
medication	B-Drug
that	O
may	O
interfere	O
with	O
memory	O
or	O
metabolic	O
measures	O
.	O

-	O
A	O
alcohol	B-Condition
or	I-Condition
drugs	I-Condition
abuse	I-Condition
.	O

-	O
The	O
cons-indications	B-Condition
to	O
MRI	B-Procedure_Device
(	O
claustrophobia	B-Condition
,	O
metallic	B-Procedure_Device
object	I-Procedure_Device
in	O
the	O
body	O
)	O
.	O

-	O
A	O
predominantly	O
left-hand	O
(	O
score	O
below	O
50%	O
in	O
Edinburgh	O
Inventory	O
)	O
.	O

-	O
Protected	O
adults	O
and	O
persons	O
not	O
affiliated	O
with	O
a	O
social	O
security	O
system	O
will	O
not	O
participate	O
in	O
this	O
study	O
.	O

-	O
The	O
inclusion	O
of	O
a	O
participant	O
in	O
another	O
biomedical	O
research	O
protocol	O
.	O

>>NCT01962753	O
Inclusion	O
Criteria	O
.	O

-	O
Adult	O
60	O
years	O
or	O
older	O
.	O

-	O
Native	O
language	O
:	O
french	O
.	O

-	O
Study	O
period	O
>	O
7	O
years	O
.	O

-	O
Major	B-Condition
depression	I-Condition
defined	O
on	O
the	O
DSM-IV	B-Observation
criteria	I-Observation
assessed	O
by	O
MINI	B-Observation
and	I-Observation
HDRS	I-Observation
score	I-Observation
of	O
10	O
or	O
over	O
.	O

-	O
Affiliation	O
to	O
the	O
national	O
health	O
insurance	O
system	O
.	O

-	O
Signed	O
informed	O
consent	O
.	O

Exclusion	O
Criteria	O
.	O

-	O
History	O
of	O
alcoholism	B-Condition
or	O
drug	B-Condition
addiction	I-Condition
.	O

-	O
MMSE	B-Observation
less	O
than	O
or	O
equal	O
to	O
17	O
.	O

-	O
Major	B-Condition
depression	I-Condition
with	I-Condition
psychotic	I-Condition
features	I-Condition
.	O

-	O
Depressive	B-Condition
episode	I-Condition
resistant	I-Condition
patient	O
who	O
received	O
two	O
different	O
antidepressants	B-Drug
well	O
conducted	O
without	B-Negation_cue
significant	O
therapeutic	B-Condition
response	I-Condition
.	O

-	O
Any	O
current	O
or	O
past	O
episode	O
of	O
mania	B-Condition
,	O
schizophrenia	B-Condition
or	O
any	O
other	O
psychotic	B-Condition
disorder	I-Condition
.	O

-	O
Any	O
past	O
history	O
of	O
stroke	B-Condition
or	O
Parkinson's	B-Condition
disease	I-Condition
.	O

-	O
Any	O
current	O
significant	O
unstable	O
illness	B-Condition
.	O

-	O
Any	O
past	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Any	O
current	O
treatment	B-Drug
by	O
AcethylCholinesterae	B-Drug
inhibitor	I-Drug
memantine	B-Drug
or	O
antidepressant	B-Drug
therapy	O
.	O

-	O
Contraindications	B-Condition
to	O
MRI	B-Procedure_Device
in	O
patients	O
with:	O
.	O

1	O
.	O

Metallic	B-Procedure_Device
foreign	I-Procedure_Device
body	I-Procedure_Device
eye	I-Procedure_Device
.	O

2	O
.	O

Any	O
implanted	B-Procedure_Device
electronic	I-Procedure_Device
medical	I-Procedure_Device
irremovably	O
(	O
pacemaker	B-Procedure_Device
,	O
neurostimulator	B-Procedure_Device
,	O
cochlear	B-Procedure_Device
implants	I-Procedure_Device
...)	O
.	O

3	O
.	O

Metal	B-Procedure_Device
heart	I-Procedure_Device
valve	I-Procedure_Device
.	O

4	O
.	O

Vascular	B-Procedure_Device
clips	I-Procedure_Device
formerly	O
located	O
on	O
cranial	B-Condition
aneurysm	I-Condition
.	O

-	O
Contraindications	B-Condition
to	O
antidepressants	B-Drug
.	O

-	O
History	O
of	O
progressive	B-Condition
disease	I-Condition
that	O
can	O
affect	O
the	O
central	O
nervous	O
system	O
such	O
as	O
uncontrolled	O
diabetes	B-Condition
,	O
blood	B-Observation
pressure	I-Observation
greater	O
than	O
or	O
equal	O
to	O
180	O
-	O
100;	O
chronic	O
lung	B-Condition
disease	I-Condition
with	O
hypoxia	B-Condition
,	O
head	B-Condition
trauma	I-Condition
with	O
loss	B-Observation
of	I-Observation
consciousness	I-Observation
greater	O
than	O
or	O
equal	O
to	O
15	O
minutes;	O
brain	B-Procedure_Device
surgery	I-Procedure_Device
encephalitis	B-Condition
,	O
recently	O
treated	O
cancer	B-Condition
(	O
<	O
1	O
year	O
),	O
altered	B-Condition
cerebral	I-Condition
metabolism	I-Condition
including	O
subjects	O
with	O
stroke	B-Condition
sequelae	O
extended	O
.	O

Patients	O
with	O
lacunar	B-Condition
stroke	I-Condition
without	B-Negation_cue
thalamic	B-Condition
or	O
striatal	B-Condition
may	O
be	O
included	O
.	O

>>NCT01982578	O
Inclusion	O
Criteria:	O
.	O

-	O
Patients	O
with	O
mild	B-Condition
cognitive	I-Condition
impairment	I-Condition
(	I-Condition
MCI	I-Condition
)	I-Condition
compatible	O
with	O
prodromal	B-Condition
AD	I-Condition
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Examinations	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
between	O
over	O
24	O
inclusive	O
.	O

-	O
CSF	B-Observation
levels	I-Observation
of	I-Observation
AB,	I-Observation
p-TAU	I-Observation
compatible	O
with	O
AD	B-Condition
.	O

-	O
18	O
years	O
or	O
older	O
.	O

-	O
Must	O
have	O
a	O
study	O
partner	O
who	O
is	O
able	O
and	O
willing	O
to	O
comply	O
with	O
all	O
required	O
study	O
procedures	O
.	O

-	O
Willing	O
and	O
able	O
to	O
provide	O
informed	O
consent	O
by	O
either	O
the	O
subject	O
or	O
subject's	O
legal	O
representative	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Patient	O
who	O
does	O
not	O
meet	O
the	O
inclusion	O
criteria	O
.	O

-	O
Thyroid	B-Condition
abnormalities	I-Condition
with	O
or	O
without	O
treatment	O
.	O

-	O
Immune	B-Condition
abnormalities	I-Condition
in	O
blood	B-Observation
analyses	I-Observation
.	O

-	O
Patient	O
suffers	O
hormone	B-Condition
dependent	I-Condition
neoplasia	I-Condition
.	O

-	O
Take	O
a	O
diet	O
rich	O
on	O
isoflavones	B-Drug
.	O

>>NCT00480220	O
Inclusion	O
Criteria:	O
.	O

-	O
patient	O
seen	O
in	O
consultation	O
in	O
one	O
of	O
the	O
centres	O
participating	O
in	O
the	O
study	O
.	O

-	O
patient	O
with	O
probable	O
or	O
possible	O
AD	B-Condition
according	O
to	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
.	O

-	O
patient	O
with	O
an	O
MMSE	B-Observation
score	I-Observation
between	O
12	O
and	O
26	O
(	O
mild	O
to	O
moderate	O
disease	B-Condition
)	O
.	O

-	O
patient	O
capable	O
of	O
understanding	O
and	O
responding	O
to	O
the	O
evaluations	O
made	O
.	O

-	O
patient	O
who	O
is	O
not	O
confined	O
to	O
bed	O
or	O
chair	O
.	O

-	O
patient	O
living	O
at	O
home	O
with	O
an	O
informal	O
caregiver	O
.	O

-	O
informed	O
consent	O
of	O
the	O
patient	O
(	O
or	O
legal	O
representative	O
)	O
and	O
of	O
the	O
caregiver	O
agreeing	O
to	O
take	O
part	O
in	O
the	O
study	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
patient	O
with	O
an	O
MMSE	B-Observation
score	I-Observation
of	O
less	O
than	O
12	O
or	O
over	O
26	O
.	O

-	O
patient	O
incapable	O
of	O
understanding	O
and	O
responding	O
to	O
the	O
evaluations	O
made	O
.	O

-	O
patient	O
confined	O
to	O
bed	O
or	O
chair	O
.	O

-	O
patient	O
living	O
at	O
home	O
without	O
an	O
informal	O
carer	O
or	O
in	O
an	O
institution	O
.	O

-	O
patient	O
with	O
a	O
concomitant	B-Condition
disorder	I-Condition
threatening	O
the	O
vital	O
prognosis	O
at	O
two	O
years	O
.	O

-	O
patient	O
with	O
a	O
dementia	B-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
.	O

-	O
patient	O
already	O
included	O
in	O
another	O
research	O
programme.	O

>>NCT02137460	O
Participants	O
will	O
be	O
classified	O
as	O
either	O
Alzheimer's	B-Condition
disease	I-Condition
(	I-Condition
AD	I-Condition
)	I-Condition
group,	O
mild	B-Condition
cognitive	I-Condition
impairment	I-Condition
(	I-Condition
MCI	I-Condition
)	I-Condition
group,	O
elderly	O
normal	O
controls	O
or	O
young	O
normal	O
controls	O
.	O

Specific	O
inclusion	O
criteria	O
for	O
each	O
group	O
is	O
described	O
below	O
.	O

[Inclusion	O
criteria:	O
AD	B-Condition
]	O
.	O

-	O
Age	B-Observation
:	O
55	O
-	O
90	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)=	O
0.5	O
or	O
1	O
.	O

-	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual-IV	I-Observation
(	I-Observation
DSM-IV	I-Observation
)	I-Observation
criteria	I-Observation
for	O
dementia	B-Condition
.	O

-	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Aging	I-Observation
and	I-Observation
the	I-Observation
Alzheimer's	I-Observation
Association	I-Observation
(	I-Observation
NIA-AA	I-Observation
)	I-Observation
Probable	O
AD	B-Condition
dementia	I-Condition
.	O

-	O
Study	O
partner	O
or	O
caregiver	O
to	O
accompany	O
patient	O
to	O
all	O
scheduled	O
visits	O
.	O

-	O
Written	O
informed	O
consent	O
.	O

[Inclusion	O
criteria:	O
MCI	B-Condition
(	I-Condition
amnestic	I-Condition
)	I-Condition
.	O

-	O
Age	B-Observation
:	O
55	O
-	O
90	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
0.5	O
.	O

-	O
Concern	O
regarding	O
a	O
change	O
in	O
cognition	O
(	O
obtained	O
from	O
the	O
subject,	O
from	O
an	O
informant	O
who	O
knows	O
the	O
subject	O
or	O
from	O
a	O
skilled	O
clinician	O
observing	O
the	O
subject	O
)	O
.	O

-	O
Lower	O
performance	O
in	O
episodic	O
memory	O
domains	O
that	O
is	O
greater	O
than	O
would	O
be	O
expected	O
for	O
the	O
subject's	O
age	O
and	O
educational	O
background	O
.	O

-	O
Preservation	O
of	O
independence	O
in	O
functional	O
abilities	O
.	O

-	O
Study	O
partner	O
or	O
caregiver	O
to	O
accompany	O
subject	O
to	O
all	O
scheduled	O
visits	O
.	O

-	O
Written	O
informed	O
consent	O
.	O

[Inclusion	O
criteria:	O
Elderly	O
normal	O
controls]	O
.	O

-	O
Age	B-Observation
:	O
55	O
-	O
90	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
0	O
.	O

-	O
Those	O
with	O
contactable	O
Informant	O
.	O

-	O
Written	O
informed	O
consent	O
.	O

[Inclusion	O
criteria:	O
Young	O
normal	O
controls]	O
.	O

-	O
Age	B-Observation
:	O
20	O
-	O
55	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
0	O
.	O

-	O
Written	O
informed	O
consent	O
.	O

[Exclusion	O
criteria:	O
general]	O
.	O

-	O
Past	O
history	O
or	O
presence	O
of	O
major	O
psychiatric	B-Condition
illness	I-Condition
(	O
eg	O
schizophrenia	B-Condition
,	O
bipolar	B-Condition
disorder	I-Condition
alcohol	B-Condition
/	I-Condition
substance	I-Condition
abuse	I-Condition
or	O
dependence	B-Condition
,	O
delirium	B-Condition
)	O
.	O

-	O
Significant	O
neurologic	B-Condition
or	I-Condition
medical	I-Condition
condition	I-Condition
that	O
can	O
influence	O
the	O
mental	O
state	O
.	O

-	O
Contraindications	B-Condition
for	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
(	O
eg	O
pacemaker	B-Procedure_Device
,	O
claustrophobia	B-Condition
)	O
.	O

-	O
Illiteracy	O
.	O

-	O
Significant	O
visual	B-Condition
or	I-Condition
hearing	I-Condition
difficulty	I-Condition
.	O

-	O
Taking	O
investigational	B-Drug
drug	I-Drug
.	O

-	O
In	O
pregnancy	B-Condition
or	O
breast-feeding	B-Condition
.	O

>>NCT00082602	O
Inclusion	O
Criteria:	O
.	O

-	O
Male	O
or	O
female	O
outpatients	O
diagnosed	O
with	O
Alzheimer's	B-Condition
Disease	I-Condition
.	O

-	O
Age	B-Observation
>=	O
60	O
years	O
.	O

-	O
Presence	O
of	O
mild	O
to	O
moderate	O
dementia	B-Condition
as	O
evidenced	O
by	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
of	O
10	O
-	O
24	O
inclusive	O
at	O
screening	O
.	O

-	O
History	O
of	O
cognitive	B-Condition
decline	I-Condition
that	O
had	O
been	O
gradual	O
in	O
onset	O
and	O
progressive	O
over	O
a	O
period	O
of	O
at	O
least	O
six	O
months	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Neurodegenerative	B-Condition
disorders	I-Condition
.	O

-	O
One	O
of	O
the	O
following	O
conditions	O
possibly	O
resulting	O
in	O
cognitive	B-Condition
impairment	I-Condition
Acute	O
cerebral	B-Condition
trauma	I-Condition
or	O
injuries	B-Condition
secondary	O
to	O
chronic	O
trauma	B-Condition
(	O
such	O
as	O
boxing	O
),	O
hypoxic	B-Condition
cerebral	I-Condition
damage	I-Condition
whether	O
or	O
not	O
due	O
to	O
acute	O
or	O
chronic	O
cerebral	B-Condition
hypoperfusion	I-Condition
.	O

-	O
Vitamin	B-Condition
deficiency	I-Condition
states	I-Condition
such	O
as	O
folate,	B-Condition
vitamin	I-Condition
B12	I-Condition
or	I-Condition
other	I-Condition
B	I-Condition
complex	I-Condition
deficiencies	I-Condition
.	O

-	O
Neurosyphilis	B-Condition
or	O
other	O
infections	B-Condition
resulting	O
in	O
cerebral	B-Condition
abscesses	I-Condition
meningitis	B-Condition
or	O
encephalitides	B-Condition
such	O
as	O
AIDS	B-Condition
.	O

-	O
Primary	O
or	O
metastatic	O
cerebral	B-Condition
neoplasia	I-Condition
.	O

-	O
Significant	O
endocrine	B-Condition
or	I-Condition
metabolic	I-Condition
disease	I-Condition
eg	O
,	O
untreated	O
or	O
uncontrolled	O
thyroid,	B-Condition
parathyroid	I-Condition
or	I-Condition
pituitary	I-Condition
disease	I-Condition
Cushing's	B-Condition
syndrome	I-Condition
severe	O
renal	B-Condition
failure	I-Condition
or	O
uncontrolled	O
diabetes	B-Condition
mellitus	I-Condition
.	O

-	O
Mental	B-Condition
retardation	I-Condition
or	O
oligophrenia	B-Condition
.	O

-	O
Multi-infarct	B-Condition
dementia	I-Condition
or	O
clinically	O
active	O
cerebrovascular	B-Condition
disease	I-Condition
as	O
evidenced	O
by:	O
a	O
history	O
of	O
a	O
significant	O
cerebrovascular	B-Condition
event	I-Condition
yielding	O
a	O
physical	B-Condition
or	I-Condition
neurologic	I-Condition
deficit	I-Condition
likely	O
to	O
confound	O
the	O
assessment	O
of	O
the	O
subject's	O
intellectual	O
function,	O
multiple	O
focal	B-Condition
signs	I-Condition
on	O
neurological	B-Procedure_Device
examination	I-Procedure_Device
indicative	O
of	O
multiple	B-Condition
ischemic	I-Condition
attacks	I-Condition
significant	O
findings	O
on	O
an	O
available	O
CT	B-Procedure_Device
or	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
taken	O
within	O
the	O
last	O
12	O
months	O
.	O

-	O
Subjects	O
with	O
the	O
following	O
co-existing	O
medical	O
conditions:	O
Any	O
history	O
of	O
epilepsy	B-Condition
or	O
convulsions	B-Condition
except	B-Negation_cue
for	I-Negation_cue
febrile	B-Condition
convulsions	I-Condition
during	O
childhood	O
.	O

-	O
Current	O
clinically	O
significant	O
psychiatric	B-Condition
disease	I-Condition
in	O
particular	O
current	O
major	B-Condition
depression	I-Condition
schizophrenia	B-Condition
,	O
bipolar	B-Condition
disorder	I-Condition
moderate	O
to	O
severe	O
or	O
uncontrolled	O
behavioral	B-Condition
disturbances	I-Condition
.	O

-	O
Peptic	B-Condition
ulcer	I-Condition
disease	I-Condition
if	O
the	O
ulcer	O
is	O
considered	O
to	O
be	O
still	O
active	O
or	O
if	O
treatment	O
is	O
not	O
successful	O
(	O
symptoms	O
present	O
)	O
.	O

-	O
Clinically	O
significant	O
hepatic,	B-Condition
renal,	I-Condition
pulmonary,	I-Condition
metabolic	I-Condition
or	I-Condition
endocrine	I-Condition
disturbances	I-Condition
.	O

-	O
Clinically	O
significant	O
urinary	B-Condition
outflow	I-Condition
obstruction	I-Condition
.	O

-	O
Current,	O
clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
that	O
would	O
be	O
expected	O
to	O
limit	O
the	O
subject's	O
ability	O
to	O
participate	O
in	O
and	O
complete	O
a	O
12	O
-Week	O
trial	O
.	O

The	O
following	O
would	O
usually	O
be	O
considered	O
clinically	O
significant	O
cardiovascular	B-Condition
diseases	I-Condition
cardiac	B-Procedure_Device
surgery	I-Procedure_Device
or	O
myocardial	B-Condition
infarction	I-Condition
within	O
the	O
past	O
6	O
months,	O
angina	B-Condition
or	O
coronary	B-Condition
artery	I-Condition
disease	I-Condition
that	O
required	O
a	O
change	O
in	O
anti-angina	B-Drug
medication	I-Drug
within	O
the	O
last	O
3	O
months,	O
decompensated	B-Condition
congestive	I-Condition
heart	I-Condition
failure	I-Condition
cardiac	B-Condition
disease	I-Condition
potentially	O
resulting	O
in	O
syncope	B-Condition
,	O
near	B-Condition
syncope	I-Condition
or	O
other	O
alterations	B-Condition
of	I-Condition
mental	I-Condition
status	I-Condition
atrial	B-Condition
fibrillation	I-Condition
bradycardia	B-Condition
<	O
50	O
/	O
min.,	O
atrio-ventricular	B-Condition
block	I-Condition
>	O
first	O
degree	O
.	O

-	O
Severe	O
mitral	B-Condition
or	I-Condition
aortic	I-Condition
valvular	I-Condition
disease	I-Condition
.	O

-	O
Uncontrolled	O
high	B-Condition
blood	I-Condition
pressure	I-Condition
(	O
systolic	B-Observation
blood	I-Observation
pressure	I-Observation
>	O
170	O
mmHg	O
or	O
diastolic	B-Observation
blood	I-Observation
pressure	I-Observation
>	O
110	O
mmHg	O
)	O
or	O
sustained	O
hypotension	B-Condition
.	O

-	O
Any	O
agent	O
being	O
used	O
for	O
the	O
treatment	O
of	O
dementia	B-Condition
(	O
approved,	O
experimental	O
or	O
over	O
the	O
counter	O
agents	O
.	O

-	O
Subjects	O
who	O
have	O
previously	O
received	O
Cognex	B-Drug
,	O
Aricept	B-Drug
,	O
metrifonate	B-Drug
,	O
Exelon	B-Drug
,	O
Reminyl	B-Drug
or	O
Namenda	B-Drug
for	O
treatment	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
no	O
matter	O
if	O
approved	O
or	O
experimental	O
can	O
be	O
included	O
in	O
this	O
trial	O
provided	O
that	O
during	O
the	O
30	O
days	O
prior	O
to	O
baseline	O
they	O
were	O
not	O
taking	O
these	O
agents	O
.	O

-	O
O	O
History	O
of	O
drug	B-Condition
or	I-Condition
alcohol	I-Condition
abuse	I-Condition
within	O
the	O
last	O
year	O
or	O
prior	O
prolonged	O
history	O
of	O
the	O
same	O
.	O

-	O
Female	O
subjects	O
of	O
childbearing	B-Condition
potential	I-Condition
.	O

-	O
Subjects	O
who	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
are	O
otherwise	O
unsuitable	O
for	O
a	O
trial	O
of	O
this	O
type	O
.	O

-	O
History	O
of	O
severe	O
drug	B-Condition
allergy	I-Condition
or	O
hypersensitivity	B-Condition
,	O
including	O
recorded	O
hypersensitivity	B-Condition
to	O
cholinesterase	B-Drug
inhibitors	I-Drug
choline	B-Drug
agonists	I-Drug
or	O
identical	B-Drug
agents	I-Drug
or	O
bromide	B-Drug
.	O

-	O
Subjects	O
who	O
have	O
previously	O
been	O
enrolled	O
in	O
other	O
galantamine	B-Drug
trials	O
.	O

-	O
Subjects	O
who	O
have	O
received	O
an	O
investigational	B-Drug
medication	I-Drug
within	O
the	O
last	O
30	O
days	O
.	O

-	O
Conditions	O
that	O
could	O
interfere	O
with	O
the	O
absorption	O
of	O
the	O
compound	O
or	O
with	O
the	O
evaluation	O
of	O
the	O
disease	O
.	O

-	O
Employees	O
of	O
the	O
investigator	O
.	O

>>NCT01320527	O
Inclusion	O
Criteria:	O
.	O

-	O
Clinical	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
or	O
Mild	B-Condition
Cognitive	I-Condition
Impairment	I-Condition
.	O

-	O
must	O
be	O
able	O
to	O
swallow	O
pills	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
known	O
or	O
suspected	O
bipolar	B-Condition
disorder	I-Condition
.	O

>>NCT01434940	O
Inclusion	O
Criteria:	O
.	O

-	O
subject	O
whose	O
visual	B-Observation
acuity	I-Observation
>	O
9	O
-	O
10	O
.	O

-	O
subject	O
without	B-Negation_cue
a	O
diagnosis	O
of	O
eye	B-Condition
disease	I-Condition
.	O

-	O
subject	O
without	B-Negation_cue
a	O
neuropsychological	B-Condition
sequelae	I-Condition
.	O

-	O
for	O
depressed	O
patients	O
:subject	O
with	O
a	O
diagnosis	O
of	O
depression	B-Condition
confirmed	O
by	O
a	O
psychiatric	O
evaluation	O
and	O
MADRS	B-Observation
(	I-Observation
Montgomery	I-Observation
and	I-Observation
Asberg	I-Observation
Depression	I-Observation
Rating	I-Observation
Scale	I-Observation
)	I-Observation
score	I-Observation
>	O
25	O
and	O
without	B-Negation_cue
cognitive	B-Condition
impairment	I-Condition
or	O
any	O
other	O
psychiatric	B-Condition
pathology	I-Condition
and	O
MMSE	B-Observation
(	I-Observation
Mini	I-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
)	I-Observation
>=	O
18	O
and	O
without	B-Negation_cue
symptoms	O
of	O
AD	B-Condition
.	O

-	O
for	O
Alzheimer	B-Condition
patients	O
:subject	O
with	O
AD	B-Condition
diagnosed	O
according	O
to	O
NINCDS-ADRDA	B-Observation
(	I-Observation
National	I-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke	I-Observation
-Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
)	I-Observation
criteria	I-Observation
and	O
MMSE	B-Observation
>=	O
18	O
and	O
without	B-Negation_cue
psychiatric	B-Condition
disorder	I-Condition
and	O
MADRS	B-Observation
score	I-Observation
<	O
25	O
.	O

-	O
for	O
control	O
patients	O
:	O
subject	O
without	B-Negation_cue
AD	B-Condition
,	O
depression	B-Condition
or	O
any	O
other	O
psychiatric	B-Condition
condition	I-Condition
identified	O
by	O
the	O
diagnostic	O
criteria	O
or	O
cognitive	B-Condition
disorders	I-Condition
and	O
MADRS	B-Observation
score	I-Observation
<	O
25	O
and	O
MMSE	B-Observation
>	O
20	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
subject	O
age	B-Observation
under	O
60	O
.	O

>>NCT00408525	O
Inclusion	O
Criteria:	O
.	O

-	O
Subjects	O
may	O
report	O
experiencing	O
subjective	O
memory	B-Condition
dysfunction	I-Condition
however	O
they	O
must	O
be	O
found	O
by	O
clinical	B-Observation
evaluation	I-Observation
to	O
have	O
no	B-Negation_cue
memory	B-Condition
dysfunction	I-Condition
.	O

-	O
Neuropsychological	B-Observation
test	I-Observation
battery	I-Observation
in	O
the	O
normal	O
range	O
.	O

-	O
Ages	B-Observation
40	O
-	O
85	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Dementia	B-Condition
(	O
Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
less	O
than	O
25	O
-	O
30	O
)	O
.	O

-	O
Left-handedness	O
.	O

-	O
Current	O
medication	B-Drug
that	O
could	O
influence	O
cognition	B-Observation
.	O

-	O
Medical,	B-Condition
psychiatric	I-Condition
and	I-Condition
neurologic	I-Condition
conditions	I-Condition
including	O
cerebrovascular	B-Condition
disease	I-Condition
or	O
uncontrolled	O
hypertension	B-Condition
.	O

-	O
Claustrophobia	B-Condition
.	O

-	O
Surgical	B-Procedure_Device
clips	I-Procedure_Device
or	O
implants	B-Procedure_Device
.	O

-	O
Pacemakers	B-Procedure_Device
or	O
other	O
implanted	B-Procedure_Device
electronic	I-Procedure_Device
devices	I-Procedure_Device
.	O

-	O
History	O
of	O
sheet	O
metal	O
work	O
.	O

>>NCT01054976	O
Inclusion	O
Criteria:	O
.	O

-	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
the	O
criteria	B-Observation
of	I-Observation
DSM-IV,	I-Observation
NINCDS-ADRDA	I-Observation
.	O

-	O
K-MMSE	B-Observation
(	I-Observation
Korean	I-Observation
-	I-Observation
Mini	I-Observation
Mental	I-Observation
State	I-Observation
Exam	I-Observation
)	I-Observation
is	O
10	O
to	O
24	O
.	O

-	O
Reliable	O
Guardian	O
available	O
to	O
the	O
patients	O
.	O

-	O
Patient	O
or	O
guardian	O
provided	O
written	O
informed	O
consent	O
before	O
entering	O
into	O
the	O
clinical	O
trial	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Acetylcholine	B-Drug
esterase	I-Drug
inhibitors	I-Drug
used	O
to	O
treat	O
dementia	B-Condition
taken	O
within	O
30	O
days	O
of	O
the	O
beginning	O
in	O
this	O
clinical	O
trial	O
.	O

-	O
Neurodegenerative	B-Condition
diseases	I-Condition
(	O
eg	O
Parkinson's	B-Condition
disease	I-Condition
Pick's	B-Condition
disease	I-Condition
Huntington's	B-Condition
disease	I-Condition
Down	B-Condition
syndrome	I-Condition
)	O
.	O

-	O
Dementia	B-Condition
related	O
to	O
head	B-Condition
trauma	I-Condition
and	O
dementia	B-Condition
related	O
to	O
brain	B-Condition
damage	I-Condition
due	O
to	O
cerebral	B-Condition
hypoxia	I-Condition
(	O
hypoxic	B-Condition
brain	I-Condition
damage	I-Condition
after	O
cardiopulmonary	B-Procedure_Device
resuscitation	I-Procedure_Device
hypoxic	B-Condition
brain	I-Condition
damage	I-Condition
after	O
surgery	B-Procedure_Device
,	O
hypoxic	B-Condition
brain	I-Condition
damage	I-Condition
due	O
to	O
addiction	B-Condition
,	O
hypoxic	B-Condition
brain	I-Condition
damage	I-Condition
due	O
to	O
shock	B-Condition
)	O
.	O

-	O
brain	B-Condition
tumor	I-Condition
nerve	B-Condition
syphilis	I-Condition
meningitis	B-Condition
,	O
encephalitis	B-Condition
.	O

-	O
epilepsy	B-Condition
.	O

>>NCT02349191	O
Inclusion	O
Criteria:	O
.	O

1	O
.	O

Male	O
or	O
female	O
subjects	O
between	O
60	O
to	O
85	O
years	O
of	O
age	B-Observation
.	O

2	O
.	O

Montreal	B-Observation
Cognitive	I-Observation
Assessment	I-Observation
(	I-Observation
MoCA	I-Observation
)	I-Observation
score	I-Observation
of	O
11	O
to	O
18	O
(	O
mild	O
AD	B-Condition
)	O
.	O

3	O
.	O

Healthy	O
enough	O
to	O
undergo	O
the	O
surgical	O
procedure	O
based	O
on	O
surgical	O
risk	O
factor	O
definitions	O
(	O
ASA	B-Observation
<=	O
3,	O
using	O
the	O
ASA	O
classification	O
)	O
.	O

4	O
.	O

Must	O
be	O
able	O
to	O
read	O
and	O
understand	O
English	O
in	O
order	O
to	O
complete	O
all	O
AD	O
assessments	O
.	O

5	O
.	O

All	O
medical	B-Condition
illnesses	I-Condition
other	B-Negation_cue
than	I-Negation_cue
dementia	B-Condition
must	O
be	O
well	O
controlled	O
.	O

6	O
.	O

Must	O
have	O
legally	O
authorized	O
caregiver	O
if	O
incapable	O
of	O
making	O
their	O
own	O
decisions	O
who	O
is	O
willing	O
and	O
able	O
to	O
perform	O
the	O
following:	O
.	O

1	O
.	O
provide	O
informed	O
consent	O
if	O
the	O
subject	O
is	O
unable	O
to	O
do	O
so;	O
.	O

2	O
.	O
monitor	O
the	O
subject;	O
.	O

3	O
.	O
answer	O
informant	O
based	O
questionnaires;	O
.	O

4	O
.	O
provide	O
transportation	O
and	O
accompany	O
the	O
subject	O
to	O
all	O
visits	O
.	O

7	O
.	O

Subject	O
or	O
caregiver	O
is	O
willing	O
and	O
able	O
to	O
provide	O
written	O
informed	O
consent	O
and	O
assent	O
(	O
if	O
applicable	O
)	O
.	O

8	O
.	O

Subject	O
and	O
/	O
or	O
caregiver	O
are	O
willing	O
to	O
comply	O
with	O
the	O
study	O
procedures	O
and	O
complete	O
the	O
entire	O
study	O
as	O
specified	O
in	O
the	O
protocol	O
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

Life	B-Observation
expectancy	I-Observation
<	O
2	O
years	O
.	O

2	O
.	O

Subject	O
who	O
had	O
or	O
has	O
cancer	B-Condition
and	O
is	O
undergoing	O
cancer	B-Drug
therapy	I-Drug
.	O

3	O
.	O

Previous	O
course	O
of	O
abdominal,	B-Procedure_Device
cranial	I-Procedure_Device
or	I-Procedure_Device
neck	I-Procedure_Device
radiotherapy	I-Procedure_Device
or	O
chemotherapy	B-Drug
.	O

4	O
.	O

Patients	O
with	O
neck	B-Condition
calcifications	I-Condition
may	O
be	O
excluded	O
.	O

5	O
.	O

Subject	O
with	O
uncontrolled	O
heart	B-Condition
disease	I-Condition
renal	B-Condition
disease	I-Condition
or	O
liver	B-Condition
disease	I-Condition
.	O

6	O
.	O

Subject	O
with	O
diabetes	B-Condition
mellitus	I-Condition
whose	O
glycoslated	B-Observation
Hb	I-Observation
(	I-Observation
A1C	I-Observation
)	I-Observation
>	O
7	O
.	O

7	O
.	O

Complete	B-Observation
blood	I-Observation
count	I-Observation
(	I-Observation
CBC	I-Observation
)	I-Observation
with	O
white	B-Observation
blood	I-Observation
cell	I-Observation
<	O
4000	O
or	O
platelets	B-Observation
>	O
125000	O
.	O

8	O
.	O

Subject	O
with	O
uncontrollable	O
hypertension	B-Condition
(	I-Condition
HTN	I-Condition
)	I-Condition
.	O

9	O
.	O

Subject	O
with	O
previous	O
abdominal	B-Procedure_Device
surgery	I-Procedure_Device
or	O
disorder	B-Condition
that	O
could	O
negatively	O
influence	O
the	O
outcome	O
of	O
the	O
OT	B-Procedure_Device
surgery	I-Procedure_Device
.	O

10	O
.	O

Subject	O
who	O
has	O
had	O
a	O
craniotomy	B-Procedure_Device
in	O
the	O
past	O
.	O

11	O
.	O

Recent	O
major	B-Procedure_Device
surgery	I-Procedure_Device
within	O
the	O
past	O
6	O
months	O
.	O

12	O
.	O

Use	O
of	O
cholinesterase	B-Drug
inhibitors	I-Drug
within	O
the	O
last	O
30	O
days	O
and	O
inability	O
to	O
not	O
take	O
cholinesterase	B-Drug
inhibitors	I-Drug
throughout	O
the	O
length	O
of	O
the	O
study	O
(	O
about	O
25	O
mos	O
)	O
.	O

13	O
.	O

Subject	O
uses	O
non-prescribed	B-Condition
drugs	I-Condition
of	I-Condition
abuse	I-Condition
or	O
has	O
a	O
history	O
of	O
drug	B-Condition
or	I-Condition
alcohol	I-Condition
abuse	I-Condition
/	I-Condition
dependence	I-Condition
.	O

14	O
.	O

Use	O
of	O
anticoagulants	B-Drug
other	B-Negation_cue
then	I-Negation_cue
anti-platelet	B-Drug
medications	I-Drug
.	O

15	O
.	O

Subject	O
has	O
significant	O
central	B-Condition
nervous	I-Condition
system	I-Condition
(	I-Condition
CNS	I-Condition
)	I-Condition
disorder	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
.	O

16	O
.	O

Subject	O
has	O
clinical	O
evidence	O
or	O
history	O
of	O
stroke	B-Condition
,	O
transient	B-Condition
ischemic	I-Condition
attack	I-Condition
significant	O
head	B-Condition
injury	I-Condition
or	O
other	O
unexplained	O
or	O
recurrent	O
loss	B-Condition
of	I-Condition
consciousness	I-Condition
>=	O
15	O
minutes	O
.	O

17	O
.	O

Major	B-Condition
depressive	I-Condition
disorder	I-Condition
schizophrenia	B-Condition
,	O
other	O
psychotic	B-Condition
disorders	I-Condition
or	O
bipolar	B-Condition
disorder	I-Condition
.	O

18	O
.	O

Subject	O
has	O
epilepsy	B-Condition
.	O

19	O
.	O

Patients	O
with	O
severe	O
extra	B-Condition
pyramidal	I-Condition
signs	I-Condition
.	O

20	O
.	O

Patients	O
with	O
plastic	B-Procedure_Device
surgery	I-Procedure_Device
of	O
the	O
neck	O
or	O
face	O
.	O

21	O
.	O

Subject	O
resides	O
in	O
hospital	O
or	O
moderate	O
to	O
high	O
dependency	O
continuous	O
care	O
facility	O
.	O

22	O
.	O

Non-English	O
speaking	O
subjects	O
and	O
/	O
or	O
caregivers	O
.	O

23	O
.	O

Subject	O
has	O
any	O
condition	O
that,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
would	O
preclude	O
the	O
use	O
of	O
the	O
study	O
procedure,	O
may	O
interfere	O
with	O
the	O
evaluation	O
of	O
the	O
procedure-related	O
outcomes	O
or	O
preclude	O
the	O
subject	O
from	O
completing	O
the	O
follow-up	O
requirements	O
.	O

>>NCT01430286	O
Inclusion	O
criteria	O
:	O
.	O

-	O
Family	O
caregivers	O
of	O
AD	B-Condition
patients	O
DSM	B-Observation
IV-TR	I-Observation
(	O
American	O
Psychiatric	O
Association	O
2004	O
)	O
or	O
NINCDS	B-Observation
/	I-Observation
ADRDA	I-Observation
(	O
McKhann	O
et	O
al	O
.	O

1984	O
)	O
.	O

-	O
Age	B-Observation
:	O
over	O
18	O
years	O
old	O
.	O

-	O
score	O
12	O
or	O
over	O
on	O
the	O
Perceived	B-Observation
Stress	I-Observation
Scale	I-Observation
14	I-Observation
items	I-Observation
(	O
PSS-	O
14,	O
Cohen	O
)	O
Need	O
for	O
information	O
or	O
help	O
.	O

-	O
Sign	O
informed	O
consent	O
.	O

Exclusion	O
criteria	O
:	O
.	O

-	O
Professional	O
or	O
paid	O
caregiver	O
.	O

-	O
Physical	B-Condition
or	I-Condition
mental	I-Condition
disease	I-Condition
incompatible	O
with	O
patient's	O
management	O
.	O

-	O
Impossibility	O
to	O
participate	O
in	O
the	O
educational	O
program	O
.	O

-	O
Absence	O
of	O
perceived	O
stress	O
.	O

-	O
Ongoing	O
psychotherapy	B-Procedure_Device
or	O
a	O
similar	O
program	O
in	O
parallel	O
.	O

>>NCT01600469	O
Inclusion	O
Criteria:	O
.	O

-	O
Clinical	O
diagnosis	O
of	O
mild	B-Condition
cognitive	I-Condition
impairment	I-Condition
or	O
mild	O
Alzheimer's	B-Condition
.	O

-	O
MMSE	B-Observation
between	O
17	O
-	O
26	O
.	O

-	O
CDR	B-Observation
0.5	O
or	O
1	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Hachinski	B-Observation
Ischemic	I-Observation
Score	I-Observation
>	O
4	O
.	O

-	O
substance	B-Condition
abuse	I-Condition
/	I-Condition
dependence	I-Condition
.	O

-	O
Parkinson	B-Condition
disease	I-Condition
.	O

-	O
epilepsy	B-Condition
.	O

-	O
major	B-Condition
depressive	I-Condition
disorder	I-Condition
.	O

-	O
dementia	B-Condition
with	I-Condition
psychotic	I-Condition
features	I-Condition
.	O

-	O
major	O
physical	B-Condition
illnesses	I-Condition
.	O

-	O
severe	O
visual	B-Condition
or	I-Condition
hearing	I-Condition
impairment	I-Condition
.	O

>>NCT00814801	O
Inclusion	O
Criteria:	O
.	O

-	O
Outpatients	O
with	O
a	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
the	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
the	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINCDS-ADRDA	I-Observation
)	I-Observation
criteria	I-Observation
.	O

-	O
Having	O
a	O
Mini-Mental	B-Observation
Status	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
of	O
10	O
-	O
22	O
inclusive	O
.	O

-	O
Having	O
an	O
Alzheimer's	B-Observation
Disease	I-Observation
Assessment	I-Observation
Scale	I-Observation
-	I-Observation
Japan	I-Observation
cognitive	I-Observation
subscale	I-Observation
(	I-Observation
ADAS-J	I-Observation
cog	I-Observation
)	I-Observation
score	I-Observation
of	O
at	O
least	O
18	O
.	O

-	O
Exhibiting	O
an	O
onset	O
and	O
progression	O
of	O
cognitive	B-Condition
dysfunction	I-Condition
during	O
at	O
least	O
6	O
months	O
prior	O
to	O
the	O
screening	O
period	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Patients	O
with	O
neurodegenerative	B-Condition
diseases	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
such	O
as	O
Lewy	B-Condition
bodies	I-Condition
disease	I-Condition
(	O
dementia	B-Condition
due	O
to	O
tiny	O
round	O
structures	O
made	O
of	O
proteins	O
that	O
develop	O
within	O
nerve	O
cells	O
in	O
the	O
brain	O
),	O
Parkinsonism	B-Condition
,	O
etc	O
.	O

-	O
Patients	O
with	O
cognitive	B-Condition
dysfunction	I-Condition
due	O
to	O
cerebral	B-Condition
damage	I-Condition
resulting	O
from	O
a	O
lack	B-Condition
of	I-Condition
oxygen	I-Condition
a	O
brain	B-Condition
injury	I-Condition
etc	O
.	O

-	O
Patients	O
with	O
multi-infarct	B-Condition
dementia	I-Condition
(	O
brought	O
on	O
by	O
a	O
series	O
of	O
strokes	B-Condition
)	O
or	O
active	O
cerebrovascular	B-Condition
disease	I-Condition
.	O

-	O
Patients	O
with	O
clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
.	O

-	O
Patients	O
currently	O
taking	O
drugs	B-Drug
such	O
as	O
a	O
cholinesterase	B-Drug
inhibitors	I-Drug
which	O
improve	O
cerebral	B-Condition
circulation	I-Condition
/	I-Condition
metabolism	I-Condition
.	O

>>NCT02518412	O
Inclusion	O
Criteria:	O
.	O

-	O
Alzheimers	B-Condition
disease	I-Condition
according	O
to	O
(	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Disorders	O
and	O
Stroke	O
and	O
the	O
Alzheimer's	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
)	O
.	O

-	O
The	O
cognitive	B-Condition
impairment	I-Condition
and	I-Condition
decline	I-Condition
must	O
be	O
documented	O
by	O
cognitive	B-Observation
/	I-Observation
neuropsychological	I-Observation
testing	I-Observation
and	O
from	O
an	O
informant	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Stroke	B-Condition
,	O
.	O

-	O
Cancer	B-Condition
,	O
.	O

-	O
Psychiatric	B-Condition
disorders	I-Condition
(	O
major	B-Condition
depression	I-Condition
psychosis	B-Condition
)	O
or	O
diseases	B-Condition
/	O
injuries	B-Condition
in	O
the	O
central	O
nervous	O
system.	O

>>NCT00088751	O
-	O
INCLUSION	O
CRITERIA:	O
.	O

1	O
.	O

FTD	B-Condition
as	O
diagnosed	O
by	O
the	O
Lund-Manchester	B-Observation
criteria	I-Observation
including	O
patients	O
with	O
diagnoses	O
of	O
Semantic	B-Condition
Dementia	I-Condition
or	O
Primary	B-Condition
Progressive	I-Condition
Aphasia	I-Condition
.	O

2	O
.	O

Ages	B-Observation
45	O
to	O
95	O
years	O
old	O
.	O

3	O
.	O

Mild-to-moderate	O
(	O
CDR	B-Observation
1	O
to	O
2	O
)	O
FTD	B-Condition
with	O
an	O
assigned	O
durable	O
power	O
of	O
attorney	O
.	O

EXCLUSION	O
CRITERIA:	O
.	O

1	O
.	O

Diagnosis	O
of	O
any	O
form	O
of	O
dementia	B-Condition
besides	O
FTD	B-Condition
,	O
including	O
AD	B-Condition
,	O
Lewy	B-Condition
body	I-Condition
dementia	I-Condition
vascular	B-Condition
dementia	I-Condition
dementia	B-Condition
associated	I-Condition
with	I-Condition
Parkinson's	I-Condition
disease	I-Condition
Corticobasal	B-Condition
Degeneration	I-Condition
and	O
Progressive	B-Condition
Supranuclear	I-Condition
Palsy	I-Condition
.	O

2	O
.	O

Severe	O
dementia	B-Condition
(	O
CDR	B-Observation
3	O
)	O
.	O

3	O
.	O

Known	O
allergy	B-Condition
or	O
serious	O
adverse	B-Condition
reaction	I-Condition
to	O
quetiapine	B-Drug
or	O
dextroamphetamine	B-Drug
.	O

4	O
.	O

Patient	O
is	O
already	O
receiving	O
a	O
stimulant	B-Drug
(	O
methylphenidate	B-Drug
,	O
dextroamphetamine	B-Drug
,	O
pemoline	B-Drug
or	O
modafinil	B-Drug
)	O
or	O
an	O
antipsychotic	B-Drug
medication	I-Drug
typical	O
or	O
atypical,	O
including	O
prochlorperazine	B-Drug
and	O
metoclopromide	B-Drug
.	O

5	O
.	O

Patients	O
taking	O
any	O
of	O
the	O
following	O
medications	O
because	O
of	O
their	O
potential	O
interaction	O
with	O
dextroamphetamine:	O
MAO	B-Drug
use	O
currently	O
or	O
within	O
14	O
days	O
prior	O
to	O
start	O
of	O
study,	O
Furazolidone	B-Drug
,	O
Guanethidine	B-Drug
,	O
norepinephrine	B-Drug
,	O
sibutramine	B-Drug
,	O
tricyclic	B-Drug
antidepressants	I-Drug
carbonic	B-Drug
anhydrase	I-Drug
inhibitors	I-Drug
.	O

6	O
.	O

Patients	O
taking	O
the	O
following	O
medications	O
because	O
of	O
their	O
potential	O
interaction	O
with	O
quetiapine:	O
Carbamazepine	B-Drug
,	O
clozapine	B-Drug
,	O
lithium	B-Drug
,	O
thioridazine	B-Drug
.	O

7	O
.	O

History	O
of	O
CVA	B-Condition
or	O
at	O
significantly	O
increased	O
risk	B-Condition
for	O
CVA	B-Condition
(	O
eg	O
,	O
atrial	B-Condition
fibrillation	I-Condition
recent	O
TIA	B-Condition
etc.)	O
.	O

8	O
.	O

Symptomatic	B-Condition
cardiovascular	I-Condition
disease	I-Condition
(	O
i.e.,	O
angina	B-Condition
,	O
claudication	B-Condition
,	O
TIAs	B-Condition
,	O
syncope	B-Condition
),	O
uncontrolled	O
hyper	B-Condition
or	I-Condition
hypotension	I-Condition
or	O
a	O
tic	B-Condition
disorder	I-Condition
.	O

9	O
.	O

Any	O
medical	O
contraindication	B-Condition
to	O
performing	O
the	O
procedures	O
involved	O
in	O
the	O
study	O
including	O
blood	B-Procedure_Device
draws	I-Procedure_Device
or	O
lumbar	B-Procedure_Device
puncture	I-Procedure_Device
.	O

10	O
.	O

We	O
will	O
require	O
a	O
woman	O
of	O
child-bearing	B-Observation
age	I-Observation
to	O
have	O
a	O
pregnancy	B-Observation
test	I-Observation
prior	O
to	O
starting	O
the	O
study	O
medications	O
and	O
to	O
use	O
contraception	O
during	O
the	O
course	O
of	O
the	O
study	O
.	O

11	O
.	O

Patients	O
with	O
a	O
previous	O
negative	O
trial	O
of	O
a	O
stimulant	B-Drug
.	O

12	O
.	O

Patients	O
with	O
a	O
history	O
of	O
severe	O
psychosis	B-Condition
.	O

13	O
.	O

Patients	O
with	O
a	O
history	O
of	O
recent	O
substance	B-Condition
abuse	I-Condition
.	O

14	O
.	O

Patients	O
with	O
QTc	B-Observation
prolongation	I-Observation
on	O
a	O
baseline	B-Procedure_Device
EKG	I-Procedure_Device
.	O

15	O
.	O

A	O
score	O
of	O
2	O
or	O
less	O
on	O
the	O
Communication	B-Observation
Functional	I-Observation
Ratings	I-Observation
-	I-Observation
Swallowing	I-Observation
Domain	I-Observation
.	O

>>NCT01979432	O
Inclusion	O
Criteria:	O
.	O

-	O
free-living	O
community-dwelling	O
men	O
and	O
women	O
aged	B-Observation
>=	O
70	O
years,	O
.	O

-	O
subjects	O
free	B-Negation_cue
of	O
clinical	B-Condition
CVD	I-Condition
related	O
to	O
atherosclerosis	B-Condition
.	O

-	O
preserved	O
basic	O
activities	O
of	O
daily	O
living	O
(	O
ADL	B-Observation
=	O
6	O
)	O
.	O

-	O
without	B-Negation_cue
cognitive	B-Condition
impairment	I-Condition
(	O
MMSE	B-Observation
>=	O
24	O
)	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
subjects	O
with	O
clinical	O
history	O
of	O
any	O
of	O
the	O
following	O
CVD	B-Condition
diseases	I-Condition
:	O
coronary	B-Condition
artery	I-Condition
disease	I-Condition
(	O
angina	B-Condition
,	O
myocardial	B-Condition
infarction	I-Condition
coronary	B-Procedure_Device
revascularization	I-Procedure_Device
),	O
cerebrovascular	B-Condition
disease	I-Condition
(	O
stroke	B-Condition
,	O
TIA	B-Condition
,	O
carotid	B-Condition
revascularization	I-Condition
),	O
clinical	B-Condition
peripheral	I-Condition
artery	I-Condition
disease	I-Condition
(	O
claudication	B-Condition
,	O
critical	B-Condition
limb	I-Condition
ischemia	I-Condition
)	O
.	O

-	O
subjects	O
with	O
neurodegenerative,	B-Condition
locomotor	I-Condition
and	I-Condition
ophtalmological	I-Condition
diseases	I-Condition
unable	O
to	O
perform	O
the	O
cognitive	O
tests	O
.	O

-	O
subjects	O
unable	O
to	O
give	O
written	O
informed	O
consent	O
.	O

>>NCT02608021	O
Inclusion	O
Criteria:	O
.	O

1	O
.	O

Clinical	O
diagnosis	O
based	O
on	O
recent	O
(	O
within	O
1	O
year	O
)	O
consensus	O
meeting,	O
cross-referenced	O
with	O
standard	B-Observation
neuropsychological	I-Observation
scores	I-Observation
.	O

-	O
Cognitively	B-Condition
Normal	I-Condition
(	I-Condition
CN	I-Condition
)	I-Condition
Subjects:	O
based	O
on	O
MMSE	B-Observation
scores	I-Observation
CDR	B-Observation
and	O
GDS	B-Observation
.	O

-	O
Amnestic	B-Condition
Mild	I-Condition
Cognitive	I-Condition
Impairment	I-Condition
(	I-Condition
aMCI	I-Condition
)	I-Condition
Subjects:	O
Diagnosis	O
of	O
aMCI	B-Condition
,	O
based	O
on	O
MMSE	B-Observation
scores	I-Observation
CDR	B-Observation
and	O
GDS	B-Observation
.	O

2	O
.	O

Normal	O
or	O
corrected-to-normal	O
vision	B-Observation
and	I-Observation
hearing	I-Observation
(	O
able	O
to	O
see	O
images	O
on	O
computer	O
screen	O
and	O
hear	O
auditory	O
events	O
delivered	O
through	O
the	O
computer	O
speaker	O
)	O
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

Significant	O
history	O
of	O
mental	B-Condition
illness	I-Condition
drug	B-Condition
or	I-Condition
alcohol	I-Condition
abuse	I-Condition
severe	O
trauma	B-Condition
preventing	O
normal	O
use	O
of	O
dominant	O
hand	O
(	O
needed	O
to	O
move	O
the	O
mouse	O
cursor	O
);	O
clinical	B-Condition
depression	I-Condition
(	O
unless	B-Negation_cue
medically	O
controlled	O
);	O
other	O
neurologic	B-Condition
conditions	I-Condition
(	O
i.e	O
.	O

stroke	B-Condition
)	O
or	O
learning	B-Condition
disability	I-Condition
ophthalmologic	B-Condition
/	I-Condition
visual	I-Condition
problems	I-Condition
that	O
prevent	O
viewing	O
a	O
computer	O
screen	O
at	O
a	O
normal	O
distance	O
(	O
such	O
as	O
legal	B-Condition
blindness	I-Condition
detached	B-Condition
retinas	I-Condition
occlusive	B-Condition
cataracts	I-Condition
)	O
.	O

2	O
.	O

Having	O
pacemakers	B-Procedure_Device
,	O
aneurysm	B-Procedure_Device
clips	I-Procedure_Device
cochlear	B-Procedure_Device
implants	I-Procedure_Device
pulse	B-Procedure_Device
oximeters	I-Procedure_Device
EKG	B-Procedure_Device
leads	I-Procedure_Device
tattoos	B-Procedure_Device
or	O
other	O
metal	B-Procedure_Device
/	I-Procedure_Device
foreign	I-Procedure_Device
objects	I-Procedure_Device
in	O
body	O
or	O
face	O
and	O
therefore	O
unable	O
to	O
receive	O
MRI	B-Procedure_Device
.	O

3	O
.	O

Lack	O
the	O
capacity	O
to	O
give	O
informed	O
consent	O
and	O
lack	O
of	O
an	O
authorized	O
surrogate	O
to	O
provide	O
consent	O
if	O
the	O
prospective	O
subject	O
is	O
found	O
to	O
lack	O
adequate	O
consent	O
capacity	O
.	O

4	O
.	O

Pregnancy	B-Condition
,	O
breastfeeding	B-Condition
or	O
planning	O
to	O
have	O
a	O
baby	O
.	O

>>NCT02509117	O
Inclusion	O
Criteria:	O
.	O

-	O
Healthy	B-Condition
male	O
and	O
/	O
or	O
female	O
subjects	O
of	O
non-childbearing	B-Condition
potential	I-Condition
between	O
the	O
ages	B-Observation
of	O
18	O
and	O
55	O
years	O
or	O
between	O
the	O
ages	B-Observation
of	O
65	O
and	O
85	O
years,	O
inclusive	O
.	O

-	O
Body	B-Observation
Mass	I-Observation
Index	I-Observation
(	I-Observation
BMI	I-Observation
)	I-Observation
of	O
17.5	O
to	O
30.5	O
kg	O
/	O
m2;	O
and	O
a	O
total	B-Observation
body	I-Observation
weight	I-Observation
>	O
50	O
kg	O
(	O
110	O
lbs	O
)	O
at	O
Screening	O
.	O

-	O
Evidence	O
of	O
a	O
personally	O
signed	O
and	O
dated	O
informed	O
consent	O
document	O
indicating	O
that	O
the	O
subject	O
or	O
a	O
legally	O
acceptable	O
representative	O
has	O
been	O
informed	O
of	O
all	O
pertinent	O
aspects	O
of	O
the	O
study	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Evidence	O
or	O
history	O
of	O
clinically	O
significant	O
hematological,	B-Condition
renal,	I-Condition
endocrine,	I-Condition
pulmonary,	I-Condition
gastrointestinal,	I-Condition
cardiovascular,	I-Condition
hepatic,	I-Condition
psychiatric,	I-Condition
neurologic	I-Condition
or	I-Condition
allergic	I-Condition
disease	I-Condition
(	O
including	O
drug	B-Condition
allergies	I-Condition
but	O
excluding	B-Negation_cue
untreated	B-Condition
,	O
asymptomatic,	B-Condition
seasonal	I-Condition
allergies	I-Condition
at	O
the	O
time	O
of	O
dosing	O
)	O
.	O

-	O
Male	O
subjects	O
with	O
partners	O
currently	O
pregnant;	O
male	O
subjects	O
able	O
to	O
father	O
children	O
who	O
are	O
unwilling	O
or	O
unable	O
to	O
use	O
a	O
highly	O
effective	O
method	O
of	O
contraception	O
as	O
outlined	O
in	O
this	O
protocol	O
for	O
the	O
duration	O
of	O
the	O
study	O
and	O
for	O
at	O
least	O
28	O
days	O
after	O
the	O
last	O
dose	O
of	O
investigational	O
product	O
.	O

-	O
Unwilling	O
or	O
unable	O
to	O
comply	O
with	O
the	O
Lifestyle	O
Guidelines	O
described	O
in	O
this	O
protocol	O
.	O

-	O
Subjects	O
who	O
are	O
investigational	O
site	O
staff	O
members	O
directly	O
involved	O
in	O
the	O
conduct	O
of	O
the	O
study	O
and	O
their	O
family	O
members,	O
site	O
staff	O
members	O
otherwise	O
supervised	O
by	O
the	O
Investigator	O
or	O
subjects	O
who	O
are	O
Pfizer	O
employees	O
directly	O
involved	O
in	O
the	O
conduct	O
of	O
the	O
study	O
.	O

-	O
Any	O
severe	O
acute	O
or	O
chronic	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
condition	I-Condition
including	O
recent	O
(	O
within	O
the	O
past	O
year	O
)	O
or	O
active	O
suicidal	B-Condition
ideation	I-Condition
or	O
behavior	B-Condition
or	I-Condition
laboratory	I-Condition
abnormality	I-Condition
that	O
may	O
increase	O
the	O
risk	O
associated	O
with	O
study	O
participation	O
or	O
investigational	O
product	O
administration	O
or	O
may	O
interfere	O
with	O
the	O
interpretation	O
of	O
study	O
results	O
and,	O
in	O
the	O
judgment	O
of	O
the	O
Investigator,	O
would	O
make	O
the	O
subject	O
inappropriate	O
for	O
entry	O
into	O
this	O
study	O
.	O

>>NCT02260700	O
Inclusion	O
Criteria:	O
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
(	O
BMI	B-Observation
;	O
weight	O
[kilogram	O
(	O
kg	O
)]/height^2	O
[meter	O
square	O
(	O
m^2	O
)])	O
between	O
18	O
and	O
30	O
kg	O
/	O
m^2,	O
(	O
inclusive	O
)	O
.	O

-	O
Be	O
healthy	B-Condition
for	O
their	O
age	O
group	O
with	O
or	O
without	O
medication	O
on	O
the	O
basis	O
of	O
physical	B-Observation
examination	I-Observation
medical	B-Observation
history	I-Observation
vital	B-Observation
signs	I-Observation
and	O
12	B-Procedure_Device
-lead	I-Procedure_Device
electrocardiogram	I-Procedure_Device
(	I-Procedure_Device
ECG	I-Procedure_Device
)	I-Procedure_Device
performed	O
at	O
Screening	O
or	O
admission	O
.	O

Minor	O
deviations	O
in	O
ECG	B-Procedure_Device
,	O
which	O
are	O
not	B-Negation_cue
considered	O
to	O
be	O
of	O
clinical	O
significance	O
to	O
the	O
investigator,	O
are	O
acceptable	O
.	O

-	O
Be	O
healthy	B-Condition
on	O
the	O
basis	O
of	O
clinical	B-Observation
laboratory	I-Observation
tests	I-Observation
performed	O
at	O
Screening	O
.	O

If	O
the	O
results	O
of	O
the	O
serum	B-Observation
chemistry	I-Observation
panel	I-Observation
[including	O
liver	B-Observation
enzymes	I-Observation
hematology	B-Observation
or	O
urinalysis	B-Observation
are	O
outside	O
the	O
normal	O
reference	O
ranges,	O
the	O
participant	O
may	O
be	O
included	O
only	O
if	O
the	O
investigator	O
judges	O
the	O
abnormalities	B-Condition
or	O
deviations	B-Condition
from	I-Condition
normal	I-Condition
to	O
be	O
not	B-Negation_cue
clinically	O
significant	O
.	O

This	O
determination	O
must	O
be	O
recorded	O
in	O
the	O
participants'	O
source	O
documents	O
and	O
initialed	O
by	O
the	O
investigator	O
.	O

-	O
Men	O
who	O
are	O
sexually	O
active	O
with	O
a	O
woman	O
of	O
childbearing	O
potential	O
and	O
have	O
not	O
had	O
a	O
vasectomy	O
must	O
agree	O
to	O
use	O
a	O
barrier	O
method	O
of	O
birth	O
control	O
for	O
example,	O
either	O
condom	O
with	O
spermicidal	O
foam	O
/	O
gel	O
/	O
film	O
/	O
cream	O
/	O
suppository	O
or	O
partner	O
with	O
occlusive	O
cap	O
(	O
diaphragm	O
or	O
cervical	O
/	O
vault	O
caps	O
)	O
with	O
spermicidal	O
foam	O
/	O
gel	O
/	O
film	O
/	O
cream	O
/	O
suppository	O
and	O
all	O
men	O
must	O
also	O
not	O
donate	O
sperm	O
during	O
the	O
study	O
and	O
for	O
3	O
months	O
after	O
receiving	O
the	O
last	O
dose	O
of	O
study	O
drug	O
.	O

In	O
addition,	O
their	O
female	O
partners	O
should	O
also	O
use	O
an	O
appropriate	O
method	O
of	O
birth	O
control	O
for	O
at	O
least	O
the	O
same	O
duration	O
.	O

-	O
Participants'	O
must	O
have	O
signed	O
an	O
informed	O
consent	O
document	O
indicating	O
that	O
they	O
understand	O
the	O
purpose	O
of	O
and	O
procedures	O
required	O
for	O
the	O
study	O
and	O
are	O
willing	O
to	O
participate	O
in	O
the	O
study	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Participant	O
has	O
a	O
clinically	O
significant	O
abnormal	O
physical	B-Observation
examination	I-Observation
vital	B-Observation
signs	I-Observation
or	O
12	B-Procedure_Device
lead	I-Procedure_Device
ECG	I-Procedure_Device
(	O
including	O
QTc	B-Observation
greater	O
than	O
(>)	O
450msec,	O
Left	B-Condition
Bundle	I-Condition
Branch	I-Condition
Block	I-Condition
permanent	O
pacemaker	B-Procedure_Device
or	O
implantable	B-Procedure_Device
cardioverter	I-Procedure_Device
defibrillator	I-Procedure_Device
)	O
at	O
Screening	O
or	O
admission	O
.	O

-	O
Participant	O
has	O
a	O
history	O
of	O
or	O
current	O
liver	B-Condition
or	I-Condition
renal	I-Condition
insufficiency	I-Condition
significant	O
cardiac,	B-Condition
vascular,	I-Condition
pulmonary,	I-Condition
gastrointestinal,	I-Condition
endocrine,	I-Condition
neurologic,	I-Condition
hematologic,	I-Condition
rheumatologic,	I-Condition
psychiatric	I-Condition
or	I-Condition
metabolic	I-Condition
disturbances	I-Condition
.	O

-	O
Use	O
of	O
any	O
prescription	O
or	O
over-the-counter	B-Drug
medication	I-Drug
herbal	B-Drug
medication	I-Drug
vitamins	B-Drug
or	O
mineral	B-Drug
supplements	I-Drug
within	O
14	O
days	O
prior	O
to	O
study	O
drug	O
administration	O
(	O
not	B-Negation_cue
including	O
paracetamol	B-Drug
)	O
.	O

Medication	O
for	O
chronic	O
use	O
in	O
age	O
related	O
disease	O
will	O
be	O
allowed	O
after	O
approval	O
by	O
both	O
the	O
investigator	O
and	O
to	O
the	O
sponsor	O
.	O

No	O
change	O
in	O
dose	O
or	O
regimen	O
will	O
be	O
permitted	O
during	O
the	O
study	O
that	O
is,	O
from	O
the	O
Screening	O
visit	O
until	O
the	O
follow-up	O
visit	O
.	O

-	O
Participant	O
has	O
a	O
history	O
of	O
spontaneous,	B-Condition
prolonged	I-Condition
or	I-Condition
severe	I-Condition
bleeding	I-Condition
of	I-Condition
unclear	I-Condition
origin	I-Condition
.	O

-	O
Participant	O
has	O
a	O
history	O
of	O
epilepsy	B-Condition
or	O
fits	B-Condition
or	O
unexplained	O
black-outs	B-Condition
other	B-Negation_cue
than	I-Negation_cue
vasovagal	B-Condition
collapse	I-Condition

>>NCT00702780	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Age	B-Observation
:	O
40	O
-	O
90	O
years	O
.	O

-	O
Education	O
:	O
not	O
illiterate	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
0.5	O
-	O
2	O
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
Ischemic	I-Observation
Score	I-Observation
(	O
Rosen	O
et	O
al.,	O
1979	O
):	O
less	O
than	O
4	O
.	O

-	O
Dementia	B-Condition
according	O
to	O
DSM-IV	B-Observation
criteria	I-Observation
.	O

-	O
Probable	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
.	O

-	O
Current	O
ongoing	O
donepezil	B-Drug
medication	I-Drug
at	O
stable	O
doses	O
(	O
5	O
-	O
10	O
mg	O
/	O
day	O
)	O
for	O
at	O
least	O
2	O
months	O
.	O

Exclusion	O
criteria	O
:	O
.	O

-	O
Evidence	O
of	O
delirium	B-Condition
,	O
confusion	B-Condition
or	O
altered	B-Condition
consciousness	I-Condition
.	O

-	O
Evidence	O
of	O
Parkinson's	B-Condition
disease	I-Condition
stroke	B-Condition
,	O
brain	B-Condition
tumor	I-Condition
and	O
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
.	O

-	O
Evidence	O
of	O
infectious	B-Condition
or	I-Condition
inflammatory	I-Condition
brain	I-Condition
disease	I-Condition
.	O

-	O
Evidence	O
of	O
serious	O
cerebrovascular	B-Condition
diseases	I-Condition
.	O

-	O
Current	O
major	O
depressive	B-Condition
disorder	I-Condition
or	O
other	O
major	O
psychiatric	B-Condition
illnesses	I-Condition
.	O

-	O
Evidence	O
of	O
serious	O
or	O
unstable	O
medical	B-Condition
illnesses	I-Condition
which	O
can	O
significantly	O
change	O
cognitive	O
state	O
.	O

-	O
History	O
of	O
alcohol	B-Condition
or	I-Condition
other	I-Condition
substance	I-Condition
dependence	I-Condition
.	O

-	O
Any	O
antidepressant	B-Drug
medications	I-Drug
within	O
the	O
previous	O
4	O
weeks	O
.	O

-	O
Absence	O
of	O
a	O
reliable	O
and	O
cooperative	O
collateral	O
informant	O
.	O

-	O
Any	O
conditions	B-Condition
which	O
prohibit	B-Negation_cue
MRI	B-Procedure_Device
scan	I-Procedure_Device
such	O
as	O
presence	O
of	O
pacemaker	B-Procedure_Device
or	O
cerebrovascular	B-Procedure_Device
clip	I-Procedure_Device
and	O
claustrophobia	B-Condition
.	O

-	O
Evidence	O
of	O
focal	B-Condition
brain	I-Condition
lesions	I-Condition
on	O
MRI	B-Procedure_Device
including	O
lacunes	B-Condition
and	O
white	B-Condition
matter	I-Condition
hyperintensity	I-Condition
lesions	I-Condition
of	O
grade	O
2	O
or	O
more	O
by	O
Fazeka	B-Observation
scale	I-Observation
.	O

>>NCT00285025	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Male	O
/	O
female	O
outpatients	O
.	O

-	O
Age	B-Observation
>	O
50	O
years	O
at	O
screening	O
.	O

-	O
Dementia	B-Condition
of	I-Condition
Alzheimers	I-Condition
Type	I-Condition
(	O
DSM-IV	B-Observation
290.0	I-Observation
)	O
according	O
to	O
DSM-IV	B-Observation
criteria	I-Observation
Probable	O
AD	B-Condition
according	O
to	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
score	I-Observation
>	O
12	O
and	O
<	O
26	O
.	O

-	O
Untreated	O
or	O
treated	O
for	O
a	O
minimum	O
of	O
6	O
months	O
before	O
randomization	O
with	O
a	O
stable	O
dose	O
of	O
the	O
cholinesterase	B-Drug
inhibitors	I-Drug
.	O

-	O
Generally	O
healthy	O
and	O
ambulatory	O
or	O
ambulatory-aided	O
(	O
i.e.,	O
walker	O
or	O
cane	O
)	O
.	O

-	O
Presence	O
of	O
a	O
reliable	O
caregiver	O
.	O

-	O
Patient,	O
identified	O
caregiver	O
and,	O
if	O
applicable,	O
patient	O
surrogate	O
(	O
primary	O
relative,	O
legal	O
guardian,	O
medical	O
proxy	O
)	O
have	O
given	O
their	O
informed	O
written	O
consent	O
and	O
are	O
capable	O
of	O
following	O
study	O
procedures	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Any	O
cause	O
of	O
dementia	B-Condition
not	B-Negation_cue
due	O
to	O
Alzheimers	B-Condition
disease	I-Condition
Delusions	B-Condition
,	O
delirium	B-Condition
,	O
psychosis	B-Condition
,	O
depression	B-Condition
or	O
other	O
significant	O
psychiatric	B-Condition
disorder	I-Condition
.	O

-	O
Treatment	O
with	O
any	O
registered	O
or	O
putative	O
cognitive	B-Drug
enhancer	I-Drug
or	O
disease	B-Drug
modifier	I-Drug
other	B-Negation_cue
than	I-Negation_cue
donepezil	B-Drug
,	O
rivastigmine	B-Drug
or	O
galantamine	B-Drug
.	O

-	O
Females	O
who	O
are	O
pregnant	B-Condition
or	O
breast-feeding	B-Condition
.	O

Females	O
of	O
child	B-Condition
bearing	I-Condition
potential	I-Condition
(	O
premenopausal	O
female	O
biologically	O
capable	O
of	O
becoming	O
pregnant	O
)	O
must	O
have	O
a	O
confirmed	O
negative	O
serum	B-Observation
bHCG	I-Observation
pregnancy	I-Observation
test	I-Observation
at	O
the	O
screening	O
visit	O
and	O
must	O
use	O
an	O
acceptable	O
method	O
of	O
birth	O
control	O
.	O

-	O
Severe	O
or	O
unstable	O
cardiovascular,	B-Condition
respiratory,	I-Condition
renal,	I-Condition
hematological,	I-Condition
endocrinological,	I-Condition
neurological	I-Condition
or	I-Condition
other	I-Condition
somatic	I-Condition
disease	I-Condition
.	O

-	O
Use	O
of	O
CYP3A4	B-Drug
strong	I-Drug
inhibitors	I-Drug
.	O

-	O
Evidence	O
(	O
detected	O
by	O
history	B-Observation
,	O
physical	B-Observation
examination	I-Observation
and	O
/	O
or	O
laboratory	B-Observation
/	O
ECG	B-Procedure_Device
tests	I-Procedure_Device
)	O
of	O
any	O
clinically	O
significant	O
or	O
unstable	O
medical	B-Condition
disorder	I-Condition
that	O
could	O
interfere	O
with	O
the	O
subject's	O
participation	O
in	O
the	O
clinical	O
trial;	O
interfere	O
with	O
the	O
absorption	B-Observation
,	O
metabolism	B-Observation
or	O
excretion	B-Observation
of	O
the	O
study	O
medication;	O
or	O
interfere	O
with	O
the	O
evaluation	O
of	O
the	O
study	O
drug	O
.	O

Alterations	O
of	O
laboratory	O
tests	O
or	O
ECG	O
findings	O
of	O
potential	O
clinical	O
significance	O
.	O

>>NCT01126099	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
No	O
age	O
limit	O
.	O

-	O
Probable	O
or	O
Possible	O
Alzheimer's	B-Condition
Disease	I-Condition
.	O

-	O
Disruptive	B-Condition
agitated	I-Condition
behaviors	I-Condition
at	O
least	O
twice	O
a	O
week	O
(	O
overly	O
anxious	O
or	O
excited,	O
making	O
offensive	O
comments.....)	O
.	O

-	O
Stable	O
medications	B-Drug
for	O
2	O
weeks	O
.	O

-	O
Must	O
have	O
a	O
caregiver	O
who	O
spends	O
10	O
hours	O
per	O
week	O
caring	O
for	O
the	O
participant	O
and	O
agrees	O
to	O
participate	O
in	O
all	O
evaluation	O
sessions	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Cardiovascular	O
:	O
unstable	O
angina	B-Condition
,	O
recent	O
myocardial	B-Condition
infarction	I-Condition
preexisting	O
hypotension	B-Condition
(	O
systolic	B-Observation
BP	I-Observation
less	O
than	O
110	O
)	O
or	O
orthostatic	B-Condition
hypotension	I-Condition
(	O
>=	O
20	O
mmHg	O
drop	O
in	O
systolic	B-Observation
BP	I-Observation
following	O
2	O
minutes	O
of	O
standing	O
posture	O
)	O
.	O

-	O
Any	O
unstable	O
medical	B-Condition
condition	I-Condition
.	O

-	O
Exclusionary	B-Drug
medications	I-Drug
:	O
current	O
treatment	O
with	O
prazosin	B-Drug
,	O
other	O
alpha-	B-Drug
1	I-Drug
blockers	I-Drug
(	O
trazodone	B-Drug
,	O
sildenafil	B-Drug
,	O
vardenafil	B-Drug
or	O
tadalafil	B-Drug
)	O
.	O

-	O
Psychoactive	B-Drug
medications	I-Drug
:	O
subjects	O
may	O
be	O
psychoactive	B-Condition
medication-free	I-Condition
or	O
be	O
partial	O
responders	O
(	O
by	O
subjective	O
assessment	O
of	O
referring	O
health	O
care	O
professional	O
)	O
to	O
one	O
psychoactive	B-Drug
medication	I-Drug
from	O
any	O
of	O
the	O
following	O
classes	O
:	O
antipsychotics	B-Drug
,	O
anticonvulsants	B-Drug
,	O
mood	B-Drug
stabilizers	I-Drug
antidepressants	B-Drug
,	O
benzodiazepines	B-Drug
or	O
buspirone	B-Drug
.	O

Partial	O
response	O
is	O
defined	O
as	O
some	O
improvement	O
in	O
agitated	O
behavior	O
but	O
persistence	O
of	O
agitated	O
behaviors	O
severe	O
enough	O
to	O
cause	O
patient	O
distress	O
and	O
/	O
or	O
difficulty	O
with	O
caregiving	O
.	O

Although	O
not	O
formally	O
rated,	O
this	O
improvement	O
is	O
equivalent	O
to	O
a	O
Clinical	O
Global	O
Impression	O
of	O
Change	O
rating	O
of	O
no	O
more	O
than	O
minimal	O
improvement	O
(	O
improvement	O
is	O
noticed	O
by	O
not	O
enough	O
to	O
improve	O
patient	O
function	O
or	O
caregiver's	O
practical	O
management	O
of	O
the	O
patient	O
)	O
.	O

-	O
Psychiatric	O
/	O
behavioral	O
:	O
lifetime	O
schizophrenia	B-Condition
;	O
current	O
delirium	B-Condition
,	O
mania	B-Condition
,	O
depression	B-Condition
or	O
uncontrolled	O
persistent	O
distressing	B-Condition
psychotic	I-Condition
symptoms	I-Condition
(	O
hallucinations	B-Condition
,	O
delusions	B-Condition
),	O
substance	B-Condition
abuse	I-Condition
panic	B-Condition
disorder	I-Condition
or	O
any	O
behavior	O
which	O
poses	O
an	O
immediate	O
danger	O
to	O
patient	O
or	O
others	O
or	O
which	O
results	O
in	O
the	O
patient	O
being	O
too	O
uncooperative	O
to	O
meet	O
the	O
requirements	O
of	O
study	O
participation	O
.	O

>>NCT01388478	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Informed	O
consent	O
provided	O
by	O
the	O
participant	O
or	O
the	O
participant's	O
legally	O
acceptable	O
representative	O
.	O

-	O
Age	B-Observation
55	O
years	O
or	O
older	O
.	O

-	O
Possible	O
/	O
probable	O
Alzheimer's	B-Condition
Disease	I-Condition
(	I-Condition
AD	I-Condition
)	I-Condition
.	O

-	O
Community	O
dwelling	O
with	O
a	O
caregiver	O
able	O
and	O
willing	O
to	O
accompany	O
the	O
participant	O
on	O
all	O
visits,	O
if	O
necessary	O
.	O

Caregiver	O
must	O
visit	O
with	O
the	O
subject	O
>	O
5	O
times	O
per	O
week	O
.	O

-	O
Rosen	B-Observation
Modified	I-Observation
Hachinski	I-Observation
score	I-Observation
of	O
4	O
or	O
less	O
.	O

-	O
Imaging	B-Procedure_Device
Study	I-Procedure_Device
(	O
CT	B-Procedure_Device
or	O
MRI	B-Procedure_Device
)	O
compatible	O
with	O
AD	B-Condition
or	O
age-related	O
changes	O
(	O
absence	B-Negation_cue
of	O
significant	O
abnormalities	B-Condition
that	O
may	O
explain	O
cognitive	B-Condition
decline	I-Condition
such	O
as	O
multiple	B-Condition
lacunar	I-Condition
infarcts	I-Condition
or	O
a	O
single	B-Condition
prior	I-Condition
infarct	I-Condition
>	O
1	O
cubic	O
cm,	O
microhemorrhages	B-Condition
or	O
evidence	O
of	O
a	O
prior	O
hemorrhage	B-Condition
>	O
1	O
cubic	O
cm,	O
evidence	O
of	O
cerebral	B-Condition
contusion	I-Condition
encephalomalacia	I-Condition
aneurysm	B-Condition
,	O
vascular	B-Condition
malformation	I-Condition
or	O
space	B-Condition
occupying	I-Condition
lesion	I-Condition
such	O
as	O
an	O
arachnoid	B-Condition
cyst	I-Condition
or	O
brain	B-Condition
tumor	I-Condition
)	O
.	O

-	O
Adequate	O
visual	B-Observation
and	I-Observation
auditory	I-Observation
abilities	I-Observation
to	O
perform	O
all	O
aspects	O
of	O
the	O
cognitive	O
and	O
functional	O
assessments	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Significant	O
neurological	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
,	O
that	O
may	O
affect	O
cognition	O
.	O

-	O
Current	O
clinically-significant	O
systemic	B-Condition
illness	I-Condition
that	O
is	O
likely	O
to	O
result	O
in	O
deterioration	O
of	O
the	O
patient's	O
condition	O
or	O
affect	O
the	O
patient's	O
safety	O
during	O
the	O
study	O
.	O

-	O
History	O
of	O
clinically-evident	O
stroke	B-Condition
.	O

-	O
Clinically-significant	O
infection	B-Condition
within	O
the	O
last	O
30	O
days	O
.	O

-	O
Myocardial	B-Condition
infarction	I-Condition
or	O
symptoms	O
of	O
active	O
coronary	B-Condition
artery	I-Condition
disease	I-Condition
(	O
eg	O
,	O
angina	B-Condition
)	O
in	O
the	O
last	O
two	O
years	O
.	O

-	O
Uncontrolled	O
hypertension	B-Condition
within	O
the	O
last	O
6	O
months	O
.	O

-	O
History	O
of	O
cancer	B-Condition
within	O
the	O
last	O
5	O
years	O
(	O
except	B-Negation_cue
non-metastatic	B-Condition
basal	I-Condition
or	I-Condition
squamous	I-Condition
cell	I-Condition
carcinoma	I-Condition
)	O
.	O

-	O
History	O
of	O
drug	B-Condition
or	I-Condition
alcohol	I-Condition
abuse	I-Condition
as	O
defined	O
by	O
DSM-IV	B-Observation
criteria	I-Observation
within	O
the	O
last	O
2	O
years	O
.	O

-	O
Insulin	B-Condition
dependent	I-Condition
diabetes	I-Condition
mellitus	I-Condition
.	O

-	O
Significant	O
pain	B-Condition
or	O
musculoskeletal	B-Condition
disorder	I-Condition
that	O
would	O
prohibit	O
participation	O
in	O
metabolic	O
testing	O
.	O

>>NCT01707719	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Outpatients	O
of	O
both	O
sexes	O
diagnosed	O
with	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
.	O

-	O
Age	B-Observation
and	O
sex-matched	O
elderly	O
subjects	O
without	B-Negation_cue
dementia	B-Condition
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Recent	O
neoplasia	B-Condition
(	O
<	O
1	O
year	O
)	O
.	O

-	O
Vitamin	B-Condition
B12	I-Condition
deficiency	I-Condition
positive	O
serology	B-Observation
for	O
syphilis	B-Condition
,	O
thyroid	B-Condition
function	I-Condition
abnormalities	I-Condition
considered	O
to	O
be	O
significant	O
by	O
the	O
care	O
provider	O
.	O

-	O
Use	O
of	O
vitamin	B-Drug
or	O
mineral	B-Drug
supplements	I-Drug
.	O

-	O
Diagnosis	O
of	O
malnutrition	B-Condition
(	O
based	O
on	O
body	B-Observation
mass	I-Observation
index	I-Observation
and	O
total	B-Observation
protein	I-Observation
levels	I-Observation
)	O
.	O

-	O
Metabolic	B-Condition
syndrome	I-Condition
or	O
diabetes	B-Condition
.	O

-	O
Hormonal	B-Drug
replacement	I-Drug
therapy	I-Drug
.	O

-	O
Smoking	B-Observation
.	O

-	O
Chronic	O
inflammatory	B-Condition
disease	I-Condition
(	O
eg	O
rheumatoid	B-Condition
arthritis	I-Condition
)	O
and	O
any	O
other	O
acute	O
illness	B-Condition
.	O

>>NCT00299988	O
Inclusion	O
Criteria	O
:	O
.	O

1	O
.	O

Diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
(	I-Condition
AD	I-Condition
)	I-Condition
of	O
mild	O
to	O
moderate	O
severity	O
(	O
as	O
determined	O
by	O
a	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
of	O
14	O
-	O
26	O
inclusive	O
)	O
.	O

2	O
.	O

Ability	O
to	O
give	O
informed	O
consent,	O
designate	O
a	O
decision-maker	O
or	O
have	O
an	O
already	O
recognized	O
decision-maker	O
(	O
such	O
as	O
a	O
legal	O
guardian	O
or	O
health	O
care	O
proxy	O
)	O
.	O

3	O
.	O

Ability	O
to	O
comply	O
with	O
testing	O
and	O
infusion	O
regimen	O
.	O

4	O
.	O

An	O
able	O
caregiver	O
willing	O
to	O
participate	O
(	O
such	O
as	O
a	O
spouse,	O
child,	O
other	O
relative,	O
close	O
friend,	O
aide	O
or	O
other	O
professional	O
caregiver	O
closely	O
involved	O
in	O
helping	O
the	O
patient	O
take	O
care	O
of	O
himself	O
/	O
herself	O
)	O
.	O

5	O
.	O

Venous	O
access	O
suitable	O
for	O
repeated	O
infusion	O
and	O
phlebotomy	O
.	O

6	O
.	O

On	O
stable	O
doses	O
of	O
approved	B-Drug
AD	I-Drug
medications	I-Drug
for	O
at	O
least	O
3	O
months	O
.	O

7	O
.	O

As	O
applicable,	O
on	O
stable	O
doses	O
of	O
psychoactive	B-Drug
medications	I-Drug
(	O
eg	O
antidepressants	B-Drug
,	O
antipsychotics	B-Drug
)	O
for	O
at	O
least	O
6	O
weeks	O
.	O

8	O
.	O

Neuroimaging	B-Procedure_Device
performed	O
after	O
symptom	O
onset	O
consistent	O
with	O
the	O
patient's	O
diagnosis	O
.	O

9	O
.	O

Clinical	B-Observation
laboratory	I-Observation
values	I-Observation
within	O
normal	O
limits	O
or	O
if	O
abnormal,	O
judged	O
clinically	O
insignificant	O
by	O
the	O
Principal	O
Investigator	O
.	O

10	O
.	O

Women	O
who	O
want	O
to	O
take	O
part	O
in	O
this	O
study	O
must	O
either	O
be	O
post-menopausal	B-Condition
,	O
surgically	B-Condition
sterilized	I-Condition
or	O
agree	O
to	O
avoid	O
becoming	O
pregnant	O
during	O
the	O
entire	O
period	O
of	O
their	O
participation	O
in	O
this	O
study	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

1	O
.	O

Non-Alzheimer	B-Condition
dementia	I-Condition
.	O

2	O
.	O

Active	O
renal	B-Condition
disease	I-Condition
.	O

3	O
.	O

Abnormally	O
high	O
serum	B-Observation
viscosity	I-Observation
levels	I-Observation
.	O

4	O
.	O

Immunoglobulin	B-Condition
A	I-Condition
(	I-Condition
IgA	I-Condition
)	I-Condition
deficiency	I-Condition
.	O

5	O
.	O

Untreated	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
unstable	O
angina	B-Condition
or	O
a	O
history	O
of	O
recent	O
myocardial	B-Condition
infarction	I-Condition
.	O

6	O
.	O

Unstable	O
arrhythmia	B-Condition
.	O

7	O
.	O

Untreated	O
or	O
poorly	O
controlled	O
hypercholesterolemia	B-Condition
.	O

8	O
.	O

Untreated	O
or	O
poorly	O
controlled	O
hypertension	B-Condition
.	O

9	O
.	O

Poorly	O
controlled	O
diabetes	B-Condition
.	O

10	O
.	O

Thrombosis	B-Condition
(	O
central	O
or	O
peripheral	O
)	O
in	O
the	O
past	O
year	O
.	O

11	O
.	O

Modified	B-Observation
Hachinski	I-Observation
score	I-Observation
>	O
5	O
.	O

12	O
.	O

Active	O
cancer	B-Condition
diagnosis,	O
except	B-Negation_cue
basal	B-Condition
cell	I-Condition
carcinoma	I-Condition
.	O

13	O
.	O

Active	O
autoimmune	B-Condition
or	I-Condition
neuroimmunologic	I-Condition
disorder	I-Condition
.	O

14	O
.	O

History	O
of	O
IVIg	B-Drug
treatment	I-Drug
in	O
past	O
6	O
months	O
.	O

15	O
.	O

Untreated	O
major	B-Condition
depression	I-Condition
or	O
other	O
major	O
psychiatric	B-Condition
disorders	I-Condition
.	O

16	O
.	O

Known	O
coagulopathy	B-Condition
or	O
platelet	B-Observation
counts	I-Observation
<	O
100000	O
.	O

17	O
.	O

Positive	O
serology	B-Observation
for	O
Hepatitis	B-Observation
B	I-Observation
or	I-Observation
C	I-Observation
or	O
HIV	B-Observation
.	O

18	O
.	O

Active	O
migraines	B-Condition
or	O
frequent	O
headaches	B-Condition
(	O
3	O
or	O
more	O
times	O
per	O
week	O
)	O
.	O

19	O
.	O

Taking	O
immunosuppressive	B-Drug
drugs	I-Drug
.	O

20	O
.	O

Chronic	O
(	O
more	O
than	O
thrice	O
weekly	O
)	O
use	O
of	O
non-steroidal	B-Drug
anti-inflammatory	I-Drug
drugs	I-Drug
(	I-Drug
NSAIDs	I-Drug
)	I-Drug
excluding	B-Negation_cue
aspirin	B-Drug
81	O
milligrams	O
daily	O
.	O

21	O
.	O

Received	O
an	O
investigational	B-Drug
treatment	I-Drug
for	O
AD	B-Condition
within	O
3	O
months	O
of	O
study	O
entry	O
.	O

22	O
.	O

A	O
history	O
of	O
or	O
current	O
disorder	B-Condition
or	O
disease	B-Condition
that	O
in	O
a	O
physician	O
co-investigator's	O
judgment	O
may	O
impede	O
the	O
subject's	O
participation	O
in	O
the	O
study,	O
pose	O
immoderate	O
risk	O
to	O
the	O
patient	O
or	O
confound	O
the	O
results	O
of	O
the	O
study	O
.	O

>>NCT01049555	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
male	O
or	O
female,	O
>	O
65	O
years	O
;	O
.	O

-	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
the	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
(	O
McKhann,Drachman	O
et	O
al	O
.	O

1984	O
)	O
;	O
.	O

-	O
Mini	B-Observation
Mental	I-Observation
Test	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
>	O
20	O
;	O
.	O

-	O
no	B-Negation_cue
motor	B-Condition
anomaly	I-Condition
according	O
to	O
UPDRS	B-Observation
III	I-Observation
(	O
tremblements	B-Condition
,	O
rigidit	B-Condition
musculaire	I-Condition
)	O
;	O
.	O

-	O
no	B-Negation_cue
depression	B-Condition
criteria	O
according	O
to	O
DSM	B-Observation
IV-R	I-Observation
criteria	I-Observation
;	O
.	O

-	O
patient	O
with	O
a	O
cholinergic	B-Drug
treatment	I-Drug
at	O
dose	O
stable	O
since	O
3	O
months	O
;	O
.	O

-	O
patient	O
with	O
social	O
insurance	O
;	O
.	O

-	O
signature	O
of	O
informed	O
consent	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
neuropsychologics	O
assessment	O
impossible	O
due	O
to	O
sensorial	O
and	O
disrupt	O
;	O
.	O

-	O
prescription	O
of	O
psychotrop	B-Drug
treatment	I-Drug
(	O
hypnotic	B-Drug
,	O
anxiolytic	B-Drug
,	O
antidepressant	B-Drug
,	O
antipsychotic	B-Drug
)	O
in	O
the	O
week	O
previous	O
actigraphy	B-Procedure_Device
recording	I-Procedure_Device
.	O

>>NCT01481558	O
Inclusion	O
criteria	O
:	O
.	O

1	O
.	O

Dementia	B-Condition
defined	O
by	O
DSM-IV	B-Observation
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
version	O
IV	O
)	O
.	O

2	O
.	O

Possible	O
Alzheimer's	B-Condition
Disease	I-Condition
defined	O
by	O
NINCDS-ADRDA	B-Observation
(	O
National	O
Institute	O
for	O
Neurological	O
and	O
Communicative	O
Disorders	O
and	O
Stroke	O
and	O
the	O
Alzheimer's	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
)	O
.	O

3	O
.	O

Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
scores	I-Observation
from	O
10	O
to	O
20	O
.	O

4	O
.	O

Apathy	B-Condition
defined	O
by	O
a	O
score	O
equal	O
or	O
higher	O
to	O
14	O
in	O
Apathy	B-Observation
Scale	I-Observation
.	O

Exclusion	O
criteria	O
:	O
.	O

1	O
.	O

Clinical	B-Condition
instability	I-Condition
.	O

2	O
.	O

Epilepsy	B-Condition
.	O

3	O
.	O

Metallic	B-Procedure_Device
clip	I-Procedure_Device
in	O
the	O
head	O
.	O

4	O
.	O

Use	O
of	O
alcohol	B-Drug
and	O
psychotropic	B-Drug
drugs	I-Drug

>>NCT00678431	O
Inclusion	O
Criteria	O
:	O
.	O

1	O
.	O

Consenting	O
individuals	O
as	O
defined	O
by	O
IRB	O
guidelines	O
.	O

2	O
.	O

NINCDS	B-Observation
/	I-Observation
ADRDA	I-Observation
criteria	I-Observation
for	O
probable	O
AD	B-Condition
.	O

3	O
.	O

Community	O
dwelling	O
.	O

4	O
.	O

Age	B-Observation
:	O
greater	O
than	O
or	O
equal	O
to	O
50	O
years	O
.	O

5	O
.	O

MMSE	B-Observation
between	O
12	O
and	O
26,	O
inclusive	O
.	O

6	O
.	O

Stable	O
medical	B-Condition
condition	I-Condition
for	O
3	O
months	O
prior	O
to	O
screening	O
visit	O
.	O

7	O
.	O

Stable	O
doses	O
of	O
(	O
non	O
excluded	O
)	O
medications	B-Drug
with	O
central	O
nervous	O
system	O
activity	O
for	O
4	O
weeks	O
prior	O
to	O
the	O
screening	O
visit	O
(	O
For	O
cholinesterase	B-Drug
inhibitors	I-Drug
there	O
should	O
be	O
no	O
plan	O
of	O
dose	O
escalation	O
)	O
.	O

8	O
.	O

Physically	O
acceptable	O
for	O
this	O
study	O
as	O
confirmed	O
by	O
medical	B-Observation
history	I-Observation
physical	B-Observation
exam	I-Observation
neurologic	B-Observation
exam	I-Observation
and	O
clinical	B-Observation
laboratory	I-Observation
tests	I-Observation
.	O

9	O
.	O

Supervision	O
available	O
for	O
administration	O
of	O
study	O
medications	O
.	O

10	O
.	O

Study	O
partner	O
to	O
accompany	O
subject	O
to	O
all	O
scheduled	O
visits	O
and	O
complete	O
informant-based	O
assessments	O
.	O

11	O
.	O

Fluent	O
in	O
English	O
or	O
Spanish	O
.	O

12	O
.	O

Modified	B-Observation
Hachinski	I-Observation
<	O
4	O
.	O

13	O
.	O

CT	B-Procedure_Device
or	O
MRI	B-Procedure_Device
since	O
onset	O
of	O
memory	B-Condition
impairment	I-Condition
demonstrating	O
absence	B-Negation_cue
of	O
clinically	O
significant	O
focal	B-Condition
lesion	I-Condition
(	O
One	O
lacune	B-Condition
in	O
a	O
non-critical	O
brain	O
region	O
is	O
acceptable	O
)	O
.	O

14	O
.	O

Able	O
to	O
complete	O
baseline	O
assessments	O
.	O

15	O
.	O

6	O
years	O
of	O
education	O
or	O
work	O
history	O
sufficient	O
to	O
exclude	O
mental	O
retardation	O
.	O

16	O
.	O

Able	O
to	O
ingest	O
oral	O
medication	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

1	O
.	O

Active	O
liver	B-Condition
disease	I-Condition
or	O
persistent	O
elevation	O
in	O
serum	B-Observation
transaminase	I-Observation
.	O

2	O
.	O

Severe	O
renal	B-Condition
disease	I-Condition
.	O

3	O
.	O

-	O
Hx	O
of	O
diabetes	B-Condition
mellitus	I-Condition
(	O
both	O
insulin-dependent	O
and	O
non-insulin-dependent	O
)	O
or	O
blood	B-Observation
glucose	I-Observation
>	O
150	O
mg	O
/	O
dl	O
.	O

4	O
.	O

Active	O
neoplastic	B-Condition
disease	I-Condition
(	O
skin	B-Condition
tumors	I-Condition
other	B-Negation_cue
than	I-Negation_cue
melanoma	B-Condition
are	O
not	O
exclusionary;	O
subjects	O
with	O
stable	O
prostate	B-Condition
cancer	I-Condition
or	O
other	O
stable	O
cancers	B-Condition
may	O
be	O
included	O
at	O
the	O
discretion	O
of	O
the	O
PI	O
(	O
Sano	O
)	O
.	O

5	O
.	O

Use	O
of	O
another	O
investigational	B-Drug
agent	I-Drug
within	O
2	O
months	O
of	O
the	O
screening	O
visit	O
.	O

6	O
.	O

History	O
of	O
clinically	O
significant	O
stroke	B-Condition
.	O

7	O
.	O

Current	O
evidence	O
or	O
history	O
in	O
the	O
past	O
2	O
years	O
of	O
seizures	B-Condition
,	O
head	B-Condition
injury	I-Condition
with	I-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition
and	O
/	O
or	O
immediate	B-Condition
confusion	I-Condition
after	I-Condition
the	I-Condition
injury	I-Condition
.	O

8	O
.	O

Current	O
DSM-IV	B-Observation
criteria-based	O
diagnosis	O
for	O
major	B-Condition
psychiatric	I-Condition
disorder	I-Condition
including	O
psychosis	B-Condition
,	O
major	B-Condition
depression	I-Condition
bipolar	B-Condition
disorder	I-Condition
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
.	O

9	O
.	O

Blindness	B-Condition
,	O
deafness	B-Condition
,	O
language	B-Condition
difficulties	I-Condition
or	O
any	O
other	O
disability	B-Condition
which	O
may	O
interfere	O
with	O
testing	O
ability	O
.	O

10	O
.	O

In	O
female	B-Observation
subjects,	O
no	B-Negation_cue
history	O
of	O
menopause	B-Condition
.	O

11	O
.	O

Use	O
of	O
medications	B-Drug
containing	I-Drug
aluminum	I-Drug
hydroxide	I-Drug
including	O
anti-ulcer	B-Drug
antacids	I-Drug
such	O
as	O
Alternagel	B-Drug
,	O
Amphojel	B-Drug
,	O
Alu-tab	B-Drug
,	O
Maalox	B-Drug
and	O
Mylanta	B-Drug
.	O

>>NCT00551161	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Written	O
informed	O
consent	O
must	O
be	O
obtained	O
from	O
either	O
the	O
subject	O
(	O
if	O
they	O
have	O
decisional	O
capacity	O
)	O
or	O
a	O
Legally	O
Authorized	O
Representative	O
(	O
LAR	O
)	O
(	O
as	O
required	O
by	O
state	O
or	O
local	O
law	O
and	O
the	O
IRB	O
),	O
prior	O
to	O
the	O
initiation	O
of	O
any	O
study-specific	O
procedures	O
.	O

(	O
If	O
a	O
subject	O
is	O
unable	O
to	O
fully	O
consent	O
for	O
himself	O
/	O
herself	O
but	O
has	O
capacity	O
to	O
appoint	O
a	O
research	O
proxy,	O
the	O
legally	O
authorized	O
research	O
proxy	O
will	O
be	O
asked	O
to	O
sign	O
consent,	O
with	O
the	O
subject	O
signing	O
assent.)	O
.	O

-	O
Male	O
or	O
female	O
outpatients	O
at	O
least	O
50	O
years	O
of	O
age	B-Observation
at	O
Screening	O
.	O

-	O
If	O
female,	O
the	O
patient	O
must	O
be	O
at	O
least	O
two	O
years	O
postmenopausal	B-Condition
or	O
surgically	B-Condition
sterile	I-Condition
at	O
Screening	O
.	O

-	O
The	O
patient	O
has	O
a	O
current	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
consistent	O
with	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
.	O

-	O
The	O
patient	O
has	O
a	O
knowledgeable	O
and	O
reliable	O
caregiver	O
who	O
will	O
accompany	O
the	O
patient	O
to	O
all	O
clinic	O
visits	O
during	O
the	O
course	O
of	O
the	O
study	O
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
of	O
at	O
least	O
15	O
and	O
not	O
greater	O
than	O
26	O
at	O
Screening	O
.	O

-	O
Ongoing	O
therapy	O
with	O
a	O
stable	O
dose	O
of	O
donepezil	B-Drug
,	O
rivastigmine	B-Drug
or	O
galantamine	B-Drug
for	O
at	O
least	O
three	O
months	O
at	O
the	O
time	O
of	O
Screening	O
.	O

-	O
Physical	B-Observation
examination	I-Observation
laboratory	B-Observation
evaluations	I-Observation
and	O
EKG	B-Procedure_Device
results	O
at	O
Screening	O
must	O
be	O
normal	O
or	O
abnormal	O
findings	B-Observation
must	O
be	O
judged	O
not	B-Negation_cue
clinically	O
significant	O
by	O
the	O
Investigator	O
.	O

-	O
The	O
patient's	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
conducted	O
as	O
part	O
of	O
Screening	O
(	O
Visit	O
1	O
)	O
must	O
be	O
consistent	O
with	O
a	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
and	O
must	O
not	O
include	O
any	O
findings	O
that	O
could	O
confound	O
the	O
spectroscopic	O
analysis	O
of	O
subsequent	O
MRIs	B-Procedure_Device
(	O
eg	O
,	O
large	B-Condition
cortical	I-Condition
stroke	I-Condition
tumor	B-Condition
or	O
other	O
space-occupying	B-Condition
brain	I-Condition
lesions	I-Condition
)	O
.	O

-	O
Vision	B-Observation
and	I-Observation
hearing	I-Observation
(	O
hearing	O
aid	O
permissible	O
)	O
must	O
be	O
sufficient	O
for	O
compliance	O
with	O
testing	O
procedures	O
.	O

-	O
The	O
patient	O
and	O
/	O
or	O
their	O
Legally	O
Authorized	O
Representative	O
and	O
their	O
caregiver	O
must	O
be	O
able	O
to	O
speak,	O
read	O
and	O
understand	O
English	O
sufficiently	O
to	O
understand	O
the	O
nature	O
of	O
the	O
study,	O
to	O
provide	O
written	O
informed	O
consent	O
and	O
to	O
allow	O
completion	O
of	O
all	O
study	O
assessments	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Clinically	O
significant	O
vitamin	B-Condition
B12	I-Condition
deficiency	I-Condition
at	O
Screening	O
.	O

-	O
Patients	O
with	O
a	O
modified	B-Observation
Hachinski	I-Observation
ischemia	I-Observation
score	I-Observation
greater	O
than	O
4	O
at	O
Screening	O
.	O

-	O
Patients	O
with	O
evidence	O
of	O
clinically	O
significant	O
and	O
active	O
pulmonary,	B-Condition
gastrointestinal,	I-Condition
renal,	I-Condition
hepatic,	I-Condition
endocrine	I-Condition
or	I-Condition
cardiovascular	I-Condition
system	I-Condition
disease	I-Condition
.	O

Patients	O
with	O
controlled	O
hypertension	B-Condition
and	O
right	B-Condition
bundle	I-Condition
branch	I-Condition
block	I-Condition
(	O
complete	O
or	O
partial	O
)	O
may	O
be	O
included	O
in	O
the	O
study	O
.	O

Patients	O
with	O
thyroid	B-Condition
disease	I-Condition
may	O
also	O
be	O
included	O
in	O
the	O
study	O
provided	O
they	O
are	O
euthyroid	O
on	O
treatment	O
.	O

Patients	O
with	O
controlled	O
diabetes	B-Condition
may	O
also	O
be	O
included	O
.	O

-	O
Patients	O
with	O
severe	O
renal	B-Condition
impairment	I-Condition
(	O
estimated	O
creatinine	B-Observation
clearance	I-Observation
<	O
35	O
mL	O
/	O
min	O
)	O
.	O

-	O
Patients	O
with	O
systolic	B-Observation
blood	I-Observation
pressure	I-Observation
(	O
while	O
sitting	O
)	O
greater	O
then	O
than	O
180	O
mm	O
Hg	O
or	O
less	O
then	O
90	O
mm	O
Hg	O
or	O
diastolic	B-Observation
blood	I-Observation
pressure	I-Observation
(	O
while	O
sitting	O
)	O
greater	O
than	O
100	O
mm	O
Hg	O
or	O
less	O
than	O
50	O
mm	O
Hg	O
at	O
Screening	O
.	O

-	O
Patients	O
with	O
evidence	O
of	O
other	O
neurological	B-Condition
disorders	I-Condition
including	O
but	O
not	O
limited	O
to,	O
stroke	B-Condition
,	O
Parkinson's	B-Condition
disease	I-Condition
seizure	B-Condition
disorder	I-Condition
hydrocephalus	B-Condition
or	O
head	B-Condition
injury	I-Condition
with	I-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition
within	O
the	O
past	O
five	O
years	O
at	O
Screening	O
.	O

-	O
Patients	O
with	O
a	O
current	O
DSM-IV	B-Condition
Axis	I-Condition
I	I-Condition
disorder	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
including	O
schizophrenia	B-Condition
or	O
schizoaffective	B-Condition
disorder	I-Condition
bipolar	B-Condition
disorder	I-Condition
current	O
major	B-Condition
depressive	I-Condition
episode	I-Condition
psychosis	B-Condition
,	O
panic	B-Condition
disorder	I-Condition
or	O
post-traumatic	B-Condition
stress	I-Condition
disorder	I-Condition
.	O

-	O
Patients	O
with	O
dementia	B-Condition
complicated	O
by	O
other	O
organic	B-Condition
disease	I-Condition
.	O

-	O
Patients	O
who	O
have	O
had	O
a	O
previous	O
brain	B-Procedure_Device
scan	I-Procedure_Device
(	O
MRI	B-Procedure_Device
or	O
CT	B-Procedure_Device
)	O
with	O
results	O
inconsistent	B-Negation_cue
with	O
a	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Patients	O
with	O
an	O
oncological	B-Condition
diagnosis	I-Condition
(	O
hematological	B-Condition
or	I-Condition
solid	I-Condition
tumor	I-Condition
)	O
which	O
is	O
currently	O
being	O
treated	O
or	O
for	O
which	O
there	O
has	O
been	O
treatment	B-Drug
within	O
the	O
year	O
preceding	O
Screening	O
or	O
for	O
which	O
there	O
is	O
still	O
evidence	O
of	O
active	O
disease	B-Condition
.	O

(	O
Note	O
:	O
Patients	O
with	O
local	B-Condition
dermatological	I-Condition
tumors	I-Condition
at	O
such	O
as	O
basal	B-Condition
or	I-Condition
squamous	I-Condition
cell	I-Condition
carcinoma	I-Condition
may	O
be	O
included.)	O
.	O

-	O
Patients	O
with	O
an	O
object	B-Procedure_Device
in	O
the	O
head	O
or	O
neck	O
which	O
would	O
invalidate	O
or	O
obstruct	O
the	O
successful	O
completion	O
of	O
an	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
or	O
patients	O
who	O
have	O
other	O
contraindications	B-Condition
to	O
MRI	B-Procedure_Device
,	O
including	O
those	O
with	O
implanted	B-Procedure_Device
ferromagnetic	I-Procedure_Device
material	I-Procedure_Device
or	I-Procedure_Device
devices	I-Procedure_Device
such	O
as	O
cardiac	B-Procedure_Device
pacemakers	I-Procedure_Device
deep	B-Procedure_Device
brain	I-Procedure_Device
stimulators	I-Procedure_Device
cochlear	B-Procedure_Device
implants	I-Procedure_Device
or	O
intraocular	B-Procedure_Device
metallic	I-Procedure_Device
shards	I-Procedure_Device
.	O

-	O
Patients	O
who	O
are	O
claustrophobic	B-Condition
and	O
/	O
or	O
unable	O
to	O
tolerate	O
MRI	B-Procedure_Device
at	O
Screening	O
or	O
whom	O
the	O
Investigator	O
believes	O
will	O
not	O
be	O
able	O
to	O
tolerate	O
further	O
scans	O
scheduled	O
during	O
the	O
course	O
of	O
the	O
study	O
.	O

-	O
Patients	O
with	O
a	O
known	O
or	O
suspected	O
history	O
(	O
within	O
the	O
past	O
5	O
years	O
at	O
Screening	O
)	O
of	O
alcoholism	B-Condition
or	O
drug	B-Condition
abuse	I-Condition
.	O

-	O
Patients	O
who	O
are	O
on	O
an	O
unstable	O
dose	O
of	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
(	O
donepezil	B-Drug
,	O
rivastigmine	B-Drug
or	O
galantamine	B-Drug
),	O
are	O
currently	O
taking	O
more	O
than	O
one	O
cholinesterase	B-Drug
inhibitor	I-Drug
at	O
Screening,	O
who	O
are	O
likely	O
to	O
require	O
a	O
change	O
in	O
cholinesterase	B-Drug
drug	I-Drug
dose	O
during	O
the	O
course	O
of	O
the	O
study	O
or	O
for	O
whom	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
therapy	O
is	O
contraindicated	B-Condition
.	O

-	O
Patients	O
with	O
a	O
history	O
of	O
severe	O
drug	B-Condition
allergy	I-Condition
or	O
hypersensitivity	B-Condition
or	O
patients	O
with	O
known	O
hypersensitivity	B-Condition
to	O
memantine	B-Drug
,	O
amantadine	B-Drug
,	O
rimantadine	B-Drug
or	O
lactose	B-Drug
.	O

-	O
Patients	O
who	O
have	O
been	O
previously	O
treated	O
with	O
or	O
have	O
participated	O
in	O
an	O
investigational	O
study	O
of	O
neramexane	B-Drug
,	O
memantine	B-Drug
or	O
amantadine	B-Drug
.	O

-	O
Patients	O
previously	O
treated	O
with	O
commercial	O
memantine	O
.	O

-	O
Patients	O
who	O
have	O
been	O
in	O
an	O
investigational	B-Drug
drug	I-Drug
study	O
or	O
who	O
have	O
received	O
treatment	O
with	O
an	O
investigational	B-Drug
drug	I-Drug
within	O
30	O
days	O
or	O
5	O
half-lives	O
(	O
whichever	O
is	O
longer	O
)	O
of	O
Screening	O
.	O

-	O
Patients	O
or	O
caregivers	O
who	O
are	O
unwilling	O
or	O
unable	O
to	O
abide	O
by	O
the	O
visit	O
schedule	O
and	O
other	O
requirements	O
of	O
the	O
study	O
.	O

-	O
Any	O
condition	O
which	O
would	O
make	O
the	O
patient	O
or	O
caregiver	O
unsuitable	O
for	O
the	O
study	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
.	O

>>NCT01119638	O
Inclusion	O
Criteria	O
:	O
.	O

Eligible	O
participants	O
will	O
fulfill	O
criteria	O
for	O
dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
type	I-Condition
(	O
according	O
to	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders,	O
fourth	O
edition	O
)	O
.	O

The	O
score	O
on	O
the	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
has	O
to	O
be	O
between	O
5	O
and	O
26	O
.	O

Eligible	O
patients	O
will	O
suffer	O
from	O
delusions	B-Condition
,	O
hallucinations	B-Condition
,	O
aggression	B-Condition
or	O
agitation	B-Condition
that	O
developed	O
after	O
the	O
onset	O
of	O
dementia	B-Condition
and	O
is	O
severe	O
enough	O
to	O
disrupt	O
their	O
functioning	O
and,	O
in	O
the	O
opinion	O
of	O
the	O
study	O
physicians,	O
to	O
justify	O
treatment	O
with	O
antipsychotic	B-Drug
drugs	I-Drug
.	O

Signs	B-Condition
and	I-Condition
symptoms	I-Condition
of	O
psychosis	B-Condition
,	O
aggression	B-Condition
or	O
agitation	B-Condition
will	O
have	O
to	O
occur	O
nearly	O
daily	O
during	O
the	O
week	O
prior	O
to	O
enrollment	O
.	O

A	O
frequency	O
rating	O
of	O
"often"	O
or	O
"more	O
frequently"	O
and	O
a	O
severity	O
rating	O
of	O
at	O
least	O
"moderate"	O
are	O
required	O
for	O
delusions	B-Condition
,	O
hallucinations	B-Condition
,	O
agitation	B-Condition
or	O
aberrant	B-Condition
motor	I-Condition
behavior	I-Condition
in	O
the	O
Neuropsychiatric	B-Observation
Inventory	I-Observation
(	I-Observation
NPI	I-Observation
)	I-Observation
.	O

Exclusion	O
Criteria	O
:	O
.	O

Patients	O
will	O
be	O
excluded	O
if	O
they	O
had	O
received	O
a	O
diagnosis	O
of	O
a	O
primary	O
psychotic	B-Condition
disorder	I-Condition
(	O
eg	O
,	O
schizophrenia	B-Condition
),	O
delirium	B-Condition
,	O
other	O
dementia	B-Condition
.	O

Patients	O
will	O
also	O
be	O
excluded	O
if	O
they	O
were	O
going	O
to	O
receive	O
treatment	O
with	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
or	O
antidepressant	B-Drug
medication	I-Drug
had	O
previously	O
been	O
treated	O
with	O
escitalopram	B-Drug
for	O
BPSD	O
or	O
had	O
contraindications	B-Condition
to	O
the	O
two	O
study	B-Drug
drugs	I-Drug
.	O

>>NCT00857649	O
Inclusion	O
Criteria	O
:	O
.	O

Outpatients	O
who	O
:	O
.	O

-	O
had	O
a	O
primary	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
Disease	I-Condition
(	I-Condition
AD	I-Condition
)	I-Condition
according	O
to	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke	I-Observation
and	I-Observation
the	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINDS-ADRDA	I-Observation
)	I-Observation
criteria	I-Observation
and	O
with	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Disorders,	I-Observation
4th	I-Observation
edition,	I-Observation
text	I-Observation
revised	I-Observation
(	I-Observation
DSM	I-Observation
IV	I-Observation
TR	I-Observation
)	I-Observation
criteria	I-Observation
for	O
dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
type	I-Condition
.	O

-	O
had	O
moderate	O
to	O
severe	O
dementia	B-Condition
,	O
defined	O
as	O
a	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
total	I-Observation
score	I-Observation
>=	O
5	O
and	O
<=	O
15	O
at	O
screening	O
.	O

Before	O
substantial	O
protocol	O
amendment	O
SA04	O
(	O
dated	O
7	O
October	O
2004	O
)	O
was	O
implemented,	O
the	O
MMSE	B-Observation
total	I-Observation
score	I-Observation
range	O
at	O
screening	O
was	O
>=	O
8	O
and	O
<=	O
18	O
.	O

Substantial	O
protocol	O
amendment	O
SA07	O
(	O
dated	O
4	O
September	O
2009	O
)	O
allowed	O
patients	O
who	O
had	O
previously	O
had	O
an	O
MMSE	B-Observation
score	I-Observation
of	O
16	O
or	O
17	O
to	O
be	O
re-screened	O
>	O
6	O
months	O
after	O
their	O
initial	O
screening	O
and,	O
if	O
there	O
was	O
documented	O
evidence	O
of	O
cognitive	B-Condition
decline	I-Condition
to	O
be	O
enrolled	O
in	O
the	O
study	O
.	O

-	O
had	O
a	O
Neuropsychiatric	B-Observation
Inventory	I-Observation
(	I-Observation
NPI	I-Observation
)	I-Observation
total	I-Observation
score	I-Observation
>=	O
13	O
and	O
an	O
NPI	B-Observation
agitation	I-Observation
/	I-Observation
aggression	I-Observation
subitem	I-Observation
score	I-Observation
>=	O
1	O
at	O
screening	O
and	O
baseline	O
.	O

-	O
did	O
not	B-Negation_cue
have	O
vascular	B-Condition
dementia	I-Condition
or	O
a	O
modified	B-Observation
Hachinski	I-Observation
Ischaemia	I-Observation
Scale	I-Observation
score	I-Observation
>	O
4	O
at	O
screening	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Evidence	O
of	O
clinically	O
significant	O
active	O
disease	B-Condition
,	O
evidence	O
of	O
other	O
neurological	B-Condition
disorders	I-Condition
and	O
previous	O
treatment	O
with	O
memantine	B-Drug
.	O

>>NCT00456417	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
The	O
participant	O
is	O
50	O
years	O
or	O
older	O
.	O

-	O
Written	O
informed	O
consent	O
is	O
obtained	O
.	O

-	O
Participants	O
have	O
a	O
clinical	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
based	O
on	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke	I-Observation
/	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINCDS	I-Observation
.	O

-	O
Mini-Mental	B-Observation
Status	I-Observation
Exam	I-Observation
score	I-Observation
>	O
16	O
and	O
<	O
25	O
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
Scale	I-Observation
score	I-Observation
of	O
<=	O
4	O
.	O

-	O
Geriatric	B-Observation
Depression	I-Observation
Scales	I-Observation
(	I-Observation
GDS	I-Observation
)	I-Observation
<=	O
10	O
.	O

-	O
For	O
females,	O
non-child	B-Condition
bearing	I-Condition
potential	I-Condition
or	O
negative	O
urine	B-Observation
or	I-Observation
blood	I-Observation
pregnancy	I-Observation
test	I-Observation
on	O
day	O
of	O
123	O
-I	O
MNI-	O
187	O
injection	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
The	O
subject	O
has	O
signs	O
or	O
symptoms	O
of	O
another	O
neurodegenerative	B-Condition
disease	I-Condition
including	O
Parkinson's	B-Condition
disease	I-Condition
diffuse	B-Condition
Lewy	I-Condition
body	I-Condition
dementia	I-Condition
or	O
history	O
of	O
significant	O
cerebrovascular	B-Condition
disease	I-Condition
.	O

-	O
The	O
subject	O
has	O
a	O
clinically	O
significant	O
abnormal	O
laboratory	B-Observation
value	I-Observation
and	O
/	O
or	O
clinically	O
significant	O
unstable	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
.	O

-	O
The	O
subject	O
has	O
any	O
disorder	B-Condition
that	O
may	O
interfere	O
with	O
drug	B-Observation
absorption	I-Observation
distribution	I-Observation
metabolism	B-Observation
or	O
excretion	B-Observation
(	O
including	O
gastrointestinal	B-Procedure_Device
surgery	I-Procedure_Device
)	O
.	O

-	O
The	O
subject	O
has	O
evidence	O
of	O
clinically	O
significant	O
gastrointestinal,	B-Condition
cardiovascular,	I-Condition
hepatic,	I-Condition
renal,	I-Condition
hematological,	I-Condition
neoplastic,	I-Condition
endocrine,	I-Condition
neurological,	I-Condition
immunodeficiency,	I-Condition
pulmonary	I-Condition
or	I-Condition
other	I-Condition
disorder	I-Condition
or	I-Condition
disease	I-Condition
.	O

-	O
Pregnancy	B-Condition
.	O

>>NCT00842673	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Diagnostic	O
evidence	O
of	O
mild	O
to	O
moderate	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
CT	B-Procedure_Device
or	O
MRI	B-Procedure_Device
results	O
within	O
the	O
past	O
12	O
months	O
that	O
rule	B-Negation_cue
out	I-Negation_cue
dementia	B-Condition
due	I-Condition
to	I-Condition
non-Alzheimer's	I-Condition
etiology	I-Condition
.	O

-	O
A	O
reliable	O
and	O
capable	O
caregiver	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Subjects	O
who	O
reside	O
in	O
a	O
skilled	O
nursing	O
facility	O
.	O

-	O
Subjects	O
with	O
B12	B-Condition
or	I-Condition
folate	I-Condition
deficiency	I-Condition
.	O

-	O
Subjects	O
with	O
chronic	O
hepatic	B-Condition
disease	I-Condition
.	O

-	O
Subjects	O
with	O
a	O
recent	O
history	O
of	O
hematologic	B-Condition
/	I-Condition
oncologic	I-Condition
disorders	I-Condition
.	O

-	O
Subjects	O
who	O
have	O
experienced	O
a	O
myocardial	B-Condition
infarction	I-Condition
with	O
the	O
past	O
year	O
.	O

-	O
Dementia	B-Condition
caused	O
or	O
complicated	O
by	O
other	O
organic	B-Condition
disease	I-Condition

>>NCT00811122	O
Inclusion	O
Criteria	O
:	O
.	O

1	O
.	O

All	O
participants	O
will	O
be	O
between	O
30	O
-	O
90	O
years	O
old,	O
inclusive,	O
clinically	O
characterized	O
as	O
having	O
AD	B-Condition
,	O
having	O
FTD	B-Condition
or	O
being	O
cognitively	O
normal	O
controls	O
(	O
NC	O
)	O
.	O

2	O
.	O

All	O
subjects	O
must	O
be	O
willing	O
and	O
able	O
to	O
undergo	O
testing	O
procedures	O
.	O

3	O
.	O

Cholinesterase	B-Drug
inhibitors	I-Drug
and	O
memantine	B-Drug
-	O
symptomatic	B-Drug
drugs	I-Drug
approved	O
for	O
AD	B-Condition
-	O
will	O
be	O
allowed	O
since	O
these	O
drugs	O
are	O
not	O
expected	O
to	O
significantly	O
affect	O
amyloid	O
load	O
.	O

General	O
inclusion	O
criteria	O
are	O
shown	O
below	O
:	O
.	O

1	O
.	O

Normal	O
subjects	O
:	O
Healthy	B-Condition
individuals	O
aged	O
to	O
match	O
AD	B-Condition
and	O
FTD	B-Condition
groups,	O
who	O
are	O
non-depressed	B-Condition
,	O
non-demented	B-Condition
and	O
without	B-Negation_cue
a	O
complaint	B-Condition
of	I-Condition
memory	I-Condition
loss	I-Condition
.	O

A	O
brief	O
neuropsychological	B-Observation
test	I-Observation
the	O
3MS-R	B-Observation
or	O
Modified	B-Observation
Mini-Mental	I-Observation
State	I-Observation
Examination	I-Observation
Revised	O
(	O
Tschanz	O
et	O
al.,	O
2002	O
),	O
will	O
be	O
given	O
to	O
confirm	O
that	O
the	O
subject	O
is	O
not	B-Negation_cue
cognitively	B-Condition
impaired	I-Condition
.	O

2	O
.	O

FTD	B-Condition
subjects	O
:	O
Patients	O
seen	O
in	O
the	O
University	O
of	O
Utah	O
(	O
UU	O
)	O
Cognitive	O
Disorders	O
Clinic	O
(	O
CDC	O
)	O
who	O
have	O
been	O
clinically	O
characterized	O
and	O
meet	O
Neary	B-Observation
criteria	I-Observation
for	O
frontotemporal	B-Condition
dementia	I-Condition
(	O
Neary	O
et	O
al.,	O
1998	O
)	O
.	O

3	O
.	O

AD	B-Condition
subjects	O
:	O
Patients	O
seen	O
in	O
the	O
UU	O
CDC	O
who	O
have	O
been	O
clinically	O
characterized	O
to	O
meet	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
for	O
probable	O
AD	B-Condition
(	O
McKhann	O
et	O
al.,	O
1984	O
)	O
.	O

These	O
criteria	O
were	O
established	O
in	O
1984	O
for	O
diagnosis	O
of	O
AD	B-Condition
by	O
the	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke	I-Observation
(	I-Observation
NINCDS	I-Observation
)	I-Observation
and	O
Alzheimer's	B-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
ADRDA	I-Observation
)	I-Observation
.	O

Exclusion	O
Criteria	O
:	O
.	O

1	O
.	O

Subjects	O
with	O
medical	B-Condition
conditions	I-Condition
that	O
have	O
a	O
high	O
risk	B-Condition
of	O
associated	B-Condition
cognitive	I-Condition
symptoms	I-Condition
such	O
as	O
transient	B-Condition
ischemic	I-Condition
attack	I-Condition
(	I-Condition
TIA	I-Condition
)	I-Condition
stroke	B-Condition
,	O
seizures	B-Condition
or	O
head	B-Condition
injury	I-Condition
with	I-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition
within	O
five	O
years	O
.	O

2	O
.	O

Subjects	O
with	O
Axis	B-Condition
I	I-Condition
psychiatric	I-Condition
diagnoses	I-Condition
other	B-Negation_cue
than	I-Negation_cue
treated	O
depression	B-Condition
.	O

3	O
.	O

Subjects	O
who	O
are	O
not	B-Negation_cue
medically	O
stable	O
will	O
be	O
excluded	O
from	O
the	O
study	O
.	O

Examples	O
of	O
medically	O
unstable	O
patients	O
include	O
uncontrolled	O
hypertension	B-Condition
,	O
heart	B-Condition
/	I-Condition
liver	I-Condition
and	O
other	O
conditions	B-Condition
requiring	O
acute	O
medical	O
attention	O
.	O

4	O
.	O

Subjects	O
cannot	O
have	O
a	O
serum	B-Observation
glucose	I-Observation
level	I-Observation
greater	O
than	O
180	O
mg	O
/	O
dl	O
for	O
FDG-PET	B-Procedure_Device
imaging	I-Procedure_Device
.	O

5	O
.	O

Subjects	O
who	O
are	O
too	O
claustrophobic	B-Condition
to	O
undergo	O
FDG-PET	B-Procedure_Device
or	O
11C	B-Procedure_Device
PIB-PET	I-Procedure_Device
imaging	I-Procedure_Device
.	O

6	O
.	O

Subjects	O
who	O
require	O
conscious	O
sedation	O
or	O
anesthesia	O
to	O
undergo	O
FDG-PET	O
or	O
11C	O
PIB-PET	O
imaging	O
.	O

7	O
.	O

Subjects	O
who	O
are	O
unable	O
to	O
follow	O
instructions	O
to	O
urinate	O
after	O
completing	O
scanning	O
procedures	O
.	O

>>NCT01428453	O
Inclusion	O
Criteria	O
:	O
.	O

1	O
.	O

A	O
clinical	O
diagnosis	O
of	O
possible	O
Alzheimer's	B-Condition
disease	I-Condition
in	O
accordance	O
with	O
the	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Diseases	I-Observation
and	I-Observation
Stroke	I-Observation
/	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINCDS-ADRDA	I-Observation
)	I-Observation
criteria	I-Observation
with	O
radiological	O
(	O
Magnetic	B-Procedure_Device
Resonance	I-Procedure_Device
Imaging	I-Procedure_Device
[MRI]	I-Procedure_Device
or	O
Computed	B-Procedure_Device
Tomography	I-Procedure_Device
[CT]	I-Procedure_Device
evidence	O
of	O
significant	O
cerebrovascular	B-Condition
disease	I-Condition
(	I-Condition
CVD	I-Condition
)	I-Condition
assessed	O
within	O
the	O
last	O
12	O
months	O
.	O

2	O
.	O

Male	O
or	O
female	O
between	O
50	O
and	O
80	O
years	O
of	O
age	B-Observation
inclusive,	O
at	O
the	O
time	O
of	O
signing	O
the	O
informed	O
consent	O
.	O

3	O
.	O

Subject	O
has	O
a	O
documented	O
history	O
of	O
at	O
least	O
6	O
months	O
of	O
ongoing	O
Alzheimer's	B-Drug
disease	I-Drug
therapy	I-Drug
(	O
AChEIs	B-Drug
and	O
/	O
or	O
memantine	B-Drug
)	O
with	O
stable	O
dosing	O
for	O
at	O
least	O
the	O
last	O
2	O
months	O
(	O
and	O
with	O
no	O
intent	O
to	O
change	O
for	O
the	O
duration	O
of	O
the	O
study	O
)	O
.	O

4	O
.	O

Mini-Mental	B-Observation
Status	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
between	O
20	O
and	O
26	O
at	O
Screening	O
.	O

5	O
.	O

Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
Scale	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
score	I-Observation
of	O
0.5	O
or	O
1.0	O
at	O
Screening	O
.	O

6	O
.	O

A	O
female	O
subject	O
is	O
eligible	O
to	O
participate	O
if	O
she	O
is	O
of	O
non-childbearing	O
potential	O
defined	O
as	O
pre-menopausal	O
females	O
with	O
a	O
documented	O
tubal	O
ligation	O
or	O
hysterectomy;	O
or	O
postmenopausal	O
defined	O
as	O
12	O
months	O
of	O
spontaneous	O
amenorrhea;	O
or	O
of	O
child-bearing	O
potential	O
and	O
agrees	O
to	O
use	O
acceptable	O
contraception	O
methods	O
.	O

7	O
.	O

Subject	O
has	O
provided	O
full	O
written	O
informed	O
consent	O
prior	O
to	O
the	O
performance	O
of	O
any	O
protocol-specified	O
procedure;	O
or	O
if	O
the	O
subject	O
is	O
unable	O
to	O
provide	O
informed	O
consent	O
due	O
to	O
cognitive	O
status,	O
the	O
subject	O
will	O
provide	O
assent	O
and	O
full	O
written	O
informed	O
consent	O
will	O
be	O
provided	O
by	O
a	O
legally	O
acceptable	O
representative	O
.	O

8	O
.	O

The	O
subject	O
has	O
a	O
dedicated	O
caregiver	O
who	O
is	O
willing	O
to	O
supervise	O
participation	O
in	O
the	O
study	O
.	O

9	O
.	O

In	O
the	O
opinion	O
of	O
the	O
investigator,	O
the	O
subject	O
has	O
the	O
ability	O
to	O
comply	O
with	O
study	O
procedures	O
(	O
cognitive	O
and	O
other	O
testing	O
)	O
and	O
is	O
fluent	O
in	O
the	O
language	O
used	O
for	O
the	O
administration	O
of	O
the	O
cognitive	O
tests	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

1	O
.	O

History	O
and	O
/	O
or	O
evidence	O
of	O
any	O
other	O
CNS	B-Condition
disorder	I-Condition
that	O
could	O
be	O
interpreted	O
as	O
a	O
cause	B-Condition
of	I-Condition
dementia	I-Condition
:	O
eg	O
structural	B-Condition
or	I-Condition
developmental	I-Condition
abnormality	I-Condition
epilepsy	B-Condition
,	O
infectious,	B-Condition
degenerative	I-Condition
or	I-Condition
inflammatory	I-Condition
/	I-Condition
demyelinating	I-Condition
CNS	I-Condition
conditions	I-Condition
such	O
as,	O
Parkinson's	B-Condition
disease	I-Condition
and	O
frontotemporal	B-Condition
dementia	I-Condition
.	O

2	O
.	O

History	O
of	O
significant	O
psychiatric	B-Condition
illness	I-Condition
such	O
as	O
schizophrenia	B-Condition
or	O
bipolar	B-Condition
affective	I-Condition
disorder	I-Condition
that	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
would	O
interfere	O
with	O
participation	O
in	O
the	O
study;	O
major	O
depressive	B-Condition
disorder	I-Condition
(	O
according	O
to	O
DSM-IV	B-Observation
)	O
in	O
the	O
past	O
year;	O
current	O
active	O
depression	B-Condition
requiring	O
initiation	O
of	O
treatment	O
(	O
or	O
is	O
believed	O
to	O
account	O
for	O
substantial	O
degree	O
of	O
cognitive	O
impairment	O
)	O
.	O

3	O
.	O

Evidence	O
of	O
the	O
following	O
disorders	O
:	O
current	O
vitamin	B-Condition
B12	I-Condition
deficiency	I-Condition
positive	O
syphilis	B-Observation
serology	I-Observation
(	O
unless	O
neurosyphilis	B-Condition
was	O
ruled	B-Negation_cue
out	I-Negation_cue
)	O
or	O
active	O
thyroid	B-Condition
dysfunction	I-Condition
(	O
particularly	O
suggestive	O
of	O
hypothyroidism	B-Condition
),	O
including	O
abnormally	O
high	O
or	O
low	O
serum	B-Observation
levels	I-Observation
of	I-Observation
thyroid	I-Observation
stimulating	I-Observation
hormone	I-Observation
(	I-Observation
TSH	I-Observation
)	I-Observation
where	O
this	O
is	O
thought	O
to	O
be	O
the	O
cause	O
of	O
or	O
to	O
contribute	O
to	O
the	O
severity	O
of	O
the	O
subject's	O
dementia	B-Condition
.	O

4	O
.	O

History	O
of	O
alcohol	B-Condition
or	I-Condition
other	I-Condition
substance	I-Condition
abuse	I-Condition
according	O
to	O
the	O
DSM-IV	B-Observation
criteria	I-Observation
or	O
recent	O
or	O
remote	O
history	O
of	O
the	O
same	B-Condition
if	O
that	O
could	O
be	O
a	O
contributing	B-Condition
factor	I-Condition
to	I-Condition
dementia	I-Condition
.	O

5	O
.	O

History	O
of	O
intra	B-Condition
cerebral	I-Condition
haemorrhage	I-Condition
due	O
to	O
any	O
of	O
the	O
following	O
causes	O
:	O
cerebral	B-Condition
amyloid	I-Condition
angiopathy	I-Condition
uncontrolled	O
hypertension	B-Condition
,	O
cerebral	B-Condition
arteriovenous	I-Condition
malformation	I-Condition
coagulopathy	B-Condition
,	O
CNS	B-Condition
vasculitis	I-Condition
or	O
any	O
other	O
condition	B-Condition
that	O
the	O
investigator	O
and	O
/	O
or	O
medical	O
monitor	O
considers	O
as	O
a	O
relevant	O
risk	O
factor	O
for	O
intracerebral	B-Condition
haemorrhage	I-Condition
.	O

6	O
.	O

Recent	O
(	O
i.e.,	O
<	O
6	O
months	O
from	O
Screening	O
Visit	O
)	O
cardiovascular	B-Condition
event	I-Condition
defined	O
as	O
:	O
.	O

1	O
.	O

ST-elevation	B-Condition
MI	I-Condition
or	O
non-ST-elevation	B-Condition
MI	I-Condition
confirmed	O
by	O
cardiac	B-Observation
enzyme	I-Observation
elevation	I-Observation
and	O
ECG	B-Procedure_Device
changes	O
.	O

2	O
.	O
coronary	B-Procedure_Device
revascularization	I-Procedure_Device
(	O
percutaneous	B-Procedure_Device
coronary	I-Procedure_Device
intervention	I-Procedure_Device
or	O
coronary	B-Procedure_Device
artery	I-Procedure_Device
bypass	I-Procedure_Device
graft	I-Procedure_Device
)	O
.	O

3	O
.	O
stroke	B-Condition
of	O
any	O
etiology	B-Condition
.	O

4	O
.	O
resuscitated	B-Condition
sudden	I-Condition
death	I-Condition
.	O

5	O
.	O
prior	O
carotid	B-Procedure_Device
surgery	I-Procedure_Device
or	O
stenting	B-Procedure_Device
procedure	I-Procedure_Device
.	O

7	O
.	O

Poorly	O
controlled	O
hypertension	B-Condition
despite	B-Negation_cue
lifestyle	O
modifications	O
and	O
pharmacotherapy	B-Drug
(	O
either	O
systolic	B-Observation
blood	I-Observation
pressure	I-Observation
>	O
160mmHg	O
or	O
diastolic	B-Observation
blood	I-Observation
pressure	I-Observation
>	O
110mmHg	O
)	O
.	O

8	O
.	O

QTcB	B-Observation
interval	I-Observation
>	O
450	O
msec;	O
or	O
QTcB	B-Observation
>	O
480	O
msec	O
in	O
subjects	O
with	O
bundle	B-Condition
branch	I-Condition
block	I-Condition
based	O
on	O
ECG	B-Procedure_Device
assessment	O
at	O
the	O
Screening	O
visit	O
.	O

9	O
.	O

HbA1c	B-Observation
>	O
12.0	O
at	O
Screening	O
or	O
uncontrolled	O
diabetes	B-Condition
in	O
the	O
opinion	O
of	O
the	O
investigator	O
.	O

10	O
.	O

History	O
of	O
glaucoma	B-Condition
or	O
any	O
other	O
findings	O
in	O
the	O
baseline	B-Observation
eye	I-Observation
exam	I-Observation
that,	O
in	O
the	O
opinion	O
of	O
the	O
investigator,	O
would	O
exclude	O
the	O
subject	O
from	O
participation	O
in	O
the	O
study	O
.	O

11	O
.	O

History	O
of	O
adult	B-Condition
asthma	I-Condition
(	O
or	O
reactive	B-Condition
airway	I-Condition
disease	I-Condition
)	O
manifested	O
by	O
bronchospasm	B-Condition
in	O
the	O
past	O
6	O
months	O
or	O
currently	O
taking	O
regular	O
anti-asthmatic	B-Drug
medication	I-Drug
(	I-Drug
s	I-Drug
)	I-Drug
.	O

12	O
.	O

Previous	O
history	O
of	O
anaphylaxis	B-Condition
,	O
severe	O
allergic	B-Condition
reaction	I-Condition
or	O
history	O
of	O
hypersensitivity	B-Condition
to	O
any	O
of	O
the	O
components	O
of	O
the	O
formulation	O
.	O

13	O
.	O

Significant	O
abnormalities	B-Condition
on	O
clinical	B-Observation
chemistry	I-Observation
haematology	B-Observation
or	O
urinalysis	B-Observation
at	O
Screening,	O
including	O
clinically	O
significant	O
anaemia	B-Condition
.	O

14	O
.	O

History	O
of	O
chronic	O
viral	B-Condition
hepatitis	I-Condition
(	O
including	O
presence	O
of	O
B	B-Observation
surface	I-Observation
antigen	I-Observation
or	O
hepatitis	B-Observation
C	I-Observation
antibody	I-Observation
)	O
or	O
other	O
chronic	O
hepatic	B-Condition
disorders	I-Condition
.	O

15	O
.	O

Abnormal	O
Screening	O
blood	B-Observation
tests	I-Observation
exceeding	O
any	O
of	O
the	O
limits	O
defined	O
below	O
:	O
.	O

1	O
.	O

Alanine	B-Observation
transaminase	I-Observation
(	I-Observation
ALT	I-Observation
)	I-Observation
or	O
aspartate	B-Observation
transaminase	I-Observation
(	I-Observation
AST	I-Observation
)	I-Observation
>	O
1.5	O
x	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
.	O

2	O
.	O

Alkaline	B-Observation
phosphatase	I-Observation
(	I-Observation
AP	I-Observation
)	I-Observation
and	O
bilirubin	B-Observation
>	O
1.5X	O
ULN	O
(	O
isolated	B-Observation
bilirubin	I-Observation
>	O
1.5x	O
ULN	O
is	O
acceptable	O
if	O
bilirubin	B-Observation
is	O
fractionated	O
and	O
direct	B-Observation
bilirubin	I-Observation
<	O
35%)	O
.	O

3	O
.	O

Calculated	O
creatinine	B-Observation
clearance	I-Observation
<	O
30	O
ml	O
/	O
min	O
(	O
per	O
Cockcroft	O
&	O
Gault	O
)	O
at	O
Screening	O
.	O

16	O
.	O

Other	O
clinically	O
significant	O
abnormality	B-Condition
on	O
physical	B-Observation
(	O
including	O
neurological	B-Observation
),	O
laboratory	B-Observation
or	O
ECG	B-Procedure_Device
examination	I-Procedure_Device
that	O
could	O
be	O
detrimental	O
to	O
the	O
subject	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
or	O
could	O
compromise	O
the	O
integrity	O
of	O
the	O
study	O
.	O

17	O
.	O

Planned	O
major	O
surgery	B-Procedure_Device
within	O
the	O
study	O
period	O
.	O

18	O
.	O

Use	O
of	O
systemic	B-Drug
steroids	I-Drug
or	O
other	O
immunosuppressants	B-Drug
within	O
the	O
last	O
30	O
days	O
prior	O
to	O
screening	O
.	O

19	O
.	O

Current	O
treatment	O
with	O
barbiturates	B-Drug
,	O
MAO	B-Drug
inhibitors	I-Drug
butyrophenones	B-Drug
,	O
phenothiazines	B-Drug
and	O
other	O
"conventional"	B-Drug
antipsychotic	I-Drug
within	O
30	O
days	O
or	O
5	O
half-lives	O
prior	O
to	O
Screening,	O
whichever	O
is	O
longer	O
.	O

20	O
.	O

Treatment	O
with	O
antidepressants	B-Drug
,	O
(	O
other	B-Negation_cue
than	I-Negation_cue
MAO	B-Drug
inhibitors	I-Drug
),	O
thyroid	B-Drug
hormones	I-Drug
atypical	B-Drug
antipsychotics	I-Drug
(	O
eg	O
risperidone	B-Drug
),	O
benzodiazepines	B-Drug
and	O
other	O
sedatives	B-Drug
/	O
hypnotics	B-Drug
unless	O
prescribed	O
at	O
a	O
stable	O
dose	O
for	O
at	O
least	O
2	O
months	O
prior	O
to	O
Screening	O
.	O

Note	O
:	O
Benzodiazepines	O
or	O
other	O
sedatives	O
/	O
hypnotics	O
(	O
including	O
antihistamines	O
)	O
with	O
half-life	O
less	O
than	O
6	O
hours	O
can	O
be	O
taken	O
on	O
a	O
prn	O
(	O
as	O
needed	O
)	O
basis	O
but	O
must	O
not	O
be	O
taken	O
within	O
5	O
half	O
lives	O
prior	O
to	O
cognitive	O
testing	O
.	O

21	O
.	O

Current	O
treatment	O
with	O
known	O
potent	B-Drug
inhibitors	I-Drug
of	I-Drug
CYP3A4	I-Drug
(	O
eg	O
ketoconazole	B-Drug
,	O
rifampin	B-Drug
,	O
modafinil	B-Drug
)	O
.	O

22	O
.	O

Current	O
treatment	O
with	O
known	O
potent	B-Drug
Pgp	I-Drug
inhibitors	I-Drug
(	O
itraconazole	B-Drug
,	O
ketoconazole	B-Drug
,	O
cyclosporin	B-Drug
,	O
loperamide	B-Drug
,	O
diltiazem	B-Drug
,	O
verapamil	B-Drug
,	O
spironolactone	B-Drug
,	O
quinidine	B-Drug
,	O
bepridil	B-Drug
,	O
quinine	B-Drug
,	O
carvedilol	B-Drug
)	O
.	O

23	O
.	O

Cognitive	O
tasks	O
prescribed	O
for	O
cognitive	B-Procedure_Device
rehabilitation	I-Procedure_Device
and	O
performed	O
under	O
medical	O
supervision	O
in	O
the	O
6	O
months	O
prior	O
to	O
screening	O
and	O
/	O
or	O
during	O
study	O
.	O

24	O
.	O

Investigational	B-Drug
medications	I-Drug
or	O
devices	B-Procedure_Device
including	O
symptomatic	B-Procedure_Device
AD	I-Procedure_Device
treatment	I-Procedure_Device
during	O
the	O
60	O
days	O
prior	O
to	O
the	O
Screening	O
visit	O
or	O
within	O
5	O
half-lives	O
of	O
use	O
of	O
the	O
investigational	B-Drug
drug	I-Drug
prior	O
to	O
the	O
Screening	O
Visit,	O
whichever	O
is	O
longer	O
.	O

25	O
.	O

Participation	O
in	O
another	O
investigational	B-Drug
drug	I-Drug
(	O
with	O
the	O
exception	B-Negation_cue
of	O
anti-amyloid	B-Drug
monoclonal	I-Drug
antibodies	I-Drug
[mAbs]	I-Drug
or	O
device	O
study	O
where	O
subject	O
was	O
treated	O
chronically	O
(	O
i.e	O
.	O

>	O
1	O
single	O
dose	O
)	O
with	O
a	O
study	B-Drug
agent	I-Drug
intended	O
to	O
impact	O
AD	B-Condition
progression	O
during	O
the	O
12	O
months	O
prior	O
to	O
the	O
Screening	O
visit	O
.	O

1	O
.	O

Subjects	O
who	O
participated	O
in	O
an	O
investigational	B-Drug
drug	I-Drug
study	O
that	O
involved	O
chronic	O
dosing	O
with	O
a	O
monoclonal	B-Drug
antibody	I-Drug
at	O
any	O
time	O
in	O
the	O
past	O
are	O
excluded	O
from	O
this	O
study,	O
unless	O
it	O
is	O
known	O
that	O
they	O
received	O
placebo	O
during	O
the	O
previous	O
study	O
.	O

2	O
.	O

Subjects	O
who	O
participated	O
in	O
previous	O
single-dose	O
studies	O
of	O
anti-amyloid	B-Drug
mAbs	I-Drug
will	O
be	O
permitted	O
provided	O
the	O
subject's	O
dose	O
of	O
the	O
mAb	B-Drug
is	O
at	O
least	O
5	O
half-lives	O
removed;	O
the	O
subjects	O
did	O
not	B-Negation_cue
experience	O
any	O
moderate	O
adverse	B-Condition
events	I-Condition
classified	O
as	O
possibly	O
drug-related	O
or	O
any	O
serious	O
adverse	O
event	O
during	O
that	O
study;	O
the	O
subject	O
did	O
not	O
drop	O
out	O
of	O
the	O
previous	O
study	O
(	O
i.e	O
.	O

completed	O
all	O
safety	O
assessments	O
)	O
.	O

26	O
.	O

Subjects,	O
who	O
in	O
the	O
investigator's	O
judgement,	O
pose	O
a	O
significant	O
suicide	B-Condition
risk	I-Condition
(	O
eg	O
history	O
of	O
suicidal	B-Condition
behaviour	I-Condition
in	O
the	O
last	O
6	O
months	O
and	O
/	O
or	O
any	O
suicidal	B-Condition
ideation	I-Condition
of	O
type	O
4	O
or	O
5	O
on	O
the	O
C-SSRS	B-Observation
in	O
the	O
last	O
2	O
months	O
)	O
.	O

27	O
.	O

Subject	O
or	O
caregiver	O
is	O
an	O
immediate	O
family	O
member	O
or	O
employee	O
of	O
the	O
participating	O
Investigator,	O
any	O
of	O
the	O
participating	O
site	O
staff	O
or	O
GSK	O
staff	O
.	O

28	O
.	O

Any	O
contraindication	B-Condition
to	O
lumbar	B-Procedure_Device
puncture	I-Procedure_Device
or	O
insertion	B-Procedure_Device
of	I-Procedure_Device
CSF	I-Procedure_Device
catheter	I-Procedure_Device
including	O
but	O
not	O
limited	O
to	O
.	O

1	O
.	O

Thrombocytopenia	B-Condition
or	O
other	O
coagulation	B-Condition
disorders	I-Condition
(	O
including	O
subjects	O
receiving	O
coumarin-derived	B-Drug
anti-coagulants	I-Drug
or	O
low-molecular-weight	B-Drug
heparin	I-Drug
)	O
.	O

2	O
.	O

The	O
presence	O
of	O
cutaneous	B-Condition
or	I-Condition
soft	I-Condition
tissue	I-Condition
infection	I-Condition
overlying	O
or	O
adjacent	O
to	O
the	O
site	O
of	O
lumbar	B-Procedure_Device
puncture	I-Procedure_Device
.	O

3	O
.	O

Previous	O
spinal	B-Procedure_Device
surgery	I-Procedure_Device
that	O
could	O
complicate	O
access	O
to	O
the	O
subarachnoid	O
space	O
.	O

4	O
.	O

Suspicion	O
of	O
increased	O
intracranial	B-Observation
pressure	I-Observation
due	O
to	O
a	O
cerebral	B-Condition
mass	I-Condition
.	O

>>NCT00469456	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Male	O
and	O
female	O
outpatients,	O
50	O
years	O
or	O
older,	O
native	O
English	O
speakers,	O
meeting	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke--Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINCDS-ADRDA	I-Observation
)	I-Observation
criteria	I-Observation
for	O
probable	O
AD	B-Condition
with	O
a	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
of	O
10	O
to	O
19	O
at	O
Screening	O
and	O
Baseline	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Current	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders--Fourth	O
Edition	O
(	O
DSM-IV	O
)	O
Axis	B-Condition
I	I-Condition
disorder	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
.	O

-	O
Previous	O
imaging	B-Procedure_Device
results	I-Procedure_Device
not	B-Negation_cue
consistent	O
with	O
the	O
diagnosis	O
of	O
AD	B-Condition
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
Score	I-Observation
greater	O
than	O
4	O
.	O

-	O
Evidence	O
of	O
other	O
neurologic	B-Condition
disorders	I-Condition
.	O

-	O
Clinically	O
significant	O
systemic	B-Condition
disease	I-Condition
.	O

-	O
A	O
known	O
or	O
suspected	O
history	O
of	O
alcohol	B-Condition
or	I-Condition
drug	I-Condition
abuse	I-Condition
in	O
the	O
past	O
5	O
years	O
.	O

-	O
Taking	O
excluded	O
medication	B-Condition
.	O

-	O
Previous	O
treatment	O
with	O
commercial	B-Drug
memantine	I-Drug
.	O

>>NCT00814697	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Subjects	O
must	O
have	O
a	O
diagnosis	O
of	O
probable	O
or	O
possible	O
Alzheimer's	B-Condition
disease	I-Condition
diagnosed	O
using	O
standardized	O
criteria	O
.	O

-	O
If	O
subjects	O
are	O
determined	O
by	O
the	O
PI	O
to	O
lack	O
decisional	O
capacity	O
to	O
consent	O
to	O
the	O
study,	O
a	O
legally	O
authorized	O
representative	O
must	O
be	O
available	O
to	O
sign	O
the	O
informed	O
consent	O
on	O
behalf	O
of	O
the	O
subject	O
.	O

In	O
this	O
case	O
the	O
assent	O
of	O
each	O
subject	O
will	O
be	O
obtained	O
as	O
well	O
.	O

If	O
at	O
any	O
time	O
the	O
subject	O
withdraws	O
his	O
or	O
her	O
assent,	O
the	O
subject	O
will	O
be	O
disenrolled	O
from	O
the	O
study	O
.	O

-	O
Subjects	O
will	O
score	O
at	O
or	O
below	O
30	O
on	O
the	O
60	B-Observation
item	I-Observation
naming	I-Observation
section	I-Observation
of	I-Observation
the	I-Observation
Boston	I-Observation
Diagnostic	I-Observation
Aphasia	I-Observation
and	O
/	O
or	O
below	O
50%	O
on	O
the	O
Controlled	B-Observation
Word	I-Observation
Association	I-Observation
(	I-Observation
CFL	I-Observation
)	I-Observation
Category	I-Observation
Naming	I-Observation
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Subjects	O
newly	O
diagnosed	O
with	O
AD	B-Condition
and	O
not	O
yet	O
receiving	O
usual	O
care	O
are	O
not	O
eligible	O
.	O

-	O
Subjects	O
must	O
not	B-Negation_cue
have	O
pacemakers	B-Procedure_Device
.	O

-	O
They	O
must	O
not	B-Negation_cue
have	O
a	O
history	O
of	O
implanted	B-Condition
metal	I-Condition
objects	I-Condition
.	O

-	O
They	O
must	O
not	B-Negation_cue
have	O
a	O
history	O
of	O
seizures	B-Condition
or	O
epilepsy	B-Condition
.	O

-	O
There	O
must	O
not	B-Negation_cue
be	O
any	O
recent	O
history	O
of	O
migraines	B-Condition
.	O

-	O
There	O
must	O
not	B-Negation_cue
be	O
any	O
history	O
of	O
uncontrolled	O
depression	B-Condition
.	O

-	O
They	O
must	O
not	B-Negation_cue
be	O
on	O
any	O
medications	B-Drug
that	O
will	O
significantly	O
lower	O
the	O
seizure	O
threshold	O
.	O

-	O
Any	O
other	O
medical	B-Condition
condition	I-Condition
that	O
is	O
judged	O
by	O
the	O
PI	O
to	O
make	O
rTMS	B-Procedure_Device
unsafe	O
for	O
the	O
subject	O
.	O

>>NCT00034762	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
A	O
diagnosis	O
of	O
dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
type	I-Condition
with	O
or	O
without	O
a	O
vascular	O
component,	O
a	O
score	O
of	O
2	O
or	O
more	O
on	O
any	O
item	O
of	O
the	O
BEHAVE-AD	B-Observation
psychosis	I-Observation
subscale	I-Observation
at	O
screening	O
and	O
a	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
of	O
5	O
to	O
23	O
.	O

-	O
Residents	O
of	O
nursing	O
homes	O
or	O
long-term	O
care	O
facilities	O
and	O
deemed	O
in	O
need	O
of	O
treatment	O
with	O
an	O
atypical	O
antipsychotic	O
medication	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Disease	B-Condition
that	O
could	O
significantly	O
diminish	O
cognitive	B-Observation
function	I-Observation
.	O

-	O
history	O
of	O
neuroleptic	B-Condition
malignant	I-Condition
syndrome	I-Condition
.	O

-	O
hypersensitivity	B-Condition
to	O
risperidone	B-Drug
.	O

>>NCT00087789	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Alzheimer's	B-Condition
disease	I-Condition
as	O
determined	O
by	O
NINCDS	B-Observation
/	I-Observation
ADRDA	I-Observation
criteria	I-Observation
.	O

-	O
Score	O
of	O
<=	O
4	O
on	O
a	O
modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
Scale	I-Observation
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
in	O
the	O
range	O
of	O
16	O
to	O
28,	O
inclusive	O
.	O

-	O
No	B-Negation_cue
significant	O
neurological	B-Condition
or	I-Condition
medical	I-Condition
abnormalities	I-Condition
contraindicating	B-Condition
surgery	B-Procedure_Device
,	O
MRI	B-Procedure_Device
/	I-Procedure_Device
PET	I-Procedure_Device
imaging	I-Procedure_Device
or	O
study	O
participation	O
.	O

-	O
Subjects	O
stable	O
on	O
standard-of-care	B-Drug
medications	I-Drug
(	O
i.e.,	O
acetylcholinesterase	B-Drug
inhibitors	I-Drug
)	O
for	O
Alzheimer's	B-Condition
disease	I-Condition
for	O
3	O
months	O
prior	O
to	O
entry	O
.	O

-	O
A	O
Hamilton	B-Observation
Depression	I-Observation
Scale	I-Observation
score	I-Observation
of	O
<=	O
12	O
on	O
a	O
17	O
-item	O
scale	O
and	O
no	B-Negation_cue
history	O
of	O
major	O
depressive	B-Condition
episode	I-Condition
within	O
the	O
last	O
2	O
years	O
.	O

-	O
A	O
score	O
of	O
<	O
15	O
on	O
the	O
Beck	B-Observation
Depression	I-Observation
Inventory	I-Observation
.	O

-	O
Adequate	O
visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
to	O
allow	O
neuropsychological	O
testing	O
.	O

-	O
Good	O
health	B-Condition
with	O
no	B-Negation_cue
clinically	O
significant	O
medical	B-Condition
or	I-Condition
psychological	I-Condition
conditions	I-Condition
.	O

-	O
An	O
MRI	B-Procedure_Device
of	O
the	O
head	O
at	O
screen	O
that	O
is	O
negative	O
for	O
evidence	O
of	O
infection	B-Condition
,	O
tumor	B-Condition
,	O
infarction	B-Condition
or	O
other	O
focal	B-Condition
(	O
eg	O
,	O
subdural	B-Condition
hematoma	I-Condition
)	O
or	O
generalized	B-Condition
lesions	I-Condition
(	O
eg	O
,	O
v	B-Condition
hydrocephalus	I-Condition
)	O
and	O
without	B-Negation_cue
clinical	O
symptoms	O
suggestive	O
of	O
ntervening	B-Condition
neurological	I-Condition
disease	I-Condition
.	O

-	O
Normal	O
serum	B-Observation
B12,	I-Observation
thyroid	I-Observation
function	I-Observation
tests	I-Observation
and	O
negative	O
syphilis	B-Observation
antibody	I-Observation
test	I-Observation
.	O

-	O
The	O
informed	O
consent	O
document	O
must	O
be	O
signed	O
by	O
both	O
:	O
.	O

a	O
competent	O
and	O
willing	O
subject	O
and	O
a	O
surrogate	O
identified	O
by	O
the	O
participant	O
or	O
a	O
legally	O
authorized	O
power	O
of	O
attorney	O
for	O
Health	O
Care	O
or	O
a	O
family	O
member	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
History	O
of	O
cancer	B-Condition
within	O
the	O
last	O
five	O
years,	O
except	B-Negation_cue
superficial	O
basal	B-Condition
or	I-Condition
squamous	I-Condition
cell	I-Condition
skin	I-Condition
cancer	I-Condition
or	O
cervical	B-Condition
carcinoma	I-Condition
in	I-Condition
situ	I-Condition
.	O

-	O
History	O
of	O
alcohol	B-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
within	O
the	O
last	O
two	O
years	O
.	O

-	O
Liver	B-Observation
serum	I-Observation
transaminases	I-Observation
(	O
AST	B-Observation
and	O
/	O
or	O
ALT	B-Observation
)	O
>	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal;	O
total	B-Observation
and	I-Observation
/	I-Observation
or	I-Observation
direct	I-Observation
bilirubin	I-Observation
>	O
1.5	O
mg	O
/	O
dL,	O
hemoglobin	B-Observation
<	O
9mg	O
/	O
dL;	O
PT	B-Observation
and	I-Observation
PTT	I-Observation
>	O
2	O
times	O
the	O
upper	O
limit	O
of	O
normal;	O
creatinine	B-Observation
clearance	I-Observation
<	O
30	O
mL	O
/	O
min;	O
positive	O
serology	B-Observation
for	I-Observation
HBV	I-Observation
or	I-Observation
HCV	I-Observation
absolute	B-Observation
neutrophil	I-Observation
count	I-Observation
<	O
1500	O
cells	O
/	O
mm3	O
and	O
a	O
platelet	B-Observation
count	I-Observation
<	O
100000	O
/	O
mm3	O
.	O

-	O
Any	O
significant	O
systemic	B-Condition
illness	I-Condition
unstable	O
or	O
severe	O
medical	B-Condition
condition	I-Condition
(	I-Condition
s	I-Condition
)	I-Condition
that	O
could	O
put	O
the	O
subject	O
at	O
risk	O
during	O
the	O
study,	O
interfere	O
with	O
outcome	O
measures	O
or	O
affect	O
compliance	O
with	O
the	O
protocol	O
procedures	O
.	O

-	O
Centrally	B-Drug
active	I-Drug
beta-blockers	I-Drug
anti-Parkinsonian	B-Drug
medications	I-Drug
psychostimulants	B-Drug
,	O
antipsychotics	B-Drug
,	O
neuroleptics	B-Drug
or	O
narcotic	B-Drug
analgesics	I-Drug
long-acting	O
benzodiazepines	B-Drug
or	O
barbiturates	B-Drug
,	O
hypertensive	B-Drug
agents	I-Drug
with	O
a	O
CNS	O
effect,	O
short-acting	O
anxiolytics	B-Drug
or	O
sedative	B-Drug
hypnotics	I-Drug
more	O
frequently	O
than	O
two	O
times	O
per	O
week	O
within	O
14	O
days	O
of	O
screening,	O
herbal	B-Drug
products	I-Drug
for	O
Alzheimer's	B-Condition
disease	I-Condition
antidepressants	B-Drug
with	O
significant	O
cholinergic	B-Condition
side	I-Condition
effects	I-Condition
(	O
eg	O
,	O
tricyclics	B-Drug
),	O
initiation	O
or	O
change	O
in	O
dose	O
of	O
standard	B-Drug
treatment	I-Drug
for	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Other	O
medication	B-Drug
with	O
significant	O
cholinergic	B-Condition
or	I-Condition
anticholinergic	I-Condition
side	I-Condition
effects	I-Condition
.	O

-	O
Warfarin	B-Drug
(	O
coumadin	B-Drug
),	O
nonsteroidal	B-Drug
anti-inflammatory	I-Drug
drugs	I-Drug
aspirin	B-Drug
,	O
Prozac	B-Drug
or	I-Drug
Ginkgo	I-Drug
biloba	I-Drug
within	O
14	O
days	O
of	O
surgery	B-Procedure_Device
.	O

-	O
Subjects	O
who	O
have	O
received	O
investigational	B-Drug
agents	I-Drug
or	O
been	O
exposed	O
to	O
investigational	B-Procedure_Device
devices	I-Procedure_Device
for	O
30	O
days	O
prior	O
to	O
enrollment	O
.	O

-	O
Subjects	O
with	O
a	O
history	O
of	O
receiving	O
gene	B-Drug
transfer	I-Drug
products	I-Drug
of	O
any	O
kind	O
.	O

-	O
Subjects	O
who	O
cannot	B-Negation_cue
undergo	O
MRI	B-Procedure_Device
or	O
PET	B-Procedure_Device
screening.	O

>>NCT00216515	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Male	O
or	O
female	O
patients	O
aged	B-Observation
50	O
years	O
or	O
older	O
.	O

-	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
the	O
criteria	O
of	O
DSM-IV15	B-Observation
,	O
NINCDS-ADRDA16	B-Observation
.	O

-	O
Measuring	O
standard	B-Observation
MMSE-K	I-Observation
10	O
to	O
26	O
.	O

-	O
Patients	O
who	O
are	O
literate	O
.	O

-	O
Dementia	B-Condition
patients	O
being	O
nursed	O
by	O
the	O
family	O
.	O

-	O
Patients	O
who	O
submitted	O
written	O
consent	O
before	O
entering	O
into	O
the	O
clinical	O
trial	O
(	O
the	O
guardian	O
consent	O
is	O
also	O
effective	O
)	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
If	O
the	O
patient	O
was	O
taking	O
AChEI	B-Drug
(	O
Tacrine	B-Drug
,	O
Donepezil	B-Drug
,	O
Rivastigmine	B-Drug
)	O
to	O
treat	O
dementia	B-Condition
,	O
the	O
patient	O
can	O
enter	O
into	O
this	O
clinical	O
trial	O
as	O
long	O
as	O
he	O
/	O
she	O
has	O
not	O
taken	O
the	O
drug	B-Drug
within	O
15	O
days	O
of	O
the	O
beginning	O
of	O
the	O
clinical	O
trial	O
.	O

-	O
Neurodegenerative	B-Condition
diseases	I-Condition
(	O
eg	O
Parkinson's	B-Condition
disease	I-Condition
Pick's	B-Condition
disease	I-Condition
Huntington's	B-Condition
disease	I-Condition
Down	B-Condition
syndrome	I-Condition
)	O
.	O

-	O
Dementia	B-Condition
related	O
to	O
head	B-Condition
trauma	I-Condition
and	O
dementia	B-Condition
related	O
to	O
brain	B-Condition
damage	I-Condition
due	O
to	O
cerebral	B-Condition
hypoxia	I-Condition
(	O
hypoxic	B-Condition
brain	I-Condition
damage	I-Condition
after	O
cardiopulmonary	B-Procedure_Device
resuscitation	I-Procedure_Device
hypoxic	B-Condition
brain	I-Condition
damage	I-Condition
after	O
surgery	B-Procedure_Device
,	O
hypoxic	B-Condition
brain	I-Condition
damage	I-Condition
due	O
to	O
addiction	B-Condition
,	O
hypoxic	B-Condition
brain	I-Condition
damage	I-Condition
due	O
to	O
shock	B-Condition
)	O
.	O

-	O
brain	B-Condition
tumor	I-Condition
nerve	B-Condition
syphilis	I-Condition
meningitis	B-Condition
,	O
encephalitis	B-Condition
,	O
brain	B-Condition
tumor	I-Condition
.	O

-	O
amentia	B-Condition
.	O

-	O
epilepsy	B-Condition
.	O

-	O
major	O
psychiatric	B-Condition
patients	O
such	O
as	O
major	B-Condition
depression	I-Condition
and	O
schizophrenia	B-Condition
.	O

-	O
treatment-resistant	B-Condition
gastric	I-Condition
and	O
peptic	B-Condition
ulcer	I-Condition
.	O

-	O
patients	O
with	O
clinically	O
serious	O
hepatic,	B-Condition
renal,	I-Condition
lung,	I-Condition
endocrinal	I-Condition
or	I-Condition
metabolic	I-Condition
disease	I-Condition
(	O
thyroid	B-Condition
,	O
parathyroid	B-Condition
,	O
pituitary	B-Condition
,	O
renal	B-Condition
failure	I-Condition
diabetes	B-Condition
mellitus	I-Condition
)	O
.	O

-	O
patients	O
complaining	O
of	O
severe	O
difficulty	O
in	O
urination	O
.	O

-	O
patients	O
who	O
have	O
undergone	O
heart	B-Procedure_Device
surgery	I-Procedure_Device
within	O
6	O
months	O
or	O
patients	O
who	O
experienced	O
myocardial	B-Condition
infarction	I-Condition
patients	O
with	O
untreated	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
patients	O
with	O
severe	O
disorders	B-Condition
in	O
the	O
mitral	O
valve	O
or	O
aortic	O
valve	O
.	O

-	O
patients	O
who	O
have	O
once	O
taken	O
the	O
investigational	B-Drug
drugs	I-Drug
within	O
the	O
past	O
1	O
month	O
from	O
the	O
beginning	O
day	O
of	O
the	O
clinical	O
trial	O
.	O

-	O
patients	O
with	O
uncontrolled	O
diabetes	B-Condition
mellitus	I-Condition
(	O
if	O
the	O
patient	O
is	O
taking	O
medication	O
and	O
consults	O
the	O
doctor	O
on	O
a	O
regular	O
basis,	O
he	O
/	O
she	O
can	O
participate	O
in	O
this	O
clinical	O
trial	O
)	O
.	O

-	O
patients	O
who	O
experienced	O
hypersensitivity	B-Condition
or	O
allergy	B-Condition
by	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
.	O

-	O
patients	O
who	O
have	O
not	O
given	O
their	O
consent	O
to	O
the	O
clinical	O
trial,	O
patients	O
who	O
are	O
judged	O
inappropriate	O
to	O
participate	O
in	O
this	O
clinical	O
trial	O
by	O
the	O
investigator	O
.	O

>>NCT02537496	O
Inclusion	O
Criteria	O
for	O
AD	O
participants	O
:	O
.	O

1	O
.	O

Age	B-Observation
55	O
years	O
or	O
above	O
.	O

2	O
.	O

Ability	O
to	O
understand	O
and	O
speak	O
English	O
.	O

3	O
.	O

Confirmed	O
Diagnosis	O
of	O
Probable	O
AD	B-Condition
by	O
NIA-AA	B-Observation
criteria	I-Observation
.	O

4	O
.	O

Either	O
not	O
taking	O
Cognitive	B-Drug
enhancers	I-Drug
or	O
taking	O
them	O
at	O
a	O
stable	O
dose	O
for	O
the	O
last	O
3	O
months	O
.	O

5	O
.	O

Willingness	O
and	O
ability	O
to	O
provide	O
informed	O
consent	O
or	O
an	O
ability	O
to	O
assent	O
and	O
availability	O
of	O
a	O
substitute	O
decision	O
maker	O
willing	O
to	O
provide	O
consent	O
on	O
participant's	O
behalf	O
.	O

6	O
.	O

Corrected	O
visual	B-Observation
acuity	I-Observation
enough	O
to	O
read	O
newspaper	O
headlines	O
.	O

7	O
.	O

Ability	O
to	O
hear	O
a	O
raised	O
conversational	O
voice,	O
with	O
hearing	O
aids	O
if	O
needed	O
.	O

Inclusion	O
criteria	O
for	O
healthy	B-Condition
control	O
participants	O
:	O
.	O

1	O
.	O

Age	B-Observation
55	O
or	O
above	O
.	O

2	O
.	O

Willingness	O
and	O
ability	O
to	O
speak	O
English	O
.	O

3	O
.	O

Willingness	O
and	O
ability	O
to	O
provide	O
informed	O
consent	O
.	O

4	O
.	O

Corrected	O
visual	B-Observation
acuity	I-Observation
enough	O
to	O
read	O
newspaper	O
headlines	O
.	O

5	O
.	O

Ability	O
to	O
hear	O
a	O
raised	O
conversational	O
voice,	O
with	O
hearing	O
aids	O
if	O
needed	O
.	O

Exclusion	O
Criteria	O
for	O
AD	B-Condition
participants	O
:	O
.	O

1	O
.	O

MOCA	B-Observation
score	I-Observation
<	O
10	O
.	O

2	O
.	O

DSM	B-Observation
IV	I-Observation
-	I-Observation
TR	I-Observation
diagnosis	O
of	O
a	O
current	O
episode	O
of	O
mood	B-Condition
disorder	I-Condition
in	O
the	O
last	O
3	O
months	O
.	O

3	O
.	O

DSM	B-Observation
IV	I-Observation
-	I-Observation
TR	I-Observation
diagnosis	O
of	O
a	O
current	O
anxiety	B-Condition
disorder	I-Condition
in	O
the	O
last	O
3	O
months	O
.	O

4	O
.	O

DSM	B-Observation
IV	I-Observation
-	I-Observation
TR	I-Observation
diagnosis	O
of	O
a	O
current	O
substance	B-Condition
use	I-Condition
disorder	I-Condition
in	O
the	O
last	O
3	O
months	O
.	O

5	O
.	O

DSM	B-Observation
IV	I-Observation
-	I-Observation
TR	I-Observation
diagnosis	O
of	O
a	O
current	O
or	O
lifetime	O
primary	B-Condition
psychotic	I-Condition
disorder	I-Condition
.	O

6	O
.	O

Diagnosis	O
of	O
intellectual	B-Condition
disability	I-Condition
or	O
a	O
neurodevelopmental	B-Condition
disorder	I-Condition
.	O

7	O
.	O

Electroconvulsive	B-Procedure_Device
Therapy	I-Procedure_Device
treatment	I-Procedure_Device
in	O
the	O
last	O
6	O
months	O
.	O

8	O
.	O

History	O
of	O
a	O
seizure	B-Condition
other	B-Negation_cue
than	I-Negation_cue
a	O
febrile	B-Condition
seizure	I-Condition
in	O
infancy	O
.	O

9	O
.	O

Currently	O
taking	O
Anticonvulsants	B-Drug
or	O
Benzodiazepines	B-Drug
.	O

10	O
.	O

Any	O
contraindication	B-Condition
for	O
TMS	B-Procedure_Device
or	O
any	O
other	O
medical	B-Condition
condition	I-Condition
/	I-Condition
circumstances	I-Condition
that	O
would	O
make	O
the	O
study	O
participation	O
difficult	O
for	O
the	O
participant	O
.	O

Exclusion	O
criteria	O
for	O
healthy	B-Condition
control	O
participants	O
:	O
.	O

1	O
.	O

Meets	O
criteria	O
for	O
a	O
DSM	B-Observation
IV	I-Observation
-	I-Observation
TR	I-Observation
diagnosis	O
other	B-Negation_cue
than	I-Negation_cue
simple	B-Condition
phobias	I-Condition
or	O
Adjustment	B-Condition
disorder	I-Condition
.	O

2	O
.	O

Any	O
other	O
neurological	B-Condition
disorder	I-Condition
affecting	O
central	O
nervous	O
system	O
.	O

3	O
.	O

Psychotropic	B-Drug
medication	I-Drug
except	B-Negation_cue
for	O
sedative	B-Drug
hypnotics	B-Drug
at	O
a	O
stable	O
dose	O
for	O
at	O
least	O
4	O
weeks	O
.	O

4	O
.	O

History	O
of	O
seizure	B-Condition
other	B-Negation_cue
than	I-Negation_cue
a	O
febrile	B-Condition
seizure	I-Condition
in	O
infancy	O
.	O

5	O
.	O

Currently	O
taking	O
Anticonvulsants	B-Drug
or	O
Benzodiazepines	B-Drug
.	O

6	O
.	O

Any	O
contraindication	B-Condition
for	O
TMS	B-Procedure_Device
or	O
any	O
other	O
medical	B-Condition
condition	I-Condition
/	I-Condition
circumstances	I-Condition
that	O
would	O
make	O
the	O
study	O
participation	O
difficult	O
for	O
the	O
participant	O
.	O

>>NCT00439010	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
The	O
participant	O
is	O
50	O
years	O
or	O
older	O
.	O

-	O
Written	O
informed	O
consent	O
is	O
obtained	O
.	O

-	O
Participants	O
have	O
a	O
clinical	O
diagnosis	O
of	O
Alzheimer's	B-Condition
diseas	I-Condition
based	O
on	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke	I-Observation
/	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINCDS	I-Observation
.	O

-	O
Mini-Mental	B-Observation
Status	I-Observation
Exam	I-Observation
score	I-Observation
<	O
25	O
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
Scale	I-Observation
score	I-Observation
of	O
<=	O
4	O
.	O

-	O
Geriatric	B-Observation
Depression	I-Observation
Scales	I-Observation
(	I-Observation
GDS	I-Observation
)	I-Observation
<=	O
10	O
.	O

-	O
For	O
females,	O
non-child	B-Condition
bearing	I-Condition
potential	I-Condition
or	O
negative	O
urine	B-Observation
or	I-Observation
blood	I-Observation
pregnancy	I-Observation
test	I-Observation
on	O
day	O
of	O
123	O
-I	O
AV39	O
injection	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
The	O
subject	O
has	O
signs	O
or	O
symptoms	O
of	O
another	O
neurodegenerative	B-Condition
disease	I-Condition
including	O
Parkinson's	B-Condition
disease	I-Condition
diffuse	B-Condition
Lewy	I-Condition
body	I-Condition
dementia	I-Condition
or	O
history	O
of	O
significant	O
cerebrovascular	B-Condition
disease	I-Condition
.	O

-	O
The	O
subject	O
has	O
a	O
clinically	O
significant	O
abnormal	O
laboratory	B-Observation
value	I-Observation
and	O
/	O
or	O
clinically	O
significant	O
unstable	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
.	O

-	O
The	O
subject	O
has	O
any	O
disorder	B-Condition
that	O
may	O
interfere	O
with	O
drug	O
absorption	B-Observation
distribution	I-Observation
metabolism	B-Observation
or	O
excretion	B-Observation
(	O
including	O
gastrointestinal	B-Procedure_Device
surgery	I-Procedure_Device
)	O
.	O

-	O
The	O
subject	O
has	O
evidence	O
of	O
clinically	O
significant	O
gastrointestinal,	B-Condition
cardiovascular,	I-Condition
hepatic,	I-Condition
renal,	I-Condition
hematological,	I-Condition
neoplastic,	I-Condition
endocrine,	I-Condition
neurological,	I-Condition
immunodeficiency,	I-Condition
pulmonary	I-Condition
or	I-Condition
other	I-Condition
disorder	I-Condition
or	I-Condition
disease	I-Condition
.	O

-	O
Pregnancy	O
.	O

>>NCT01928420	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
NINCDS	B-Observation
/	I-Observation
ADRDA	I-Observation
criteria	I-Observation
for	O
probable	O
AD	B-Condition
.	O

-	O
MMSE	B-Observation
between	O
12	O
-	O
27	O
.	O

-	O
Treatment	O
with	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
or	O
an	O
NMDA	B-Drug
(	I-Drug
N-methyl-D-asparate	I-Drug
)	I-Drug
antagonist	I-Drug
with	O
stable	O
dose	O
for	O
at	O
least	O
12	O
weeks	O
.	O

-	O
Home	O
monitoring	O
available	O
for	O
supervision	O
of	O
medications	O
.	O

-	O
Caregiver	O
available	O
to	O
accompany	O
patient	O
to	O
all	O
visits	O
and	O
willing	O
to	O
participate	O
in	O
study	O
as	O
informant	O
.	O

-	O
Fluent	O
in	O
English	O
or	O
Spanish	O
.	O

-	O
Medical	O
stability	O
for	O
this	O
study	O
as	O
confirmed	O
by	O
review	O
of	O
records,	O
internist's	O
physical	O
exam,	O
neurological	O
exam	O
and	O
laboratory	O
tests	O
.	O

-	O
Stable	O
doses	O
of	O
non-excluded	B-Condition
medication	I-Condition
.	O

-	O
No	B-Negation_cue
evidence	O
of	O
hepatic	B-Condition
insufficiency	I-Condition
.	O

-	O
Able	O
to	O
swallow	O
oral	O
medications	O
.	O

-	O
Ability	O
to	O
participate	O
in	O
the	O
informed	O
consent	O
process	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
History	O
of	O
Diabetes	B-Condition
Mellitus	I-Condition
(	O
OGTT	B-Observation
criteria	I-Observation
)	O
requiring	O
treatment	O
with	O
an	O
excluded	B-Drug
antidiabetic	I-Drug
medication	I-Drug
(	O
see	O
below	O
)	O
or	O
history	O
of	O
hypoglycemia	B-Condition
.	O

-	O
Active	O
hepatic	B-Condition
or	I-Condition
renal	I-Condition
disease	I-Condition
.	O

-	O
Cardiac	B-Condition
disease	I-Condition
including	O
history	O
of	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
or	O
current	O
treatment	B-Drug
for	O
CHF	B-Condition
;	O
history	O
of	O
recent	O
myocardial	B-Condition
infarction	I-Condition
.	O

-	O
Use	O
of	O
another	O
investigational	B-Drug
drug	I-Drug
within	O
the	O
past	O
two	O
months	O
.	O

-	O
History	O
of	O
clinically	O
significant	O
stroke	B-Condition
.	O

-	O
History	O
of	O
seizure	B-Condition
or	O
head	B-Condition
trauma	I-Condition
with	I-Condition
disturbance	I-Condition
of	I-Condition
consciousness	I-Condition
within	O
the	O
past	O
two	O
years	O
.	O

-	O
Major	O
mental	B-Condition
illness	I-Condition
including	O
psychotic	B-Condition
disorders	I-Condition
bipolar	B-Condition
disorder	I-Condition
or	O
major	B-Condition
depressive	I-Condition
episode	I-Condition
within	O
the	O
past	O
two	O
years	O
Medication	O
Exclusion	O
.	O

-	O
Current	O
use	O
of	O
oral	B-Drug
hypoglycemic	I-Drug
agents	I-Drug
including	O
sulfonylureas	B-Drug
and	O
meglintinides	B-Drug
.	O

-	O
Current	O
or	O
past	O
treatment	O
with	O
insulin	B-Drug
for	O
longer	O
than	O
two	O
weeks	O
.	O

-	O
Current	O
use	O
of	O
drugs	B-Drug
with	I-Drug
significant	I-Drug
anticholinergic	I-Drug
or	I-Drug
antihistaminic	I-Drug
properties	I-Drug
.	O

>>NCT00948766	O
Core	O
study	O
.	O

Inclusion	O
Criteria	O
:	O
.	O

-	O
Diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
(	I-Condition
AD	I-Condition
)	I-Condition
according	O
to	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke	I-Observation
and	I-Observation
the	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINCDS	I-Observation
/	I-Observation
ADRDA	I-Observation
)	I-Observation
criteria	I-Observation
.	O

-	O
A	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
of	O
>=	O
3	O
and	O
<=	O
12	O
.	O

-	O
Be	O
able	O
to	O
complete	O
at	O
least	O
1	O
item	O
on	O
the	O
Severe	O
Impairment	O
Battery	O
(	O
SIB	O
)	O
.	O

-	O
Residing	O
with	O
someone	O
in	O
the	O
community	O
or	O
in	O
regular	O
contact	O
with	O
the	O
primary	O
caregiver	O
.	O

-	O
Be	O
ambulatory	O
or	O
ambulatory	O
with	O
aid	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
An	O
advanced,	O
severe,	O
progressive	O
or	O
unstable	O
disease	O
of	O
any	O
type	O
that	O
may	O
interfere	O
with	O
efficacy	O
and	O
safety	O
assessments	O
or	O
put	O
the	O
patient	O
at	O
special	O
risk	O
.	O

-	O
Patients	O
currently	O
residing	O
in	O
a	O
nursing	O
home	O
.	O

-	O
Any	O
current	O
medical	B-Condition
or	I-Condition
neurological	I-Condition
condition	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
that	O
could	O
explain	O
the	O
patient's	O
dementia	O
.	O

-	O
A	O
current	O
diagnosis	O
of	O
probable	O
or	O
possible	O
vascular	B-Condition
dementia	I-Condition
.	O

-	O
A	O
current	O
diagnosis	O
of	O
severe	O
or	O
unstable	O
cardiovascular	B-Condition
disease	I-Condition
.	O

-	O
A	O
current	O
diagnosis	O
of	O
bradycardia	B-Condition
(<	O
50	O
beats	O
per	O
minute	O
[bpm]),	O
sick-sinus	B-Condition
syndrome	I-Condition
or	O
conduction	B-Condition
defects	I-Condition
.	O

-	O
Clinically	O
significant	O
urinary	B-Condition
obstruction	I-Condition
.	O

-	O
History	O
of	O
malignancy	B-Condition
of	O
any	O
organ	O
system	O
within	O
the	O
past	O
5	O
years	O
unless	O
patient	O
is	O
verified	O
to	O
be	O
in	O
stable	O
condition	O
with	O
no	O
active	O
metastasis	O
.	O

-	O
Current	O
diagnosis	O
of	O
an	O
active	O
skin	B-Condition
lesion	I-Condition
/	I-Condition
disorder	I-Condition
that	O
would	O
prevent	O
the	O
patient	O
from	O
using	O
a	O
transdermal	O
patch	O
every	O
day	O
.	O

-	O
A	O
known	O
exaggerated	B-Condition
pharmacological	I-Condition
sensitivity	I-Condition
or	I-Condition
hypersensitivity	I-Condition
to	O
drugs	B-Drug
similar	O
to	O
rivastigmine	B-Drug
or	O
to	O
other	O
cholinergic	B-Drug
compounds	I-Drug
.	O

-	O
Taken	O
any	O
of	O
the	O
following	O
substances	O
(	O
at	O
the	O
time	O
of	O
the	O
Baseline	O
Visit	O
[Visit	O
2])	O
.	O

-	O
Succinylcholine-type	B-Drug
muscle	I-Drug
relaxants	I-Drug
during	O
the	O
previous	O
2	O
weeks	O
.	O

-	O
Lithium	B-Drug
during	O
the	O
previous	O
2	O
weeks	O
.	O

-	O
An	O
investigational	B-Drug
drug	I-Drug
during	O
the	O
previous	O
4	O
weeks	O
.	O

-	O
A	O
drug	B-Drug
or	O
treatment	O
known	O
to	O
cause	O
major	B-Condition
organ	I-Condition
system	I-Condition
toxicity	I-Condition
during	O
the	O
previous	O
4	O
weeks	O
.	O

-	O
Rivastigmine	B-Drug
(	O
oral	O
or	O
transdermal	O
patch	O
),	O
donepezil	B-Drug
,	O
galantamine	B-Drug
,	O
other	O
cholinesterase	B-Drug
inhibitors	I-Drug
(	O
eg,	O
tacrine	B-Drug
,	O
physostigmine	B-Drug
or	O
pyridostigmine	B-Drug
)	O
or	O
other	O
approved	B-Drug
treatments	I-Drug
for	O
Alzheimer's	B-Condition
disease	I-Condition
during	O
the	O
previous	O
2	O
weeks,	O
with	O
exception	O
of	O
stable	O
treatment	O
with	O
memantine	B-Drug
for	O
at	O
least	O
3	O
months	O
before	O
study	O
entry	O
(	O
Visit	O
1	O
)	O
.	O

-	O
Centrally	O
acting	O
anticholinergic	B-Drug
drugs	I-Drug
including	O
tricyclic	B-Drug
and	I-Drug
tetracyclic	I-Drug
antidepressants	I-Drug
during	O
the	O
previous	O
4	O
weeks	O
.	O

-	O
Selegiline	B-Drug
unless	O
taken	O
at	O
a	O
stable	O
dose	O
during	O
the	O
previous	O
4	O
weeks	O
.	O

-	O
Peripheral	B-Drug
anticholinergics	I-Drug
not	B-Negation_cue
taken	O
at	O
a	O
stable	O
dose	O
during	O
the	O
previous	O
4	O
weeks	O
.	O

Extension	O
study	O
.	O

Inclusion	O
Criteria	O
:	O
.	O

-	O
Complete	O
the	O
double-blind	O
phase	O
(	O
Week	O
24	O
)	O
of	O
the	O
core	O
study	O
.	O

-	O
Provide,	O
if	O
mentally	O
competent,	O
a	O
separate	O
written	O
informed	O
consent	O
prior	O
to	O
participation	O
in	O
the	O
extension	O
study	O
.	O

In	O
addition,	O
the	O
patient's	O
caregiver,	O
will	O
provide	O
written	O
informed	O
consent	O
prior	O
to	O
the	O
patient's	O
participation	O
in	O
the	O
open-label	O
extension	O
study	O
.	O

If	O
the	O
patient	O
is	O
not	O
able	O
to	O
provide	O
written	O
informed	O
consent,	O
written	O
informed	O
consent	O
must	O
be	O
obtained	O
from	O
the	O
legally	O
authorized	O
representative	O
on	O
the	O
patient's	O
behalf	O
.	O

-	O
Continue	O
to	O
reside	O
with	O
someone	O
in	O
the	O
community	O
or	O
in	O
regular	O
contact	O
with	O
the	O
primary	O
caregiver;	O
patients	O
who	O
reside	O
in	O
an	O
assisted	O
living	O
facility	O
are	O
eligible	O
to	O
participate	O
.	O

-	O
Continue	O
to	O
have	O
a	O
primary	O
caregiver	O
willing	O
to	O
accept	O
responsibility	O
for	O
supervising	O
treatment	O
(	O
eg,	O
application	O
and	O
removal	O
of	O
the	O
patch	O
daily	O
at	O
approximately	O
the	O
same	O
time	O
of	O
day	O
),	O
assessing	O
the	O
condition	O
of	O
the	O
patient	O
throughout	O
the	O
extension	O
study	O
.	O

-	O
Must	O
be	O
medically	O
stable	O
and	O
tolerating	O
the	O
current	O
dose	O
of	O
rivastigmine	B-Drug
patch	I-Drug
as	O
determined	O
by	O
the	O
investigator	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

Refer	O
to	O
the	O
core	O
study	O
protocol	O
for	O
full	O
details	O
of	O
the	O
exclusion	O
criteria	O
.	O

-	O
Patients	O
who	O
discontinued	O
the	O
core	O
study	O
due	O
to	O
any	O
reason	O
are	O
excluded	O
.	O

-	O
No	O
additional	O
exclusions	O
may	O
be	O
applied	O
by	O
the	O
investigator,	O
in	O
order	O
to	O
ensure	O
that	O
the	O
study	O
population	O
will	O
be	O
representative	O
of	O
all	O
eligible	O
patients	O
.	O

Other	O
protocol-defined	O
inclusion	O
/	O
exclusion	O
criteria	O
applied	O
to	O
the	O
study	O
.	O

>>NCT02073318	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Patient	O
provides	O
oral	O
consent	O
and	O
written	O
consent	O
obtains	O
from	O
next	O
of	O
kin	O
.	O

-	O
Older	O
than	O
65	O
years	O
.	O

-	O
Diagnosis	O
of	O
dementia	B-Condition
,	O
based	O
on	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Disorders,	I-Observation
Fourth	I-Observation
Edition	I-Observation
(	I-Observation
DSM-IV	I-Observation
)	I-Observation
or	O
The	B-Observation
International	I-Observation
Statistical	I-Observation
Classification	I-Observation
of	I-Observation
Diseases	I-Observation
and	I-Observation
Related	I-Observation
Health	I-Observation
Problems	I-Observation
10th	I-Observation
Revision	I-Observation
(	I-Observation
ICD-	I-Observation
10	I-Observation
)	I-Observation
.	O

-	O
Can	O
follow	O
order	O
to	O
complete	O
the	O
screening	O
test	O
(	O
Timed	O
Up	O
and	O
Go	O
test	O
)	O
.	O

-	O
Has	O
balance	O
and	O
gait	O
problems	O
.	O

-	O
Can	O
standing	O
independently	O
with	O
/	O
without	O
assistive	O
device	O
or	O
can	O
standing	O
with	O
minimal	O
assistance	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Newly	O
developed	O
cardiopulmonary	B-Condition
disease	I-Condition
and	O
other	O
exercise	B-Condition
contraindications	I-Condition
.	O

-	O
Other	O
neuromuscular	B-Condition
or	I-Condition
musculoskeletal	I-Condition
disease	I-Condition
that	O
might	O
affect	O
the	O
outcome	O
(	O
ex	O
.	O

Recent	O
stroke	B-Condition
,	O
fracture	B-Condition
or	O
orthopedic	B-Procedure_Device
surgery	I-Procedure_Device
).	O

>>NCT02180269	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Signed	O
an	O
informed	O
consent	O
document	O
indicating	O
they	O
understand	O
the	O
purpose	O
of	O
and	O
procedures	O
required	O
for	O
the	O
study	O
and	O
are	O
willing	O
to	O
participate	O
in	O
the	O
study	O
.	O

-	O
A	O
man,	O
who	O
is	O
sexually	O
active	O
with	O
a	O
woman	O
of	O
child-bearing	O
potential	O
and	O
has	O
not	O
had	O
a	O
vasectomy,	O
must	O
agree	O
to	O
use	O
an	O
adequate	O
contraception	O
method	O
as	O
deemed	O
appropriate	O
by	O
the	O
investigator	O
and	O
must	O
not	O
donate	O
sperm	O
during	O
the	O
study	O
and	O
for	O
90	O
days	O
after	O
receiving	O
the	O
study	O
drug	O
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
between	O
18	O
and	O
30	O
kilogram	O
(	O
kg	O
)	O
per	O
square	O
meter	O
.	O

-	O
Blood	B-Observation
pressure	I-Observation
(	O
supine	O
for	O
5	O
minutes	O
)	O
between	O
90	O
and	O
150	O
millimeter	O
of	O
mercury	O
(	O
mm	O
Hg	O
)	O
systolic	B-Observation
and	O
no	O
higher	O
than	O
90	O
mm	O
Hg	O
diastolic	B-Observation
.	O

-	O
Must	O
be	O
healthy	B-Condition
on	O
the	O
basis	O
of	O
physical	B-Observation
and	I-Observation
neurological	I-Observation
examination	I-Observation
medical	B-Observation
history	I-Observation
vital	B-Observation
signs	I-Observation
and	O
12	B-Procedure_Device
-lead	I-Procedure_Device
electrocardiogram	I-Procedure_Device
(	I-Procedure_Device
ECG	I-Procedure_Device
)	I-Procedure_Device
performed	O
at	O
screening	O
or	O
admission	O
(	O
up	O
to	O
Day	O
1	O
predose	O
)	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
History	O
of	O
or	O
current	O
liver	B-Condition
or	I-Condition
renal	I-Condition
impairment	I-Condition
significant	O
cardiac,	B-Condition
vascular,	I-Condition
pulmonary,	I-Condition
gastrointestinal,	I-Condition
endocrine,	I-Condition
neurologic,	I-Condition
hematologic,	I-Condition
rheumatologic,	I-Condition
psychiatric,	I-Condition
dermatological	I-Condition
(	I-Condition
at	I-Condition
the	I-Condition
puncture	I-Condition
site	I-Condition
)	I-Condition
or	I-Condition
metabolic	I-Condition
disturbances	I-Condition
.	O

-	O
History	O
of	O
spontaneous,	B-Condition
prolonged	I-Condition
and	I-Condition
severe	I-Condition
bleeding	I-Condition
of	I-Condition
unclear	I-Condition
origin	I-Condition
.	O

-	O
History	O
of	O
epilepsy	B-Condition
or	O
fits	B-Condition
.	O

-	O
History	O
of	O
human	B-Observation
immunodeficiency	I-Observation
virus	I-Observation
(	I-Observation
HIV	I-Observation
)	I-Observation
antigen	I-Observation
/	I-Observation
antibody	I-Observation
positive	O
or	O
tests	O
positive	O
for	O
HIV	B-Observation
at	O
screening	O
.	O

>>NCT01887535	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Good	O
general	B-Condition
health	I-Condition
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
(	I-Observation
BMI	I-Observation
)	I-Observation
between	O
18	O
and	O
32	O
kg	O
/	O
m2,	O
inclusive	O
.	O

-	O
Women	O
must	O
be	O
postmenopausal	B-Condition
,	O
permanently	O
sterilized	B-Condition
or	O
otherwise	O
be	O
incapable	O
of	O
pregnancy	O
.	O

-	O
Must	O
adhere	O
to	O
required	O
contraception	O
during	O
and	O
for	O
3	O
months	O
after	O
study	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Clinically	O
significant	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
.	O

-	O
Alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
excessive	O
nicotine	B-Condition
or	I-Condition
caffeine	I-Condition
use	I-Condition
.	O

-	O
Recently	O
received	O
an	O
investigational	B-Drug
drug	I-Drug
vaccine	B-Drug
or	O
invasive	B-Procedure_Device
medical	I-Procedure_Device
device	I-Procedure_Device
.	O

-	O
Unable	O
to	O
abide	O
by	O
protocol	O
restrictions	O
on	O
use	O
of	O
other	O
medications	O
.	O

-	O
Relevant	O
history	O
of	O
lower	B-Condition
back	I-Condition
pain	I-Condition
or	O
scoliosis	B-Condition
and	O
/	O
or	O
major	O
(	O
lumbar	O
)	O
back	B-Procedure_Device
surgery	I-Procedure_Device
.	O

-	O
Allergic	B-Condition
to	O
local	B-Drug
anesthetics	I-Drug
and	O
/	O
or	O
iodine	B-Drug
.	O

>>NCT01827982	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Good	O
general	B-Condition
health	I-Condition
.	O

-	O
Must	O
adhere	O
to	O
required	O
contraception	O
during	O
and	O
for	O
3	O
months	O
after	O
study	O
.	O

Specific	O
Inclusion	O
Criteria	O
for	O
Part	O
1	O
:	O
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
between	O
18	O
and	O
30	O
kg	O
/	O
m2	O
.	O

-	O
Male	B-Observation
volunteers,	O
between	O
18	O
and	O
54	O
years	O
of	O
age	B-Observation
,	O
inclusive	O
.	O

Specific	O
Inclusion	O
Criteria	O
for	O
Part	O
2	O
:	O
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
between	O
18	O
and	O
32	O
kg	O
/	O
m2	O
.	O

-	O
Women	O
must	O
be	O
postmenopausal	B-Condition
,	O
permanently	O
sterilized	B-Condition
or	O
otherwise	O
be	O
incapable	O
of	O
pregnancy	O
.	O

-	O
Healthy	B-Condition
male	O
or	O
female	O
volunteers,	O
between	O
55	O
and	O
75	O
years	O
of	O
age	B-Observation
,	O
inclusive	O
.	O

Specific	O
Inclusion	O
Criteria	O
for	O
Part	O
3	O
:	O
.	O

-	O
Male	B-Observation
volunteers	O
.	O

-	O
If	O
participated	O
in	O
Parts	O
1	O
or	O
2,	O
specific	O
inclusion	O
criteria	O
for	O
Part	O
1	O
(	O
young	O
)	O
or	O
Part	O
2	O
(	O
elderly	O
)	O
may	O
apply	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Clinically	O
significant	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
.	O

-	O
Alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
excessive	O
nicotine	B-Condition
or	I-Condition
caffeine	I-Condition
use	I-Condition
.	O

-	O
Recently	O
received	O
an	O
investigational	B-Drug
drug	I-Drug
vaccine	B-Drug
or	O
invasive	B-Procedure_Device
medical	I-Procedure_Device
device	I-Procedure_Device
.	O

-	O
Unable	O
to	O
abide	O
by	O
protocol	O
restrictions	O
on	O
use	O
of	O
other	O
medications	O
.	O

-	O
History	O
or	O
family	O
history	O
of	O
spontaneous,	O
prolonged	O
or	O
severe	O
bleeding	B-Condition
of	I-Condition
unclear	I-Condition
origin	I-Condition
or	I-Condition
of	I-Condition
blood	I-Condition
clotting	I-Condition
.	O

-	O
Current	O
anemia	B-Condition
.	O

Specific	O
Exclusion	O
Criteria	O
for	O
Part	O
2	O
:	O
.	O

-	O
History	O
of	O
lower	B-Condition
back	I-Condition
pain	I-Condition
or	O
scoliosis	B-Condition
and	O
/	O
or	O
major	O
(	O
lumbar	O
)	O
back	B-Procedure_Device
surgery	I-Procedure_Device
.	O

-	O
Allergic	B-Condition
to	O
local	B-Drug
anesthetics	I-Drug
and	O
/	O
or	O
iodine	B-Drug
.	O

-	O
Increased	O
intracranial	B-Observation
pressure	I-Observation
based	O
on	O
fundoscopy	B-Procedure_Device
.	O

>>NCT01029132	O
Inclusion	O
Criteria	O
:	O
.	O

1	O
.	O

A	O
diagnosis	O
of	O
probable	O
AD	B-Condition
according	O
to	O
the	O
criteria	O
of	O
the	O
NINCDS-ADRDA	B-Observation
.	O

2	O
.	O

Korean	B-Observation
version	I-Observation
Mini-Mental	I-Observation
State	I-Observation
Examination	I-Observation
scores	I-Observation
between	O
10	O
and	O
26	O
.	O

3	O
.	O

History	O
of	O
cognitive	B-Condition
decline	I-Condition
that	O
had	O
been	O
gradual	O
in	O
onset	O
and	O
progressive	O
over	O
at	O
least	O
6	O
months	O
.	O

4	O
.	O

A	O
caregiver	O
who	O
could	O
assist	O
the	O
patient	O
with	O
medication,	O
attend	O
the	O
assessment	O
and	O
provide	O
information	O
about	O
the	O
patient	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

1	O
.	O
they	O
had	O
evidence	O
of	O
any	O
neurodegenerative	B-Condition
diseases	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
(	O
i.e	O
.	O

Parkinson's	B-Condition
disease	I-Condition
Huntington's	B-Condition
disease	I-Condition
)	O
.	O

2	O
.	O

Psychiatric	B-Condition
disorder	I-Condition
or	O
severe	O
behavioral	B-Condition
disturbances	I-Condition
that	O
required	O
psychotropic	B-Drug
medications	I-Drug
.	O

3	O
.	O

Cerebral	B-Condition
injuries	I-Condition
induced	O
by	O
trauma	B-Condition
,	O
hypoxia	B-Condition
,	O
and	O
/	O
or	O
ischemia	B-Condition
.	O

4	O
.	O

Clinically	O
active	O
cerebrovascular	B-Condition
disease	I-Condition
History	O
of	O
seizure	B-Condition
disorder	I-Condition
.	O

5	O
.	O

Other	O
physical	B-Condition
conditions	I-Condition
that	O
required	O
acute	O
treatment	O
.	O

>>NCT02518243	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Subjects	O
with	O
a	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
NINCDS-ADRDA	B-Observation
(	O
McKhann,	O
Drachman	O
et	O
al	O
.	O

1984	O
)	O
or	O
typical	O
or	O
atypical	O
Alzheimer's	B-Condition
disease	I-Condition
(	O
Dubois	O
B	O
.	O
et	O
al	O
.	O

2007	O
)	O
.	O

-	O
Score	O
at	O
Mini	B-Observation
Mental	I-Observation
Test	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
>=	O
16	O
.	O

-	O
Subjects	O
residing	O
in	O
nursing	O
homes	O
.	O

-	O
Subjects	O
beneficiaries	O
of	O
a	O
social	O
security	O
scheme	O
.	O

-	O
Signature	O
of	O
free	O
and	O
informed	O
consent	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Failure	O
to	O
pass	O
the	O
neuropsychological	B-Observation
tests	I-Observation
because	O
of	O
a	O
sensory	B-Condition
or	I-Condition
motor	I-Condition
deficit	I-Condition
.	O

-	O
Sensory	B-Condition
deficit	I-Condition
(	O
olfactory	O
or	O
visual	O
)	O
preventing	O
the	O
patient	O
made	O
perfectly	O
meet	O
the	O
therapeutic	O
solutions	O
.	O

-	O
Prescription	O
of	O
a	O
new	O
treatment	B-Drug
psychotropic	I-Drug
(	O
hypnotic	B-Drug
,	O
anxiolytic	B-Drug
,	O
antidepressant	B-Drug
,	O
antipsychotic	B-Drug
)	O
in	O
the	O
week	O
before	O
the	O
evaluation;	O
.	O

-	O
Persons	O
deprived	O
of	O
liberty	O
(	O
administrative	O
or	O
judicial	O
)	O
.	O

>>NCT02008357	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Has	O
a	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
at	O
screening	O
of	O
25	O
to	O
30	O
.	O

-	O
Has	O
a	O
global	B-Observation
Clinical	I-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
scale	I-Observation
score	I-Observation
at	O
screening	O
of	O
0	O
.	O

-	O
Has	O
a	O
Logical	B-Observation
Memory	I-Observation
II	I-Observation
score	I-Observation
at	O
screening	O
of	O
6	O
to	O
18	O
.	O

-	O
Has	O
a	O
florbetapir	B-Procedure_Device
positron	I-Procedure_Device
emission	I-Procedure_Device
tomography	I-Procedure_Device
(	I-Procedure_Device
PET	I-Procedure_Device
)	I-Procedure_Device
scan	I-Procedure_Device
that	O
shows	O
evidence	O
of	O
brain	B-Observation
amyloid	I-Observation
pathology	I-Observation
at	O
screening	O
.	O

-	O
Has	O
a	O
study	O
partner	O
that	O
is	O
willing	O
to	O
participate	O
as	O
a	O
source	O
of	O
information	O
and	O
has	O
at	O
least	O
weekly	O
contact	O
with	O
the	O
participant	O
(	O
contact	O
can	O
be	O
in-person,	O
via	O
telephone	O
or	O
electronic	O
communication	O
)	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Is	O
receiving	O
a	O
prescription	B-Drug
acetylcholinesterase	I-Drug
inhibitor	I-Drug
(	O
AChEI	B-Drug
)	O
and	O
/	O
or	O
memantine	B-Drug
at	O
screening	O
or	O
baseline	O
.	O

-	O
Lacks	O
good	O
venous	O
access,	O
such	O
that	O
intravenous	O
drug	O
delivery	O
or	O
multiple	O
blood	O
draws	O
would	O
be	O
precluded	O
.	O

-	O
Has	O
current	O
serious	O
or	O
unstable	O
illness	B-Condition
including	O
cardiovascular,	B-Condition
hepatic,	I-Condition
renal,	I-Condition
gastroenterologic,	I-Condition
respiratory,	I-Condition
endocrinologic,	I-Condition
neurologic,	I-Condition
psychiatric,	I-Condition
immunologic	I-Condition
or	I-Condition
hematologic	I-Condition
disease	I-Condition
or	O
other	O
conditions	B-Condition
that,	O
in	O
the	O
investigator's	O
opinion,	O
could	O
interfere	O
with	O
the	O
analyses	O
of	O
safety	O
and	O
efficacy	O
in	O
this	O
study	O
.	O

-	O
Has	O
had	O
a	O
history	O
within	O
the	O
last	O
5	O
years	O
of	O
a	O
serious	O
infectious	B-Condition
disease	I-Condition
affecting	O
the	O
brain	O
(	O
including	O
neurosyphilis	B-Condition
,	O
meningitis	B-Condition
or	O
encephalitis	B-Condition
)	O
or	O
head	B-Condition
trauma	I-Condition
resulting	O
in	O
protracted	B-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition
.	O

-	O
Has	O
had	O
a	O
history	O
within	O
the	O
last	O
5	O
years	O
of	O
a	O
primary	O
or	O
recurrent	O
malignant	B-Condition
disease	I-Condition
with	O
the	O
exception	B-Negation_cue
of	O
resected	O
cutaneous	B-Condition
squamous	I-Condition
cell	I-Condition
carcinoma	I-Condition
in	I-Condition
situ	I-Condition
basal	B-Condition
cell	I-Condition
carcinoma	I-Condition
cervical	B-Condition
carcinoma	I-Condition
in	I-Condition
situ	I-Condition
or	O
in	B-Condition
situ	I-Condition
prostate	I-Condition
cancer	I-Condition
with	O
normal	O
prostate-specific	O
antigen	O
posttreatment	O
.	O

-	O
Has	O
a	O
known	O
history	O
of	O
human	B-Condition
immunodeficiency	I-Condition
virus	I-Condition
(	I-Condition
HIV	I-Condition
)	I-Condition
clinically	O
significant	O
multiple	O
or	O
severe	O
drug	B-Condition
allergies	I-Condition
or	O
severe	O
post-treatment	B-Condition
hypersensitivity	I-Condition
reactions	I-Condition
(	O
including	O
but	O
not	O
limited	O
to,	O
erythema	B-Condition
multiforme	I-Condition
major	I-Condition
linear	B-Condition
immunoglobulin	I-Condition
A	I-Condition
dermatosis	I-Condition
toxic	B-Condition
epidermal	I-Condition
necrolysis	I-Condition
or	O
exfoliative	B-Condition
dermatitis	I-Condition
)	O
.	O

-	O
Is	O
clinically	O
judged	O
by	O
the	O
investigator	O
to	O
be	O
at	O
serious	O
risk	O
for	O
suicide	O
.	O

-	O
Has	O
a	O
history	O
within	O
the	O
past	O
2	O
years	O
of	O
major	B-Condition
depression	I-Condition
or	O
bipolar	B-Condition
disorder	I-Condition
as	O
defined	O
by	O
the	O
most	O
current	O
version	O
of	O
the	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Disorders	I-Observation
(	I-Observation
DSM	I-Observation
)	I-Observation
.	O

-	O
Has	O
a	O
history	O
within	O
the	O
past	O
5	O
years	O
of	O
chronic	O
alcohol	B-Condition
or	I-Condition
drug	I-Condition
abuse	I-Condition
/	I-Condition
dependence	I-Condition
as	O
defined	O
by	O
the	O
most	O
current	O
version	O
of	O
the	O
DSM	B-Observation
.	O

>>NCT02434393	O
Inclusion	O
Criteria	O
:	O
.	O

1	O
.	O

Current	O
DSM-IV	B-Observation
diagnosis	O
of	O
Major	B-Condition
Depressive	I-Condition
Disorder	I-Condition
unipolar	B-Condition
type	I-Condition
without	B-Negation_cue
psychotic	B-Condition
features	I-Condition
and	O
six	O
week	O
minimum	O
duration	O
of	O
current	O
depressive	B-Condition
episode	I-Condition
.	O

2	O
.	O

English	O
Speaking	O
.	O

3	O
.	O

65+	O
years	O
of	O
age	B-Observation
.	O

4	O
.	O

Hamilton	B-Observation
Depression	I-Observation
Rating	I-Observation
Scale	I-Observation
score	I-Observation
>=	O
15	O
.	O

5	O
.	O

Able	O
to	O
give	O
informed	O
consent	O
.	O

6	O
.	O

Willing	O
to	O
undergo	O
one	O
MRI	B-Procedure_Device
(	O
3	O
Tesla	O
)	O
and	O
one	O
PET	B-Procedure_Device
scan	I-Procedure_Device
(	O
Amyloid	B-Procedure_Device
imaging	I-Procedure_Device
)	O
.	O

7	O
.	O

Able	O
to	O
fit	O
in	O
an	O
MRI	B-Procedure_Device
machine	O
comfortably	O
(	O
BMI	B-Observation
<=	O
38	O
)	O
.	O

8	O
.	O

Agrees	O
to	O
collection	O
of	O
blood	O
for	O
GWAS,	O
apolipoprotein	O
E	O
(	O
APOE	O
)	O
testing	O
and	O
DNA	O
and	O
RNA	O
testing	O
.	O

9	O
.	O

Agrees	O
to	O
collection	O
of	O
blood	O
for	O
biomarker	O
testing	O
.	O

10	O
.	O

Agrees	O
to	O
collection	O
of	O
additional	O
blood	O
sample	O
for	O
to-be-determined	O
assays	O
and	O
telomere	O
length	O
measurement	O
.	O

11	O
.	O

Visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
adequate	O
for	O
neuropsychological	O
testing	O
.	O

12	O
.	O

Completed	O
six	O
grades	O
of	O
education	O
or	O
has	O
established	O
work	O
history	O
(	O
sufficient	O
to	O
exclude	O
mental	O
retardation	O
)	O
.	O

13	O
.	O

Study	O
partner	O
is	O
available	O
who	O
has	O
frequent	O
contact	O
with	O
the	O
subject	O
(	O
eg	O
an	O
average	O
of	O
10	O
hours	O
per	O
week	O
or	O
more	O
)	O
and	O
can	O
accompany	O
the	O
subject	O
to	O
clinical	O
visits	O
for	O
the	O
duration	O
of	O
the	O
protocol	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

1	O
.	O

Current	O
diagnosis	O
of	O
other	O
axis	B-Condition
1	I-Condition
psychiatric	I-Condition
disorders	I-Condition
(	O
with	O
the	O
exception	B-Negation_cue
of	O
Simple	B-Condition
Phobias	I-Condition
and	I-Condition
Generalized	I-Condition
Anxiety	I-Condition
Disorder	I-Condition
)	O
.	O

2	O
.	O

Evidence	O
of	O
Dementia	B-Condition
(	O
MMSE	B-Observation
<	O
25	O
)	O
.	O

3	O
.	O

Any	O
electroconvulsive	B-Procedure_Device
therapy	I-Procedure_Device
within	O
the	O
past	O
6	O
months	O
.	O

4	O
.	O

Undergoing	O
anti-depressant	B-Drug
or	O
psychotherapy	B-Drug
treatment	I-Drug
(	O
exceptions	O
listed	O
4.3	O
.	O

Treatment	O
Exclusion	O
Exceptions	O
)	O
.	O

5	O
.	O

Any	O
significant	O
neurological	B-Condition
diseases	I-Condition
(	O
i.e	O
.	O

Parkinson's	B-Condition
disease	I-Condition
epilepsy	B-Condition
,	O
cortical	B-Condition
stroke	I-Condition
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
)	O
.	O

6	O
.	O

History	O
of	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
within	O
the	O
past	O
2	O
years	O
(	O
DSM-IV	B-Observation
criteria	I-Observation
)	O
.	O

7	O
.	O

Any	O
active	O
and	O
serious	O
suicidal	B-Condition
ideation	I-Condition
including	O
ideation,	O
plan	O
and	O
intent	O
to	O
carry	O
out	O
that	O
plan,	O
as	O
assessed	O
by	O
the	O
Hamilton	B-Observation
Depression	I-Observation
Rating	I-Observation
Scale	I-Observation
(	I-Observation
HDRS	I-Observation
)	I-Observation
.	O

8	O
.	O

Any	O
significant	O
systemic	B-Condition
illness	I-Condition
or	O
unstable	O
medical	B-Condition
condition	I-Condition
which	O
could	O
lead	O
to	O
difficulty	O
complying	O
with	O
the	O
protocol	O
.	O

9	O
.	O

History	O
of	O
surgical	B-Procedure_Device
procedures	I-Procedure_Device
effecting	O
study	O
outcomes	O
.	O

10	O
.	O

Residence	O
in	O
skilled	O
nursing	O
facility	O
.	O

11	O
.	O

Participation	O
in	O
clinical	O
studies	O
involving	O
the	O
same	O
neuropsychological	O
measures	O
used	O
in	O
ADNI-D	O
that	O
may	O
impact	O
study	O
outcomes	O
.	O

12	O
.	O

Investigational	B-Drug
agents	I-Drug
are	O
prohibited	B-Negation_cue
one	O
month	O
prior	O
to	O
entry	O
and	O
for	O
the	O
duration	O
of	O
the	O
trial	O
.	O

13	O
.	O

Exclusion	O
for	O
amyloid	B-Procedure_Device
imaging	I-Procedure_Device
with	I-Procedure_Device
florbetapir	I-Procedure_Device
:	O
Current	O
or	O
recent	O
participation	O
in	O
any	O
procedures	O
involving	O
radioactive	B-Drug
agents	I-Drug
such	O
that	O
the	O
total	B-Drug
radiation	I-Drug
dose	I-Drug
exposure	I-Drug
to	O
the	O
subject	O
in	O
any	O
given	O
year	O
would	O
exceed	O
the	O
limits	O
of	O
annual	O
and	O
total	O
dose	O
commitment	O
set	O
forth	O
in	O
the	O
US	O
Code	O
of	O
Federal	O
Regulations	O
(	O
CFR	O
)	O
Title	O
21	O
Section	O
361.1	O
.	O

14	O
.	O

Known	O
history	O
of	O
MRI	B-Procedure_Device
scans	I-Procedure_Device
with	O
evidence	O
of	O
infection	B-Condition
,	O
infarction	B-Condition
or	O
other	O
focal	B-Condition
lesions	I-Condition
.	O

Subjects	O
with	O
multiple	B-Condition
lacunes	I-Condition
or	O
lacunes	B-Condition
in	O
a	O
critical	O
memory	O
structure	O
are	O
excluded	O
.	O

15	O
.	O

Presence	O
of	O
pacemakers	B-Procedure_Device
,	O
aneurysm	B-Procedure_Device
clips	I-Procedure_Device
artificial	B-Procedure_Device
heart	I-Procedure_Device
valves	I-Procedure_Device
ear	B-Procedure_Device
implants	I-Procedure_Device
metal	B-Procedure_Device
fragments	I-Procedure_Device
or	O
foreign	B-Procedure_Device
objects	I-Procedure_Device
in	O
the	O
eyes,	O
skin	O
or	O
body,	O
claustrophobia	B-Condition
.	O

16	O
.	O

Pregnant	B-Condition
,	O
lactating	B-Condition
or	O
of	B-Condition
childbearing	I-Condition
potential	I-Condition
(	O
i.e	O
.	O

women	O
must	O
be	O
two	O
years	O
post-menopausal	B-Condition
or	O
surgically	B-Condition
sterile	I-Condition
).	O

>>NCT01835717	O
Inclusion	O
Criteria	O
:	O
.	O

1	O
.	O

Men	O
and	O
women,	O
aged	B-Observation
between	O
45	O
and	O
65	O
years	O
.	O

2	O
.	O

Spanish	O
and	O
/	O
or	O
Catalan	O
speakers	O
.	O

3	O
.	O

Agreement	O
with	O
the	O
study	O
procedures	O
and	O
tests	O
:	O
.	O

1	O
.	O

Clinical	O
Interview	O
and	O
questionnaires	O
associated	O
to	O
risk	O
factors	O
.	O

2	O
.	O

Cognitive	O
tests	O
.	O

3	O
.	O

Blood	O
sample	O
extraction	O
for	O
DNA	O
analysis	O
.	O

4	O
.	O

Close	O
relative	O
involvement	O
for	O
functional	O
evaluation	O
of	O
the	O
volunteer	O
.	O

5	O
.	O

Signature	O
of	O
informed	O
consent	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

1	O
.	O

Cognitive	B-Condition
impairment	I-Condition
:	O
MMSE	B-Observation
<	O
26,	O
or	O
MIS	B-Observation
<	O
6	O
or	O
orientation	O
subtest	O
of	O
the	O
Barcelona	B-Observation
Test	I-Observation
II	I-Observation
<	O
68,	O
or	O
category	B-Observation
fluency	I-Observation
(	I-Observation
animals	I-Observation
)	I-Observation
<	O
12	O
.	O

2	O
.	O

Functional	B-Condition
status	I-Condition
impairment	I-Condition
:	O
CDR	B-Observation
>	O
0	O
.	O

3	O
.	O

Severe	O
auditory	B-Condition
and	I-Condition
/	I-Condition
or	I-Condition
visual	I-Condition
impairment	I-Condition
.	O

4	O
.	O

Neurodevelopmental	B-Condition
and	I-Condition
/	I-Condition
or	I-Condition
psychomotor	I-Condition
disorder	I-Condition
.	O

5	O
.	O

Significant	O
diseases	B-Condition
that	O
could	O
currently	O
interfere	O
with	O
cognition	O
:	O
renal	B-Condition
failure	I-Condition
on	O
hemodialysis	B-Procedure_Device
,	O
liver	B-Condition
cirrhosis	I-Condition
chronic	O
lung	B-Condition
disease	I-Condition
with	O
oxygen	B-Procedure_Device
therapy	I-Procedure_Device
solid	B-Procedure_Device
organ	I-Procedure_Device
transplantation	I-Procedure_Device
fibromyalgia	B-Condition
,	O
active	O
cancer	B-Condition
in	I-Condition
treatment	I-Condition
or	O
any	O
other	O
disease	B-Condition
the	O
investigator	O
considers	O
could	O
affect	O
the	O
participant	O
cognition	B-Observation
.	O

6	O
.	O

Major	O
psychiatric	B-Condition
disorders	I-Condition
(	O
DSM-IV-TR	B-Observation
)	O
or	O
diseases	B-Condition
that	O
could	O
affect	O
cognitive	B-Observation
abilities	I-Observation
:	O
major	B-Condition
depression	I-Condition
bipolar	B-Condition
disorder	I-Condition
schizophrenia	B-Condition
and	O
dementia	B-Condition
.	O

7	O
.	O

Neurological	B-Condition
disorders	I-Condition
:	O
Parkinson's	B-Condition
disease	I-Condition
stroke	B-Condition
,	O
epilepsy	B-Condition
and	O
treatment	O
with	O
frequent	O
seizures	B-Condition
(>	O
1	O
/	O
month	O
)	O
in	O
the	O
past	O
year,	O
multiple	B-Condition
sclerosis	I-Condition
or	O
other	O
serious	O
neurological	B-Condition
disease	I-Condition
.	O

8	O
.	O

Brain	B-Condition
injury	I-Condition
interfering	O
with	O
cognition	B-Observation
:	O
history	O
of	O
head	B-Condition
trauma	I-Condition
with	O
parenchymal	B-Condition
lesion	I-Condition
or	O
extraaxial	B-Condition
macroscopic	I-Condition
large	I-Condition
vessel	I-Condition
ischemic	I-Condition
stroke	I-Condition
or	O
hemorrhagic	B-Condition
stroke	I-Condition
brain	B-Procedure_Device
surgery	I-Procedure_Device
brain	B-Condition
tumors	I-Condition
and	O
other	O
causes	O
that	O
can	O
generate	O
acquired	O
brain	B-Condition
damage	I-Condition
(	O
cerebral	B-Drug
chemotherapy	I-Drug
or	O
radiotherapy	B-Procedure_Device
)	O
.	O

9	O
.	O

Family	O
history	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
with	O
autosomal	O
dominant	O
(	O
3	O
affected	O
in	O
two	O
different	O
generations	O
)	O
and	O
early	O
onset	B-Observation
age	I-Observation
(	O
<	O
60	O
years	O
)	O
.	O

>>NCT01302340	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Diagnosis	O
of	O
Alzheimer's	B-Condition
Disease	I-Condition
(	I-Condition
AD	I-Condition
)	I-Condition
Vascular	B-Condition
Dementia	I-Condition
(	I-Condition
VD	I-Condition
)	I-Condition
or	O
mixed	B-Condition
,	O
according	O
to	O
the	O
criteria	O
of	O
NINCDS-ADRDA	B-Observation
or	O
NINCDS-AIREN	B-Observation
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
score	I-Observation
between	O
0.5	O
and	O
3	O
.	O

-	O
NPS	B-Condition
symptoms	I-Condition
with	O
at	O
least	O
agitation	B-Condition
or	O
aggression	B-Condition
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Diagnosis	O
of	O
Lewy	B-Condition
Body	I-Condition
Dementia	I-Condition
(	I-Condition
LBD	I-Condition
)	I-Condition
or	O
Fronto-Temporal	B-Condition
Dementia	I-Condition
(	I-Condition
FTD	I-Condition
)	I-Condition
.	O

-	O
Major	O
psychiatric	B-Condition
disorder	I-Condition
.	O

-	O
Severe	O
concomitant	B-Condition
illness	I-Condition
seizure	B-Condition
,	O
arrhythmias	B-Condition
(	O
except	B-Negation_cue
sinus	B-Condition
arrhythmia	I-Condition
and	O
atrial	B-Condition
fibrillation	I-Condition
),	O
heart	B-Observation
failure	I-Observation
New	I-Observation
York	I-Observation
Heart	I-Observation
Association	I-Observation
(	I-Observation
NYHA	I-Observation
)	I-Observation
class	O
III	O
or	O
IV	O
.	O

-	O
Tri	B-Drug
Cyclic	I-Drug
Antidepressives	I-Drug
(	I-Drug
TCA	I-Drug
)	I-Drug
or	O
opioids	B-Drug
used	O
within	O
30	O
days	O
before	O
randomization	O
till	O
the	O
end	O
of	O
the	O
study	O
.	O

-	O
Changes	O
in	O
dosage	O
of	O
antidepressives	B-Drug
within	O
6	O
weeks	O
before	O
randomization	O
and	O
during	O
study	O
and	O
changes	O
in	O
dosage	O
of	O
antipsychotics	B-Drug
or	O
benzodiazepines	B-Drug
within	O
2	O
weeks	O
prior	O
to	O
randomization	O
and	O
during	O
study	O
.	O

>>NCT02414607	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
CDR	B-Observation
score	I-Observation
of	O
0.5	O
.	O

-	O
MMSE	B-Observation
of	O
at	O
least	O
24	O
.	O

-	O
Age	B-Observation
50	O
or	O
older	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Known	O
history	O
of	O
sensitivity	B-Condition
to	O
elderberry	B-Drug
products	I-Drug
.	O

-	O
Diabetes	B-Condition
.	O

-	O
Bleeding	B-Condition
disorder	I-Condition
.	O

-	O
Current	O
Pregnancy	B-Condition
.	O

-	O
Known	O
allergy	B-Condition
to	O
honeysuckle	B-Drug
.	O

-	O
Currently	O
making	O
changes	O
to	O
other	O
drugs	B-Drug
that	O
might	O
affect	O
cognitive	B-Observation
performance	I-Observation
(	O
subjects	O
showing	O
the	O
greatest	O
cognitive	B-Condition
decline	I-Condition
and	O
other	O
signs	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
may	O
be	O
prescribed	O
cholinesterase	B-Drug
inhibitors	I-Drug
as	O
this	O
is	O
a	O
standard	O
of	O
care	O
for	O
Alzheimer's	B-Condition
disease	I-Condition
but	O
not	B-Negation_cue
MCI	B-Condition
)	O
.	O

-	O
Presence	O
of	O
any	O
condition	B-Condition
the	O
health	O
professional	O
believes	O
will	O
impair	O
ability	O
to	O
complete	O
study	O
procedures	O
(	O
ex	O
.	O

terminal	B-Condition
illness	I-Condition
comorbid	O
major	O
psychiatric	B-Condition
disorders	I-Condition
such	O
as	O
schizophrenia	B-Condition
or	O
drug	B-Condition
abuse	I-Condition
)	O
.	O

-	O
Potentially	O
confounding	O
neurodegenerative	B-Condition
diseases	I-Condition
(	O
eg	O
MS	B-Condition
)	O
.	O

>>NCT01594541	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Individuals	O
between	O
the	O
ages	B-Observation
of	O
55	O
and	O
89	O
years	O
old	O
.	O

-	O
Meeting	O
criteria	O
for	O
Mild	B-Condition
Cognitive	I-Condition
Impairment	I-Condition
or	O
dementia	B-Condition
with	O
a	O
minimum	B-Observation
MOST	I-Observation
score	I-Observation
of	O
5	O
but	O
not	O
over	O
23	O
.	O

-	O
Has	O
a	O
minimum	O
of	O
3	O
months	O
evaluation	O
.	O

-	O
Able	O
to	O
undergo	O
testing	O
for	O
cognition	O
and	O
complete	O
the	O
GDS	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Known	O
allergy	B-Condition
/	I-Condition
intolerance	I-Condition
to	O
any	O
ingredient	O
in	O
Cerefolin	B-Drug
NAC	I-Drug
.	O

-	O
Substantial	O
impediments	O
to	O
adherence,	O
such	O
as	O
severe	O
dementia	B-Condition
without	O
caregiver	O
to	O
administer	O
medication	O
.	O

-	O
Inability	O
to	O
swallow	O
pill-form	O
medication	O
.	O

-	O
Unstable	O
medical	B-Condition
illness	I-Condition
including	O
cardiovascular,	B-Condition
hepatic,	I-Condition
renal,	I-Condition
respiratory,	I-Condition
endocrine,	I-Condition
neurological	I-Condition
or	I-Condition
hematological	I-Condition
disease	I-Condition
.	O

-	O
Hcy	B-Observation
score	I-Observation
lower	O
than	O
11	O
.	O

>>NCT02267057	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Patients	O
residing	O
in	O
long	O
term	O
nursing	O
home	O
units	O
for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
study	O
.	O

-	O
Diagnosed	O
with	O
probable	O
or	O
possible	O
dementia	B-Condition
according	O
to	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Disorders	I-Observation
(	I-Observation
DSM-IV	I-Observation
)	I-Observation
FAST	B-Observation
score	I-Observation
>	O
4	O
.	O

-	O
Diagnosed	O
with	O
depression	B-Condition
>=	O
4	O
week	O
duration	O
as	O
measured	O
by	O
CSDD	B-Observation
>=	O
8	O
.	O

-	O
Written,	O
informed	O
consent	O
provided	O
by	O
the	O
participant	O
(	O
if	O
they	O
have	O
capacity	O
)	O
or	O
assent	O
(	O
if	O
they	O
do	O
not	O
have	O
capacity	O
)	O
and	O
a	O
written	O
proxy	O
informed	O
consent	O
from	O
a	O
legally	O
authorized	O
representative	O
empowered	O
to	O
make	O
health-related	O
decisions	O
for	O
the	O
potential	O
study	O
participant	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
The	O
patient	O
is	O
contra-indicated	B-Condition
to	O
study	B-Drug
drugs	I-Drug
of	O
pain	O
treatment,	O
in	O
another	O
trial	O
or	O
had	O
no	O
carer	O
.	O

-	O
Participants	O
are	O
ineligible	O
if	O
they	O
are	O
clinical	O
critical	O
(	O
eg	O
suicide	B-Condition
risk	I-Condition
)	O
.	O

-	O
Clinician	O
responsible	O
for	O
care	O
or	O
study	O
clinician	O
considers	O
that	O
the	O
patient	O
suffers	O
from	O
any	O
physical	O
condition,	O
which	O
would	O
make	O
participation	O
in	O
the	O
trial	O
distressing	O
or	O
likely	O
to	O
increase	O
suffering	O
.	O

-	O
Advanced	O
severe	O
medical	B-Condition
disease	I-Condition
/	I-Condition
disorder	I-Condition
with	O
expected	B-Observation
survival	I-Observation
less	O
than	O
6	O
months	O
or	O
that	O
could	O
interfere	O
with	O
participation	O
.	O

-	O
Psychosis	B-Condition
or	O
other	O
severe	O
mental	B-Condition
disorder	I-Condition
prior	O
to	O
dementia	B-Condition
diagnosis	O
.	O

-	O
Severe	O
aggression	B-Condition
(	O
>=	O
8	O
)	O
on	O
item	O
3	O
of	O
the	O
NPI	B-Observation
subscale	I-Observation
with	O
aggression	B-Condition
as	O
the	O
predominant	O
symptom	O
.	O

-	O
Schizophrenia	B-Condition
,	O
schizoaffective	B-Condition
disorder	I-Condition
and	O
bipolar	B-Condition
disorder	I-Condition
.	O

-	O
Uncontrolled	O
epilepsy	B-Condition
.	O

-	O
Severe	O
liver	B-Condition
impairment	I-Condition
.	O

-	O
Renal	B-Condition
failure	I-Condition
.	O

-	O
Severe	O
injury	B-Condition
or	O
anaemia	B-Condition
(	O
Hb	B-Observation
<	O
8.5	O
mmol	O
/	O
l	O
),	O
comatose	B-Condition
state	I-Condition
current	O
enrolment	O
in	O
another	O
experimental	O
protocol	O
.	O

-	O
Known	O
allergy	B-Condition
or	O
adverse	B-Condition
reaction	I-Condition
to	O
paracetamol	B-Drug
or	O
buprenorphine	B-Drug
transdermal	I-Drug
patch	I-Drug
.	O

-	O
Advanced	O
severe	O
medical	B-Condition
disease	I-Condition
with	O
expected	B-Observation
survival	I-Observation
of	O
less	O
than	O
six	O
months,	O
severe	O
psychiatric	B-Condition
or	I-Condition
neurological	I-Condition
disorder	I-Condition
.	O

-	O
Patients	O
with	O
diseases	O
that	O
make	O
it	O
impossible	O
to	O
follow	O
the	O
research	O
schedule	O
are	O
excluded	O
.	O

>>NCT00966966	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
in	O
the	O
range	O
of	O
18	O
to	O
30	O
kg	O
/	O
m2	O
and	O
body	B-Observation
weight	I-Observation
greater	O
than	O
50	O
kg	O
.	O

-	O
Healthy	B-Condition
as	O
determined	O
by	O
the	O
investigator	O
on	O
the	O
basis	O
of	O
medical	B-Observation
history	I-Observation
physical	B-Observation
examination	I-Observation
findings	I-Observation
clinical	B-Observation
laboratory	I-Observation
test	I-Observation
results	I-Observation
vital	B-Observation
sign	I-Observation
measurements	I-Observation
and	O
digital	B-Procedure_Device
12	I-Procedure_Device
-lead	I-Procedure_Device
ECG	I-Procedure_Device
readings	I-Procedure_Device
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Presence	O
or	O
history	O
of	O
any	O
disorder	B-Condition
that	O
may	O
prevent	O
the	O
successful	O
completion	O
of	O
the	O
study	O
.	O

-	O
Any	O
significant	O
cardiovascular,	B-Condition
hepatic,	I-Condition
renal,	I-Condition
respiratory,	I-Condition
gastrointestinal	I-Condition
(	I-Condition
GI	I-Condition
),	I-Condition
endocrine,	I-Condition
immunologic,	I-Condition
dermatologic,	I-Condition
hematologic,	I-Condition
neurologic	I-Condition
or	I-Condition
psychiatric	I-Condition
disease	I-Condition
.	O

>>NCT00547560	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Men	O
or	O
women,	O
greater	O
than	O
or	O
equal	O
to	O
65	O
years	O
of	O
age	B-Observation
.	O

-	O
Women	O
of	O
nonchildbearing	B-Condition
potential	I-Condition
(	O
WONCP	O
)	O
may	O
be	O
included	O
if	O
they	O
are	O
either	O
surgically	B-Condition
sterile	I-Condition
(	O
hysterectomy	O
and	O
/	O
or	O
oophorectomy	O
)	O
or	O
postmenopausal	B-Condition
for	O
greater	O
than	O
or	O
equal	O
to	O
1	O
year	O
(	O
with	O
FSH	B-Observation
greater	O
than	O
or	O
equal	O
to	O
38	O
mIU	O
/	O
mL	O
)	O
and	O
must	O
have	O
a	O
negative	O
pregnancy	B-Observation
test	I-Observation
result	I-Observation
within	O
48	O
hours	O
before	O
administration	O
of	O
test	O
article	O
.	O

Women	O
who	O
are	O
surgically	B-Condition
sterile	I-Condition
must	O
provide	O
documentation	O
of	O
the	O
procedure	O
by	O
an	O
operative	O
report	O
or	O
by	O
ultrasound	O
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
(	I-Observation
BMI	I-Observation
)	I-Observation
in	O
the	O
range	O
of	O
18.0	O
to	O
30.0	O
kg	O
/	O
m2	O
and	O
body	B-Observation
weight	I-Observation
>	O
50	O
kg	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

>>NCT02005991	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Males	O
and	O
females	O
must	O
be	O
at	O
least	O
18	O
years	O
of	O
age	B-Observation
and	O
no	O
older	O
than	O
55	O
years	O
of	O
age	B-Observation
with	O
a	O
Body	B-Observation
Mass	I-Observation
Index	I-Observation
(	I-Observation
BMI	I-Observation
)	I-Observation
must	O
be	O
between	O
17.5	O
and	O
30.5	O
.	O

-	O
Subjects	O
must	O
sign	O
a	O
consent	O
form	O
and	O
comply	O
with	O
all	O
scheduled	O
visits,	O
treatment	O
plan,	O
lab	O
tests	O
and	O
other	O
study	O
procedures	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Females	O
must	O
not	B-Negation_cue
be	O
pregnant	B-Condition
,	O
breastfeeding	B-Condition
or	O
able	O
to	O
have	O
children	O
.	O

-	O
Subjects	O
must	O
not	O
have	O
a	O
severe	O
acute	O
or	O
chronic	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
condition	I-Condition
history	O
or	O
evidence	O
of	O
blood,	B-Condition
kidney,	I-Condition
glandular,	I-Condition
lung,	I-Condition
stomach,	I-Condition
intestine,	I-Condition
heart,	I-Condition
blood	I-Condition
vessel,	I-Condition
liver,	I-Condition
psychiatric,	I-Condition
nerve	I-Condition
or	I-Condition
allergic	I-Condition
problems	I-Condition
(	O
including	O
drug	B-Condition
allergies	I-Condition
),	O
except	B-Negation_cue
mild	O
seasonal	B-Condition
allergies	I-Condition
.	O

-	O
Subjects	O
must	O
not	B-Negation_cue
drink	O
alcohol	B-Drug
excessively	O
or	O
take	O
illicit	B-Drug
drugs	I-Drug
.	O

-	O
Male	O
subjects	O
use	O
condoms	O
to	O
prevent	O
the	O
potential	O
transfer	O
of	O
drug	O
through	O
the	O
semen	O
to	O
their	O
partner	O
beginning	O
with	O
the	O
dose	O
of	O
study	O
drug	O
and	O
use	O
a	O
highly	O
effective	O
method	O
of	O
birth	O
control	O
with	O
any	O
partner	O
(	O
s	O
)	O
of	O
childbearing	O
potential	O
through	O
28	O
days	O
after	O
the	O
last	O
dose	O
.	O

>>NCT02256072	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Age	B-Observation
65	O
and	O
older	O
.	O

-	O
English	O
speaking	O
.	O

-	O
Score	O
>=	O
4	O
questions	O
correctly	O
on	O
the	O
Brief	B-Observation
Cognitive	I-Observation
screener	I-Observation
.	O

-	O
Self-identified	O
comfort	O
using	O
a	O
computer	O
.	O

-	O
Self-identified	O
comfort	O
using	O
the	O
Internet	O
to	O
navigate	O
a	O
Website	O
.	O

-	O
Have	O
not	O
previously	O
participated	O
in	O
study's	O
focus	O
groups	O
or	O
pilot	O
study	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Less	O
than	O
age	B-Observation
65	O
.	O

-	O
Non-English	O
speaking	O
.	O

-	O
Score	O
<	O
4	O
questions	O
correctly	O
on	O
the	O
Brief	B-Observation
Cognitive	I-Observation
screener	I-Observation
.	O

-	O
Not	O
comfortable	O
using	O
a	O
computer	O
.	O

-	O
Not	O
comfortable	O
using	O
the	O
Internet	O
to	O
navigate	O
a	O
Website	O
.	O

-	O
Previous	O
participation	O
in	O
this	O
study's	O
focus	O
groups	O
or	O
pilot	O
study.	O

>>NCT01800214	O
Patient	O
Inclusion	O
Criteria	O
(	O
General	O
):	O
.	O

-	O
Age	B-Observation
between	O
40	O
and	O
90	O
(	O
inclusive	O
)	O
.	O

-	O
Fluent	O
in	O
English	O
.	O

-	O
Completed	O
six	O
grades	O
of	O
education	O
or	O
higher	O
.	O

-	O
Visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
adequate	O
for	O
neuropsychological	O
testing	O
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
>	O
10	O
.	O

Patient	O
Exclusion	O
Criteria	O
(	O
General	O
):	O
.	O

-	O
Possible	O
secondary	O
causes	B-Condition
of	I-Condition
dementia	I-Condition
concomitant	O
or	O
history	O
of	O
neurological	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
(	O
other	B-Negation_cue
than	I-Negation_cue
stroke	B-Condition
or	O
Parkinsonism	B-Condition
)	O
.	O

-	O
History	O
of	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
within	O
the	O
past	O
2	O
years	O
.	O

Normal	O
Control	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Age	B-Observation
between	O
50	O
-	O
90	O
.	O

-	O
Fluent	O
in	O
English	O
.	O

-	O
Completed	O
six	O
grades	O
of	O
education	O
or	O
higher	O
.	O

-	O
No	B-Negation_cue
significant	O
memory	B-Observation
complaints	I-Observation
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
>	O
24	O
.	O

Normal	O
Control	O
Exclusion	O
Criteria	O
:	O
.	O

-	O
Being	O
treated	O
or	O
history	O
of	O
being	O
treated	O
for	O
psychiatric	B-Condition
or	I-Condition
neurological	I-Condition
illness	I-Condition
.	O

-	O
History	O
of	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
within	O
the	O
past	O
2	O
years	O
.	O

-	O
Current	O
use	O
of	O
psychoactive	B-Drug
medications	I-Drug
(	O
eg	O
antidepressant	B-Drug
,	O
neuroleptics	B-Drug
,	O
chronic	B-Drug
anxiolytics	I-Drug
or	O
sedative	B-Drug
hypnotics	I-Drug
etc.)	O
.	O

-	O
Medical	O
contraindications	B-Condition
to	O
MRI	B-Procedure_Device
.	O

>>NCT02322021	O
Inclusion	O
criteria	O
:	O
.	O

Subjects	O
must	O
meet	O
all	O
of	O
the	O
following	O
criteria	O
to	O
be	O
included	O
in	O
this	O
study	O
:	O
.	O

1	O
.	O

Meets	O
the	O
core	O
clinical	O
research	O
criteria	O
of	O
the	O
NIA-AA	B-Observation
for	O
MCI	B-Condition
due	O
to	O
AD	B-Condition
(	O
which	O
is	O
consistent	O
with	O
Prodromal	B-Condition
AD	I-Condition
)	O
or	O
AD	B-Condition
dementia	I-Condition
and	O
is	O
'staged'	O
or	O
classified	O
as	O
either	O
MCI	B-Condition
or	O
mild	O
to	O
moderate	O
dementia	B-Condition
.	O

2	O
.	O

Amyloid	O
positive	O
Positron	B-Procedure_Device
Emission	I-Procedure_Device
Tomography	I-Procedure_Device
(	I-Procedure_Device
PET	I-Procedure_Device
)	I-Procedure_Device
image	O
based	O
on	O
centralized	O
PET	B-Procedure_Device
scan	I-Procedure_Device
reading	O
.	O

3	O
.	O

Male	O
or	O
female,	O
age	B-Observation
50	O
to	O
85	O
years,	O
inclusive	O
at	O
time	O
of	O
consent	O
.	O

4	O
.	O

Must	O
have	O
an	O
identified	O
caregiver	O
or	O
informant	O
who	O
is	O
willing	O
and	O
able	O
to	O
provide	O
follow-up	O
information	O
on	O
the	O
subject	O
throughout	O
the	O
course	O
of	O
the	O
study	O
.	O

5	O
.	O

If	O
receiving	O
an	O
Acetylcholinesterase	B-Drug
Inhibitor	I-Drug
(	I-Drug
AChEI	I-Drug
)	I-Drug
or	O
memantine	B-Drug
,	O
must	O
have	O
been	O
on	O
a	O
stable	O
dose	O
for	O
at	O
least	O
12	O
weeks	O
before	O
the	O
Baseline	O
cognitive	O
assessments,	O
with	O
no	O
plans	O
for	O
dose	O
adjustment	O
in	O
the	O
foreseeable	O
future	O
.	O

Treatment-naive	O
subjects	O
can	O
be	O
entered	O
into	O
the	O
study	O
but	O
there	O
should	O
be	O
no	B-Negation_cue
plans	O
to	O
initiate	O
treatment	O
with	O
AChEIs	B-Drug
or	O
memantine	B-Drug
at	O
the	O
time	O
of	O
entry	O
into	O
the	O
study	O
.	O

6	O
.	O

Must	O
have	O
been	O
on	O
stable	O
doses	O
of	O
all	O
other	O
permitted	O
chronically	O
used	O
concomitant	O
medications	B-Drug
(	O
ie,	O
not	B-Negation_cue
related	O
to	O
their	O
cognitive	B-Condition
decline	I-Condition
)	O
for	O
at	O
least	O
4	O
weeks	O
before	O
randomization	O
.	O

Exclusion	O
criteria	O
:	O
.	O

Subjects	O
who	O
meet	O
any	O
of	O
the	O
following	O
criteria	O
will	O
be	O
excluded	O
from	O
this	O
study	O
:	O
.	O

1	O
.	O

Any	O
neurological	B-Condition
condition	I-Condition
that	O
may	O
be	O
contributing	O
to	O
cognitive	B-Condition
impairment	I-Condition
above	O
and	O
beyond	O
that	O
caused	O
by	O
the	O
subject's	O
AD	B-Condition
pathology	I-Condition
including	O
any	O
co-morbidities	B-Condition
such	O
as	O
cerebrovascular	B-Condition
disease	I-Condition
detected	O
by	O
medical	B-Observation
history	I-Observation
neurological	B-Observation
examination	I-Observation
or	O
MRI	B-Procedure_Device
.	O

2	O
.	O

History	O
of	O
transient	B-Condition
ischemic	I-Condition
attacks	I-Condition
or	O
stroke	B-Condition
within	O
12	O
months	O
of	O
Screening	O
.	O

3	O
.	O

History	O
of	O
epilepsy	B-Condition
.	O

4	O
.	O

Evidence	O
of	O
depression	B-Condition
on	O
a	O
rating	O
scale	O
at	O
Screening	O
or	O
any	O
psychiatric	O
diagnosis	O
or	O
symptoms,	O
(	O
eg,	O
hallucinations	B-Condition
,	O
major	B-Condition
depression	I-Condition
etc.)	O

that	O
could	O
confound	O
the	O
diagnosis	O
or	O
could	O
interfere	O
with	O
study	O
assessments	O
or	O
procedures	O
.	O

This	O
includes	O
suicidal	B-Condition
ideation	I-Condition
or	O
suicidal	B-Condition
behavior	I-Condition
within	O
6	O
months	O
prior	O
to	O
Screening	O
or	O
hospitalization	O
or	O
treatment	B-Drug
for	O
suicidal	B-Condition
behavior	I-Condition
in	O
the	O
past	O
5	O
years	O
.	O

5	O
.	O

Abnormally	O
low	O
serum	B-Observation
vitamin	I-Observation
B12	I-Observation
.	O

6	O
.	O

Thyroid	B-Observation
stimulating	I-Observation
hormone	I-Observation
above	O
the	O
normal	O
range	O
.	O

This	O
applies	O
to	O
all	O
subjects	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
are	O
taking	O
thyroid	O
supplements	O
.	O

7	O
.	O

Subjects	O
with	O
liver	B-Condition
disease	I-Condition
(	O
hepatic	B-Condition
impairment	I-Condition
),	O
at	O
Screening	O
or	O
Baseline	O
.	O

Subjects	O
with	O
Gilbert's	B-Condition
syndrome	I-Condition
need	O
not	B-Negation_cue
be	O
excluded	B-Negation_cue
.	O

8	O
.	O

Not	B-Negation_cue
able	O
to	O
have	O
a	O
MRI	B-Procedure_Device
,	O
PET	B-Procedure_Device
scanning	I-Procedure_Device
or	O
CSF	B-Procedure_Device
collection	O
by	O
Lumbar	B-Procedure_Device
Puncture	I-Procedure_Device
(	I-Procedure_Device
LP	I-Procedure_Device
)	I-Procedure_Device
.	O

9	O
.	O

Severe	O
visual	B-Condition
or	I-Condition
hearing	I-Condition
impairment	I-Condition
that	O
would	O
prevent	O
the	O
subject	O
from	O
performing	O
psychometric	O
tests	O
accurately	O
.	O

10	O
.	O

History	O
of	O
immunodeficiency	B-Condition
disorders	I-Condition
.	O

11	O
.	O

Subjects	O
with	O
chronic	O
viral	B-Condition
hepatitis	I-Condition
.	O

12	O
.	O

History	O
of	O
Tuberculosis	B-Condition
(	I-Condition
TB	I-Condition
)	I-Condition
.	O

Subjects	O
with	O
no	B-Negation_cue
history	O
of	O
TB	B-Condition
will	O
be	O
tested	O
for	O
previous	O
TB	O
exposure	O
and	O
a	O
positive	O
test	O
will	O
be	O
exclusionary	O
.	O

13	O
.	O

History	O
of	O
ophthalmic	B-Condition
shingles	I-Condition
or	O
ocular	B-Condition
Herpes	I-Condition
Simplex	I-Condition
Virus	I-Condition
(	I-Condition
HSV	I-Condition
)	I-Condition
infection	I-Condition
.	O

14	O
.	O

Any	O
live	B-Drug
vaccine	I-Drug
in	O
the	O
3	O
months	O
or	O
any	O
active	O
infection	B-Condition
within	O
the	O
last	O
4	O
weeks	O
before	O
study	O
drug	O
administration	O
(	O
i.e	O
.	O

randomization	O
)	O
.	O

15	O
.	O

Any	O
chronic	O
inflammatory	B-Condition
disease	I-Condition
that	O
is	O
not	O
adequately	O
controlled	O
or	O
requires	O
immunosuppressive	B-Drug
or	I-Drug
immunomodulatory	I-Drug
therapy	I-Drug
.	O

16	O
.	O

T	B-Observation
helper	I-Observation
cell	I-Observation
cytotoxic	B-Observation
T	I-Observation
cell	I-Observation
or	O
B	B-Observation
cell	I-Observation
absolute	I-Observation
counts	I-Observation
below	O
normal	O
.	O

17	O
.	O

Immunoglobulin	B-Observation
(	I-Observation
Ig	I-Observation
)	I-Observation
IgG,	I-Observation
IgA	I-Observation
or	I-Observation
IgM	I-Observation
levels	I-Observation
below	O
normal	O
at	O
Screening	O
or	O
Baseline,	O
unless	O
both	O
the	O
Investigator	O
and	O
the	O
Medical	O
Monitor	O
agree	O
that	O
the	O
finding	O
is	O
not	O
clinically	O
significant	O
.	O

18	O
.	O

Clinically	O
significant	O
deviation	O
from	O
normal	O
in	O
physical	B-Observation
examination	I-Observation
vital	B-Observation
signs	I-Observation
or	O
clinical	B-Observation
laboratory	I-Observation
tests	I-Observation
at	O
Screening	O
or	O
Baseline	O
.	O

19	O
.	O

Exclusionary	O
cardiac	O
factors	O
include	O
:	O
prolonged	B-Observation
QT	I-Observation
interval	I-Observation
greater	O
than	O
450	O
msec	O
from	O
Electrocardiograms	B-Procedure_Device
(	I-Procedure_Device
ECGs	I-Procedure_Device
)	I-Procedure_Device
history	O
of	O
risk	O
factors	O
for	O
torsade	B-Condition
de	I-Condition
pointes	I-Condition
or	O
the	O
use	O
of	O
concomitant	O
medications	B-Drug
that	O
prolong	O
the	O
QT	O
/	O
QTc	O
interval;	O
left	B-Condition
bundle	I-Condition
branch	I-Condition
block	I-Condition
persistent	O
low	O
or	O
high	O
heart	B-Observation
rate	I-Observation
persistent	O
low	O
or	O
high	O
blood	B-Observation
pressure	I-Observation
history	O
of	O
cardiac	B-Condition
arrhythmias	I-Condition
other	O
clinically	O
significant	O
ECG	B-Condition
abnormalities	I-Condition
.	O

20	O
.	O

Type	B-Condition
1	I-Condition
or	I-Condition
Type	I-Condition
2	I-Condition
diabetes	I-Condition
mellitus	I-Condition
that	O
is	O
not	B-Negation_cue
well	O
controlled	O
.	O

21	O
.	O

Malignant	B-Condition
neoplasms	I-Condition
within	O
5	O
years	O
before	O
Screening	O
(	O
except	B-Negation_cue
for	O
basal	B-Condition
or	I-Condition
squamous	I-Condition
cell	I-Condition
carcinoma	I-Condition
in	I-Condition
situ	I-Condition
of	I-Condition
the	I-Condition
skin	I-Condition
or	O
localized	B-Condition
prostate	I-Condition
cancer	I-Condition
that	O
did	O
not	O
require	O
systemic	O
therapy;	O
these	O
do	O
not	O
exclude	O
the	O
subject	O
)	O
.	O

22	O
.	O

Medical	B-Condition
conditions	I-Condition
(	O
eg,	O
cardiac,	B-Condition
respiratory,	I-Condition
gastrointestinal,	I-Condition
renal	I-Condition
disease	I-Condition
)	O
that	O
are	O
not	B-Negation_cue
stably	O
controlled	O
or	O
which,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
(	O
s	O
),	O
could	O
affect	O
the	O
subject's	O
safety	O
or	O
interfere	O
with	O
the	O
study	O
assessments	O
.	O

23	O
.	O

Hypopigmentation	B-Condition
conditions	I-Condition
(	O
eg,	O
albinism	B-Condition
and	O
vitiligo	B-Condition
)	O
.	O

24	O
.	O

Known	O
or	O
suspected	O
history	O
of	O
drug	B-Condition
or	I-Condition
alcohol	I-Condition
dependency	I-Condition
or	I-Condition
abuse	I-Condition
within	O
2	O
years,	O
current	O
use	O
of	O
recreational	B-Drug
drugs	I-Drug
or	O
a	O
positive	O
urine	B-Observation
drug	I-Observation
test	I-Observation
.	O

25	O
.	O

Planned	O
surgery	O
that	O
requires	O
general,	O
spinal	O
or	O
epidural	O
anesthesia	O
that	O
would	O
take	O
place	O
during	O
the	O
study	O
.	O

26	O
.	O

Participation	O
in	O
any	O
other	O
interventional	O
clinical	O
study	O
related	O
to	O
cognitive	B-Condition
impairment	I-Condition
within	O
6	O
months	O
before	O
Screening	O
unless	O
it	O
can	O
be	O
documented	O
that	O
the	O
subject	O
was	O
in	O
a	O
placebo	O
treatment	O
arm	O
.	O

27	O
.	O

Currently	O
enrolled	O
in	O
another	O
clinical	O
study	O
or	O
used	O
any	O
investigational	B-Drug
drug	I-Drug
or	O
device	B-Procedure_Device
within	O
60	O
days	O
or	O
5	O
half-lives	O
of	O
the	O
investigational	B-Drug
medication	I-Drug
(	O
whichever	O
is	O
longer	O
)	O
proceeding	O
informed	O
consent	O
.	O

28	O
.	O

Hypersensitivity	B-Condition
to	O
the	O
study	B-Drug
drug	I-Drug
or	O
any	O
of	O
the	O
excipients	B-Drug
or	O
to	O
other	O
Beta	B-Drug
Secretase	I-Drug
Cleaving	I-Drug
Enzyme	I-Drug
(	I-Drug
BACE	I-Drug
)	I-Drug
inhibitors	I-Drug
or	O
to	O
the	O
PET	B-Drug
tracer	I-Drug
or	O
components	O
of	O
its	O
formulation	O
.	O

29	O
.	O

Females	O
who	O
are	O
lactating	B-Condition
or	O
pregnant	B-Condition
.	O

Females	O
of	O
childbearing	B-Condition
potential	I-Condition
who	O
do	O
not	O
agree	O
to	O
adhere	O
to	O
the	O
protocol	O
specified	O
methods	O
for	O
avoiding	O
pregnancy	B-Condition
.	O

30	O
.	O

Males	O
who	O
do	O
not	O
meet	O
the	O
protocol	O
requirements	O
for	O
avoiding	O
their	O
partners	O
becoming	O
pregnant	O
.	O

Sperm	O
donation	O
is	O
not	O
permitted	O
.	O

>>NCT01862640	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Male	O
and	O
female	O
subjects	O
55	O
to	O
90	O
years	O
of	O
age	B-Observation
,	O
inclusive,	O
at	O
the	O
time	O
of	O
informed	O
consent	O
.	O

-	O
Subjects	O
who	O
are	O
residing	O
either	O
in	O
an	O
institutionalized	O
setting	O
(	O
eg	O
,	O
dementia	O
unit,	O
nursing	O
home,	O
assisted	O
living	O
facility	O
or	O
other	O
residential	O
care	O
facility	O
)	O
or	O
in	O
a	O
non-institutionalized	O
setting	O
where	O
the	O
subject	O
is	O
not	O
living	O
alone	O
.	O

Subjects	O
must	O
have	O
been	O
at	O
their	O
current	O
location	O
for	O
at	O
least	O
14	O
days	O
before	O
screening	O
and	O
plan	O
to	O
remain	O
at	O
the	O
same	O
location	O
for	O
the	O
duration	O
of	O
the	O
trial	O
.	O

-	O
Subjects	O
with	O
a	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
NINCDS-ADRDA	B-Observation
.	O

-	O
Subjects	O
with	O
a	O
MMSE	B-Observation
score	I-Observation
of	O
5	O
to	O
22,	O
inclusive,	O
at	O
screening	O
and	O
baseline	O
visits	O
.	O

-	O
Subjects	O
with	O
onset	O
of	O
symptoms	O
of	O
agitation	B-Condition
at	O
least	O
2	O
weeks	O
prior	O
to	O
the	O
screening	O
visit	O
.	O

-	O
Subjects	O
with	O
a	O
score	O
of	O
>=	O
4	O
on	O
the	O
agitation	B-Observation
/	I-Observation
aggression	I-Observation
item	I-Observation
of	I-Observation
the	I-Observation
NPI-NH	I-Observation
at	O
the	O
screening	O
and	O
baseline	O
visits	O
.	O

-	O
Subjects	O
who	O
require	O
pharmacotherapy	O
for	O
treatment	O
of	O
agitation	O
per	O
the	O
investigator's	O
judgment,	O
after	O
an	O
evaluation	O
for	O
reversible	O
factors	O
(	O
eg,	O
pain,	O
infection,	O
polypharmacy	O
)	O
and	O
a	O
trial	O
of	O
nonpharmacological	O
intervention	O
.	O

-	O
Subjects	O
must	O
have	O
a	O
previous	O
MRI	B-Procedure_Device
or	O
CT	B-Procedure_Device
scan	I-Procedure_Device
of	O
the	O
brain,	O
which	O
was	O
performed	O
after	O
the	O
onset	O
of	O
symptoms	O
of	O
dementia	B-Condition
,	O
with	O
findings	O
consistent	O
with	O
the	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Subjects	O
with	O
dementia	B-Condition
or	O
other	O
memory	B-Condition
impairment	I-Condition
not	B-Negation_cue
due	O
to	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Subjects	O
with	O
a	O
history	O
of	O
stroke	B-Condition
,	O
well-documented	O
transient	B-Condition
ischemic	I-Condition
attack	I-Condition
pulmonary	B-Condition
or	I-Condition
cerebral	I-Condition
embolism	I-Condition
.	O

-	O
Subjects	O
who	O
currently	O
have	O
clinically	O
significant	O
neurological,	B-Condition
hepatic,	I-Condition
renal,	I-Condition
metabolic,	I-Condition
hematological,	I-Condition
immunological,	I-Condition
cardiovascular,	I-Condition
pulmonary,	I-Condition
gastrointestinal	I-Condition
or	I-Condition
psychiatric	I-Condition
disorders	I-Condition
.	O

-	O
Subjects	O
who	O
have	O
been	O
diagnosed	O
with	O
an	O
Axis	B-Condition
I	I-Condition
disorder	I-Condition
(	O
DSM-IV-TR	B-Observation
criteria	I-Observation
)	O
.	O

-	O
Subjects	O
with	O
uncontrolled	O
hypertension	B-Condition
.	O

-	O
Subjects	O
with	O
uncontrolled	O
insulin-dependent	B-Condition
diabetes	I-Condition
mellitus	I-Condition
(	I-Condition
IDDM	I-Condition
)	I-Condition
.	O

-	O
Subjects	O
with	O
epilepsy	B-Condition
or	O
a	O
history	O
of	O
seizures	B-Condition
.	O

-	O
Subjects	O
considered	O
in	O
poor	O
general	O
health	O
based	O
on	O
the	O
investigator's	O
judgment	O
.	O

>>NCT00675090	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Male	O
or	O
female	O
subjects	O
with	O
a	O
clinical	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
The	O
subject	O
has	O
an	O
MMSE	B-Observation
score	I-Observation
at	O
screening	O
of	O
12	O
to	O
26	O
for	O
Part	O
A	O
and	O
16	O
-	O
26	O
for	O
Part	O
B	O
.	O

-	O
Age	B-Observation
>=	O
50	O
and	O
above	O
.	O

-	O
If	O
female,	O
the	O
subject	O
must	O
be	O
post-menopausal	B-Condition
(	O
i.e	O
.	O

12	O
months	O
without	O
menstrual	O
period	O
)	O
or	O
surgically	B-Condition
sterile	I-Condition
.	O

-	O
Male	O
subjects	O
must	O
be	O
willing	O
to	O
abstain	O
from	O
sexual	O
intercourse	O
with	O
pregnant	O
or	O
lactating	O
women;	O
or	O
be	O
willing	O
to	O
use	O
a	O
condom	O
/	O
spermicide	O
in	O
addition	O
to	O
having	O
their	O
female	O
partner	O
use	O
another	O
form	O
of	O
contraception	O
if	O
the	O
woman	O
could	O
become	O
pregnant,	O
from	O
the	O
time	O
of	O
the	O
first	O
dose	O
of	O
GSK239512	O
until	O
84	O
days	O
following	O
completion	O
of	O
the	O
study	O
.	O

-	O
The	O
subject	O
has	O
the	O
ability	O
to	O
comply	O
with	O
the	O
study	O
procedures	O
.	O

-	O
The	O
subject	O
has	O
a	O
permanent	O
caregiver	O
and	O
is	O
willing	O
to	O
attend	O
all	O
study	O
visits	O
for	O
Parts	O
A	O
and	O
B	O
.	O

-	O
The	O
subject	O
has	O
provided	O
full	O
written	O
informed	O
consent	O
prior	O
to	O
the	O
performance	O
of	O
any	O
protocol	O
specific	O
procedure	O
or	O
if	O
unable	O
to	O
provide	O
informed	O
consent	O
due	O
to	O
cognitive	O
status,	O
full	O
written	O
informed	O
consent	O
on	O
behalf	O
of	O
the	O
subject	O
has	O
been	O
provided	O
by	O
a	O
legally	O
acceptable	O
representative	O
.	O

-	O
The	O
caregiver	O
has	O
provided	O
his	O
/	O
her	O
written	O
consent	O
prior	O
to	O
the	O
performance	O
of	O
any	O
protocol	O
specific	O
procedure	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
In	O
the	O
opinion	O
of	O
the	O
investigator,	O
following	O
review	O
of	O
CT	B-Procedure_Device
MRI	B-Procedure_Device
scans	I-Procedure_Device
in	O
the	O
past	O
12	O
months	O
and	O
completion	O
of	O
neurological	O
review	O
there	O
could	O
be	O
other	O
probable	O
causes	B-Condition
of	I-Condition
dementia	I-Condition
.	O

-	O
History	O
of	O
significant	O
psychiatric	B-Condition
illness	I-Condition
such	O
as	O
schizophrenia	B-Condition
or	O
bipolar	B-Condition
affective	I-Condition
disorder	I-Condition
that	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
would	O
interfere	O
with	O
participation	O
in	O
the	O
study	O
or	O
current	O
depression	B-Condition
(	O
a	O
score	O
of	O
>=	O
8	O
on	O
the	O
Cornell	B-Observation
Scale	I-Observation
for	O
Depression	B-Condition
in	O
Dementia	B-Condition
)	O
or	O
subjects	O
with	O
other	O
psychiatric	B-Condition
features	I-Condition
in	O
their	O
AD	B-Condition
which	O
would	O
in	O
the	O
opinion	O
of	O
the	O
investigator,	O
would	O
increase	O
risk	O
to	O
safety	O
.	O

-	O
History	O
of	O
significant	O
sleep	B-Condition
disturbance	I-Condition
for	O
example,	O
when	O
it	O
is	O
associated	O
with	O
nocturnal	B-Condition
wandering	I-Condition
nocturnal	B-Condition
confusion	I-Condition
/	I-Condition
disorientation	I-Condition
/	I-Condition
agitation	I-Condition
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator,	O
may	O
increase	O
safety	O
risk	O
.	O

-	O
History	O
or	O
presence	O
of	O
known	O
or	O
suspected	O
seizures	B-Condition
,	O
unexplained	O
significant	O
loss	B-Condition
of	I-Condition
consciousness	I-Condition
within	O
last	O
6	O
months	O
.	O

Subjects	O
who	O
had	O
febrile	B-Condition
seizures	I-Condition
in	O
childhood	O
may	O
be	O
included	O
if	O
these	O
ceased	O
by	O
age	B-Observation
10	O
and	O
they	O
have	O
had	O
no	B-Negation_cue
other	O
type	O
of	O
seizure	B-Condition
in	O
their	O
medical	B-Observation
history	I-Observation
and	O
have	O
not	B-Negation_cue
been	O
on	O
anti-epileptic	B-Drug
medications	I-Drug
.	O

-	O
History	O
or	O
presence	O
of	O
significant	O
cardiovascular,	B-Condition
gastro-intestinal,	I-Condition
hepatic	I-Condition
or	I-Condition
renal	I-Condition
disease	I-Condition
or	O
other	O
condition	B-Condition
known	O
to	O
interfere	O
with	O
the	O
absorption	B-Observation
,	O
distribution	B-Observation
,	O
metabolism	B-Observation
or	O
excretion	B-Observation
of	O
drugs	O
or	O
any	O
other	O
clinically	O
relevant	O
abnormality	B-Condition
,	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
condition	I-Condition
which,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator,	O
makes	O
the	O
subject	O
unsuitable	O
for	O
inclusion	O
in	O
the	O
study	O
.	O

-	O
History	O
of	O
alcohol	B-Condition
or	I-Condition
other	I-Condition
substance	I-Condition
abuse	I-Condition
according	O
to	O
the	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Disorders	I-Observation
-	I-Observation
Substance	I-Observation
related	I-Observation
disorders	I-Observation
(	I-Observation
DSM-IV	I-Observation
)	I-Observation
criteria	I-Observation
.	O

-	O
Clinically	O
significant	O
abnormalities	B-Condition
in	O
laboratory	B-Observation
tests	I-Observation
including	O
subjects	O
with	O
active	O
liver	B-Condition
disease	I-Condition
or	O
uncontrolled	O
thyroid	B-Condition
disease	I-Condition
.	O

-	O
Uncontrolled	O
hypertension	B-Condition
with	O
systolic	B-Observation
BP	I-Observation
>=	O
160	O
and	O
/	O
or	O
diastolic	B-Observation
>=	O
95	O
mmHg	O
.	O

Subjects	O
with	O
controlled	O
hypertension	B-Condition
with	O
systolic	B-Observation
BP	I-Observation
<	O
160	O
mmHg	O
and	O
diastolic	B-Observation
<	O
95	O
mmHg	O
for	O
at	O
least	O
4	O
weeks	O
are	O
acceptable	O
.	O

-	O
Systolic	B-Observation
BP	I-Observation
<	O
100	O
mmHg	O
and	O
/	O
or	O
diastolic	B-Observation
<	O
60	O
mmHg	O
.	O

-	O
Subjects	O
with	O
ECG	O
criteria	O
outside	O
ranges	O
specified	O
in	O
the	O
protocol	O
.	O

-	O
History	O
of	O
hypersensitivity	B-Condition
to	O
GSK239512	B-Drug
or	O
its	O
excipients	B-Drug
.	O

-	O
Treatment	O
with	O
cholinesterase	B-Drug
inhibitors	I-Drug
(	O
including	O
Tacrine	B-Drug
),	O
memantine	B-Drug
or	O
selegiline	B-Drug
within	O
the	O
previous	O
month	O
.	O

No	B-Negation_cue
patients	O
with	O
AD	B-Condition
who	O
are	O
already	O
on	O
these	O
medications	O
at	O
the	O
time	O
of	O
screening	O
will	O
be	O
recruited,	O
as	O
it	O
would	O
be	O
unethical	O
to	O
withdraw	O
these	O
medications	O
for	O
study	O
participation	O
.	O

Only	O
AD	B-Condition
subjects	O
who	O
are	O
not	O
yet	O
on	O
these	O
medications	O
or	O
who	O
have	O
withdrawn	O
from	O
these	O
medications	O
for	O
other	O
reasons	O
previously,	O
may	O
be	O
enrolled	O
into	O
this	O
study	O
.	O

-	O
Subjects	O
who	O
are	O
currently	O
taking	O
or	O
who	O
have	O
taken	O
in	O
the	O
last	O
month	O
anti-psychotic	B-Drug
drugs	I-Drug
(	O
typical	O
or	O
atypical	O
dopaminergic	B-Drug
antagonists	I-Drug
or	O
modulators	B-Drug
)	O
or	O
mood	B-Drug
stabilization	I-Drug
drugs	I-Drug
(	O
including	O
SSRI	B-Drug
,	O
DNRI	B-Drug
,	O
SNRI	B-Drug
,	O
MAO	B-Drug
inhibitors	I-Drug
tricyclic	B-Drug
antidepressants	I-Drug
lithium	B-Drug
,	O
valproate	B-Drug
,	O
carbamazepine	B-Drug
)	O
.	O

-	O
Subjects	O
who	O
are	O
currently	O
taking	O
Pgp	B-Drug
inhibitors	I-Drug
or	O
any	O
CYP3A4	B-Drug
inhibitors	I-Drug
.	O

-	O
Subjects	O
on	O
chronic	O
sedative	B-Drug
medications	I-Drug
(>=	O
4	O
days	O
per	O
week	O
for	O
the	O
past	O
4	O
weeks	O
)	O
.	O

-	O
Subject	O
or	O
caregiver	O
is	O
an	O
immediate	O
family	O
member	O
or	O
employee	O
of	O
the	O
participating	O
Investigator,	O
any	O
of	O
the	O
participating	O
site	O
staff	O
or	O
GSK	O
staff	O
.	O

-	O
Has	O
received	O
any	O
other	O
investigational	B-Drug
treatment	I-Drug
in	O
the	O
previous	O
3	O
months	O
.	O

>>NCT00000176	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Healthy	B-Condition
women	O
65	O
or	O
older	O
with	O
a	O
family	O
history	O
of	O
memory	B-Condition
problems	I-Condition
not	B-Negation_cue
currently	O
on	O
estrogen	B-Drug
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Significant	O
neurological	B-Condition
impairment	I-Condition
.	O

-	O
Current	O
estrogen	B-Drug
use	O
.	O

-	O
History	O
of	O
breast	B-Condition
cancer	I-Condition
.	O

>>NCT02256306	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
(	O
NIA-AA	B-Observation
criteria	I-Observation
)	O
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
12	O
-	O
24	O
.	O

-	O
Availability	O
of	O
a	O
study	O
partner	O
who	O
knows	O
the	O
patient	O
well	O
and	O
is	O
willing	O
to	O
accompany	O
the	O
patient	O
to	O
all	O
trial	O
visits	O
and	O
to	O
participate	O
in	O
questionnaires	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Pregnancy	B-Condition
or	O
unwilling	O
to	O
use	O
adequate	O
birth	O
control	O
method	O
for	O
duration	O
of	O
and	O
6	O
months	O
beyond	O
study	O
participation	O
.	O

-	O
Positive	O
for	O
Hepatitis	B-Observation
B	I-Observation
Hepatitis	B-Observation
C	I-Observation
or	O
HIV	B-Observation
at	O
screening	O
.	O

-	O
Any	O
other	O
condition	O
or	O
situation	O
that	O
the	O
investigator	O
believes	O
may	O
interfere	O
with	O
the	O
safety	O
of	O
the	O
subject	O
or	O
the	O
intent	O
and	O
conduct	O
of	O
the	O
study	O
.	O

-	O
Related	O
to	O
medical	O
history	O
:	O
.	O

-	O
Stroke	B-Condition
.	O

-	O
Anaphylaxis	B-Condition
.	O

-	O
Prior	O
adverse	B-Condition
reaction	I-Condition
to	O
any	O
human	B-Drug
blood	I-Drug
product	I-Drug
.	O

-	O
Any	O
history	O
of	O
a	O
blood	B-Condition
coagulation	I-Condition
disorder	I-Condition
or	O
hypercoagulability	B-Condition
.	O

-	O
Congestive	B-Condition
heart	I-Condition
failure	I-Condition
.	O

-	O
Renal	B-Condition
failure	I-Condition
.	O

-	O
Prior	O
intolerance	B-Condition
to	O
intravenous	B-Drug
fluids	I-Drug
.	O

-	O
Recent	O
history	O
of	O
uncontrolled	O
atrial	B-Condition
fibrillation	I-Condition
.	O

-	O
IgA	B-Condition
deficiency	I-Condition
(	O
by	O
history	O
)	O
.	O

-	O
Related	O
to	O
medications	O
or	O
other	O
treatments	O
:	O
.	O

-	O
Any	O
concurrent	O
use	O
of	O
an	O
anticoagulant	B-Drug
therapy	I-Drug
.	O

Antiplatelet	B-Drug
drugs	I-Drug
(	O
eg	O
,	O
aspirin	B-Drug
or	O
clopidogrel	B-Drug
)	O
are	O
acceptable	O
.	O

-	O
Initiation	O
or	O
change	O
in	O
the	O
dosage	O
of	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
or	O
memantine	B-Drug
during	O
the	O
trial	O
.	O

A	O
participant	O
already	O
on	O
a	O
cholinesterase	B-Drug
inhibitor	I-Drug
or	O
memantine	B-Drug
must	O
be	O
on	O
a	O
stable	O
dose	O
for	O
at	O
least	O
one	O
month	O
prior	O
to	O
Screening	O
.	O

-	O
Concurrent	O
participation	O
in	O
another	O
treatment	O
trial	O
for	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

If	O
there	O
was	O
prior	O
participation,	O
the	O
last	O
dose	O
of	O
the	O
investigational	B-Drug
agent	I-Drug
must	O
have	O
been	O
at	O
least	O
6	O
months	O
prior	O
to	O
Screening	O
.	O

-	O
Treatment	O
with	O
any	O
human	B-Drug
blood	I-Drug
product	I-Drug
including	O
intravenous	B-Drug
immunoglobulin	I-Drug
during	O
the	O
6	O
months	O
prior	O
to	O
Screening	O
or	O
during	O
the	O
trial	O
.	O

-	O
Concurrent	O
daily	O
treatment	O
with	O
benzodiazepines	B-Drug
,	O
typical	O
or	O
atypical	O
antipsychotics	B-Drug
,	O
long-acting	O
opioids	B-Drug
or	O
other	O
medications	B-Drug
that,	O
in	O
the	O
investigator's	O
opinion,	O
interfere	O
with	O
cognition	B-Observation
.	O

Intermittent	O
treatment	O
with	O
short-acting	O
benzodiazepines	B-Drug
or	O
atypical	O
antipsychotics	B-Drug
may	O
be	O
permitted,	O
provided	O
that	O
no	B-Negation_cue
dose	B-Drug
is	O
administered	O
within	O
the	O
72	O
hours	O
preceding	O
any	O
cognitive	B-Observation
assessment	I-Observation
.	O

-	O
Related	O
to	O
magnetic	B-Procedure_Device
resonance	I-Procedure_Device
imaging	I-Procedure_Device
:	O
.	O

Claustrophobia	B-Condition
.	O

Any	O
metallic	B-Procedure_Device
surgical	I-Procedure_Device
implant	I-Procedure_Device
like	O
a	O
pacemaker	B-Procedure_Device
or	O
clip	B-Procedure_Device
that	O
is	O
incompatible	O
with	O
3T	B-Procedure_Device
MRI	I-Procedure_Device
.	O

Certain	O
metallic	O
implants	O
like	O
joint	O
replacements	O
may	O
be	O
permitted,	O
provided	O
that	O
specific	O
manufacturer	O
specifications	O
are	O
available	O
and	O
that	O
the	O
device	O
is	O
known	O
to	O
be	O
safe	O
for	O
3T	O
MRI.	O

>>NCT01255163	O
-	O
INCLUSION	O
.	O

-	O
Age	B-Observation
>	O
60	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
global	I-Observation
CDR	I-Observation
)	I-Observation
of	O
0.5	O
or	O
1	O
.	O

Memory	B-Observation
box	I-Observation
score	I-Observation
must	O
be	O
at	O
least	O
0.5	O
.	O

-	O
Mini	B-Observation
Mental	I-Observation
Status	I-Observation
Exam	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
>	O
20	O
.	O

-	O
Clinical	O
diagnosis	O
of	O
(	O
amnestic	O
or	O
mixed	O
)	O
MCI	B-Condition
or	O
early	O
AD	B-Condition
,	O
at	O
the	O
judgment	O
of	O
the	O
Principal	O
Investigator	O
.	O

Memory	B-Condition
deficit	I-Condition
on	O
neuropsychological	B-Observation
or	I-Observation
clinical	I-Observation
testing	I-Observation
.	O

-	O
Hamilton	B-Observation
Depression	I-Observation
Scale	I-Observation
score	I-Observation
of	O
less	O
than	O
or	O
equal	O
to	O
12	O
on	O
the	O
17	O
-item	O
scale	O
.	O

-	O
CSF	B-Observation
A	I-Observation
beta	I-Observation
42	I-Observation
<	O
192	O
(+-	O
10%)	O
pg	O
/	O
ml	O
(	O
given	O
an	O
intra-subject	O
laboratory	O
variability	O
~	O
10%)	O
.	O

-	O
Medications	B-Drug
stable	O
for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

In	O
particular	O
:	O
.	O

-	O
Participants	O
may	O
take	O
stable	O
doses	B-Procedure_Device
of	O
antidepressants	B-Drug
,	O
chronic	B-Drug
anxiolytics	I-Drug
or	O
sedative	B-Drug
hypnotics	I-Drug
at	O
the	O
discretion	O
of	O
the	O
Principal	O
Investigator,	O
if	O
started	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Cholinesterase	B-Drug
inhibitors	I-Drug
and	O
/	O
or	O
memantine	B-Drug
are	O
allowable,	O
if	O
started	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Participants	O
will	O
not	O
be	O
asked	O
to	O
discontinue	O
medications	O
without	O
permission	O
from	O
their	O
physician	O
.	O

-	O
Fluency	O
in	O
English	O
.	O

-	O
At	O
the	O
time	O
of	O
enrollment,	O
participants	O
must	O
have	O
the	O
ability	O
to	O
provide	O
informed	O
consent	O
and	O
make	O
health	O
care	O
decisions	O
.	O

-	O
An	O
informant	O
or	O
caregiver	O
who	O
has	O
frequent	O
contact	O
with	O
the	O
participant	O
(	O
eg	O
an	O
average	O
of	O
10	O
hours	O
per	O
week	O
or	O
more	O
)	O
must	O
be	O
appointed	O
to	O
serve	O
as	O
Durable	O
Power	O
of	O
Attorney	O
(	O
DPA	O
)	O
for	O
research	O
and	O
medical	O
care	O
at	O
NIA,	O
accompany	O
the	O
participant	O
to	O
clinic	O
visits	O
and	O
provide	O
historical	O
information	O
regarding	O
the	O
participant	O
s	O
cognitive	O
status	O
and	O
assist	O
participants	O
with	O
/	O
administer	O
injections	O
of	O
the	O
investigational	O
medication	O
.	O

-	O
Good	O
general	B-Condition
health	I-Condition
with	O
no	B-Negation_cue
additional	O
disease	B-Condition
states	I-Condition
that	O
could	O
interfere	O
with	O
the	O
study,	O
at	O
the	O
discretion	O
of	O
the	O
Principal	O
Investigator	O
.	O

-	O
Willing	O
and	O
able	O
to	O
complete	O
all	O
baseline	O
assessments	O
(	O
including	O
ApoE	O
genotyping	O
)	O
.	O

-	O
Willing	O
to	O
have	O
an	O
initial	O
Lumbar	O
Puncture	O
and	O
provide	O
CSF	O
at	O
protocol	O
specified	O
time	O
points	O
.	O

-	O
Willing	O
and	O
able	O
to	O
participate	O
in	O
a	O
18	O
-month	O
protocol	O
.	O

EXCLUSION	O
.	O

-	O
Other	O
significant	O
neurological	B-Condition
disease	I-Condition
of	O
the	O
Central	O
Nervous	O
System	O
(	O
such	O
as	O
Parkinson	B-Condition
s	I-Condition
disease	I-Condition
Multi-infarct	B-Condition
Dementia	I-Condition
Frontotemporal	B-Condition
Dementia	I-Condition
Huntington	B-Condition
s	I-Condition
disease	I-Condition
Normal	B-Condition
Pressure	I-Condition
Hydrocephalus	I-Condition
brain	B-Condition
tumor	I-Condition
Progressive	B-Condition
Supranuclear	I-Condition
Palsy	I-Condition
Epilepsy	B-Condition
,	O
Subdural	B-Condition
Hematoma	I-Condition
or	O
Multiple	B-Condition
Sclerosis	I-Condition
)	O
.	O

-	O
A	O
history	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
followed	O
by	O
persistent	O
neurologic	B-Condition
defaults	I-Condition
or	O
known	O
structural	B-Condition
brain	I-Condition
abnormalities	I-Condition
.	O

-	O
Significant	O
neuroimaging	B-Condition
abnormalities	I-Condition
previously	O
known	O
or	O
discovered	O
on	O
the	O
initial	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
including	O
evidence	O
of	O
infection	B-Condition
,	O
infarction	B-Condition
(>	O
3	O
mm	O
in	O
size	B-Observation
),	O
brain	B-Condition
tumors	I-Condition
(	O
other	B-Negation_cue
than	I-Negation_cue
small	B-Condition
meningiomas	I-Condition
or	O
other	O
benign	B-Condition
lesions	I-Condition
)	O
or	O
other	O
focal	B-Condition
lesions	I-Condition
multiple	B-Condition
lacunes	I-Condition
or	O
lacunes	B-Condition
in	O
a	O
critical	O
memory	O
structure	O
or	O
severe	O
confluent	B-Condition
microvascular	I-Condition
disease	I-Condition
(	O
but	O
not	B-Negation_cue
mild	O
white	B-Condition
matter	I-Condition
changes	I-Condition
which	O
are	O
frequent	O
with	O
aging	O
)	O
.	O

-	O
Positive	O
RPR	B-Observation
or	O
HIV	B-Observation
.	O

-	O
Coagulopathy	B-Condition
or	O
anti-coagulant	B-Drug
therapy	I-Drug
(	O
such	O
as	O
coumadin	B-Drug
)	O
increasing	O
the	O
risk	O
for	O
LP	B-Procedure_Device
resulting	O
in	O
PT	B-Observation
/	I-Observation
PTT	I-Observation
and	O
INR	B-Observation
within	O
1.5	O
standard	O
deviation	O
over	O
the	O
upper	O
normal	O
limit	O
.	O

-	O
Investigators	O
unable	O
to	O
obtain	O
CSF	B-Procedure_Device
,	O
at	O
the	O
clinical	O
judgment	O
of	O
the	O
investigator	O
performing	O
the	O
procedure	O
(	O
failure	O
of	O
Lumbar	B-Procedure_Device
Puncture	I-Procedure_Device
after	O
a	O
limited	O
number	O
of	O
unsuccessful	O
attempts	O
)	O
.	O

-	O
History	O
of	O
significant	O
psychiatric	B-Condition
disease	I-Condition
at	O
the	O
discretion	O
of	O
the	O
Principal	O
Investigator	O
.	O

Participants	O
who	O
develop	O
psychiatric	B-Condition
conditions	I-Condition
necessitating	O
treatment	B-Procedure_Device
after	O
their	O
enrollment	O
will	O
not	O
be	O
dropped	O
from	O
the	O
study	O
.	O

The	O
high	O
incidence	O
of	O
late-onset	B-Condition
depression	I-Condition
among	O
individuals	O
with	O
MCI	B-Condition
and	O
AD	B-Condition
requires	O
that	O
certain	O
participants	O
with	O
depression	B-Condition
,	O
at	O
the	O
discretion	O
of	O
the	O
Principal	O
Investigator,	O
should	O
be	O
included	O
in	O
the	O
cohort	O
to	O
maintain	O
the	O
ecological	O
validity	O
of	O
the	O
results	O
.	O

-	O
Significant	O
history	O
of	O
alcoholism	B-Condition
or	O
substance	B-Condition
abuse	I-Condition
at	O
the	O
discretion	O
of	O
the	O
Principal	O
Investigator	O
.	O

-	O
Known	O
diagnosis	O
of	O
diabetes	B-Condition
at	O
the	O
time	O
of	O
enrollment	O
or	O
new	O
diagnosis	O
of	O
diabetes	B-Condition
based	O
on	O
the	O
findings	O
of	O
elevated	O
fasting	B-Observation
blood	I-Observation
glucose	I-Observation
(=	O
or	O
>	O
126	O
mg	O
/	O
dl	O
)	O
and	O
/	O
or	O
the	O
oral	B-Observation
glucose	I-Observation
tolerance	I-Observation
test	I-Observation
at	O
screening	O
(>	O
200	O
mg	O
/	O
dl	O
at	O
two	O
hours	O
)	O
.	O

-	O
Severe	O
renal	B-Condition
impairment	I-Condition
(	O
creatinine	B-Observation
clearance	I-Observation
<	O
30	O
ml	O
/	O
min	O
)	O
or	O
end-stage	O
renal	B-Condition
disease	I-Condition
.	O

Individuals	O
with	O
moderate	O
renal	B-Condition
impairment	I-Condition
(	O
creatinine	B-Observation
clearance	I-Observation
30	O
to	O
50	O
ml	O
/	O
min	O
)	O
may	O
be	O
enrolled	O
in	O
the	O
study	O
but	O
their	O
BUN	O
and	O
Creatinine	O
will	O
be	O
followed	O
closely	O
.	O

All	O
participants,	O
in	O
whom	O
BUN	O
or	O
creatinine	O
increased	O
after	O
switching	O
from	O
5	O
microgram	O
SC	O
bid	O
to	O
10	O
microgram	O
SC	O
bid	O
(	O
but	O
not	O
with	O
5	O
microgram	O
SC	O
bid	O
),	O
will	O
be	O
switched	O
back	O
to	O
5	O
microgram	O
SC	O
bid	O
.	O

If	O
the	O
BUN	O
/	O
Creatinine	O
elevation	O
persists	O
one	O
week	O
later	O
with	O
the	O
lower	O
dose,	O
the	O
participant	O
will	O
be	O
withdrawn	O
from	O
the	O
study	O
.	O

-	O
Current	O
or	O
previous	O
treatment	O
with	O
Exendin-	B-Drug
4	I-Drug
.	O

-	O
History	O
of	O
pancreatitis	B-Condition
,	O
active	O
upper	B-Condition
GI,	I-Condition
hepatic	I-Condition
or	I-Condition
gallbladder	I-Condition
disease	I-Condition
.	O

-	O
Personal	O
or	O
family	O
history	O
of	O
medullary	B-Condition
thyroid	I-Condition
carcinoma	I-Condition
or	O
Multiple	B-Condition
Endocrine	I-Condition
Neoplasia	I-Condition
syndrome	I-Condition
type	I-Condition
2	I-Condition
.	O

-	O
History	O
of	O
repeated	O
hypoglycemia	B-Condition
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
(	I-Observation
BMI	I-Observation
)	I-Observation
<	O
20	O
on	O
enrollment	O
(	O
given	O
the	O
expected	O
weight	B-Observation
loss	I-Observation
caused	O
by	O
Exendin-	B-Drug
4	I-Drug
and	O
dementia	B-Condition
)	O
.	O

In	O
the	O
BLSA,	O
participants	O
with	O
age	B-Observation
>	O
65	O
had	O
a	O
mean	B-Observation
BMI	I-Observation
of	O
25.8	O
with	O
SD	B-Observation
of	O
3.9	O
Exendin-	B-Drug
4	I-Drug
has	O
been	O
shown	O
to	O
cause	O
an	O
average	O
5.3	O
kg	O
weight	B-Observation
loss	I-Observation
with	O
95%	B-Observation
CI	I-Observation
:	O
6	O
to	O
4.5	O
kg	O
.	O

-	O
Allergy	B-Condition
to	O
Exendin-	B-Drug
4	I-Drug
or	O
to	O
substances	B-Drug
in	O
the	O
injection	O
pen	O
(	O
metacresol	B-Drug
,	O
mannitol	B-Drug
,	O
glacial	B-Drug
acetic	I-Drug
acid	I-Drug
sodium	B-Drug
acetate	I-Drug
trihydrate	I-Drug
water	B-Drug
for	O
injection	O
)	O
.	O

-	O
Participation	O
in	O
other	O
studies	O
of	O
investigational	B-Drug
treatments	I-Drug
for	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Refusal	O
to	O
consent	O
to	O
the	O
initial	O
Lumbar	O
Puncture	O
and	O
ApoE	O
genotyping	O
.	O

>>NCT00066157	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Postmenopausal	B-Condition
women	O
with	O
Alzheimer's	B-Condition
disease	I-Condition
and	O
without	B-Negation_cue
other	O
dementias	B-Condition
(	O
diagnosed	O
by	O
study	O
staff	O
or	O
from	O
an	O
outside	O
clinic	O
)	O
.	O

-	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
score	I-Observation
greater	O
than	O
15	O
-	O
30	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
History	O
of	O
cancer	B-Condition
of	I-Condition
reproductive	I-Condition
tissues	I-Condition
.	O

-	O
History	O
of	O
deep	B-Condition
vein	I-Condition
thrombosis	I-Condition
or	O
blot	B-Condition
clots	I-Condition
.	O

-	O
Diabetes	B-Condition
.	O

-	O
Heart	B-Condition
disease	I-Condition
or	O
stroke	B-Condition
.	O

-	O
Liver	B-Condition
problems	I-Condition
including	O
hepatitis	B-Condition
.	O

-	O
Severe	O
vision	B-Condition
or	I-Condition
hearing	I-Condition
problems	I-Condition
.	O

-	O
Tobacco	B-Drug
use	O
.	O

-	O
Lack	O
of	O
an	O
adequate	O
caregiver	O
.	O

-	O
inability	O
to	O
perform	O
psychometric	B-Procedure_Device
testing	I-Procedure_Device
.	O

>>NCT01231971	O
Inclusion	O
Criteria	O
:	O
.	O

Participants	O
will	O
be	O
classified	O
as	O
either	O
normal	O
controls,	O
SMC,	O
EMCI,	O
LMCI	O
or	O
AD	O
participants	O
.	O

General	O
Inclusion	O
Criteria	O
will	O
apply	O
to	O
all	O
groups,	O
with	O
specific	O
criteria	O
for	O
each	O
group	O
as	O
described	O
below	O
:	O
.	O

General	O
(	O
applies	O
to	O
each	O
category	O
):	O
.	O

-	O
Geriatric	B-Observation
Depression	I-Observation
Scale	I-Observation
less	O
than	O
6	O
.	O

-	O
Age	B-Observation
between	O
*55	O
-	O
90	O
(	O
inclusive	O
)	O
.	O

*For	O
normal	O
controls	O
and	O
SMC	O
participants,	O
age	B-Observation
must	O
be	O
between	O
65	O
-	O
90	O
.	O

-	O
Study	O
partner	O
is	O
available	O
who	O
has	O
frequent	O
contact	O
with	O
the	O
participant	O
(	O
eg	O
an	O
average	O
of	O
10	O
hours	O
per	O
week	O
or	O
more	O
)	O
and	O
can	O
accompany	O
the	O
participant	O
to	O
all	O
clinic	O
visits	O
for	O
the	O
duration	O
of	O
the	O
protocol	O
.	O

-	O
Visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
adequate	O
for	O
neuropsychological	O
testing	O
.	O

-	O
Good	O
general	B-Condition
health	I-Condition
with	O
no	O
diseases	O
expected	O
to	O
interfere	O
with	O
the	O
study	O
.	O

-	O
Participant	O
is	O
not	B-Negation_cue
pregnant	B-Condition
,	O
lactating	B-Condition
or	O
of	B-Condition
childbearing	I-Condition
potential	I-Condition
(	O
i.e	O
.	O

women	O
must	O
be	O
two	O
years	O
post-menopausal	B-Condition
or	O
surgically	B-Condition
sterile	I-Condition
)	O
.	O

-	O
Willing	O
and	O
able	O
to	O
participate	O
in	O
a	O
longitudinal	O
imaging	O
study	O
.	O

-	O
Hachinski	B-Observation
less	O
than	O
or	O
equal	O
to	O
4	O
.	O

-	O
Completed	O
six	O
grades	O
of	O
education	O
or	O
has	O
a	O
good	O
work	O
history	O
(	O
sufficient	O
to	O
exclude	O
mental	O
retardation	O
)	O
.	O

-	O
Must	O
speak	O
English	O
or	O
Spanish	O
fluently	O
.	O

-	O
Willing	O
to	O
undergo	O
repeated	O
MRIs	O
(	O
3Tesla	O
)	O
and	O
at	O
least	O
two	O
PET	O
scans	O
(	O
one	O
FDG	O
and	O
one	O
Amyloid	O
imaging	O
)	O
and	O
no	B-Negation_cue
medical	O
contraindications	B-Condition
to	O
MRI	B-Procedure_Device
.	O

-	O
Agrees	O
to	O
collection	O
of	O
blood	O
for	O
Genome	O
Wide	O
Association	O
Studies	O
(	O
GWAS	O
),	O
APOE	O
testing	O
and	O
DNA	O
and	O
RNA	O
banking	O
.	O

-	O
Agrees	O
to	O
collection	O
of	O
blood	O
for	O
biomarker	O
testing	O
.	O

-	O
Agrees	O
to	O
at	O
least	O
one	O
lumbar	O
puncture	O
for	O
the	O
collection	O
of	O
CSF	O
.	O

Specific	O
Inclusion	O
Criteria	O
for	O
normal	O
controls	O
:	O
.	O

-	O
Participant	O
must	O
be	O
free	B-Negation_cue
of	O
memory	B-Condition
complaints	I-Condition
verified	O
by	O
a	O
study	O
partner	O
.	O

-	O
Normal	O
memory	B-Observation
function	I-Observation
score	I-Observation
on	O
Wechsler	B-Observation
Memory	I-Observation
Scale	I-Observation
(	O
adjusted	O
for	O
education	O
)	O
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
between	O
24	O
and	O
30	O
(	O
inclusive	O
)	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
=	O
0;	O
Memory	B-Observation
Box	I-Observation
score	I-Observation
must	O
be	O
0	O
.	O

-	O
Cognitively	B-Observation
normal,	O
based	O
on	O
an	O
absence	B-Negation_cue
of	O
significant	O
impairment	B-Condition
in	O
cognitive	B-Observation
functions	I-Observation
or	O
activities	O
of	O
daily	O
living	O
.	O

-	O
Stability	O
of	O
Permitted	B-Drug
Medications	I-Drug
for	O
4	O
weeks	O
.	O

In	O
particular,	O
participants	O
may	O
take	O
:	O
.	O

-	O
Antidepressants	B-Drug
lacking	B-Negation_cue
significant	O
anticholinergic	B-Condition
side	I-Condition
effects	I-Condition
.	O

-	O
Estrogen	B-Drug
replacement	I-Drug
therapy	I-Drug
is	O
permissible	O
.	O

-	O
Gingko	B-Drug
biloba	I-Drug
is	O
permissible	O
but	O
discouraged	O
.	O

-	O
Washout	O
from	O
psychoactive	B-Drug
medication	I-Drug
(	O
eg	O
,	O
excluded	B-Negation_cue
antidepressants	B-Drug
,	O
neuroleptics	B-Drug
,	O
chronic	B-Drug
anxiolytics	I-Drug
or	O
sedative	B-Drug
hypnotics	I-Drug
etc.)	O

for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

Specific	O
Inclusion	O
Criteria	O
for	O
SMC	O
participants	O
:	O
.	O

-	O
Subjects	O
that	O
are	O
"self-referrals"	O
that	O
have	O
a	O
significant	O
subjective	B-Condition
memory	I-Condition
concern	I-Condition
.	O

-	O
Significant	O
memory	B-Condition
concern	I-Condition
confirmed	O
by	O
a	O
Cognitive	B-Observation
Change	I-Observation
Index	I-Observation
score	I-Observation
of	O
more	O
than	O
or	O
equal	O
to	O
16	O
.	O

-	O
Normal	O
memory	B-Observation
function	I-Observation
score	I-Observation
on	O
Wechsler	B-Observation
Memory	I-Observation
Scale	I-Observation
(	O
adjusted	O
for	O
education	O
)	O
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
between	O
24	O
and	O
30	O
(	O
inclusive	O
)	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
=	O
0;	O
Memory	B-Observation
Box	I-Observation
score	I-Observation
must	O
be	O
0	O
.	O

-	O
Cognitively	B-Observation
normal,	O
based	O
on	O
the	O
absence	B-Negation_cue
of	O
significant	O
memory	B-Condition
impairment	I-Condition
in	O
cognitive	O
function	O
or	O
activities	O
of	O
daily	O
living	O
.	O

-	O
Stability	O
of	O
Permitted	B-Drug
Medications	I-Drug
for	O
4	O
weeks	O
.	O

In	O
particular,	O
subjects	O
may	O
take	O
:	O
.	O

-	O
Antidepressants	B-Drug
lacking	B-Negation_cue
significant	O
anticholinergic	B-Condition
side	I-Condition
effects	I-Condition
.	O

-	O
Estrogen	B-Drug
replacement	I-Drug
therapy	I-Drug
is	O
permissible	O
.	O

-	O
Gingko	B-Drug
biloba	I-Drug
is	O
permissible	O
but	O
discouraged	O
.	O

-	O
Washout	B-Procedure_Device
from	O
psychoactive	B-Drug
medication	I-Drug
(	O
eg	O
,	O
excluded	B-Negation_cue
antidepressants	B-Drug
,	O
neuroleptics	B-Drug
,	O
chronic	B-Drug
anxiolytics	I-Drug
or	O
sedative	B-Drug
hypnotics	I-Drug
etc.)	O

for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

Specific	O
Inclusion	O
Criteria	O
for	O
EMCI	O
and	O
LMCI	O
participants	O
:	O
.	O

-	O
Participant	O
must	O
have	O
a	O
subjective	B-Condition
memory	I-Condition
concern	I-Condition
as	O
reported	O
by	O
participant,	O
study	O
partner	O
or	O
clinician	O
.	O

-	O
Abnormal	O
memory	B-Observation
function	I-Observation
score	I-Observation
on	O
Wechsler	B-Observation
Memory	I-Observation
Scale	I-Observation
(	O
adjusted	O
for	O
education	O
)	O
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
between	O
24	O
and	O
30	O
(	O
inclusive	O
)	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
=	O
0.5;	O
Memory	B-Observation
Box	I-Observation
score	I-Observation
must	O
be	O
at	O
least	O
0.5	O
.	O

-	O
General	O
cognition	O
and	O
functional	O
performance	O
sufficiently	O
preserved	O
such	O
that	O
a	O
diagnosis	O
of	O
AD	B-Condition
cannot	B-Negation_cue
be	O
made	O
by	O
the	O
site	O
physician	O
at	O
the	O
time	O
of	O
the	O
screening	O
visit	O
.	O

-	O
Stability	O
of	O
Permitted	B-Drug
Medications	I-Drug
for	O
4	O
weeks	O
.	O

In	O
particular,	O
participants	O
may	O
take	O
:	O
.	O

-	O
Antidepressants	B-Drug
lacking	B-Negation_cue
significant	O
anticholinergic	B-Condition
side	I-Condition
effects	I-Condition
.	O

-	O
Estrogen	B-Drug
replacement	I-Drug
therapy	I-Drug
.	O

-	O
Gingko	B-Drug
biloba	I-Drug
is	O
permissible	O
but	O
discouraged	O
.	O

-	O
Washout	O
from	O
psychoactive	B-Drug
medication	I-Drug
(	O
eg	O
,	O
excluded	B-Negation_cue
antidepressants	B-Drug
,	O
neuroleptics	B-Drug
,	O
chronic	B-Drug
anxiolytics	I-Drug
or	O
sedative	B-Drug
hypnotics	I-Drug
etc.)	O

for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Cholinesterase	B-Drug
inhibitors	I-Drug
and	O
memantine	B-Drug
are	O
allowable	O
if	O
stable	O
for	O
12	O
weeks	O
prior	O
to	O
screening	O
.	O

Specific	O
Inclusion	O
Criteria	O
for	O
AD	O
participants	O
:	O
.	O

-	O
Participant	O
must	O
have	O
a	O
subjective	B-Condition
memory	I-Condition
concern	I-Condition
as	O
reported	O
by	O
participant,	O
study	O
partner	O
or	O
clinician	O
.	O

-	O
Abnormal	O
memory	B-Observation
function	I-Observation
score	I-Observation
on	O
Wechsler	B-Observation
Memory	I-Observation
Scale	I-Observation
(	O
adjusted	O
for	O
education	O
)	O
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
between	O
20	O
and	O
26	O
(	O
inclusive	O
)	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
=	O
0.5	O
or	O
1.0	O
.	O

-	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Diseases	I-Observation
and	I-Observation
Stroke	I-Observation
/	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINCDS	I-Observation
for	O
probable	O
AD	B-Condition
.	O

-	O
Stability	O
of	O
Permitted	B-Drug
Medications	I-Drug
for	O
4	O
weeks	O
.	O

In	O
particular,	O
participants	O
may	O
take	O
:	O
.	O

-	O
Antidepressants	B-Drug
lacking	B-Negation_cue
significant	O
anticholinergic	B-Condition
side	I-Condition
effects	I-Condition
.	O

-	O
Estrogen	B-Drug
replacement	I-Drug
therapy	I-Drug
.	O

-	O
Gingko	B-Drug
biloba	I-Drug
is	O
permissible	O
but	O
discouraged	O
.	O

-	O
Washout	B-Procedure_Device
from	O
psychoactive	B-Drug
medication	I-Drug
(	O
eg	O
,	O
excluded	B-Negation_cue
antidepressants	B-Drug
,	O
neuroleptics	B-Drug
,	O
chronic	B-Drug
anxiolytics	I-Drug
or	O
sedative	B-Drug
hypnotics	I-Drug
etc.)	O

for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Cholinesterase	B-Drug
inhibitors	I-Drug
and	O
memantine	B-Drug
are	O
allowable	O
if	O
stable	O
for	O
12	O
weeks	O
prior	O
to	O
screening	O
.	O

Specific	O
Inclusion	O
Criteria	O
for	O
follow-up	O
participants	O
from	O
ADNI1	O
and	O
ADNI	O
GO	O
:	O
.	O

-	O
Must	O
have	O
been	O
enrolled	O
and	O
followed	O
in	O
ADNI1	B-Procedure_Device
for	O
at	O
least	O
one	O
year	O
or	O
enrolled	O
in	O
ADNI-GO	B-Procedure_Device
with	O
original	O
diagnosis	O
of	O
Cognitively	B-Condition
Normal	I-Condition
(	I-Condition
CN	I-Condition
)	I-Condition
Mild	B-Condition
Cognitive	I-Condition
Impairment	I-Condition
(	I-Condition
MCI	I-Condition
)	I-Condition
or	O
Early	B-Condition
Mild	I-Condition
Cognitive	I-Condition
Impairment	I-Condition
(	I-Condition
EMCI	I-Condition
)	I-Condition
regardless	O
of	O
whether	O
a	O
diagnostic	O
conversion	O
has	O
occurred	O
since	O
initial	O
enrollment	O
in	O
ADNI	O
.	O

-	O
Willing	O
and	O
able	O
to	O
continue	O
to	O
participate	O
in	O
an	O
ongoing	O
longitudinal	O
study	O
.	O

A	O
reduced	O
battery	O
of	O
tests	O
is	O
allowable	O
if	O
the	O
participant	O
is	O
not	O
able	O
/	O
willing	O
to	O
complete	O
the	O
full	O
battery	O
.	O

-	O
Study	O
partner	O
is	O
available	O
who	O
has	O
frequent	O
contact	O
with	O
the	O
participant	O
(	O
eg	O
an	O
average	O
of	O
10	O
hours	O
per	O
week	O
or	O
more	O
)	O
and	O
can	O
accompany	O
the	O
participant	O
to	O
all	O
clinic	O
visits	O
for	O
the	O
duration	O
of	O
the	O
protocol	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

General	O
(	O
applies	O
to	O
each	O
category	O
):	O
.	O

-	O
Screening	O
/	O
baseline	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
with	O
evidence	O
of	O
infection	B-Condition
,	O
infarction	B-Condition
or	O
other	O
focal	B-Condition
lesions	I-Condition
Participants	O
with	O
multiple	B-Condition
lacunes	I-Condition
or	O
lacunes	B-Condition
in	O
a	O
critical	O
memory	O
structure	O
are	O
excluded	B-Negation_cue
.	O

-	O
Presence	O
of	O
pacemakers	B-Procedure_Device
,	O
aneurysm	B-Procedure_Device
clips	I-Procedure_Device
artificial	B-Procedure_Device
heart	I-Procedure_Device
valves	I-Procedure_Device
ear	B-Procedure_Device
implants	I-Procedure_Device
metal	B-Procedure_Device
fragments	I-Procedure_Device
or	O
foreign	B-Procedure_Device
objects	I-Procedure_Device
in	O
the	O
eyes,	O
skin	O
or	O
body	O
.	O

-	O
Major	B-Condition
depression	I-Condition
bipolar	B-Condition
disorder	I-Condition
as	O
described	O
in	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Disorders,	I-Observation
Fourth	I-Observation
Edition	I-Observation
(	I-Observation
DSM-IV	I-Observation
)	I-Observation
within	O
the	O
past	O
1	O
year	O
.	O

-	O
Currently	O
treated	O
with	O
medication	B-Drug
for	O
obsessive-compulsive	B-Condition
disorder	I-Condition
or	O
attention	B-Condition
deficit	I-Condition
disorder	I-Condition
.	O

-	O
History	O
of	O
schizophrenia	B-Condition
.	O

-	O
History	O
of	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
within	O
the	O
past	O
2	O
years	O
.	O

-	O
Any	O
significant	O
systemic	B-Condition
illness	I-Condition
or	O
unstable	O
medical	B-Condition
condition	I-Condition
which	O
could	O
lead	O
to	O
difficulty	O
complying	O
with	O
the	O
protocol	O
.	O

-	O
Clinically	O
significant	O
abnormalities	B-Condition
in	I-Condition
B12	I-Condition
or	I-Condition
TFTs	I-Condition
that	O
might	O
interfere	O
with	O
the	O
study	O
.	O

-	O
Residence	O
in	O
skilled	O
nursing	O
facility	O
.	O

-	O
Current	O
use	O
of	O
specific	O
psychoactive	B-Drug
medications	I-Drug
(	O
eg	O
,certain	O
antidepressants	B-Drug
,	O
neuroleptics	B-Drug
,	O
chronic	B-Drug
anxiolytics	I-Drug
or	O
sedative	B-Drug
hypnotics	I-Drug
etc	O
.	O

);	O
Current	O
use	O
of	O
warfarin	B-Drug
or	O
dabigatran	B-Drug
(	O
exclusionary	O
for	O
lumbar	B-Procedure_Device
puncture	I-Procedure_Device
)	O
.	O

-	O
Use	O
of	O
investigational	B-Drug
agents	I-Drug
one	O
month	O
prior	O
to	O
entry	O
and	O
for	O
the	O
duration	O
of	O
the	O
trial	O
.	O

-	O
Participation	O
in	O
clinical	O
studies	O
involving	O
neuropsychological	B-Observation
measures	I-Observation
being	O
collected	O
more	O
than	O
one	O
time	O
per	O
year	O
.	O

-	O
Exclusion	B-Negation_cue
for	O
FDG	B-Procedure_Device
PET	I-Procedure_Device
scan	I-Procedure_Device
and	O
amyloid	B-Procedure_Device
imaging	I-Procedure_Device
with	I-Procedure_Device
Florbetapir	I-Procedure_Device
F	I-Procedure_Device
18	I-Procedure_Device
:	O
Current	O
or	O
recent	O
participation	O
in	O
any	O
procedures	O
involving	O
radioactive	B-Drug
agents	I-Drug
such	O
that	O
the	O
total	B-Observation
radiation	I-Observation
dose	I-Observation
exposure	I-Observation
to	O
the	O
participant	O
in	O
any	O
given	O
year	O
would	O
exceed	O
the	O
limits	O
of	O
annual	O
and	O
total	O
dose	O
commitment	O
set	O
forth	O
in	O
the	O
US	O
Code	O
of	O
Federal	O
Regulations	O
(	O
CFR	O
)	O
Title	O
21	O
Section	O
361.1	O
.	O

-	O
Exceptions	O
to	O
these	O
guidelines	O
may	O
be	O
considered	O
on	O
a	O
case-by-case	O
basis	O
at	O
the	O
discretion	O
of	O
the	O
protocol	O
director	O
.	O

Specific	O
Exclusion	O
Criteria	O
for	O
normal	O
controls	O
and	O
SMC	O
participants	O
:	O
.	O

-	O
Any	O
significant	O
neurologic	B-Condition
disease	I-Condition
such	O
as	O
Parkinson's	B-Condition
disease	I-Condition
multi-infarct	B-Condition
dementia	I-Condition
Huntington's	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
brain	B-Condition
tumor	I-Condition
progressive	B-Condition
supranuclear	I-Condition
palsy	I-Condition
seizure	B-Condition
disorder	I-Condition
subdural	B-Condition
hematoma	I-Condition
multiple	B-Condition
sclerosis	I-Condition
or	O
history	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
followed	O
by	O
persistent	O
neurologic	B-Condition
defaults	I-Condition
or	O
known	O
structural	B-Condition
brain	I-Condition
abnormalities	I-Condition
.	O

Specific	O
Exclusion	O
Criteria	O
for	O
EMCI	O
and	O
LMCI	O
participants	O
:	O
.	O

-	O
Any	O
significant	O
neurologic	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
suspected	O
incipient	O
Alzheimer's	B-Condition
disease	I-Condition
such	O
as	O
Parkinson's	B-Condition
disease	I-Condition
multi-infarct	B-Condition
dementia	I-Condition
Huntington's	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
brain	B-Condition
tumor	I-Condition
progressive	B-Condition
supranuclear	I-Condition
palsy	I-Condition
seizure	B-Condition
disorder	I-Condition
subdural	B-Condition
hematoma	I-Condition
multiple	B-Condition
sclerosis	I-Condition
or	O
history	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
followed	O
by	O
persistent	O
neurologic	B-Condition
defaults	I-Condition
or	O
known	O
structural	B-Condition
brain	I-Condition
abnormalities	I-Condition
.	O

Specific	O
Exclusion	O
Criteria	O
for	O
AD	O
participants	O
:	O
.	O

-	O
Any	O
significant	O
neurologic	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
such	O
as	O
Parkinson's	B-Condition
disease	I-Condition
multi-infarct	B-Condition
dementia	I-Condition
Huntington's	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
brain	B-Condition
tumor	I-Condition
progressive	B-Condition
supranuclear	I-Condition
palsy	I-Condition
seizure	B-Condition
disorder	I-Condition
subdural	B-Condition
hematoma	I-Condition
multiple	B-Condition
sclerosis	I-Condition
or	O
history	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
followed	O
by	O
persistent	O
neurologic	B-Condition
defaults	I-Condition
or	O
known	O
structural	O
brain	O
abnormalities	O
.	O

Specific	O
Exclusion	O
Criteria	O
for	O
follow-up	O
participants	O
from	O
ADNI1	O
and	O
ADNI	O
GO	O
:	O
.	O

-	O
Participants	O
will	O
not	B-Procedure_Device
be	O
able	O
to	O
participate	O
in	O
FDG	B-Procedure_Device
PET	I-Procedure_Device
scan	I-Procedure_Device
and	O
amyloid	B-Procedure_Device
imaging	I-Procedure_Device
with	I-Procedure_Device
Florbetapir	I-Procedure_Device
F	I-Procedure_Device
18	I-Procedure_Device
if	O
the	O
following	O
is	O
true	O
:	O
Current	O
or	O
recent	O
participation	O
in	O
any	O
procedures	O
involving	O
radioactive	B-Drug
agents	I-Drug
such	O
that	O
the	O
total	B-Observation
radiation	I-Observation
dose	I-Observation
exposure	I-Observation
to	O
the	O
participant	O
in	O
any	O
given	O
year	O
would	O
exceed	O
the	O
limits	O
of	O
annual	O
and	O
total	O
dose	O
commitment	O
set	O
forth	O
in	O
the	O
US	O
Code	O
of	O
Federal	O
Regulations	O
(	O
CFR	O
)	O
Title	O
21	O
Section	O
361.1	O
.	O

>>NCT02021682	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Member	O
of	O
the	O
Memory	O
and	O
Aging	O
Project	O
at	O
Washington	O
University	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
and	O
PET	O
/	O
	B-Observation
PIB	I-Observation
scores	I-Observation

.	O
-	O
Age	B-Observation
60	O
or	O
greater	O

.	O
Exclusion	O
Criteria	O
:	O

.	O
-	O
Clotting	B-Condition
disorder	I-Condition

.	O
-	O
Active	O
anticoagulation	B-Drug
therapy	I-Drug

.	O
-	O
Active	O
infection	B-Condition

.	O
-	O
Meningitis	B-Condition

.	O
-	O
Recent	O
syncope	B-Condition

.	O
-	O
Currently	O
on	O
experimental	B-Drug
treatment	I-Drug
targeting	O
A	O
or	O
medications	O
thought	O
to	O
influence	O
A	O
production	O
or	O
clearance	O
rates	O
(	O
benzodiazepines	B-Drug
,	O
muscarinic	B-Drug
agents	I-Drug
or	O
anti-epileptics	B-Drug
)	O

.	O
>>NCT01825330	O
Inclusion	O
Criteria	O
:	O

.	O
1	O

.	O
Male	O
or	O
female	O
age	B-Observation
60	O
-	O
90	O
years	O

.	O
2	O

.	O
Patients	O
diagnosed	O
with	O
mild	O
or	O
moderate	O
stage	O
of	O
Alzheimer's	B-Condition
Disease	I-Condition
according	O
to	O
the	O
DSM-IV	B-Observation
criteria	I-Observation

.	O
3	O

.	O
MMSE	B-Observation
score	I-Observation
18	O
to	O
26	O

.	O
4	O

.	O
ADAS-Cog	B-Observation
above	O
17	O

.	O
5	O

.	O
Physical	O
clearance	O
for	O
study	O
participation	O
as	O
evaluated	O
by	O
the	O
clinician	O

.	O
6	O

.	O
Spouse,	O
family	O
member	O
or	O
professional	O
caregiver	O
agree	O
and	O
capable	O
of	O
taking	O
care	O
and	O
be	O
responsible	O
for	O
the	O
participation	O
of	O
the	O
patient	O
in	O
the	O
study	O
(	O
answering	O
questions	O
regarding	O
the	O
patient's	O
condition	O
and	O
assuming	O
responsibility	O
for	O
medication	O
)	O

.	O
7	O

.	O
Agreement	O
to	O
participate	O
in	O
approximately	O
14	O
weeks	O
during	O
the	O
study	O

.	O
8	O

.	O
Normal	O
to	O
near-normal	O
vision	B-Observation
and	I-Observation
hearing	I-Observation
with	O
correction	O
as	O
needed	O
(	O
eg	O
corrective	O
lenses,	O
hearing	O
aid	O
)	O

.	O
9	O

.	O
Fluent	O
in	O
English	O
or	O
Hebrew	O

.	O
10	O

.	O
Minimum	O
of	O
8th	O
grade	O
education	O

.	O
11	O

.	O
If	O
medicated	O
for	O
AD	B-Condition
,	O
then	O
use	O
of	O
cholinesterase	B-Drug
inhibitors	I-Drug
memantine	B-Drug
or	O
Ginko-biloba	B-Drug
for	O
at	O
least	O
3	O
months	O
and	O
on	O
stable	O
dose	B-Procedure_Device
for	O
at	O
least	O
60	O
days	O
prior	O
to	O
screening	O

.	O
Exclusion	O
Criteria	O
:	O

.	O
1	O

.	O
CDR	B-Observation
0,	O
0.5	O
or	O
3	O

.	O
2	O

.	O
Severe	O
agitation	B-Condition

.	O
3	O

.	O
Mental	B-Condition
retardation	I-Condition

.	O
4	O

.	O
Patient	O
lacking	O
capacity	O
to	O
consent	O
to	O
study	O
participation	O

.	O
5	O

.	O
Unstable	O
medical	B-Condition
condition	I-Condition

.	O
6	O

.	O
Use	O
of	O
benzodiazepines	B-Drug
or	O
barbiturates	B-Drug
2	O
weeks	O
prior	O
to	O
screening	O

.	O
7	O

.	O
Pharmacological	B-Condition
immunosuppression	I-Condition

.	O
8	O

.	O
Participation	O
in	O
a	O
clinical	O
trial	O
with	O
any	O
investigational	B-Drug
agent	I-Drug
within	O
6	O
months	O
prior	O
to	O
study	O
enrollment	O

.	O
9	O

.	O
History	O
of	O
Epileptic	B-Condition
Seizures	I-Condition
or	O
Epilepsy	B-Condition

.	O
10	O

.	O
Contraindication	B-Condition
for	O
performing	O
MRI	B-Procedure_Device
scanning	I-Procedure_Device

.	O
11	O

.	O
Contraindication	B-Condition
for	O
receiving	O
TMS	B-Procedure_Device
treatment	I-Procedure_Device
according	O
to	O
a	O
TMS	O
questionnaire	O

.	O
12	O

.	O
Pregnant	O
women	O
and	O
women	O
who	O
have	O
the	O
ability	O
to	O
become	O
pregnant	O
unless	O
they	O
are	O
on	O
an	O
acceptable	O
method	O
of	O
contraception	O
during	O
the	O
study	O

.	O
13	O

.	O
Patients	O
with	O
depression	B-Condition
,	O
bipolar	B-Condition
disorder	I-Condition
or	O
psychotic	B-Condition
disorders	I-Condition
or	O
any	O
other	O
neurological	B-Condition
or	I-Condition
psychiatric	I-Condition
condition	I-Condition
(	O
whether	O
now	O
or	O
in	O
the	O
past	O
),	O
which	O
the	O
Investigator	O
finds	O
as	O
interfering	O
with	O
the	O
study	O

.	O
14	O

.	O
Alcoholism	B-Condition
or	I-Condition
drug	I-Condition
addiction	I-Condition
as	O
defined	O
by	O
DSM-IV	B-Observation
within	O
last	O
5	O
years	O
(	O
addicted	O
more	O
than	O
one	O
year	O
and	O
or	O
in	O
remission	O
less	O
than	O
3	O
years	O
)	O
or	O
severe	O
sleep	B-Condition
deprivation	I-Condition

.	O
15	O

.	O
Patients	O
with	O
metal	B-Procedure_Device
implants	I-Procedure_Device
in	O
the	O
head,	O
(	O
i.e	O

.	O
cochlear	B-Procedure_Device
implants	I-Procedure_Device
implanted	B-Procedure_Device
brain	I-Procedure_Device
stimulators	I-Procedure_Device
aneurysm	B-Procedure_Device
clips	I-Procedure_Device
)	O
with	O
the	O
exception	B-Negation_cue
of	O
metal	B-Procedure_Device
implants	I-Procedure_Device
in	O
mouth	O

.	O
16	O

.	O
Patients	O
with	O
personal	O
history	O
of	O
either	O
any	O
clinically	O
defined	O
medical	B-Condition
disorder	I-Condition
(	O
which	O
the	O
investigator	O
finds	O
as	O
interfering	O
with	O
the	O
study	O
)	O
or	O
any	O
clinically	O
defined	O
neurological	B-Condition
/	I-Condition
psychiatric	I-Condition
disorder	I-Condition
(	O
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
),	O
including	O
(	O
but	O
not	O
limited	O
to	O
):	O
epilepsy	B-Condition
,	O
stroke	B-Condition
,	O
brain	B-Condition
lesions	I-Condition
substance	B-Condition
abuse	I-Condition
vitamin	B-Condition
B12	I-Condition
deficiency	I-Condition
abnormal	B-Condition
thyroid	I-Condition
function	I-Condition
cerebrovascular	B-Condition
condition	I-Condition
other	O
neurodegenerative	B-Condition
disease	I-Condition
head	B-Condition
trauma	I-Condition
multiple	B-Condition
sclerosis	I-Condition
or	O
personal	O
history	O
of	O
previous	O
neurosurgery	B-Procedure_Device
or	O
head	B-Condition
trauma	I-Condition
that	O
resulted	O
in	O
loss	B-Condition
of	I-Condition
consciousness	I-Condition

.	O
17	O

.	O
Patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
increased	O
intracranial	B-Observation
pressure	I-Observation
as	O
determined	O
in	O
a	O
neurological	B-Observation
exam	I-Observation

.	O
18	O

.	O
Cardiac	B-Procedure_Device
pacemakers	I-Procedure_Device

.	O
19	O

.	O
Implanted	B-Procedure_Device
medication	I-Procedure_Device
pumps	I-Procedure_Device

.	O
20	O

.	O
Intracardiac	B-Condition
lines	I-Condition

.	O
21	O

.	O
Significant	O
heart	B-Condition
disease	I-Condition

.	O
22	O

.	O
Currently	O
taking	O
medication	B-Drug
that	I-Drug
lower	I-Drug
the	I-Drug
seizure	I-Drug
threshold	I-Drug

.	O
23	O

.	O
Patients	O
on	O
which	O
TMS	O
Motor	O
Threshold	O
cannot	O
be	O
found	O

.	O
24	O

.	O
Patient	O
underwent	O
TMS	B-Procedure_Device
treatment	I-Procedure_Device
in	O
the	O
past	O

.	O
>>NCT00951834	O
Inclusion	O
Criteria	O
:	O

.	O
-	O
early	O
stage	O
of	O
AD	B-Condition
(	O
Diagnosis	O
DSM-IV	B-Observation
and	I-Observation
NINCDS	I-Observation
/	I-Observation
ADRDA,	I-Observation
Dubois-criteria	I-Observation
2007	I-Observation
)	O

.	O
-	O
age	B-Observation
60	O
-	O
100	O

.	O
-	O
MMSE	B-Observation
20	O
-	O
26	O

.	O
-	O
patient	O
lives	O
at	O
home	O
with	O
at	O
least	O
one	O
relative	O
who	O
perform	O
external	O
ratings	O
/	O
assessment	O

.	O
-	O
co-medication	O
with	O
Donepezil	B-Drug
(	O
Aricept	B-Drug
,	O
Pfizer	B-Drug
Pharma	I-Drug
GmbH	I-Drug
)	O
with	O
at	O
least	O
3	O
months	O
to	O
maximum	O
6	O
months	O
of	O
existing	O
stable	O
medication	B-Drug

.	O
-	O
maximum	O
of	O
2	O
cups	O
of	O
black	O
tea	O
/	O
die,	O
no	O
green	O
tea,	O
not	O
more	O
than	O
>	O
500	O
ml	O
/	O
die	O
of	O
grapefruit	O
juice	O

.	O
Exclusion	O
Criteria	O
:	O

.	O
-	O
co-medication	O
with	O
NSAIDs	B-Drug
(	O
longterm	O
medication	O
)	O
(	O
ASS	O
is	O
not	O
an	O
exclusion	O
criteria	O
),	O
Gingko-	B-Drug
or	O
other	O
natural	B-Drug
extracts	I-Drug
other	O
anti-dementiva	B-Drug
except	B-Negation_cue
of	O
Donepezil	B-Drug

.	O
-	O
familial	B-Condition
autosomal-dominant	I-Condition
inherited	I-Condition
AD	I-Condition

.	O
-	O
instable	O
medical	B-Condition
condition	I-Condition

.	O
-	O
other	O
primary	O
psychiatric	B-Condition
/	I-Condition
neurologic	I-Condition
disorders	I-Condition

.	O
-	O
missing	O
informed	O
consent	O

.	O
-	O
no	O
readiness	O
to	O
save	O
and	O
refer	O
pseudonym	O
personal	O
data	O

.	O
-	O
hospitalisation	O
due	O
to	O
juridical	O
or	O
legal	O
regulation	O

.	O
-	O
any	O
condition	O
disturbing	O
or	O
making	O
MRI	B-Procedure_Device
and	O
other	O
measures	O
impossible	O

.	O
-	O
clinically	O
relevant	O
GI-disorders	B-Condition
at	O
screening	O
and	O
1	O
year	O
before	O

.	O
-	O
clinically	O
relevant	O
lung,	B-Condition
infectious,	I-Condition
heart	I-Condition
or	I-Condition
other	I-Condition
CNS	I-Condition
disorders	I-Condition
clinical	O
or	O
paraclinical	O
suspicion	O
of	O
TBC	B-Condition
,	O
history	O
of	O
vascular	B-Condition
CNS-disorders	I-Condition
at	O
screening	O
and	O
1	O
year	O
before	O

.	O
-	O
clinically	O
relevant	O
liver	B-Condition
disorders	I-Condition
at	O
screening	O
and	O
1	O
year	O
before	O

.	O
-	O
clinically	O
relevant	O
functional	B-Condition
disorders	I-Condition
of	O
liver,	O
kidney	O
or	O
bone	O
marrow	O
defined	O
by	O
following	O
lab	O
values	O
at	O
screening	O
:	O

.	O
-	O
Marrow	B-Condition
dysfunction	I-Condition
:	O

.	O
-	O
HB	B-Observation
<	O
8.5	O
g	O
/	O
dl	O

.	O
-	O
WBC	B-Observation
<	O
2.5	O
/	O
nl	O

.	O
-	O
Thrombocytes	B-Observation
<	O
125	O
/	O
nl	O

.	O
-	O
Kidney	B-Condition
dysfunction	I-Condition
:	O

.	O
-	O
Creatinin-Clearance	B-Condition
according	O
to	O
Cockcroft-Gault-Formula	B-Observation
:	O
Cl	B-Observation
<	O
110ml	O
/	O
min	O
(	O
male	B-Observation
)	O
resp	O

.	O
Cl	B-Observation
<	O
95ml	O
/	O
min	O
(	O
female	B-Observation
),	O
from	O
the	O
age	O
of	O
30	O
decline	O
of	O
10ml	O
/	O
min	O
per	O
decade	O

.	O
-	O
Liver	B-Condition
dysfunction	I-Condition
:	O

.	O
-	O
ASAT	B-Observation
/	I-Observation
ALAT	I-Observation
>	O
3.5	O
x	O
higher	O
than	O
the	O
upper	O
reference	O
value	O

.	O
-	O
Bilirubin	B-Observation
>	O
2.0	O
mg	O
/	O
dl	O

.	O
-	O
known	O
allergy	B-Condition
of	O
elements	B-Drug
of	I-Drug
Sunphenon	I-Drug
EGCg	I-Drug
or	O
additives	B-Drug
of	I-Drug
Sunphenon	I-Drug
EGCg	I-Drug
resp	O

.	O
placebo	O

.	O
-	O
long-term	O
hepatotoxic	B-Drug
medication	I-Drug

.	O
-	O
current	O
intake	O
of	O
cytochrom	B-Drug
P450	I-Drug
3A4	I-Drug
-inhibitors	I-Drug
or	I-Drug
-inductors	I-Drug
such	O
as	O
antimycotics	B-Drug
of	I-Drug
the	I-Drug
azol-type	I-Drug
or	O
macrolide-antibiotics	B-Drug

.	O
-	O
clinical-anamnestic	B-Observation
or	O
paraclinical	B-Observation
manifestations	I-Observation
suggesting	O
an	O
alcohol	B-Condition
or	I-Condition
drug	I-Condition
abuse	I-Condition

.	O
-	O
participation	O
in	O
any	O
clinical	O
trial	O
<	O
3	O
months	O
prior	O
to	O
screening	O
or	O
ongoing	O

.	O
-	O
any	O
medical,	B-Condition
psychiatric	I-Condition
or	I-Condition
other	I-Condition
condition	I-Condition
which	O
might	O
constrain	O
the	O
ability	O
of	O
the	O
patient	O
to	O
understand	O
the	O
informed	O
consent,	O
to	O
give	O
consent,	O
to	O
adhere	O
to	O
the	O
protocol	O
or	O
to	O
accomplish	O
the	O
study	O

.	O
-	O
massive	O
and	O
extended	O
sun	O

>>NCT00105547	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Have	O
had	O
a	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Men	O
or	O
women	O
ages	B-Observation
55	O
years	O
or	O
greater	O
and	O
living	O
in	O
the	O
community	O
at	O
the	O
time	O
of	O
enrollment	O
(	O
i.e.,	O
not	O
living	O
in	O
a	O
rest	O
home	O
or	O
nursing	O
care	O
facility	O
)	O
.	O

-	O
Signed	O
the	O
subject	O
Informed	O
Consent	O
Form	O
and	O
is	O
willing	O
and	O
able	O
to	O
participate	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

-	O
Ability	O
to	O
read	O
and	O
understand	O
English	O
or	O
Spanish	O
to	O
ensure	O
compliance	O
with	O
cognitive	O
testing	O
and	O
study	O
visit	O
procedures	O
.	O

-	O
Female	O
subjects	O
must	O
be	O
surgically	B-Condition
sterile	I-Condition
or	O
postmenopausal	B-Condition
for	O
>	O
1	O
year	O
.	O

-	O
Subjects	O
currently	O
taking	O
approved	B-Drug
medication	I-Drug
for	O
Alzheimer's	B-Condition
disease	I-Condition
for	O
at	O
least	O
six	O
months	O
prior	O
to	O
day	O
1	O
may	O
be	O
enrolled	O
.	O

-	O
Subjects	O
must	O
have	O
a	O
reliable	O
caregiver	O
who	O
can	O
read,	O
understand	O
and	O
speak	O
English	O
or	O
Spanish	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Current	O
evidence	O
of	O
other	O
causes	B-Condition
of	I-Condition
dementia	I-Condition
.	O

-	O
History	O
or	O
evidence	O
of,	O
active	O
malignancy	B-Condition
,	O
except	B-Negation_cue
for	O
basal	B-Condition
cell	I-Condition
carcinoma	I-Condition
or	O
squamous	B-Condition
cell	I-Condition
carcinoma	I-Condition
of	I-Condition
the	I-Condition
skin	I-Condition
within	O
the	O
24	O
months	O
prior	O
to	O
entry	O
.	O

Men	O
with	O
prostate	B-Condition
cancer	I-Condition
may	O
be	O
enrolled	O
at	O
the	O
discretion	O
of	O
the	O
sponsor	O
.	O

-	O
Chronic	O
or	O
acute	O
renal,	B-Condition
hepatic	I-Condition
or	I-Condition
metabolic	I-Condition
disorder	I-Condition
.	O

-	O
Use	O
of	O
any	O
investigational	B-Drug
therapy	I-Drug
within	O
30	O
days	O
or	O
5	O
half-lives,	O
whichever	O
is	O
longer,	O
and	O
/	O
or	O
use	O
of	O
AD	B-Drug
immunotherapy	I-Drug
prior	O
to	O
screening	O
.	O

-	O
Major	B-Procedure_Device
surgery	I-Procedure_Device
and	O
related	O
complications	B-Condition
not	O
resolved	O
within	O
12	O
weeks	O
prior	O
to	O
Day	O
1	O
.	O

>>NCT00401167	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Signed	O
informed	O
consent	O
obtained	O
from	O
a	O
legally	O
acceptable	O
representative	O
.	O

-	O
Male	O
or	O
female	O
>	O
65	O
years	O
of	O
age	B-Observation
,	O
residing	O
in	O
long-term	O
care	O
.	O

-	O
Diagnosis	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Disorders	I-Observation
(	I-Observation
DSM-IV-TR	I-Observation
)	I-Observation
diagnosis	O
of	O
Dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
type	I-Condition
(	O
code	O
290.1	O
)	O
.	O

-	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
total	I-Observation
score	I-Observation
<=	O
15	O
.	O

-	O
Neuropsychiatric	B-Observation
Inventory-Nursing	I-Observation
Home	I-Observation
Version	I-Observation
total	I-Observation
score	I-Observation
>	O
10	O
and	O
a	O
score	O
>	O
1	O
on	O
the	O
agitation	B-Observation
/	I-Observation
aggression	I-Observation
subscale	I-Observation
.	O

-	O
A	O
current	O
order	O
for	O
any	O
prescription	B-Drug
medication	I-Drug
for	O
behavioral	B-Condition
and	I-Condition
psychological	I-Condition
symptoms	I-Condition
of	O
dementia	B-Condition
(	O
eg	O
benzodiazepine	B-Drug
,	O
antipsychotic	B-Drug
,	O
trazodone	B-Drug
),	O
with	O
at	O
least	O
1	O
dose	O
used	O
in	O
the	O
prior	O
3	O
months	O
.	O

-	O
Patients	O
with	O
a	O
current	O
order	O
for	O
any	O
regularly	O
administered	O
psychotropic	B-Drug
(	O
example,	O
selective	B-Drug
serotonin	I-Drug
reuptake	I-Drug
inhibitors	I-Drug
serotonin-norepinephrine	B-Drug
reuptake	I-Drug
inhibitors	I-Drug
trazodone	B-Drug
,	O
atypical	B-Drug
antipsychotics	I-Drug
typical	B-Drug
antipsychotics	I-Drug
or	O
cholinesterase	B-Drug
inhibitors	I-Drug
)	O
must	O
have	O
been	O
on	O
a	O
stable	O
dose	B-Procedure_Device
for	O
3	O
months	O
prior	O
to	O
entry	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Current	O
evidence	O
of	O
any	O
uncontrolled	O
medical	B-Condition
illness	I-Condition
that	O
would	O
interfere	O
with	O
the	O
subject's	O
participation	O
in	O
the	O
study	O
.	O

-	O
Dementia	B-Condition
due	O
to	O
any	O
etiology	O
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
Disease	I-Condition
.	O

-	O
Subjects	O
experiencing	O
significant	O
difficulties	O
ingesting	O
oral	O
medications	O
.	O

>>NCT01689246	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Diagnosis	O
of	O
all	O
cause	O
dementia	B-Condition
and	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
total	I-Observation
score	I-Observation
of	O
1	O
(	O
mild	O
)	O
to	O
2	O
(	O
moderate	O
)	O
and	O
MMSE	B-Observation
score	I-Observation
of	O
14	O
-	O
26	O
(	O
inclusive	O
)	O
.	O

-	O
Age	B-Observation
<	O
90	O
years	O
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
ischemic	I-Observation
score	I-Observation
of	O
<=	O
4	O
.	O

-	O
Females,	O
if	O
of	O
child-bearing	O
potential,	O
must	O
practice	O
true	O
abstinence	O
or	O
be	O
competent	O
to	O
use	O
adequate	O
contraception	O
and	O
agree	O
to	O
maintain	O
this	O
throughout	O
the	O
study	O
.	O

-	O
Subject,	O
and	O
/	O
or,	O
in	O
the	O
case	O
of	O
reduced	O
decision-making	O
capacity,	O
legally	O
acceptable	O
representative	O
(	O
s	O
)	O
consistent	O
with	O
national	O
law	O
is	O
/	O
are	O
able	O
to	O
read,	O
understand	O
and	O
provide	O
written	O
informed	O
consent	O
.	O

-	O
Has	O
one	O
(	O
or	O
more	O
)	O
identified	O
adult	O
caregiver	O
who	O
is	O
willing	O
to	O
provide	O
written	O
informed	O
consent	O
for	O
his	O
/	O
her	O
own	O
participation;	O
is	O
able	O
to	O
read,	O
understand	O
and	O
speak	O
the	O
designated	O
language	O
at	O
the	O
study	O
site;	O
either	O
lives	O
with	O
the	O
subject	O
or	O
sees	O
the	O
subject	O
for	O
>=	O
2	O
hours	O
/	O
day	O
>=	O
3	O
days	O
/	O
week;	O
agrees	O
to	O
accompany	O
the	O
subject	O
to	O
each	O
study	O
visit;	O
and	O
is	O
able	O
to	O
verify	O
daily	O
compliance	O
with	O
study	O
drug	O
.	O

-	O
If	O
currently	O
taking	O
an	O
acetylcholinesterase	B-Drug
inhibitor	I-Drug
and	O
/	O
or	O
memantine	B-Drug
at	O
the	O
time	O
of	O
Screening,	O
the	O
subject	O
must	O
have	O
been	O
taking	O
such	O
medication	B-Drug
(	I-Drug
s	I-Drug
)	I-Drug
for	O
>=	O
3	O
months	O
.	O

The	O
dosage	B-Procedure_Device
regimen	O
must	O
have	O
remained	O
stable	O
for	O
>=	O
6	O
weeks	O
and	O
it	O
must	O
be	O
planned	O
to	O
remain	O
stable	O
throughout	O
participation	O
in	O
the	O
study	O
.	O

-	O
Able	O
to	O
comply	O
with	O
the	O
study	O
procedures	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Significant	O
central	B-Condition
nervous	I-Condition
system	I-Condition
(	I-Condition
CNS	I-Condition
)	I-Condition
disorder	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Significant	O
focal	B-Condition
or	I-Condition
vascular	I-Condition
intracranial	I-Condition
pathology	I-Condition
seen	O
on	O
brain	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
.	O

-	O
Clinical	O
evidence	O
or	O
history	O
of	O
stroke	B-Condition
,	O
transient	B-Condition
ischemic	I-Condition
attack	I-Condition
significant	O
head	B-Condition
injury	I-Condition
or	O
other	O
unexplained	O
or	O
recurrent	O
loss	B-Condition
of	I-Condition
consciousness	I-Condition
>=	O
15	O
minutes	O
.	O

-	O
Epilepsy	B-Condition
.	O

-	O
Major	O
depressive	B-Condition
disorder	I-Condition
schizophrenia	B-Condition
or	O
other	O
psychotic	B-Condition
disorders	I-Condition
bipolar	B-Condition
disorder	I-Condition
or	O
substance	B-Condition
(	I-Condition
including	I-Condition
alcohol	I-Condition
)	I-Condition
related	I-Condition
disorders	I-Condition
.	O

-	O
Metal	B-Procedure_Device
implants	I-Procedure_Device
in	O
the	O
head	O
(	O
except	O
dental	O
),	O
pacemaker	B-Procedure_Device
,	O
cochlear	B-Procedure_Device
implants	I-Procedure_Device
or	O
any	O
other	O
non-removable	O
items	O
that	O
are	O
contraindications	B-Condition
to	O
MRI	B-Procedure_Device
.	O

-	O
Resides	O
in	O
hospital	O
or	O
moderate	O
to	O
high	O
dependency	O
continuous	O
care	O
facility	O
.	O

-	O
History	O
of	O
swallowing	B-Condition
difficulties	I-Condition
.	O

-	O
Pregnant	B-Condition
or	O
breastfeeding	B-Condition
.	O

-	O
Glucose-6-phosphate	B-Condition
dehydrogenase	I-Condition
deficiency	I-Condition
.	O

-	O
History	O
of	O
significant	O
hematological	B-Condition
abnormality	I-Condition
or	O
current	O
acute	O
or	O
chronic	O
clinically	O
significant	O
abnormality	B-Condition
.	O

-	O
Abnormal	O
serum	B-Observation
chemistry	I-Observation
laboratory	I-Observation
value	I-Observation
at	O
Screening	O
deemed	O
to	O
be	O
clinically	O
relevant	O
by	O
the	O
investigator	O
.	O

-	O
Clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
or	O
abnormal	O
assessments	B-Observation
.	O

-	O
Preexisting	O
or	O
current	O
signs	O
or	O
symptoms	O
of	O
respiratory	B-Condition
failure	I-Condition
.	O

-	O
Concurrent	O
acute	O
or	O
chronic	O
clinically	O
significant	O
immunologic,	B-Condition
hepatic	I-Condition
or	I-Condition
endocrine	I-Condition
disease	I-Condition
(	O
not	O
adequately	O
treated	O
)	O
and	O
/	O
or	O
other	O
unstable	O
or	O
major	O
disease	B-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Diagnosis	O
of	O
cancer	B-Condition
within	O
the	O
past	O
2	O
years	O
prior	O
to	O
Baseline	O
(	O
other	B-Negation_cue
than	I-Negation_cue
basal	B-Condition
cell	I-Condition
or	I-Condition
squamous	I-Condition
cell	I-Condition
skin	I-Condition
cancer	I-Condition
or	O
Stage	O
1	O
prostate	B-Condition
cancer	I-Condition
)	O
unless	O
treatment	O
has	O
resulted	O
in	O
complete	O
freedom	B-Condition
from	I-Condition
disease	I-Condition
for	O
at	O
least	O
2	O
years	O
.	O

-	O
Prior	O
intolerance	B-Condition
or	O
hypersensitivity	B-Condition
to	O
methylthioninium-containing	B-Drug
drug	I-Drug
similar	B-Drug
organic	I-Drug
dyes	I-Drug
or	O
any	O
of	O
the	O
excipients	B-Drug
.	O

-	O
Treatment	B-Drug
currently	O
or	O
within	O
3	O
months	O
before	O
Baseline	O
with	O
any	O
of	O
the	O
following	O
medications	O
:	O
.	O

-	O
Tacrine	B-Drug
.	O

-	O
Clozapine	B-Drug
,	O
olanzapine	B-Drug
(	O
and	O
there	O
is	O
no	O
intent	O
to	O
initiate	O
therapy	O
during	O
the	O
course	O
of	O
the	O
study	O
)	O
.	O

-	O
Carbamazepine	B-Drug
,	O
primidone	B-Drug
.	O

-	O
Drugs	B-Drug
associated	O
with	O
methemoglobinemia	B-Condition
.	O

-	O
Current	O
or	O
prior	O
participation	O
in	O
a	O
clinical	O
trial	O
as	O
follows	O
:	O
.	O

-	O
Clinical	O
trial	O
of	O
a	O
product	B-Drug
for	O
cognition	B-Condition
within	O
3	O
months	O
(	O
unless	O
confirmed	O
to	O
have	O
been	O
randomized	O
to	O
placebo	O
)	O
.	O

-	O
A	O
clinical	O
trial	O
of	O
a	O
drug	B-Drug
,	O
biologic,	B-Procedure_Device
therapeutic	I-Procedure_Device
device	I-Procedure_Device
or	O
medical	B-Drug
food	I-Drug
in	O
which	O
the	O
last	O
dose	B-Procedure_Device
/	I-Procedure_Device
administration	I-Procedure_Device
was	O
received	O
within	O
28	O
days	O
prior	O
to	O
Baseline	O
.	O

>>NCT00501111	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Provision	O
of	O
informed	O
consent	O
from	O
patient	O
and	O
caregiver	O
.	O

-	O
Clinical	O
prognosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Patient	O
must	O
have	O
a	O
caregiver	O
visiting	O
the	O
patient	O
at	O
least	O
three	O
times	O
weekly	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Significant	O
neurologic	B-Condition
disease	I-Condition
or	O
dementia	B-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Major	B-Condition
depressive	I-Condition
disorder	I-Condition
other	O
major	B-Condition
psychiatric	I-Condition
disorder	I-Condition
.	O

-	O
Use	O
of	O
acetylcholinesterase	B-Drug
inhibitor	I-Drug
or	O
memantine	B-Drug
for	O
treatment	O
of	O
Alzheimer's	B-Condition
diseas	I-Condition
within	O
8	O
weeks	O
prior	O
to	O
enrollment	O
.	O

-	O
Impaired	O
vision	O
and	O
/	O
or	O
hearing	O
making	O
cognitive	O
testing	O
difficult	O
.	O

>>NCT00448318	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Clinical	O
diagnosis	O
of	O
dementia	B-Condition
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
delirium	B-Condition
.	O

-	O
acute	O
medical	B-Condition
conditions	I-Condition
(	O
eg	O
pneumonia	B-Condition
,	O
cardiac	B-Condition
failure	I-Condition
)	O
.	O

-	O
primary	O
psychiatric	B-Condition
conditions	I-Condition
(	O
eg	O
schizophrenia	B-Condition
)	O
.	O

-	O
severe	O
hearing	B-Condition
impairment	I-Condition
.	O

>>NCT00355498	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Agreement	O
to	O
participate	O
in	O
a	O
clinical	O
and	O
brain	O
imaging	O
study	O
.	O

-	O
Age	B-Observation
30	O
years	O
or	O
older	O
.	O

-	O
No	B-Negation_cue
significant	O
cerebrovascular	B-Condition
disease	I-Condition
-	O
modified	B-Observation
Ischemic	I-Observation
Score	I-Observation
of	O
<=	O
4	O
.	O

-	O
For	O
volunteers	O
with	O
MCI	B-Condition
or	O
dementia	B-Condition
,	O
there	O
must	O
be	O
a	O
family	O
member	O
or	O
potential	O
caregiver	O
available	O
.	O

-	O
Adequate	O
visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
to	O
allow	O
neuropsychological	O
testing	O
.	O

-	O
Screening	B-Observation
laboratory	I-Observation
tests	I-Observation
and	O
ECG	B-Procedure_Device
without	B-Negation_cue
significant	O
abnormalities	B-Condition
that	O
might	O
interfere	O
with	O
the	O
study	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Evidence	O
of	O
neurologic	B-Condition
or	I-Condition
other	I-Condition
physical	I-Condition
illness	I-Condition
that	O
could	O
produce	O
cognitive	B-Condition
deterioration	I-Condition
in	O
addition	O
to	O
a	O
physical	O
and	O
neurological	O
examination,	O
volunteers	O
will	O
be	O
screened	O
for	O
Parkinson's	B-Condition
disease	I-Condition
.	O

-	O
History	O
of	O
myocardial	B-Condition
infarction	I-Condition
within	O
the	O
previous	O
year	O
or	O
unstable	O
cardiac	B-Condition
disease	I-Condition
.	O

-	O
Uncontrolled	O
hypertension	B-Condition
(	O
systolic	B-Observation
BP	I-Observation
>	O
170	O
or	O
diastolic	B-Observation
BP	I-Observation
>	O
100	O
),	O
history	O
of	O
significant	O
liver	B-Condition
disease	I-Condition
clinically	O
significant	O
pulmonary	B-Condition
disease	I-Condition
diabetes	B-Condition
or	O
cancer	B-Condition
.	O

-	O
Major	O
psychiatric	B-Condition
disorders	I-Condition
such	O
as	O
bipolar	B-Condition
disorder	I-Condition
or	O
schizophrenia	B-Condition
.	O

-	O
Because	O
medications	O
can	O
affect	O
cognitive	O
functioning,	O
volunteers	O
needing	O
medicines	O
that	O
could	O
influence	O
psychometric	O
test	O
results	O
will	O
be	O
excluded;	O
use	O
of	O
any	O
of	O
the	O
following	O
drugs	O
will	O
also	O
exclude	O
volunteers	O
:	O
centrally	B-Drug
active	I-Drug
beta-blockers	I-Drug
narcotics	B-Drug
,	O
clonidine	B-Drug
,	O
anti-Parkinsonian	B-Drug
medications	I-Drug
benzodiazepines	B-Drug
,	O
systemic	B-Drug
corticosteroids	I-Drug
and	O
medications	B-Drug
with	I-Drug
significant	I-Drug
cholinergic	I-Drug
or	I-Drug
anticholinergic	I-Drug
effects	I-Drug
anti-convulsants	B-Drug
or	O
warfarin	B-Drug
.	O

-	O
Current	O
diagnosis	O
or	O
history	O
of	O
alcoholism	B-Condition
or	O
drug	B-Condition
dependence	I-Condition
.	O

-	O
Evidence	O
of	O
untreated	O
depression	B-Condition
as	O
determined	O
by	O
a	O
HAM-D	B-Observation
(	I-Observation
Hamilton,	I-Observation
1960	I-Observation
)	I-Observation
score	I-Observation
of	O
>=	O
12	O
(	O
17	O
-item	O
version	O
)	O
or	O
untreated	O
anxiety	B-Condition
by	O
a	O
score	O
of	O
>=	O
8	O
on	O
the	O
Hamilton	B-Observation
Anxiety	I-Observation
Scale	I-Observation
(	O
HAM-A;	O
Hamilton,	O
1959	O
)	O
.	O

-	O
Use	O
of	O
any	O
investigational	B-Drug
drugs	I-Drug
within	O
the	O
previous	O
month	O
or	O
longer,	O
depending	O
on	O
drug	O
half-life	O
.	O

-	O
Contraindication	B-Condition
for	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
(	O
eg	O
,	O
metal	B-Procedure_Device
in	O
body,	O
claustrophobia	B-Condition
)	O
.	O

>>NCT00551772	O
Inclusion	O
criteria	O
:	O
.	O

-	O
Men	O
or	O
surgically	B-Condition
sterile	I-Condition
or	O
post-menopausal	B-Condition
women	O
.	O

-	O
Healthy	B-Condition
as	O
judged	O
by	O
a	O
responsible	O
physician	O
.	O

No	B-Negation_cue
clinically	O
significant	O
abnormality	B-Condition
identified	O
on	O
the	O
medical	B-Observation
or	I-Observation
lab	I-Observation
evaluation	I-Observation
.	O

-	O
BMI	B-Observation
between	O
18.5	O
and	O
32.0	O
kg	O
/	O
m2	O
.	O

Exclusion	O
criteria	O
:	O
.	O

-	O
A	O
positive	O
pre-study	B-Observation
urine	I-Observation
screen	I-Observation
for	O
drugs	B-Condition
of	I-Condition
abuse	I-Condition
.	O

-	O
Abuse	B-Condition
of	I-Condition
alcohol	I-Condition
.	O

-	O
Subjects	O
who	O
smoke	B-Observation
more	O
than	O
10	O
cigarettes	O
or	O
equivalent	O
a	O
day	O
.	O

-	O
Use	O
of	O
prescription	B-Drug
drugs	I-Drug
as	O
well	O
as	O
herbal	B-Drug
and	O
dietary	B-Drug
supplements	I-Drug
within	O
7	O
days	O
prior	O
to	O
the	O
first	O
dose	O
of	O
study	O
medication,	O
unless	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
and	O
sponsor	O
the	O
medication	O
will	O
not	O
interfere	O
with	O
the	O
study	O
procedures	O
or	O
compromise	O
subject	O
safety	O
.	O

-	O
Where	O
participation	O
in	O
the	O
study	O
would	O
result	O
in	O
donation	B-Procedure_Device
of	I-Procedure_Device
blood	I-Procedure_Device
in	O
excess	O
of	O
500ml	O
within	O
a	O
56	O
day	O
period	O
.	O

-	O
Has	O
a	O
history	O
or	O
presence	O
of	O
gastro-intestinal,	B-Condition
hepatic	I-Condition
or	I-Condition
renal	I-Condition
disease	I-Condition
or	O
other	O
condition	B-Condition
known	O
to	O
interfere	O
with	O
the	O
absorption	B-Observation
,	O
distribution	B-Observation
,	O
metabolism	B-Observation
or	O
excretion	B-Observation
of	O
drugs	O
.	O

-	O
The	O
subject	O
has	O
received	O
an	O
investigational	B-Drug
drug	I-Drug
or	O
participated	O
in	O
another	O
research	O
trial	O
within	O
30	O
days	O
or	O
5	O
half-lives	O
or	O
twice	O
the	O
duration	O
of	O
the	O
biological	O
effect	O
of	O
any	O
drug	O
(	O
whichever	O
is	O
longer	O
)	O
prior	O
to	O
the	O
first	O
dose	O
of	O
current	O
study	O
medication	O
.	O

-	O
Known	O
or	O
suspected	O
history	O
of	O
seizures	B-Condition
,	O
including	O
febrile	B-Condition
seizures	I-Condition
unexplained	O
recent	O
loss	B-Condition
of	I-Condition
consciousness	I-Condition
or	O
history	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
with	I-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition

>>NCT02103673	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Clinical	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
or	O
probable	O
vascular	B-Condition
dementia	I-Condition
.	O

-	O
For	O
patients	O
with	O
vascular	B-Condition
dementia	I-Condition
the	O
post-stroke	B-Observation
period	I-Observation
must	O
be	O
more	O
than	O
3	O
months	O
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
scores	I-Observation
between	O
5	O
-	O
26	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
score	I-Observation
equal	O
to	O
or	O
greater	O
than	O
1	O
.	O

-	O
Behavioral	B-Observation
Pathology	I-Observation
in	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
Rating	I-Observation
Scale	I-Observation
score	I-Observation
equal	O
to	O
or	O
greater	O
than	O
2	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Current	O
substance	B-Condition
abuse	I-Condition
or	O
history	O
of	O
substance	B-Condition
dependence	I-Condition
in	O
the	O
past	O
6	O
months	O
.	O

-	O
Other	O
major	O
psychiatric	B-Condition
diagnoses	I-Condition
such	O
as	O
schizophrenia	B-Condition
,	O
major	B-Condition
depressive	I-Condition
disorder	I-Condition
bipolar	B-Condition
disorder	I-Condition
and	O
mental	B-Condition
retardation	I-Condition
etc	O
.	O

-	O
Serious	O
medical	B-Condition
or	I-Condition
neurological	I-Condition
illness	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
or	O
vascular	B-Condition
dementia	I-Condition
and	O
other	O
secondary	B-Condition
dementia	I-Condition
.	O

>>NCT01780974	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
55	O
years	O
or	O
older	O
.	O

-	O
Non-demented	O
:	O
Montreal	B-Observation
Cognitive	I-Observation
Assessment	I-Observation
>	O
26	O
and	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
=	O
0	O
.	O

-	O
Diagnosis	O
of	O
Essential	B-Condition
Hypertension	I-Condition
with	O
systolic	B-Observation
90	O
-	O
160	O
mm	O
Hg	O
and	O
diastolic	B-Observation
60	O
-	O
90	O
mm	O
Hg	O
.	O

-	O
Stable	O
dose	B-Procedure_Device
of	O
antihypertensive	B-Drug
medication	I-Drug
4	O
month	O
prior	O
to	O
study	O
enrollment	O
.	O

-	O
Stable	O
dose	B-Procedure_Device
of	O
lipid	B-Drug
lowering	I-Drug
medication	I-Drug
-	O
dose	B-Procedure_Device
must	O
be	O
stable	O
for	O
4	O
months	O
prior	O
to	O
study	O
enrollment	O
.	O

-	O
Low	O
Omega-	B-Observation
3	I-Observation
fatty	I-Observation
acid	I-Observation
Status	I-Observation
:	O
Omega-	B-Observation
3	I-Observation
index	I-Observation
<	O
4%	O
of	O
total	O
fatty	O
acid	O
of	O
combined	O
docsahexanoic	B-Observation
acid	I-Observation
and	O
eicosapentanoic	B-Observation
acid	I-Observation
.	O

-	O
Geriatric	B-Observation
Depression	I-Observation
Scale	I-Observation
<	O
5	O
.	O

-	O
General	O
health	O
status	O
that	O
will	O
not	O
interfere	O
with	O
the	O
participant's	O
ability	O
to	O
complete	O
the	O
study	O
.	O

-	O
Screening	B-Observation
laboratory	I-Observation
values	I-Observation
within	O
normal	O
limits	O
or,	O
if	O
abnormal,	O
deemed	O
clinically	O
insignificant	O
by	O
the	O
investigator	O
.	O

-	O
Sufficient	O
English	O
language	O
skills	O
to	O
complete	O
all	O
testing	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Alzheimer's	B-Condition
,	O
Dementia	B-Condition
or	O
other	O
neurodegenerative	B-Condition
disease	I-Condition
.	O

-	O
Health	O
conditions	O
such	O
as	O
cancer	B-Condition
diagnosed	O
<	O
5	O
years	O
prior	O
to	O
enrollment	O
(	O
prostate	B-Condition
cancer	I-Condition
gleason	B-Observation
grade	I-Observation
<	O
3	O
and	O
non	B-Condition
metastatic	I-Condition
skin	I-Condition
cancers	I-Condition
are	O
acceptable	O
),	O
liver	B-Condition
disease	I-Condition
history	O
of	O
ventricular	B-Condition
fibrillation	I-Condition
or	O
ventricular	B-Condition
tachycardia	I-Condition
major	O
psychiatric	B-Condition
disorder	I-Condition
central	B-Condition
nervous	I-Condition
system	I-Condition
diseases	I-Condition
(	O
eg	O
brain	B-Condition
tumor	I-Condition
seizure	B-Condition
disorder	I-Condition
)	O
.	O

-	O
Insulin	B-Condition
dependent	I-Condition
diabetes	I-Condition
or	O
uncontrolled	O
diabetes	B-Condition
(	O
diabetes	B-Condition
controlled	O
on	O
medications	B-Drug
other	O
than	O
insulin	B-Drug
are	O
acceptable	O
)	O
.	O

-	O
Fish	B-Drug
intake	I-Drug
of	O
one	O
6	O
ounce	O
serving	O
>	O
once	O
a	O
week	O
less	O
than	O
4	O
months	O
prior	O
to	O
enrollment	O
.	O

-	O
Omega-	B-Drug
3	I-Drug
fatty	I-Drug
acid	I-Drug
supplement	I-Drug
intake	O
(	O
eg	O
fish	B-Drug
oil	I-Drug
capsules	I-Drug
cod	B-Drug
liver	I-Drug
oil	I-Drug
)	O
less	O
than	O
4	O
months	O
prior	O
to	O
enrollment	O
.	O

-	O
Lipoic	B-Drug
Acid	I-Drug
supplementation	I-Drug
less	O
than	O
1	O
month	O
prior	O
to	O
enrollment	O
.	O

-	O
Taking	O
systemic	B-Drug
corticosteroids	I-Drug
neuroleptics	B-Drug
,	O
antiparkinsonian	B-Drug
agents	I-Drug
and	O
/	O
or	O
narcotic	B-Drug
analgesics	I-Drug
.	O

Low	O
dose	B-Procedure_Device
sinemet	B-Drug
and	O
dopamine	B-Drug
agonist	I-Drug
taken	O
once	O
a	O
day	O
for	O
restless	B-Condition
leg	I-Condition
syndrome	I-Condition
is	O
not	O
an	O
exclusion	O
.	O

-	O
Contraindications	B-Condition
to	O
MRI	B-Procedure_Device
,	O
including	O
:	O
subjects	O
with	O
intrathecal	B-Procedure_Device
pumps	I-Procedure_Device
stimulators	B-Procedure_Device
,	O
pacemakers	B-Procedure_Device
,	O
aneurysm	B-Procedure_Device
clips	I-Procedure_Device
non-removable	B-Procedure_Device
hearing	I-Procedure_Device
aids	I-Procedure_Device
or	O
metal	B-Procedure_Device
fragments	I-Procedure_Device
in	O
the	O
eyes	O
.	O

Other	O
exclusion	O
criteria	O
include	O
the	O
inability	O
to	O
lie	O
flat	O
on	O
the	O
back	O
for	O
40	O
minutes	O
at	O
a	O
time	O
or	O
a	O
self-reported	O
history	O
of	O
claustrophobia	B-Condition
.	O

Subjects	O
with	O
a	O
history	O
of	O
hip	B-Procedure_Device
replacement	I-Procedure_Device
and	O
those	O
with	O
well-documented,	O
verifiable,	O
MRI-safe	B-Procedure_Device
cardiac	I-Procedure_Device
stents	I-Procedure_Device
will	O
not	B-Negation_cue
be	O
excluded	B-Negation_cue
from	O
the	O
study	O
.	O

-	O
Enrollment	O
in	O
another	O
treatment	O
study	O
.	O

>>NCT02226835	O
-	O
INCLUSION	O
CRITERIA	O
:	O
.	O

-	O
Patient	O
must	O
be	O
enrolled	O
in	O
the	O
09-M-0198	O
protocol	O
.	O

-	O
In	O
those	O
participants	O
that	O
require	O
special	O
assistance,	O
we	O
will	O
request	O
that	O
they	O
be	O
accompanied	O
by	O
a	O
care	O
taker	O
to	O
provide	O
proper	O
care	O
and	O
monitoring	O
.	O

EXCLUSION	O
CRITERIA	O
:	O
.	O

Patients	O
:	O
.	O

-	O
The	O
diagnosis	O
of	O
a	O
different	O
type	O
of	O
dementia	B-Condition
,	O
including	O
frontotemporal	B-Condition
dementia	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
Lewy	B-Condition
body	I-Condition
dementia	I-Condition
Parkinson	B-Condition
s	I-Condition
disease	I-Condition
dementia	I-Condition
Huntington's	B-Condition
disease	I-Condition
or	O
vascular	B-Condition
dementia	I-Condition
.	O

-	O
Any	O
medical	O
contraindication	B-Condition
to	O
the	O
procedures	B-Procedure_Device
performed	O
in	O
the	O
study	O
or	O
any	O
current	O
severe	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer	B-Condition
s	I-Condition
disease	I-Condition
.	O

-	O
Behavioral	O
symptoms	O
that	O
would	O
preclude	O
the	O
gathering	O
of	O
data	O
for	O
the	O
study	O
or	O
advanced	O
disease	O
such	O
that	O
participants	O
cannot	O
provide	O
assent	O
.	O

Controls	O
:	O
.	O

-	O
The	O
diagnosis	O
of	O
a	O
brain	B-Condition
disorder	I-Condition
.	O

-	O
Any	O
medical	O
contraindication	B-Condition
to	O
the	O
procedures	B-Procedure_Device
performed	O
in	O
the	O
study	O
or	O
any	O
current	O
severe	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
.	O

>>NCT01303744	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Diagnosis	O
of	O
amnestic	B-Condition
or	I-Condition
non-amnestic	I-Condition
Mild	I-Condition
Cognitive	I-Condition
Impairment	I-Condition
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
score	I-Observation
higher	O
than	O
24	O
at	O
screening	O
.	O

-	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
of	O
the	O
brain	O
at	O
screening	O
with	O
fluid-attenuation	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
and	O
T2*-weighted	O
gradient-recalled-echo	O
(	O
GRE	O
)	O
sequences	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
the	O
DSM-IV-TR	B-Observation
or	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
.	O

-	O
Any	O
medical	B-Condition
condition	I-Condition
that	O
could	O
explain	O
the	O
patients	O
cognitive	B-Condition
deficits	I-Condition
.	O

-	O
CT	B-Procedure_Device
or	O
MRI	B-Procedure_Device
brain	I-Procedure_Device
imaging	I-Procedure_Device
results	O
obtained	O
within	O
12	O
months	O
prior	O
to	O
baseline	O
showing	O
evidence	O
of	O
infection	B-Condition
,	O
infarction	B-Condition
or	O
focal	B-Condition
lesions	I-Condition
of	O
clinical	O
significance	O
.	O

-	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
at	O
screening	O
showing	O
more	O
than	O
4	O
cerebral	B-Condition
microhemorrhages	I-Condition
(	O
lesions	B-Condition
with	O
diameter	B-Observation
<=	O
10	O
mm	O
)	O
.	O

-	O
Geriatric	B-Observation
Depression	I-Observation
Scale	I-Observation
(	I-Observation
30	I-Observation
-point	I-Observation
scale	I-Observation
)	I-Observation
score	I-Observation
>	O
9	O
at	O
screening	O
.	O

-	O
History	O
of	O
stroke	B-Condition
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
ischemic	I-Observation
scale	I-Observation
score	I-Observation
>	O
4	O
at	O
screening	O
.	O

-	O
Women	O
of	O
childbearing	B-Condition
potential	I-Condition
.	O

-	O
Vitamin	B-Condition
B12	I-Condition
or	I-Condition
folate	I-Condition
deficiency	I-Condition
.	O

-	O
Diagnosis	O
of	O
schizophrenia	B-Condition
or	O
recurrent	O
mood	B-Condition
disorder	I-Condition
(	O
including	O
unipolar	B-Condition
and	I-Condition
bipolar	I-Condition
disorders	I-Condition
)	O
within	O
3	O
years	O
of	O
screening	O
.	O

-	O
Current	O
diagnosis	O
of	O
peptic	B-Condition
ulcer	I-Condition
or	O
gastrointestinal	B-Condition
bleeding	I-Condition
within	O
the	O
last	O
year	O
and	O
/	O
or	O
chronic	B-Condition
inflammatory	I-Condition
bowel	I-Condition
disease	I-Condition
.	O

-	O
Concomitant	O
use	O
of	O
donepezil	B-Drug
at	O
doses	B-Procedure_Device
>	O
5	O
mg	O
/	O
day	O
or	O
other	O
cholinesterase	B-Drug
inhibitors	I-Drug
(	O
rivastigmine	B-Drug
or	O
galantamine	B-Drug
)	O
at	O
any	O
dose	B-Procedure_Device
.	O

-	O
Concomitant	O
use	O
of	O
memantine	B-Drug
at	O
dose	B-Procedure_Device
>	O
20	O
mg	O
/	O
day	O
.	O

-	O
Concomitant	O
use	O
of	O
psychoactive	B-Drug
drugs	I-Drug
(	O
sedatives	B-Drug
,	O
hypnotics	B-Drug
,	O
etc	O
)	O
.	O

>>NCT01258452	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Subject	O
is	O
judged	O
to	O
be	O
in	O
good	B-Condition
health	I-Condition
on	O
the	O
basis	O
of	O
medical	B-Observation
history	I-Observation
complete	B-Observation
physical	I-Observation
examination	I-Observation
including	O
vital	B-Observation
signs	I-Observation
12	B-Procedure_Device
-lead	I-Procedure_Device
electrocardiogram	I-Procedure_Device
(	I-Procedure_Device
ECG	I-Procedure_Device
)	I-Procedure_Device
and	O
standard	B-Observation
laboratory	I-Observation
tests	I-Observation
.	O

-	O
Subject	O
has	O
a	O
body	B-Observation
mass	I-Observation
index	I-Observation
between	O
18	O
and	O
30	O
kg	O
/	O
m^2,	O
inclusive	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Medical	O
history	O
(	O
within	O
the	O
last	O
10	O
years	O
)	O
of	O
major	O
cardiovascular,	B-Condition
hepatic	I-Condition
or	I-Condition
renal	I-Condition
disease	I-Condition
.	O

-	O
Abnormal	O
result	O
of	O
liver	B-Observation
function	I-Observation
tests	I-Observation
renal	B-Observation
function	I-Observation
tests	I-Observation
or	O
thyroid	B-Observation
tests	I-Observation
performed	O
at	O
screening	O
.	O

-	O
Significant	O
allergic	B-Condition
conditions	I-Condition
that	O
require	O
medical	O
treatment	O
.	O

-	O
Use	O
of	O
any	O
psychoactive,	B-Drug
recreational	I-Drug
or	I-Drug
prescription	I-Drug
drug	I-Drug
within	O
the	O
4	O
weeks	O
prior	O
to	O
study	O
drug	O
administration	O
.	O

-	O
Use	O
of	O
ibuprofen	B-Drug
,	O
sulindac	B-Drug
sulfide	I-Drug
indomethacin	B-Drug
,	O
flurbiprofen	B-Drug
within	O
2	O
weeks	O
prior	O
to	O
study	O
drug	O
administration.	O

>>NCT02120664	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Cognitively	B-Observation
Normal	O
Subjects	O
.	O

-	O
Males	O
or	O
females	O
>=	O
21	O
and	O
<=	O
45	O
years	O
of	O
age	B-Observation
.	O

-	O
Mini-mental	B-Observation
state	I-Observation
examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
>=	O
29	O
.	O

-	O
Clinically	O
Diagnosed	O
AD	B-Condition
Subject	O
.	O

-	O
Males	O
or	O
females	O
>=	O
50	O
years	O
of	O
age	B-Observation
.	O

-	O
Meet	O
clinical	O
criteria	O
for	O
dementia	B-Condition
due	O
to	O
probable	O
AD	B-Condition
.	O

-	O
MMSE	B-Observation
>=	O
16	O
and	O
<=	O
26	O
.	O

-	O
Possible	O
AD	B-Condition
Subject	O
.	O

-	O
Males	O
or	O
females	O
>=	O
50	O
years	O
of	O
age	B-Observation
.	O

-	O
Meet	O
clinical	O
criteria	O
for	O
dementia	B-Condition
due	O
to	O
possible	O
AD	B-Condition
.	O

-	O
MMSE	B-Observation
>=	O
16	O
and	O
<=	O
26	O
.	O

-	O
MCI	B-Condition
Subject	O
.	O

-	O
Males	O
or	O
females	O
>=	O
60	O
years	O
of	O
age	B-Observation
with	O
cognitive	B-Condition
impairment	I-Condition
(	O
not	B-Negation_cue
dementia	B-Condition
)	O
.	O

-	O
MMSE	B-Observation
>	O
24	O
and	O
<	O
29	O
.	O

-	O
At	O
Risk	O
Elderly	O
Subject	O
.	O

-	O
Cognitively	B-Condition
normal	I-Condition
males	O
or	O
females	O
that	O
are	O
known	O
ApoE4	O
carriers	O
and	O
>=	O
75	O
years	O
of	O
age	B-Observation
.	O

-	O
MMSE	B-Observation
>=	O
27	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Have	O
had	O
or	O
currently	O
have	O
a	O
diagnosis	O
of	O
neurodegenerative	B-Condition
disorders	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
.	O

-	O
Have	O
a	O
current	O
serious	O
or	O
unstable	O
illness	B-Condition
that	O
could	O
interfere	O
with	O
completion	O
of	O
the	O
study	O
.	O

-	O
Subject	O
has	O
a	O
known	O
brain	B-Condition
lesion	I-Condition
pathology	B-Condition
or	O
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
.	O

-	O
Have	O
received	O
or	O
participated	O
in	O
a	O
trial	O
with	O
investigational	B-Drug
medications	I-Drug
in	O
the	O
past	O
30	O
days	O
.	O

-	O
Have	O
had	O
a	O
radiopharmaceutical	B-Procedure_Device
imaging	I-Procedure_Device
or	I-Procedure_Device
treatment	I-Procedure_Device
procedure	O
within	O
7	O
days	O
of	O
study	O
imaging	O
session	O
.	O

-	O
Females	O
of	O
childbearing	O
potential	O
who	O
are	O
not	O
surgically	O
sterile,	O
not	O
refraining	O
from	O
sexual	O
activity	O
or	O
not	O
using	O
reliable	O
methods	O
of	O
contraception	O
.	O

>>NCT01163825	O
Inclusion	O
Criteria	O
:	O
.	O

1	O
.	O

Age	B-Observation
50	O
-	O
80	O
years	O
.	O

2	O
.	O

All	O
patients	O
must	O
fulfil	O
the	O
NINDNDS-ARDRA	B-Observation
criteria	I-Observation
of	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

3	O
.	O

The	O
subject	O
must	O
have	O
a	O
score	O
between	O
15	O
-	O
24	O
inclusive,	O
on	O
the	O
mini-mental	B-Observation
state	I-Observation
examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
.	O

4	O
.	O

The	O
subject	O
must	O
have	O
a	O
caregiver	O
who	O
is	O
able	O
and	O
committed	O
to	O
assist	O
the	O
subject	O
to	O
comply	O
with	O
the	O
trial	O
protocol	O
and	O
who	O
is	O
willing	O
to	O
provide	O
the	O
information	O
required	O
at	O
assessment	O
interviews	O
.	O

5	O
.	O

Informed	O
consent	O
must	O
be	O
obtained	O
from	O
the	O
subject	O
together	O
with	O
a	O
close	O
caregiver,	O
in	O
accordance	O
with	O
the	O
requirements	O
of	O
the	O
ethical	O
committee	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

1	O
.	O

A	O
diagnosis	O
of	O
Schizophrenia	B-Condition
,	O
Schizo-affective	B-Condition
disorder	I-Condition
or	O
paranoid	B-Condition
disorder	I-Condition
according	O
to	O
DSM	B-Observation
IV	I-Observation
without	B-Negation_cue
any	O
suspicion	O
cognitive	B-Condition
decline	I-Condition
.	O

2	O
.	O

Patients	O
with	O
the	O
following	O
co-existing	O
medical	O
conditions	O
:	O
.	O

3	O
.	O

History	O
of	O
seizures	B-Condition
.	O

4	O
.	O

Brain	B-Condition
tumor	I-Condition
including	O
meningeoma	B-Condition
.	O

5	O
.	O

Clinically	O
significant	O
hepatic,	B-Condition
renal,	I-Condition
pulmonary,	I-Condition
metabolic	I-Condition
or	I-Condition
endocrine	I-Condition
disturbances	I-Condition
.	O

6	O
.	O

Clinically	O
significant	O
back	B-Condition
pain	I-Condition
.	O

7	O
.	O

Bleeding	B-Condition
disorders	I-Condition
.	O

8	O
.	O

Patients	O
who,	O
in	O
the	O
opinion	O
of	O
the	O
investigator,	O
are	O
otherwise	O
unsuitable	O
for	O
a	O
trial	O
of	O
this	O
type	O
.	O

>>NCT00253123	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Patients	O
with	O
a	O
diagnosis	O
of	O
dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
type	I-Condition
mixed	B-Condition
dementia	I-Condition
or	O
vascular	B-Condition
dementia	I-Condition
as	O
classified	O
by	O
the	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Diseases,	I-Observation
4th	I-Observation
edition	I-Observation
(	I-Observation
DSM-IV	I-Observation
)	I-Observation
.	O

-	O
a	O
score	O
of	O
4	O
or	O
more	O
on	O
the	O
Functional	B-Observation
Assessment	I-Observation
Staging	I-Observation
(	I-Observation
FAST	I-Observation
)	I-Observation
a	O
diagnostic	O
tool	O
for	O
determining	O
the	O
stage	O
of	O
dementia	B-Condition
.	O

-	O
a	O
score	O
of	O
23	O
or	O
lower	O
on	O
the	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
a	O
clinical	O
measure	O
used	O
to	O
evaluate	O
cognition	B-Condition
.	O

-	O
a	O
BEHAVE-AD	B-Observation
total	I-Observation
score	I-Observation
of	O
at	O
least	O
8	O
and	O
a	O
BEHAVE-AD	B-Observation
global	I-Observation
rating	I-Observation
of	O
at	O
least	O
1	O
.	O

-	O
residence	O
in	O
a	O
psychiatric	O
hospital,	O
nursing	O
home	O
or	O
other	O
long-term	O
care	O
facility	O
for	O
at	O
least	O
1	O
month	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Patients	O
with	O
untreated,	O
reversible	B-Condition
causes	I-Condition
of	I-Condition
dementia	I-Condition
.	O

-	O
with	O
general	O
medical	B-Condition
or	I-Condition
neurological	I-Condition
conditions	I-Condition
in	O
which	O
cognition	B-Condition
is	O
diminished	O
(	O
for	O
example,	O
untreated	O
vitamin	B-Condition
deficiency	I-Condition
severe	O
liver	B-Condition
or	I-Condition
kidney	I-Condition
malfunctions	I-Condition
brain	B-Condition
tumor	I-Condition
etc.)	O
.	O

-	O
with	O
dementia	B-Condition
related	O
to	O
HIV	B-Condition
infection	I-Condition
(	I-Condition
human	I-Condition
immunodeficiency	I-Condition
virus	I-Condition
)	I-Condition
.	O

-	O
with	O
a	O
substance-induced	B-Condition
persisting	I-Condition
dementia	I-Condition
.	O

-	O
with	O
psychiatric	B-Condition
disorders	I-Condition
that	O
could	O
account	O
for	O
the	O
behavior	B-Condition
disturbances	I-Condition
such	O
as	O
schizophrenia	B-Condition
.	O

>>NCT01723553	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
over	O
the	O
age	B-Observation
of	O
21	O
.	O

-	O
will	O
have	O
an	O
informant	O
/	O
study	O
partner	O
who	O
will	O
be	O
able	O
to	O
provide	O
independent	O
evaluation	O
of	O
functioning	O
.	O

-	O
must	O
fulfill	O
clinical	O
diagnostic	O
criteria	O
for	O
atypical	B-Condition
AD	I-Condition
and	O
hence	O
should	O
either	O
have	O
a	O
chief	B-Observation
complaint	I-Observation
of	O
difficulty	O
with	O
language	O
and	O
fulfill	O
criteria	O
for	O
logopenic	O
variant	O
of	O
primary	B-Condition
progressive	I-Condition
aphasia	I-Condition
or	O
present	O
with	O
visuospatial	B-Condition
/	I-Condition
perceptual	I-Condition
deficits	I-Condition
and	O
fulfill	O
criteria	O
for	O
posterior	B-Condition
cortical	I-Condition
atrophy	I-Condition
.	O

-	O
speaks	O
English	O
as	O
their	O
primary	O
language	O
(	O
including	O
bilingual	O
patients	O
whose	O
primary	O
language	O
is	O
English	O
)	O
.	O

-	O
agrees	O
to	O
and	O
is	O
eligible	O
to	O
undergo	O
MRI	B-Procedure_Device
and	O
PET	B-Procedure_Device
scanning	I-Procedure_Device
.	O

-	O
if	O
woman	O
of	O
child	O
bearing	O
age,	O
must	O
agree	O
to	O
pregnancy	B-Observation
test	I-Observation
no	O
more	O
than	O
48	O
hours	O
before	O
the	O
PET	B-Procedure_Device
scans	I-Procedure_Device
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
subjects	O
with	O
concurrent	O
illnesses	B-Condition
that	O
could	O
account	O
for	O
the	O
presenting	O
syndrome	B-Condition
,	O
such	O
as	O
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
strokes	B-Condition
or	O
developmental	B-Condition
syndromes	I-Condition
.	O

-	O
subjects	O
meeting	O
criteria	O
for	O
another	O
neurodegenerative	B-Condition
disease	I-Condition
particularly	O
typical	O
Alzheimer's	B-Condition
dementia	I-Condition
.	O

-	O
women	O
that	O
are	O
pregnant	B-Condition
or	O
post-partum	B-Condition
and	O
breast-feeding	B-Condition
.	O

-	O
subjects	O
will	O
also	O
be	O
excluded	O
if	O
MRI	B-Procedure_Device
is	O
contraindicated	B-Condition
(	O
metal	B-Procedure_Device
in	O
head,	O
cardiac	B-Procedure_Device
pace	I-Procedure_Device
maker	I-Procedure_Device
e.t.c	O
.	O

),	O
if	O
there	O
is	O
severe	O
claustrophobia	B-Condition
and	O
if	O
there	O
are	O
conditions	B-Condition
that	O
may	O
confound	O
brain	B-Procedure_Device
imaging	I-Procedure_Device
studies	I-Procedure_Device
(	O
eg	O
structural	B-Condition
abnormalities	I-Condition
including	O
subdural	B-Condition
hematoma	I-Condition
or	O
intracranial	B-Condition
neoplasm	I-Condition
)	O
.	O

-	O
subjects	O
will	O
also	O
be	O
excluded	O
if	O
they	O
do	O
not	O
have	O
an	O
informant,	O
do	O
not	O
consent	O
to	O
research	O
or	O
do	O
not	O
complete	O
all	O
components	O
of	O
the	O
study	O
(	O
neurological	O
exam,	O
neuropsychometric	O
tests,	O
MRI,	O
PiB	O
PET	O
)	O
.	O

>>NCT00997425	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
veterans	O
age	B-Observation
60	O
and	O
over	O
with	O
an	O
Alzheimer's-like	B-Condition
dementia	I-Condition
diagnosis,	O
documented	O
in	O
medical	O
record	O
with	O
International	B-Observation
Codes	I-Observation
for	I-Observation
Diagnosis	I-Observation
(	I-Observation
ICD-9	I-Observation
)	I-Observation
codes	I-Observation
that	O
include	O
all	O
290	O
diagnoses	O
and	O
331.0	O
.	O

-	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
24	O
or	O
less	O
.	O

-	O
evidence	O
of	O
pre-elopement	O
behaviors	O
operationalized	O
as	O
scoring	O
1	O
standard	O
deviation	O
(	O
SD	O
)	O
above	O
mean	O
on	O
any	O
one	O
of	O
the	O
three	O
items	O
that	O
comprise	O
the	O
Revised	O
Algase	O
Wandering	O
Scale-Community	O
Version	O
(	O
RAWS-CV	O
)	O
eloping	O
subscale	O
(	O
#16	O
-	O
He	O
/	O
she	O
attempts	O
to	O
get	O
outside;	O
#27	O
-	O
He	O
/	O
she	O
stands	O
at	O
the	O
out	O
door	O
wanting	O
to	O
go	O
out;	O
#30	O
-	O
He	O
/	O
she	O
attempts	O
to	O
find	O
or	O
go	O
to	O
familiar	O
locations,	O
even	O
unrealistic	O
ones	O
)	O
.	O

-	O
living	O
in	O
a	O
non-institutional	O
private	O
family	O
home	O
or	O
foster	O
home	O
.	O

-	O
independently	O
ambulatory	O
(	O
with	O
or	O
without	O
canes,	O
walkers	O
or	O
wheelchairs	O
to	O
assist	O
)	O
.	O

-	O
living	O
within	O
a	O
60-mile	O
radius	O
of	O
the	O
James	O
A	O
.	O
Haley	O
Veterans	O
Administration	O
Medical	O
Center	O
(	O
VAMC	O
),	O
Tampa,	O
Florida	O
.	O

-	O
living	O
with	O
a	O
caregiver	O
(	O
CG	O
)	O
who	O
is	O
willing	O
and	O
able	O
to	O
serve	O
as	O
a	O
study	O
partner	O
and	O
provide	O
informant	O
reports	O
and	O
who	O
intends	O
to	O
be	O
with	O
the	O
PDW	O
for	O
three	O
months	O
(	O
allowing	O
for	O
being	O
away	O
for	O
seven	O
days	O
or	O
less	O
during	O
the	O
three-month	O
study	O
period	O
)	O
.	O

-	O
English	O
speaking	O
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
living	O
in	O
a	O
nursing	O
home,	O
group	O
home	O
or	O
assisted	O
living	O
facility	O
at	O
point	O
of	O
entry	O
(	O
foster	O
homes	O
allowed	O
)	O
.	O

-	O
previous	O
exposure	O
to	O
any	O
visual	O
exit	O
barrier	O
for	O
wandering	O
management	O
.	O

-	O
no	O
live-in	O
CG	O
.	O

-	O
bilaterally	O
deaf	B-Condition
or	O
blind	B-Condition
.	O

-	O
currently	O
taking	O
anti-psychotic	B-Drug
medications	I-Drug
.	O

-	O
current	O
use	O
of	O
any	O
visual	O
exit	O
barrier	O
on	O
any	O
main	O
exit	O
doorway	O
.	O

CG	O
will	O
be	O
allowed	O
to	O
use	O
other	O
wandering	O
management	O
interventions	O
that	O
are	O
not	O
specific	O
to	O
the	O
exit	O
doorways	O
.	O

For	O
example,	O
they	O
may	O
use	O
a	O
stop	O
sign	O
at	O
the	O
entrance	O
to	O
the	O
kitchen	O
but	O
may	O
not	O
use	O
a	O
stop	O
sign	O
on	O
an	O
experimentally	O
monitored	O
door	O
.	O

>>NCT02273895	O
Inclusion	O
Criteria	O
:	O
.	O

Healthy	B-Condition
subjects	O
:	O
.	O

-	O
Between	O
60	O
-	O
80	O
years	O
of	O
age	B-Observation
.	O

-	O
Volunteers	O
will	O
have	O
to	O
be	O
in	O
good	O
general	B-Condition
health	I-Condition
as	O
determined	O
by	O
standard	O
physical	O
examination	O
.	O

-	O
Normal	O
Electrocardiograph	B-Procedure_Device
(	I-Procedure_Device
ECG	I-Procedure_Device
)	I-Procedure_Device
.	O

MCI	B-Condition
subjects	O
:	O
.	O

-	O
Diagnosed	O
with	O
MCI	B-Condition
at	O
the	O
Memory	O
Clinic	O
at	O
the	O
Landspitali	O
University	O
Hospital	O
using	O
F	O
06.7	O
according	O
to	O
International	B-Observation
Classification	I-Observation
of	I-Observation
Diseases	I-Observation
(	I-Observation
ICD	I-Observation
)	I-Observation
-	I-Observation
10	I-Observation
.	O

-	O
Between	O
60	O
-	O
80	O
years	O
of	O
age	B-Observation
.	O

-	O
Subjects	O
need	O
to	O
score	O
between	O
2	O
and	O
3	O
on	O
the	O
Global	B-Observation
Deterioration	I-Observation
Scale	I-Observation
(	I-Observation
GDS	I-Observation
)	I-Observation
.	O

-	O
Normal	O
ECG	B-Procedure_Device
.	O

Alzheimer's	B-Condition
patients	O
:	O
.	O

-	O
Diagnosed	O
with	O
AD	B-Condition
according	O
to	O
ICD	B-Observation
-	I-Observation
10	I-Observation
in	O
Follow	O
up	O
at	O
the	O
Memory	O
Clinic	O
at	O
the	O
Landspitali	O
University	O
Hospital	O
.	O

-	O
Between	O
60	O
-	O
80	O
years	O
of	O
age	B-Observation
.	O

-	O
Subjects	O
need	O
to	O
score	O
between	O
3	O
-	O
5	O
on	O
the	O
GDS	B-Observation
.	O

-	O
Normal	O
ECG	B-Procedure_Device
.	O

-	O
Treated	O
with	O
Reminyl	B-Drug
for	O
the	O
Alzheimer	B-Condition
disease	I-Condition
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Smoking	B-Observation
or	O
any	O
other	O
use	O
of	O
tobacco	B-Drug
.	O

-	O
Taking	O
neuroleptics	B-Drug
or	O
benzodiazepines	B-Drug
(	O
allowed	O
to	O
take	O
oxazepam	B-Drug
ad	O
vesp	B-Drug
)	O
.	O

-	O
Neurological-,	B-Condition
cardiovascular-,	I-Condition
gastrointestinal-	I-Condition
or	I-Condition
genitourinary	I-Condition
disorders	I-Condition
of	O
medical	O
importance	O
.	O

-	O
Glaucoma	B-Condition
or	O
history	O
of	O
possibly	O
raised	O
intraocular	B-Observation
pressure	I-Observation
.	O

-	O
Impaired	B-Condition
liver	I-Condition
or	I-Condition
kidney	I-Condition
function	I-Condition
.	O

-	O
Hypersensitivity	B-Condition
to	O
Scopolamine	B-Drug
or	O
any	O
component	O
in	O
the	O
formulation	O
.	O

-	O
Any	O
indication	O
of	O
drug,	B-Condition
alcohol	I-Condition
or	I-Condition
medicine	I-Condition
abuse	I-Condition
.	O

-	O
Participation	O
in	O
another	O
investigational	O
study	O
at	O
the	O
same	O
time	O
.	O

>>NCT01047254	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
Mild	O
to	O
moderate	O
Alzheimer's	B-Condition
dementia	I-Condition
male	O
and	O
female	O
(	O
NINCDS	B-Observation
/	I-Observation
ADRDA	I-Observation
criteria	I-Observation
)	O
.	O

-	O
Presence	O
of	O
clinically	O
relevant	O
apathy	B-Condition
defined	O
by	O
the	O
Neuropsychiatric	B-Observation
Inventory	I-Observation
(	I-Observation
NPI	I-Observation
)	I-Observation
apathy	I-Observation
item	I-Observation
(	O
score	O
of	O
>/=	O
4	O
points	O
)	O
and	O
the	O
Marin	B-Observation
/	I-Observation
Starkstein	I-Observation
criteria	I-Observation
for	O
apathy	O
.	O

-	O
MMSE	B-Observation
:	O
10	O
-	O
25	O
.	O

-	O
Outpatient	O
status,	O
not	O
institutionalized	O
.	O

-	O
Presence	O
of	O
reliable	O
caregiver	O
.	O

-	O
Stable	O
treatment	O
with	O
antidementia	B-Drug
drugs	I-Drug
for	O
at	O
least	O
three	O
months	O
prior	O
to	O
entry	O
or	O
no	B-Negation_cue
treatment	O
with	O
antidementia	B-Drug
drugs	I-Drug
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Other	O
Dementia	B-Condition
(	O
eg	O
vascular	B-Condition
dementia	I-Condition
Lewy-body	B-Condition
dementia	I-Condition
fronto-temporal	B-Condition
dementia	I-Condition
)	O
.	O

-	O
Presence	O
of	O
a	O
clinically	O
relevant	O
depression	B-Condition
defined	O
by	O
either	O
the	O
NPI	B-Observation
depression	I-Observation
item	I-Observation
(	O
score	O
>/=	O
4	O
points	O
)	O
or	O
DSM-IV	B-Observation
criteria	I-Observation
for	O
major	B-Condition
depressive	I-Condition
episode	I-Condition
(	O
with	O
depressed	O
mood	O
)	O
.	O

-	O
Alcoholism	B-Condition
and	O
Benzodiazepine	B-Condition
addiction	I-Condition
.	O

-	O
Current	O
treatment	O
with	O
antipsychotics	B-Drug
and	O
antidepressants	B-Drug
(	O
including	O
St.	B-Drug
John's	I-Drug
wart	I-Drug
)	O
.	O

-	O
Current	O
treatment	O
with	O
dopaminergic	B-Drug
agents	I-Drug
or	O
Amantadin	B-Drug
.	O

-	O
Current	O
treatment	O
with	O
benzodiazepines	B-Drug
.	O

-	O
Current	O
treatment	O
with	O
MAO	B-Drug
inhibitor	I-Drug
(	O
Bupropion	B-Drug
contraindication	B-Condition
)	O
.	O

-	O
Known	O
sensibility	B-Condition
to	O
Bupropion	B-Drug
treatment	I-Drug
.	O

-	O
Severe	O
psychiatric	B-Condition
disease	I-Condition
(	O
including	O
hospitalization	O
)	O
in	O
the	O
last	O
6	O
months,	O
suicide	B-Condition
attempt	I-Condition
acute	O
psychotic	B-Condition
symptoms	I-Condition
.	O

-	O
Severe	O
physical	B-Condition
illness	I-Condition
that	O
do	O
not	O
allow	O
a	O
participation	O
in	O
a	O
12-week	O
period	O
of	O
treatment	O
.	O

-	O
Medical	O
history	O
with	O
seizures	B-Condition
.	O

-	O
Medical	O
history	O
with	O
tumors	B-Condition
of	O
the	O
central	O
nervous	O
system	O
.	O

-	O
Severe	O
craniocerebral	B-Condition
injury	I-Condition
and	O
medical	O
history	O
with	O
cerebral	B-Condition
substance	I-Condition
defect	I-Condition
.	O

-	O
Clinically	O
relevant	O
renal	B-Condition
disease	I-Condition
liver	B-Condition
insufficiency	I-Condition
.	O

-	O
Simultaneous	O
treatment	B-Drug
,	O
which	O
reduces	O
the	O
seizure	O
threshold	O
(	O
eg	O
antipsychotics	B-Drug
,	O
antidepressants	B-Drug
,	O
antimalarial	B-Drug
agents	I-Drug
Tramadol	B-Drug
,	O
Theophyllin	B-Drug
,	O
systemic	B-Drug
steroids	I-Drug
in	O
higher	O
dose	B-Procedure_Device
,	O
Chinolone	B-Drug
,	O
sedative	B-Drug
antihistamines	I-Drug
)	O
.	O

-	O
Simultaneous	O
treatment	B-Drug
,	O
which	O
is	O
metabolized	O
through	O
Cytochrom	B-Drug
P450-Isoenzym	I-Drug
2D6	I-Drug
(	O
eg	O
these	O
beta	B-Drug
blockers	I-Drug
:	O
Metoprolol	B-Drug
,	O
Proanolol	B-Drug
,	O
Timolol	B-Drug
,	O
Carvediol	B-Drug
,	O
Nebivolol	B-Drug
,	O
Typ-1C-Antiarrhyhtmics	B-Drug
for	O
eg	O
Propafenon	B-Drug
,	O
Flecinid	B-Drug
)	O
(	O
except	B-Negation_cue
Donepezil	B-Drug
and	O
Galantamin	B-Drug
)	O
.	O

-	O
Simultaneous	O
treatment	B-Drug
with	O
drugs,	O
which	O
may	O
interfere	O
with	O
the	O
metabolization	O
of	O
Bupropion	B-Drug
(	O
eg	O
Carbamazepin	B-Drug
,	O
Phenytoin	B-Drug
,	O
Valproat	B-Drug
,	O
Ritonavir	B-Drug
,	O
Lopinavir	B-Drug
)	O
.	O

-	O
Diabetes	B-Condition
mellitus	I-Condition
which	O
is	O
therapeutically	O
poorly	O
regulated	O
and	O
treated	O
by	O
medication	O
.	O

-	O
Treatment	O
with	O
stimulants	B-Drug
and	O
appetite	B-Drug
depressants	I-Drug
.	O

-	O
Participation	O
in	O
other	O
clinical	O
trials	O
with	O
in	O
the	O
last	O
3	O
months	O
.	O

-	O
Suicidal	B-Condition
tendency	I-Condition
.	O

-	O
Known	O
lactose	B-Condition
intolerance	I-Condition
.	O

>>NCT00654563	O
Inclusion	O
Criteria	O
:	O
.	O

-	O
18	O
years	O
of	O
age	B-Observation
and	O
older	O
.	O

-	O
Capable	O
of	O
providing	O
informed	O
consent	O
and	O
having	O
a	O
legal	O
representative	O
able	O
to	O
consent	O
out	O
of	O
concern	O
for	O
future	O
competency	O
to	O
consent	O
(	O
as	O
defined	O
by	O
a	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Exam	I-Observation
score	I-Observation
of	O
<	O
24	O
)	O
or	O
capable	O
of	O
assent	O
but	O
incapable	O
of	O
giving	O
competent	O
informed	O
consent	O
but	O
with	O
a	O
legal	O
representative	O
able	O
to	O
provide	O
informed	O
consent	O
.	O

-	O
Subject	O
or	O
family	O
voices	O
concern	O
about	O
their	O
memory	O
or	O
possess	O
knowledge	O
that	O
they	O
have	O
been	O
diagnosed	O
with	O
a	O
memory	B-Condition
disorder	I-Condition
such	O
as	O
Age	B-Condition
Associated	I-Condition
memory	I-Condition
Impairment	I-Condition
Alzheimer's	B-Condition
disease	I-Condition
Parkinson	B-Condition
disease	I-Condition
Huntington	B-Condition
disease	I-Condition
vascular	B-Condition
dementia	I-Condition
mixed	B-Condition
dementia	I-Condition
dementia	B-Condition
with	I-Condition
Lewy	I-Condition
Bodies	I-Condition
or	O
frontotemporal	B-Condition
dementia	I-Condition
.	O

Exclusion	O
Criteria	O
:	O
.	O

-	O
Children	O
(	O
less	O
than	O
18	O
years	O
of	O
age	B-Observation
).	O

>>NCT02273895	O
Inclusion	O
Criteria:	O
.	O

Healthy	B-Condition
subjects:	O
.	O

-	O
Between	O
60	O
-	O
80	O
years	O
of	O
age	B-Observation
.	O

-	O
Volunteers	O
will	O
have	O
to	O
be	O
in	O
good	O
general	B-Condition
health	I-Condition
as	O
determined	O
by	O
standard	O
physical	O
examination	O
.	O

-	O
Normal	O
Electrocardiograph	B-Procedure_Device
(	I-Procedure_Device
ECG	I-Procedure_Device
)	I-Procedure_Device
.	O

MCI	B-Condition
subjects:	O
.	O

-	O
Diagnosed	O
with	O
MCI	B-Condition
at	O
the	O
Memory	O
Clinic	O
at	O
the	O
Landspitali	O
University	O
Hospital	O
using	O
F	O
06.7	O
according	O
to	O
International	B-Observation
Classification	I-Observation
of	I-Observation
Diseases	I-Observation
(	I-Observation
ICD	I-Observation
)	I-Observation
-	I-Observation
10	I-Observation
.	O

-	O
Between	O
60	O
-	O
80	O
years	O
of	O
age	B-Observation
.	O

-	O
Subjects	O
need	O
to	O
score	O
between	O
2	O
and	O
3	O
on	O
the	O
Global	B-Observation
Deterioration	I-Observation
Scale	I-Observation
(	I-Observation
GDS	I-Observation
)	I-Observation
.	O

-	O
Normal	O
ECG	B-Procedure_Device
.	O

Alzheimer's	O
patients:	O
.	O

-	O
Diagnosed	O
with	O
AD	B-Condition
according	O
to	O
ICD	B-Observation
-	I-Observation
10	I-Observation
in	O
Follow	O
up	O
at	O
the	O
Memory	O
Clinic	O
at	O
the	O
Landspitali	O
University	O
Hospital	O
.	O

-	O
Between	O
60	O
-	O
80	O
years	O
of	O
age	B-Observation
.	O

-	O
Subjects	O
need	O
to	O
score	O
between	O
3	O
-	O
5	O
on	O
the	O
GDS	B-Observation
.	O

-	O
Normal	O
ECG	B-Procedure_Device
.	O

-	O
Treated	O
with	O
Reminyl	B-Drug
for	O
the	O
Alzheimer	B-Condition
disease	I-Condition
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Smoking	B-Observation
or	O
any	O
other	O
use	O
of	O
tobacco	B-Drug
.	O

-	O
Taking	O
neuroleptics	B-Drug
or	O
benzodiazepines	B-Drug
(	O
allowed	O
to	O
take	O
oxazepam	B-Drug
ad	O
vesp	O
)	O
.	O

-	O
Neurological-,	B-Condition
cardiovascular-,	I-Condition
gastrointestinal-	I-Condition
or	I-Condition
genitourinary	I-Condition
disorders	I-Condition
of	O
medical	O
importance	O
.	O

-	O
Glaucoma	B-Condition
or	O
history	O
of	O
possibly	O
raised	B-Condition
intraocular	I-Condition
pressure	I-Condition
.	O

-	O
Impaired	B-Condition
liver-	I-Condition
or	I-Condition
kidney	I-Condition
function	I-Condition
.	O

-	O
Hypersensitivity	B-Condition
to	O
Scopolamine	B-Drug
or	O
any	O
component	O
in	O
the	O
formulation	O
.	O

-	O
Any	O
indication	O
of	O
drug,	B-Condition
alcohol	I-Condition
or	I-Condition
medicine	I-Condition
abuse	I-Condition
.	O

-	O
Participation	O
in	O
another	O
investigational	B-Procedure_Device
study	I-Procedure_Device
at	O
the	O
same	O
time	O
.	O

>>NCT02323334	O
Inclusion	O
Criteria:	O
.	O

-	O
For	O
Parts	O
A,	O
B	O
and	O
C,	O
are	O
overtly	O
healthy	B-Condition
males	O
or	O
females	O
(	O
nonchildbearing	B-Condition
potential	I-Condition
),	O
as	O
determined	O
by	O
medical	O
history	O
and	O
physical	O
examination	O
.	O

-	O
Have	O
a	O
body	B-Observation
mass	I-Observation
index	I-Observation
(	I-Observation
BMI	I-Observation
)	I-Observation
of	O
18	O
to	O
32	O
kilograms	O
per	O
square	O
meter	O
(	O
kg	O
/	O
m^2	O
)	O
.	O

-	O
For	O
Part	O
D,	O
present	O
with	O
Mild	B-Condition
Cognitive	I-Condition
Impairment	I-Condition
(	I-Condition
MCI	I-Condition
)	I-Condition
due	O
to	O
Alzheimer's	B-Condition
Disease	I-Condition
(	I-Condition
AD	I-Condition
)	I-Condition
or	O
mild	O
to	O
moderate	O
AD	B-Condition
.	O

-	O
Have	O
venous	O
access	O
sufficient	O
to	O
allow	O
for	O
blood	O
sampling	O
.	O

-	O
Are	O
reliable	O
and	O
willing	O
to	O
make	O
themselves	O
available	O
for	O
the	O
duration	O
of	O
the	O
study	O
and	O
are	O
willing	O
to	O
follow	O
study	O
procedures	O
and	O
research	O
unit	O
policies	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Taking	O
over-the-counter	B-Drug
or	I-Drug
prescription	I-Drug
medication	I-Drug
with	O
the	O
exception	B-Negation_cue
of	O
vitamins	B-Drug
or	O
minerals	B-Drug
.	O

-	O
Smoke	B-Condition
more	O
than	O
10	O
cigarettes	O
per	O
day	O
.	O

-	O
Are	O
unwilling	O
or	O
unable	O
to	O
refrain	O
from	O
eating	O
any	O
food	O
or	O
drinking	O
any	O
beverage	O
containing	O
grapefruit	O
or	O
grapefruit	O
juice	O
for	O
at	O
least	O
2	O
weeks	O
prior	O
to	O
first	O
dose	O
until	O
completion	O
of	O
the	O
study	O
.	O

>>NCT02147652	O
Inclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
dementia	B-Condition
with	O
possible	O
or	O
probable	O
cause	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
Vascular	B-Condition
disease	I-Condition
mixed	B-Condition
dementia	I-Condition
.	O

-	O
moderate	O
stage	O
of	O
dementia	B-Condition
,	O
a	O
score	O
of	O
<	O
20	O
on	O
MMSE	B-Observation
;	O
.	O

-	O
Age	B-Observation
60	O
to	O
90	O
inclusive;	O
.	O

-	O
Preserved	O
hearing	O
(	O
hearing	O
aids	O
are	O
permissible	O
);	O
.	O

-	O
Pittsburgh	B-Observation
agitation	I-Observation
scale	I-Observation
score	I-Observation
of	O
>=	O
3	O
on	O
at	O
least	O
on	O
3	O
occasions	O
over	O
a	O
period	O
of	O
5	O
days	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
auditory	B-Condition
deficits	I-Condition
requiring	O
correction	O
beyond	O
hearing	O
aids	O
.	O

-	O
no	O
substitute	O
decision	O
maker	O
available	O
to	O
indicate	O
music	O
preference	O
and	O
patient	O
unable	O
to	O
answer	O
for	O
themselves	O
.	O

-	O
recent	O
acute	O
event	B-Condition
eg	O
.	O

MI	B-Condition
,	O
fractures	B-Condition
or	O
major	O
infection	B-Condition
(	O
not	B-Negation_cue
UTI	B-Condition
)	O
.	O

-	O
patients	O
receiving	O
standing	O
orders	O
of	O
medication	O
for	O
personal	O
care	O
.	O

>>NCT00099242	O
Inclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
type	I-Condition
.	O

-	O
Males	O
and	O
females	O
who	O
are	O
surgically	B-Condition
sterile	I-Condition
or	O
one	O
year	O
postmenopausal	B-Condition
.	O

-	O
A	O
primary	O
caregiver	O
willing	O
to	O
accept	O
responsibility	O
for	O
supervising	O
the	O
treatment	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Any	O
condition	B-Condition
(	O
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
)	O
that	O
could	O
explain	O
patient's	O
dementia	B-Condition
.	O

-	O
An	O
advanced,	O
severe	O
or	O
unstable	O
disease	B-Condition
that	O
may	O
put	O
the	O
patient	O
at	O
special	O
risk	O
.	O

-	O
Current	O
diagnosis	O
of	O
active,	O
uncontrolled	O
seizure	B-Condition
disorder	I-Condition
or	O
unstable	O
cardiovascular	B-Condition
disease	I-Condition
.	O

>>NCT00017940	O
-	O
Neurologist	O
certified	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Early	O
stage	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
(	O
generally	O
within	O
three	O
years	O
of	O
onset	O
)	O
.	O

-	O
Normal	O
speaking	O
ability	O
and	O
normal	O
ability	O
to	O
understand	O
.	O

-	O
Ability	O
to	O
understand	O
the	O
potential	O
risks	O
of	O
participation	O
in	O
this	O
study	O
.	O

-	O
Willing	O
to	O
visit	O
the	O
San	O
Diego	O
area	O
and	O
be	O
available	O
for	O
many	O
visits	O
in	O
the	O
first	O
year	O
.	O

-	O
Willing	O
to	O
discontinue	B-Procedure_Device
use	O
of	O
drugs	O
Cognex	B-Drug
,	O
Aricept	B-Drug
,	O
Exelon	B-Drug
or	O
Reminyl	B-Drug
for	O
the	O
first	O
18	O
months	O
of	O
the	O
trial	O
.	O

>>NCT01515982	O
Inclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
Alzheimer	B-Condition
Disease	I-Condition
according	O
to	O
the	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke-	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINCDS-ADRDA	I-Observation
)	I-Observation
and	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke-	I-Observation
Association	I-Observation
Internationale	I-Observation
pour	I-Observation
la	I-Observation
Recherche	I-Observation
et	I-Observation
l'	I-Observation
Enseignement	I-Observation
en	I-Observation
Neurosciences	I-Observation
(	I-Observation
NINDS-AIREN	I-Observation
)	I-Observation
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
>=	O
15	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
score	I-Observation
1	O
.	O

-	O
Regular	O
use	O
of	O
anticholinesterase	B-Drug
drugs	I-Drug
for	O
at	O
least	O
six	O
months	O
.	O

-	O
Cardiologist's	O
authorization	O
.	O

-	O
At	O
least	O
six	O
months	O
without	B-Negation_cue
practicing	O
physical	B-Procedure_Device
exercises	I-Procedure_Device
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Clinical	B-Condition
depression	I-Condition
or	O
Cornell	B-Observation
Scale	I-Observation
>=	O
7	O
.	O

-	O
Other	O
types	O
of	O
dementia	B-Condition
.	O

-	O
Physical	O
limitation	O
due	O
to	O
other	O
pathologies	O
or	O
associated	O
neurological	O
disease	O
.	O

-	O
Severe	O
or	O
uncontrolled	O
arterial	B-Condition
hypertension	I-Condition
.	O

-	O
Marked	O
visual	B-Condition
and	I-Condition
/	I-Condition
or	I-Condition
auditory	I-Condition
deficit	I-Condition
.	O

-	O
Incapacity	O
to	O
perform	O
physical	B-Procedure_Device
exercise	I-Procedure_Device
due	O
to	O
neurological	B-Condition
or	I-Condition
neuromuscular	I-Condition
impairments	I-Condition
.	O

-	O
Illiteracy	O
.	O

-	O
Less	O
than	O
six	O
months	O
of	O
treatment	B-Drug
at	O
the	O
outpatient	O
unit	O
.	O

>>NCT02551809	O
Inclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
mild	O
Alzheimer's	B-Condition
Disease	I-Condition
.	O

-	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
scores	I-Observation
between	O
20	O
and	O
26	O
(	O
inclusive	O
)	O
.	O

-	O
Clinical	B-Observation
dementia	I-Observation
rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
scores	I-Observation
of	O
0.5	O
or	O
1	O
.	O

-	O
Other	O
inclusion	O
criteria	O
apply	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Clinically	O
significant	O
neurological	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Major	O
psychiatric	B-Condition
disorder	I-Condition
.	O

-	O
Severe	O
systemic	B-Condition
disease	I-Condition
.	O

-	O
Serious	O
adverse	B-Condition
reactions	I-Condition
to	O
any	O
vaccine	B-Drug
.	O

-	O
Other	O
exclusion	O
criteria	O
apply	O
.	O

>>NCT00291161	O
Inclusion	O
Criteria:	O
.	O

-	O
Dementia	B-Condition
Diagnosis	O
.	O

-	O
veteran	O
.	O

-	O
reside	O
outside	O
of	O
a	O
long-term	O
care	O
facility	O
.	O

-	O
live	O
within	O
local	O
Alzheimer	O
Association	O
chapter	O
service	O
of	O
Houston,	O
Oklahoma	O
City,	O
Boston	O
or	O
Providence	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Live	O
in	O
long-term	O
care	O
.	O

>>NCT02681172	O
Inclusion	O
Criteria:	O
.	O

-	O
Patients	O
being	O
evaluated	O
for	O
Alzheimer	B-Condition
disease	I-Condition
and	O
related	O
dementias	B-Condition
according	O
to	O
the	O
HAS	O
recommendations	O
(	O
atypical	B-Condition
dementia	I-Condition
early	O
onset	O
and	O
rapid	O
progressive	O
dementia	B-Condition
)	O
.	O

-	O
Patients	O
who	O
have	O
previously	O
been	O
evaluated	O
for	O
AD	B-Condition
and	O
related	O
dementias	B-Condition
to	O
whom	O
a	O
CSF	B-Procedure_Device
examination	I-Procedure_Device
was	O
recommended	O
in	O
the	O
last	O
12	O
months	O
but	O
lumbar	B-Procedure_Device
puncture	I-Procedure_Device
was	O
contraindicated	B-Condition
or	O
refused	O
or	O
CSF	B-Observation
results	I-Observation
were	O
ambiguous,	O
or	O
.	O

-	O
Patients	O
currently	O
being	O
evaluated	O
for	O
AD	B-Condition
and	O
related	O
dementias	B-Condition
to	O
whom	O
a	O
CSF	B-Procedure_Device
examination	I-Procedure_Device
is	O
recommended	O
but	O
lumbar	B-Procedure_Device
puncture	I-Procedure_Device
is	O
contraindicated	B-Condition
or	O
refused	O
.	O

-	O
Patients	O
have	O
a	O
study	O
partner	O
who	O
is	O
willing	O
and	O
able	O
to	O
accompany	O
him	O
/	O
her	O
to	O
all	O
clinic	O
visits	O
for	O
the	O
duration	O
of	O
the	O
protocol	O
.	O

-	O
Patients	O
able	O
to	O
complete	O
all	O
clinical	O
visits	O
according	O
to	O
the	O
protocol	O
.	O

-	O
Patients	O
able	O
to	O
tolerate	O
a	O
20	O
-minute	O
FBB	B-Procedure_Device
PET	I-Procedure_Device
scan	I-Procedure_Device
.	O

-	O
Patient	O
or	O
legal	O
representative	O
to	O
provide	O
informed	O
consent	O
for	O
study	O
participation,	O
visits	O
and	O
data	O
source	O
verification	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
The	O
subject	O
had	O
a	O
previous	O
beta	B-Procedure_Device
amyloid	I-Procedure_Device
imaging	I-Procedure_Device
scan	I-Procedure_Device
.	O

-	O
Any	O
significant	O
systemic	B-Condition
illness	I-Condition
or	O
unstable	O
medical	B-Condition
condition	I-Condition
which	O
could	O
lead	O
to	O
difficulty	O
complying	O
with	O
the	O
protocol	O
.	O

-	O
Is	O
currently	O
receiving	O
any	O
investigational	B-Drug
pharmaceutical	I-Drug
product	I-Drug
or	O
has	O
participated	O
in	O
a	O
clinical	O
trial	O
with	O
an	O
investigational	B-Drug
pharmaceutical	I-Drug
product	I-Drug
within	O
30	O
days	O
prior	O
to	O
screening	O
and	O
/	O
or	O
was	O
administered	O
a	O
radiopharmaceutical	B-Drug
within	O
10	O
radioactive	O
half-lives	O
prior	O
to	O
study	O
drug	O
administration	O
in	O
this	O
study	O
.	O

-	O
For	O
females	O
of	O
childbearing	O
age,	O
a	O
positive	O
pregnancy	B-Observation
test	I-Observation
.	O

>>NCT02664584	O
Inclusion	O
Criteria:	O
.	O

-	O
>	O
60	O
years	O
of	O
age	B-Observation
.	O

Exclusion	O
Criteria:	O
.	O

-	O
<	O
60	O
years	O
of	O
age	B-Observation
.	O

-	O
Born	O
outside	O
the	O
island	O
of	O
Ireland	O
.	O

-	O
Severe	O
dementia	B-Condition
.	O

>>NCT00438724	O
Inclusion	O
Criteria:	O
Couples,	O
in	O
which	O
one	O
partner	O
has	O
been	O
diagnosed	O
with	O
AD	B-Condition
and	O
is	O
in	O
the	O
mild	O
stage	O
of	O
the	O
disease	B-Condition
Ages	B-Observation
21	O
to	O
90	O
Exclusion	O
Criteria:	O
Severe	O
psychological	B-Condition
or	I-Condition
physical	I-Condition
illness	I-Condition
Unwillingness	O
to	O
participate	O
in	O
all	O
aspects	O
of	O
the	O
study	O
>>NCT02500784	O
Inclusion	O
Criteria:	O
Males	O
and	O
females	O
between	O
the	O
ages	B-Observation
of	O
50-85,	O
Mild-to-moderate	O
AD	B-Condition
NINCDS	B-Observation
/	I-Observation
ADRDA	I-Observation
criteria	I-Observation
for	O
probable	O
AD	B-Condition
will	O
be	O
used	O
to	O
establish	O
AD	O
diagnosis)	O
MMSE	B-Observation
16-26	O
Exclusion	O
Criteria:	O
Non-AD	B-Condition
dementia	I-Condition
or	O
significant	O
neurological	B-Condition
disease	I-Condition
such	O
as	O
Parkinson's	B-Condition
disease	I-Condition
stroke	B-Condition
,	O
brain	B-Condition
tumor	I-Condition
multiple	B-Condition
sclerosis	I-Condition
seizure	B-Condition
disorder	I-Condition
focal	B-Condition
brain	I-Condition
lesion	I-Condition
or	O
head	B-Condition
injury	I-Condition
with	I-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition
Hypothyroidism	B-Condition
,	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
New	B-Observation
York	I-Observation
Heart	I-Observation
Association	I-Observation
Class	O
III	O
or	O
IV),	O
significant	O
extrapyramidal	B-Condition
symptoms	I-Condition
on	O
neurological	B-Procedure_Device
examination	I-Procedure_Device
serum	B-Observation
creatinine	I-Observation
>1.3	O
mg	O
/	O
dl,	O
significant	O
arrhythmias	B-Condition
or	O
conduction	B-Condition
defect	I-Condition
abnormalities	I-Condition
on	O
ECG	B-Procedure_Device
,	O
Use	O
of	O
another	O
beta2	B-Drug
adrenergic	I-Drug
drug	I-Drug
within	O
the	O
last	O
2	O
months	O
Residence	O
in	O
a	O
long-term	O
care	O
facility	O
Evidence	O
of	O
any	O
significant	O
clinical	B-Condition
disorder	I-Condition
or	O
laboratory	O
finding	O
that	O
renders	O
the	O
person	O
unsuitable	B-Negation_cue
for	O
receiving	O
an	O
investigational	B-Drug
new	I-Drug
drug	I-Drug
Known	O
hypersensitivity	B-Condition
or	O
prior	O
exposure	O
to	O
formoterol	B-Drug
Active	O
asthma	B-Condition
or	O
family	O
history	O
of	O
asthma	B-Condition
>>NCT01231295	O
Inclusion	O
Criteria	O
for	O
the	O
group	O
with	O
memory	B-Condition
problems	I-Condition
patient	O
consulting	O
for	O
memory	B-Condition
problems	I-Condition
caucasian	O
memory	B-Condition
complaint	I-Condition
is	O
validated	O
by	O
a	O
clinical	B-Observation
evaluation	I-Observation
cognitive	B-Observation
performance	I-Observation
is	O
sufficiently	O
well	O
preserved	O
so	O
that	O
a	O
diagnostic	O
of	O
dementia	B-Condition
cannot	B-Negation_cue
be	O
made	O
(according	O
to	O
the	O
DSM-IV-R	B-Observation
and	I-Observation
NINCDS-ADRDA	I-Observation
criteria	I-Observation
at	O
the	O
time	O
of	O
inclusion	O
the	O
patient	O
speaks	O
French	O
presence	O
of	O
an	O
informant	O
accepts	O
to	O
sign	O
consent	O
Inclusion	O
Criteria	O
for	O
the	O
group	O
without	O
memory	O
problems	O
(reference	O
population):	O
at	O
least	O
four	O
years	O
of	O
formal	O
education	O
patient	O
consulting	O
for	O
memory	B-Condition
problems	I-Condition
memory	B-Condition
problem	I-Condition
reported	O
by	O
the	O
patient	O
is	O
not	O
validated	O
by	O
the	O
consultation,	O
nor	O
by	O
the	O
battery	O
of	O
tests	O
specified	O
during	O
screening	O
presence	O
of	O
an	O
informant	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
>	O
0	O
accepts	O
to	O
sign	O
consent	O
Exclusion	O
Criteria:	O
Instrumental	B-Observation
Activities	I-Observation
of	I-Observation
Daily	I-Observation
Living	I-Observation
(	I-Observation
IADL	I-Observation
)	I-Observation
at	O
least	O
two	O
items	O
1	O
Anticholinesterasic	B-Drug
treatments	I-Drug
and	O
/	O
or	O
memantine	B-Drug
before	O
study	O
inclusion	O
major	B-Condition
depressive	I-Condition
syndrome	I-Condition
according	O
to	O
the	O
Global	B-Observation
Depressive	I-Observation
Scale	I-Observation
Known	O
neurodegenerative	B-Condition
disease	I-Condition
or	O
general	B-Condition
disease	I-Condition
or	O
major	O
physical	B-Condition
problems	I-Condition
that	O
could	O
interfere	O
with	O
cognitive	O
functioning	O
and	O
testing	O
Pathology	O
that	O
might	O
lead	O
to	O
death	O
in	O
the	O
short	O
term	O
(evolving	O
cancer	B-Condition
,	O
non	O
stable	O
cardiopathy	B-Condition
,	O
hepatic,	B-Condition
renal	I-Condition
or	I-Condition
respiratory	I-Condition
insufficiency	I-Condition
contra-indications	B-Condition
for	O
MRI	B-Procedure_Device
,	O
PET	B-Procedure_Device
or	O
SPECT	B-Procedure_Device
scans	I-Procedure_Device
not	O
affiliated	O
with	O
a	O
social	O
security	O
regimen	O
>>NCT01743534	O
Inclusion	O
Criteria:	O
Men	O
and	O
women	O
of	O
more	O
than	O
75	O
years	O
Patients	O
suffering	O
from	O
insanities	B-Condition
of	I-Condition
type	I-Condition
Alzheimer	I-Condition
Severe	O
stage	O
of	O
the	O
disease	B-Condition
Residents	O
in	O
a	O
Hospital	O
for	O
dependent	O
old	O
persons,	O
with	O
its	O
own	O
dining	O
room	O
Persons	O
accommodated	O
in	O
the	O
clinical	O
service	O
for	O
more	O
than	O
30	O
days	O
EBS	B-Observation
score	I-Observation
<	O
16	O
Information	O
in	O
the	O
participation	O
of	O
the	O
resident,	O
their	O
legal	O
representative	O
and	O
their	O
family	O
Patients	O
affiliated	O
to	O
the	O
Social	O
Security	O
Filled	O
and	O
signed	O
form	O
of	O
participation	O
Patient	O
having	O
a	O
appointed	O
reliable	O
person	O
or	O
one	O
helping	O
known	O
whose	O
references	O
are	O
indicated	O
in	O
the	O
patient	O
file	O
Exclusion	O
Criteria:	O
Patients	O
presenting	O
pathologies	O
being	O
able	O
to	O
interfere	O
with	O
the	O
evaluation	O
Participating	O
patients	O
in	O
another	O
research	O
for	O
type	O
clinical	O
trial	O
Undernutrition	B-Condition
patients	O
Patients	O
presenting	O
oral	B-Condition
hurts	I-Condition
Protected	O
patient	O
or	O
having	O
nobody	O
helping	O
>>NCT01524887	O
Inclusion	O
Criteria:	O
Males	O
or	O
females	O
of	O
age	B-Observation
50	O
to	O
89	O
years	O
inclusive	O
at	O
the	O
time	O
of	O
screening	O
Written	O
informed	O
consent	O
obtained	O
from	O
either	O
the	O
subject	O
or	O
the	O
subject's	O
legally	O
authorized	O
representative	O
prior	O
to	O
any	O
study-related	O
procedures	O
Written	O
informed	O
consent	O
obtained	O
from	O
an	O
able	O
and	O
competent	O
caregiver	O
who	O
is	O
willing	O
to	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
protocol	O
pertaining	O
to	O
him	O
/	O
her,	O
including	O
facilitating	O
the	O
subject's	O
participation	O
in	O
the	O
study	O
Diagnosis	O
of	O
Probable	O
Alzheimers	B-Condition
Disease	I-Condition
(	I-Condition
AD	I-Condition
)	I-Condition
according	O
to	O
NINCDS-ADRDA*	B-Observation
1984	I-Observation
criteria	I-Observation
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Disorders	O
and	O
Stroke	O
Alzheimer's	O
Disease	O
and	O
Related	O
Disorders	O
Association)	O
Dementia	B-Condition
of	O
mild	O
to	O
moderate	O
severity	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
MMSE	I-Observation
16-26	O
inclusive	O
at	O
the	O
time	O
of	O
screening)	O
Neuroimaging	B-Procedure_Device
computed	B-Procedure_Device
tomography	I-Procedure_Device
CT	I-Procedure_Device
or	O
MRI	B-Procedure_Device
)	O
performed	O
after	O
symptom	O
onset	O
consistent	O
with	O
AD	B-Condition
diagnosis	O
Willingness	O
to	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
protocol	O
and	O
ability	O
to	O
comply	O
with	O
testing	O
and	O
infusion	O
regimen,	O
including	O
adequate	O
corrected	O
visual	O
acuity	O
and	O
hearing	O
ability	O
For	O
at	O
least	O
12	O
weeks	O
prior	O
to	O
screening,	O
on	O
stable	O
doses	B-Procedure_Device
of	O
AD	B-Drug
medication(	I-Drug
s	I-Drug
)	I-Drug
approved	O
by	O
local	O
regulatory	O
authorities	O
Subjects	O
must	O
not	B-Negation_cue
be	O
on	O
two	O
acetylcholinesterase	B-Drug
inhibitors	I-Drug
concurrently	O
Venous	O
access	O
for	O
repeated	O
infusion	B-Procedure_Device
and	O
phlebotomy	B-Procedure_Device
If	O
receiving	O
psychoactive	B-Drug
medications	I-Drug
(eg	O
,	O
antidepressants	B-Drug
other	B-Negation_cue
than	I-Negation_cue
monoamine	B-Drug
oxidase	I-Drug
inhibitors	I-Drug
MAOIs	I-Drug
and	O
most	O
tricyclics	B-Drug
,	O
antipsychotics	B-Drug
,	O
anxiolytics	B-Drug
,	O
anticonvulsants	B-Drug
,	O
mood	B-Drug
stabilizers	I-Drug
etc	O
must	O
be	O
on	O
stable	O
doses	B-Procedure_Device
for	O
at	O
least	O
6	O
weeks	O
prior	O
to	O
screening	O
For	O
women	O
of	O
childbearing	B-Condition
potential	I-Condition
the	O
subject	O
must	O
have	O
a	O
negative	O
pregnancy	B-Observation
test	I-Observation
at	O
screening	O
and	O
must	O
agree	O
to	O
employ	O
adequate	O
contraceptive	O
measures	O
(eg	O
,	O
birth	O
control	O
pills	O
/	O
patches,	O
intrauterine	O
device,	O
or	O
diaphragm	O
or	O
condom	O
for	O
male	O
partner]	O
with	O
spermicidal	O
jelly	O
or	O
foam)	O
throughout	O
the	O
course	O
of	O
the	O
study	O
For	O
subjects	O
with	O
a	O
coronary	B-Procedure_Device
artery	I-Procedure_Device
stent	I-Procedure_Device
the	O
subject	O
must	O
receive	O
documented	O
medical	O
clearance	O
from	O
an	O
interventional	O
cardiologist	O
stating	O
that	O
the	O
subject	O
is	O
not	B-Negation_cue
at	O
increased	O
risk	B-Observation
for	O
stent	B-Condition
occlusion	I-Condition
with	O
immunoglobulin	B-Drug
treatment	I-Drug
For	O
subjects	O
with	O
an	O
endovascular	B-Procedure_Device
stent	I-Procedure_Device
the	O
subject	O
must	O
receive	O
documented	O
medical	O
clearance	O
from	O
a	O
vascular	O
surgeon	O
stating	O
that	O
the	O
subject	O
is	O
not	B-Negation_cue
at	O
increased	O
risk	B-Observation
for	O
thromboembolic	B-Condition
events	I-Condition
with	O
immunoglobulin	B-Drug
treatment	I-Drug
Main	O
Exclusion	O
Criteria:	O
Possible	O
AD	B-Condition
by	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
or	O
non-Alzheimer	B-Condition
dementia	I-Condition
(eg	O
vascular	B-Condition
dementia	I-Condition
dementia	B-Condition
with	I-Condition
Lewy	I-Condition
bodies	I-Condition
frontotemporal	B-Condition
dementia	I-Condition
or	O
dementia	B-Condition
arising	I-Condition
from	I-Condition
other	I-Condition
diseases	I-Condition
or	O
conditions	B-Condition
such	O
as	O
Parkinson's	B-Condition
disease	I-Condition
vitamin	B-Condition
B12	I-Condition
deficiency	I-Condition
thyroid	B-Condition
abnormalities	I-Condition
Current	O
residence	O
in	O
a	O
skilled	O
nursing	O
facility	O
Contraindication	B-Condition
to	O
undergoing	O
MRI	B-Procedure_Device
(eg	O
pacemaker	B-Procedure_Device
with	O
the	O
exception	B-Negation_cue
of	O
an	O
MRI-compatible	B-Procedure_Device
pacemaker	I-Procedure_Device
severe	O
claustrophobia	B-Condition
,	O
ferromagnetic	B-Procedure_Device
implants	I-Procedure_Device
such	O
as	O
a	O
metal	B-Procedure_Device
plate	I-Procedure_Device
Clinically	O
significant	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
(eg	O
New	B-Observation
York	I-Observation
Heart	I-Observation
Association	I-Observation
NYHA	I-Observation
Class	O
III	O
/	O
IV	O
symptoms	O
or	O
untreated	O
Class	O
II)	O
Current	O
atrial	B-Condition
fibrillation	I-Condition
of	I-Condition
unstable	I-Condition
angina	I-Condition
angina	B-Condition
at	I-Condition
rest	I-Condition
or	O
history	O
of	O
myocardial	B-Condition
infarction	I-Condition
within	O
the	O
12	O
months	O
prior	O
to	O
screening	O
Uncontrolled	O
hypertension	B-Condition
defined	O
as	O
systolic	B-Observation
blood	I-Observation
pressure	I-Observation
160	O
mm	O
Hg	O
and	O
/	O
or	O
diastolic	B-Observation
100	O
mm	O
Hg	O
confirmed	O
upon	O
repeated	O
measures	O
History	O
of	O
thrombosis	B-Condition
and	O
/	O
or	O
thromboembolic	B-Condition
disease	I-Condition
(central	O
or	O
peripheral)	O
within	O
the	O
12	O
months	O
prior	O
to	O
screening	O
Known	O
history	O
of	O
procoagulant	B-Condition
abnormalities	I-Condition
(eg	O
factor	B-Condition
V	I-Condition
Leiden	I-Condition
antiphospholipid	B-Condition
syndrome	I-Condition
protein	B-Condition
S	I-Condition
/	I-Condition
protein	I-Condition
C	I-Condition
deficiency	I-Condition
AT	B-Condition
III	I-Condition
deficiency	I-Condition
History	O
of	O
intracerebral	B-Condition
hemorrhage	I-Condition
within	O
the	O
5	O
years	O
prior	O
to	O
screening	O
Evidence	O
on	O
MRI	B-Procedure_Device
of:	O
greater	O
than	O
4	O
microhemorrhages	B-Condition
(regardless	O
of	O
their	O
anatomical	O
location	O
or	O
diagnostic	O
characterization	O
as	O
possible"	O
or	O
definite"),	O
a	O
single	O
area	O
of	O
superficial	O
siderosis	B-Condition
,	O
vasogenic	O
edema	B-Condition
,	O
a	O
macrohemorrhage	B-Condition
,	O
major	O
stroke	B-Condition
,	O
prominent	O
white	B-Condition
matter	I-Condition
disease	I-Condition
with	O
a	O
rating	O
score	O
of	O
3	O
on	O
the	O
age-related	B-Observation
white	I-Observation
matter	I-Observation
changes	I-Observation
(	I-Observation
ARWMC	I-Observation
)	I-Observation
scale	I-Observation
from	O
the	O
European	O
Task	O
Force	O
on	O
ARWMC,	O
or	O
multiple	B-Condition
lacunae	I-Condition
(defined	O
as	O
more	O
than	O
2	O
lacunae	B-Observation
that	O
are	O
greater	O
than	O
0.5	O
mm	O
in	O
size	B-Observation
)	O
Head	B-Condition
trauma	I-Condition
with	I-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition
contusion	B-Condition
,	O
or	O
open	B-Condition
head	I-Condition
injury	I-Condition
within	O
the	O
12	O
months	O
prior	O
to	O
screening	O
Uncontrolled	O
seizure	B-Condition
disorder	I-Condition
as	O
defined	O
by	O
two	O
or	O
more	O
breakthrough	O
seizures	B-Condition
per	O
year	O
despite	O
adequate	O
antiepileptic	B-Drug
drug	I-Drug
(	I-Drug
AED	I-Drug
)	I-Drug
treatment	O
Modified	B-Observation
Hachinski	I-Observation
score	I-Observation
4	O
at	O
time	O
of	O
screening	O
Subjects	O
with	O
active	O
malignancy	B-Condition
or	O
history	O
of	O
malignancy	B-Condition
within	O
5	O
years	O
prior	O
to	O
screening	O
with	O
the	O
exception	B-Negation_cue
of	O
the	O
following:	O
adequately	O
treated	O
basal	B-Condition
cell	I-Condition
or	I-Condition
squamous	I-Condition
cell	I-Condition
carcinoma	I-Condition
of	I-Condition
the	I-Condition
skin	I-Condition
carcinoma	B-Condition
in	I-Condition
situ	I-Condition
of	I-Condition
the	I-Condition
cervix	I-Condition
and	O
stable	O
prostate	B-Condition
cancer	I-Condition
not	O
requiring	O
treatment	O
Active	O
autoimmune	B-Condition
or	I-Condition
neuro-immunologic	I-Condition
disorder	I-Condition
Uncontrolled	O
major	B-Condition
depression	I-Condition
psychosis	B-Condition
,	O
or	O
other	O
major	O
psychiatric	B-Condition
disorder	I-Condition
Poorly	O
controlled	O
diabetes	B-Condition
,	O
defined	O
as	O
glycosylated	B-Observation
(	I-Observation
or	I-Observation
glycated	I-Observation
)	I-Observation
hemoglobin	I-Observation
(HbA1c)	I-Observation
>	O
6.5%	O
at	O
screening	O
Creatinine	B-Observation
clearance	I-Observation
50%	O
of	O
normal	O
adjusted	O
for	O
age	O
and	O
gender,	O
as	O
calculated	O
according	O
to	O
the	O
Cockcroft-Gault	O
formula,	O
at	O
the	O
time	O
of	O
screening	O
Known	O
history	O
of	O
untreated	O
vitamin	B-Condition
B12	I-Condition
deficiency	I-Condition
within	O
6	O
months	O
prior	O
to	O
screening,	O
or	O
clinically	O
significant	O
abnormally	O
low	O
vitamin	B-Observation
B12	I-Observation
at	O
the	O
time	O
of	O
screening	O
Abnormal	O
clinical	B-Observation
chemistry	I-Observation
panel	I-Observation
or	O
hematology	O
panel	O
meeting	O
any	O
one	O
of	O
the	O
following	O
criteria:	O
Serum	B-Observation
alanine	I-Observation
aminotransferase	I-Observation
(	I-Observation
ALT	I-Observation
)	I-Observation
>	O
2.5	O
x	O
upper	O
limit	O
of	O
normal	O
(ULN)	O
Clinically	O
significant	O
anemia	B-Condition
that	O
precludes	O
repeated	O
blood	O
sampling	O
or	O
hemoglobin	B-Observation
(	I-Observation
Hgb	I-Observation
)	I-Observation
<	O
10.0	O
g	O
/	O
dL	O
Absolute	B-Observation
neutrophil	I-Observation
count	I-Observation
(	I-Observation
ANC	I-Observation
)	I-Observation
<	O
1000	O
cells	O
/	O
L	O
Known	O
coagulopathy	B-Condition
or	O
platelet	B-Observation
counts	I-Observation
<	O
100,000	O
cells	O
/	O
L	O
Total	B-Observation
serum	I-Observation
protein	I-Observation
>	O
9	O
g	O
/	O
dL	O
Known	O
history	O
of	O
or	O
positive	O
serology	B-Observation
at	O
screening	O
for	O
one	O
or	O
more	O
of	O
the	O
following:	O
hepatitis	B-Observation
B	I-Observation
surface	I-Observation
antigen	I-Observation
(	I-Observation
HBsAg	I-Observation
)	I-Observation
hepatitis	B-Observation
C	I-Observation
virus	I-Observation
(	I-Observation
HCV	I-Observation
)	I-Observation
antibody	I-Observation
or	O
human	B-Observation
immunodeficiency	I-Observation
virus	I-Observation
(	I-Observation
HIV	I-Observation
)	I-Observation
type	I-Observation
1	I-Observation
/	I-Observation
2	I-Observation
antibody	I-Observation
Immunoglobulin	B-Condition
A	I-Condition
(	I-Condition
IgA	I-Condition
)	I-Condition
deficiency	I-Condition
8	O
mg	O
/	O
dL)	O
Known	O
history	O
of	O
hypersensitivity	B-Condition
following	O
infusions	O
of	O
human	B-Drug
blood	I-Drug
or	O
blood	B-Drug
components	I-Drug
(eg	O
human	B-Drug
immunoglobulins	I-Drug
or	O
human	B-Drug
albumin	I-Drug
Currently	O
receiving	O
or	O
has	O
received:	O
anti-CD20	B-Drug
therapy	I-Drug
within	O
12	O
months	O
prior	O
to	O
screening,	O
or	O
other	O
immunomodulatory	B-Drug
therapies	I-Drug
(eg	O
m	O
anti-TNF	B-Drug
,	O
anti-IL-1	B-Drug
,	O
interferon	B-Drug
)	O
within	O
12	O
weeks	O
prior	O
to	O
screening	O
The	O
following	O
exceptions	O
are	O
allowed:	O
non-systemic	B-Drug
corticosteroids	I-Drug
(eg	O
topical,	B-Drug
ophthalmic	I-Drug
or	I-Drug
inhaled	I-Drug
glucocorticoids	I-Drug
and	O
low	O
dose	B-Procedure_Device
systemic	B-Drug
corticosteroids	I-Drug
prednisone	B-Drug
10	O
mg	O
/	O
day	O
or	O
its	O
equivalent)	O
Currently	O
receiving	O
or	O
has	O
received	O
intravenous	O
or	O
subcutaneous	O
immunoglobulin	B-Drug
treatment	I-Drug
within	O
the	O
2	O
years	O
prior	O
to	O
screening,	O
or	O
has	O
received	O
immunoglobulin	B-Drug
in	O
Baxter	O
Protocol	O
160701	O
Currently	O
receiving	O
or	O
has	O
received	O
at	O
any	O
time	O
active	O
immunization	B-Drug
aimed	O
at	O
modulating	O
AD	B-Condition
progression	O
Currently	O
receiving	O
or	O
has	O
received	O
within	O
12	O
months	O
prior	O
to	O
screening	O
any	O
investigational	B-Procedure_Device
device	I-Procedure_Device
drug	B-Drug
or	O
biologic	B-Drug
(eg	O
passive	B-Drug
immunotherapies	I-Drug
with	O
monoclonal	B-Drug
or	I-Drug
polyclonal	I-Drug
antibodies	I-Drug
aimed	O
at	O
modulating	O
AD	B-Condition
progression	O
Subject	O
has	O
been	O
exposed	O
to	O
an	O
investigational	B-Drug
product	I-Drug
(	I-Drug
IP	I-Drug
)	I-Drug
or	O
investigational	B-Procedure_Device
device	I-Procedure_Device
within	O
12	O
weeks	O
prior	O
to	O
screening	O
or	O
is	O
scheduled	O
to	O
participate	O
in	O
another	O
clinical	O
study	O
involving	O
an	O
IP	B-Drug
or	O
investigational	B-Procedure_Device
device	I-Procedure_Device
during	O
the	O
course	O
of	O
this	O
study	O
Subject	O
is	O
a	O
family	O
member	O
or	O
employee	O
of	O
the	O
investigator	O
The	O
subject	O
is	O
nursing	O
or	O
intends	O
to	O
begin	O
nursing	O
during	O
the	O
course	O
of	O
the	O
study	O
Any	O
disorder	B-Condition
or	O
disease	B-Condition
,	O
or	O
clinically	O
significant	O
abnormality	B-Condition
on	O
laboratory	B-Observation
or	O
other	O
clinical	B-Observation
test(	I-Observation
s	I-Observation
)	I-Observation
(eg	O
blood	B-Observation
tests	I-Observation
urine	B-Observation
tests	I-Observation
electrocardiogram	B-Procedure_Device
,	O
chest	B-Procedure_Device
x-ray	I-Procedure_Device
that	O
in	O
medical	O
judgment	O
may	O
impede	O
the	O
subject's	O
participation	O
in	O
the	O
study,	O
pose	O
increased	O
risk	O
to	O
the	O
subject,	O
or	O
confound	O
the	O
results	O
of	O
the	O
study	O
Currently	O
receiving	O
anti-coagulant	B-Drug
agent	I-Drug
and	O
/	O
or	O
anti-platelet	B-Drug
agent	I-Drug
other	B-Negation_cue
than	I-Negation_cue
acetylsalicylic	B-Drug
acid	I-Drug
(aka	O
.	O

aspirin	B-Drug
)	O
>>NCT02167256	O
Inclusion	O
Criteria	O
1	O
.	O

NIA-Alzheimer's	B-Observation
Association	I-Observation
core	I-Observation
clinical	I-Observation
criteria	I-Observation
for	O
probable	O
AD	B-Condition
2	O
.	O

18F-Florbetapir	O
scan	O
with	O
evidence	O
of	O
elevated	O
A	O
(based	O
on	O
central	O
review)	O
3	O
.	O

Age	B-Observation
between	O
55-85	O
(inclusive)	O
4	O
.	O

MMSE	B-Observation
score	I-Observation
between	O
18	O
and	O
26	O
(inclusive)	O
5	O
.	O

Stability	O
of	O
permitted	B-Condition
medications	I-Condition
for	O
4	O
weeks	O
In	O
particular:	O
Stable	O
doses	B-Procedure_Device
of	O
antidepressants	B-Drug
lacking	O
significant	O
anticholinergic	B-Condition
side	I-Condition
effects	I-Condition
(if	O
they	O
are	O
not	O
currently	O
depressed	O
and	O
do	O
not	O
have	O
a	O
history	O
of	O
major	O
depression	O
within	O
the	O
past	O
1	O
year)	O
Cholinesterase	B-Drug
inhibitors	I-Drug
and	O
memantine	B-Drug
are	O
allowable	O
if	O
stable	O
for	O
12	O
weeks	O
prior	O
to	O
screen	O
6	O
.	O

Geriatric	B-Observation
Depression	I-Observation
Scale	I-Observation
less	O
than	O
6	O
Note:	O
a	O
score	O
6	O
on	O
this	O
screening	O
scale	O
may	O
be	O
permissible,	O
if	O
the	O
subject	O
is	O
examined	O
by	O
a	O
site	O
clinician	O
and	O
judged	O
not	O
to	O
be	O
depressed	O
7	O
.	O

Study	O
partner	O
is	O
available	O
who	O
has	O
frequent	O
contact	O
with	O
the	O
subject	O
(eg	O
,average	O
of	O
10	O
hours	O
per	O
week	O
or	O
more),	O
and	O
can	O
accompany	O
the	O
subject	O
to	O
most	O
visits	O
to	O
answer	O
questions	O
about	O
the	O
subject	O
8	O
.	O

Visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
adequate	O
for	O
neuropsychological	O
testing	O
9	O
.	O

Good	O
general	B-Condition
health	I-Condition
with	O
no	B-Negation_cue
disease	B-Condition
expected	O
to	O
interfere	O
with	O
the	O
study	O
10	O
.	O

Subject	O
is	O
not	B-Negation_cue
pregnant	B-Condition
,	O
lactating	B-Condition
,	O
or	O
of	B-Condition
childbearing	I-Condition
potential	I-Condition
(i.e	O
.	O

women	O
must	O
be	O
two	O
years	O
post-menopausal	B-Condition
or	O
surgically	B-Condition
sterile	I-Condition
11	O
.	O

Modified	B-Observation
Hackinski	I-Observation
less	O
than	O
or	O
equal	O
to	O
4	O
12	O
.	O

Completed	O
six	O
grades	O
of	O
education	O
or	O
has	O
a	O
good	O
work	O
history	O
13	O
.	O

Must	O
speak	O
English	O
or	O
Spanish	O
fluently	O
Exclusion	O
Criteria	O
1	O
.	O

Any	O
significant	O
neurologic	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
,	O
such	O
as	O
Parkinson's	B-Condition
disease	I-Condition
multi-infarct	B-Condition
dementia	I-Condition
Huntington's	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
brain	B-Condition
tumor	I-Condition
progressive	B-Condition
supranuclear	I-Condition
palsy	I-Condition
seizure	B-Condition
disorder	I-Condition
subdural	B-Condition
hematoma	I-Condition
multiple	B-Condition
sclerosis	I-Condition
or	O
history	O
of	O
significant	O
head	B-Condition
trauma	I-Condition
followed	O
by	O
persistent	O
neurologic	B-Condition
defaults	I-Condition
or	O
known	O
structural	B-Condition
brain	I-Condition
abnormalities	I-Condition
2	O
.	O

Screening	O
/	O
baseline	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
with	O
evidence	O
of	O
infection	B-Condition
,	O
infarction	B-Condition
,	O
or	O
other	O
focal	B-Condition
lesions	I-Condition
or	O
multiple	O
lacunes	B-Condition
or	O
lacunes	B-Condition
in	O
a	O
critical	O
memory	O
structure	O
3	O
.	O

Subjects	O
that	O
have	O
any	O
contraindications	B-Condition
for	O
MRI	B-Procedure_Device
studies	I-Procedure_Device
including	O
claustrophobia	B-Condition
,	O
the	O
presence	O
of	O
metal	B-Procedure_Device
(	I-Procedure_Device
ferromagnetic	I-Procedure_Device
)	I-Procedure_Device
implants	I-Procedure_Device
or	O
cardiac	B-Procedure_Device
pacemaker	I-Procedure_Device
4	O
.	O

Major	B-Condition
depression	I-Condition
bipolar	B-Condition
disorder	I-Condition
as	O
described	O
in	O
DSM-IV	B-Observation
within	O
the	O
past	O
1	O
year	O
or	O
psychotic	B-Condition
features	I-Condition
agitation	B-Condition
or	O
behavioral	B-Condition
problems	I-Condition
within	O
3	O
months,	O
which	O
could	O
lead	O
to	O
difficulty	O
complying	O
with	O
the	O
protocol	O
5	O
.	O

History	O
of	O
schizophrenia	B-Condition
DSM	B-Observation
V	I-Observation
criteria	I-Observation
6	O
.	O

History	O
of	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
within	O
the	O
past	O
2	O
years	O
DSM	B-Observation
V	I-Observation
criteria	I-Observation
7	O
.	O

Clinically	O
significant	O
or	O
unstable	O
medical	B-Condition
condition	I-Condition
including	O
uncontrolled	O
hypertension	B-Condition
,	O
uncontrolled	O
diabetes	B-Condition
,	O
or	O
significant	O
cardiac,	B-Condition
pulmonary,	I-Condition
renal,	I-Condition
hepatic,	I-Condition
endocrine,	I-Condition
or	I-Condition
other	I-Condition
systemic	I-Condition
disease	I-Condition
in	O
the	O
opinion	O
of	O
the	O
Investigator,	O
may	O
either	O
put	O
the	O
subject	O
at	O
risk	O
because	O
of	O
participation	O
in	O
the	O
study,	O
or	O
influence	O
the	O
results,	O
or	O
the	O
subject's	O
ability	O
to	O
participate	O
in	O
the	O
study	O
8	O
.	O

Has	O
had	O
a	O
history	O
within	O
the	O
last	O
5	O
years	O
of	O
a	O
primary	O
or	O
recurrent	O
malignant	B-Condition
disease	I-Condition
with	O
the	O
exception	B-Negation_cue
of	O
non-melanoma	B-Condition
skin	I-Condition
cancers	I-Condition
resected	O
cutaneous	B-Condition
squamous	I-Condition
cell	I-Condition
carcinoma	I-Condition
in	I-Condition
situ	I-Condition
basal	B-Condition
cell	I-Condition
carcinoma	I-Condition
cervical	B-Condition
carcinoma	I-Condition
in	I-Condition
situ	I-Condition
or	O
in	B-Condition
situ	I-Condition
prostate	I-Condition
cancer	I-Condition
with	O
normal	O
prostate-specific	B-Drug
antigen	I-Drug
post-treatment	O
9	O
.	O

Clinically	O
significant	O
abnormalities	B-Condition
in	O
B12	B-Observation
or	O
TFTs	B-Observation
that	O
might	O
interfere	O
with	O
the	O
study	O
A	O
low	O
B12	B-Observation
is	O
exclusionary,	O
unless	O
follow-up	B-Observation
labs	I-Observation
homocysteine	B-Observation
HC	B-Observation
)	O
and	O
methylmalonic	B-Observation
acid	I-Observation
MMA	B-Observation
))	O
indicate	O
that	O
it	O
is	O
not	B-Negation_cue
physiologically	O
significant	O
10	O
.	O

Residence	O
in	O
skilled	O
nursing	O
facility	O
11	O
.	O

Use	O
of	O
any	O
excluded	O
medication	B-Condition
as	O
described	O
in	O
study	O
protocol	O
12	O
.	O

Current	O
or	O
recent	O
participation	O
in	O
any	O
procedures	O
involving	O
radioactive	B-Drug
agents	I-Drug
including	O
current,	O
past,	O
or	O
anticipated	O
exposure	O
to	O
radiation	B-Drug
in	O
the	O
workplace,	O
such	O
that	O
the	O
total	B-Drug
radiation	I-Drug
dose	I-Drug
exposure	O
to	O
the	O
subject	O
in	O
a	O
given	O
year	O
would	O
exceed	O
the	O
limits	O
of	O
annual	O
and	O
total	O
dose	O
commitment	O
set	O
forth	O
in	O
the	O
US	O
Code	O
of	O
Federal	O
Regulations	O
(CFR)	O
Title	O
21	O
Section	O
361.1	O
This	O
guideline	O
is	O
an	O
effective	O
dose	O
of	O
5	O
rem	O
received	O
per	O
year	O
13	O
.	O

Neutropenia	B-Condition
defined	O
as	O
absolute	B-Observation
neutrophils	I-Observation
count	I-Observation
of	O
<	O
1,500	O
/	O
microliter	O
14	O
.	O

Thrombocytopenia	B-Condition
defined	O
as	O
platelet	B-Observation
count	I-Observation
>	O
100x103	O
/	O
microliter	O
15	O
.	O

For	O
CSF	O
sub-study	O
participants,	O
a	O
current	O
blood	B-Condition
clotting	I-Condition
or	O
bleeding	B-Condition
disorder	I-Condition
or	O
significantly	O
abnormal	O
PT	B-Observation
or	O
PTT	B-Observation
at	O
screening	O
16	O
.	O

Clinically	O
significant	O
abnormalities	B-Condition
in	O
screening	O
laboratories,	O
including:	O
Aspartate	B-Observation
aminotransferase	I-Observation
(	I-Observation
AST	I-Observation
)	I-Observation
>	O
1.5	O
times	O
ULN	O
Alanine	B-Observation
aminotransferase	I-Observation
(	I-Observation
ALT	I-Observation
)	I-Observation
>	O
1.5	O
times	O
ULN	O
Total	B-Observation
bilirubin	I-Observation
>	O
1.5	O
times	O
ULN	O
Serum	B-Observation
creatinine	I-Observation
>	O
2.0	O
times	O
ULN	O
17	O
.	O

History	O
of	O
interstitial	B-Condition
lung	I-Condition
disease	I-Condition
18	O
.	O

Patients	O
whom	O
the	O
PI	O
deems	O
to	O
be	O
otherwise	O
ineligible	O
>>NCT01018875	O
Inclusion	O
Criteria:	O
1	O
.	O

Have	O
voluntarily	O
signed	O
an	O
informed	O
consent	O
2	O
.	O

Subject	O
meets	O
diagnostic	O
criteria	O
criteria	O
for	O
probable	O
AD	B-Condition
(	I-Condition
Alzheimer's	I-Condition
Disease	I-Condition
)	I-Condition
3	O
.	O

Female	O
subjects	O
must	O
be	O
postmenopausal	B-Condition
for	O
at	O
least	O
2	O
years	O
or	O
surgically	B-Condition
sterile	I-Condition
4	O
.	O

Male	O
subjects	O
must	O
be	O
surgically	B-Condition
sterile	I-Condition
sexually	O
inactive	O
or	O
using	O
a	O
barrier	O
method	O
of	O
birth	O
control	O
5	O
.	O

Subject	O
has	O
an	O
identified,	O
reliable	O
caregiver	O
6	O
.	O

Subject	O
has	O
a	O
CT	B-Procedure_Device
or	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
within	O
36	O
months	O
prior	O
to	O
randomization	O
7	O
.	O

With	O
the	O
exception	O
of	O
a	O
diagnosis	O
of	O
mild-to-moderate	O
AD	B-Condition
and	O
the	O
presence	O
of	O
stable	O
medical	B-Condition
conditions	I-Condition
the	O
subject	O
is	O
generally	O
in	O
good	O
health	B-Condition
based	O
on	O
medical	B-Observation
history	I-Observation
physical	B-Observation
examination	I-Observation
vital	B-Observation
signs	I-Observation
clinical	B-Observation
lab	I-Observation
tests	I-Observation
and	O
ECG	B-Procedure_Device
Exclusion	O
Criteria:	O
1	O
.	O

Subject	O
is	O
currently	O
taking	O
or	O
has	O
taken	O
a	O
medication	B-Drug
for	O
the	O
treatment	O
of	O
AD	B-Condition
or	O
dementia	B-Condition
with	O
60	O
days	O
of	O
Screening	O
visit,	O
or	O
is	O
participating	O
in	O
cognitive	B-Procedure_Device
therapy	I-Procedure_Device
for	O
the	O
treatment	O
of	O
AD	B-Condition
or	O
dementia	B-Condition
2	O
.	O

Subject	O
uses	O
non-prescribed	B-Condition
drugs	I-Condition
of	I-Condition
abuse	I-Condition
or	O
has	O
a	O
history	O
of	O
drug	B-Condition
or	I-Condition
alcohol	I-Condition
abuse	I-Condition
/	I-Condition
dependence	I-Condition
3	O
.	O

Subject	O
has	O
a	O
history	O
of	O
any	O
significant	O
neurologic	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
4	O
.	O

Subject	O
has	O
a	O
history	O
of	O
intolerance	B-Condition
or	O
adverse	B-Condition
reaction	I-Condition
to	O
donepezil	B-Drug
that	O
led	O
to	O
discontinuation	O
5	O
.	O

Subject	O
has	O
received	O
any	O
investigation	B-Drug
product	I-Drug
within	O
6	O
weeks	O
prior	O
to	O
study	O
drug	O
administration	O
>>NCT00153010	O
INCLUSION	O
CRITERIA	O
Patients	O
may	O
be	O
included	O
in	O
this	O
study	O
if	O
they	O
meet	O
all	O
of	O
the	O
following	O
criteria:	O
1	O
.	O

Male,	O
and	O
female	O
without	O
child	O
bearing	O
potential	O
between	O
40	O
and	O
85	O
years	O
of	O
age	B-Observation
,	O
inclusive	O
Women	O
who	O
have	O
been	O
postmenopausal	B-Condition
for	O
less	O
than	O
2	O
years	O
must	O
have	O
a	O
negative	O
pregnancy	B-Observation
test	I-Observation
at	O
screening	O
2	O
.	O

Diagnosis	O
of	O
probable	O
mild	O
to	O
moderate	O
Dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
Type	I-Condition
as	O
defined	O
by	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Disorders	O
and	O
Stroke	O
and	O
the	O
Alzheimer's	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
(NINCDS	O
ADRDA)	O
guidelines	O
.	O

3	O
.	O

Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
of	O
10-24	O
and	O
Alzheimer's	B-Observation
Disease	I-Observation
Assessment	I-Observation
Scale	I-Observation
Cognitive	I-Observation
Subscale	I-Observation
(	I-Observation
ADAS-Cog	I-Observation
)	I-Observation
score	I-Observation
than	O
12	O
at	O
screening	O
4	O
.	O

Modified	B-Observation
Hachinski	I-Observation
Scale10	I-Observation
score	I-Observation
no	O
greater	O
than	O
4	O
5	O
.	O

Central	B-Procedure_Device
nervous	I-Procedure_Device
system	I-Procedure_Device
imaging	I-Procedure_Device
CT	B-Procedure_Device
or	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
of	O
brain)	O
compatible	O
with	O
Dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
Type	I-Condition
within	O
the	O
past	O
year	O
(also	O
see	O
exclusion	O
criteria)	O
6	O
.	O

Exhibits	O
reliability	O
and	O
physiologic	O
capability	O
sufficient	O
to	O
comply	O
with	O
all	O
protocol	O
procedures	O
Patient	O
must	O
be	O
familiar	O
with	O
and	O
fluent	O
in	O
English	O
(i.e	O
.	O

sufficient	O
to	O
complete	O
all	O
study	O
assessments	O
from	O
the	O
language	O
perspective)	O
7	O
.	O

Patients	O
and	O
/	O
or	O
a	O
legal	O
representative	O
and	O
their	O
caregivers	O
must	O
have	O
given	O
informed	O
consent	O
The	O
legal	O
representative	O
and	O
caregiver	O
may	O
be	O
the	O
same	O
person	O
8	O
.	O

Patient	O
must	O
have	O
a	O
reliable	O
caregiver	O
that	O
is	O
in	O
frequent	O
or	O
daily	O
contact	O
with	O
the	O
patient,	O
who	O
will	O
accompany	O
the	O
patient	O
to	O
the	O
office	O
and	O
who	O
will	O
monitor	O
the	O
administration	O
of	O
prescribed	O
medications	O
The	O
caregiver	O
will	O
be	O
able	O
to	O
communicate	O
in	O
English	O
and	O
be	O
willing	O
to	O
comply	O
with	O
protocol	O
requirements	O
EXCLUSION	O
CRITERIA	O
Patients	O
must	O
be	O
excluded	O
from	O
this	O
study	O
if	O
they	O
meet	O
any	O
of	O
the	O
following	O
criteria:	O
1	O
.	O

Secondary	B-Condition
disorders	I-Condition
inducing	O
dementia	B-Condition
such	O
as	O
neurosyphilis	B-Condition
,	O
craniocerebral	B-Condition
trauma	I-Condition
CT	B-Procedure_Device
/	I-Procedure_Device
MRI	I-Procedure_Device
hyperthyroidism	B-Condition
,	O
or	O
folic	B-Condition
acid	I-Condition
deficiency	I-Condition
2	O
.	O

History	O
of	O
malignancy	B-Condition
within	O
3	O
years,	O
except	B-Negation_cue
for	O
basal	B-Condition
cell	I-Condition
carcinoma	I-Condition
3	O
.	O

History	O
or	O
diagnosis	O
of	O
symptomatic	B-Condition
and	O
/	O
or	O
unstable	O
/	O
uncontrolled:	O
Cardiovascular	B-Condition
illnesses	I-Condition
such	O
as	O
chronic	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
(with	O
or	O
without	O
edema	B-Condition
),	O
arrhythmias	B-Condition
,	O
labile	B-Condition
hypertension	I-Condition
ischemic	B-Condition
heart	I-Condition
disease	I-Condition
myocardial	B-Condition
infarction	I-Condition
(with	O
residual	B-Condition
angina	I-Condition
orthopnea	B-Condition
,	O
conduction	B-Condition
defects	I-Condition
ECG	B-Procedure_Device
),	O
or	O
other	O
heart	B-Condition
disease	I-Condition
classified	O
NYHA	B-Observation
III	O
or	O
IV	O
Liver	B-Condition
disease	I-Condition
such	O
as	O
cirrhosis	B-Condition
,	O
hepatitis	B-Condition
B	I-Condition
hepatitis	B-Condition
C	I-Condition
or	O
primary	O
or	O
metastatic	O
neoplasm	O
Gastrointestinal	B-Condition
disorder	I-Condition
such	O
as	O
GI	B-Condition
bleeding	I-Condition
malabsorption	B-Condition
syndromes	I-Condition
post-gastrectomy	B-Condition
,	O
or	O
active	O
peptic	B-Condition
ulcer	I-Condition
disease	I-Condition
Renal	B-Condition
disease	I-Condition
(primary	O
or	O
secondary)	O
such	O
as	O
chronic	B-Condition
renal	I-Condition
failure	I-Condition
CLCR	B-Observation
30	O
mL	O
/	O
min)	O
Endocrine	B-Condition
disease	I-Condition
such	O
as	O
diabetes	B-Condition
mellitus	I-Condition
or	O
hypothyroidism	B-Condition
Neurological	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
Type	I-Condition
such	O
as	O
Huntington's	B-Condition
disease	I-Condition
Parkinson's	B-Condition
disease	I-Condition
encephalitis	B-Condition
,	O
epilepsy	B-Condition
,	O
stroke	B-Condition
,	O
or	O
multiple	B-Condition
sclerosis	I-Condition
and	O
psychiatric	B-Condition
disorders	I-Condition
such	O
as	O
schizophrenia	B-Condition
,	O
major	B-Condition
depression	I-Condition
or	O
mental	B-Condition
retardation	I-Condition
Significant	O
pulmonary	B-Condition
disease	I-Condition
predisposing	O
to	O
hypoxia	B-Condition
Immunological	B-Condition
disorder	I-Condition
such	O
as	O
clinically	O
significant	O
alleges	B-Condition
,	O
Lupus	B-Condition
erythematosis	I-Condition
or	O
scleroderma	B-Condition
Hematological	B-Condition
disease	I-Condition
(regardless	O
of	O
cause)	O
such	O
as	O
refractory	B-Condition
anemia	I-Condition
or	O
refractory	B-Condition
myelosuppression	I-Condition
Organ	B-Condition
system	I-Condition
diseases	I-Condition
which,	O
in	O
the	O
opinion	O
of	O
the	O
investigator,	O
would	O
impact	O
on	O
the	O
primary	O
and	O
secondary	O
endpoints	O
of	O
the	O
trial	O
such	O
as	O
dehydration	B-Condition
hematocrit	B-Observation
>	O
48%)	O
or	O
hypothyroidism	B-Condition
4	O
.	O

Significant	O
history	O
of	O
drug	B-Condition
dependence	I-Condition
or	I-Condition
abuse	I-Condition
(including	O
alcohol,	O
as	O
defined	O
in	O
DSM	B-Observation
IV	I-Observation
or	O
in	O
the	O
opinion	O
of	O
the	O
investigator)	O
within	O
two	O
years,	O
or	O
a	O
positive	O
urine	B-Observation
drug	I-Observation
screen	I-Observation
for	O
cocaine	B-Drug
,	O
heroin	B-Drug
,	O
or	O
marijuana	B-Drug
5	O
.	O

HIV	B-Observation
positive	O
6	O
.	O

Presence	O
of	O
Hepatitis	B-Observation
C	I-Observation
antibody	I-Observation
7	O
.	O

Planned	O
elective	B-Procedure_Device
surgery	I-Procedure_Device
requiring	O
general	B-Procedure_Device
anesthesia	I-Procedure_Device
or	O
hospitalization	B-Procedure_Device
for	O
more	O
than	O
1	O
day	O
during	O
the	O
study	O
period	O
8	O
.	O

Previous	O
participation	O
in	O
any	O
NS	O
2330	O
study	O
9	O
.	O

Use	O
of	O
any	O
investigational	O
drug	B-Drug
or	O
procedure	B-Procedure_Device
within	O
30	O
days	O
before	O
randomization	O
10	O
.	O

Use	O
of	O
any	O
drug	B-Drug
within	O
14	O
days	O
prior	O
to	O
randomization	O
unless:	O
the	O
dose	B-Procedure_Device
of	O
the	O
drug	B-Drug
and	O
the	O
condition	B-Condition
being	O
treated	O
have	O
been	O
stable	O
for	O
at	O
least	O
30	O
days	O
and	O
are	O
expected	O
to	O
remain	O
stable	O
during	O
the	O
study	O
neither	O
the	O
drug	O
nor	O
the	O
condition	O
being	O
treated	O
is	O
expected	O
to	O
interfere	O
with	O
the	O
study	O
endpoints	O
11	O
.	O

Treatment	O
with	O
donepezil	B-Drug
,	O
galantamine	B-Drug
,	O
rivastigmine	B-Drug
,	O
or	O
tacrine	B-Drug
,	O
is	O
prohibited	O
within	O
6	O
weeks	O
before	O
randomization	O
12	O
.	O

Treatment	O
with	O
drugs	B-Drug
that	O
inhibit	O
CYP	B-Drug
450	I-Drug
3A4	I-Drug
(see	O
Appendix	O
II	O
for	O
a	O
list	O
of	O
relevant	O
drugs	O
If	O
they	O
are	O
needed	O
under	O
emergency	O
conditions,	O
the	O
patient	O
should	O
discontinue	O
the	O
trial	O
13	O
.	O

Treatment	O
with	O
antipsychotics	B-Drug
/	I-Drug
neuroleptics	I-Drug
is	O
prohibited	O
for	O
8	O
weeks	O
prior	O
to	O
randomization	O
(see	O
listing	O
Appendix	O
II)	O
14	O
.	O

Treatment	O
with	O
monoamine	B-Drug
oxidase	I-Drug
inhibitors	I-Drug
is	O
prohibited	O
for	O
8	O
weeks	O
prior	O
to	O
randomization	O
15	O
.	O

Treatment	O
with	O
selective	B-Drug
serotonin	I-Drug
reuptake	I-Drug
inhibitors	I-Drug
is	O
prohibited	O
for	O
6	O
weeks	O
prior	O
to	O
randomization	O
16	O
.	O

Tricyclic	B-Drug
antidepressants	I-Drug
and	O
antihistamines	B-Drug
are	O
prohibited	O
for	O
4	O
weeks	O
prior	O
to	O
randomization	O
>>NCT00855868	O
Inclusion	O
Criteria:	O
Normal	O
subjects:	O
mini-mental	B-Observation
state	I-Observation
examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
27-30,	O
clinical	B-Observation
dementia	I-Observation
rating	I-Observation
(	I-Observation
CDR	I-Observation
)	I-Observation
0,	O
no	B-Negation_cue
symptoms	O
of	O
depression	B-Condition
Alzheimer's	O
subjects:	O
MMSE	B-Observation
18-26,	O
CDR	B-Observation
>=	O
0.5,	O
University	O
of	O
Pennsylvania	O
Alzheimer's	O
Disease	O
Center	O
consensus	O
diagnosis	O
of	O
probable	O
AD,	O
absence	O
of	O
abnormalities	O
on	O
MRI	B-Procedure_Device
Exclusion	O
Criteria:	O
other	O
neurological	B-Condition
disease	I-Condition
evidence	O
of	O
MRI	B-Condition
abnormality	I-Condition
psychiatric	B-Condition
disorder	I-Condition
alcohol	B-Condition
abuse	I-Condition
clinically	O
significant	O
lab	B-Condition
abnormalities	I-Condition
residence	O
in	O
nursing	O
facility	O
participation	O
in	O
clinical	O
trial	O
with	O
experimental	O
medication	O
in	O
past	O
1	O
month	O
>>NCT01677754	O
Inclusion	O
Criteria:	O
Adult	O
patients,	O
50-90	O
years	O
of	O
age	B-Observation
inclusive	O
at	O
time	O
of	O
screening	O
Probable	O
Alzheimer	B-Condition
disease	I-Condition
based	O
on	O
the	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke	I-Observation
(	I-Observation
NINCDS	I-Observation
)	I-Observation
/	O
Alzheimer's	B-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
ADRDA	I-Observation
)	I-Observation
and	O
DSM-IV-TR	B-Observation
criteria	I-Observation
MMSE	B-Observation
score	I-Observation
at	O
screening	O
between	O
13	O
and	O
20,	O
inclusive	O
Body	B-Observation
mass	I-Observation
index	I-Observation
(	I-Observation
BMI	I-Observation
)	I-Observation
between	O
18	O
and	O
36	O
kg	O
/	O
m2	O
(inclusive)	O
at	O
screening	O
Modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
Score	I-Observation
of	O
<=	O
4	O
Patients	O
with	O
Cornell	B-Observation
Scale	I-Observation
for	I-Observation
Depression	I-Observation
in	I-Observation
Dementia	I-Observation
(	I-Observation
CSDD	I-Observation
)	I-Observation
scores	I-Observation
<=	O
13	O
at	O
screening	O
Receiving	O
treatment	O
with	O
donepezil	B-Drug
or	O
rivastigmine	B-Drug
,	O
galantamine	B-Drug
or	O
any	O
of	O
these	O
AChEIs	B-Drug
in	O
combination	O
with	O
memantine	B-Drug
for	O
at	O
least	O
4	O
months	O
before	O
screening,	O
with	O
their	O
dose	B-Procedure_Device
and	O
formulation	B-Procedure_Device
stabilized	O
at	O
least	O
3	O
months	O
before	O
screening	O
All	O
formulation	B-Procedure_Device
and	O
dosages	B-Procedure_Device
are	O
allowed	O
except	B-Negation_cue
donepezil	B-Drug
23	O
mg	O
(alone	O
or	O
in	O
combination)	O
Females	O
of	O
childbearing	B-Condition
potential	I-Condition
must	O
have	O
a	O
negative	O
pregnancy	B-Observation
test	I-Observation
and	O
must	O
agree	O
to	O
use	O
effective	O
contraception	O
Generally	B-Condition
healthy	I-Condition
and	O
ambulatory	O
or	O
ambulatory-aided	O
(i.e	O
.	O

walker	O
or	O
cane)	O
Have	O
a	O
reliable	O
caregiver	O
or	O
some	O
other	O
identified	O
responsible	O
person	O
who	O
has	O
frequent	O
contact	O
with	O
the	O
patient	O
Exclusion	O
Criteria:	O
Any	O
neurological	B-Condition
or	I-Condition
psychiatric	I-Condition
condition	I-Condition
that	O
may	O
currently	O
or	O
during	O
the	O
course	O
of	O
the	O
study	O
impair	O
cognition	O
or	O
functioning	O
that	O
is	O
not	B-Negation_cue
associated	O
with	O
Alzheimer's	B-Condition
disease	I-Condition
Background	O
of	O
mental	B-Condition
retardation	I-Condition
Uncontrolled	O
behavioral	B-Condition
symptoms	I-Condition
incompatible	O
with	O
compliance	O
or	O
evaluability	O
Alcohol	B-Condition
and	I-Condition
/	I-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
DSM-IV-TR	B-Observation
)	O
in	O
the	O
past	O
2	O
years,	O
except	B-Negation_cue
nicotine	B-Drug
use	O
which	O
is	O
allowed	O
However,	O
smokers	B-Condition
treated	O
with	O
nicotine	B-Drug
replacement	I-Drug
therapy	I-Drug
or	O
bupropion	B-Drug
are	O
excluded	O
Unstable	O
or	O
poorly	O
controlled	O
hypertension	B-Condition
as	O
assessed	O
by	O
the	O
investigator	O
Unstable	O
or	O
clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
that	O
could	O
be	O
expected	O
to	O
progress,	O
recur,	O
or	O
change	O
during	O
study	O
period	O
to	O
such	O
an	O
extent	O
that	O
it	O
could	O
bias	O
the	O
assessment	O
of	O
the	O
clinical	O
or	O
mental	O
status	O
of	O
the	O
patient	O
Inadequate	B-Condition
hepatic,	I-Condition
renal	I-Condition
or	I-Condition
thyroid	I-Condition
function	I-Condition
Positive	O
for	O
hepatitis	B-Condition
B,	I-Condition
hepatitis	I-Condition
C	I-Condition
or	I-Condition
HIV	I-Condition
infection	I-Condition
Poorly	O
controlled	O
diabetes	B-Condition
Requiring	O
nursing	O
home	O
care	O
Patients	O
living	O
in	O
assisted	O
living	O
facilities	O
are	O
allowed	O
if	O
a	O
reliable	O
caregiver	O
is	O
available	O
(see	O
inclusion	O
criteria)	O
Current	O
treatment	B-Procedure_Device
for	O
AD	B-Condition
other	O
than	O
those	O
listed	O
in	O
inclusion	O
criteria	O
Participation	O
at	O
any	O
time	O
in	O
an	O
active	O
AD	B-Procedure_Device
vaccine	I-Procedure_Device
study	I-Procedure_Device
Participation	O
in	O
a	O
passive	O
AD	B-Procedure_Device
immunization	I-Procedure_Device
study	I-Procedure_Device
less	O
than	O
1	O
year	O
before	O
screening,	O
with	O
exceptions	O
as	O
per	O
protocol	O
Psychotropic	B-Drug
medication	I-Drug
as	O
defined	O
by	O
protocol	O

>>NCT00015548	O
Inclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
Dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
Type	I-Condition
.	O

-	O
Ambulatory,	O
Outpatients	O
who	O
have	O
an	O
informant	O
living	O
/	O
visiting	O
at	O
least	O
8	O
hours	O
/	O
week	O
over	O
3	O
-	O
4	O
days	O
.	O

-	O
Presence	O
of	O
delusions	B-Condition
,	O
hallucinations	B-Condition
,	O
agitation	B-Condition
impacting	O
functioning	O
and	O
requiring	O
medication	O
treatment	O
.	O

-	O
Agitation	B-Condition
or	O
psychotic	B-Condition
symptoms	I-Condition
began	O
after	O
signs	O
or	O
symptoms	O
of	O
dementia	B-Condition
.	O

Exclusion	O
(	O
prospective	O
participants	O
must	O
not:)	O
.	O

-	O
Be	O
benefiting	O
from	O
psychotropic	B-Drug
medication	I-Drug
antidepressants	B-Drug
or	O
anticonvulsants	B-Drug
.	O

-	O
Be	O
diagnosed	O
with	O
schizophrenia	B-Condition
,	O
schizoaffective	B-Condition
disorder	I-Condition
delusional	B-Condition
disorder	I-Condition
or	O
mood	B-Condition
disorder	I-Condition
with	I-Condition
psychotic	I-Condition
features	I-Condition
.	O

-	O
Have	O
severe	O
or	O
unstable	O
medical	B-Condition
illness	I-Condition
requiring	O
active	O
treatment	O
.	O

-	O
Have	O
hypersensitivity	B-Condition
or	O
intolerance	B-Condition
of	O
any	O
of	O
the	O
study	B-Drug
medications	I-Drug
.	O

>>NCT02267057	O
Inclusion	O
Criteria:	O
.	O

-	O
Patients	O
residing	O
in	O
long	O
term	O
nursing	O
home	O
units	O
for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
study	O
.	O

-	O
Diagnosed	O
with	O
probable	O
or	O
possible	O
dementia	B-Condition
according	O
to	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Disorders	I-Observation
(	I-Observation
DSM-IV	I-Observation
)	I-Observation
FAST	B-Observation
score	I-Observation
>	O
4	O
.	O

-	O
Diagnosed	O
with	O
depression	B-Condition
>=	O
4	O
week	O
duration	O
as	O
measured	O
by	O
CSDD	B-Observation
>=	O
8	O
.	O

-	O
Written,	O
informed	O
consent	O
provided	O
by	O
the	O
participant	O
(	O
if	O
they	O
have	O
capacity	O
)	O
or	O
assent	O
(	O
if	O
they	O
do	O
not	O
have	O
capacity	O
)	O
and	O
a	O
written	O
proxy	O
informed	O
consent	O
from	O
a	O
legally	O
authorized	O
representative	O
empowered	O
to	O
make	O
health-related	O
decisions	O
for	O
the	O
potential	O
study	O
participant	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
The	O
patient	O
is	O
contra-indicated	O
to	O
study	O
drugs	O
of	O
pain	O
treatment,	O
in	O
another	O
trial	O
or	O
had	O
no	O
carer	O
.	O

-	O
Participants	O
are	O
ineligible	O
if	O
they	O
are	O
clinical	O
critical	O
(	O
eg	O
suicide	B-Condition
risk	I-Condition
)	O
.	O

-	O
Clinician	O
responsible	O
for	O
care	O
or	O
study	O
clinician	O
considers	O
that	O
the	O
patient	O
suffers	O
from	O
any	O
physical	O
condition,	O
which	O
would	O
make	O
participation	O
in	O
the	O
trial	O
distressing	O
or	O
likely	O
to	O
increase	O
suffering	O
.	O

-	O
Advanced	O
severe	O
medical	B-Condition
disease	I-Condition
/	I-Condition
disorder	I-Condition
with	O
expected	B-Observation
survival	I-Observation
less	O
than	O
6	O
months	O
or	O
that	O
could	O
interfere	O
with	O
participation	O
.	O

-	O
Psychosis	B-Condition
or	O
other	O
severe	O
mental	B-Condition
disorder	I-Condition
prior	O
to	O
dementia	B-Condition
diagnosis	O
.	O

-	O
Severe	O
aggression	B-Observation
(	O
>=	O
8	O
)	O
on	O
item	O
3	O
of	O
the	O
NPI	B-Observation
subscale	I-Observation
with	O
aggression	B-Observation
as	O
the	O
predominant	O
symptom	O
.	O

-	O
Schizophrenia	B-Condition
,	O
schizoaffective	B-Condition
disorder	I-Condition
and	O
bipolar	B-Condition
disorder	I-Condition
.	O

-	O
Uncontrolled	O
epilepsy	B-Condition
.	O

-	O
Severe	O
liver	B-Condition
impairment	I-Condition
.	O

-	O
Renal	B-Condition
failure	I-Condition
.	O

-	O
Severe	O
injury	B-Condition
or	O
anaemia	B-Condition
(	O
Hb	B-Observation
<	O
8.5	O
mmol	O
/	O
l	O
),	O
comatose	B-Condition
state	I-Condition
current	O
enrolment	O
in	O
another	O
experimental	O
protocol	O
.	O

-	O
Known	O
allergy	B-Condition
or	I-Condition
adverse	I-Condition
reaction	I-Condition
to	O
paracetamol	B-Drug
or	O
buprenorphine	B-Drug
transdermal	I-Drug
patch	I-Drug
.	O

-	O
Advanced	O
severe	O
medical	B-Condition
disease	I-Condition
with	O
expected	O
survival	B-Observation
of	O
less	O
than	O
six	O
months,	O
severe	O
psychiatric	B-Condition
or	I-Condition
neurological	I-Condition
disorder	I-Condition
.	O

-	O
Patients	O
with	O
diseases	O
that	O
make	O
it	O
impossible	O
to	O
follow	O
the	O
research	O
schedule	O
are	O
excluded	O
.	O

>>NCT01023685	O
Inclusion	O
Criteria:	O
.	O

-	O
Patients	O
who	O
have	O
completed	O
the	O
core	O
study	O
with	O
no	O
significant	O
safety	O
concerns	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Diagnosis	O
of	O
other	O
neurodegenerative	B-Condition
disease	I-Condition
and	O
/	O
or	O
psychiatric	B-Condition
disorders	I-Condition
(	O
with	O
the	O
exception	O
of	O
successfully	O
treated	O
depression	O
)	O
.	O

-	O
Diagnosis	O
or	O
presence	O
of	O
an	O
active,	O
uncontrolled	O
seizure	B-Condition
disorder	I-Condition
and	O
/	O
or	O
cerebrovascular	B-Condition
disease	I-Condition
.	O

-	O
Diagnosis	O
or	O
presence	O
of	O
an	O
active	O
autoimmune	B-Condition
and	O
/	O
or	O
with	O
an	O
acute	O
or	O
chronic	O
inflammation	B-Condition
.	O

Other	O
protocol-defined	O
inclusion	O
/	O
exclusion	O
criteria	O
may	O
apply	O
.	O

>>NCT01600469	O
Inclusion	O
Criteria:	O
.	O

-	O
Clinical	O
diagnosis	O
of	O
mild	B-Condition
cognitive	I-Condition
impairment	I-Condition
or	O
mild	O
Alzheimer's	B-Condition
.	O

-	O
MMSE	B-Observation
between	O
17	O
-	O
26	O
.	O

-	O
CDR	B-Observation
0.5	O
or	O
1	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Hachinski	B-Observation
Ischemic	I-Observation
Score	I-Observation
>	O
4	O
.	O

-	O
substance	B-Condition
abuse	I-Condition
/	I-Condition
dependence	I-Condition
.	O

-	O
Parkinson	B-Condition
disease	I-Condition
.	O

-	O
epilepsy	B-Condition
.	O

-	O
major	B-Condition
depressive	I-Condition
disorder	I-Condition
.	O

-	O
dementia	B-Condition
with	I-Condition
psychotic	I-Condition
features	I-Condition
.	O

-	O
major	O
physical	B-Condition
illnesses	I-Condition
.	O

-	O
severe	O
visual	B-Condition
or	I-Condition
hearing	I-Condition
impairment	I-Condition
.	O

>>NCT00056524	O
Inclusion	O
Criteria:	O
.	O

-	O
18	O
to	O
75	O
years	O
of	O
age	B-Observation
,	O
inclusive	O
.	O

-	O
Clinical	O
diagnosis	O
of	O
PBA	B-Condition
(	O
pseudobulbar	B-Condition
affect	I-Condition
)	O
.	O

-	O
If	O
female,	O
must	O
not	O
be	O
pregnant	O
or	O
breast	O
feeding	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Sensitivity	B-Condition
to	O
quinidine	B-Drug
or	O
any	O
opiate	B-Drug
drugs	I-Drug
.	O

-	O
Current	O
or	O
prior	O
history	B-Observation
of	O
major	O
psychiatric	B-Condition
disturbance	I-Condition
.	O

-	O
Currently	O
participated	O
in	O
a	O
trial	O
within	O
the	O
past	O
30	O
days	O
.	O

>>NCT01354444	O
Inclusion	O
Criteria:	O
.	O

1	O
.	O

Diagnosis	O
of	O
AD	B-Condition
by	O
NINCDS	B-Observation
/	I-Observation
ADRDA	I-Observation
criteria	I-Observation
(	O
47	O
)	O
.	O

2	O
.	O

Mini-Mental	B-Observation
State	I-Observation
Exam	I-Observation
(	O
MMSE	B-Observation
)	O
16	O
-	O
26	O
.	O

This	O
range	O
corresponds	O
roughly	O
to	O
"mild"	O
AD	B-Condition
as	O
rated	O
by	O
CDR	B-Observation
below	O
and	O
provides	O
a	O
rapid	O
test	O
for	O
efficient	O
screening	O
of	O
potential	O
participants	O
.	O

3	O
.	O

Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	O
CDR	B-Observation
)	O
<	O
1	O
(	O
mild	O
dementia	B-Condition
)	O
.	O

This	O
corresponds	O
with	O
"early"	O
AD	B-Condition
(	O
see	O
D.2.5	O
above	O
)	O
.	O

Participants	O
will	O
be	O
eligible	O
if	O
they	O
have	O
AD	B-Condition
diagnosis	O
and	O
CDR	B-Observation
of	O
0.5	O
or	O
1.0	O
.	O

The	O
category	O
of	O
CDR	B-Observation
0.5	O
AD	B-Condition
is	O
particularly	O
important	O
to	O
include	O
as	O
these	O
participants	O
are	O
in	O
the	O
earliest	O
stage	O
that	O
can	O
be	O
diagnosed	O
as	O
dementia	B-Condition
(	O
as	O
opposed	O
to	O
mild	B-Condition
cognitive	I-Condition
impairment	I-Condition
)	O
and	O
thus	O
are	O
in	O
the	O
"earliest"	O
clinical	O
stage	O
of	O
AD	B-Condition
.	O

4	O
.	O

Patients	O
will	O
be	O
allowed	O
to	O
remain	O
on	O
current	O
FDA-approved	B-Drug
Alzheimer's	I-Drug
treatments	I-Drug
including	O
cholinesterase	B-Drug
inhibitors	I-Drug
and	O
memantine	B-Drug
,	O
so	O
long	O
as	O
the	O
dose	B-Observation
has	O
been	O
stable	O
for	O
>=	O
3	O
months	O
.	O

These	O
medications	O
lack	O
any	O
notable	O
effects	O
on	O
amyloid	O
synthesis	O
or	O
metabolism	O
and	O
thus	O
there	O
is	O
no	O
reason	O
to	O
exclude	O
them	O
.	O

The	O
rationale	O
behind	O
requiring	O
a	O
stable	O
dose	O
is	O
so	O
that	O
change	O
in	O
the	O
trial	O
can	O
be	O
attributed	O
to	O
the	O
study	O
intervention	O
rather	O
than	O
recent	O
changes	O
of	O
other	O
medications	O
affecting	O
cognition	O
.	O

5	O
.	O

Patients	O
will	O
be	O
allowed	O
to	O
remain	O
on	O
antidepressant	B-Drug
and	O
antipsychotics	B-Drug
medications	I-Drug
so	O
long	O
as	O
the	O
dose	B-Observation
has	O
been	O
stable	O
for	O
>=	O
3	O
months	O
.	O

The	O
rationale	O
is	O
the	O
same	O
as	O
item	O
5	O
.	O

6	O
.	O

Knowledgeable	O
informant	O
available	O
for	O
all	O
study	O
visits	O
.	O

This	O
is	O
standard	O
practice	O
in	O
AD	O
research	O
because	O
many	O
standard	O
instruments	O
(	O
in	O
this	O
trial	O
including	O
CDR,	O
NPI,	O
ADCS-ADL	O
)	O
require	O
a	O
knowledgeable	O
informant	O
.	O

Exclusion	O
criteria	O
.	O

1	O
.	O

Evidence	O
of	O
non-AD	B-Condition
dementias	I-Condition
including	O
Huntington's	B-Condition
disease	I-Condition
Parkinson's	B-Condition
disease	I-Condition
or	O
frontotemporal	B-Condition
dementia	I-Condition
.	O

2	O
.	O

Current	O
DSM-IV	O
Axis	O
I	O
diagnoses	O
other	B-Negation_cue
than	I-Negation_cue
dementia	B-Condition
,	O
including	O
major	B-Condition
depression	I-Condition
bipolar	B-Condition
disorder	I-Condition
schizophrenia	B-Condition
,	O
anxiety	B-Condition
disorders	I-Condition
alcohol	B-Condition
abuse	I-Condition
or	O
other	O
substance	B-Condition
abuse	I-Condition
.	O

These	O
diagnoses	O
would	O
merit	O
their	O
own	O
treatment	O
plans	O
and	O
changes	O
in	O
these	O
conditions	O
could	O
significantly	O
affect	O
cognitive	O
and	O
functional	O
outcomes,	O
confounding	O
our	O
efforts	O
to	O
study	O
the	O
efficacy	O
of	O
the	O
study	O
intervention	O
.	O

3	O
.	O

Any	O
clinically	O
significant	O
medical	O
condition	O
that	O
could	O
interfere	O
with	O
the	O
subject's	O
ability	O
to	O
safely	O
participate	O
in	O
the	O
study	O
or	O
to	O
be	O
followed	O
.	O

4	O
.	O

Current	O
use	O
of	O
Beta-blocking	B-Drug
agents	I-Drug
.	O

5	O
.	O

Contraindications	B-Condition
to	O
use	O
of	O
Beta-blocking	B-Drug
agents	I-Drug
to	O
be	O
determined	O
in	O
consultation	O
with	O
the	O
patient's	O
primary	O
care	O
physician	O
or	O
(	O
if	O
appropriate	O
)	O
cardiologist	O
.	O

6	O
.	O

Clinically	O
significant	O
hepatic	B-Condition
or	I-Condition
renal	I-Condition
insufficiency	I-Condition
.	O

>>NCT01926691	O
Inclusion	O
Criteria:	O
.	O

-	O
Age	B-Observation
>=	O
50	O
years	O
.	O

-	O
Israeli	O
residents	O
.	O

-	O
Acute	O
stroke	B-Condition
that	O
occurred	O
within	O
the	O
last	O
3	O
days	O
as	O
defined	O
by:	O
.	O

-	O
acute	O
focal	B-Condition
neurological	I-Condition
deficit	I-Condition
.	O

-	O
Written	O
informed	O
consent	O
by	O
patient	O
prior	O
to	O
study	O
participation	O
.	O

-	O
Willingness	O
to	O
participate	O
in	O
follow-up	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
patients	O
presenting	O
with	O
a	O
primary	B-Condition
hemorrhagic	I-Condition
stroke	I-Condition
(	O
intracerebral	O
or	O
subarachnoid	O
)	O
.	O

-	O
history	B-Observation
of	O
any	O
preceding	O
cerebral	B-Condition
vascular	I-Condition
event	I-Condition
(	O
excluding	O
TIA	B-Condition
(	O
.	O

-	O
imminent	O
death	B-Observation
or	O
unconscious	B-Observation
state	I-Observation
.	O

-	O
patients	O
unlikely	O
to	O
be	O
released	O
from	O
hospital	O
following	O
the	O
qualifying	O
stroke	O
or	O
have	O
a	O
severe	O
disability	O
after	O
the	O
.	O

-	O
qualifying	O
stroke	O
which	O
makes	O
follow-up	O
unlikely	O
.	O

-	O
known	O
malignant	B-Condition
disease	I-Condition
or	O
other	O
chronic	B-Condition
disease	I-Condition
with	O
poor	O
prognosis	B-Observation
(	O
predicted	B-Observation
survival	I-Observation
less	O
than	O
two-years	O
)	O
.	O

-	O
stroke	B-Condition
resulting	O
from	O
trauma	B-Condition
or	O
invasive	B-Procedure_Device
procedure	I-Procedure_Device
.	O

-	O
patients	O
with	O
a	O
prestroke	B-Observation
history	I-Observation
consistent	O
with	O
dementia	B-Condition
.	O

-	O
severe	O
aphasia	B-Condition
.	O

>>NCT01423396	O
Inclusion	O
criteria	O
.	O

-	O
Subjects	O
aged	B-Observation
60	O
or	O
over	O
.	O

-	O
Subjects	O
with	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
the	O
NINCDS	B-Observation
/	I-Observation
ADRDA	I-Observation
diagnostic	I-Observation
criteria	I-Observation
71	O
.	O

-	O
MMSE	B-Observation
>	O
18	O
.	O

-	O
Subjects	O
with	O
at	O
least	O
one	O
VRF	B-Condition
(	O
whether	O
treated	O
or	O
not	O
):	O
arterial	B-Condition
hypertension	I-Condition
(	O
defined	O
as	O
SBP	B-Observation
/	I-Observation
DBP	I-Observation
>=	O
140	O
-	O
90	O
mmHg	O
in	O
at	O
least	O
three	O
different	O
consultations	O
or,	O
for	O
ambulatory	O
measurements,	O
>	O
130	O
-	O
80	O
mmHg	O
with	O
a	O
Holter	O
recorder	O
or	O
>	O
135	O
-	O
85	O
mmHg	O
with	O
a	O
self-measurement	O
device	O
),	O
type	B-Condition
2	I-Condition
diabetes	I-Condition
(	O
defined	O
as	O
a	O
glycaemia	B-Observation
value	I-Observation
over	O
1.26	O
g	O
/	O
l	O
(	O
7	O
mmol	O
/	O
l	O
)	O
after	O
an	O
8	O
-hour	O
fast	O
(	O
confirmed	O
on	O
two	O
occasions	O
),	O
dyslipidaemia	B-Condition
(	O
defined	O
as	O
an	O
LDL	B-Observation
cholesterol	I-Observation
level	I-Observation
>	O
1.6	O
g	O
/	O
l	O
or	O
1.3	O
or	O
1	O
g	O
/	O
l,	O
depending	O
on	O
the	O
patient's	O
risk	O
level	O
)	O
.	O

-	O
Subjects	O
having	O
agreed	O
to	O
participate	O
in	O
the	O
study	O
(	O
provision	O
of	O
informed	O
consent	O
)	O
.	O

-	O
Subjects	O
accompanied	O
by	O
a	O
person	O
likely	O
to	O
provide	O
information	O
on	O
the	O
patient	O
(	O
during	O
the	O
visit	O
or	O
over	O
the	O
phone	O
)	O
.	O

Exclusion	O
criteria	O
.	O

-	O
Any	O
other	O
disease	O
that	O
might	O
interfere	O
with	O
the	O
evaluation	O
of	O
cognitive	B-Condition
disorders	I-Condition
.	O

-	O
No	O
formal	O
education	O
or	O
a	O
poor	O
understanding	O
of	O
French	O
(	O
interfering	O
with	O
administration	O
of	O
the	O
neuropsychological	O
tests	O
)	O
.	O

-	O
Major	O
physical	B-Condition
problems	I-Condition
likely	O
to	O
interfere	O
with	O
administration	O
of	O
the	O
tests	O
(	O
poor	O
eyesight,	O
hearing,	O
etc.)	O
.	O

-	O
Non-Alzheimer's	B-Condition
dementia	I-Condition
(	O
isolated	B-Condition
vascular	I-Condition
dementia	I-Condition
Lewy	B-Condition
body	I-Condition
dementia	I-Condition
frontotemporal	B-Condition
dementia	I-Condition
etc.)	O
.	O

-	O
Psychotropic	B-Drug
drugs	I-Drug
likely	O
to	O
modify	O
the	O
patient's	O
non-stabilized	O
cognitive	O
state	O
.	O

-	O
Patients	O
with	O
a	O
history	B-Observation
of	O
cardiovascular	B-Condition
events	I-Condition
can	O
be	O
included	O
(	O
randomization	O
will	O
be	O
balanced	O
in	O
terms	O
of	O
this	O
criterion	O
)	O
.	O

-	O
Participation	O
in	O
a	O
therapeutic	O
clinical	O
trial	O
during	O
the	O
study	O
period	O
.	O

>>NCT02579252	O
Inclusion	O
criteria	O
(	O
abbreviated	O
):	O
.	O

-	O
Diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
the	O
revised	O
National	B-Observation
Institute	I-Observation
on	I-Observation
Aging-Alzheimer's	I-Observation
Association	I-Observation
(	I-Observation
NIA-AA	I-Observation
)	I-Observation
criteria	I-Observation
(	I-Observation
McKhann	I-Observation
2011	I-Observation
)	I-Observation
.	O

-	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
>=	O
20	O
and	O
<=	O
26	O
.	O

-	O
Brain	O
MRI	B-Procedure_Device
finding	O
consistent	O
with	O
the	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Medial	B-Condition
temporal	I-Condition
lobe	I-Condition
atrophy	I-Condition
Scheltens	B-Observation
score	I-Observation
of	O
>=	O
2	O
(	O
on	O
a	O
scale	O
of	O
0	O
-	O
4	O
on	O
the	O
more	O
atrophied	O
side	O
)	O
.	O

-	O
At	O
least	O
6	O
years	O
of	O
formal	O
elementary	O
education	O
.	O

-	O
Age	B-Observation
50	O
-	O
85	O
years	O
.	O

-	O
Fluency	O
in	O
the	O
local	O
language	O
and	O
sufficient	O
auditory	O
and	O
visual	O
capacities	O
to	O
allow	O
neuropsychological	O
testing	O
.	O

-	O
Ability	O
to	O
read	O
and	O
understand	O
the	O
informed	O
consent	O
.	O

-	O
Stable	O
therapy	O
with	O
an	O
acetylcholinesterase	B-Drug
inhibitor	I-Drug
for	O
at	O
least	O
3	O
months	O
prior	O
to	O
screening	O
.	O

-	O
If	O
the	O
patient	O
is	O
on	O
memantine	O
treatment,	O
the	O
dose	O
regimen	O
must	O
be	O
stable	O
for	O
at	O
least	O
3	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Hachinski	B-Observation
Ischemia	I-Observation
Scale	I-Observation
score	I-Observation
<=	O
4	O
.	O

-	O
Availability	O
of	O
a	O
caregiver	O
.	O

-	O
Female	O
patients	O
must	O
be	O
either	O
surgically	O
sterile	O
or	O
at	O
least	O
2	O
years	O
postmenopausal	B-Condition
.	O

-	O
Male	O
patients	O
must	O
either	O
be	O
surgically	O
sterile	O
or	O
he	O
and	O
his	O
female	O
spouse	O
/	O
partner	O
who	O
is	O
of	O
childbearing	O
potential	O
must	O
be	O
using	O
highly	O
effective	O
contraception	O
starting	O
at	O
screening	O
and	O
continuing	O
throughout	O
the	O
study	O
period	O
.	O

-	O
Patient	O
provides	O
written	O
informed	O
consent	O
.	O

Exclusion	O
criteria	O
(	O
abbreviated	O
):	O
.	O

-	O
Participation	O
in	O
another	O
clinical	O
study	O
within	O
3	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Pregnant	B-Condition
or	O
breastfeeding	B-Condition
female	O
.	O

-	O
Not	O
expected	O
to	O
complete	O
the	O
clinical	O
study	O
.	O

-	O
Known	O
allergy	B-Condition
to	O
components	B-Drug
of	I-Drug
the	I-Drug
vaccine	I-Drug
.	O

-	O
Contraindication	B-Condition
for	O
MRI	B-Procedure_Device
imaging	O
.	O

-	O
Any	O
of	O
the	O
following	O
detected	O
by	O
brain	O
MRI:	O
.	O

-	O
Infarction	B-Condition
in	O
the	O
territory	O
of	O
large	O
vessels	O
.	O

-	O
More	O
than	O
one	O
lacunar	B-Observation
infarct	I-Observation
.	O

-	O
Any	O
lacunar	B-Observation
infarct	I-Observation
in	O
a	O
strategically	O
important	O
location	O
.	O

-	O
Confluent	B-Condition
hemispheric	I-Condition
deep	I-Condition
white	I-Condition
matter	I-Condition
lesions	I-Condition
(	O
Fazekas	B-Observation
grade	O
3	O
)	O
.	O

-	O
Other	O
focal	B-Condition
lesions	I-Condition
which	O
may	O
be	O
responsible	O
for	O
the	O
cognitive	O
status	O
of	O
the	O
patient	O
or	O
any	O
other	O
abnormalities	O
associated	O
with	O
significant	O
central	B-Condition
nervous	I-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Surgery	B-Procedure_Device
(	O
under	O
general	O
anaesthesia	O
)	O
within	O
3	O
months	O
prior	O
to	O
screening	O
and	O
/	O
or	O
scheduled	O
surgery	O
during	O
the	O
whole	O
study	O
period	O
.	O

-	O
Patient	O
has	O
a	O
history	B-Observation
and	O
/	O
or	O
currently	O
suffers	O
from	O
a	O
clinically	O
significant	O
autoimmune	B-Condition
disease	I-Condition
or	O
is	O
expected	O
to	O
receive	O
immunosuppressive	B-Drug
or	O
immunomodulatory	B-Drug
treatment	I-Drug
at	O
the	O
present	O
or	O
in	O
the	O
future	O
.	O

-	O
Recent	O
history	B-Observation
of	O
cancer	B-Condition
(	O
last	O
specific	O
treatment	O
<=	O
5	O
years	O
prior	O
to	O
Screening	O
)	O
.	O

-	O
Myocardial	B-Condition
infarction	I-Condition
within	O
2	O
years	O
prior	O
to	O
screening	O
.	O

-	O
Hepatitis	B-Condition
B,	I-Condition
C	I-Condition
HIV	B-Condition
or	O
Syphilis	B-Condition
.	O

-	O
Active	O
infectious	B-Condition
disease	I-Condition
.	O

-	O
Presence	B-Observation
and	O
/	O
or	O
history	B-Observation
of	O
immunodeficiency	B-Condition
.	O

-	O
Patient	O
currently	O
suffering	O
from	O
a	O
clinically	O
important	O
systemic	B-Condition
illness	I-Condition
.	O

-	O
poorly	O
controlled	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
(	O
NYHA	B-Observation
>=	O
3	O
)	O
.	O

-	O
BMI	B-Observation
>	O
40	O
.	O

-	O
poorly	O
controlled	O
diabetes	B-Condition
(	O
HbA1c	B-Observation
>	O
7.5%)	O
.	O

-	O
severe	O
renal	B-Condition
insufficiency	I-Condition
(	O
eGFR	B-Observation
<	O
30	O
mL	O
/	O
min	O
)	O
.	O

-	O
chronic	O
liver	B-Condition
disease	I-Condition
-	O
ALT	B-Observation
(	O
alanine	B-Observation
aminotransferase	I-Observation
)	O
>	O
66	O
U	O
/	O
L	O
in	O
females	O
or	O
>	O
80	O
U	O
/	O
L	O
in	O
males,	O
AST	B-Observation
(	O
aspartate	B-Observation
aminotransferase	I-Observation
)	O
>	O
82	O
U	O
/	O
L	O
.	O
-	O
QTc	B-Observation
interval	I-Observation
prolongation	I-Observation
in	O
ECG	B-Procedure_Device
(>	O
450	O
ms	O
)	O
.	O

-	O
other	O
clinically	O
significant	O
systemic	B-Condition
illness	I-Condition
if	O
considered	O
relevant	O
by	O
the	O
investigator	O
.	O

-	O
Hypothyroidism	B-Condition
,	O
defined	O
as	O
TSH	B-Observation
(	O
thyroid-stimulating	B-Observation
hormone	I-Observation
)	O
elevation	O
>	O
5.000	O
mcIU	O
/	O
mL,	O
and	O
/	O
or	O
FT4	B-Observation
levels	I-Observation
<	O
0.7	O
ng	O
/	O
dL	O
.	O

Patients	O
with	O
corrected	O
hypothyroidism	B-Condition
are	O
eligible	O
for	O
the	O
study	O
provided	O
that	O
treatment	O
has	O
been	O
stable	O
for	O
3	O
months	O
before	O
study	O
entry	O
.	O

-	O
History	B-Observation
or	O
presence	B-Observation
of	O
a	O
significant	O
psychiatric	B-Condition
illness	I-Condition
.	O

-	O
Current	O
depressive	B-Condition
episode	I-Condition
(	O
Geriatric	B-Observation
Depression	I-Observation
Scale	I-Observation
GDS	B-Observation
>=	O
6	O
)	O
or	O
major	B-Condition
depressive	I-Condition
episode	I-Condition
within	O
the	O
last	O
2	O
years	O
.	O

-	O
Metabolic	B-Condition
or	I-Condition
toxic	I-Condition
encephalopathy	I-Condition
or	O
dementia	B-Condition
due	O
to	O
a	O
general	O
medical	O
condition	O
.	O

-	O
History	B-Observation
of	O
alcohol	B-Condition
or	I-Condition
drug	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
within	O
the	O
past	O
2	O
years	O
.	O

-	O
Wernicke's	B-Condition
encephalopathy	I-Condition
.	O

-	O
History	B-Observation
or	O
evidence	B-Observation
of	O
any	O
CNS	B-Condition
disorder	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
that	O
could	O
be	O
the	O
cause	O
of	O
dementia	B-Condition
.	O

-	O
Cerebrovascular	B-Condition
disease	I-Condition
(	O
ischemic	B-Condition
or	I-Condition
haemorrhagic	I-Condition
stroke	I-Condition
)	O
or	O
diagnosis	O
of	O
possible,	O
probable	O
or	O
definite	O
vascular	B-Condition
dementia	I-Condition
.	O

-	O
Epilepsy	B-Condition
.	O

-	O
Treatment	O
with	O
experimental	B-Drug
immunotherapeutics	I-Drug
including	O
intravenous	B-Drug
immunoglobulin	I-Drug
within	O
3	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Treatment	O
with	O
experimental	O
therapies	O
for	O
AD	B-Condition
aiming	O
at	O
disease-modification	O
within	O
3	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Patient	O
is	O
currently	O
being	O
treated	O
or	O
was	O
treated	O
in	O
the	O
past	O
with	O
any	O
active	O
vaccines	O
for	O
AD	B-Condition
.	O

-	O
Treatment	O
with	O
immunosuppressive	B-Condition
drugs	I-Condition
.	O

-	O
Change	O
in	O
dose	B-Observation
of	O
previous	O
and	O
current	O
medications	B-Drug
within	O
the	O
last	O
30	O
days	O
prior	O
to	O
Screening	O
(	O
V01	O
),	O
if	O
considered	O
clinically	O
relevant	O
by	O
the	O
investigator	O
.	O

-	O
Vitamin	B-Condition
B12	I-Condition
or	I-Condition
folic	I-Condition
acid	I-Condition
deficiency	I-Condition
(	O
serum	B-Observation
vitamin	I-Observation
B12	I-Observation
<	O
191	O
pg	O
/	O
mL;	O
folic	B-Observation
acid	I-Observation
<	O
5.39	O
ng	O
/	O
mL	O
)	O
.	O

-	O
Pathogenic	O
mutation	O
in	O
the	O
MAPT	O
gene	O
.	O

>>NCT02380573	O
Inclusion	O
Criteria	O
for	O
all	O
subjects:	O
.	O

1	O
.	O

45	O
-	O
89	O
years	O
old	B-Observation
.	O

2	O
.	O

All	O
genders	O
.	O

3	O
.	O

All	O
minorities	O
.	O

4	O
.	O

English,	O
Spanish	O
or	O
multilingual	O
speakers	O
.	O

5	O
.	O

Postmenopausal	O
or	O
surgically	O
sterile	O
females	O
only	O
.	O

6	O
.	O

Inclusion	O
for	O
MCI	B-Condition
group	O
only:	O
participants	O
will	O
meet	O
the	O
criteria	O
for	O
amnestic	O
and	O
non-amnestic	B-Condition
MCI	I-Condition
such	O
as	O
those	O
currently	O
used	O
by	O
Texas	B-Observation
Alzheimer's	I-Observation
Research	I-Observation
and	I-Observation
Care	I-Observation
Consortium	I-Observation
(	O
TARCC	B-Observation
)	O
consensus	O
diagnosis	O
.	O

7	O
.	O

Inclusion	O
for	O
AD	B-Condition
group	O
only:	O
Alzheimer's	B-Condition
Early-stage,	I-Condition
sporadic-type	I-Condition
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

Pregnancy	B-Condition
or	O
breastfeeding	B-Condition
.	O

2	O
.	O

Contraindication	B-Condition
for	O
MRI	B-Procedure_Device
(	O
Claustrophobia	B-Condition
and	O
magnetic	B-Procedure_Device
metal	I-Procedure_Device
implants	I-Procedure_Device
)	O
.	O

3	O
.	O

Glucose-	B-Condition
6	I-Condition
-phosphate	I-Condition
deficiency	I-Condition
methemoglobinemia	B-Condition
.	O

4	O
.	O

Allergy	B-Condition
to	O
MB	B-Drug
.	O

5	O
.	O

Color-blindness	B-Condition
.	O

6	O
.	O

Craniotomy	B-Procedure_Device
,	O
craniectomy	B-Procedure_Device
or	O
endovascular	B-Procedure_Device
neurosurgery	I-Procedure_Device
.	O

7	O
.	O

A	O
current	O
diagnosis	O
of	O
stroke	B-Condition
,	O
transient	B-Condition
ischemic	I-Condition
attack	I-Condition
(	O
TIA	B-Condition
),	O
any	O
primary	B-Condition
neurodegenerative	I-Condition
disorder	I-Condition
or	O
any	O
other	O
causes	O
of	O
neuropsychologic	B-Condition
disturbances	I-Condition
or	O
secondary	B-Condition
dementia	I-Condition
(	O
MCI	B-Condition
or	O
AD	B-Condition
does	O
not	O
exclude	O
subject	O
)	O
.	O

8	O
.	O

A	O
serious	O
intercurrent	B-Condition
illness	I-Condition
likely	O
to	O
cause	O
death	B-Observation
within	O
the	O
next	O
5	O
years,	O
such	O
as	O
terminal	B-Condition
cancer	I-Condition
.	O

9	O
.	O

Alcohol	B-Condition
and	I-Condition
/	I-Condition
or	I-Condition
drug	I-Condition
abuse	I-Condition
.	O

10	O
.	O

Any	O
detection	O
of	O
an	O
unknown	O
disease	B-Condition
process	O
(	O
eg	O
.	O

new	B-Condition
tumor	I-Condition
)	O
on	O
the	O
study's	O
neuroimaging	B-Procedure_Device
at	O
the	O
discretion	O
of	O
the	O
investigators	O
.	O

11	O
.	O

A	O
systolic	B-Observation
blood	I-Observation
pressure	I-Observation
>=	O
180	O
mmHg	O
and	O
/	O
or	O
a	O
diastolic	B-Observation
blood	I-Observation
pressure	I-Observation
>=	O
105	O
mmHg	O
.	O

12	O
.	O

Severe	O
difficulty	O
or	O
an	O
inability	O
to	O
perform	O
any	O
one	O
of	O
the	O
6	O
Katz	O
Activities	O
of	O
Daily	O
Living	O
.	O

13	O
.	O

Patients	O
who	O
are	O
unlikely	O
to	O
comply	O
with	O
trial	O
visit	O
schedule	O
or	O
with	O
trial	O
medication,	O
.	O

14	O
.	O

On	O
any	O
psychiatric	B-Drug
serotonergic	I-Drug
antidepressant	I-Drug
medication	I-Drug
or	O
psychotropic	B-Drug
medication	I-Drug
within	O
the	O
last	O
5	O
weeks	O
.	O

15	O
.	O

Diagnosis	O
of	O
epilepsy	B-Condition
,	O
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
with	I-Condition
loss	I-Condition
of	I-Condition
consciousness	I-Condition
psychosis	B-Condition
,	O
panic	B-Condition
attacks	I-Condition
.	O

16	O
.	O

Chronic	B-Condition
kidney	I-Condition
disease	I-Condition
cirrhosis	B-Condition
,	O
liver	B-Condition
or	I-Condition
renal	I-Condition
transplants	I-Condition
.	O

17	O
.	O

Known	O
hypersensitivity	B-Condition
to	O
thiazide	B-Drug
diuretics	I-Drug
and	O
phenothiazines	B-Drug
.	O

18	O
.	O

Any	O
other	O
condition,	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator,	O
would	O
put	O
the	O
participant	O
at	O
risk	O
and	O
warrant	O
exclusion	O
from	O
the	O
study.	O

>>NCT00006187	O
Inclusion	O
Criteria:	O
.	O

-	O
Patient	O
is	O
male	O
or	O
female	O
and	O
at	O
least	O
50	O
years	O
of	O
age	B-Observation
or	O
older	O
.	O

-	O
Female	O
patients	O
must	O
be	O
postmenopausal	B-Condition
or	O
surgically	B-Condition
sterilized	I-Condition
.	O

-	O
Clinical	O
diagnosis	O
of	O
AD	B-Condition
.	O

-	O
Patient	O
must	O
be	O
in	O
good	B-Condition
health	I-Condition
except	B-Negation_cue
for	O
AD	B-Condition
diagnosis	O
.	O

-	O
Patient	O
must	O
have	O
informant	O
/	O
caregiver	O
who	O
can	O
monitor	O
and	O
assist	O
patient	O
during	O
the	O
study	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Patient	O
is	O
living	O
in	O
a	O
nursing	O
home	O
or	O
skilled	O
nursing	O
facility	O
.	O

-	O
Women	O
will	O
be	O
ineligible	O
if	O
not	B-Negation_cue
postmenopausal	B-Condition
or	O
surgically	B-Condition
sterilized	I-Condition
.	O

-	O
Site	O
physician	O
or	O
Sponsor	O
may	O
exclude	O
patients	O
with	O
serious	O
medical	B-Condition
problems	I-Condition
such	O
as	O
cancer	B-Condition
,	O
cardiovascular	B-Condition
disease	I-Condition
major	O
neurological	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
thyroid	B-Condition
disease	I-Condition
or	O
major	O
head	B-Condition
trauma	I-Condition
.	O

>>NCT00546767	O
Inclusion	O
Criteria:	O
.	O

-	O
Age	B-Observation
75	O
and	O
older	O
.	O

-	O
Willing	O
to	O
sign	O
consent	O
.	O

-	O
Willing	O
to	O
take	O
multi-vitamins	B-Drug
provided	O
by	O
the	O
study	O
.	O

-	O
Minimal	O
computer	O
skills	O
or	O
willingness	O
to	O
learn	O
(	O
as	O
demonstrated	O
by	O
completion	O
during	O
screening	O
of	O
a	O
demonstration	O
module	O
for	O
each	O
arm	O
)	O
.	O

-	O
English	O
fluency	O
.	O

-	O
MMSE	B-Observation
greater	O
than	O
26	O
.	O

-	O
Able	O
to	O
answer	O
and	O
dial	O
a	O
telephone	O
.	O

-	O
Able	O
to	O
complete	O
the	O
in-person	O
assessment	O
.	O

-	O
Able	O
to	O
complete	O
the	O
computerized	O
assessment	O
including	O
adequate	O
speech,	O
hearing	O
and	O
vision	O
.	O

-	O
Independently	O
living	O
adults,	O
defined	O
as	O
living	O
in	O
a	O
setting	O
in	O
which	O
the	O
participant	O
can	O
ensure	O
access	O
to	O
the	O
resources	O
for	O
study	O
procedures	O
.	O

-	O
Participation	O
of	O
a	O
study	O
partner	O
is	O
desirable	O
and	O
encouraged	O
but	O
not	O
required	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Dementia	B-Condition
.	O

-	O
Use	O
of	O
prescription	O
cognitive-enhancing	B-Drug
drugs	I-Drug
at	O
entry	O
(	O
eg	O
Aricept	B-Drug
,	O
Razadyne	B-Drug
,	O
Exelon	B-Drug
,	O
Namenda	B-Drug
)	O
.	O

-	O
Intent	O
to	O
continue	O
use	O
of	O
own	O
multi-vitamins	B-Drug
(	O
for	O
the	O
duration	O
of	O
the	O
study	O
participants	O
must	O
agree	O
to	O
take	O
only	O
study-distributed	B-Drug
multi-vitamins	I-Drug
)	O
.	O

-	O
History	O
or	O
presence	O
of	O
major	O
psychiatric,	B-Condition
neurological	I-Condition
or	I-Condition
neurodegenerative	I-Condition
conditions	I-Condition
associated	O
with	O
significant	O
cognitive	B-Condition
impairment	I-Condition
such	O
as	O
major	O
stroke	B-Condition
,	O
Parkinson's	B-Condition
disease	I-Condition
Multiple	B-Condition
Sclerosis	I-Condition
or	O
Huntington's	B-Condition
disease	I-Condition
.	O

Transient	B-Condition
Ischemic	I-Condition
Attack	I-Condition
(	O
TIA	B-Condition
)	O
is	O
acceptable	O
if	O
over	O
6	O
months	O
ago	O
.	O

-	O
Medical	B-Condition
conditions	I-Condition
associated	O
with	O
life	B-Observation
expectancy	I-Observation
of	O
less	O
than	O
5	O
years	O
.	O

-	O
Transient	O
domicile	O
interfering	O
with	O
ability	O
to	O
collect	O
study-related	O
data	O
.	O

-	O
Current	O
participation	O
in	O
a	O
clinical	O
trial	O
involving	O
Central	B-Drug
Nervous	I-Drug
System	I-Drug
(	I-Drug
CNS	I-Drug
)	I-Drug
medications	I-Drug
or	O
cognitive	O
testing	O
that	O
would	O
interfere	O
with	O
the	O
current	O
protocol	O
(	O
participation	O
in	O
Uniform	O
Data	O
Set	O
(	O
UDS	O
)	O
assessments	O
by	O
an	O
ADC	O
is	O
permitted	O
)	O
.	O

-	O
Cohabitation	O
with	O
another	O
participant	O
in	O
this	O
particular	O
study	O
.	O

>>NCT01780519	O
Inclusion	O
criteria:	O
.	O

-	O
MMSE	B-Observation
score	I-Observation
of	O
28	O
-	O
30	O
.	O

-	O
Hamilton	B-Observation
Depression	I-Observation
Rating	I-Observation
Scale	I-Observation
score	I-Observation
of	O
less	O
than	O
10	O
.	O

-	O
participants	O
in	O
longitudinal	O
study	O
of	O
aging	O
and	O
have	O
a	O
TOMM40	O
genotype	O
of	O
S	O
/	O
S,	O
VL	O
/	O
VL,	O
S	O
/	O
VL,	O
L	O
/	O
S	O
or	O
L	O
/	O
VL	O
.	O

Exclusion	O
criteria:	O
.	O

-	O
Alzheimer's	B-Condition
Disease	I-Condition
or	O
Mild	B-Condition
Cognitive	I-Condition
Impairment	I-Condition
.	O

-	O
any	O
significant	O
medical,	B-Condition
psychiatric	I-Condition
and	I-Condition
neurological	I-Condition
illnesses	I-Condition
eg	O
,	O
impaired	B-Condition
liver	I-Condition
or	I-Condition
kidney	I-Condition
function	I-Condition
prior	O
stroke	B-Condition
,	O
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
memory	B-Condition
impairment	I-Condition
cognitive	B-Condition
impairment	I-Condition
parkinsonism	B-Condition
,	O
a	O
lifetime	O
history	B-Observation
of	O
schizophrenia	B-Condition
,	O
bipolar	B-Condition
disorder	I-Condition
a	O
psychoactive	B-Condition
substance	I-Condition
use	I-Condition
disorder	I-Condition
or	O
current	O
major	B-Condition
depression	I-Condition
.	O

-	O
known	O
allergy	B-Condition
to	O
benzodiazepines	B-Drug
.	O

-	O
current	O
use	O
(	O
within	O
the	O
previous	O
four	O
weeks	O
)	O
of	O
benzodiazepines	B-Drug
or	O
other	O
medications	B-Drug
known	O
to	O
interact	O
with	O
lorazepam	B-Drug
,	O
current	O
use	O
of	O
sedating	B-Drug
antihistamines	I-Drug
or	O
current	O
use	O
of	O
stimulant	B-Drug
medications	I-Drug
.	O

>>NCT00134953	O
Inclusion	O
Criteria:	O
.	O

-	O
Males	O
or	O
females	O
who	O
are	O
one	O
year	O
post-menopausal	B-Condition
or	O
without	B-Negation_cue
childbearing	B-Condition
potential	I-Condition
.	O

-	O
Between	O
the	O
ages	B-Observation
of	O
50	O
and	O
85	O
years	O
old	O
.	O

-	O
Mild	B-Condition
cognitive	I-Condition
impairment	I-Condition
confirmed	O
by	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
between	O
23	O
and	O
27	O
.	O

-	O
Cooperative,	O
able	O
to	O
ingest	O
oral	O
medication	O
and	O
able	O
to	O
complete	O
all	O
aspects	O
of	O
the	O
study	O
and	O
capable	O
of	O
doing	O
so,	O
either	O
alone	O
or	O
with	O
the	O
aid	O
of	O
a	O
responsible	O
caregiver,	O
according	O
to	O
the	O
investigator's	O
judgement	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
A	O
current	O
diagnosis	O
of	O
cerebrovascular	B-Condition
disease	I-Condition
any	O
primary	O
neurodegenerative	B-Condition
disorder	I-Condition
or	O
any	O
other	O
causes	O
of	O
neuropsychologic	B-Condition
disturbances	I-Condition
or	O
secondary	B-Condition
dementia	I-Condition
.	O

-	O
A	O
current	O
diagnosis	O
of	O
epilepsy	B-Condition
or	O
depression	B-Condition
or	O
any	O
other	O
diagnosis	O
that	O
may	O
interfere	O
with	O
the	O
patient's	O
response	O
to	O
study	O
medication	O
.	O

-	O
An	O
advanced,	O
severe	O
or	O
unstable	O
disease	B-Condition
of	O
any	O
type	O
that	O
may	O
interfere	O
with	O
efficacy	O
evaluations	O
.	O

Other	O
protocol-defined	O
exclusion	O
criteria	O
may	O
apply	O
.	O

>>NCT00380302	O
Inclusion	O
Criteria:	O
.	O

-	O
The	O
diagnosis	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Recent	O
brain	B-Procedure_Device
image	I-Procedure_Device
(	O
Computerized	B-Procedure_Device
Axial	I-Procedure_Device
Tomographic	I-Procedure_Device
Scan	I-Procedure_Device
CAT	B-Procedure_Device
scan	I-Procedure_Device
or	O
Magnetic	B-Procedure_Device
Resonance	I-Procedure_Device
Imaging	I-Procedure_Device
-	O
MRI	B-Procedure_Device
)	O
.	O

-	O
Mild	O
to	O
moderate	O
range	O
of	O
disease	B-Condition
;	O
not	O
too	O
severe	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Severe	O
or	O
unstable	O
medical	B-Condition
diseases	I-Condition
.	O

-	O
Neurological	B-Condition
disorder	I-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Depression	B-Condition
that	O
is	O
not	B-Negation_cue
well	O
controlled	O
.	O

-	O
Treatment	O
with	O
memantine	B-Drug
.	O

-	O
Inpatient	O
in	O
a	O
total	O
care	O
facility	O
(	O
eg	O
:	O
Nursing	O
home	O
)	O
.	O

-	O
Lack	O
of	O
reliable	O
caregiver	O
.	O

>>NCT01189084	O
Inclusion	O
Criteria:	O
.	O

-	O
Individuals	O
with	O
mild	O
to	O
moderate	O
Alzheimer's	B-Condition
disease	I-Condition
who	O
received	O
three	O
(	O
3	O
)	O
injections	O
of	O
UB	B-Drug
311	I-Drug
in	O
the	O
initial	O
Phase	O
I	O
V118	O
-AD	O
trial	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Individuals	O
with	O
Alzheimer's	B-Condition
disease	I-Condition
who	O
are	O
currently	O
on	O
prohibited	B-Drug
medications	I-Drug
have	O
severe	O
or	O
uncontrolled	O
systemic	B-Condition
disease	I-Condition
or	O
are	O
unable	O
or	O
unwilling	O
to	O
comply	O
with	O
study	O
protocol	O
requirements	O
.	O

>>NCT01662882	O
Inclusion	O
Criteria:	O
.	O

Subjects	O
who	O
meet	O
all	O
of	O
the	O
following	O
criteria	O
are	O
eligible	O
to	O
enroll	O
in	O
the	O
arm	O
of	O
this	O
trial	O
reserved	O
for	O
subjects	O
with	O
AD:	O
.	O

1	O
.	O

Japanese	O
males	O
or	O
females	O
at	O
least	O
50	O
years	O
of	O
age	B-Observation
,	O
with	O
probable	O
AD	B-Condition
according	O
to	O
the	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
(	O
McKhann	O
et	O
al.,	O
1984	O
);	O
.	O

2	O
.	O

Subjects	O
with	O
mild	O
/	O
moderate	O
dementia	B-Condition
as	O
evidenced	O
by	O
a	O
MMSE	B-Observation
score	I-Observation
ranging	O
from	O
10	O
to	O
24,	O
boundaries	O
included,	O
at	O
screening;	O
.	O

3	O
.	O

Subjects	O
whose	O
history	B-Observation
of	O
cognitive	B-Condition
decline	I-Condition
has	O
been	O
gradual	O
in	O
onset	O
and	O
progressive	O
over	O
a	O
period	O
of	O
at	O
least	O
6	O
months	O
.	O

Evidence	O
should	O
be	O
present	O
indicating	O
sustained	O
memory	B-Condition
deterioration	I-Condition
in	O
an	O
otherwise	O
cognitively	O
normal	O
subject,	O
plus	O
additional	O
impairment	B-Condition
in	O
another	O
cognitive	B-Observation
function	I-Observation
such	O
as:	O
orientation	B-Observation
,	O
judgment	B-Observation
and	O
problem	B-Observation
solving	I-Observation
or	O
functioning	B-Observation
in	I-Observation
personal	I-Observation
care	I-Observation
.	O

4	O
.	O

Subjects	O
who	O
live	O
with	O
or	O
have	O
regular	O
visits	O
from	O
a	O
responsible	O
caregiver	O
willing	O
to	O
provide	O
information	O
about	O
the	O
subject's	O
cognitive	O
status;	O
and	O
.	O

5	O
.	O

Subjects	O
who	O
signed	O
an	O
Institutional	O
Review	O
Board	O
/	O
Independent	O
Ethics	O
Committee	O
(	O
IRB	O
/	O
IEC	O
)	O
approved	O
informed	O
consent	O
prior	O
to	O
any	O
study	O
procedures	O
.	O

If	O
the	O
subject	O
is	O
incapable	O
of	O
giving	O
informed	O
consent,	O
the	O
caregiver	O
may	O
consent	O
on	O
behalf	O
of	O
the	O
subject	O
(	O
the	O
subject	O
must	O
still	O
confirm	O
assent	O
)	O
.	O

Subjects	O
who	O
meet	O
all	O
of	O
the	O
following	O
criteria	O
are	O
eligible	O
to	O
enroll	O
in	O
the	O
arm	O
of	O
this	O
trial	O
reserved	O
for	O
subjects	O
with	O
mild	B-Condition
cognitive	I-Condition
impairment	I-Condition
.	O

1	O
.	O

Japanese	B-Observation
males	O
or	O
females	O
at	O
least	O
50	O
years	O
of	O
age	B-Observation
;	O
.	O

2	O
.	O

Subjects	O
with	O
complaint	O
of	O
memory	B-Observation
or	I-Observation
cognitive	I-Observation
decline	I-Observation
corroborated	O
by	O
an	O
informant;	O
.	O

3	O
.	O

Subjects	O
with	O
a	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
(	O
CDR	B-Observation
)	O
of	O
0.5;	O
.	O

4	O
.	O

Subjects	O
with	O
objective	O
cognitive	B-Condition
impairment	I-Condition
or	O
marginally	B-Condition
normal	I-Condition
cognition	I-Condition
with	O
a	O
documented	O
history	B-Observation
of	O
high	B-Condition
cognitive	I-Condition
performance	I-Condition
.	O

5	O
.	O

Have	O
no	O
obvious	O
causes	O
for	O
their	O
cognitive	B-Condition
impairment	I-Condition
(	O
eg	O
,	O
onset	O
coincides	O
with	O
recent	O
head	B-Condition
trauma	I-Condition
or	O
stroke	B-Condition
);	O
.	O

6	O
.	O

Have	O
sufficiently	O
preserved	O
general	O
cognition	O
and	O
functional	O
performance	O
such	O
that	O
a	O
diagnosis	O
of	O
AD	B-Condition
cannot	O
be	O
made	O
at	O
the	O
time	O
of	O
the	O
screening	O
visit;	O
.	O

7	O
.	O

Subjects	O
with	O
essentially	O
normal	O
ADL	B-Observation
;	O
.	O

8	O
.	O

Subjects	O
who	O
are	O
not	B-Negation_cue
demented	B-Observation
;	O
.	O

9	O
.	O

Subjects	O
with	O
an	O
MMSE	B-Observation
score	I-Observation
>	O
24;	O
.	O

10	O
.	O

Subjects	O
who	O
are	O
presenting	O
for	O
initial	O
diagnosis	O
of	O
cognitive	B-Condition
impairment	I-Condition
or	O
who	O
have	O
presented	O
for	O
initial	O
diagnosis	O
of	O
cognitive	B-Condition
impairment	I-Condition
within	O
the	O
past	O
year;	O
.	O

11	O
.	O

Subjects	O
who	O
live	O
with	O
or	O
have	O
regular	O
visits	O
from	O
a	O
responsible	O
caregiver	O
willing	O
to	O
provide	O
information	O
about	O
the	O
subject's	O
cognitive	O
status;	O
and	O
.	O

12	O
.	O

Subjects	O
who	O
signed	O
an	O
IRB	O
/	O
IEC	O
approved	O
informed	O
consent	O
prior	O
to	O
any	O
study	O
procedures	O
.	O

Subjects	O
who	O
meet	O
all	O
of	O
the	O
following	O
criteria	O
are	O
eligible	O
to	O
enroll	O
in	O
the	O
arm	O
of	O
this	O
trial	O
reserved	O
for	O
cognitively	O
normal	O
volunteers:	O
.	O

1	O
.	O

Japanese	B-Observation
males	O
or	O
females	O
at	O
least	O
50	O
years	O
of	O
age	B-Observation
;	O
.	O

2	O
.	O

Subjects	O
with	O
an	O
MMSE	B-Observation
score	I-Observation
>=	O
29	O
and	O
are	O
cognitively	O
normal	O
based	O
on	O
history	O
and	O
psychometric	O
test	O
battery	O
at	O
screening;	O
.	O

3	O
.	O

Subjects	O
who	O
live	O
with	O
or	O
have	O
a	O
reliable	O
person	O
who	O
can	O
verify	O
their	O
cognitive	O
status;	O
and	O
.	O

4	O
.	O

Subjects	O
who	O
signed	O
an	O
IRB	O
/	O
IEC	O
approved	O
informed	O
consent	O
prior	O
to	O
any	O
study	O
procedures	O
.	O

Exclusion	O
Criteria:	O
.	O

Subjects	O
with	O
any	O
of	O
the	O
following	O
are	O
ineligible	O
to	O
enroll	O
in	O
this	O
trial:	O
.	O

1	O
.	O

A	O
documented	O
diagnosis	O
of	O
MCI	B-Condition
for	O
greater	O
than	O
1	O
year	O
(	O
for	O
subjects	O
considered	O
for	O
the	O
MCI	O
group	O
);	O
.	O

2	O
.	O

Neurodegenerative	B-Condition
disorders	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
,	O
including	O
but	O
not	O
limited	O
to	O
Parkinson's	B-Condition
disease	I-Condition
Pick's	B-Condition
disease	I-Condition
frontotemporal	B-Condition
dementia	I-Condition
Huntington's	B-Condition
chorea	I-Condition
Down's	B-Condition
syndrome	I-Condition
Creutzfeldt-Jacob	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
and	O
progressive	O
supranuclear	B-Condition
palsy	I-Condition
.	O

3	O
.	O

Have	O
had	O
or	O
currently	O
have	O
a	O
diagnosis	O
of	O
other	O
dementing	B-Condition
/	I-Condition
neurodegenerative	I-Condition
disease	I-Condition
(	O
eg	O
Parkinson's	B-Condition
disease	I-Condition
dementia	B-Condition
with	I-Condition
Lewy	I-Condition
bodies	I-Condition
Lewy	B-Condition
body	I-Condition
variant	I-Condition
AD	I-Condition
etc.);	O
.	O

4	O
.	O

Have	O
had	O
or	O
currently	O
have	O
a	O
diagnosis	O
of	O
mixed	B-Condition
dementia	I-Condition
.	O

5	O
.	O

Cognitive	B-Condition
impairment	I-Condition
resulting	O
from:	O
.	O

-	O
Acute	O
cerebral	B-Condition
trauma	I-Condition
or	O
post-traumatic	B-Condition
brain	I-Condition
injury	I-Condition
subdural	B-Condition
hematoma	I-Condition
or	O
injuries	B-Condition
secondary	I-Condition
to	I-Condition
chronic	I-Condition
trauma	I-Condition
(	O
eg	O
sequela	O
from	O
boxing	O
);	O
.	O

-	O
Hypoxic	B-Condition
cerebral	I-Condition
damage	I-Condition
regardless	O
of	O
etiology;	O
eg	O
cognitive	B-Condition
or	I-Condition
neurological	I-Condition
deficits	I-Condition
resulting	O
from	O
cardiac	B-Condition
arrest	I-Condition
or	O
cardiac	B-Procedure_Device
surgery	I-Procedure_Device
anesthesia	B-Procedure_Device
or	O
severe	O
self-poisoning	O
episode,	O
secondary	O
to	O
severe	O
hypovolemia	B-Condition
(	O
orthostatic	B-Condition
hypotension	I-Condition
should	O
not	O
lead	O
to	O
exclusion	O
);	O
.	O

-	O
Vitamin	B-Condition
deficiency	I-Condition
states	O
documented	O
by	O
medical	O
history	O
such	O
as	O
folate,	B-Condition
vitamin	I-Condition
B	I-Condition
12	I-Condition
and	I-Condition
other	I-Condition
B	I-Condition
complex	I-Condition
deficiencies	I-Condition
eg	O
thiamin	B-Condition
deficiency	I-Condition
in	O
Korsakoff's	B-Condition
syndrome	I-Condition
.	O

(	O
Note:	O
subjects	O
taking	O
regular	O
B12	B-Drug
and	O
folate	B-Drug
are	O
not	B-Negation_cue
necessarily	O
excluded	B-Negation_cue
);	O
.	O

-	O
Cerebral	B-Condition
infection	I-Condition
including	O
abscess	B-Condition
,	O
syphilis	B-Condition
,	O
meningitis	B-Condition
,	O
encephalitis	B-Condition
or	O
AIDS	B-Condition
;	O
.	O

-	O
Primary	O
or	O
metastatic	O
cerebral	B-Condition
neoplasia	I-Condition
.	O

-	O
Significant	O
endocrine	B-Condition
or	I-Condition
metabolic	I-Condition
disease	I-Condition
eg	O
,	O
thyroid,	B-Condition
parathyroid	I-Condition
or	I-Condition
pituitary	I-Condition
disease	I-Condition
Cushing's	B-Condition
syndrome	I-Condition
or	O
severe	O
renal	B-Condition
failure	I-Condition
or	O
.	O

-	O
Mental	B-Condition
retardation	I-Condition
.	O

Before	O
enrolling	O
a	O
subject	O
with	O
past	O
or	O
current	O
history	B-Observation
of	O
any	O
of	O
the	O
above	O
conditions,	O
the	O
investigator	O
must	O
contact	O
the	O
sponsor	O
to	O
discuss	O
whether	O
the	O
condition	O
could	O
have	O
contributed	O
to	O
the	O
cognitive	B-Condition
impairment	I-Condition
.	O

6	O
.	O

Clinically	O
significant	O
infarct	B-Condition
or	O
possible	O
multi-infarct	B-Condition
dementia	I-Condition
as	O
defined	O
by	O
the	O
NINCDS	B-Observation
criteria	I-Observation
including:	O
.	O

-	O
A	O
history	B-Observation
of	O
a	O
significant	O
cerebrovascular	B-Condition
event	I-Condition
resulting	O
in	O
a	O
physical	O
or	O
neurologic	O
deficit	O
that	O
may	O
confound	O
the	O
assessment	O
of	O
the	O
subject's	O
intellectual	O
function;	O
.	O

-	O
Multiple	B-Observation
focal	I-Observation
signs	I-Observation
on	O
neurologic	B-Procedure_Device
examination	I-Procedure_Device
indicative	O
of	O
multiple	B-Condition
ischemic	I-Condition
episodes	I-Condition
.	O

-	O
One	O
or	O
more	O
of	O
the	O
following	O
findings	O
on	O
a	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
.	O

-	O
Multiple	O
(	O
two	O
or	O
more	O
)	O
infarcts	B-Observation
or	O
white	B-Observation
matter	I-Observation
lacunes	I-Observation
.	O

-	O
A	O
single	O
large	O
infarct	B-Observation
or	O
a	O
strategically	O
placed	O
infarct	B-Observation
in	O
the	O
angular	O
gyrus,	O
the	O
thalamus,	O
the	O
basal	O
forebrain,	O
the	O
posterior	O
cerebral	O
artery	O
(	O
PCA	O
)	O
or	O
anterior	O
cerebral	O
artery	O
(	O
ACA	O
)	O
territory;	O
.	O

-	O
Extensive	B-Condition
periventricular	I-Condition
white	I-Condition
matter	I-Condition
disease	I-Condition
.	O

Leukoaraiosis	B-Condition
(	O
periventricular	B-Observation
white	I-Observation
matter	I-Observation
low	B-Observation
attenuation	I-Observation
)	O
should	O
be	O
distinguished	O
from	O
multiple	B-Condition
infarctions	I-Condition
.	O

Leukoaraiosis	B-Condition
is	O
common	O
in	O
normal	O
individuals	O
and	O
patients	O
with	O
AD	B-Condition
.	O

White	B-Condition
matter	I-Condition
deterioration	I-Condition
should	O
not	B-Negation_cue
result	O
in	O
exclusion	B-Negation_cue
unless	O
it	O
is	O
abnormal	O
and	O
widespread,	O
eg	O
,	O
Binswanger's	B-Condition
disease	I-Condition
.	O

7	O
.	O

Any	O
evidence	O
on	O
screening	O
MRI	B-Procedure_Device
,	O
computed	B-Procedure_Device
tomography	I-Procedure_Device
(	O
CT	B-Procedure_Device
)	O
or	O
other	O
biomarker	B-Observation
studies	I-Observation
that	O
suggests	O
an	O
alternate	O
etiology	O
(	O
other	B-Negation_cue
than	I-Negation_cue
probable	O
AD	B-Condition
in	O
subjects	O
with	O
AD	B-Condition
)	O
for	O
cognitive	B-Condition
deficit	I-Condition
or	O
in	O
the	O
case	O
of	O
cognitively	O
normal	O
controls	O
any	O
evidence	O
on	O
screening	O
MRI	B-Procedure_Device
,	O
CT	B-Procedure_Device
or	O
other	O
biomarker	B-Observation
studies	I-Observation
that	O
suggests	O
the	O
presence	O
of	O
AD	B-Condition
pathology;	O
.	O

8	O
.	O

Current	O
clinically	O
significant	O
psychiatric	B-Condition
disease	I-Condition
as	O
judged	O
by	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Disorders,	I-Observation
4th	I-Observation
Edition	I-Observation
(	I-Observation
DSM-IV	I-Observation
)	I-Observation
criteria	I-Observation
particularly	O
current	O
major	B-Condition
depression	I-Condition
or	O
schizophrenia	B-Condition
.	O

Subjects	O
with	O
dementia	B-Condition
who	O
are	O
experiencing	O
behavioral	B-Condition
disturbances	I-Condition
that	O
may	O
require	O
treatment	O
with	O
psychotropic	B-Drug
medications	I-Drug
may	O
be	O
entered	O
only	O
after	O
discussion	O
and	O
with	O
the	O
approval	O
of	O
the	O
sponsor	O
.	O

The	O
investigator	O
and	O
sponsor	O
should	O
carefully	O
consider	O
whether	O
subjects	O
with	O
behavioral	B-Condition
dysfunction	I-Condition
will	O
be	O
able	O
to	O
complete	O
the	O
imaging	O
session;	O
.	O

9	O
.	O

History	B-Observation
of	O
epilepsy	B-Condition
or	O
convulsions	B-Condition
,	O
except	B-Negation_cue
for	O
febrile	B-Condition
convulsions	I-Condition
during	O
childhood;	O
.	O

10	O
.	O

Clinically	O
significant	O
hepatic,	B-Condition
renal,	I-Condition
pulmonary,	I-Condition
metabolic	I-Condition
or	I-Condition
endocrine	I-Condition
disturbances	I-Condition
.	O

11	O
.	O

Current	O
clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
.	O

Clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
usually	O
includes	O
one	O
or	O
more	O
of	O
the	O
following:	O
.	O

-	O
cardiac	B-Procedure_Device
surgery	I-Procedure_Device
or	O
myocardial	B-Condition
infarction	I-Condition
within	O
the	O
last	O
6	O
months;	O
.	O

-	O
unstable	O
angina	B-Condition
;	O
.	O

-	O
coronary	B-Condition
artery	I-Condition
disease	I-Condition
that	O
required	O
an	O
increase	O
in	O
medication	O
within	O
the	O
last	O
3	O
months;	O
.	O

-	O
decompensated	B-Condition
congestive	I-Condition
heart	I-Condition
failure	I-Condition
.	O

-	O
significant	O
cardiac	B-Condition
arrhythmia	I-Condition
or	O
conduction	B-Condition
disturbance	I-Condition
particularly	O
those	O
resulting	O
in	O
atrial	B-Condition
or	I-Condition
ventricular	I-Condition
fibrillation	I-Condition
or	O
causing	O
syncope	B-Condition
,	O
near	B-Condition
syncope	I-Condition
or	O
other	O
alterations	B-Condition
in	I-Condition
mental	I-Condition
status	I-Condition
.	O

-	O
severe	O
mitral	B-Condition
or	I-Condition
aortic	I-Condition
valvular	I-Condition
disease	I-Condition
.	O

-	O
uncontrolled	O
high	B-Condition
blood	I-Condition
pressure	I-Condition
.	O

-	O
congenital	B-Condition
heart	I-Condition
disease	I-Condition
.	O

-	O
clinically	O
significant	O
abnormal	O
result	O
on	O
ECG	B-Procedure_Device
,	O
including	O
but	O
not	O
limited	O
to	O
QTc	B-Observation
>	O
450	O
msec	O
.	O

Before	O
enrolling	O
a	O
subject	O
with	O
any	O
of	O
the	O
above	O
conditions,	O
the	O
investigator	O
must	O
contact	O
the	O
sponsor	O
.	O

12	O
.	O

History	B-Observation
of	O
drug	B-Condition
or	I-Condition
alcohol	I-Condition
abuse	I-Condition
within	O
the	O
last	O
year	O
or	O
prior	O
prolonged	O
history	B-Observation
of	O
abuse	B-Condition
;	O
.	O

13	O
.	O

Clinically	O
significant	O
infectious	B-Condition
disease	I-Condition
including	O
Acquired	B-Condition
Immune	I-Condition
Deficiency	I-Condition
Syndrome	I-Condition
(	O
AIDS	B-Condition
)	O
or	O
Human	B-Condition
Immunodeficiency	I-Condition
Virus	I-Condition
(	I-Condition
HIV	I-Condition
)	I-Condition
infection	I-Condition
or	O
previous	O
positive	O
test	O
for	O
hepatitis	B-Condition
;	O
.	O

14	O
.	O

Females	O
of	O
childbearing	B-Condition
potential	I-Condition
who	O
are	O
not	O
surgically	B-Condition
sterile	I-Condition
not	O
refraining	O
from	O
sexual	O
activity	O
or	O
not	O
using	O
reliable	O
methods	O
of	O
contraception	O
.	O

Females	O
of	O
childbearing	O
potential	O
must	O
not	O
be	O
pregnant	O
(	O
negative	O
serum	B-Observation
beta-hCG	I-Observation
at	O
the	O
time	O
of	O
screening	O
and	O
negative	O
urine	B-Observation
beta-hCG	I-Observation
on	O
the	O
day	O
of	O
imaging	O
)	O
or	O
breastfeeding	B-Condition
at	O
screening	O
.	O

Females	O
must	O
agree	O
to	O
avoid	O
becoming	O
pregnant	O
and	O
must	O
agree	O
to	O
refrain	O
from	O
sexual	O
activity	O
or	O
to	O
use	O
reliable	O
contraceptive	O
methods	O
such	O
as	O
prescribed	O
birth	O
control	O
or	O
IUD	O
for	O
24	O
hours	O
following	O
administration	O
of	O
florbetapir	O
(	O
18F	O
);	O
.	O

15	O
.	O

Subjects	O
who,	O
in	O
the	O
opinion	O
of	O
the	O
investigator,	O
are	O
otherwise	O
unsuitable	O
for	O
a	O
study	O
of	O
this	O
type;	O
.	O

16	O
.	O

History	B-Observation
of	O
relevant	O
severe	O
drug	B-Condition
allergy	I-Condition
or	O
hypersensitivity	B-Condition
;	O
.	O

17	O
.	O

Subjects	O
who	O
have	O
received	O
an	O
investigational	B-Drug
medication	I-Drug
within	O
the	O
last	O
30	O
days	O
.	O

Additionally,	O
the	O
time	O
between	O
the	O
last	O
dose	O
of	O
the	O
previous	O
experimental	B-Drug
medication	I-Drug
and	O
enrollment	O
(	O
completion	O
of	O
screening	O
assessments	O
)	O
must	O
be	O
at	O
least	O
equal	O
to	O
5	O
times	O
the	O
terminal	O
half-life	O
of	O
the	O
previous	O
experimental	B-Drug
medication	I-Drug
.	O

Subjects	O
who	O
have	O
ever	O
participated	O
in	O
an	O
experimental	O
study	O
with	O
an	O
amyloid	B-Drug
targeting	I-Drug
therapy	I-Drug
(	O
eg	O
,	O
immunotherapy	B-Drug
,	O
secretase	B-Drug
inhibitor	I-Drug
)	O
may	O
not	O
be	O
enrolled	O
unless	O
it	O
can	O
be	O
demonstrated	O
that	O
the	O
subject	O
received	O
only	O
placebo	O
in	O
the	O
course	O
of	O
the	O
trial;	O
.	O

18	O
.	O

Subjects	O
with	O
current	O
clinically	O
significant	O
medical	B-Condition
comorbidities	I-Condition
as	O
indicated	O
by	O
history	B-Observation
,	O
physical	B-Observation
exam	I-Observation
ECG	B-Procedure_Device
(	O
including	O
but	O
not	O
limited	O
to	O
QTc	B-Observation
>	O
450	O
msec	O
)	O
or	O
laboratory	B-Observation
evaluations	I-Observation
that	O
might	O
pose	O
a	O
potential	O
safety	O
risk,	O
interfere	O
with	O
the	O
absorption	O
or	O
metabolism	O
of	O
the	O
study	O
medication	O
or	O
limit	O
interpretation	O
of	O
the	O
trial	O
results	O
.	O

These	O
include	O
but	O
are	O
not	O
limited	O
to	O
clinically	O
significant	O
hepatic,	B-Condition
renal,	I-Condition
pulmonary,	I-Condition
metabolic	I-Condition
or	I-Condition
endocrine	I-Condition
disease	I-Condition
cancer	B-Condition
,	O
HIV	B-Condition
infection	I-Condition
and	O
AIDS	B-Condition
;	O
.	O

19	O
.	O

Subjects	O
who	O
have	O
known	O
hypersensitivity	B-Condition
to	O
alcohol	B-Drug
;	O
and	O
.	O

20	O
.	O

Subjects	O
who	O
received	O
a	O
radiopharmaceutical	B-Procedure_Device
for	I-Procedure_Device
imaging	I-Procedure_Device
or	I-Procedure_Device
therapy	I-Procedure_Device
within	O
the	O
past	O
7	O
days	O
prior	O
to	O
the	O
imaging	O
session	O
for	O
this	O
study	O
.	O

>>NCT02059356	O
Inclusion	O
Criteria:	O
.	O

-	O
cognitive	B-Condition
decline	I-Condition
(	O
suspected	O
or	O
documented	O
)	O
.	O

-	O
able	O
to	O
get	O
blood	O
drawn	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
liver	B-Condition
disease	I-Condition
/	I-Condition
cirrhosis	I-Condition
.	O

>>NCT01249196	O
Inclusion	O
Criteria:	O
.	O

-	O
Clinical	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
disease	I-Condition
(	O
DSM-IV	B-Observation
and	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
)	O
.	O

-	O
MRI	B-Procedure_Device
within	O
the	O
last	O
12	O
months	O
consistent	O
with	O
a	O
diagnosis	O
of	O
AD	B-Condition
.	O

-	O
MMSE	B-Observation
score	I-Observation
of	O
10	O
to	O
26	O
and	O
CDR	B-Observation
of	O
1	O
or	O
2	O
.	O

-	O
AChEI	B-Drug
or	O
memantine	B-Drug
was	O
not	B-Negation_cue
taken	O
at	O
least	O
3	O
months	O
prior	O
to	O
screening	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Other	O
central	B-Condition
nervous	I-Condition
disease	I-Condition
.	O

-	O
Hypothyroidism	B-Condition
,	O
Vitamin	B-Condition
B12	O
/	O
	I-Condition
Folic	I-Condition
acid	I-Condition
deficiency	I-Condition
Hypercalcemia	B-Condition
,	O
Neurosyphilis	B-Condition
,	O
AIDS	B-Condition

.	O
-	O
T.I.A	B-Condition
or	O
Major	O
infarction	B-Condition
within	O
the	O
last	O
12	O
months	O

.	O
-	O
Any	O
serious	O
disorder	B-Condition
that	O
could	O
limit	O
the	O
ability	O
of	O
the	O
patient	O
to	O
participate	O
in	O
the	O
study	O

.	O
-	O
COPD	B-Condition
or	O
asthma	B-Condition

.	O
-	O
Any	O
condition	O
which	O
would	O
make	O
the	O
patient	O
or	O
the	O
caregiver,	O
in	O
the	O
opinion	O
of	O
the	O
investigator,	O
unsuitable	O
for	O
the	O
study	O

.	O
>>NCT00267163	O
Inclusion	O
Criteria:	O

.	O
-	O
Agreement	O
to	O
participate	O
in	O
a	O
18	O
month	O
clinical	O
trial	O

.	O
-	O
NIMH	B-Observation
diagnostic	I-Observation
criteria	I-Observation
for	O
age-associated	B-Condition
memory	I-Condition
impairment	I-Condition
(	O
AAMI	B-Condition
)	O

.	O
-	O
Age	B-Observation
40	O
to	O
90	O
years	O

.	O
-	O
MMSE	B-Observation
score	I-Observation
between	O
24	O
and	O
30	O
(	O
unless	O
<	O
8	O
years	O
of	O
educational	O
achievement	O
)	O

.	O
-	O
No	B-Negation_cue
significant	O
cerebrovascular	B-Condition
disease	I-Condition
-	O
modified	B-Observation
Ischemic	I-Observation
Score	I-Observation
of	O
<	O
4	O

.	O
-	O
The	O
following	O
medications	O
are	O
allowed	O
if	O
stable	O
for	O
>	O
1	O
month:	O
antidepressants	B-Drug
(	O
without	O
anticholinergic	O
effects	O
)	O
if	O
not	O
currently	O
depressed	B-Observation
and	O
no	B-Negation_cue
history	B-Observation
of	O
major	B-Condition
depression	I-Condition
for	O
2	O
years;	O
estrogen	B-Drug
replacement	I-Drug
therapy	I-Drug
thyroid	B-Drug
replacement	I-Drug
therapy	I-Drug
as	O
long	O
as	O
patient	O
is	O
euthyroid	B-Condition

.	O
-	O
On	O
entering	O
the	O
study,	O
there	O
must	O
be	O
a	O
family	O
member	O
or	O
potential	O
caregiver	O
available	O
in	O
case	O
the	O
patient	O
develops	O
cognitive	B-Condition
impairment	I-Condition
that	O
interferes	O
with	O
independent	O
study	O
participation	O

.	O
-	O
Memory	O
and	O
verbal	O
fluency	O
cut-off	O
scores	O
increasing	O
the	O
probability	O
of	O
incipient	B-Condition
dementia	I-Condition
(	O
Buschke-Fuld	B-Observation
-	O
34;	O
verbal	B-Observation
fluency	I-Observation
-	O
46	O
for	O
letters,	O
7	O
for	O
categories;	O
Benton	B-Observation
Visual	I-Observation
Retention	I-Observation
-	O
5	O
)	O

.	O
-	O
Adequate	O
visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
to	O
allow	O
neuropsychological	O
testing	O

.	O
-	O
Screening	O
laboratory	B-Observation
tests	I-Observation
and	O
ECG	B-Procedure_Device
without	B-Negation_cue
significant	O
abnormalities	B-Observation
that	O
might	O
interfere	O
with	O
the	O
study	O

.	O
Exclusion	O
Criteria:	O

.	O
-	O
Diagnosis	O
of	O
possible	O
or	O
probable	O
AD	B-Condition
or	O
any	O
other	O
dementia	B-Condition
(	O
eg	O
,	O
vascular	B-Condition
,	O
Lewy	B-Condition
body	I-Condition
frontotemporal	B-Condition
)	O

.	O
-	O
Evidence	O
of	O
neurologic	O
or	O
other	O
physical	B-Condition
illness	I-Condition
that	O
could	O
produce	O
cognitive	B-Condition
deterioration	I-Condition
including	O
Parkinson's	B-Condition
disease	I-Condition
volunteers	O
with	O
a	O
history	B-Observation
of	O
TIAs	B-Condition
,	O
carotid	B-Observation
bruits	I-Observation
or	O
lacunes	B-Observation
on	O
MRI	B-Procedure_Device
scan	O
will	O
be	O
excluded	O

.	O
-	O
History	B-Observation
of	O
myocardial	B-Condition
infarction	I-Condition
within	O
the	O
previous	O
year	O
or	O
unstable	O
cardiac	B-Condition
disease	I-Condition

.	O
-	O
Uncontrolled	O
hypertension	B-Condition
,	O
history	B-Observation
of	O
significant	O
liver	B-Condition
disease	I-Condition
clinically	O
significant	O
pulmonary	B-Condition
disease	I-Condition
diabetes	B-Condition
or	O
cancer	B-Condition

.	O
-	O
Such	O
current	O
major	O
psychiatric	B-Condition
disorders	I-Condition
as	O
mania	B-Condition
,	O
according	O
to	O
DSMIV	B-Observation
criteria	I-Observation
within	O
the	O
previous	O
two	O
years	O

.	O
-	O
Current	O
diagnosis	O
or	O
history	B-Observation
of	O
alcoholism	B-Condition
or	O
drug	B-Condition
dependence	I-Condition

.	O
-	O
Evidence	O
of	O
untreated	O
depression	B-Condition

.	O
-	O
Use	O
of	O
any	O
of	O
the	O
following	O
drugs	B-Drug
:	O
centrally	B-Drug
active	I-Drug
beta-blockers	I-Drug
narcotics	B-Drug
,	O
clonidine	B-Drug
,	O
anti-Parkinsonian	B-Drug
medications	I-Drug
antipsychotics	B-Drug
,	O
benzodiazepines	B-Drug
,	O
systemic	B-Drug
corticosteroids	I-Drug
medications	B-Drug
with	I-Drug
significant	I-Drug
cholinergic	I-Drug
or	I-Drug
anticholinergic	I-Drug
effects	I-Drug
anti-convulsants	B-Drug
or	O
warfarin	B-Drug
;	O
vitamins	B-Drug
other	B-Negation_cue
than	I-Negation_cue
the	O
standard	B-Drug
multivitamin	I-Drug
supplement	I-Drug
ginkgo	B-Drug
biloba	I-Drug
and	O
any	O
nutraceuticals	B-Drug
will	O
not	B-Negation_cue
be	O
allowed;	O
once	O
enrolled	O
in	O
the	O
study,	O
occasional	O
chloral	B-Drug
hydrate	I-Drug
use	O
will	O
be	O
allowed	O
but	O
discouraged,	O
for	O
insomnia	B-Condition

.	O
-	O
Use	O
of	O
any	O
investigational	B-Drug
drugs	I-Drug
within	O
the	O
previous	O
month	O
or	O
longer,	O
depending	O
on	O
drug	O
half-life	O

.	O
-	O
Contraindication	B-Condition
for	O
MRI	B-Procedure_Device
scan	I-Procedure_Device
(	O
eg	O
,	O
metal	B-Procedure_Device
in	O
body,	O
claustrophobia	B-Condition

>>NCT00265148	O
Inclusion	O
criteria:	O
.	O

-	O
Is	O
male	O
or	O
if	O
female	O
meets	O
one	O
or	O
more	O
of	O
the	O
following	O
criteria:	O
.	O

-	O
Post-menopausal	B-Condition
females	O
defined	O
as	O
menopause	B-Condition
is	O
defined	O
as>6months	O
without	B-Negation_cue
menstrual	B-Condition
period	I-Condition
with	O
an	O
appropriate	O
clinical	O
profile,	O
eg	O
age	B-Observation
appropriate,	O
history	B-Observation
of	O
vasomotor	B-Observation
symptoms	I-Observation
.	O

However	O
if	O
indicated	O
this	O
should	O
be	O
confirmed	O
by	O
oestradiol	B-Observation
and	O
FSH	B-Observation
levels	I-Observation
consistent	O
with	O
menopause	B-Condition
(according	O
to	O
local	O
laboratory	O
ranges)	O
.	O

Women	O
who	O
are	O
on	O
HRT	B-Drug
treatment	I-Drug
and	O
have	O
not	O
been	O
confirmed	O
as	O
post-menopausal	O
should	O
be	O
advised	O
to	O
use	O
contraception	B-Procedure_Device
.	O

(See	O
Appendix	O
4)Pre-menopausal	O
females	O
with	O
a	O
documented	O
(medical	O
report	O
verification)	O
hysterectomy	B-Procedure_Device
and	O
/	O
or	O
bilateral	O
oophorectomy	B-Procedure_Device
only	O
when	O
the	O
reproductive	O
status	O
of	O
the	O
woman	O
has	O
been	O
confirmed	O
by	O
follow	O
up	O
hormone	O
level	O
assessment	O
.	O

-	O
Meets	O
the	O
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Diseases	I-Observation
and	I-Observation
Stroke	I-Observation
/	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
(	I-Observation
NINCDS-ADRDA	I-Observation
)	I-Observation
criteria	I-Observation
for	O
Alzheimer's	B-Condition
disease,	O
regardless	O
of	O
date	O
of	O
diagnosis	O
relative	O
to	O
study	O
entry	O
date	O
.	O

(See	O
Appendix	O
5)	O
Has	O
an	O
Alzheimer's	B-Condition
disease	I-Condition
status	O
of	O
mild	O
to	O
moderate,	O
as	O
classified	O
by	O
a	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
MMSE	B-Observation
)	O
score	O
of	O
16-26	O
inclusive	O
at	O
screening	O
.	O

Is	O
aged	B-Observation
>/=	O
50	O
to	O
</=	O
85	O
years	O
Prior	O
and	O
current	O
use	O
of	O
medication	O
corresponds	O
with	O
criteria	O
listed	O
in	O
Appendix	O
3	O
.	O

-	O
Has	O
the	O
ability	O
to	O
comply	O
with	O
requirements	O
of	O
cognitive	O
and	O
other	O
testing	O
.	O

-	O
Has	O
a	O
permanent	O
caregiver	O
who	O
is	O
willing	O
to	O
attend	O
all	O
visits,	O
oversee	O
the	O
subject's	O
compliance	O
with	O
protocol-specified	O
procedures	O
and	O
study	O
medication	O
and	O
report	O
on	O
subject's	O
status	O
.	O

(Subjects	O
living	O
alone	O
or	O
in	O
a	O
nursing	O
home	O
are	O
not	O
eligible)	O
.	O

-	O
Has	O
provided	O
full	O
written	O
informed	O
consent	O
prior	O
to	O
the	O
performance	O
of	O
any	O
protocol-specified	O
procedure;	O
or	O
if	O
unable	O
to	O
provide	O
informed	O
consent	O
due	O
to	O
cognitive	O
status,	O
provision	O
of	O
informed	O
consent	O
by	O
cognitively	O
intact	O
legally	O
acceptable	O
representative	O
(Where	O
this	O
is	O
in	O
accordance	O
with	O
local	O
laws,	O
regulations	O
and	O
ethics	O
committee	O
policy.)	O

Caregiver	O
has	O
provided	O
full	O
written	O
informed	O
consent	O
prior	O
to	O
the	O
performance	O
of	O
any	O
protocol-specified	O
procedure	O
.	O

Exclusion	O
criteria:	O
.	O

-	O
Is	O
unsuitable	O
for	O
MRI	B-Procedure_Device
scanning	O
as	O
assessed	O
by	O
local	O
pre-MRI	O
questionnaire	O
(GSK	O
to	O
review.)	O
.	O

-	O
Has	O
a	O
history	B-Observation
of	O
or	O
suffers	O
from	O
claustrophobia	B-Condition
.	O

-	O
Is	O
unable	O
to	O
lie	O
comfortably	O
on	O
a	O
bed	O
inside	O
a	O
PET	B-Procedure_Device
camera	O
with	O
their	O
head	O
in	O
the	O
field	O
of	O
view	O
for	O
at	O
least	O
60	O
minutes	O
as	O
assessed	O
by	O
physical	B-Observation
examination	I-Observation
and	O
medical	B-Observation
history	I-Observation
(eg	O
back	B-Condition
pain	I-Condition
arthritis	B-Condition
)	O
.	O

-	O
Has	O
a	O
history	B-Observation
or	O
presence	B-Observation
of	O
other	O
neurological	B-Condition
or	I-Condition
other	I-Condition
medical	I-Condition
conditions	I-Condition
that	O
may	O
influence	O
the	O
outcome	O
or	O
analysis	O
of	O
the	O
PET	B-Procedure_Device
scan	O
results	O
.	O

Examples	O
of	O
such	O
conditions	O
include	O
but	O
are	O
not	O
limited	O
to	O
stroke	B-Condition
,	O
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
epilepsy	B-Condition
or	O
space	B-Condition
occupying	I-Condition
lesions	I-Condition
.	O

-	O
History	B-Observation
of	O
Type	B-Condition
I	I-Condition
or	I-Condition
Type	I-Condition
II	I-Condition
diabetes	I-Condition
mellitus	I-Condition
.	O

-	O
Fasting	B-Observation
plasma	I-Observation
glucose	I-Observation
level	I-Observation
/	O
dL	O
(>7.0mmol	O
/	O
L)	O
or	O
HbA1c	B-Observation
>6.2%	O
.	O

-	O
History	B-Observation
or	O
clinical	O
/	O
laboratory	O
evidence	O
of	O
moderate	O
congestive	B-Condition
heart	I-Condition
failure	I-Condition
defined	O
by	O
the	O
New	B-Observation
York	I-Observation
Heart	I-Observation
Association	I-Observation
criteria	I-Observation
(class	O
I-IV)(See	O
Appendix	O
6)	O
.	O

Ejection	B-Observation
fraction	I-Observation
determined	O
by	O
echocardiogram	B-Procedure_Device
or	O
any	O
other	O
abnormality	B-Observation
on	O
echocardiography	B-Procedure_Device
which	O
in	O
the	O
view	O
of	O
the	O
investigator	O
required	O
further	O
investigation	O
or	O
intervention	O
or	O
significant	O
abnormalities	B-Observation
on	O
screening	O
ECG	B-Procedure_Device
(in	O
accordance	O
with	O
the	O
definitions	O
below)	O
.	O

Significant	O
ECG	B-Observation
abnormalities	I-Observation
for	O
the	O
purposes	O
of	O
this	O
study	O
.	O

Detection	O
of	O
any	O
of	O
the	O
following	O
abnormalities	B-Observation
renders	O
the	O
subject	O
ineligible	O
for	O
the	O
study:	O
1	O
.	O

ECG	B-Observation
heart	I-Observation
rate	I-Observation
<50	O
and	O
>100	O
bpm	O
2	O
.	O

Any	O
previously	O
unrecognised	O
sustained	B-Condition
or	I-Condition
paroxysmal	I-Condition
arrhythmia	I-Condition
requiring	O
further	O
intervention	O
eg	O
anticoagulation	B-Drug
,	O
cardioversion	B-Procedure_Device
,	O
anti-arrhythmic	B-Drug
agent	I-Drug
further	O
investigation	O
etc	O
.	O

3	O
.	O

PR	B-Observation
interval	I-Observation
>0.3	O
s,	O
2nd	B-Condition
or	I-Condition
3rd	I-Condition
degree	I-Condition
heart	I-Condition
block	I-Condition
symptomatic	B-Condition
bifascicular	I-Condition
block	I-Condition
trifascicular	B-Condition
block	I-Condition
.	O

4	O
.	O

Multifocal	B-Condition
ventricular	I-Condition
ectopy	I-Condition
.	O

5	O
.	O

Ventricular	B-Condition
bigemini	I-Condition
or	I-Condition
couplets,	I-Condition
triplets	I-Condition
etc	O
.	O

ECG	B-Observation
abnormalities	I-Observation
permitted	O
at	O
entry	O
to	O
this	O
study	O
.	O

A	O
subject	O
will	O
not	O
be	O
rendered	O
ineligible	O
by	O
the	O
presence	O
of	O
any	O
of	O
the	O
following	O
abnormalities:	O
1	O
.	O

AF	B-Condition
with	O
a	O
heart	B-Observation
rate	I-Observation
<=90	O
in	O
subjects	O
receiving	O
appropriate	O
anti-platelet	B-Drug
or	I-Drug
anticoagulant	I-Drug
therapy	I-Drug
.	O

2	O
.	O

1st	B-Condition
degree	I-Condition
heart	I-Condition
block	I-Condition
PR	B-Observation
<=0.3	O
s)	O
.	O

3	O
.	O

Subjects	O
with	O
a	O
paced	O
rhythm	O
(further	O
information	O
required	O
if	O
subject	O
has	O
an	O
implantable	O
Cardiac	O
Defibrillator)	O
.	O

4	O
.	O

Atrial	B-Condition
ectopic	I-Condition
beats	I-Condition
.	O

5	O
.	O

Unifocal	B-Condition
ventricular	I-Condition
ectopic	I-Condition
beats	I-Condition
.	O

6	O
.	O

Left	O
or	O
right	O
bundle	B-Condition
branch	I-Condition
block	I-Condition
.	O

7	O
.	O

Asymptomatice	B-Condition
bifascicular	I-Condition
block	I-Condition
.	O

8	O
.	O

Left	B-Condition
ventricular	I-Condition
hypertrophy	I-Condition
.	O

9	O
.	O

Q	B-Observation
waves	I-Observation
present	O
suggesting	O
previous	O
MI	B-Condition
.	O

10	O
.	O

Repolarisation	B-Observation
abnormalities	I-Observation
History	B-Observation
of	O
new	B-Condition
cardiovascular	I-Condition
event	I-Condition
within	O
the	O
last	O
6	O
months	O
(i.e	O
.	O

intervention	B-Procedure_Device
,	O
percutaneous	B-Procedure_Device
coronary	I-Procedure_Device
intervention	I-Procedure_Device
vascular	B-Procedure_Device
surgery	I-Procedure_Device
acute	O
coronary	B-Condition
syndrome	I-Condition
non	B-Condition
Q-wave	I-Condition
myocardial	I-Condition
infarction	I-Condition
Q-wave	B-Condition
myocardial	I-Condition
infarction	I-Condition
unstable	O
angina	B-Condition
)	O
or	O
significant	O
arrhythmia	B-Condition
;	O
or	O
major	O
intervention	B-Procedure_Device
(eg	O
cardiac	B-Procedure_Device
surgery	I-Procedure_Device
or	O
angiography	B-Procedure_Device
plus	I-Procedure_Device
stenting	I-Procedure_Device
scheduled	O
.	O

-	O
History	B-Observation
or	O
clinical	O
laboratory	O
evidence	B-Observation
of	O
cerebrovascular	B-Condition
disease	I-Condition
stroke	B-Condition
,	O
transient	B-Condition
ischaemic	I-Condition
attack	I-Condition
haemorrhage	B-Condition
)	O
or	O
diagnosis	O
of	O
possible,	O
probable	O
or	O
definite	O
vascular	B-Condition
dementia	I-Condition
in	O
accordance	O
with	O
National	O
Institute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke	O
and	O
Association	O
Internationale	O
pour	O
la	O
Recherche	O
et	O
l'Enseignement	O
en	O
Neurosciences	O
NINDS-AIREN	B-Observation
)	O
criteria	O
(See	O
Appendix	O
8)	O
.	O

-	O
History	B-Observation
or	O
evidence	B-Observation
of	O
any	O
other	O
CNS	B-Condition
disorder	I-Condition
that	O
could	O
be	O
interpreted	O
as	O
a	O
cause	O
of	O
dementia	B-Condition
:	O
eg	O
structural	B-Condition
abnormality	I-Condition
epilepsy	B-Condition
,	O
infectious	B-Condition
or	I-Condition
inflammatory	I-Condition
/	I-Condition
demyelinating	I-Condition
CNS	I-Condition
conditions	I-Condition
Parkinson's	B-Condition
disease	I-Condition
.	O

Significant	O
peripheral	B-Condition
oedema	I-Condition
at	O
the	O
time	O
of	O
screening	O
as	O
assessed	O
by	O
Clinical	O
Evaluation	O
of	O
Oedema	O
and	O
/	O
or	O
Signs	B-Observation
of	O
Congestive	B-Condition
Heart	I-Condition
Failure	I-Condition
(Appendix	O
14)	O
.	O

-	O
History	B-Observation
of	O
major	O
psychiatric	B-Condition
illness	I-Condition
such	O
as	O
schizophrenia	B-Condition
or	O
bipolar	B-Condition
affective	I-Condition
disorder	I-Condition
or	O
current	O
depression	B-Condition
(score	O
on	O
Hospital	B-Observation
Anxiety	I-Observation
and	I-Observation
Depression	I-Observation
Scale	I-Observation
HADS	B-Observation
)	O
depression	O
questions	O
>7,	O
See	O
Appendix	O
9)	O
.	O

Systolic	B-Observation
blood	I-Observation
pressure	I-Observation
>165	O
mmHg	O
or	O
diastolic	B-Observation
blood	I-Observation
pressure	I-Observation
>95	O
mmHG	O
whilst	O
receiving	O
optimal	O
antihypertensive	B-Drug
therapy	I-Drug
according	O
to	O
local	O
practice	O
.	O

Clinically	O
significant	O
anaemia	B-Condition
(i.e	O
haemoglobin	B-Observation
<11g	O
/	O
dL	O
for	O
males	O
or	O
<10	O
g	O
/	O
dL	O
for	O
females)	O
or	O
presence	O
of	O
haemoglobinopathies	B-Condition
which	O
would	O
prevent	O
accurate	O
assessment	O
of	O
HbA1c	B-Observation
.	O

Renal	B-Condition
dysfunction	I-Condition
defined	O
as	O
creatinine	B-Observation
clearance	I-Observation
<30	O
ml	O
/	O
min	O
(calculated	O
from	O
serum	O
creatinine	O
using	O
the	O
Cockcroft-Gault	O
formula,	O
See	O
Appendix	O
10)	O
.	O

ALT	B-Observation
,	O
AST	B-Observation
,	O
total	B-Observation
bilirubin	I-Observation
or	O
alkaline	B-Observation
phosphatase	I-Observation
>2.5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
laboratory	O
range	O
or	O
history	B-Observation
of	O
severe	O
hepatobiliary	B-Condition
disease	I-Condition
(eg	O
hepatitis	B-Condition
B	I-Condition
or	I-Condition
C	I-Condition
or	I-Condition
cirrhosis	I-Condition
Childs-Pugh	B-Observation
classes	I-Observation
B	O
/	O
C)	O
without	B-Negation_cue
enzyme	B-Observation
elevation	O
.	O

-	O
Fasting	B-Observation
triglycerides	I-Observation
>12mmol	O
/	O
L	O
Abnormal	O
/	O
positive	O
result	O
within	O
the	O
past	O
12	O
months	O
or	O
at	O
screening	O
for	O
any	O
of	O
the	O
following	O
tests:	O
vitamin	B-Observation
B12	I-Observation
(</=200pg	O
/	O
mL),	O
syphilis	B-Observation
serology	I-Observation
thyroid	B-Observation
stimulating	I-Observation
hormone	I-Observation
.	O

-	O
History	B-Observation
or	O
presence	B-Observation
of	O
gastro-intestinal,	B-Condition
hepatic	I-Condition
or	I-Condition
renal	I-Condition
disease	I-Condition
or	O
other	O
condition	B-Condition
known	O
to	O
interfere	O
with	O
absorption,	O
distribution,	O
metabolism	O
or	O
excretion	O
of	O
drugs	O
.	O

any	O
clinically	O
relevant	O
abnormality	B-Condition
,	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
condition	I-Condition
which,	O
in	O
the	O
opinion	O
of	O
the	O
investigator,	O
makes	O
the	O
subject	O
unsuitable	O
for	O
inclusion	O
in	O
the	O
study	O
.	O

-	O
Has	O
donated	O
>/=	O
ml	O
of	O
blood	O
within	O
the	O
past	O
2	O
months	O
.	O

Use	O
of	O
any	O
other	O
investigational	B-Drug
agent	I-Drug
within	O
30	O
days	O
or	O
5	O
half-lives	O
(whichever	O
is	O
longer)	O
prior	O
to	O
the	O
screening	O
visit	O
.	O

History	B-Observation
of	O
alcohol	B-Condition
abuse	I-Condition
or	O
of	O
drug	B-Condition
abuse	I-Condition
within	O
the	O
past	O
6	O
months	O
(or	O
has	O
tested	O
positive	O
for	O
drugs	O
of	O
abuse	O
at	O
screening)	O
.	O

Subject	O
is	O
unable	B-Negation_cue
(with	O
assistance,	O
if	O
appropriate)	O
to	O
take	O
study	B-Drug
medication	I-Drug
as	O
prescribed	O
throughout	O
the	O
study	O
.	O

-	O
History	B-Observation
of	O
non-compliance	B-Observation
with	O
prescribed	B-Drug
medication	I-Drug
or	O
risk	B-Observation
of	O
non-compliance	B-Observation
with	O
study	B-Drug
medication	I-Drug
or	O
procedures	B-Procedure_Device
.	O

Subject	O
is	O
an	O
immediate	O
family	O
member	O
or	O
employee	O
of	O
the	O
participating	O
investigator	O
or	O
of	O
any	O
of	O
the	O
participating	O
site	O
staff	O
.	O

Shows	O
any	O
neurological	B-Observation
abnormality	I-Observation
by	O
MRI	B-Procedure_Device
,	O
which	O
in	O
the	O
opinion	O
of	O
the	O
Principal	O
Investigator	O
would	O
introduce	O
additional	O
risk	O
factors,	O
study	O
procedures	O
or	O
effect	O
endpoint	O
data	O
.	O

MRI	O
scanning	O
will	O
only	O
be	O
conducted	O
on	O
subjects	O
who	O
satisfy	O
all	O
other	O
eligibility	O
criteria	O
.	O

-	O
History	B-Observation
of	O
bone	B-Procedure_Device
marrow	I-Procedure_Device
transplant	I-Procedure_Device
Exhibits	O
screening	O
/	O
baseline	O
results	O
not	B-Negation_cue
consistent	O
with	O
AD	B-Condition
eg	O
radiological	O
findings	O
or	O
results	O
on	O
cognitive	O
tests	O
.	O

Use	O
of	O
tacrine	B-Drug
within	O
30	O
days	O
prior	O
to	O
the	O
screening	O
visit	O
.	O

>>NCT01238458	O
Inclusion	O
Criteria:	O
.	O

-	O
Both	O
genders	O
>=	O
50	O
years	O
old	O
.	O

-	O
Written	O
and	O
dated	O
informed	O
consent	O
by	O
self	O
or	O
by	O
legal	O
representative,	O
to	O
be	O
obtained	O
before	O
any	O
of	O
the	O
study	O
procedures	O
.	O

-	O
30	O
cognitively	B-Condition
normal	I-Condition
volunteers	O
with	O
no	B-Negation_cue
evidence	O
of	O
significant	O
cognitive	B-Condition
impairment	I-Condition
by	O
history	B-Observation
and	O
psychometrictesting	B-Observation
MMSE	B-Observation
>	O
24)	O
.	O

-	O
60	O
subjects	O
with	O
a	O
diagnosis	O
of	O
AD	B-Condition
according	O
to	O
the	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
.	O

-	O
60	O
subjects	O
with	O
a	O
diagnosis	O
of	O
MCI	B-Condition
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

Pregnant	O
or	O
becoming	O
pregnant	B-Condition
during	O
the	O
study	O
(as	O
documented	O
by	O
pregnancy	B-Observation
testing	I-Observation
at	O
screening	O
or	O
at	O
any	O
date	O
during	O
the	O
study	O
according	O
to	O
the	O
PI	O
discretion)	O
or	O
current	O
breast	B-Condition
feeding	I-Condition
.	O

2	O
.	O

Modified	B-Observation
Hachinski	I-Observation
ischemic	I-Observation
score	I-Observation
of	O
>4	O
or	O
those	O
who	O
meet	O
the	O
NINDS-AIREN	B-Observation
criteria	I-Observation
for	O
vascular	B-Condition
dementia	I-Condition
.	O

3	O
.	O

Any	O
subject	O
who	O
has	O
a	O
clinically	O
significant	O
abnormal	O
laboratory	B-Observation
values	I-Observation
and	O
/	O
or	O
clinically	O
significant	O
or	O
unstable	O
medical	B-Condition
or	I-Condition
psychiatric	I-Condition
illness	I-Condition
.	O

-	O
Clinically	O
significant	O
hepatic,	B-Condition
renal,	I-Condition
pulmonary,	I-Condition
metabolic	I-Condition
or	I-Condition
endocrine	I-Condition
disturbances	I-Condition
especially	O
thyroid	B-Condition
disease	I-Condition
.	O

-	O
Current	O
clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
.	O

Clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
usually	O
includes	O
one	O
or	O
more	O
of	O
the	O
following:	O
.	O

-	O
cardiac	B-Procedure_Device
surgery	I-Procedure_Device
or	O
myocardial	B-Condition
infarction	I-Condition
within	O
the	O
last	O
6	O
months;	O
.	O

-	O
unstable	O
angina	B-Condition
.	O

-	O
coronary	B-Condition
artery	I-Condition
disease	I-Condition
that	O
required	O
a	O
change	O
in	O
medication	O
within	O
the	O
last	O
3	O
months	O
.	O

-	O
decompensated	B-Condition
congestive	I-Condition
heart	I-Condition
failure	I-Condition
.	O

-	O
significant	O
cardiac	B-Condition
arrhythmia	I-Condition
or	O
conduction	B-Condition
disturbance	I-Condition
particularly	O
those	O
resulting	O
in	O
atrial	B-Condition
or	I-Condition
ventricular	I-Condition
fibrillation	I-Condition
or	O
causing	O
syncope	B-Condition
,	O
near	B-Condition
syncope	I-Condition
or	O
other	O
alterations	B-Condition
in	I-Condition
mental	I-Condition
status	I-Condition
.	O

-	O
severe	O
mitral	B-Condition
or	I-Condition
aortic	I-Condition
valvular	I-Condition
disease	I-Condition
.	O

-	O
uncontrolled	O
high	B-Condition
blood	I-Condition
pressure	I-Condition
.	O

-	O
congenital	B-Condition
heart	I-Condition
disease	I-Condition
.	O

-	O
clinically	O
significant	O
abnormal	O
result	O
on	O
ECG	B-Procedure_Device
,	O
including	O
but	O
not	O
limited	O
to	O
QTc	B-Observation
>450	O
msec	O
iii	O
.	O

Clinically	O
significant	O
infectious	B-Condition
disease	I-Condition
including	O
AIDS	B-Condition
or	I-Condition
HIV	I-Condition
infection	I-Condition
or	O
active	O
hepatitis	B-Condition
B	I-Condition
active	O
hepatitis	B-Condition
C	I-Condition
HIV-1	B-Condition
or	O
HIV-2	B-Condition
.	O

4	O
.	O

History	B-Observation
of	O
drug	B-Condition
or	I-Condition
alcohol	I-Condition
abuse	I-Condition
within	O
the	O
last	O
year	O
or	O
prior	O
prolonged	O
history	B-Observation
of	O
abuse	B-Condition
.	O

5	O
.	O

Patients	O
who	O
have	O
the	O
evidence	O
of	O
neurodegenerative	B-Condition
disorders	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
,	O
cognitive	B-Condition
impairment	I-Condition
resulting	O
from	O
trauma	B-Condition
or	O
brain	B-Condition
damage	I-Condition
brain	B-Condition
infarction	I-Condition
clinically	O
significant	O
psychiatric	B-Condition
disease	I-Condition
epilepsy	B-Condition
,	O
are	O
excluded	B-Negation_cue
.	O

>>NCT01574456	O
Inclusion	O
Criteria:	O
.	O

Patients	O
with	O
AD	B-Condition
:	O
.	O

-	O
Informed	O
consent	O
before	O
participation	O
in	O
the	O
study	O
.	O

-	O
Received	O
standard	O
diagnostic	O
procedure	O
according	O
to	O
the	O
Parelsnoer	O
Initiative	O
procedure	O
.	O

-	O
Diagnosed	O
with	O
dementia	B-Condition
of	I-Condition
the	I-Condition
Alzheimer's	I-Condition
type	I-Condition
.	O

-	O
Clinical	B-Observation
dementia	I-Observation
rating	I-Observation
CDR	B-Observation
)	O
of	O
1,	O
which	O
means	O
a	O
mild	O
to	O
moderate	O
stage	O
of	O
dementia	B-Condition
.	O

-	O
MMSE	B-Observation
>=	O
20	O
and	O
patients	O
are	O
mentally	O
competent	O
(in	O
general,	O
individuals	O
with	O
an	O
MMSE	O
>=	O
18	O
are	O
considered	O
mentally	O
competent)	O
.	O

Patients	O
with	O
prodromal	B-Condition
AD	I-Condition
.	O

-	O
Informed	O
consent	O
before	O
participation	O
in	O
the	O
study	O
.	O

-	O
Received	O
standard	O
diagnostic	O
procedure	O
according	O
to	O
the	O
Parelsnoer	O
Initiative	O
procedure	O
.	O

-	O
Diagnosis	O
of	O
prodromal	B-Condition
dementia	I-Condition
according	O
to	O
the	O
Dubois	B-Observation
criteria	I-Observation
(16)	O
.	O

-	O
CDR	B-Observation
of	O
0.5,	O
which	O
suggests	O
a	O
very	O
mild	O
stage	O
of	O
dementia	B-Condition
.	O

-	O
Memory	B-Condition
impairment	I-Condition
defined	O
as	O
Delayed	B-Observation
Recall	I-Observation
on	I-Observation
Verbal	I-Observation
Learning	I-Observation
Test	I-Observation
15	B-Observation
WLT	I-Observation
<	O
1.5	O
SD	O
.	O

-	O
MMSE	B-Observation
>=	O
20	O
and	O
patients	O
are	O
mentally	O
competent	O
.	O

-	O
Medial	B-Observation
temporal	I-Observation
lobe	I-Observation
atrophy	I-Observation
scale	I-Observation
MTA	I-Observation
>=	O
1	O
(17)	O
OR	O
abnormal	O
levels	B-Observation
of	I-Observation
A42,	I-Observation
t-tau	I-Observation
or	I-Observation
p-tau	I-Observation
.	O

Healthy	B-Condition
participants:	O
.	O

-	O
Informed	O
consent	O
before	O
participation	O
in	O
the	O
study	O
.	O

-	O
No	B-Negation_cue
Diagnosis	O
of	O
dementia	B-Condition
,	O
prodromal	B-Condition
dementia	I-Condition
or	O
mild	B-Condition
cognitive	I-Condition
impairment	I-Condition
.	O

-	O
MMSE	B-Observation
>=	O
26	O
.	O

-	O
No	B-Negation_cue
substantial	B-Observation
memory	I-Observation
complaints	I-Observation
(according	O
to	O
participant)	O
.	O

-	O
Age,	O
gender	O
and	O
education	O
is	O
matched	O
to	O
the	O
patient	O
groups	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Contraindications	B-Condition
for	O
scanning	B-Procedure_Device
(eg	O
brain	B-Procedure_Device
surgery	I-Procedure_Device
cardiac	B-Procedure_Device
pacemaker	I-Procedure_Device
metal	B-Procedure_Device
implants	I-Procedure_Device
claustrophobia	B-Condition
,	O
large	B-Observation
body	I-Observation
tattoos	I-Observation
.	O

-	O
Contraindications	B-Condition
for	O
contrast	B-Drug
agent	I-Drug
Gadovist	I-Drug
renal	B-Condition
failure	I-Condition
as	O
determined	O
by	O
the	O
estimated	B-Observation
Glomular	I-Observation
Filtration	I-Observation
Rate	I-Observation
eGFR	I-Observation
<	O
30	O
mL	O
/	O
min	O
.	O

-	O
Major	O
vascular	B-Condition
disorders	I-Condition
(eg	O
stroke	B-Condition
,	O
heart	B-Condition
disease	I-Condition
.	O

-	O
Psychiatric	B-Condition
or	I-Condition
neurological	I-Condition
disorders	I-Condition
Major	B-Condition
depression	I-Condition
(<	O
12	O
months);	O
history	B-Observation
of	O
schizophrenia	B-Condition
;	O
bipolar	B-Condition
disorder	I-Condition
psychotic	B-Condition
disorder	I-Condition
NOS	I-Condition
or	O
treatment	B-Condition
for	I-Condition
a	I-Condition
psychotic	I-Condition
disorder	I-Condition
(<	O
12	O
mnd);	O
cognitive	B-Condition
impairment	I-Condition
due	O
to	O
alcohol	B-Condition
abuse	I-Condition
epilepsy	B-Condition
;	O
Parkinson's	B-Condition
disease	I-Condition
MS	B-Condition
;	O
brain	B-Condition
surgery	I-Condition
brain	B-Condition
trauma	I-Condition
electroshock	B-Condition
therapy	I-Condition
kidney	B-Condition
dialysis	I-Condition
Meniere's	B-Condition
disease	I-Condition
and	O
brain	B-Condition
infections	I-Condition
.	O

-	O
Structural	B-Observation
abnormalities	I-Observation
of	O
the	O
brain	O
.	O

-	O
Cognitive	B-Condition
impairment	I-Condition
due	O
to	O
alcohol	B-Condition
/	I-Condition
drug	I-Condition
abuse	I-Condition
.	O

-	O
Absence	O
of	O
reliable	O
informant	O
(for	O
patient	O
groups)	O
.	O

>>NCT02017340	O
Inclusion	O
Criteria:	O
.	O

1	O
.	O

Age	B-Observation
range:	O
Adult	O
subjects,	O
males	O
and	O
females	O
over	O
age	O
50	O
years	O
.	O

2	O
.	O

Prior	O
diagnosis	O
of	O
mild	O
to	O
moderate	O
probable	O
AD	B-Condition
based	O
on	O
NINCDS-ADRDA	B-Observation
criteria	I-Observation
(see	O
Appendix	O
B)	O
and	O
.	O

3	O
.	O

Standardised	B-Observation
Mini-Mental	I-Observation
State	I-Observation
Examination	I-Observation
SMMSE	B-Observation
)	O
score	O
>	O
12	O
on	O
stable	O
dose	B-Observation
(>3	O
months	O
of	O
cholinesterase	B-Drug
inhibitor	I-Drug
and	O
or	O
memantine	B-Drug
)	O
.	O

Subjects	O
who	O
are	O
not	B-Negation_cue
on	O
cholinesterase	B-Drug
inhibitors	I-Drug
or	O
memantine	B-Drug
due	O
to	O
poor	O
tolerability	O
and	O
/	O
or	O
who	O
will	O
not	O
require	O
treatment	O
with	O
these	O
medications	O
during	O
the	O
course	O
of	O
the	O
study	O
can	O
be	O
included	O
.	O

4	O
.	O

Collateral	O
informants	O
such	O
as	O
a	O
spouse,	O
family	O
member,	O
close	O
friend	O
.	O

The	O
informant	O
must	O
have	O
close	O
contact	O
with	O
the	O
subject	O
and	O
agree	O
to	O
monitor	O
/	O
manage	O
study	O
drug	O
adherence,	O
observe	O
for	O
possible	O
adverse	O
events,	O
assist	O
with	O
psychometric	O
measures	O
requiring	O
informant	O
information	O
and	O
accompany	O
the	O
subject	O
to	O
all	O
evaluation	O
visits	O
.	O

5	O
.	O

Fluency	O
in	O
relevant	O
language	O
sufficient	O
to	O
reliably	O
complete	O
all	O
study	O
assessments	O
.	O

6	O
.	O

Systolic	B-Observation
BP	I-Observation
>	O
100	O
mmHg	O
but	O
<=	O
159	O
mmHg	O
and	O
diastolic	B-Observation
BP	I-Observation
>	O
65	O
mmHg	O
but	O
<=	O
99	O
mmHg	O
on	O
resting	B-Observation
office	I-Observation
based	I-Observation
BP	I-Observation
measurements	I-Observation
or	O
a	O
Systolic	B-Observation
BP	I-Observation
>	O
105	O
mmHg	O
but	O
<=	O
140	O
mmHg	O
and	O
diastolic	B-Observation
BP	I-Observation
>	O
70	O
mmHg	O
but	O
<=	O
90	O
mmHg	O
on	O
ABPM	B-Observation
measurement	I-Observation
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

Subjects	O
with	O
co-morbid	O
dementia	B-Condition
due	O
to	O
other	O
neurological	B-Condition
disorders	I-Condition
such	O
as	O
Parkinson's	B-Condition
disease	I-Condition
vascular	B-Condition
dementia	I-Condition
Huntington's	B-Condition
disease	I-Condition
Pick's	B-Condition
disease	I-Condition
Creutzfeldt-Jakob	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
brain	B-Condition
tumor	I-Condition
progressive	B-Condition
supranuclear	I-Condition
palsy	I-Condition
seizure	B-Condition
disorder	I-Condition
subdural	B-Condition
hematoma	I-Condition
or	O
multiple	B-Condition
sclerosis	I-Condition
as	O
well	O
as	O
subjects	O
with	O
HIV	B-Condition
disease	I-Condition
neurosyphilis	B-Condition
,	O
history	B-Observation
of	O
significant	O
head	B-Condition
trauma	I-Condition
with	O
loss	B-Condition
of	I-Condition
consciousness	I-Condition
followed	O
by	O
persistent	O
neurological	B-Condition
deficits	I-Condition
known	O
structural	B-Condition
brain	I-Condition
abnormalities	I-Condition
or	O
any	O
other	O
condition	B-Condition
known	O
to	O
interfere	O
with	O
cognitive	O
function	O
.	O

2	O
.	O

Subjects	O
currently	O
taking	O
any	O
calcium	B-Drug
channel	I-Drug
blocker	I-Drug
or	O
Beta-blocker	B-Drug
.	O

3	O
.	O

Subjects	O
who	O
in	O
the	O
opinion	O
of	O
the	O
investigator,	O
have	O
a	O
medical	O
condition	O
that	O
would	O
preclude	O
them	O
from	O
participating	O
in	O
the	O
study	O
(e.g	O
hemodynamically	B-Condition
significant	I-Condition
coronary	I-Condition
artery	I-Condition
disease	I-Condition
chronic	B-Condition
heart	I-Condition
failure	I-Condition
syncope	B-Condition
within	O
the	O
past	O
year,	O
significant	O
valvular	B-Condition
heart	I-Condition
disease	I-Condition
i.e	O
.	O

severe	O
aortic	B-Condition
and	I-Condition
mitral	I-Condition
stenosis	I-Condition
.	O
symptomatic	B-Condition
orthostatic	I-Condition
hypotension	I-Condition
within	O
the	O
last	O
year,	O
subjects	O
requiring	O
more	O
than	O
one	O
agent	B-Drug
to	O
control	O
BP.)	O

or	O
subjects	O
who	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
are	O
unlikely	O
to	O
complete	O
per	O
protocol	O
due	O
to	O
care	O
issues	O
etc:	O
.	O

4	O
.	O

Current	O
Axis	O
I	O
diagnosis	O
of	O
schizophrenia	B-Condition
,	O
bipolar	B-Condition
disorder	I-Condition
major	B-Condition
depression	I-Condition
.	O

Subjects	O
who	O
are	O
currently	O
or	O
who	O
have	O
within	O
the	O
past	O
year	O
met	O
criteria	O
for	O
drug	B-Condition
or	I-Condition
alcohol	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
.	O

5	O
.	O

Pregnant	B-Condition
women	O
or	O
women	O
who	O
may	O
possibly	O
become	O
pregnant	B-Condition
.	O

6	O
.	O

Subjects	O
with	O
a	O
history	B-Observation
of	O
hypersensitivity	B-Condition
to	O
nilvadipine	B-Drug
Nivadil	B-Drug
)	O
.	O

7	O
.	O

Subjects	O
who	O
have	O
taken	O
an	O
investigational	B-Drug
or	I-Drug
other	I-Drug
unapproved	I-Drug
drug	I-Drug
during	O
the	O
30	O
days	O
or	O
five	O
half-lives,	O
whichever	O
is	O
longer,	O
prior	O
to	O
baseline	O
.	O

8	O
.	O

Subjects	O
who	O
are	O
participating	O
in	O
other	O
research	O
studies	O
.	O

9	O
.	O

Patients	O
with	O
a	O
SBP	B-Observation
of	O
<=	O
100	O
mmHg	O
and	O
/	O
or	O
a	O
DBP	B-Observation
of	O
<=	O
65	O
mmHg	O
on	O
office	O
based	O
BP	B-Observation
measurements	I-Observation
or	O
a	O
SBP	B-Observation
<=	O
105	O
mmHg	O
and	O
/	O
or	O
a	O
DBP	B-Observation
of	O
<=	O
70	O
mmHg	O
on	O
ABPM	B-Observation
will	O
not	O
be	O
included	O
in	O
the	O
study	O
.	O

>>NCT00369603	O
Inclusion	O
Criteria:	O
.	O

-	O
Must	O
meet	O
diagnosis	O
of	O
mild	O
Alzheimer's	B-Condition
disease	I-Condition
.	O

-	O
Must	O
have	O
a	O
family	O
member	O
or	O
caregiver	O
who	O
is	O
willing	O
to	O
attend	O
all	O
study	O
visits	O
and	O
provide	O
information	O
on	O
your	O
participation	O
in	O
the	O
study	O
.	O

-	O
If	O
female,	O
must	O
be	O
post-menopausal	B-Condition
.	O

-	O
Must	O
be	O
able	O
to	O
swallow	O
tablets	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Metal	B-Procedure_Device
implants	I-Procedure_Device
or	O
medical	B-Procedure_Device
devises	I-Procedure_Device
unsafe	O
for	O
MRI	B-Procedure_Device
use	O
.	O

-	O
Pre-menopausal	O
female	O
.	O

-	O
HIstory	B-Observation
of	O
recent	O
head	B-Condition
injury	I-Condition
.	O

-	O
Significant	O
major,	O
life-threatening	B-Condition
illness	I-Condition
or	I-Condition
injury	I-Condition
(eg	O
,	O
stroke	B-Condition
,	O
AIDS	B-Condition
,	O
etc.)	O
.	O

-	O
Vascular	B-Condition
dementia	I-Condition
or	O
any	O
dementia	B-Condition
other	B-Negation_cue
than	I-Negation_cue
Alzheimer's	B-Condition
Disease	I-Condition
.	O

-	O
History	B-Observation
of	O
significant	O
alcoholism	B-Condition
or	O
drug	B-Condition
abuse	I-Condition
.	O

-	O
History	B-Observation
of	O
seizure	B-Condition
disorder	I-Condition
developmental	B-Condition
delay	I-Condition
or	O
major	B-Condition
psychiatric	I-Condition
illness	I-Condition
.	O

>>NCT01565343	O
Inclusion	O
Criteria	O
AD	B-Condition
group):	O
.	O

-	O
Greater	O
than	O
50	O
years	O
of	O
age	B-Observation
.	O

-	O
Probable	O
AD	B-Condition
according	O
to	O
the	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communication	O
Disorders	O
and	O
Stroke-Alzheimer's	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
NINCDS-ADRDA	B-Observation
)	O
criteria	O
.	O

-	O
Mild	O
/	O
moderate	O
dementia	B-Condition
as	O
evidenced	O
by	O
a	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
MMSE	B-Observation
)	O
score	O
ranging	O
from	O
10	O
to	O
24,	O
boundaries	O
included,	O
at	O
screening	O
.	O

-	O
History	B-Observation
of	O
cognitive	B-Condition
decline	I-Condition
gradual	O
in	O
onset	O
and	O
progressive	O
over	O
a	O
period	O
of	O
at	O
least	O
6	O
months	O
.	O

Inclusion	O
Criteria	O
healthy	B-Condition
volunteer	O
group):	O
.	O

-	O
35	O
to	O
55	O
years	O
of	O
age	B-Observation
,	O
inclusive	O
.	O

-	O
MMSE	B-Observation
of	O
29	O
or	O
greater	O
.	O

Exclusion	O
Criteria	O
(both	O
groups):	O
.	O

-	O
Neurodegenerative	B-Condition
disorders	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
,	O
including	O
but	O
not	O
limited	O
to	O
Parkinson's	B-Condition
disease	I-Condition
Pick's	B-Condition
disease	I-Condition
fronto-temporal	B-Condition
dementia	I-Condition
Huntington's	B-Condition
chorea	I-Condition
Down	B-Condition
syndrome	I-Condition
Creutzfeldt-Jacob	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
and	O
progressive	B-Condition
supranuclear	I-Condition
palsy	I-Condition
.	O

-	O
Diagnosis	O
of	O
other	O
dementing	B-Condition
/	I-Condition
neurodegenerative	I-Condition
disease	I-Condition
.	O

-	O
Diagnosis	O
of	O
mixed	B-Condition
dementia	I-Condition
.	O

-	O
Cognitive	B-Condition
impairment	I-Condition
resulting	O
from	O
trauma	B-Condition
,	O
hypoxic	B-Condition
damage	I-Condition
vitamin	B-Condition
deficiency	I-Condition
brain	B-Condition
infection	I-Condition
brain	B-Condition
cancer	I-Condition
endocrine	B-Condition
disease	I-Condition
or	O
mental	B-Condition
retardation	I-Condition
.	O

-	O
Clinically	O
significant	O
infarct	B-Condition
or	O
possible	O
multi-infarct	B-Condition
dementia	I-Condition
as	O
defined	O
by	O
the	O
NINCDS	B-Observation
criteria	I-Observation
.	O

-	O
Evidence	O
on	O
screening	O
MRI	B-Procedure_Device
or	O
other	O
biomarker	B-Observation
that	O
suggests	O
alternate	O
etiology	O
for	O
cognitive	B-Condition
deficit	I-Condition
(for	O
healthy	O
controls,	O
evidence	O
suggesting	O
the	O
presence	O
of	O
AD	B-Condition
pathology)	O
.	O

-	O
Clinically	O
significant	O
psychiatric	B-Condition
disease	I-Condition
.	O

-	O
History	B-Observation
of	O
epilepsy	B-Condition
or	O
convulsions	B-Condition
.	O

-	O
Clinically	O
significant	O
hepatic,	B-Condition
renal,	I-Condition
pulmonary,	I-Condition
metabolic	I-Condition
or	I-Condition
endocrine	I-Condition
disturbances	I-Condition
.	O

-	O
Current	O
clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
.	O

-	O
Received	O
investigational	B-Drug
medication	I-Drug
within	O
the	O
last	O
30	O
days	O
.	O

>>NCT00898807	O
Inclusion	O
criteria	O
.	O

-	O
Probable	O
Alzheimer's	B-Condition
disease	I-Condition
National	B-Observation
Institute	I-Observation
of	I-Observation
Neurological	I-Observation
and	I-Observation
Communicative	I-Observation
Disorders	I-Observation
and	I-Observation
Stroke	I-Observation
and	I-Observation
the	I-Observation
Alzheimer's	I-Observation
Disease	I-Observation
and	I-Observation
Related	I-Observation
Disorders	I-Observation
Association	I-Observation
criteria	I-Observation
with	O
Mini-Mental	B-Observation
score	I-Observation
of	O
5-28	O
inclusive	O
.	O

-	O
A	O
medication	B-Drug
for	O
agitation	B-Condition
is	O
appropriate,	O
in	O
the	O
opinion	O
of	O
the	O
study	O
physician	O
.	O

-	O
Clinically	O
significant	O
agitation	B-Condition
for	O
which	O
either	O
.	O

1	O
.	O
the	O
frequency	O
of	O
agitation	B-Condition
as	O
assessed	O
by	O
the	O
Neuropsychiatric	B-Observation
Inventory	I-Observation
NPI	B-Observation
)	O
is	O
'Very	O
frequently',	O
or	O
.	O

2	O
.	O
the	O
frequency	O
of	O
agitation	B-Condition
as	O
assessed	O
by	O
the	O
NPI	O
is	O
'Frequently'	O
AND	O
the	O
severity	O
of	O
the	O
agitation	O
as	O
assessed	O
by	O
the	O
NPI	O
is	O
'Moderate'	O
or	O
'Marked'	O
.	O

-	O
Provision	O
of	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
study	O
by	O
patient	O
or	O
surrogate	O
(if	O
necessary)	O
and	O
caregiver	O
.	O

-	O
Availability	O
of	O
primary	O
caregiver,	O
who	O
spends	O
several	O
hours	O
a	O
week	O
with	O
the	O
patient	O
and	O
supervises	O
his	O
/	O
her	O
care,	O
to	O
accompany	O
the	O
patient	O
to	O
study	O
visits	O
and	O
to	O
participate	O
in	O
the	O
study	O
.	O

-	O
No	B-Negation_cue
change	O
to	O
Alzheimer's	B-Condition
disease	I-Condition
AD	B-Condition
)	O
medications	B-Drug
within	O
the	O
month	O
preceding	O
randomization,	O
including	O
starting,	O
stopping	O
or	O
dosage	O
modifications	O
.	O

Exclusion	O
criteria	O
.	O

-	O
Meets	O
criteria	O
for	O
Major	B-Condition
Depressive	I-Condition
Episode	I-Condition
by	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders,	O
4th	O
edition,	O
text	O
revision	O
(DSM-IV	O
(TR)	O
criteria	O
.	O

-	O
Presence	O
of	O
a	O
brain	B-Condition
disease	I-Condition
that	O
might	O
otherwise	O
explain	O
the	O
presence	O
of	O
dementia	B-Condition
,	O
such	O
as	O
extensive	O
brain	B-Condition
vascular	I-Condition
disease	I-Condition
Parkinson's	B-Condition
disease	I-Condition
dementia	B-Condition
with	I-Condition
Lewy	I-Condition
bodies	I-Condition
traumatic	B-Condition
brain	I-Condition
injury	I-Condition
or	O
multiple	B-Condition
sclerosis	I-Condition
.	O

-	O
Psychosis	B-Condition
delusions	B-Condition
or	O
hallucinations	B-Condition
)	O
requiring	O
antipsychotic	B-Procedure_Device
treatment	I-Procedure_Device
in	O
the	O
opinion	O
of	O
the	O
study	O
physician	O
.	O

-	O
Prolonged	O
measure	O
of	O
the	O
time	O
between	O
the	O
start	O
of	O
the	O
Q	O
wave	O
and	O
the	O
end	O
of	O
the	O
T	O
wave	O
in	O
the	O
heart's	O
electrical	O
cycle	O
(QT	O
interval)	O
.	O

-	O
Treatment	O
with	O
citalopram	B-Drug
is	O
contraindicated	B-Condition
in	O
the	O
opinion	O
of	O
the	O
study	O
physician	O
.	O

-	O
Failure	O
of	O
past	O
treatment	O
with	O
citalopram	B-Drug
for	O
agitation	B-Condition
after	O
adequate	O
trial	O
at	O
a	O
minimally	O
accepted	O
dose	O
(greater	O
than	O
or	O
equal	O
to	O
20	O
mg	O
/	O
day)	O
.	O

-	O
Treatment	O
with	O
a	O
medication	B-Drug
that	O
would	O
prohibit	O
the	O
safe	O
concurrent	O
use	O
of	O
citalopram	B-Drug
,	O
such	O
as	O
Monoamine	B-Drug
oxidases	I-Drug
(	I-Drug
MAO	I-Drug
)	I-Drug
inhibitors	I-Drug
.	O

-	O
Need	O
for	O
psychiatric	O
hospitalization	O
or	O
suicidal	O
.	O

-	O
Current	O
participation	O
in	O
a	O
clinical	O
trial	O
or	O
in	O
any	O
study	O
that	O
may	O
add	O
a	O
significant	O
burden	O
or	O
affect	O
neuropsychological	O
or	O
other	O
study	O
outcomes	O
.	O

-	O
Current	O
treatment	O
with	O
antipsychotics	B-Drug
,	O
anticonvulsants	B-Drug
other	B-Negation_cue
than	I-Negation_cue
dilantin	B-Drug
),	O
other	O
antidepressants	B-Drug
other	B-Negation_cue
than	I-Negation_cue
trazodone	B-Drug
,	O
less	O
than	O
or	O
equal	O
to	O
50	O
mg	O
per	O
day	O
at	O
bedtime),	O
benzodiazepines	B-Drug
other	B-Negation_cue
than	I-Negation_cue
lorazepam	B-Drug
)	O
or	O
psychostimulants	B-Drug
.	O

-	O
Any	O
condition	O
that,	O
in	O
the	O
opinion	O
of	O
the	O
study	O
physician,	O
makes	O
it	O
medically	O
inappropriate	O
or	O
risky	O
for	O
the	O
patient	O
to	O
enroll	O
in	O
the	O
trial	O
.	O

>>NCT02360657	O
Inclusion	O
Criteria:	O
.	O

-	O
Participant	O
must	O
have	O
had	O
sufficient	O
education	O
or	O
work	O
experience	O
to	O
exclude	O
mental	O
retardation	O
based	O
on	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
4th	O
edition,	O
Text	O
Revision	O
(DSM-IV-TR)	O
and	O
must	O
be	O
able	O
to	O
read	O
and	O
write	O
and	O
must	O
have	O
adequate	O
hearing	O
and	O
visual	O
acuity	O
to	O
complete	O
the	O
required	O
psychometric	O
tests	O
.	O

-	O
Participant	O
must	O
have	O
a	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
Scale-	I-Observation
Japanese	I-Observation
version	I-Observation
(	I-Observation
CDR-J	I-Observation
)	I-Observation
score	I-Observation
of	O
'0'	O
and	O
as	O
such	O
rated	O
as	O
normal	O
.	O

-	O
Participant	O
must	O
have	O
evidence	B-Observation
of	O
amyloid	B-Condition
deposition	I-Condition
as	O
demonstrated	O
by	O
low	O
Cerebrospinal	B-Observation
Fluid	I-Observation
CSF	B-Observation
)	O
Amyloid	B-Observation
(	I-Observation
A	I-Observation
)-beta	I-Observation
1-42	O
levels	O
at	O
Screening	O
.	O

-	O
Participant	O
must	O
have	O
a	O
body	B-Observation
mass	I-Observation
index	I-Observation
between	O
18	O
and	O
35	O
kilogram	O
per	O
square	O
meter,	O
inclusive,	O
at	O
Screening	O
.	O

-	O
Participant	O
must	O
be	O
otherwise	O
healthy	B-Condition
for	O
their	O
age	O
group	O
or	O
medically	O
stable	O
with	O
or	O
without	O
medication	O
on	O
the	O
basis	O
of	O
physical	B-Observation
examination	I-Observation
medical	B-Observation
history	I-Observation
vital	B-Observation
signs	I-Observation
and	O
12-lead	B-Procedure_Device
electrocardiogram	I-Procedure_Device
ECG	B-Procedure_Device
)	O
performed	O
at	O
Screening	O
or	O
at	O
Baseline	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Participant	O
has	O
evidence	O
of	O
any	O
brain	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
potential	O
very	O
early	O
signs	O
of	O
Alzheimer's	B-Condition
disease	I-Condition
AD	B-Condition
)	O
or	O
typical	O
age	O
related	O
changes	O
or	O
any	O
other	O
abnormality	B-Condition
that	O
could	O
explain	O
a	O
possible	O
cognitive	B-Condition
deficit	I-Condition
.	O

-	O
Participant	O
has	O
been	O
diagnosed	O
with	O
dementia	B-Condition
due	O
to	O
AD	B-Condition
,	O
due	O
to	O
other	O
diseases	O
or	O
with	O
AD	B-Condition
and	O
contribution	O
of	O
other	O
disorders	O
mixed	B-Condition
dementia	I-Condition
.	O

-	O
Participant	O
has	O
evidence	O
of	O
familial	B-Condition
autosomal	I-Condition
dominant	I-Condition
AD	I-Condition
.	O

-	O
Participant	O
has	O
any	O
contra-indications	B-Condition
for	O
Magnetic	B-Procedure_Device
Resonance	I-Procedure_Device
Imaging	I-Procedure_Device
MRI	B-Procedure_Device
)	O
(for	O
example,	O
prostheses	B-Procedure_Device
,	O
implants	B-Procedure_Device
,	O
claustrophobia	B-Procedure_Device
,	O
pacemakers	B-Procedure_Device
and	O
others)	O
.	O

-	O
Participant	O
has	O
a	O
clinically	O
significant	O
abnormal	O
physical-	B-Observation
or	I-Observation
neurological	I-Observation
examination	I-Observation
vital	B-Observation
signs	I-Observation
or	O
12-lead	B-Observation
ECG	I-Observation
(including	O
QTc	B-Observation
greater	O
than	O
450	O
millisecond	O
for	O
males	O
and	O
females,	O
left	B-Condition
bundle	I-Condition
branch	I-Condition
block	I-Condition
atrio-ventricular	B-Condition
[AV]	I-Condition
block	I-Condition
second	I-Condition
degree	I-Condition
or	I-Condition
higher	I-Condition
permanent	B-Procedure_Device
pacemaker	I-Procedure_Device
or	O
implantable	B-Procedure_Device
cardioverter	I-Procedure_Device
defibrillator	I-Procedure_Device
ICD	B-Procedure_Device
])	O
at	O
Screening	O
or	O
Baseline,	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
is	O
not	O
appropriate	O
and	O
reasonable	O
for	O
the	O
population	O
under	O
study	O
.	O

>>NCT00469456	O
Inclusion	O
Criteria:	O
.	O

-	O
Male	O
and	O
female	O
outpatients,	O
50	O
years	O
or	O
older,	O
native	O
English	O
speakers,	O
meeting	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Disorders	O
and	O
Stroke--Alzheimer's	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
NINCDS-ADRDA	B-Observation
)	O
criteria	O
for	O
probable	O
AD	B-Condition
with	O
a	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
of	O
10	O
to	O
19	O
at	O
Screening	O
and	O
Baseline	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Current	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders--Fourth	O
Edition	O
DSM-IV	B-Observation
)	O
Axis	O
I	O
disorder	O
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
.	O

-	O
Previous	O
imaging	B-Procedure_Device
results	O
not	B-Negation_cue
consistent	O
with	O
the	O
diagnosis	O
of	O
AD	B-Condition
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
Score	I-Observation
greater	O
than	O
4	O
.	O

-	O
Evidence	B-Observation
of	O
other	O
neurologic	B-Condition
disorders	I-Condition
.	O

-	O
Clinically	O
significant	O
systemic	B-Condition
disease	I-Condition
.	O

-	O
A	O
known	O
or	O
suspected	O
history	B-Observation
of	O
alcohol	B-Condition
or	I-Condition
drug	I-Condition
abuse	I-Condition
in	O
the	O
past	O
5	O
years	O
.	O

-	O
Taking	O
excluded	B-Negation_cue
medication	B-Drug
.	O

-	O
Previous	O
treatment	O
with	O
commercial	O
memantine	B-Drug
.	O

>>NCT02547818	O
Inclusion	O
Criteria:	O
.	O

-	O
55-79	O
years	O
old;	O
.	O

-	O
>=	O
8	O
years	O
of	O
education;	O
.	O

-	O
Study	O
partner	O
is	O
available	O
who	O
has	O
frequent	O
contact	O
with	O
the	O
participant	O
(eg	O
an	O
average	O
of	O
10	O
hours	O
per	O
week	O
or	O
more)	O
and	O
can	O
accompany	O
the	O
participant	O
to	O
all	O
clinic	O
visits	O
for	O
the	O
duration	O
of	O
the	O
protocol;	O
.	O

-	O
Evidence	O
of	O
early	O
AD	B-Condition
,	O
as	O
defined	O
by	O
all	O
of	O
the	O
following:	O
.	O

1	O
.	O

Memory	O
complaint	O
by	O
subject	O
or	O
study	O
partner	O
that	O
is	O
verified	O
by	O
a	O
study	O
partner;	O
.	O

2	O
.	O

Objective	B-Condition
memory	I-Condition
impairment	I-Condition
for	O
age,	O
documented	O
by	O
scoring	O
below	O
the	O
education	O
adjusted	O
cutoff	O
of	O
the	O
Logical	O
Memory	O
II	O
subscale	O
(Delayed	O
Paragraph	O
Recall)	O
from	O
the	O
Wechsler	O
Memory	O
Scale	O
Third	O
Edition	O
(the	O
maximum	O
score	O
is	O
25):	O
.	O

-	O
<=	O
8	O
for	O
16	O
or	O
more	O
years	O
of	O
education,	O
or	O
.	O

-	O
<=	O
4	O
for	O
8-15	O
years	O
of	O
education;	O
.	O

-	O
Essentially	O
preserved	O
general	B-Observation
cognitive	I-Observation
function	I-Observation
.	O

-	O
Largely	O
intact	O
functional	O
activities;	O
.	O

-	O
Not	B-Negation_cue
demented	B-Condition
;	O
.	O

-	O
Cerebrospinal	B-Observation
fluid	I-Observation
(	I-Observation
CSF	I-Observation
)	I-Observation
biomarker	I-Observation
results	O
consistent	O
with	O
early	O
AD	B-Condition
,	O
including	O
CSF	B-Observation
A-42	I-Observation
levels	I-Observation
>=	O
200	O
pg	O
/	O
mL	O
and	O
<=	O
600	O
pg	O
/	O
mL;	O
.	O

-	O
Clinical	B-Observation
Dementia	I-Observation
Rating	I-Observation
Global	B-Observation
)	O
=	O
0.5;	O
Memory	B-Observation
Box	I-Observation
score	I-Observation
must	O
be	O
at	O
least	O
0.5;	O
.	O

-	O
Must	O
be	O
fluent	O
in	O
the	O
language	O
of	O
the	O
cognitive	O
testing	O
material	O
being	O
administered;	O
.	O

-	O
Stability	O
of	O
permitted	O
medications	B-Drug
for	O
4	O
weeks	O
prior	O
to	O
study	O
start;	O
subjects	O
receiving	O
acetylcholinesterase	B-Drug
inhibitors	I-Drug
and	O
/	O
or	O
memantine	B-Drug
should	O
be	O
on	O
stable	O
dose	B-Observation
of	O
those	O
medications	B-Drug
for	O
at	O
least	O
12	O
weeks	O
prior	O
to	O
study	O
start	O
with	O
every	O
effort	O
to	O
maintain	O
stable	O
dose	O
for	O
the	O
duration	O
of	O
the	O
study;	O
.	O

-	O
Visual	B-Observation
and	I-Observation
auditory	I-Observation
acuity	I-Observation
adequate	O
for	O
neuropsychological	O
testing;	O
.	O

-	O
Good	O
general	B-Condition
health	I-Condition
with	O
no	O
diseases	O
expected	O
to	O
interfere	O
with	O
the	O
study;	O
.	O

-	O
Must	O
provide	O
written	O
informed	O
consent	O
for	O
APOe4	O
genotype	O
testing;	O
.	O

-	O
Must	O
provide	O
written	O
informed	O
consent	O
for	O
CSF	B-Observation
sampling	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Any	O
significant	O
neurological	B-Condition
disease	I-Condition
other	B-Negation_cue
than	I-Negation_cue
suspected	O
incipient	O
AD	B-Condition
,	O
such	O
as	O
Parkinson's	B-Condition
disease	I-Condition
multi-infarct	B-Condition
dementia	I-Condition
Huntington's	B-Condition
disease	I-Condition
normal	B-Condition
pressure	I-Condition
hydrocephalus	I-Condition
brain	B-Condition
tumor	I-Condition
progressive	B-Condition
supranuclear	I-Condition
palsy	I-Condition
seizure	B-Condition
disorder	I-Condition
subdural	B-Condition
hematoma	I-Condition
multiple	B-Condition
sclerosis	I-Condition
or	O
history	O
of	O
significant	B-Condition
head	I-Condition
trauma	I-Condition
followed	O
by	O
persistent	O
neurologic	O
defaults	O
or	O
known	O
structural	B-Condition
brain	I-Condition
abnormalities	I-Condition
.	O

-	O
Major	B-Condition
depressive	I-Condition
episode	I-Condition
as	O
described	O
in	O
the	O
Diagnostic	B-Observation
and	I-Observation
Statistical	I-Observation
Manual	I-Observation
of	I-Observation
Mental	I-Observation
Disorders	I-Observation
DSM-IV	B-Observation
)	O
within	O
the	O
past	O
6	O
months,	O
which	O
could	O
lead	O
to	O
difficulty	O
complying	O
with	O
the	O
protocol;	O
.	O

-	O
History	B-Observation
of	O
schizophrenia	B-Condition
or	O
bipolar	B-Condition
disorder	I-Condition
DSM-IV	B-Observation
criteria	I-Observation
.	O

-	O
History	B-Observation
of	O
alcohol	B-Condition
or	I-Condition
substance	I-Condition
abuse	I-Condition
or	I-Condition
dependence	I-Condition
within	O
the	O
past	O
3	O
years	O
DSM-IV	B-Observation
criteria	I-Observation
.	O

-	O
Currently	O
taking	O
medications	O
that	O
could	O
lead	O
to	O
difficulty	O
complying	O
with	O
the	O
protocol;	O
subjects	O
must	O
be	O
on	O
a	O
stable	O
dose	B-Observation
of	O
current	O
medications	B-Drug
for	O
4	O
weeks	O
prior	O
to	O
study	O
entry,	O
with	O
the	O
exception	O
of	O
acetylcholinesterase	B-Drug
inhibitors	I-Drug
and	O
/	O
or	O
memantine	B-Drug
,	O
which	O
must	O
be	O
on	O
a	O
stable	O
dose	B-Observation
for	O
at	O
least	O
12	O
weeks	O
prior	O
to	O
study	O
entry;	O
.	O

-	O
Investigational	B-Drug
agents	I-Drug
are	O
prohibited	B-Negation_cue
one	O
month	O
prior	O
to	O
entry	O
and	O
for	O
the	O
duration	O
of	O
the	O
trial;	O
.	O

-	O
Currently	O
taking	O
medications	O
known	O
to	O
be	O
CYP2C9	B-Drug
inducers	I-Drug
(i.e	O
.	O

carbamazepine	B-Drug
and	O
rifampicin	B-Drug
);	O
.	O

-	O
Currently	O
taking	O
cromolyn	B-Drug
or	O
have	O
taken	O
cromolyn	B-Drug
,	O
within	O
the	O
past	O
12	O
months;	O
.	O

-	O
Chronic	O
daily	O
use	O
of	O
high	O
dose	B-Observation
NSAID	B-Drug
for	O
osteoarthritis	B-Condition
,	O
rheumatoid	B-Condition
arthritis	I-Condition
or	O
other	O
chronic	B-Condition
inflammatory	I-Condition
diseases	I-Condition
("chronic"	O
defined	O
as	O
3200	O
mg	O
/	O
day	O
for	O
>2	O
weeks);	O
.	O

-	O
Chronic	O
daily	O
use	O
of	O
aspirin	B-Drug
exceeding	O
standard	O
of	O
care	O
guidelines	O
for	O
low	O
dose	O
aspirin	O
therapy	O
for	O
prevention	O
of	O
stroke	B-Condition
and	O
/	O
or	O
other	O
recommended	O
uses;	O
.	O

-	O
Allergy	B-Condition
to	O
cromolyn	B-Drug
(also	O
known	O
as	O
Intal	B-Drug
,	O
Nasalcrom	B-Drug
,	O
Opticrom	B-Drug
,	O
Gastrocrom	B-Drug
,	O
etc.);	O
.	O

-	O
Allergies	B-Condition
to	O
ibuprofen	B-Drug
Advil	B-Drug
,	O
Motrin	B-Drug
,	O
Nuprin	B-Drug
,	O
etc.)	O

or	O
aspirin	B-Drug
;	O
.	O

-	O
Clinically	O
significant	O
respiratory	B-Condition
disorders	I-Condition
with	O
impaired	O
respiratory	O
effort	O
or	O
difficulty	O
taking	O
inhaled	O
drugs;	O
.	O

-	O
Uncontrolled	O
chronic	O
asthma	B-Condition
;	O
.	O

-	O
Abnormal	O
pulmonary	B-Observation
function	I-Observation
test	I-Observation
defined	O
for	O
this	O
protocol	O
as:	O
FEV1	B-Observation
/	I-Observation
FVC	I-Observation
<	O
predicted	O
value	O
for	O
subject	O
AND	O
FEV1	B-Observation
<	O
70%	O
of	O
predicted	O
value,	O
indicating	O
moderate	O
or	O
severe	O
respiratory	B-Condition
obstruction	I-Condition
.	O

-	O
Taking	O
inhaled	B-Drug
protein	I-Drug
products	I-Drug
on	O
a	O
chronic	O
basis;	O
.	O

-	O
Any	O
significant	O
systemic	B-Condition
illness	I-Condition
or	O
unstable	O
medical	B-Condition
condition	I-Condition
which	O
could	O
lead	O
to	O
difficulty	O
complying	O
with	O
the	O
protocol;	O
.	O

-	O
Pregnancy	B-Condition
or	O
lactation	B-Condition
for	O
female	O
subjects	O
of	O
child-bearing	B-Condition
potential	I-Condition
(i.e.,	O
<	O
two	O
years	O
post-menopausal	B-Condition
or	O
not	B-Negation_cue
surgically	B-Condition
sterile	I-Condition
.	O

-	O
For	O
sexually	O
active	O
male	O
subjects,	O
unwillingness	O
or	O
incapability	O
of	O
using	O
appropriate	O
contraception	O
methods;	O
.	O

-	O
Severe	O
renal	B-Condition
or	I-Condition
hepatic	I-Condition
impairment	I-Condition

>>NCT02471196	O
Inclusion	O
Criteria:	O
.	O

-	O
Written	O
informed	O
consent	O
(IC)	O
for	O
participation	O
in	O
the	O
study	O
(co-signed	O
by	O
the	O
subject's	O
next	O
of	O
kin	O
or	O
caregiver	O
or	O
other	O
legally	O
acceptable	O
representative	O
.	O

-	O
Written	O
IC	O
obtained	O
from	O
a	O
consistently	O
available	O
caregiver	O
informant	O
who	O
is	O
knowledgeable	O
of	O
the	O
subject's	O
condition	O
and	O
its	O
progression	O
and	O
is	O
willing	O
to	O
accompany	O
the	O
subject	O
to	O
all	O
visits	O
and	O
supervise	O
the	O
administration	O
of	O
the	O
study	O
medication	O
.	O

-	O
Age	B-Observation
of	O
55-90	O
years	O
(inclusive)	O
.	O

-	O
Male	O
or	O
female	O
subjects	O
with	O
diagnosis	O
of	O
probable	O
Alzheimer's	B-Condition
Disease	I-Condition
.	O

-	O
Brain	O
imaging	O
computed	B-Procedure_Device
tomography	I-Procedure_Device
CT	B-Procedure_Device
]	O
or	O
magnetic	B-Procedure_Device
resonance	I-Procedure_Device
imaging	I-Procedure_Device
MRI	B-Procedure_Device
])	O
consistent	O
with	O
a	O
diagnosis	O
of	O
Alzheimer's	B-Condition
Disease	I-Condition
(within	O
18	O
months	O
or	O
at	O
screening)	O
.	O

-	O
Mini-mental	B-Observation
state	I-Observation
examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
between	O
10-24	O
(inclusive)	O
.	O

-	O
Clinically	O
significant	O
agitation	B-Condition
meeting	O
the	O
International	B-Observation
Psychogeriatric	I-Observation
Association	I-Observation
Provisional	I-Observation
Criteria	I-Observation
for	O
Agitation	O
in	O
Cognitive	B-Condition
Impairment	I-Condition
.	O

The	O
agitation	B-Observation
symptoms	I-Observation
need	O
to	O
have	O
been	O
present	O
for	O
at	O
least	O
4	O
weeks	O
before	O
the	O
screening	O
visit	O
.	O

-	O
Neuropsychiatric	B-Observation
Inventory	I-Observation
agitation	I-Observation
/	I-Observation
aggression	I-Observation
item	I-Observation
score	I-Observation
at	O
least	O
4	O
at	O
screening	O
visit	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Modified	B-Observation
Hachinski	I-Observation
Ischemia	I-Observation
Score	I-Observation
MHIS	B-Observation
)	O
>	O
4	O
.	O

-	O
Changes	O
in	O
AChE	B-Drug
inhibitor	I-Drug
donepezil	B-Drug
,	O
rivastigmine	B-Drug
or	O
galantamine	B-Drug
)	O
dosing	B-Observation
within	O
2	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Changes	O
in	O
memantine	B-Drug
dosing	B-Observation
within	O
2	O
months	O
prior	O
to	O
the	O
screening	O
.	O

-	O
Changes	O
in	O
antidepressant	B-Drug
dosing	B-Observation
or	O
addition	O
of	O
another	O
antidepressant	B-Drug
medication	O
within	O
2	O
months	O
prior	O
to	O
the	O
screening	O
.	O

-	O
Use	O
of	O
antipsychotics	B-Drug
at	O
any	O
dose	O
within	O
1	O
month	O
prior	O
to	O
screening	O
.	O

-	O
Use	O
of	O
benzodiazepines	B-Drug
,	O
other	B-Negation_cue
than	I-Negation_cue
short-acting	B-Drug
sleep	I-Drug
medications	I-Drug
for	O
night	O
at	O
a	O
maximum	O
of	O
3	O
nights	O
/	O
week,	O
within	O
2	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Use	O
of	O
any	O
anticholinergic	B-Drug
medication	I-Drug
within	O
2	O
months	O
prior	O
to	O
screening	O
.	O

-	O
Current	O
use	O
(within	O
the	O
30	O
days	O
prior	O
to	O
screening)	O
of	O
medications	B-Drug
with	I-Drug
known	I-Drug
relevant	I-Drug
alpha-2C	I-Drug
AR	I-Drug
affinity	I-Drug
(eg	O
mirtazapine	B-Drug
,	O
mianserin	B-Drug
,	O
clonidine	B-Drug
,	O
guanfacine	B-Drug
or	O
tizanidine	B-Drug
)	O
or	O
with	O
high	O
noradrenaline	O
transporter	O
affinity	O
reboxetine	B-Drug
,	O
venlafaxine	B-Drug
or	O
duloxetine	B-Drug
)	O
.	O

-	O
Current	O
use	O
of	O
other	O
psychotropic	B-Drug
agents	I-Drug
unless	O
the	O
dosing	B-Observation
has	O
been	O
stable	O
during	O
the	O
last	O
2	O
months	O
prior	O
to	O
the	O
screening	O
.	O

-	O
Myocardial	B-Condition
infarction	I-Condition
or	O
other	O
clinically	O
significant	O
ischemic	B-Condition
cardiac	I-Condition
disease	I-Condition
heart	B-Condition
failure	I-Condition
or	O
arrhythmia	B-Condition
tendency	I-Condition
within	O
the	O
past	O
2	O
years	O
.	O

-	O
Current	B-Observation
or	O
history	B-Observation
of	O
malignancy	B-Condition
within	O
5	O
years	O
before	O
screening	O
.	O

-	O
Suicidal	B-Condition
ideation	I-Condition
in	O
the	O
6	O
months	O
before	O
screening	O
or	O
current	O
suicide	B-Observation
risk	I-Observation
based	O
on	O
the	O
Colombia-Suicide	B-Observation
Severity	I-Observation
Rating	I-Observation
Scale	I-Observation
C-SSRS	B-Observation
)	O
(items	O
4	O
and	O
5	O
exclusionary)	O
or	O
current	O
risk	B-Observation
of	I-Observation
suicide	I-Observation
based	O
on	O
the	O
investigator's	O
judgement	O
.	O

-	O
Specific	O
findings	O
in	O
MRI	B-Procedure_Device
or	O
CT	B-Procedure_Device
that	O
could	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
affect	O
cognitive	B-Observation
function	I-Observation
(such	O
as	O
cortical	B-Observation
infarct	I-Observation
or	O
silent	B-Observation
lacuna	I-Observation
in	O
a	O
region	O
known	O
to	O
affect	O
cognition)	O
.	O

-	O
Supine	B-Observation
heart	I-Observation
rate	I-Observation
<	O
48	O
bpm	O
or	O
>	O
100	O
bpm	O
.	O

-	O
Systolic	B-Observation
blood	I-Observation
pressure	I-Observation
SBP	B-Observation
)	O
>	O
160	O
mmHg	O
or	O
diastolic	B-Observation
blood	I-Observation
pressure	I-Observation
DBP	B-Observation
)	O
>	O
100	O
mmHg	O
after	O
a	O
5-minute	O
rest	O
.	O

-	O
Symptomatic	B-Condition
orthostatic	I-Condition
hypotension	I-Condition
.	O

-	O
QTc-Fridericia	B-Observation
QTcF	B-Observation
)	O
repeatedly	O
>	O
450	O
ms	O
in	O
males	O
or	O
>	O
470	O
ms	O
in	O
females	O
.	O

-	O
Clinically	O
significantly	O
abnormal	O
thyroid-stimulating	B-Observation
hormone	I-Observation
(	I-Observation
TSH	I-Observation
),	I-Observation
vitamin	I-Observation
B12	I-Observation
or	I-Observation
folate	I-Observation
serum	I-Observation
levels	I-Observation
at	O
screening	O
.	O

-	O
Resides	O
in	O
a	O
skilled	O
nursing	O
facility	O
.	O

>>NCT00927108	O
Inclusion	O
Criteria:	O
.	O

-	O
Patients	O
who	O
have	O
elective	O
craniotomy	B-Procedure_Device
or	O
.	O

-	O
Patients	O
who	O
have	O
elective	O
ventriculostomy	B-Procedure_Device
surgery	I-Procedure_Device
or	O
.	O

-	O
Patients	O
who	O
have	O
elective	O
muscle	B-Procedure_Device
biopsy	I-Procedure_Device
or	O
nerve	B-Procedure_Device
biopsy	I-Procedure_Device
.	O

-	O
Patient	O
who	O
have	O
emergency	O
craniectomy	B-Condition
for	O
life	O
threatening	O
from	O
emergency	O
medical	B-Condition
and	I-Condition
surgical	I-Condition
conditions	I-Condition
such	O
as	O
Brain	B-Condition
herniation	I-Condition
or	O
head	B-Condition
injury	I-Condition
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Central	B-Condition
nervous	I-Condition
system	I-Condition
infection	I-Condition
for	O
example	O
tuberculous	B-Condition
or	O
any	O
bacterial	B-Condition
infection	I-Condition
Viral	B-Condition
infection	I-Condition
fungal	B-Condition
infection	I-Condition
.	O

-	O
Central	B-Condition
nervous	I-Condition
system	I-Condition
Tumor	I-Condition
Malignancy	B-Condition
and	O
metastasis	B-Condition
.	O

>>NCT00064870	O
Inclusion	O
Criteria:	O
.	O

-	O
Two	O
living	O
family	O
members	O
diagnosed	O
with	O
AD	B-Condition
or	O
other	O
dementia	B-Condition
with	O
any	O
age	O
of	O
onset	O
.	O

-	O
Biological	O
samples	O
available	O
.	O

-	O
Fresh	O
blood,	O
or	O
.	O

-	O
Immortalized	O
lymphoblastic	O
cell	O
lines,	O
or	O
.	O

-	O
3-5	O
grams	O
of	O
frozen	O
cerebral	O
cortex;	O
fixed	O
samples	O
are	O
not	O
accepted	O
.	O

Please	O
note:	O
this	O
study	O
does	O
not	O
include	O
genetic	O
counseling;	O
because	O
no	O
personal	O
identifying	O
information	O
such	O
as	O
name	O
or	O
date	O
of	O
birth	O
is	O
attached	O
to	O
samples,	O
results	O
of	O
individual	O
tests	O
are	O
not	O
available	O
to	O
participants	O
or	O
family	O
members	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Does	O
not	O
meet	O
inclusion	O
criteria	O
.	O

-	O
Member	O
of	O
a	O
family	O
that	O
was	O
included	O
in	O
the	O
National	O
Institute	O
of	O
Mental	O
Health	O
AD	O
Genetics	O
Sib	O
Pair	O
collection	O
.	O

>>NCT01565291	O
Inclusion	O
Criteria	O
AD	B-Condition
group):	O
.	O

-	O
Probable	O
AD	B-Condition
according	O
to	O
the	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communication	O
Disorders	O
and	O
Stroke-Alzheimer's	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
NINCDS-ADRDA	B-Observation
)	O
criteria	O
.	O

-	O
Mild	O
/	O
moderate	O
dementia	B-Condition
as	O
evidenced	O
by	O
a	O
mini	B-Observation
mental	I-Observation
state	I-Observation
exam	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
ranging	O
from	O
10	O
to	O
24,	O
boundaries	O
included,	O
at	O
screening	O
.	O

-	O
History	B-Observation
of	O
cognitive	B-Condition
decline	I-Condition
had	O
been	O
gradual	O
in	O
onset	O
and	O
progressive	O
over	O
a	O
period	O
of	O
at	O
least	O
6	O
months	O
.	O

Inclusion	O
Criteria	O
(healthy	O
volunteer	O
group):	O
.	O

-	O
No	B-Negation_cue
evidence	O
of	O
significant	O
cognitive	B-Condition
impairment	I-Condition
by	O
history	B-Observation
and	O
psychometric	B-Observation
testing	I-Observation
.	O

-	O
MMSE	B-Observation
of	O
29	O
or	O
higher	O
.	O

Exclusion	O
Criteria	O
(both	O
groups):	O
.	O

-	O
Neurodegenerative	B-Condition
disorders	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
.	O

-	O
Cognitive	B-Condition
impairment	I-Condition
resulting	O
from	O
trauma	B-Condition
,	O
hypoxic	B-Condition
damage	I-Condition
vitamin	B-Condition
deficiency	I-Condition
brain	B-Condition
infection	I-Condition
brain	B-Condition
cancer	I-Condition
endocrine	B-Condition
disease	I-Condition
or	O
mental	B-Condition
retardation	I-Condition
.	O

-	O
Clinically	O
significant	O
infarct	B-Condition
or	O
possible	O
multi-infarct	B-Condition
dementia	I-Condition
as	O
defined	O
by	O
the	O
NINCDS	B-Observation
criteria	I-Observation
.	O

-	O
Evidence	O
on	O
screening	O
MRI	B-Procedure_Device
or	O
other	O
biomarker	B-Observation
that	O
suggests	O
alternate	O
etiology	O
for	O
cognitive	B-Condition
deficit	I-Condition
(for	O
healthy	O
controls,	O
evidence	O
suggesting	O
the	O
presence	O
of	O
AD	B-Condition
pathology)	O
.	O

-	O
Clinically	O
significant	O
psychiatric	B-Condition
disease	I-Condition
.	O

-	O
History	B-Observation
of	O
epilepsy	B-Condition
or	O
convulsions	B-Condition
.	O

-	O
Clinically	O
significant	O
hepatic,	B-Condition
renal,	I-Condition
pulmonary,	I-Condition
metabolic	I-Condition
or	I-Condition
endocrine	I-Condition
disturbances	I-Condition
.	O

-	O
Current	O
clinically	O
significant	O
cardiovascular	B-Condition
disease	I-Condition
.	O

-	O
Received	O
investigational	B-Drug
medication	I-Drug
within	O
the	O
last	O
30	O
days	O
.	O

>>NCT01294540	O
Inclusion:	O
.	O

-	O
Healthy	B-Condition
males	O
and	O
females	O
.	O

-	O
Aged	B-Observation
30	O
to	O
55	O
years,	O
inclusive	O
(Cohorts	O
1	O
through	O
5);	O
aged	B-Observation
65	O
to	O
85	O
years,	O
inclusive	O
(Cohort	O
6)	O
.	O

-	O
Body	B-Observation
mass	I-Observation
index	I-Observation
BMI	B-Observation
)	O
of	O
18	O
to	O
32kg	O
/	O
m^2	O
at	O
Screening	O
.	O

-	O
Additional	O
inclusion	O
criteria	O
for	O
Cohort	O
6	O
(healthy	O
elderly	O
subjects)	O
.	O

Exclusion	O
.	O

-	O
Females	O
of	O
child-bearing	B-Condition
potential	I-Condition
.	O

-	O
Personal	O
or	O
family	B-Observation
history	I-Observation
of	O
neurological	B-Condition
abnormalities	I-Condition
.	O

-	O
Any	O
clinical	O
abnormality	B-Observation
of	O
the	O
electrocardiogram	B-Procedure_Device
(	I-Procedure_Device
ECG	I-Procedure_Device
)	I-Procedure_Device
Screening	O
and	O
check-in	O
.	O

-	O
A	O
family	O
history	B-Observation
of	O
cardiac	B-Condition
abnormalities	I-Condition
.	O

-	O
Thyroid	B-Condition
abnormalities	I-Condition
.	O

>>NCT01316562	O
Inclusion	O
Criteria:	O
.	O

-	O
Age	B-Observation
>=	O
65	O
years	O
.	O

-	O
Community-dwellers	O
.	O

-	O
Volunteers	O
receiving	O
a	O
free	O
medical	O
examination	O
in	O
Health	O
examination	O
centre	O
.	O

-	O
Subjective	B-Observation
memory	I-Observation
complaint	I-Observation
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Known	O
dementia	B-Condition
.	O

-	O
Sensory	B-Condition
deficit	I-Condition
compromising	O
the	O
cognitive	O
evaluation	O
.	O

-	O
Poor	O
workmanship	O
of	O
the	O
written	O
or	O
oral	O
French	O
language	O
.	O

>>NCT02621606	O
Inclusion	O
Criteria:	O
.	O

Part	O
I,	O
II	O
and	O
III:	O
.	O

-	O
Male	O
or	O
non-pregnant	B-Condition
and	O
non-breast	B-Condition
feeding	I-Condition
female	O
of	O
18	O
to	O
55	O
years	O
of	O
age	B-Observation
(Part	O
I)	O
or	O
55	O
to	O
85	O
years	O
of	O
age	B-Observation
(Parts	O
II	O
and	O
III);	O
in	O
addition:	O
.	O

-	O
Male	O
participant	O
who	O
is	O
sexually	O
active	O
with	O
females	O
of	O
childbearing	O
potential	O
must	O
be	O
willing	O
to	O
use	O
a	O
condom	O
from	O
the	O
first	O
dose	O
of	O
study	O
drug	O
until	O
3	O
months	O
post	O
the	O
last	O
dose	O
of	O
study	O
drug	O
.	O

-	O
Female	O
participant	O
with	O
reproductive	B-Condition
potential	I-Condition
must	O
have	O
serum	B-Observation
-human	I-Observation
chorionic	I-Observation
gonadotropin	I-Observation
(	I-Observation
-hCG	I-Observation
)	I-Observation
test	I-Observation
result	O
consistent	O
with	O
non-pregnant	B-Condition
state	O
at	O
screening	O
and	O
agree	O
to	O
use	O
two	O
acceptable	O
methods	O
of	O
birth	O
control	O
beginning	O
at	O
screening	O
visit,	O
during	O
study	O
and	O
until	O
2	O
weeks	O
after	O
the	O
last	O
dose	O
of	O
study	O
drug	O
.	O

-	O
Female	O
participant	O
of	O
non-childbearing	B-Condition
potential	I-Condition
must	O
be	O
post-menopausal	B-Condition
female	O
(participant	O
has	O
been	O
without	O
menses	O
for	O
at	O
least	O
1	O
year	O
and	O
has	O
a	O
follicle	B-Observation
stimulating	I-Observation
hormone	I-Observation
[FSH]	I-Observation
level	I-Observation
in	O
the	O
postmenopausal	O
range	O
at	O
screening)	O
or	O
surgically	B-Procedure_Device
sterile	I-Procedure_Device
female	O
(status	O
post	O
hysterectomy	B-Procedure_Device
,	O
oophorectomy	B-Procedure_Device
or	O
tubal	B-Procedure_Device
ligation	I-Procedure_Device
.	O

-	O
Body	B-Observation
Mass	I-Observation
Index	I-Observation
BMI	B-Observation
)	O
<=35	O
kg	O
/	O
m^2,	O
with	O
height	B-Observation
<=195	O
cm	O
and	O
weight	B-Observation
<=136	O
kg	O
.	O

-	O
In	O
good	O
health	B-Condition
(Part	O
I)	O
or	O
generally	O
healthy	B-Condition
(Parts	O
II	O
and	O
III)	O
based	O
on	O
medical	B-Observation
history	I-Observation
physical	B-Observation
examination	I-Observation
vital	B-Observation
sign	I-Observation
measurements	I-Observation
and	O
electrocardiogram	B-Procedure_Device
ECG	B-Procedure_Device
)	O
.	O

-	O
Nonsmoker	B-Observation
and	O
/	O
or	O
has	O
not	B-Negation_cue
used	O
nicotine	B-Drug
or	O
nicotine-containing	B-Drug
products	I-Drug
for	O
at	O
least	O
approximately	O
3	O
months	O
.	O

Part	O
II	O
Only:	O
.	O

-	O
Willing	O
to	O
allow	O
placement	O
of	O
an	O
arterial	O
catheter	O
in	O
the	O
radial	O
artery	O
.	O

-	O
Mini	B-Observation
Mental	I-Observation
Status	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
score	I-Observation
>=27	O
.	O

-	O
No	B-Negation_cue
history	B-Observation
of	O
subjective	B-Observation
memory	I-Observation
or	I-Observation
other	I-Observation
cognitive	I-Observation
complaints	I-Observation
.	O

-	O
No	B-Negation_cue
objective	O
evidence	B-Observation
of	O
memory	B-Condition
or	I-Condition
cognitive	I-Condition
impairment	I-Condition
.	O

Part	O
III	O
Only:	O
.	O

-	O
Moderate	O
to	O
severe	O
AD	B-Condition
as	O
defined	O
by:	O
.	O

-	O
MMSE	B-Observation
score	I-Observation
<=20	O
.	O

-	O
Meets	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Diseases	O
and	O
Stroke	O
/	O
Alzheimer's	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
NINCDS-ADRDA	B-Observation
)	O
criteria	O
for	O
probable	O
AD	B-Condition
.	O

-	O
Meets	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders,	O
5th	O
Edition	O
DSM-V	B-Observation
)	O
criteria	O
for	O
AD	B-Condition
.	O

-	O
Rosen-Modified	B-Observation
Hachinski	I-Observation
score	I-Observation
<=4	O
.	O

-	O
Screening	O
magnetic	B-Procedure_Device
resonance	I-Procedure_Device
imaging	I-Procedure_Device
MRI	B-Procedure_Device
)	O
scan	O
consistent	O
with	O
a	O
diagnosis	O
of	O
AD	B-Condition
.	O

-	O
Clear	O
history	B-Observation
of	O
cognitive	B-Condition
and	I-Condition
functional	I-Condition
decline	I-Condition
over	O
>=1	O
year	O
.	O

-	O
On	O
a	O
stable	O
dose	B-Observation
of	O
one	O
of	O
protocol-defined	O
acetylcholinesterase	B-Drug
inhibitors	I-Drug
AChEIs	B-Drug
)	O
(i.e.,	O
donepezil	B-Drug
,	O
rivastigmine	B-Drug
and	O
tacrine	B-Drug
)	O
for	O
symptomatic	B-Drug
treatment	I-Drug
of	O
AD	B-Condition
.	O

Dose	B-Observation
must	O
be	O
stable	O
for	O
at	O
least	O
the	O
last	O
4	O
weeks	O
before	O
screening	O
.	O

-	O
Has	O
a	O
reliable	O
trial	O
partner	O
/	O
caregiver	O
who	O
is	O
able	O
to	O
accompany	O
the	O
participant	O
to	O
all	O
clinic	O
visits,	O
if	O
needed	O
and	O
able	O
to	O
provide	O
information	O
to	O
study	O
investigator	O
/	O
staff	O
via	O
telephone	O
contact	O
.	O

Exclusion	O
Criteria:	O
.	O

Part	O
I,	O
II	O
and	O
III:	O
.	O

-	O
Mentally	O
or	O
legally	O
incapacitated,	O
has	O
significant	O
emotional	B-Condition
problems	I-Condition
at	O
the	O
time	O
of	O
screening	O
visit	O
or	O
expected	O
during	O
the	O
conduct	O
of	O
the	O
trial	O
or	O
has	O
a	O
history	B-Observation
of	O
clinically	O
significant	O
psychiatric	B-Condition
disorder	I-Condition
of	O
the	O
last	O
5	O
years,	O
except	B-Negation_cue
(for	O
Part	O
III	O
only)	O
for	O
psychiatric	B-Condition
disorders	I-Condition
associated	O
with	O
AD	B-Condition
.	O

-	O
History	B-Observation
of	O
clinically	O
significant	O
endocrine,	B-Condition
gastrointestinal,	I-Condition
cardiovascular,	I-Condition
hematological,	I-Condition
hepatic,	I-Condition
immunological,	I-Condition
renal,	I-Condition
respiratory,	I-Condition
genitourinary	I-Condition
or	I-Condition
major	I-Condition
neurological	I-Condition
abnormalities	I-Condition
or	I-Condition
diseases	I-Condition
unless	O
(for	O
Part	O
II	O
and	O
III	O
only)	O
adequately	O
controlled	O
through	O
a	O
stable	O
medication	B-Drug
regimen	O
.	O

-	O
History	B-Observation
of	O
cancer	B-Condition
.	O

-	O
History	B-Observation
of	O
significant	O
multiple	B-Condition
and	I-Condition
/	I-Condition
or	I-Condition
severe	I-Condition
allergies	I-Condition
or	O
has	O
had	O
an	O
anaphylactic	B-Condition
reaction	I-Condition
or	O
significant	O
intolerability	B-Observation
to	O
prescription	B-Drug
or	I-Drug
non-prescription	I-Drug
drugs	I-Drug
or	I-Drug
food	I-Drug
.	O

For	O
Part	O
II,	O
this	O
includes	O
any	O
known	O
allergy	B-Condition
to	O
lidocaine	B-Drug
which	O
may	O
be	O
used	O
as	O
an	O
anesthetic	O
for	O
the	O
placement	O
of	O
the	O
arterial	O
catheter	O
.	O

-	O
Has	O
positive	O
test	O
result	O
for	O
hepatitis	B-Observation
B	I-Observation
surface	I-Observation
antigen	I-Observation
hepatitis	B-Observation
C	I-Observation
antibodies	I-Observation
or	O
human	B-Observation
immunodeficiency	I-Observation
virus	I-Observation
HIV	B-Observation
)	O
.	O

-	O
Has	O
had	O
major	B-Procedure_Device
surgery	I-Procedure_Device
or	O
donated	B-Procedure_Device
or	O
lost	B-Condition
1	O
unit	O
of	O
blood	O
(approximately	O
500	O
mL)	O
within	O
4	O
weeks	O
prior	O
to	O
screening	O
.	O

-	O
Has	O
participated	O
in	O
another	O
investigational	B-Procedure_Device
trial	I-Procedure_Device
within	O
4	O
weeks	O
of	O
screening	O
.	O

-	O
Corrected	B-Observation
QT	I-Observation
(	I-Observation
QTc	I-Observation
)	I-Observation
interval	I-Observation
>=470	O
msec	O
(for	O
males)	O
or	O
>=480	O
msec	O
(for	O
females)	O
.	O

-	O
Is	O
unable	O
to	O
refrain	O
from	O
or	O
anticipates	O
the	O
use	O
of	O
any	O
medication,	O
including	O
prescription	O
and	O
non-prescription	O
drugs	B-Drug
or	O
herbal	B-Drug
remedies	I-Drug
beginning	O
approximately	O
2	O
weeks	O
prior	O
to	O
administration	O
of	O
the	O
initial	O
dose	O
of	O
study	O
drug	O
and	O
throughout	O
the	O
study	O
.	O

-	O
Consumes	O
>3	O
servings	O
of	O
alcohol	B-Drug
a	O
day	O
.	O

-	O
Consumes	O
>6	O
caffeine	B-Drug
servings	O
a	O
day	O
.	O

-	O
Is	O
currently	O
a	O
regular	O
or	O
recreational	O
user	O
of	O
cannabis	B-Drug
,	O
any	O
illicit	B-Drug
drugs	I-Drug
or	O
has	O
a	O
history	B-Observation
of	O
drug	B-Condition
(	I-Condition
including	I-Condition
alcohol	I-Condition
)	I-Condition
abuse	I-Condition
within	O
approximately	O
3	O
months	O
.	O

-	O
Has	O
participated	O
in	O
a	O
PET	O
research	O
study	O
or	O
other	O
study	O
involving	O
administration	O
of	O
a	O
radioactive	B-Drug
substance	I-Drug
or	O
ionizing	B-Drug
radiation	I-Drug
within	O
12	O
months	O
prior	O
to	O
screening	O
or	O
has	O
undergone	O
an	O
extensive	B-Procedure_Device
radiological	I-Procedure_Device
examination	I-Procedure_Device
within	O
this	O
period	O
.	O

-	O
Suffers	O
from	O
claustrophobia	B-Condition
or	O
an	O
inability	O
to	O
tolerate	O
confinement	O
in	O
small	O
places	O
and	O
would	O
be	O
unable	O
to	O
undergo	O
MRI	B-Procedure_Device
or	O
PET	B-Procedure_Device
scanning	I-Procedure_Device
.	O

Part	O
II	O
Only:	O
.	O

-	O
Has	O
been	O
administered	O
an	O
AChEI	B-Drug
within	O
the	O
prior	O
3	O
months	O
or	O
will	O
require	O
administration	O
of	O
an	O
AChEI	B-Drug
during	O
study	O
.	O

Part	O
III	O
Only:	O
.	O

-	O
Has	O
been	O
administered	O
galantamine	B-Drug
within	O
the	O
prior	O
7	O
days	O
or	O
will	O
require	O
administration	O
of	O
galantamine	B-Drug
during	O
study	O
.	O

-	O
History	B-Observation
within	O
2	O
years	O
prior	O
to	O
screening	O
or	O
current	O
evidence	O
of	O
any	O
neurological	B-Condition
or	I-Condition
neurodegenerative	I-Condition
disorder	I-Condition
other	B-Negation_cue
than	I-Negation_cue
AD	B-Condition
that	O
is	O
associated	O
with	O
transient	O
or	O
sustained	O
alterations	O
in	O
cognition	O
.	O

-	O
History	B-Observation
within	O
2	O
years	O
prior	O
to	O
screening	O
or	O
current	O
evidence	O
of	O
a	O
psychotic	B-Condition
disorder	I-Condition
or	O
a	O
major	B-Condition
depressive	I-Condition
disorder	I-Condition
.	O

Part	O
II	O
and	O
III	O
Only:	O
.	O

-	O
Has	O
or	O
is	O
suspected	O
to	O
have	O
implanted	O
or	O
embedded	O
metal	B-Procedure_Device
objects	I-Procedure_Device
or	I-Procedure_Device
fragments	I-Procedure_Device
in	O
the	O
head	O
or	O
body	O
that	O
would	O
present	O
a	O
risk	B-Observation
during	O
the	O
MRI	B-Procedure_Device
scanning	O
procedure	O
.	O

>>NCT02546310	O
Inclusion	O
Criteria:	O
.	O

-	O
Healthy	B-Condition
on	O
the	O
basis	O
of	O
medical	B-Observation
history	I-Observation
physical	B-Observation
examination	I-Observation
vital	B-Observation
signs	I-Observation
12-lead	B-Procedure_Device
ECG	I-Procedure_Device
haematology	B-Observation
,	O
blood	B-Observation
chemistry	I-Observation
urinalysis	B-Observation
and	O
a	O
pre-study	B-Observation
psychological	I-Observation
assessment	I-Observation
.	O

-	O
Mini	B-Observation
Mental	I-Observation
State	I-Observation
Examination	I-Observation
(	I-Observation
MMSE	I-Observation
)	I-Observation
Score	I-Observation
of	O
>=24	O
.	O

-	O
Intermediate	O
or	O
extensive	O
metaboliser	O
as	O
determined	O
by	O
CYP2D6	O
genotype	O
.	O

-	O
Fluent	O
English	O
speaker	O
.	O

-	O
Right-handed	O
.	O

-	O
Not	O
a	O
regular	O
smoker	O
.	O

Exclusion	O
Criteria:	O
.	O

-	O
Recreational	B-Drug
drug	I-Drug
use	O
within	O
3	O
months	O
prior	O
to	O
Screening	O
Visit	O
.	O

-	O
Positive	O
alcohol	B-Observation
breath	I-Observation
test	I-Observation
.	O

-	O
Positive	O
urine	B-Observation
drug	I-Observation
screen	I-Observation
.	O

-	O
Consumption	O
of	O
large	O
amounts	O
of	O
caffeinated	B-Drug
drinks	I-Drug
.	O

-	O
Consumption	O
of	O
any	O
food	O
or	O
any	O
drinks	O
containing	O
cranberry	B-Drug
,	O
pomegranate	B-Drug
,	O
star	B-Drug
fruit	I-Drug
grapefruit	B-Drug
,	O
pomelos	B-Drug
,	O
exotic	B-Drug
citrus	I-Drug
fruits	I-Drug
or	O
Seville	B-Drug
oranges	I-Drug
.	O

-	O
Ultra-rapid	O
or	O
poor	O
metabolizer	O
as	O
determined	O
by	O
CYP2D6	O
genotype	O
.	O

-	O
By	O
self-report,	O
taking	O
two	O
or	O
more	O
daytime	O
naps	O
per	O
week	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
is	O
likely	O
to	O
interfere	O
with	O
the	O
ability	O
of	O
the	O
subject	O
to	O
complete	O
the	O
study	O
procedures	O
.	O

-	O
History	B-Observation
of	O
or	O
presents	B-Observation
(in	O
the	O
opinion	O
of	O
the	O
Investigator)	O
with,	O
significant	O
neurological	B-Condition
or	I-Condition
psychiatric	I-Condition
conditions	I-Condition
.	O

-	O
Personal	B-Observation
or	I-Observation
family	I-Observation
history	I-Observation
of	O
congenital	B-Condition
long	I-Condition
QT	I-Condition
syndrome	I-Condition
or	O
sudden	B-Condition
death	I-Condition
.	O

-	O
Concomitant	O
use	O
of	O
drugs	O
that	O
are	O
metabolised	O
by	O
and	O
/	O
or	O
are	O
inhibitors	O
of	O
CYP2D6	O
.	O

-	O
Concomitant	O
use	O
of	O
drugs	O
that	O
are	O
substrates	O
for	O
the	O
organic	O
cation	O
transporter	O
2	O
.	O

-	O
History	B-Observation
of	O
significant	O
claustrophobia	B-Condition
.	O

-	O
Fulfils	O
any	O
of	O
the	O
MRI	B-Procedure_Device
contraindications	B-Condition
on	O
the	O
standard	O
site	O
radiography	O
screening	O
questionnaire	O
(eg	O
history	B-Observation
of	O
surgery	B-Procedure_Device
involving	I-Procedure_Device
metal	I-Procedure_Device
implants	I-Procedure_Device
.	O

>>NCT00585572	O
Individuals	O
enrolled	O
in	O
the	O
longitudinal	O
study	O
of	O
the	O
Alzheimer's	O
Disease	O
Research	O
Center	O
(ADRC),	O
additional	O
studies	O
affiliated	O
with	O
the	O
ADRC	O
or	O
select	O
additional	O
donors	O
are	O
invited	O
to	O
participate	O
.	O

>>NCT02467413	O
Inclusion	O
Criteria:	O
.	O

A	O
patient	O
is	O
eligible	O
for	O
the	O
study	O
if	O
all	O
of	O
the	O
following	O
apply:	O
.	O

1	O
.	O

With	O
either	O
gender	O
aged	B-Observation
at	O
least	O
40	O
years	O
old	O
.	O

2	O
.	O

With	O
a	O
diagnosis	O
of	O
one	O
of	O
the	O
following	O
disease	O
i	O
.	O
Vascular	B-Condition
dementia	I-Condition
according	O
to	O
the	O
NINDS-AIREN	B-Observation
International	I-Observation
Workshop	I-Observation
criteria	I-Observation
or	O
ii	O
.	O

Alzheimer's	B-Condition
disease	I-Condition
according	O
to	O
the	O
NIAAA	B-Observation
criteria	I-Observation
iii	I-Observation
.	O

"Mixed"	B-Condition
dementia	I-Condition
(possible	O
Alzheimer's	B-Condition
disease	I-Condition
with	O
cerebrovascular	B-Condition
disease	I-Condition
according	O
to	O
the	O
NIAAA	B-Observation
criteria	I-Observation
.	O

Note:	O
.	O

1	O
.	O

NINDS-AIREN:	O
National	O
Institute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke	O
and	O
Association	O
Internationale	O
pour	O
la	O
Recherche	O
et	O
l'Enseignement	O
en	O
Neurosciences	O
.	O

2	O
.	O

NIAAA:	O
National	O
Institute	O
on	O
Aging-Alzheimer's	O
Association	O
.	O

3	O
.	O

With	O
mild-to-moderate	O
dementia	B-Condition
(score	O
of	O
the	O
Mini-Mental	B-Observation
State	I-Observation
Examination	I-Observation
MMSE	B-Observation
)	O
defined	O
as	O
between	O
10	O
to	O
24)	O
.	O

4	O
.	O

Able	O
to	O
read,	O
write,	O
communicate	O
and	O
understand	O
cognitive	O
testing	O
instructions	O
.	O

5	O
.	O

Having	O
a	O
responsible	O
caregiver	O
who	O
spends	O
adequate	O
time	O
daily	O
with	O
the	O
patient;	O
the	O
caregiver	O
will	O
accompany	O
the	O
patient	O
to	O
all	O
clinic	O
visits	O
during	O
the	O
study	O
and	O
supervise	O
all	O
study	O
dosing	O
requirements	O
and	O
concomitant	O
medications	O
.	O

6	O
.	O

Signed,	O
by	O
patients	O
and	O
the	O
responsible	O
caregiver,	O
the	O
written	O
informed	O
consent	O
form	O
.	O

Exclusion	O
Criteria:	O
.	O

1	O
.	O

With	O
large-artery	B-Condition
stroke	I-Condition
thrombotic	B-Condition
stroke	I-Condition
.	O

2	O
.	O

With	O
radiological	B-Observation
evidence	I-Observation
of	O
other	O
brain	B-Condition
disorders	I-Condition
subdural	B-Condition
hematoma	I-Condition
post-traumatic	B-Condition
/	I-Condition
post-surgery	I-Condition
.	O

3	O
.	O

With	O
dementia	B-Condition
caused	O
by	O
other	O
brain	B-Condition
diseases	I-Condition
except	B-Negation_cue
Alzheimer's	B-Condition
disease	I-Condition
and	O
vascular	B-Condition
dementia	I-Condition
(eg	O
Parkinson's	B-Condition
disease	I-Condition
demyelinated	B-Condition
disease	I-Condition
of	O
the	O
central	O
nervous	O
system,	O
tumor	B-Condition
,	O
hydrocephalus	B-Condition
,	O
head	B-Condition
injury	I-Condition
central	B-Condition
nervous	I-Condition
system	I-Condition
infection	I-Condition
including	O
syphilis	B-Condition
,	O
acquired	B-Condition
immune	I-Condition
deficiency	I-Condition
syndrome	I-Condition
etc.)	O
.	O

4	O
.	O

With	O
clinical	O
evidence	O
of	O
pulmonary,	B-Condition
hepatic,	I-Condition
gastrointestinal,	I-Condition
metabolic,	I-Condition
endocrine	I-Condition
or	I-Condition
other	I-Condition
life	I-Condition
threatening	I-Condition
diseases	I-Condition
judged	O
by	O
investigators	O
not	O
suitable	O
to	O
enter	O
the	O
study	O
.	O

5	O
.	O

With	O
clinically	O
unstable	O
hypertension	B-Condition
,	O
diabetes	B-Condition
mellitus	I-Condition
and	O
cardiac	B-Condition
disease	I-Condition
for	O
the	O
last	O
3	O
months	O
.	O

6	O
.	O

With	O
history	B-Observation
of	O
stroke	B-Condition
and	O
hospitalized	O
for	O
stroke	B-Condition
in	O
the	O
previous	O
3	O
months	O
.	O

7	O
.	O

With	O
history	B-Observation
of	O
alcohol	B-Condition
or	I-Condition
drug	I-Condition
abuse	I-Condition
.	O

8	O
.	O

With	O
one	O
of	O
the	O
following	O
abnormal	O
laboratory	O
parameters:	O
hemoglobin	B-Observation
<	O
10	O
mg	O
/	O
dL	O
or	O
platelet	B-Observation
<	O
100*109	O
/	O
L;	O
creatinine	B-Observation
or	O
total	B-Observation
bilirubin	I-Observation
more	O
than	O
1.5	O
times	O
the	O
upper	O
limit	O
value;	O
alanine	B-Observation
aminotransferase	I-Observation
ALT	B-Observation
),	O
aspartate	B-Observation
aminotransferase	I-Observation
AST	B-Observation
),	O
alkaline	B-Observation
phosphates	I-Observation
ALP	B-Observation
)	O
or	O
-glutamyl	B-Observation
transferase	I-Observation
-GT	B-Observation
)	O
more	O
than	O
2	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O

9	O
.	O

With	O
depression	B-Condition
,	O
not	O
well-controlled	O
with	O
medications	B-Drug
.	O

10	O
.	O

With	O
any	O
uncontrolled	O
illness	B-Condition
judged	O
by	O
the	O
investigator	O
that	O
entering	O
the	O
trial	O
may	O
be	O
detrimental	O
to	O
the	O
patient	O
.	O

11	O
.	O

With	O
known	O
or	O
suspected	O
hypersensitivity	B-Condition
to	O
any	O
ingredients	B-Drug
of	O
study	O
product	O
and	O
vehicle	O
.	O

12	O
.	O

Pregnant	B-Condition
or	O
lactating	B-Condition
or	O
premenopausal	B-Condition
with	I-Condition
childbearing	I-Condition
potential	I-Condition
but	O
not	B-Negation_cue
taking	O
reliable	O
contraceptive	B-Procedure_Device
method(	I-Procedure_Device
s	I-Procedure_Device
)	I-Procedure_Device
during	O
the	O
study	O
period	O
.	O

13	O
.	O

Enrollment	O
in	O
any	O
investigational	O
drug	O
trial	O
within	O
4	O
weeks	O
before	O
entering	O
this	O
study.	O

